

# Health Economics, Outcomes & Epidemiology

PUBLISHED RESEARCH AND PRESENTATIONS



# Health Economics, Outcomes & Epidemiology

PUBLISHED RESEARCH AND PRESENTATIONS

## A COMPENDIUM OF OUR RESEARCH

Health outcomes research is playing an increasingly important role in pharmaceutical development as new products enter competitive markets and face demands for economic evidence, safety, and efficacy. A clear and early understanding of value is critical to commercial success, and requires companies to have capabilities in health economics and associated disciplines of epidemiology, biostatistics, outcomes research, and pharmacoeconomics in place for ready use across their customers and therapeutic areas.

For nearly three decades, Analysis Group has been distinguished by a unique combination of expertise in health economics, outcomes research, epidemiology, biostatistics, and health policy. Our outcomes research has resulted in thought leadership and a robust record of publications and presentations across the leading medical, outcomes, and health economics journals and conferences, covering a range of clinical and methodological areas. This compendium includes published manuscripts as well as abstracts through October 2019.

For more information on our research activities and health care consulting practice, please visit our website, <https://www.analysisgroup.com/>.

**CONTENTS**

Autoimmune/Inflammatory	4
Cardiovascular	21
Dermatology	43
Endocrine/Metabolic/Diabetes	60
Gastrointestinal	80
Hematology	94
Infectious Diseases	112
Neurology	121
Oncology	162
Renal	234
Respiratory	239
Substance Abuse	252
Other Diseases & Conditions	257
Other (Health Policy, Market Access, and other topics)	271





## Autoimmune/Inflammatory

### **Predictors of High-cost Patients With Noninfectious Inflammatory Eye Diseases.**

*Publication:* Clinical Therapeutics 2019 10. e-pub ahead of print 2019/10/15; doi: 10.1016/j.clinthera.2019.09.011.

*Authors:* Nelson WW, Rice JB, White AG, Johnson M, Reiff J, Lima AF, Bartels-Peculis L, Ciepielewska G, Albin TA.

### **Early Predictors of Sjogren's Syndrome: A Machine Learning Approach.**

*Abstract:* ISPOR 24th Annual International Meeting, New Orleans, LA May 18-22, 2019.

*Authors:* Royer JS, J; Pivneva, I; Huber, W; Capkun, G.

### **Economic Burden of Switching to Different Biologic Therapies Among Tumor Necrosis Factor Inhibitor-Experienced Patients with Psoriatic Arthritis.**

*Publication:* Rheumatol Ther 2019 05; 6(2): 285-297. e-pub ahead of print 2019/05/06; doi: 10.1007/s40744-019-0158-2.

*Authors:* Song Y, Betts KA, Lu Y, Singh R, Clewell J, Griffith J.

### **Economic Burden of Illness Among Commercially Insured Patients with Systemic Sclerosis with Interstitial Lung Disease in the USA: A Claims Data Analysis.**

*Publication:* Advances in Therapy 2019 03. e-pub ahead of print 2019/04/01; doi: 10.1007/s12325-019-00929-2.

*Authors:* Zhou Z, Fan Y, Thomason D, Tang W, Liu X, Zhou ZY, Macaulay D, Fischer A.

### **Economic Burden among Commercially Insured Patients with Systemic Sclerosis in the United States.**

*Publication:* Journal of Rheumatology 2019 02: jrheum.180445. e-pub ahead of print 2019/02/17; doi: 10.3899/jrheum.180445.

*Authors:* Zhou Z, Fan Y, Tang W, Liu X, Thomason D, Zhou ZY, Macaulay D, Fischer A.

### **Characteristics of Patients with Psoriatic Arthritis Receiving Secukinumab and Reasons for Initiation: A US Retrospective Medical Chart Review.**

*Publication:* Rheumatol Ther 2019 01. e-pub ahead of print 2019/01/07; doi: 10.1007/s40744-018-0137-z.

*Authors:* Sunkureddi P, Latremouille-Viau D, Meiselbach MK, Xie J, Hur P, Joshi R.

### **Characterization of Patients with Ankylosing Spondylitis Receiving Secukinumab and Reasons for Initiating Treatment: A US Physician Survey and Retrospective Medical Chart Review.**

*Publication:* Drugs Real World Outcomes 2019 01. e-pub ahead of print 2019/01/09; doi: 10.1007/s40801-018-0146-9.

*Authors:* Joshi R, Latremouille-Viau D, Meiselbach MK, Xie J, Park Y, Sunkureddi P.

### **Short-term costs associated with non-medical switching in autoimmune conditions.**

*Publication:* Clinical and Experimental Rheumatology 2019 01; 37(1): 97-105. e-pub ahead of print 2018/07/13.

*Authors:* Gibofsky A, Skup M, Yang M, Mittal M, Macaulay D, Ganguli A.

### **Comparison of real-world treatment outcomes with infliximab vs. vedolizumab in biologic-naive patients with inflammatory bowel disease.**

*Abstract:* 14th Congress of ECCO - Inflammatory Bowel Diseases 2019, Copenhagen, Denmark Mar 6-9, 2019.

*Authors:* Latremouille-Viau D, Burne R, Shi S, Adsul S, Patel H.

### **A systematic literature review to assess long-term outcomes associated with splenectomy in patients with chronic immune thrombocytopenia.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Nellesen D, Said Q, Shak N, Patton C, Lucas S, Graves JA, Nezami B, Cuker A.

**Incidence of inflammatory bowel disease (IBD) among patients (PTS) with other chronic inflammatory diseases (CID) treated with interleukin-17A (IL-17A) or phosphodiesterase 4 (PDE4) inhibitors.**

*Abstract:* ACR/ARHP Annual Meeting, Chicago, IL Oct 19-24, 2018.

*Authors:* Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P.

**Inflammatory bowel disease is associated with a substantial economic burden in patients with psoriatic arthritis and in patients with ankylosing spondylitis.**

*Abstract:* ACR/ARHP Annual Meeting, Chicago, IL Oct 19-24, 2018.

*Authors:* Bergman MJ, Zueger P, Song J, Pivneva I, Betts KA, Joshi AD.

**Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population.**

*Publication:* Journal of Medical Economics 2018 09; 21(9): 846-852. e-pub ahead of print 2018/05/10; doi: 10.1080/13696998.2018.1474750.

*Authors:* Rice JB, White AG, Johnson M, Wagh A, Qin Y, Bartels-Peculis L, Ciepielewska G, Nelson WW.

**Network meta-analysis of targeted immunomodulators in the treatment of psoriatic arthritis patients without prior biologic treatment.**

*Abstract:* ACR/ARHP Annual Meeting, Chicago, IL Oct 19-24, 2018.

*Authors:* Strand V, Husni ME, Griffith J, Song Y, Singh R, Zhao J, Betts KA.

**Upadacitinib monotherapy improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to methotrexate.**

*Abstract:* ACR/ARHP Annual Meeting, Chicago, IL Oct 19-24, 2018.

*Authors:* Strand V, Buch M, Tundia N, Camp HS, Suboticki J, Goldschmidt D, Wells AF.

**Quantitative characterization of the relationship between levels of extended corticosteroid use and related adverse events in a US population.**

*Publication:* Current Medical Research and Opinion 2018 08; 34(8): 1519-1527. e-pub ahead of print 2018/05/10; doi: 10.1080/03007995.2018.1474090.

*Authors:* Rice JB, White AG, Johnson M, Wagh A, Qin Y, Bartels-Peculis L, Ciepielewska G, Nelson WW.

**Estimating the economic value of a patient support program in rheumatoid arthritis in the United Kingdom.**

*Abstract:* Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, Netherlands Jun 13-16, 2018.

*Authors:* Ostor A, Garg V, Yang M, Chamberlain C, Skup M.

**Estimating the short-term costs associated with non-medical switching in rheumatic diseases.**

*Abstract:* Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, Netherlands Jun 13-16, 2018.

*Authors:* Gibofsky A, Garg V, Yang M, Qi CZ, Skup M.

**Patient reported outcomes of upadacitinib: Results from biologic inadequate responders (select beyond phase iii trial).**

*Abstract:* Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, Netherlands Jun 13-16, 2018.

*Authors:* Strand V, Schiff M, Tundia N, Friedman A, Meerwein S, Pangan A, Ganguli A, Fuldeore M, Song Y, Pope J.

**Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs: Results from selectnext.**

*Abstract:* Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, Netherlands Jun 13-16, 2018.

*Authors:* Strand V, Pope J, Tundia N, Friedman A, Camp HS, Pangan A, Ganguli A, Fuldeore M, Goldschmidt D, Schiff M.

**Burden of Illness of Systemic Sclerosis with Interstitial Lung Disease among Commercially Insured Patients.**

*Abstract:* American Thoracic Society International Conference, San Diego, CA May 19-23, 2018.

*Authors:* Zhou Z, Yu Y, Liu X, Tang W, Zhou Z, Thomason D, Macaulay D, Fischer A.

**Burden of Work Instability in Patients with Rheumatoid Arthritis in US and Its Association with Work Productivity and Transitions.**

*Abstract:* Academy of Managed Care & Specialty Pharmacy Annual Meeting, Boston, MA April 23-26, 2018.

*Authors:* Tundia N, Zhou J, Yang M, Macaulay D, JR C.

**Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis.**

*Publication:* J Manag Care Spec Pharm 2018 04; 24(4): 344-352. e-pub ahead of print 2018/03/27; doi: 10.18553/jmcp.2018.24.4.344.

*Authors:* Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.

**Patterns of Immunosuppressive Therapy among Patients with Newly Diagnosed Systemic Sclerosis (SSc) and SSc-Associated Interstitial Lung Disease (SSc-ILD).**

*Abstract:* AMCP's 30th Annual Meeting, Boston, MA Apr 23-26, 2018.

*Authors:* Thomason D, Yu Y, Zhou Z, Tang W, Liu X, Zhou Z, Macaulay D, Fischer A.

**Burden of illness of systemic sclerosis among commercially insured patients.**

*Abstract:* 5th Systemic Sclerosis World Congress, Bordeaux, France Feb 15-17, 2018.

*Authors:* Yu Y, Tang W, Liu X, Zhou Z, MacAulay D, Fischer A.

**Economic burden of illness among commercially-insured patients with systemic sclerosis in the United States.**

*Abstract:* Systemic Sclerosis World Congress, 5th Annual, Bordeaux, France February 15-17, 2018.

*Authors:* Zhou Z, Yu Y, Tang W, Liu X, Thomason D, Zhou Z, Macaulay D, Fischer A.

**Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis.**

*Publication:* BMC Rheumatology 2018 01; 2 (1) (no pagination)(3). doi: <http://dx.doi.org/10.1186/s41927-018-0011-1>.

*Authors:* Strand V, Elaine Husni M, Betts KA, Song Y, Singh R, Griffith J, Beppu M, Zhao J, Ganguli A.

**Healthcare resource utilization and costs by age and joint location among osteoarthritis patients in a privately insured population.**

*Publication:* Journal of Medical Economics 2017 12; 20(12): 1299-1306. e-pub ahead of print 2017/09/08; doi: 10.1080/13696998.2017.1377717.

*Authors:* Wang SX, Ganguli AX, Bodhani A, Medema JK, Reichmann WM, Macaulay D.

**High-Cost Sarcoidosis Patients in the United States: Patient Characteristics and Patterns of Health Care Resource Utilization.**

*Publication:* J Manag Care Spec Pharm 2017 12; 23(12): 1261-1269. e-pub ahead of print 2017/11/28; doi: 10.18553/jmcp.2017.17203.

*Authors:* Rice JB, White A, Lopez A, Nelson WW.

**Association of corticosteroid exposure with ophthalmologic complications and systemic adverse events in non-infectious uveitis patients using administrative claims in the United States.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, San Diego, CA Nov 3-8, 2017.

*Authors:* Acharya N, Betts KA, Patterson-Lomba O, Ganguli A, Schonfeld S, Griffith J.

**Long-term Systemic Corticosteroid Exposure: A Systematic Literature Review.**

*Publication:* Clinical Therapeutics 2017 11; 39(11): 2216-2229. e-pub ahead of print 2017/10/23; doi: 10.1016/j.clinthera.2017.09.011.

*Authors:* Rice JB, White AG, Scarpati LM, Wan G, Nelson WW.

**Quantifying clinical and economic outcomes associated with chronic corticosteroid exposure in a US population.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, San Diego, CA Nov 3 - 8, 2017.

*Authors:* Rice JB, White A, Lopez A, Wagh A, Qin Y, Mitri G, Bartels-Peculis L, Ciepielewska G, Nelson W.

**Burden of high disease activity in systemic lupus erythematosus (SLE): Results of a targeted literature review.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Tan R, Adamski K, Tuttle E, Guenther O, Henke C.

**Economic burden of sarcoidosis in a commercially-insured population in the United States.**

*Publication:* Journal of Medical Economics 2017 10; 20(10): 1048-1055. e-pub ahead of print 2017/07/06; doi: 10.1080/13696998.2017.1351371.

*Authors:* Rice JB, White A, Lopez A, Conway A, Wagh A, Nelson WW, Philbin M, Wan GJ.

**Network meta-analysis of targeted immunomodulators in the treatment of biologic-naïve psoriatic arthritis.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, San Diego, CA Nov 3-8, 2017.

*Authors:* Strand V, Husni ME, Singh R, Betts K, Song Y, Griffith J, Ganguli A.

**Effectiveness and healthcare costs among stabilised rheumatoid arthritis patients with dose reduction of adalimumab or etanercept in real world.**

*Publication:* Clinical and Experimental Rheumatology 2017 09; 35(5): 791-798. e-pub ahead of print 2017/03/25.

*Authors:* Yang M, Galebach PJ, Signorovitch JE, Garg V.

**Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.**

*Publication:* Clinical Therapeutics 2017 08; 39(8): 1618-1627. e-pub ahead of print 2017/07/22; doi: 10.1016/j.clinthera.2017.06.009.

*Authors:* Li N, Betts KA, Messali AJ, Skup M, Garg V.

**Systematic Literature Review and Meta-analysis of Tumor Necrosis Factor-Alpha Experienced Rheumatoid Arthritis.**

*Publication:* Clinical Therapeutics 2017 08; 39(8): 1680-1694 e1682. e-pub ahead of print 2017/07/25; doi: 10.1016/j.clinthera.2017.06.013.

*Authors:* Wells AF, Curtis JR, Betts KA, Douglas K, Du EX, Ganguli A.

**Comparative Effectiveness of Adalimumab versus Secukinumab for the Treatment of Psoriatic Arthritis: A Matching-Adjusted Indirect Comparison.**

*Publication:* Rheumatol Ther 2017 07; 4(2): 349-362. e-pub ahead of print 2017/08/02; doi: 10.1007/s40744-017-0070-6.

*Authors:* Strand V, Betts KA, Mittal M, Song J, Skup M, Joshi A.

**Benefit-risk trade-offs for treatment decisions in moderate-to-severe rheumatoid arthritis: focus on the patient perspective.**

*Publication:* Rheumatology International 2017 06; 1-12. doi: 10.1007/s00296-017-3760-z.

*Authors:* Husni ME, Betts KA, Griffith J, Song Y, Ganguli A.



**HPR predicting the future development of spondyloarthritis among patients with idiopathic acute anterior uveitis using real-world data.**

*Abstract:* Annual European Congress of Rheumatology, Madrid, Spain June 14-17, 2017.

*Authors:* Haroon M, Betts KA, Mu F, Skup M, Anderson JK, Joshi AD.

**Association between disease activity level improvement and reduction in healthcare resource utilization in patients with rheumatoid arthritis receiving targeted therapy.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Lopez A, Priest J, Duh MS, McDonnell E, Bobbili PJ, Haider BA, Sundaresan D, Yood RA, Reed JL.

**Clinical Outcomes Associated with Switching or Discontinuation from Anti-TNF Inhibitors for Nonmedical Reasons.**

*Publication:* Clinical Therapeutics 2017 04; 39(4): 849-862 e846. e-pub ahead of print 2017/04/02; doi: 10.1016/j.clinthera.2017.03.005.

*Authors:* Wolf D, Skup M, Yang H, Fang AP, Kageleiry A, Chao J, Mittal M, Lebwohl M.

**The economic burden of dermatomyositis and polymyositis in the US.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, Washington, DC Nov 11-16, 2016.

*Authors:* Rice JB, White A, Galebach P, Lopez A, Schepman P, Popelar B, Philbin M, Boing E.

**Economic burden of non-responders to biologic DMARD treatments in rheumatoid arthritis.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, Washington, DC Nov 11-16, 2016.

*Authors:* Strand V, Tundia N, Song Y, Macaulay D, Fuldeore M.

**Thresholds of benefit-risk trade-offs from the patient perspective for treatment decisions in moderate-to-severe rheumatoid arthritis.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, Washington, DC Nov 11-16, 2016.

*Authors:* Husni ME, Griffith J, Betts K, Song Y, Ganguli A.

**Incremental benefit of radiographic inhibition on long-term outcomes in patients with rheumatoid arthritis.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, Washington, DC Oct 11-16, 2016.

*Authors:* Keystone EC, Betts KA, Schlacher CA, Song Y, Ganguli A, Griffith J.

**Economic Evaluation of Timely versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US.**

*Publication:* Rheumatology Therapeutics 2016 09. doi: 10.1007/s40744-016-0042-2.

*Authors:* Strand V, Husni E, Griffith J, Zhou ZY, Signorovitch J, Ganguli A.

**Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia and Mexico.**

*Publication:* Journal of Medical Economics 2016 07: 1-49. e-pub ahead of print 2016/07/05; doi:

10.1080/13696998.2016.1209508.

*Authors:* Tundia N, Gustavo Kotze P, Rojas Serrano J, Mendes de Abreu M, Skup M, Macaulay D, Signorovitch J, Chaves L, Chao J, Bao Y.

**Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population.**

*Publication:* Journal of Medical Economics 2016 07; 19(7): 649-654. e-pub ahead of print 2016/02/07; doi:

10.3111/13696998.2016.1151433.

*Authors:* Bradford Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M.

**Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor-alpha and Interleukin Inhibitors in the Treatment of Active Ankylosing Spondylitis.**

*Publication:* Rheumatology Therapeutics 2016 07: 1-14. doi: 10.1007/s40744-016-0038-y.

*Authors:* Betts KA, Griffith J, Song Y, Mittal M, Joshi A, Wu EQ, Ganguli A.

**Prediction of flaring in rheumatoid arthritis patients upon biologics dose tapering: a chart review study in Taiwan.**

*Abstract:* European League Against Rheumatism Congress, London, UK Jun 8-11, 2016.

*Authors:* Chang C, Chen K, Chen Y, Cheng T, Hsu P, Lai N, Lan J, Lee C, Lee S, Lin H, Tsay G, Yen J, Tsai C, Garg V, Bao Y, Yang M, Wun EQ.

**Real-world Impact of Taiwan Health Policy on Dose Tapering and Withdrawing Biologics in Rheumatoid Arthritis Patients: A Retrospective Chart Review Study.**

*Abstract:* European League Against Rheumatism Congress, London, UK Jun 8-11, 2016.

*Authors:* Chang C, Chen K, Chen Y, Cheng T, Hsu P, Lai N, Lan J, Lee C, Lee S, Lin H, Tsay G, Yen J, Tsai C, Bao Y, Skup M, Yang M, Wu EQ, wGarg V.

**Relative efficacy of adalimumab versus secukinumab in active ankylosing spondylitis: A matching-adjusted indirect comparison.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, London, UK Jun 8-11, 2016.

*Authors:* Betts KA, Mittal M, Song J, Skup M, Joshi A.

**Economic Burden and Treatment Patterns of Cycling between Conventional Synthetic Disease-modifying Antirheumatic Drugs Among Biologic-treated Patients with Rheumatoid Arthritis.**

*Publication:* Clinical Therapeutics 2016 05; 38(5): 1205-1216. e-pub ahead of print 2016/04/06; doi: 10.1016/j.clinthera.2016.03.013.

*Authors:* Betts KA, Griffith J, Ganguli A, Li N, Douglas K, Wu EQ.

**Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.**

*Publication:* Advances in Therapy 2016 05; 33(5): 807-823. e-pub ahead of print 2016/04/17; doi: 10.1007/s12325-016-0318-5.

*Authors:* Zhou ZY, Griffith J, Du EX, Chin D, Betts KA, Ganguli A.

**Comparison of Annual Treatment Costs for Patients Treated with Infusion versus Injectable Biologics.**

*Abstract:* Academy of Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA Apr 19-22, 2016.

*Authors:* Skup M, Macaulay D, Wei J, Terasawa E, Chao J.

**An indirect comparison and cost per responder analysis of adalimumab, methotrexate and apremilast in the treatment of methotrexate-naïve patients with psoriatic arthritis.**

*Publication:* Current Medical Research and Opinion 2016 04; 32(4): 721-729. e-pub ahead of print 2016/01/09; doi: 10.1185/03007995.2016.1140026.

*Authors:* Betts KA, Griffith J, Friedman A, Zhou ZY, Signorovitch JE, Ganguli A.

**Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons in psoriatic disease patients.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Lewwohl M, Skup M, Sundaram M, Yang H, Faust E, Kageleiry A, Chao J, Wolf D.

**Effects of Adalimumab on Health-related Quality of Life in Psoriasis Patients With and Without Comorbid Psoriatic Arthritis: Value of Reducing PASI Scores and Systemic Inflammation.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington DC March 4-8, 2016.

*Authors:* Okun M, Yang M, Koo V, Sundaram M, Signorovitch J.

**Evaluation of timely versus delayed use of tumor necrosis factor inhibitors in the treatment of psoriatic arthritis: Economic and clinical results from a modeling study.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Strand V, Husni ME, Griffith J, Zhou ZY, Signorovitch J, Ganguli A.

**Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor, Interleukin, and Phosphodiesterase Inhibitors in the Treatment of Psoriatic Arthritis.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington DC Mar 4-8, 2016.

*Authors:* Strand V HM, Betts K, Griffith J, Song Y, Beppu M, Ganguli A.

**Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: A matching-adjusted indirect comparison.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Betts K, Mittal M, Joshi A, Song J, Bao Y.

**ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.**

*Publication:* Rheumatology 2016 01; 55(1): 80-88. doi: 10.1093/rheumatology/kev267.

*Authors:* van der Heijde D, Joshi A, Pangan AL, Chen N, Betts K, Mittal M, Bao Y.

**Comorbidity burden and medication use among patients with psoriatic arthritis in the US.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting San Francisco, CA Nov 6-11, 2015.

*Authors:* Merola J, Han S, Xie J, Song H, Herrera V, Wei J, Wu EQ, Palmer JB.

**Economic Burden and Treatment Patterns of Cycling between Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) among Patients with Rheumatoid Arthritis (RA).**

*Abstract:* ACR Annual Meeting, San Francisco, CA Nov 6-11, 2015.

*Authors:* Li N, Betts KA, Griffith J, Ristovska L, Douglas K, Ganguli A.

**Economic Impact of Expanded Use of Biologic Therapy for Crohn's Disease In Latin American Countries.**

*Abstract:* ISPOR 5th Latin America Conference, Santiago, Chile Sept 6-8, 2015.

*Authors:* Kotze PG, Tundia N, Gumen A, Macaulay D, Chaves L, Bao Y.

**Network Meta-Analysis of Tumor Necrosis Factor, Interleukins, and Phosphodiesterase-4 Inhibitor in the Treatment of Psoriatic Arthritis.**

*Abstract:* ACR/ARHP Annual Meeting, San Francisco, CA Nov 7-11, 2015.

*Authors:* Strand V, Husni ME, Reichmann W, Betts K, Griffith J, Song Y, Beppu M, Ganguli A.

**Relative efficacy of adalimumab versus secukinumab in active psoriatic arthritis: A matching-adjusted indirect comparison.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting, San Francisco, CA Nov 6-11, 2015.

*Authors:* Betts KA, Mittal M, Joshi A, Song J, Bao Y.

**Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured population in the US.**

*Abstract:* AMCP Nexus 2015, Orlando, FL Oct 26-29, 2015.

*Authors:* Bradford Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M.

**Impact of Taiwan health policy for dose tapering and withdrawing biologics in rheumatoid arthritis patients: A real-world chart review study.**

*Abstract:* 17th Congress of the Asia Pacific League of Associations for Rheumatology in Conjunction with IRA Annual Congress, Chennai, India Sep 6-9, 2015.

*Authors:* Chang CC, Chen KH, Chen YH, Cheng TT, Hsu PN, Lai NS, Lan JL, Lee CS, Lee SS, Lin HY, Tsay GJ, Yen JH, Bao YJ, Tundia N, Yang M, Macaulay D, Huang YC, Garg V.

**Projected economic impact of increased use of biologic treatments for rheumatoid arthritis in Argentina, Colombia, and Mexico over 10 years.**

*Abstract:* ISPOR 5th Latin America Conference, Santiago, Chile Sep 6-8, 2015.

*Authors:* Rojas Serrano J, de Abreu M, Tundia N, Skup M, Sorg R, Macaulay D, Bao Y, Chaves L, Chao J.

**Short-term clinical outcomes and healthcare resource utilization in patients with rheumatoid arthritis tapering anti-TNF agents in Taiwan.**

*Abstract:* 17th Asia Pacific League of Associations for Rheumatology Congress, Chennai, India Sep 6-9, 2015.

*Authors:* Chang C, Chen K, Chen Y, Cheng T, Hsu P, Lai N, Lan J, Lee C, Lee S, Lin H, Tsay G, Yen J, Bao Y, Tundia N, Yang M, Macaulay D, Huang Y, Garg Vishvas.

**Real-world treatment patterns of gout patients treated with colchicine or other common treatments for gout in acute care settings: a retrospective chart review study.**

*Publication:* Current Medical Research and Opinion 2015 08; 31(8): 1611-1620. doi: 10.1185/03007995.2015.1062750.

*Authors:* Shiozawa A, Cloutier M, Heroux J, Guerin A, Wu EQ, Jackson R.

**Assessment of salary growth in patients with ankylosing spondylitis treated with and without anti-tumor necrosis factor therapy.**

*Abstract:* European League Against Rheumatism Congress, Rome, Italy Jun 10-13, 2015.

*Authors:* Deodhar A, Mittal M, Joshi A, Signorovitch JE, Yang M, Bao Y.

**Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.**

*Publication:* Arthritis Care Res (Hoboken) 2015 05; 67(5): 708-717. doi: 10.1002/acr.22492.

*Authors:* Feldman SR, Zhao Y, Shi L, Tran MH, Lu J.

**Economic evaluation of timely versus delayed use of anti-tumor necrosis factor (TNF) biologics in the treatment of psoriatic arthritis (PSA) in the US.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Zhou Z, Signorovitch JE, Griffith JM, Zhong Y, Ganguli A.

**Comparison of Annual Treatment Costs for Patients Treated with Infusion versus Injectable Biologics.**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA Apr 7-10, 2015.

*Authors:* Macaulay D, Wei J, Terasawa E.

**Indirect Treatment Comparison of Adalimumab, Etanercept, Certolizumab, Golimumab, and Infliximab for the Treatment of Ankylosing Spondylitis.**

San Diego, CA Apr 7-10, 2015.

*Authors:* Betts KA, K. H.

**Network Meta-Analysis and Cost per Responder of Tumor Necrosis Factor and Phosphodiesterase Inhibitors in the Treatment of Psoriatic Arthritis.**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA Apr 7-10, 2015.

*Authors:* Betts K, Reichmann W, Guo J.

**Comorbid psoriatic arthritis significantly impairs health-related quality of life in patients with moderate to severe psoriasis.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 20-24, 2015.

*Authors:* Kimball AB, Sundaram M, Signorovitch J, Yang M, Taska B.

**Rates and risk factors of PsA disease progression amongst newly diagnosed PsA patients.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 20-24, 2015.

*Authors:* Merolola J, Guerin A, Sundaram M, Jarvis J, Cummings AK, Ghorayeb E.

**Clinical outcomes associated with switching or discontinuation of anti-TNF inhibitors for non-medical reasons.**

*Abstract:* 10th Congress of the European Crohn's and Colitis Organisation, Barcelona, Spain Feb 18-21, 2015.

*Authors:* Wolf D, Skup M, Yang H, Faust E, Kageleiry A, Chao J, Lebwohl M.

**Assessment of income growth in patients with rheumatoid arthritis treated with anti-tumor necrosis factor therapy.**

*Publication:* Journal of Medical Economics 2015 01; 18(1): 37-44. doi: 10.3111/13696998.2014.925465.

*Authors:* Bergman M, De G, Ganguli A, Signorovitch J, Bao Y.

**Economic implications of flares among patients with early rheumatoid arthritis (ra).**

*Abstract:* 2014 ACR/ARHP Annual Meeting, Boston, MA Nov 14-19, 2014.

*Authors:* Signorovitch J, Betts K, Garg V, Bao Y.

**An indirect comparison and cost per responder analysis of adalimumab, methotrexate (MTX) and apremilast in the treatment of MTX-naïve psoriatic arthritis (PSA) patients.**

*Abstract:* 2014 ACR/ARHP Annual Meeting Boston, MA Nov 14-19, 2014.

*Authors:* Strand V, Griffith J, Betts K, Friedman A, Signorovitch J, Ganguli A.

**Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment.**

*Abstract:* International Congress of Drug Therapy in HIV Infection 2014 Glasgow, UK Nov 2-6, 2014.

*Authors:* Sweet D, Song J, Zhong Y, Signorovitch J.

**Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs.**

*Publication:* Arthritis Research & Therapy 2014 08; 16(4): 420. doi: 10.1186/s13075-014-0420-5.

*Authors:* Zhang HF, Gauthier G, Hiscock R, Curtis JR.

**ASAS40 and ASDAS responses are associated with improved physical function, HRQOL, and work productivity in patients with non-radiographic axial spondyloarthritis.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Paris, France June 11-14, 2014.

*Authors:* Van Der Heijde D, Joshi A, Mittal M, Pangan A, Chen N, Betts K, Qi C, Bao Y.

**Claims database analysis of adherence to adalimumab therapy and health care costs for patients with rheumatoid arthritis.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Paris, France Jun 11-14, 2014.

*Authors:* Liu Y, Tundia N, Skup M, Ayyagari R, Du EX, Chao J, Mulani P, Bao Y.

**A prediction model that identifies patients most likely to benefit from first-line therapy with adalimumab plus methotrexate in early rheumatoid arthritis.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Paris, France Jun 11-14, 2014.

*Authors:* Van Vollenhoven RF, Betts K, Signorovitch J, Bao C, Shaw JW, Ganguli A.

**Real-world risk of fall-related injuries among rheumatoid arthritis (RA) patients treated with tumor necrosis factor inhibitors (anti-TNFs) or methotrexate (MTX).**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Paris, France Jun 11-14, 2014.

*Authors:* Bao Y, Ganguli A, De G, Kelkar S, Curtis JR.

**Real-world persistence with single versus multiple tablet regimens for HIV-1 treatment.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Sweet DE, Kim Y, Song J, Zhong Y, Signorovitch J.

**The economic burden of osteoarthritis in Americans: Analysis from a privately insured population.**

*Abstract:* 2014 Osteoarthritis Research Society International World Congress, Paris, France Apr 24-27, 2014.

*Authors:* Wang SX, Ganguli AX, Macaulay D, Reichmann W, Medema JK, Cifaldi MA.

**Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes.**

*Publication:* Appl Health Econ Health Policy 2014 04; 12(2): 179-190. doi: 10.1007/s40258-014-0085-x.

*Authors:* Oglesby A, Korves C, Laliberte F, Dennis G, Rao S, Suthoff ED, Wei R, Duh MS.

**Real-world treatment patterns during and after an emergency room or acute care facility visit for gout.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Krishnan E, Cloutier M, Guérin A, Héroux J.

**Incremental burden of psoriatic arthritis is substantial among patients with mild and moderate to severe psoriasis.**

*Abstract:* 72nd Annual Meeting of the American Academy of Dermatology, Denver, CO Mar 21-25, 2014.

*Authors:* Merola J, Guerin A, Jarvis JL, Wang K, Sundaram M.

**Cost-per-responder analysis of biological agents for the treatment of active ankylosing spondylitis in Germany.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin, Ireland Nov 2-6, 2013.

*Authors:* Betts KA, Joshi AD, Yan SY, Zhou Z, Rao S, Wolff M, Cifaldi M.

**Indirect comparison of joint damage prevention with adalimumab v. Abatacept, each in combination with methotrexate, in early rheumatoid arthritis.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin, Ireland Nov 2-6, 2013.

*Authors:* Wu EQ, Cifaldi M, Diener M, Kaltenboeck A, Ganguli A, Bergman M.

**Assessment of wage and salary growth in patients with rheumatoid arthritis (RA).**

*Abstract:* American College of Rheumatology Annual Scientific Meeting San Diego, CA Oct 25-30, 2013.

*Authors:* Bergman MJ, De G, Ganguli A, Signorovitch J, Bao Y.

**Cost-effectiveness of different treatment sequences including adalimumab in the treat-to-target framework for early rheumatoid arthritis in Germany.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting San Diego, CA Oct 25-30, 2013.

*Authors:* Wolff M, Zhou ZY, Signorovitch J, Shaw JW, Ganguli A.

**The economic burden of osteoarthritis in Americans: Analysis from a privately insured population.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting San Diego, CA Oct 25-30, 2013.

*Authors:* Wang SX, Ganguli AX, Macaulay D, Reichmann W, Medema J, Cifaldi MA.

**Spondyloarthritis epidemiology and burden phase 2 [speed 2] study: Disease progression in axial spondyloarthropathy (SpA).**

*Abstract:* American College of Rheumatology Annual Scientific Meeting San Diego, CA Oct 25-30, 2013.

*Authors:* Ruderman E, Strand V, Joshi A, Bao Y, Betts K, Chopra P, McGuire MB, Rao SA.

**Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.**

*Publication:* QJM 2013 08; 106(8): 721-729. doi: 10.1093/qjmed/hct093.

*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L.

**Serum urate and incidence of kidney disease among veterans with gout.**

*Publication:* Journal of Rheumatology 2013 07; 40(7): 1166-1172. doi: 10.3899/jrheum.121061.

*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu E, Tawk RH, Liu J, Shi L.

**Clinical outcomes and healthcare utilization following early versus late diagnosis of systemic lupus.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism Berlin, Germany Jun 6-9, 2012.

*Authors:* Korves C, Laliberte F, Suthoff E, Wei R, Oglesby A, Dennis G, Duh MS.

**Effect of adalimumab on physical function, health-related quality of life, and work productivity in patients with peripheral spondyloarthritis: Results from the ability-2 clinical trial.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Madrid, Spain Jun 12-15, 2013.

*Authors:* Mease PJ, Rao S, Betts KA, Lu M, Fan L, Pangan AL, Van Der Heijde D, Cifaldi MA.

**The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

*Authors:* Burmester G, Emery P, Signorovitch J, Williams D, Valdes J, Bao Y, Mulani PM.

**Progression from undifferentiated spondyloarthritis to ankylosing spondylitis: Is USPA a proxy for non-radiographic axial SPA?**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

*Authors:* Boonen A, Kirson NY, Rao SA, Birnbaum HG, Swallow E, Yushkina Y, Jarvis J, Mease PJ, Cifaldi MA.

**Switching from adalimumab to other disease-modifying antirheumatic drugs without apparent medical reasons in rheumatoid arthritis: Impact on health care service use.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

*Authors:* Signorovitch J, Bao Y, Samuelson T, Mulani PM.

**Treatment patterns in psoriatic arthritis (PSA) patients newly initiated on oral disease-modifying anti-rheumatic drugs (DMARDs).**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

*Authors:* Zhang F, Guerin A, Gauthier G, Curtis J.

**Use of anti-TNF therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

*Authors:* Nurmohamed MT, Bao Y, Signorovitch J, Mulani PM, Furst DE.

**Health care resource utilization (HRU) and costs associated with disease activity in systemic lupus erythematosus (SLE): A retrospective observational cohort analysis.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Kan H, Guerin A, Kaminsky M, Yu AP, Wu EQ, Denio AE, Jhingran PM, Narayanan S, Molta CT.

**A longitudinal analysis of costs associated with change in disease activity in systemic lupus erythematosus.**

*Publication:* Journal of Medical Economics 2013 05; 16(6): 793-800. doi: 10.3111/13696998.2013.802241.

*Authors:* Kan H, Guerin A, Kaminsky MS, Yu AP, Wu EQ, Denio A, Priti J, Narayanan S, Molta C.

**Matching-adjusted indirect comparison of lipid profile at 48 weeks among treatment naive HIV-1 patients treated with atazanavir/ritonavir versus darunavir/ritonavir.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Xie J, Juday TR, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

**Matching-adjusted indirect comparison of adalimumab vs etanercept and infliximab for the treatment of psoriatic arthritis.**

*Publication:* Journal of Medical Economics 2013 02; 16(4): 479-489. doi: 10.3111/13696998.2013.768530.

*Authors:* Kirson NY, Rao S, Birnbaum HG, Kantor E, Wei RS, Cifaldi M.

**Benefits of treat-to-target guideline compliance in patients with rheumatoid arthritis: A retrospective claims analysis.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

*Authors:* Bergman MJ, Shaw JW, Cifaldi MA, Guerin A, Chopra P, Signorovitch J.

**Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.**

*Publication:* American Journal of Therapeutics 2012 11; 19(6): e157-166. doi: 10.1097/MJT.0b013e31820543c5.

*Authors:* Wu EQ, Forsythe A, Guerin A, Yu AP, Latremouille-Viau D, Tsaneva M.

**Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).**

*Publication:* Inflammatory Bowel Diseases 2012 11; 18(11): 2043-2055. doi: 10.1002/ibd.22873.

*Authors:* Sussman DA, Kubiliun N, Mulani PM, Chao J, Gillis CA, Yang M, Lu M, M TA.

**Comparison of rheumatoid arthritis-related health care resource use and comorbidities among patients with rheumatoid arthritis treated with adalimumab vs etanercept.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

*Authors:* Xie J, Ganguli A, Yang H, Parikh K, Wu EQ, Cifaldi M.

**Differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012, Washington, DC Nov 9-14,, 2012.

*Authors:* Van Vollenhoven RF, Shaw JW, Cifaldi MA, Signorovitch J, Wu EQ, Samuelson T, Faust E, Emery P.

**Health care costs in psoriatic arthritis (PSA) patients newly initiated on a biologic disease-modifying anti-rheumatic drug (DMARDs) or methotrexate (MTX).**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Zhang F, Hiscock R, Curtis J.



**Healthcare costs in psoriatic arthritis patients newly initiated on a biologic disease-modifying anti-rheumatic drug or methotrexate.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

*Authors:* Zhang F, Hiscock R, Curtis J.

**Patient-reported outcomes associated with achieving and maintaining low disease activity in rheumatoid arthritis.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14 2012.

*Authors:* Bergman MJ, Shaw JW, Cifaldi M, De G, He T, Ayyagari R, Signorovitch J.

**Risk differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone.**

*Abstract:* 2012 ACR/ARHP Annual Meeting, Washington, DC Nov 9-14, 2012.

*Authors:* Van Vollenhoven R, Shaw JW, Cifaldi MA, Signorovitch JE, Wu EQ, Samuelson TM, Faust E, Emery P.

**Treatment patterns in psoriatic arthritis (PSA) patients newly initiated on non-biologic disease modifying anti-rheumatic drugs (DMARDS).**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Curtis J, Gauthier G, Hiscock R, Zhang F.

**Treatment patterns in psoriatic arthritis patients newly initiated on non-biologic disease-modifying anti-rheumatic drugs.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

*Authors:* Curtis J, Gauthier G, Hiscock R, Zhang F.

**Use of anti-tumor necrosis factor therapy is associated with reduced cardiovascular event risk in rheumatoid arthritis.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Washington, DC Nov 9-14, 2012.

*Authors:* Nurmohamed MT, Bao Y, Signorovitch J, Mulani PM, Furst DE.

**Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain.**

*Publication:* Pain Medicine 2012 09; 13(9): 1110-1120. doi: 10.1111/j.1526-4637.2012.01454.x.

*Authors:* Kavanagh S, Kwong W, Hammond G, Nelson W, Upmalis D, Yang M.

**Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.**

*Publication:* Pain Pract 2012 09; 12(7): 533-540. doi: 10.1111/j.1533-2500.2011.00526.x.

*Authors:* Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R.

**Adherence to subcutaneous vs. Oral disease-modifying antirheumatic drugs in rheumatoid arthritis.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

*Authors:* Bergman M, Bao Y, Ayyagari R, Mulani PM.

**Impact of early versus late systemic lupus erythematosus (SLE) diagnosis on clinical and economic outcomes.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Oglesby AK, Dennis GL, Korves C, Laliberte F, Suthoff ED, Wei R, Duh MS.

**Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

**Variation in the use of biologics in the management of rheumatoid arthritis across the United Kingdom.**

*Abstract:* British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meeting, Glasgow, UK May 1-3, 2012.

*Authors:* Choy E, McAuliffe S, Roberts K, Sargeant I.

**Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006.**

*Publication:* Pharmacoeconomics 2012 04; 30(4): 323-336. doi: 10.2165/11589470-000000000-00000.

*Authors:* Birnbaum HG, Pike C, Banerjee R, Waldman T, Cifaldi M.

**Glucocorticoid-induced tumor necrosis factor receptor family-related protein exacerbates collagen-induced arthritis by enhancing the expansion of Th17 cells.**

*Publication:* American Journal of Pathology 2012 03; 180(3): 1059-1067. doi: 10.1016/j.ajpath.2011.11.018.

*Authors:* Wang S, Shi Y, Yang M, Ma J, Tian J, Chen J, Mao C, Jiao Z, Ko KH, Baidoo SE, Xu H, Hua Z, Lu L.

**Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.**

*Abstract:* 70th Annual Meeting of the American Academy of Dermatology, San Diego, CA Mar 16-20, 2012.

*Authors:* Guerin A, Zhang F, Gauthier G, Day R, Khan Z.

**Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE.**

*Abstract:* 7th Congress of ECCO European Crohn's and Colitis Organization, Barcelona, Spain Feb 16-18, 2012.

*Authors:* Sandborn WJ, Colombel J-F, Louis E, Panaccione R, Yang M, Chao J, Thakkar R, Robinson A, Pollack P, Mulani PM.

**Economic burden of psoriatic arthritis and diabetes in patients with psoriatic arthritis in the United States.**

*Abstract:* ACR/ARHP Annual Scientific Meeting, Chicago, IL Nov 4-9, 2011.

*Authors:* Guérin A, Gauthier G, Day R, Khan Z, Zhang F.

**Economic burden of psoriatic arthritis and obesity in patients with psoriatic arthritis in the United States.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.

*Authors:* Zhang F, Guerin A, Latremouille-Viau D, Day RR, Khan Z.

**Prevalence of autoimmune diseases and other comorbidities in patients with psoriatic arthritis in the United States.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.

*Authors:* Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

**Uncontrolled serum uric acid in veteran gout patients is associated with a higher risk of diabetes.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.

*Authors:* Pandya BJ, Marynchenko M, Sharma H, Yu A, Wu E, Shi L, Liu J.

**Uncontrolled serum uric acid is associated with an increased risk of developing renal disease in veterans with gout.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.

*Authors:* Krishnan E, Sharma H, Pandya BJ, Marynchenko M, Yu A, Wu E, Liu J.

**Biologic disease-modifying drug treatment patterns and associated costs for patients with rheumatoid Arthritis.**

*Publication:* Journal of Rheumatology 2011 10; 38(10): 2141-2149. doi: 10.3899/jrheum.101195.

*Authors:* McBride S, Sarsour K, White LA, Nelson DR, Chawla AJ, Johnston JA.

**Economic model of workplace impacts of anti-TNF therapy for rheumatoid arthritis in Brazil.**

*Abstract:* ISPOR 3rd Latin America Conference Mexico City, Mexico Sep 8-10, 2011.

*Authors:* Teich V, Chaves L, Birnbaum H, Pike C, Waryas C, Cifaldi M.

**Indirect comparison of adalimumab versus etanercept for the treatment of psoriatic arthritis.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Kirson NR, S.; Birnbaum, H. G.; Kantor, E.; Wei, R.; Cifaldi, M.

**Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.**

*Abstract:* 30th Annual Scientific Meeting of the American Pain Society, Austin, TX May 19-21, 2011.

*Authors:* Swindle R, Birnbaum H, Ivanova J, Schiller M, Waldman T, Mullen R, Reed C.

**Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (Compairs).**

*Abstract:* Annual General Meeting of the British Society of Gastroenterology Conference, Birmingham, UK Mar 14-17, 2011.

*Authors:* Sussman DA, Kubiliun N, Chao J, Mulani PM, Gillis CA, Yang M, Lu M, Abreu MT.

**Refractory gout brings economic pain.**

*Publication:* PharmacoEconomics & Outcomes News 2011 03; 623: 5.

*Authors:* Wu E.

**Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-alpha inhibitors.**

*Publication:* Arthritis Research & Therapy 2011 02; 13(1): R25. doi: 10.1186/ar3249.

*Authors:* Rendas-Baum R, Wallenstein GV, Koncz T, Kosinski M, Yang M, Bradley J, Zwillich SH.

**Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.**

*Publication:* Dermatology 2010 11; 220(1): 1-7. doi: 10.1159/000260371.

*Authors:* Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

**Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (compairs).**

*Abstract:* 75th Annual Scientific Meeting of the American College of Gastroenterology, San Antonio, TX Oct 15-20, 2010.

*Authors:* Sussman D, Kubiliun N, Chao J, Mulani P, Gillis C, Yang M, Lu M, Abreu M.

**Direct and indirect costs of spondyloarthritis patients pre-and post-diagnosis.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting Philadelphia, PA Oct 16-21, 2009.

*Authors:* Kirson N, Birnbaum H, Rao S, Swallow E, Waldman T, Dayoub E, Cifaldi M.

**Evaluation of cardiovascular diseases (CVDs) risk for patients with fibromyalgia syndrome in the United States.**

*Abstract:* 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Brighton, UK Aug 19-22, 2010.

*Authors:* Mease PJ, Duh MS, Vekeman F, Lefebvre P, Laliberte F, Boerstoeel-Streefland M, Jiang W, Zimetbaum PJ.

**Diagnostic and resource use profiles before and after diagnosis of spondyloarthritis.**

*Abstract:* European League Against Rheumatism Congress, Rome, Italy Jun 16-19, 2010.

*Authors:* Kirson N, Birnbaum H, Rao S, Swallow K, Waldman T, Dayoub E, Cifaldi M.

**Longer psoriasis duration is independently associated with greater persistent functional impairment in patients with psoriatic arthritis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Signorovitch J, Mulani P, Bao Y.

**Societal cost of rheumatoid arthritis patients in the US.**

*Publication:* Current Medical Research and Opinion 2010 01; 26(1): 77-90. doi: 10.1185/03007990903422307.

*Authors:* Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M.

**Changes in health care utilization and costs for employed patients with rheumatoid arthritis from 1997-2006.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting Atlanta, GA Nov 6-11, 2010.

*Authors:* Birnbaum H, Pike C, Banerjee R, Waldman T, Cifaldi M.

**The costs of treatment failure gout: A claims-based analysis.**

*Abstract:* American College of Rheumatology Annual Scientific Meeting Atlanta, GA Nov 6-11, 2010.

*Authors:* Wu EQ, Yu AP, Guerin A, Latremouille-Viau D, Tsaneva M, Forsythe A.

**Employer model of workplace impacts of anti-TNF therapy for rheumatoid arthritis.**

*Publication:* Journal of Occupational Environmental Medicine 2009 10; 51(10): 1167-1176. doi: 10.1097/JOM.0b013e3181b8c397.

*Authors:* Birnbaum H, Pike C, Kaufman R, Cifaldi M.

**Frequency, risk, and cost of gout-related episodes among the elderly: does serum uric acid level matter?**

*Publication:* Journal of Rheumatology 2009 05; 36(5): 1032-1040. doi: 10.3899/jrheum.080487.

*Authors:* Wu EQ, Patel PA, Mody RR, Yu AP, Cahill KE, Tang J, Krishnan E.

**Societal cost of rheumatoid arthritis (RA) in the United States: Methodology for incorporating intangible costs.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M.

**Impact of adalimumab treatment in the workplace in patients with rheumatoid arthritis.**

*Abstract:* British Society for Rheumatology and British Health Professionals in Rheumatology Annual Meeting, Glasgow, UK Apr 28 - May 1, 2009.

*Authors:* Cifaldi MA, Birnbaum H, Pike C, Kaufman R, Schiller M, Shi L, Sun P, Ray S.

**Adalimumab reduces symptoms of depression in patients with moderate to severe psoriasis.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Menter A, Signorovitch J, Mulani P, Gupta S.

**Adalimumab reduces symptoms of psoriatic arthritis among psoriasis patients with comorbid psoriatic arthritis.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Mease P, Signorovitch J, Mulani P, Gupta S.

**The effect of adalimumab treatment for moderate to severe psoriasis on concurrent response for both psoriasis and psoriatic arthritis.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 3-10, 2009.

*Authors:* Mease P, Signorovitch J, Mulani P, Gupta S.

**Workplace impacts of anti-TNF therapies in rheumatoid arthritis: review of the literature.**

*Publication:* Expert Opinion on Pharmacotherapy 2009 02; 10(2): 255-269. doi: 10.1517/14656560802682163.

*Authors:* Birnbaum H, Shi L, Pike C, Kaufman R, Sun P, Cifaldi M.

**Direct and indirect costs of pain therapy for osteoarthritis in an insured population in the United States.**

*Publication:* Journal of Occupational and Environmental Medicine 2008 09; 50(9): 998-1005. e-pub ahead of print 2008/09/12; doi: 10.1097/JOM.0b013e3181715111.

*Authors:* White AG, Birnbaum HG, Janagap C, Buteau S, Schein J.

**Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis.**

*Publication:* Current Medical Research and Opinion 2008 08; 24(8): 2229-2240. doi: 10.1185/03007990802229548.

*Authors:* Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.

**Disease-related and all-cause health care costs of elderly patients with gout.**

*Publication:* Journal of Managed Care Pharmacy 2008 03; 14(2): 164-175.

*Authors:* Wu EQ, Patel PA, Yu AP, Mody RR, Cahill KE, Tang J, Krishnan E.

**Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data.**

*Publication:* Current Medical Research and Opinion 2007 08; 23(8): 1749-1759. doi: 10.1185/030079907X210615.

*Authors:* Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M.

**Cost and Risk of Gout Flares among the Elderly: Does Serum Uric Acid Level Matter?**

*Abstract:* American Geriatrics Society Annual Scientific Meeting, Seattle, WA May 2-6, 2007.

*Authors:* Wu EQ, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R.

**Healthcare Cost of Gout in an Elderly Population: A Claims Database Analysis.**

*Abstract:* American Geriatrics Society Annual Scientific Meeting, Seattle, WA May 2-6, 2007.

*Authors:* Wu EQ, Patel P, Krishnan E, Yu AP, Cahill KE, Tang J, Mody R.

**Treatment Cost of Gout in an Elderly Population: A Claims Database Analysis.**

*Abstract:* American Geriatrics Society Annual Scientific Meeting, Seattle, WA May 2-6, 2007.

*Authors:* Wu EQ, Patel P, Krishnan E, Yu AP.

**Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial.**

*Publication:* Rheumatology 2006 10; 45(10): 1238-1246. doi: 10.1093/rheumatology/kei066.

*Authors:* Westhovens R, Cole JC, Li T, Martin M, Maclean R, Lin P, Blaisdell B, Wallenstein GV, Aranda R, Sherrer Y.

**Tighter control of serum uric acid in gout is associated with lower morbidity and health care costs.**

*Publication:* Arthritis and Rheumatism 2006 09; 54(9): S332-S332.

*Authors:* Wu EQ, Mody RR, Krishnan E, Yu AP, Cahill KE, Tang J, Patel PA.

**Book Section: Linking administrative claims data with archival productivity measures to inform employer decision making.** In: Kessler R, Stang P (eds).

*Book Title:* *Health and Work Productivity: Emerging Issues in Research and Policy.* University of Chicago Press: Chicago, IL, 2006.

*Authors:* Greenberg PE, Birnbaum HG.

**Direct and indirect costs of rheumatoid arthritis to an employer.**

*Publication:* Journal of Occupational Environmental Medicine 2000 06; 42(6): 588-596.

*Authors:* Birnbaum HG, Barton M, Greenberg PE, Sisitsky T, Auerbach R, Wanke LA, Buatti MC.

## Cardiovascular

### **Adherence to heart failure management medications following cardiac resynchronization therapy.**

*Publication:* Current Medical Research and Opinion 2019 09; 1. e-pub ahead of print 2019/09/20; doi: 10.1080/03007995.2019.1670474.

*Authors:* Shah BR, DerSarkissian M, Tsintzos SI, Xiao Y, May D, Lu X, Kinrich D, Davis E, Lefebvre P, Duh MS, Dasta JF.

### **Factors that impact a patient's experience when undergoing single-photon emission computed tomography myocardial perfusion imaging (SPECT-MPI) in the US: A survey of patients, imaging center staff, and physicians.**

*Publication:* Journal of Nuclear Cardiology 2019 08. e-pub ahead of print 2019/08/31; doi: 10.1007/s12350-019-01863-0.

*Authors:* Li J, Walker DR, Biesbrock G, Kristy RM, Yang H, Gao E, Koenigsberg S, Spalding JR, Kitt TM.

### **Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial.**

*Publication:* JACC Heart Fail 2019 08; 7(8): 717-724. e-pub ahead of print 2019/07/16; doi: 10.1016/j.jchf.2019.03.019.

*Authors:* Kristensen SL, Levy WC, Shadman R, Nielsen JC, Haarbo J, Videbaek L, Bruun NE, Eiskjaer H, Wiggers H, Brandes A, Thøgersen AM, Hassager C, Svendsen JH, Hofsten DE, Torp-Pedersen C, Pehrson S, Signorovitch J, Kober L, Thune JJ.

### **Risk of Ischemic Stroke in Patients Newly Diagnosed With Heart Failure: Focus on Patients Without Atrial Fibrillation.**

*Publication:* Journal of Cardiac Failure 2019 06; 25(6): 436-447. doi: <http://dx.doi.org/10.1016/j.cardfail.2018.03.012>.

*Authors:* Berger JS, Peterson E, Lalibert EF, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir MR.

### **Cardiac arrhythmia detection outcomes among patients monitored with the Zio patch system: a systematic literature review.**

*Publication:* Current Medical Research and Opinion 2019 05; 1-12. e-pub ahead of print 2019/05/03; doi: 10.1080/03007995.2019.1610370.

*Authors:* Yenikomshian M, Jarvis J, Patton C, Yee C, Mortimer R, Birnbaum H, Topash M.

### **Healthcare costs of stroke and major bleeding in patients with atrial fibrillation treated with non-vitamin K antagonist oral anticoagulants.**

*Publication:* Journal of Medical Economics. 2019 05; 1-9. e-pub ahead of print 2019/04/04; doi: <http://dx.doi.org/10.1080/13696998.2019.1603156>.

*Authors:* Rozjabek HM, Coleman CI, Ashton V, Laliberte F, Oyefesobi P, Lejeune D, Germain G, Schein JR, Yuan Z, Lefebvre P, Peterson ED.

### **The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure.**

*Publication:* Europace: European Pacing, Arrhythmias, and Cardiac Electrophysiology 2019 04. e-pub ahead of print 2019/07/20; doi: 10.1093/europace/euz114.

*Authors:* Rorth R, Thune JJ, Nielsen JC, Haarbo J, Videbaek L, Korup E, Signorovitch J, Bruun NE, Eiskjaer H, Hassager C, Svendsen JH, Hofsten DE, Torp-Pedersen C, Pehrson S, Kober L, Kristensen SL.

### **Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients.**

*Publication:* Current Medical Research and Opinion 2019 04; 35(4): 653-660. doi: <http://dx.doi.org/10.1080/03007995.2018.1530205>.

*Authors:* McHorney CA, Peterson ED, Ashton V, Laliberte F, Crivera C, Germain G, Sheikh N, Schein J, Lefebvre P.

**Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.**

*Publication:* Journal of Medical Economics 2019 03; 22(3): 280-287. e-pub ahead of print 2018/12/24; doi: 10.1080/13696998.2018.1562817.

*Authors:* Kamstra R, Durkin M, Cai J, Bookhart B, Lafeuille MH, Pilon D, Tiggelaar S, Manceur AM, Lefebvre P.

**Right Ventricular Dysfunction and the Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure.**

*Publication:* Circ Arrhythm Electrophysiol 2019 03; 12(3): e007022. e-pub ahead of print 2019/03/15; doi: 10.1161/CIRCEP.118.007022.

*Authors:* Elming MB, Hammer-Hansen S, Voges I, Nyktari E, Raja AA, Svendsen JH, Pehrson S, Signorovitch J, Kober LV, Prasad SK, Thune JJ.

**Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vs Aspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population.**

*Publication:* Chest 2018 12; 154(6): 1371-1378. doi: <http://dx.doi.org/10.1016/j.chest.2018.08.1059>.

*Authors:* Wells PS, Prins MH, Beyer-Westendorf J, Lensing AWA, Haskell L, Levitan B, Laliberte F, Ashton V, Xiao Y, Lejeune D, Crivera C, Lefebvre P, Zhao Q, Yuan Z, Schein J, Prandoni P.

**Healthcare costs in patients with cancer increase with increasing risk of venous thromboembolism.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Streiff MB, McCrae KR, Kuderer NM, Milentijevic D, Germain G, Laliberte F, Le N, Lefebvre P, Lyman GH, Khorana AA.

**The rate of venous thromboembolism in cancer patients varies by khorana risk category.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Khorana AA, Kuderer NM, McCrae KR, Milentijevic D, Germain G, Laliberte F, Le N, Lefebvre P, Lyman GH, Streiff MB.

**Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).**

*Publication:* Circulation 2018 10; 138(14): 1387-1398. e-pub ahead of print 2018/10/10; doi: 10.1161/CIRCULATIONAHA.117.033200.

*Authors:* Ho CY, Day SM, Ashley EA, Michels M, Pereira AC, Jacoby D, Cirino AL, Fox JC, Lakdawala NK, Ware JS, Caleshu CA, Helms AS, Colan SD, Girolami F, Cecchi F, Seidman CE, Sajeev G, Signorovitch J, Green EM, Olivetto I.

**An answer to "anticoagulant treatment of cancer-associated venous thromboembolism: Interpreting real-world data with caution".**

*Publication:* American Journal of Hematology 2018 09; 93(9): E225-E227. e-pub ahead of print 2018/06/16; doi: 10.1002/ajh.25165.

*Authors:* Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Lejeune D, Nelson WW, Laliberte F, Crivera C, Lefebvre P, Schein J, Khorana AA.

**Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.**

*Publication:* Cardiovascular Diabetology 2018 08; 17(1): 118. e-pub ahead of print 2018/08/26; doi: 10.1186/s12933-018-0759-z.

*Authors:* Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, Duh MS, Bookhart B, Wysham CH.

**Cost comparison of continued anticoagulation with rivaroxaban versus placebo based on the 1-year EINSTEIN-Extension trial efficacy and safety results.**

*Publication:* Journal of Medical Economics 2018 06; 21(6): 587-594. doi: <http://dx.doi.org/10.1080/13696998.2018.1444615>.

*Authors:* Wells PS, Lensing AWA, Haskell L, Levitan B, Laliberte F, Durkin M, Ashton V, Xiao Y, Crivera C, Lejeune D, Schein J, Lefebvre P.

**A retrospective study evaluating the tolerability and effectiveness of adjunctive antihypertensive drugs in patients with inadequate response to initial treatment.**

*Publication:* Journal of Clinical Hypertension (Greenwich, Conn.) 2018 06; 20(6): 1058-1066. e-pub ahead of print 2018/06/15; doi: 10.1111/jch.13312.

*Authors:* Ayyagari R, Xie J, Cheng D, Wu EQ, Huang XY, Chen S.

**Adherence to heart failure medications pre-and post-cardiac resynchronization therapy.**

*Abstract:* 39th Annual Scientific Sessions of the Heart Rhythm Society, Heart Rhythm 2018, Boston, MA May 9-12, 2018.

*Authors:* Shah B, DerSarkissian M, Xiao Y, Davis E, Kinrich D, Lefebvre P, Duh MS, May D, Tsintzos S, Dasta J.

**Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.**

*Publication:* American Journal of Hematology 2018 05; 93(5): 664-671. e-pub ahead of print 2018/02/06; doi: <http://dx.doi.org/10.1002/ajh.25059>.

*Authors:* Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW, Laliberte F, Crivera C, Lefebvre P, Schein J, Khorana AA.

**Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function.**

*Publication:* Clinical Nephrology 2018 05; 89(5): 314-329. doi: <http://dx.doi.org/10.5414/CN109281>.

*Authors:* Weir MR, Haskell L, Berger JS, Ashton V, Laliberte F, Crivera C, Brown K, Lefebvre P, Schein J.

**Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users.**

*Publication:* PloS One 2018 04; 13(4): e0194099. e-pub ahead of print 2018/04/06; doi: 10.1371/journal.pone.0194099.

*Authors:* McHorney CA, Crivera C, Laliberte F, Germain G, Wynant W, Lefebvre P.

**Community health workers improve disease control and medication adherence among patients with diabetes and/or hypertension in Chiapas, Mexico: an observational stepped-wedge study.**

*Publication:* BMJ Glob Health 2018 03; 3(1): e000566. e-pub ahead of print 2018/03/13; doi: 10.1136/bmjgh-2017-000566.

*Authors:* Newman PM, Franke MF, Arrieta J, Carrasco H, Elliott P, Flores H, Friedman A, Graham S, Martinez L, Palazuelos L, Savage K, Tymeson H, Palazuelos D.

**Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.**

*Publication:* Current Medical Research and Opinion 2018 02; 34(2): 275-284. doi: <http://dx.doi.org/10.1080/03007995.2017.1409200>.

*Authors:* Kaatz S, Coleman CI, Bookhart B, Laliberte F, Nelson WW, Brown K, Martin S, Schein J, Lefebvre P.

**Clinical outcomes of prolonged anticoagulation with rivaroxaban after unprovoked venous thromboembolism.**

*Publication:* Research and Practice in Thrombosis and Haemostasis 2018 01; 2(1): 58-68. doi: <http://dx.doi.org/10.1002/rth2.12050>.

*Authors:* Berger JS, Seheult R, Laliberte F, Crivera C, Lejeune D, Xiao Y, Schein J, Lefebvre P, Kaatz S.



**Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.**

*Publication:* Menopause 2018 25(11): 1297-1305. doi: <http://dx.doi.org/10.1097/GME.0000000000001232>.

*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

**Healthcare costs associated with venous thromboembolism in cancer patients treated with anticoagulants.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Streiff MB, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Khorana AA.

**VTE recurrence and safety of anticoagulants among patients with cancer treated for venous thromboembolism.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff MB.

**Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure.**

*Publication:* Circulation 2017 11; 136(19): 1772-1780. e-pub ahead of print 2017/09/08; doi: 10.1161/CIRCULATIONAHA.117.028829.

*Authors:* Elming MB, Nielsen JC, Haarbo J, Videbaek L, Korup E, Signorovitch J, Olesen LL, Hildebrandt P, Steffensen FH, Bruun NE, Eiskjaer H, Brandes A, Thogersen AM, Gustafsson F, Egstrup K, Videbaek R, Hassager C, Svendsen JH, Hofsten DE, Torp-Pedersen C, Pehrson S, Kober L, Thune JJ.

**Anticoagulant treatment patterns for cancer-associated thrombosis in a commercial insurance population.**

*Abstract:* Resuscitation Science Symposium, Anaheim, CA Nov 11-15, 2017.

*Authors:* Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff M.

**Elevated b-type natriuretic peptide levels and cardiovascular outcomes in patients with heart failure across different ejection fraction levels.**

*Abstract:* Resuscitation Science Symposium, Anaheim, CA Nov 11-15, 2017.

*Authors:* Greenberg B, Berger JS, Peterson ED, Laliberte F, Zhao Q, Germain G, Lejeune D, Wu JW, Lefebvre P, Fonarow GC.

**Healthcare resource utilization associated with venous thromboembolism in cancer patients treated with anticoagulants in a commercial insurance population.**

*Abstract:* Resuscitation Science Symposium, Anaheim, CA Nov 11-15, 2017.

*Authors:* Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff M.

**Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.**

*Publication:* Current Medical Research and Opinion 2017 10; 33(10): 1891-1900. e-pub ahead of print 2017/06/08; doi: 10.1080/03007995.2017.1339674.

*Authors:* Weir MR, Berger JS, Ashton V, Laliberte F, Brown K, Lefebvre P, Schein J.

**Adherence to rivaroxaban compared with other oral anticoagulant agents among patients with nonvalvular atrial fibrillation.**

*Publication:* Journal of Managed Care and Specialty Pharmacy 2017 09; 23(9): 980-988. doi: <http://dx.doi.org/10.18553/jmcp.2017.23.9.980>.

*Authors:* McHorney CA, Ashton V, Laliberte F, Germain G, Wynant W, Crivera C, Schein JR, Lefebvre P, Peterson ED.

**Stroke and myocardial infarction risk among newly diagnosed heart failure patients with reduced, borderline, and preserved left ventricle ejection fraction.**

*Abstract:* 21st Annual Scientific Meeting of the Heart Failure Society of America, Grapevine, TX Sept 16-19, 2017.

*Authors:* Fonarow GC, Peterson ED, Greenberg B, Berger JS, Laliberte F, Zhao Q, Germain G, Lejeune D, Lefebvre P.

**Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests.**

*Publication:* Journal of Medical Economics 2017 08; 20(8): 777-785. e-pub ahead of print 2017/04/14; doi:

10.1080/13696998.2017.1314969.

*Authors:* Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ.

**Myocardial fibrosis and the effect of defibrillator implantation in patients with non-ischemic systolic heart failure - DANISH-MRI.**

*Abstract:* European Society of Cardiology, Barcelona, Spain Aug 26-30, 2017.

*Authors:* Elming MB, Hammer-Hansen S, Nyktari E, Voges I, Raja AA, Signorovitch J, Koeber L, Prasad S, Thune JJ.

**Current practice patterns and patient persistence with anticoagulant treatments for cancer-associated thrombosis.**

*Publication:* Research and Practice in Thrombosis and Haemostasis 2017 07; 1(1): 14-22. doi:

<http://dx.doi.org/10.1002/rth2.12002>.

*Authors:* Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Laliberte F, Crivera C, Lefebvre P, Yannicelli D, Schein J.

**Risk for Venous Thromboembolism Recurrence Among Rivaroxaban-treated Patients Who Continued Versus Discontinued Therapy: Analyses Among Patients with VTE.**

*Publication:* Clinical Therapeutics 2017 07; 39(7): 1396-1408. doi: <http://dx.doi.org/10.1016/j.clinthera.2017.05.357>.

*Authors:* Khorana AA, Berger JS, Wells PS, Seheult R, Ashton V, Laliberte F, Crivera C, Lejeune D, Schein J, Wildgoose P, Lefebvre P, Kaatz S.

**Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban.**

*Publication:* Current Medical Research and Opinion 2017 06; 33(6): 1033-1043. doi: 10.1080/03007995.2017.1297932.

*Authors:* Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberte F, Lefebvre P, Peterson ED.

**Impact of renal function on clinical outcomes among nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Weir MR, Haskell L, Berger JS, Ashton V, Laliberte F, Crivera C, Brown K, Lefebvre P, Schein JR.

**A single-center experience with low-dose warfarin in patients undergoing total hip or knee replacement surgery.**

*Publication:* Current Orthopaedic Practice 2017 05; 23(3): 221-228.

*Authors:* Balcom WB, Mishol DN, Eapen S, Bookhart BK, Nutescu EA, Schein JR, Duh MS.

**Adherence to rivaroxaban versus apixaban among patients with atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users.**

*Abstract:* American Heart Association's Quality of Care and Outcomes Research, Arlington, VA Apr 2-3, 2017.

*Authors:* McHorney CA, Crivera C, Laliberte F, Germain G, Wynant W, Lefebvre P.

**Impact of differences in once-vs twice-daily medications adherence on the risk of bleed and stroke in non-valvular atrial fibrillation: Analysis of randomized trials and claims data sources.**

*Abstract:* American Heart Association's Quality of Care and Outcomes Research, Arlington, VA Apr 2-3, 2017.

*Authors:* McHorney CA, Peterson ED, Durkin M, Ashton V, Laliberte F, Crivera C, Sheikh N, Germain G, Schein JR, Xiao Y, Lefebvre P.

**Importance of balanced follow-up time and other study design considerations when evaluating adherence using two novel oral anticoagulants.**

*Abstract:* American Heart Association's Quality of Care and Outcomes Research, Arlington, VA Apr 2-3, 2017.

*Authors:* Coleman C, Yuan Z, Schein J, Crivera C, Ashton V, Laliberte F, Lefebvre P, Peterson E.

**Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk.**

*Publication:* Current Medical Research and Opinion 2017 04; 33(4): 631-638. doi: 10.1080/03007995.2016.1275936.

*Authors:* Nelson WW, Laliberte F, Patel AA, Germain G, Pilon D, McCormick N, Lefebvre P.

**Incremental risk of ischemic stroke over time in newly diagnosed heart failure patients without atrial fibrillation.**

*Abstract:* 66th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, Washington, DC Mar 17-19, 2017.

*Authors:* Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir M.

**Rivaroxaban users have significantly less treatment discontinuation compared with users of other oral anticoagulants in non-valvular atrial fibrillation.**

*Abstract:* 66th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, Washington, DC Mar 17-19, 2017.

*Authors:* McHorney C, Ashton V, Laliberte F, Germain G, Wynant W, Crivera C, Schein J, Lefebvre P, Peterson E.

**Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate.**

*Publication:* Journal of the American Academy of Dermatology 2017 01; 76(1): 81-90. doi: 10.1016/j.jaad.2016.07.042.

*Authors:* Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P.

**Adherence to QD vs. BID medications in nvaf patients is associated with reduced risk of ischemic stroke: A modeling study using rct and claims data.**

*Abstract:* American Heart Association's 2016 Scientific Sessions and Resuscitation Science Symposium, Nov 2016.

*Authors:* McHorney CA, Peterson E, Ashton V, Laliberte F, Crivera C, Sheikh N, Germain G, Schein J, Xiao Y, Lefebvre P.

**Clinical and economic outcomes of venous thromboembolism (VTE) among hospitalized patients in china: An analysis of electronic medical record data.**

*Abstract:* ISPOR 19th Annual European Congress, Vienna, Austria Oct 29 - Nov 2, 2016.

*Authors:* Wu C, Chen H, Xie J, Han S, Horblyuk R, Wang PF, Liu L, Lu J, Song H, Du EX, Wu EQ.

**Comparison of Adherence to Rivaroxaban versus Apixaban Among Patients with Atrial Fibrillation.**

*Publication:* Clinical Therapeutics 2016 11; 38(11): 2477-2488. doi: 10.1016/j.clinthera.2016.09.014.

*Authors:* McHorney CA, Peterson ED, Laliberte F, Germain G, Nelson WW, Crivera C, Schein J, Lefebvre P.

**Cost of hyperkalemia among patients with heart failure.**

*Abstract:* American Heart Association's 2016 Scientific Sessions and Resuscitation Science Symposium., New Orleans, LA Nov 12-14, 2016.

*Authors:* Woolley JM, Betts K, Mu F, Xiang C, Tang W, Wu E.

**The Long-Term Benefits of Increased Aspirin Use by At-Risk Americans Aged 50 and Older.**

*Publication:* PloS One 2016 11; 11(11): e0166103. doi: 10.1371/journal.pone.0166103.

*Authors:* Agus DB, Gaudette E, Goldman DP, Messali A.

**Patient characteristics and treatment patterns of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data.**

*Abstract:* ISPOR 19th Annual European Congress, Vienna, Austria Oct 29 - Nov 2, 2016.

*Authors:* Wu C, Chen H, Xie J, Han S, Horblyuk R, Wang PF, Liu L, Lu J, Song H, Du EX, Wu EQ.

**Risk of ischemic stroke in newly diagnosed heart failure patients.**

*Abstract:* American Heart Association's 2016 Scientific Sessions and Resuscitation Science Symposium, New Orleans, LA Nov 12-14, 2016.

*Authors:* Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir M.

**The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure.**

*Abstract:* AMCP Nexus 2016, Baltimore, MD Oct 3-6, 2016.

*Authors:* Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhanian A, Wu E.

**Cardiac resynchronization therapy and adherence to heart failure management regimens.**

*Abstract:* 20th Annual Scientific Meeting of the Heart Failure Society of America, Orlando, FL Sep 17-20, 2016.

*Authors:* Der Sarkissian M, Xiao Y, Shen Y, May D, Tsintzos SI, Lefebvre P, Duh MS.

**Clinical and economic outcomes of venous thromboembolism (VTE) among hospitalized patients in China: An analysis of electronic medical record data.**

*Abstract:* ISPOR 7th Asia-Pacific Conference, Singapore Sep 3-6, 2016.

*Authors:* Wu C, Chen H, Xie J, Han S, Horblyuk R, Wang P, Liu L, Lu J, Song H, Du E, Wu EQ.

**Patient characteristics and treatment patterns of venous thromboembolism (VTE) among hospitalized patients in China: an analysis of electronic medical record data.**

*Abstract:* ISPOR 7th Asia-Pacific Conference, Singapore Sep 3-6, 2016.

*Authors:* Wu C, Chen H, Xie J, Han S, Horblyuk R, Wang P, Liu L, Lu J, Song H, Du E, Wu EQ.

**Time to treatment intensification and its association with subsequent microvascular outcomes among patients with type 2 diabetes.**

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany Sep 12-16, 2016.

*Authors:* Desai U, Kirson NY, Kim J, Khunti KK, King SB, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.

**Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.**

*Publication:* Clinical Therapeutics 2016 08; 38(8): 1803-1816.e1803. doi:

<http://dx.doi.org/10.1016/j.clinthera.2016.07.002>.

*Authors:* Deitelzweig S, Laliberte F, Crivera C, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P.

**Risk of venous thromboembolism recurrences in patients who continued versus discontinued rivaroxaban therapy after an initial six-month therapy.**

*Abstract:* European Society of Cardiology, Rome, Italy Aug 27-31, 2016.

*Authors:* Berger JS, Seheult R, Laliberte F, Crivera C, Lejeune D, Xiao Y, Schein J, Lefebvre P, Kaatz S.

**Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.**

*Publication:* Menopause 2016 06; 23(6): 600-610. doi: <http://dx.doi.org/10.1097/GME.0000000000000590>.

*Authors:* Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

**Cost impact of switching from metoprolol to nebivolol for hypertension.**

*Publication:* American Journal of Pharmacy Benefits 2016 05; 8(3): e48-e54, 15-16.

*Authors:* Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, Wu E.

**Healthcare costs among patients diagnosed with deep vein thrombosis in the outpatient setting and treated with Rivaroxaban versus low-molecular-weight Heparin and Warfarin.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Laliberte F, Germain G, Bookhart BK, Olson WH, Schein J, Lefebvre P.

**Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin.**

*Publication:* Journal of Medical Economics 2016 04; 19(1): 84-90. doi:

<http://dx.doi.org/10.3111/13696998.2015.1096274>.

*Authors:* Merli GJ, Hollander JE, Lefebvre P, Laliberte F, Raut MK, Germain G, Bookhart B, Pollack CV.

**Impact of a Telehealth and Care Management Program on All-Cause Mortality and Healthcare Utilization in Patients with Heart Failure.**

*Publication:* Telemedicine Journal and e-Health 2016 01; 22(1): 2-11. doi: 10.1089/tmj.2015.0007.

*Authors:* Kao DP, Lindenfeld J, Macaulay D, Birnbaum HG, Jarvis JL, Desai US, Page RL, 2nd.

**Daily costs of hospitalization in non-valvular atrial fibrillation patients treated with anticoagulant therapy.**

*Publication:* Journal of Medical Economics 2015 12; 18(12): 1041-1049. doi: 10.3111/13696998.2015.1074583.

*Authors:* Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberte F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

**Longer durations of antitumour necrosis factor treatment are associated with reduced risk of cardiovascular events in patients with rheumatoid arthritis.**

*Publication:* RMD Open 2015 11; 1(1): e000080. e-pub ahead of print 2015/11/05; doi: 10.1136/rmdopen-2015-000080.

*Authors:* Nurmohamed M, Bao Y, Signorovitch J, Trahey A, Mulani P, Furst DE.

**The Relationship between Local Economic Conditions and Acute Myocardial Infarction Hospital Utilization by Adults and Seniors in the United States, 1995-2011.**

*Publication:* Health Services Research 2015 10; 50(5): 1688-1709. doi: 10.1111/1475-6773.12298.

*Authors:* Carls GS, Henke RM, Karaca Z, Marder WD, Wong HS.

**Glycemic and Cholesterol Control versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study.**

*Publication:* Diabetes Therapy 2015 09; 6(3): 339-355. doi: 10.1007/s13300-015-0122-2.

*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Zhang M, Wang Y, Fonseca VA.

**Development of a shared decision-making tool to assist patients and clinicians with assessing the individualized risks and benefits of oral anticoagulation therapy for atrial fibrillation.**

*Abstract:* ISPE's 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA August 22-26, 2015.

*Authors:* Kaiser K, Cheng W, Jensen S, Clayman M, Schwiep F, Thappa A, Chawla A, Goldberger J, Col N, Schein J.

**Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users.**

*Publication:* Journal of Medical Economics 2015 08; 18(12): 1074-1084. doi:

<http://dx.doi.org/10.3111/13696998.2015.1076429>.

*Authors:* Olson WH, Ma YW, Crivera C, Schein J, Lefebvre P, Laliberte F, Dea K, Germain G, Lynch SM.

**Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.**

*Publication:* Journal of Acquired Immune Deficiency Syndromes 2015 08; 69(4): 413-421. doi: 10.1097/QAI.0000000000000662.

*Authors:* Young J, Xiao Y, Moodie EE, Abrahamowicz M, Klein MB, Bernasconi E, Schmid P, Calmy A, Cavassini M, Cusini A, Weber R, Bucher HC, Swiss HIVCS.

**The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat, and reduce cardiovascular risk.**

*Publication:* Journal of Medical Economics 2015 07; 18(7): 483-491. doi: 10.3111/13696998.2015.1029490.

*Authors:* Penn MS, Yenikomshian MA, Cummings AK, Klemes A, Damron JM, Purvis S, Beidelschies M, Birnbaum HG.

**Psoriasis and risk of diabetes-associated microvascular and macrovascular complications.**

*Publication:* Journal of the American Academy of Dermatology 2015 06; 72(6): 968-977 e962. doi: 10.1016/j.jaad.2015.02.1095.

*Authors:* Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Iltu R, Mulani P.

**Rates of hospitalization among patients with deep vein thrombosis before and after the introduction of rivaroxaban.**

*Publication:* Hosp Pract (1995) 2015 04; 43(2): 85-93. doi: 10.1080/21548331.2015.1021659.

*Authors:* Merli GJ, Hollander JE, Lefebvre P, Laliberte F, Raut MK, Olson WH, Pollack CV, Jr.

**Effect of rivaroxaban versus warfarin on health care costs among nonvalvular atrial fibrillation patients: observations from rivaroxaban users and matched warfarin users.**

*Publication:* Advances in Therapy 2015 03; 32(3): 216-227. doi: 10.1007/s12325-015-0189-1.

*Authors:* Laliberte F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.

**Effects of rivaroxaban versus warfarin on hospitalization days and other health care resource utilization in patients with nonvalvular atrial fibrillation: an observational study from a cohort of matched users.**

*Publication:* Clinical Therapeutics 2015 03; 37(3): 554-562. doi: 10.1016/j.clinthera.2015.02.001.

*Authors:* Laliberte F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein J, Vanderpoel J, Germain G, Lefebvre P.

**Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.**

*Publication:* Thrombosis Research 2015 02; 135(2): 303-310. doi: 10.1016/j.thromres.2014.11.024.

*Authors:* Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberte F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

**Economic benefits associated with beta blocker persistence in the treatment of hypertension: a retrospective database analysis.**

*Publication:* Current Medical Research and Opinion 2015 02: 1-30. doi: 10.1185/03007995.2015.1013624.

*Authors:* Chen S, Swallow E, Li N, Faust E, Kelley C, Xie J, Wu E.

**Prasugrel vs. clopidogrel in acute coronary syndrome patients treated with prasugrel.**

*Publication:* Journal of Clinical Pharmacy and Therapeutics 2014 12; 39(6): 663-672. doi: 10.1111/jcpt.12209.

*Authors:* Olson WH, Ma YW, Laliberte F, Lefebvre P, Crivera C, Schein JR, Fields LE, Dea K, Germain G, Lynch SM.

**Pulse pressure and stroke risk: development and validation of a new stroke risk model.**

*Publication:* Current Medical Research and Opinion 2014 12; 30(12): 2453-2460. doi: 10.1185/03007995.2014.971357.

*Authors:* Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

**Effects of rivaroxaban vs warfarin on hospitalization days, healthcare resource utilization, and costs in nonvalvular atrial fibrillation patients using rivaroxaban.**

*Abstract:* American Heart Association Scientific Sessions, Chicago, IL Nov 15-19, 2014.

*Authors:* Laliberté F, Cloutier M, Crivera C, Nelson WW, Olson WH, Schein JR, Vanderpoel J, Germain G, Lefebvre P.

**Is addition of vasodilators to loop diuretics of value in the care of hospitalized acute heart failure patients? Real-world evidence from a retrospective analysis of a large United States hospital database.**

*Publication:* Journal of Cardiac Failure 2014 11; 20(11): 853-863. doi: 10.1016/j.cardfail.2014.08.006.

*Authors:* Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh MS.

**Treatment and monitoring of venous thromboembolism (VTE) among hospitalized patients in China.**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.

*Authors:* Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

**Economic benefits associated with medication persistence in the treatment of hypertension: a retrospective analysis in patients who received beta-blockers.**

*Abstract:* AMCP Nexus 2014, Boston, MA Oct 7-10, 2014.

*Authors:* Chen Y, Swallow E, Li N, Faust E, Kelly C, Xie J, Wu EQ.

**Gastrointestinal comorbidities associated with atrial fibrillation.**

*Publication:* Springerplus 2014 10; 3: 603. doi: 10.1186/2193-1801-3-603.

*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Schein JR, Lefebvre P.

**Pulse pressure and stroke risk: Development and validation of a new stroke risk model.**

*Abstract:* 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Taipei, Taiwan (Republic of China) Oct 24-27, 2014.

*Authors:* Vekeman F, Ayyagari R, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

**Treatment and monitoring of venous thromboembolism (VTE) among hospitalized patients in China.**

*Abstract:* ISPOR 6th Annual Asia-Pacific Conference, Beijing, China Sep 6-9, 2014.

*Authors:* Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

**Hospital length of stay of nonvalvular atrial fibrillation patients who were administered Rivaroxaban versus Warfarin with and without pretreatment parenteral anticoagulants therapies.**

*Publication:* Hosp Pract (1995) 2014 08; 42(3): 17-25. doi: 10.3810/hp.2014.08.1114.

*Authors:* Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

**Is rivaroxaban associated with lower inpatient costs compared to warfarin among patients with non-valvular atrial fibrillation?**

*Publication:* Current Medical Research and Opinion 2014 08; 30(8): 1521-1528. doi: 10.1185/03007995.2014.916159.

*Authors:* Laliberte F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

**Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.**

*Publication:* Current Medical Research and Opinion 2014 08; 30(8): 1513-1520. doi: 10.1185/03007995.2014.915801.

*Authors:* Laliberte F, Coleman CI, Bookhart B, Lefebvre P, Cloutier M, Damaraju CV, Schein JR, Kaatz S.

**Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.**

*Publication:* Current Medical Research and Opinion 2014 07; 30(7): 1317-1325. doi: 10.1185/03007995.2014.907140.

*Authors:* Laliberte F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, Lefebvre P.

**Anticoagulant options and inpatient costs for patients with non-valvular atrial fibrillation.**

*Abstract:* Quality of Care and Outcomes Research (QCOR) Scientific Sessions 2014, Baltimore, MD June 02-04, 2014.

*Authors:* Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

**Economic impact of switching from metoprolol to nebivolol for the treatment of hypertension.**

*Abstract:* American Association of Nurse Practitioners 2014 National Conference, Nashville, TN June 17-22, 2014.

*Authors:* Chen S, Swallow E, Jarvis J, Ohashi E, Kelley C, Xie J, Wu EQ.

**Costs of venous thromboembolism (VTE) among hospitalized patients in China.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.

**The economic impact of implementing a multiple inflammatory biomarker-based approach to identify, treat , and reduce cardiovascular risk.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Penn MS, Yenikomshian MA, Cummings AKG, Damron JM, Purvis S, Birnbaum HG.

**Effect of prasugrel vs clopidogrel on hospital readmission among acute coronary syndrome patients treated with prasugrel.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Olson WH, Ma Y, Lefebvre P, Laliberté F, Crivera C, Schein JR, Fields LE, Dea K, Germain G, Lynch SM.

**Hospital length of stay: Does rivaroxaban reduce inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Laliberté F, Pilon D, Raut M, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

**Real-World Comparative Effectiveness and Safety of Rivaroxaban and Warfarin in Nonvalvular Atrial Fibrillation Patients.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Laliberté F, Cloutier M, Nelson WW, Coleman CI, Pilon D, Olson WH, Damaraju CV, Schein JR, P. L.

**Specialized adult congenital heart disease care: the impact of policy on mortality.**

*Publication:* Circulation 2014 05; 129(18): 1804-1812. doi: 10.1161/CIRCULATIONAHA.113.005817.

*Authors:* Mylotte D, Pilote L, Ionescu-Ittu R, Abrahamowicz M, Khairy P, Therrien J, Mackie AS, Marelli A.

**Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension.**

*Publication:* Current Medical Research and Opinion 2014 04; 30(4): 637-643. doi: 10.1185/03007995.2013.864267.

*Authors:* Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, Wu EQ.

**Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.**

*Publication:* Pharmacoepidemiology and Drug Safety 2014 03; 23(3): 268-277.

*Authors:* Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP.

**Treatment, monitoring, and economic outcomes of venous thromboembolism among hospitalized patients in China.**

*Publication:* Pharmacoeconomics 2014 03; 32(3): 305-313. doi: 10.1007/s40273-014-0131-4.

*Authors:* Wu EQ, Xie J, Wu C, Du EX, Li N, Tan R, Liu Y.



**Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.**

*Publication:* Journal of Medical Economics 2014 01; 17(1): 52-64. doi: 10.3111/13696998.2013.858634.

*Authors:* Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, Zhuo DY, Huynh L, Nutescu EA.

**Risk factors associated with myocardial infarction in venous thromboembolism patients.**

*Publication:* Current Medical Research and Opinion 2014 01; 30(1): 27-35. doi: 10.1185/03007995.2013.852525.

*Authors:* Laliberte F, Nutescu EA, Lefebvre P, Rondeau-Leclaire J, Bookhart BK, LaMori JC, Damaraju CV, Schein J, Kaatz S.

**All-cause and disease-related health care costs associated with recurrent venous thromboembolism.**

*Publication:* Thrombosis and Haemostasis 2013 12; 110(6): 1288-1297. doi: 10.1160/TH13-05-0425.

*Authors:* Lefebvre P, Laliberte F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein J, Kaatz S.

**Hospital length of stay: Does rivaroxaban reduce inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?**

*Abstract:* American Heart Association 2013 Scientific Sessions and Resuscitation Science Symposium, Dallas, TX Nov 16-20, 2013.

*Authors:* Laliberte F, Pilon D, Raut M, Nelson WW, Duh MS, Schein JR, Lefebvre P.

**Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients.**

*Abstract:* American Heart Association 2013 Scientific Sessions and Resuscitation Science Symposium Dallas, TX Nov 16-20, 2013.

*Authors:* Laliberte F, Cloutier M, Nelson WW, Coleman CI, Sheng Duh M, Pilon D, Damaraju CV, Schein JR, Lefebvre P.

**Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes.**

*Publication:* Diabetes Care 2013 10; 36(10): 3297-3304. doi: 10.2337/dc13-0149.

*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Fonseca VA.

**Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.**

*Abstract:* 2013 Annual Meeting of the American College of Clinical Pharmacy, Albuquerque, NM Oct 13-16, 2013.

*Authors:* Lefebvre P, Coleman CI, Bookhart B, Wang ST, Mody SH, Tran K, Zhuo D, Huynh L, Nutescu EA.

**Venous thromboembolism and cardiovascular disease complications in women using transdermal versus oral menopausal estrogen therapy.**

*Abstract:* 24th Annual Meeting of the North American Menopause Society, Dallas, TX Oct 9-12, 2013.

*Authors:* Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

**Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors.**

*Publication:* Circulation 2013 09; 128(13): 1412-1419. doi: 10.1161/CIRCULATIONAHA.113.001827.

*Authors:* Rushani D, Kaufman JS, Ionescu-Iltu R, Mackie AS, Pilote L, Therrien J, Marelli AJ.

**Pulse pressure and stroke risk: Development and validation of a stroke risk equation.**

*Abstract:* ISPOR 4th Latin America Conference, Buenos Aires, Argentina Sep 12-14, 2013.

*Authors:* Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

**Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

**Impact of once-daily versus twice-daily dosing frequency on adherence to chronic medications among patients with venous thromboembolism.**

*Publication:* Patient 2013 07; 6(3): 213-224. doi: 10.1007/s40271-013-0020-5.

*Authors:* Laliberte F, Bookhart BK, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS.

**Outcomes in atrial fibrillation patients on combined warfarin & antiarrhythmic therapy.**

*Publication:* International Journal of Cardiology 2013 07; 167(2): 564-569. doi: 10.1016/j.ijcard.2012.01.047.

*Authors:* Guerin A, Lin J, Jhaveri M, Wu EQ, Yu AP, Cloutier M, Gauthier G, Alpert JS.

**The effect of adalimumab on risk of major adverse cardiovascular events in rheumatoid arthritis: A meta-analysis of randomized trials.**

*Abstract:* Annual European Congress of Rheumatology of the European League Against Rheumatism, Berlin, Germany Jun 6-9, 2012.

*Authors:* Burmester G, Emery P, Signorovitch J, Williams D, Valdes J, Bao Y, Mulani PM.

**All-cause and disease-related costs associated with recurrent venous thromboembolism.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Lefebvre P, Laliberte F, Nutescu E, Duh MS, LaMori JC, Bookhart B, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

**Association of patient characteristics with the initiation of dabigatran versus warfarin among anticoagulant naive patients with non-valvular atrial fibrillation.**

*Abstract:* American Heart Association's Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2013 Scientific Sessions, Baltimore, MD May 15-17, 2013.

*Authors:* Walker DR, Ivanova J, Betts KA, Rao S, Wu EQ.

**Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

**Treating acute heart failure in the elderly: A comparison of three inpatient treatment alternatives in the united states.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Lacomte P, Ong SH, Duh MS.

**Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients: a matched cohort study.**

*Publication:* Hypertension 2013 02; 61(2): 309-318. doi: 10.1161/HYPERTENSIONAHA.112.201566.

*Authors:* Gradman AH, Parise H, Lefebvre P, Falvey H, Lafeuille MH, Duh MS.

**Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?**

*Publication:* Current Medical Research and Opinion 2013 30(4): 645-653.

*Authors:* Laliberté F, Pilon D, Raut MK, Nelson WW, Olson WH, Germain G, Schein JR, Lefebvre P.

**Integrated telehealth and care management program reduces all cause mortality in Medicare beneficiaries with heart failure.**

*Abstract:* American Heart Association 2012 Scientific Sessions and Resuscitation Science Symposium, Los Angeles, CA Nov 3-6, 2012.

*Authors:* Page RL, Kao DP, Macaulay D, Birnbaum HG, Jarvis J, Desai U, Lindenfeld J.

**Comparisons of costs and clinical outcomes in hypertensive patients treated with angiotensin receptor blockers plus chlorthalidone or hydrochlorothiazide.**

*Abstract:* AMCP's 2012 Educational Conference, Cincinnati, OH Oct 3-5, 2012.

*Authors:* Leahy MJ, Sun SX, Yu AP, Chen KS, Wu EQ, Mattson M, Tang J.

**Comparisons of costs and clinical outcomes in hypertensive patients treated with chlorthalidone or hydrochlorothiazide.**

*Abstract:* AMCP's 2012 Educational Conference, Cincinnati, OH Oct 3-5, 2012.

*Authors:* Sun SX, Leahy MJ, Dabbous O, Yu AP, Lu M, Chen KS, Wu EQ.

**Risk of venous thromboembolism complications associated with recurrent venous thromboembolism.**

*Abstract:* 2012 Annual Meeting of the American College of Clinical Pharmacy, Hollywood, FL Oct 21-24, 2012.

*Authors:* Lefebvre P, Laliberté F, Nutescu E, Duh MS, LaMori JC, Bookhart BK, Olson WH, Dea K, Hossou Y, Schein JR, Kaatz S.

**Tolerability and effectiveness of nebivolol compared to other add-on therapies for hypertension: A retrospective chart review.**

*Abstract:* Canadian Hypertension Congress, Toronto, Canada Oct 25-28, 2012.

*Authors:* Ayyagari R, Cheng D, Xie J, Huang XY, Wu EQ, Chen S.

**Are vasodilators of value in the care of patients hospitalized for acute heart failure?**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Duh MS, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Gradman AH.

**Chronic heart failure in the elderly: Clinical characteristics and resource utilization following initial hospitalization.**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Korves C, Eldar-Lissai A, Wei R, Sharma H, Chen K, Ong SH, Duh MS.

**Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients.**

*Publication:* Advances in Therapy 2012 08; 29(8): 675-690. doi: 10.1007/s12325-012-0040-x.

*Authors:* Laliberte F, Nelson WW, Lefebvre P, Schein JR, Rondeau-Leclaire J, Duh MS.

**Risk of gastrointestinal conditions among patients with atrial fibrillation.**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

**Acute heart failure patients with and without renal impairment: A study of heart failure-related resource utilization and costs in the United States.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Eldar-lissai A, Eapen S, Ong SH, Rodermund D, Duh MS.

**All-cause and disease-specific health care utilization and costs associated with venous thromboembolism in commercial, Medicare and Medicaid beneficiaries.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Lefebvre P, Laliberte F, Nutescu EA, Duh MS, Lamori JC, Bookhart B, Olson W, Dea K, Schein J, Kaatz S.

**All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.**

*Publication:* Journal of Managed Care Pharmacy 2012 06; 18(5): 363-374.

*Authors:* Lefebvre P, Laliberte F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S.

**Are vasodilators of value in the care of patients hospitalized for acute heart failure?**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Gradman AH, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh MS.

**Chronic heart failure in the elderly: Costs and resource utilization following initial hospitalization.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Eldar-lissai A, Korves C, Wei R, Sharma H, Chen K, Ong SH, Duh MS.

**Risk of gastrointestinal conditions among patients with atrial fibrillation.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Laliberte F, Dea K, Lamori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

**Associations of hypertension with risk of cardiovascular events among chinese stroke patients in the US.**

*Abstract:* American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition, New York, NY May 19-22, 2012.

*Authors:* Fung G, Kahler K, Xie J, Marynchenko M, Wu E, Kam I, Yang W.

**Compliance and persistence with nebivolol vs. Diuretics as first add-on hypertension treatment.**

*Abstract:* American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition New York, NY May 19-22, 2012.

*Authors:* Chen S, Macaulay D, Xie J, Swallow E, Diener M, Farooqui S, Wu E.

**Impact of once-daily vs. Twice-daily dosing frequency on adherence in chronic medications among patients with non-valvular atrial fibrillation.**

*Abstract:* Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2012 Scientific Sessions, Atlanta, GA May 9-11, 2012.

*Authors:* Laliberte F, Nelson WW, Schein JR, Rondeau-Leclerc J, Lefebvre P, Duh MS.

**Resource utilization and costs following hospitalization of patients with chronic heart failure in the US.**

*Publication:* Journal of Medical Economics 2012 05; 15(5): 925-937. doi: 10.3111/13696998.2012.685136.

*Authors:* Korves C, Eldar-Lissai A, McHale J, Lafeuille MH, Hwa Ong S, Sheng Duh M.

**Risk of cardiovascular events associated with hypertension among chinese and caucasian stroke patients in the US.**

*Abstract:* American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition, New York, NY May 19-22, 2012.

*Authors:* Fung G, Kahler K, Xie J, Liu N, Wu E, Kam I, Yang W.

**Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis.**

*Publication:* Current Medical Research and Opinion 2012 04; 28(4): 591-599. doi: 10.1185/03007995.2012.668495.

*Authors:* Signorovitch JE, Samuelson TM, Ramakrishnan K, Marynchenko M, Wu EQ, Blum SI, Ramasamy A, Chen S.

**Are vasodilators of any value in the care of hospitalized acute heart failure patients?**

*Abstract:* 61th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, Chicago, IL Mar 24-27, 2012.

*Authors:* Gradman A, Vekeman F, Eldar-Lissai A, Trahey A, Ong SH, Duh M.

**Gastrointestinal conditions among patients with atrial fibrillation.**

*Abstract:* 61th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, Chicago, IL Mar 24-27, 2012.

*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge M, Damaraju CV, Duh MS, Schein J, Lefebvre P.

**In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty.**

*Publication:* Journal of Medical Economics 2012 02; 15(4): 644-653. doi: 10.3111/13696998.2012.669438.

*Authors:* Vekeman F, LaMori JC, Laliberte F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

**Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia.**

*Publication:* Quality of Life Research 2011 12; 20(10): 1737-1744. doi: 10.1007/s11136-011-9912-9.

*Authors:* Signorovitch J, Brainsky A, Grotzinger KM.

**Cardiovascular and economic outcomes after initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.**

*Publication:* American Journal of Therapeutics 2011 11; 18(6): 436-448. doi: 10.1097/MJT.0b013e3181e4de68.

*Authors:* Simpson RJ, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A.

**Comparison of bleeding rates between statin and statin-free patients on warfarin: A claims database approach.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Guerin A, Hylek EM, Frois C, Ponce De Leon Barido D, Marrone C, Bae JP, Zhao Z.

**Factors associated with failing to achieve low density lipoprotein cholesterol goal with existing statin therapy: A chart extraction-based approach.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Zhao Z, Ivanova J, Bae JP, Boykin SD, McCracken R, Molife C, Waldman T, Frois C.

**Low lipoprotein cholesterol goal attainment in dyslipidemic patients with existing statin therapy: A chart extraction-based approach.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Ivanova J, Frois C, Bae JP, Boykin SD, McCracken R, Molife C, Waldman T, Zhao Z.

**Risk of gastrointestinal conditions among patients with atrial fibrillation.**

*Abstract:* American Heart Association's Scientific Sessions, Orlando, FL Nov 12-16, 2011.

*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

**Does route of administration for estrogen hormone therapy and estradiol transdermal system dosage strength impact risk of venous thromboembolism.**

*Abstract:* 22nd Annual Meeting of the North American Menopause Society, Washington, DC Sept 21-24, 2011.

*Authors:* Kahler KH, Nyirady J, Beresford E, Laliberte F, Dea K, Sheng Duh M, Lefebvre P.

**Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.**

*Publication:* Appl Health Econ Health Policy 2011 09; 9(5): 293-303. doi: 10.2165/11592430-000000000-00000.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

**Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States.**

*Publication:* Current Medical Research and Opinion 2011 09; 27(9): 1763-1768. doi: 10.1185/03007995.2011.604310.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

**Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.**

*Abstract:* 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Chicago, IL Aug 14-17, 2011.

*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

**Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the US.**

*Abstract:* 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) (ICPE), Chicago, IL Aug 14-17, 2011.

*Authors:* Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

**Antithrombotic treatment patterns, hospitalizations, and associated costs in acute coronary syndrome (ACS) patients.**

*Abstract:* Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC May 12-14, 2011.

*Authors:* Lefebvre P, Laliberte F, Dea K, Nelson W, Crivera C, Ellis L, Schein JR, Damaraju CV, Mody S, Duh MS.

**Clinical characteristics, blood pressure (BP) control, and antihypertensive treatment (TRX) patterns among elderly patients (PTS) with hypertension (HTN).**

*Abstract:* 26th Annual Scientific Meeting and Exposition of the American Society of Hypertension, Inc., New York, NY May 21-24, 2011.

*Authors:* Sarda SP, Wang ST, Ramamurthy P, Wei R, Parkt J, Andrews LM, Frech-Tamas F, Duh MS.

**Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system versus oral estrogen-only hormone therapy.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

**Hospitalization due to heart failure is associated with significant medical resource utilization and costs.**

*Abstract:* Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2010 Scientific Sessions, Washington, DC May 19-21, 2010.

*Authors:* Korves C, McHale J, Lafeuille MH, Ariely R, Duh MS.

**Impact of initial antihypertensive treatment with a single-pill combination on blood pressure (BP) goal attainment: A matched cohort study.**

*Abstract:* 26th Annual Scientific Meeting and Exposition of the American Society of Hypertension, Inc., New York, NY May 21-24, 2011.

*Authors:* Gradman AH, Parish H, Lafeuille MH, Falvey H, Lefebvre P, Duh MS.

**Impact of initial combination therapy vs monotherapy on major cardiovascular (CV) events: A matched cohort study.**

*Abstract:* 26th Annual Scientific Meeting and Exposition of the American Society of Hypertension, Inc., New York, NY May 21-24, 2011.

*Authors:* Gradman AH, Parish H, Lafeuille MH, Falvey H, Lefebvre P, Duh MS.

**Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the united states.**

*Abstract:* Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC May 12-14, 2011.

*Authors:* Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

**Medical resource utilization and costs following hospitalization of patients with chronic heart failure in the United States.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Korves C, Eldar-Lissai A, Rodermund D, Swallow E, Cummings AK, Ariely R, Duh MS.

**A single-center experience with low-dose warfarin in patients undergoing total hip or total knee replacement surgery.**

*Abstract:* Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC May 12-14, 2011.

*Authors:* Balcom WB, Bookhart BK, Mishol DN, Eapen S, Nutescu EA, Schein JR, Duh MS.

**Treatment persistence among atrial fibrillation/flutter patients on combination warfarin and antiarrhythmic drug therapy in the real-world setting.**

*Abstract:* Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2011 Scientific Sessions, Washington, DC May 12-14, 2011.

*Authors:* Alpert JS, Guerin A, Lin J, Jhaveri M, Wu EQ.

**Evaluation of international normalized ratio monitoring and anticoagulation control in atrial fibrillation/flutter patients using warfarin and antiarrhythmic drug therapy.**

*Abstract:* 60th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, New Orleans, LA Apr 2-5, 2011.

*Authors:* Alpert JS, Guerin A, Lin J, Jhaveri M, Wu EQ.

**Long-term consequences and costs associated with venous thromboembolism.**

*Abstract:* AMCP's 23rd Annual Meeting, Minneapolis, MN Apr 27-29, 2011.

*Authors:* Mody S, Lefebvre P, Laliberte F, Nutescu E, Duh MS, LaMori J, Bookhart BK, Olson W, Dea K, Schein J, Kaatz S.

**Real-world clinical outcomes and costs in atrial fibrillation/flutter patients on combined warfarin and antiarrhythmic drug therapy.**

*Abstract:* AMCP's 23rd Annual Meeting, Minneapolis, MN Apr 27-29, 2011.

*Authors:* Guerin A, Lin J, Jhaveri M, Wu E, Alpert J.

**Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.**

*Publication:* Journal of Medical Economics 2011 04; 14(3): 324-334. doi: 10.3111/13696998.2011.578698.

*Authors:* Vekeman F, LaMori JC, Laliberte F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

**Copayment level, treatment persistence, and healthcare utilization in hypertension patients treated with single-pill combination therapy.**

*Publication:* Journal of Medical Economics 2011 03; 14(3): 267-278. doi: 10.3111/13696998.2011.570401.

*Authors:* Yang W, Kahler KH, Fellers T, Orloff J, Chang J, Bensimon AG, Wu EQ, Fan CP, Yu AP.

**Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data (February).**

*Publication:* Annals of Pharmacotherapy 2011 02. doi: 10.1345/aph.1P391.

*Authors:* Mease PJ, Zimetbaum PJ, Duh MS, Vekeman F, Guerin A, Boerstoeel-Streefland M, Jiang W, Lefebvre P.

**Predictors and prognostic impact of recurrent myocardial infarction in patients with left ventricular dysfunction, heart failure, or both following a first myocardial infarction.**

*Publication:* European Journal of Heart Failure 2011 02; 13(2): 148-153. doi: 10.1093/eurjhf/hfq194.

*Authors:* Thune JJ, Signorovitch JE, Kober L, McMurray JJ, Swedberg K, Rouleau J, Maggioni A, Velazquez E, Califf R, Pfeffer MA, Solomon SD.

**Compliance, persistence, healthcare resource use, and treatment costs associated with aliskiren plus ARB versus ACE inhibitor plus ARB combination therapy: in US patients with hypertension.**

*Publication:* American Journal of Cardiovascular Drugs 2011 01; 11(1): 21-32. doi: 10.2165/11586570-000000000-00000.

*Authors:* Chang J, Yang W, Kahler KH, Fellers T, Orloff J, Bensimon AG, Yu AP, Fan CP, Wu EQ.

**Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.**

*Abstract:* 21st Annual Meeting of the North American Menopause Society, Chicago, IL Oct 6-9 2010.

*Authors:* Laliberte F, Dea K, Dub MS, Kahler KH, Rolli M, Lefebvre P.

**Persistence with nebivolol compared to other beta-blockers in the treatment of hypertension: A retrospective claims analysis.**

*Abstract:* High Blood Pressure Research 2010 Scientific Sessions, HBPR 2010 Washington, DC Oct 13-16, 2010.

*Authors:* Signorovitch J, Samuelson T, Ramakrishnan K, Marynchenko M, Blum SI, Ramasamy A, Wu EQ.

**Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.**

*Abstract:* Chest 2010 Meeting, Vancouver, BC, Canada Oct 30 - Nov 4, 2010.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

**Chart review of patients on valsartan-based single-pill combinations vs. ARB-based free combinations for BP goal achievement.**

*Publication:* Current Medical Research and Opinion 2010 09; 26(9): 2203-2212. doi: 10.1185/03007995.2010.500883.

*Authors:* Chang J, Yang W, Fellers T, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ.

**Evaluation of compliance and health care utilization in patients treated with single pill vs. free combination antihypertensives.**

*Publication:* Current Medical Research and Opinion 2010 09; 26(9): 2065-2076. doi: 10.1185/03007995.2010.494462.

*Authors:* Yang W, Chang J, Kahler KH, Fellers T, Orloff J, Wu EQ, Bensimon AG.

**The epidemiology, treatment and care patterns, and medical resource utilization following hospitalization for heart failure.**

*Abstract:* International Conference on Pharmacoepidemiology & Risk Management, Brighton, UK Aug 19-22, 2010.

*Authors:* Korves C, McHale J, Lafeuille MH, Ariely R, Duh MS.

**Clinical outcomes and medical care costs among Medicare beneficiaries receiving therapy for peripheral arterial disease.**

*Publication:* Annals of Vascular Surgery 2010 07; 24(5): 577-587. doi: 10.1016/j.avsg.2010.03.015.

*Authors:* Jaff MR, Cahill KE, Yu AP, Birnbaum HG, Engelhart LM.



**Aliskiren combined with angiotensin II-receptor blockers (ARB) resulted in better outcomes compared to ARB combined with angiotensin-converting enzyme inhibitors (ACEI): Results from a claims database analysis.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Chang JR, Yang W, Kahler KH, Fellers TS, Orloff J, Bensimon AG, Yu AP, Fan CPS, Wu EQ.

**Blood pressure goal achievement among hypertension patients treated with valsartan-based single pill combination vs. ARB-based free combination in South Central region.**

*Abstract:* ISPOR 15th Annual International Meeting Atlanta, GA May 15-19, 2010.

*Authors:* Chang JR, Yang W, Fellers TS, Kahler KH, Orloff J, Xie J, Tsaneva M, Yu AP, Wu EQ.

**Cardiovascular and economic outcomes following initiation of atorvastatin versus simvastatin in an employed population stratified by cardiovascular risk.**

*Abstract:* Quality of Care and Outcomes Research in Cardiovascular Disease and Stroke 2010 Scientific Sessions, Washington, DC May 19-21, 2010.

*Authors:* Simpson Jr R, Signorovitch J, Ramakrishnan K, Ivanova J, Birnbaum H, Kuznik A.

**Compliance and health care utilization among patients with hypertension treated with single pill vs. free combination antihypertensive therapy: U.S. national and state level results from a claims database analysis.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Yang W, Chang JR, Kahler KH, Fellers TS, Orloff J, Wu EQ, Bensimon AG, Fan CPS, Yu AP.

**Economic impact of switching from valsartan to other angiotensin II receptor blockers (ARBs) in patients with hypertension.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani H, Kahler KH.

**Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.**

*Publication:* American Journal of Medicine 2010 04; 123(4): 350-357. doi: 10.1016/j.amjmed.2009.08.022.

*Authors:* Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P.

**Economic impact of switching from valsartan to other angiotensin receptor blockers in patients with hypertension.**

*Publication:* Current Medical Research and Opinion 2010 04; 26(4): 849-860. doi: 10.1185/03007991003613910.

*Authors:* Signorovitch J, Zhang J, Wu EQ, Latremouille-Viau D, Yu AP, Dastani HB, Kahler KH.

**Incidence rate of venous thromboembolism and hemorrhage in patients undergoing total hip or knee arthroplasty: A managed care perspective.**

*Abstract:* AMCP's 22nd Annual Meeting, San Diego, CA Apr 7-10, 2010.

*Authors:* Lefebvre P, Vekeman F, Nutescu E, Duh M, Bookhart B, Schein J, Dea K.

**Cardiovascular and economic outcomes after initiation of lipid-lowering therapy with atorvastatin vs simvastatin in an employed population.**

*Publication:* Mayo Clinic Proceedings 2009 12; 84(12): 1065-1072. doi: 10.4065/mcp.2009.0298.

*Authors:* Simpson RJ, Jr., Signorovitch J, Birnbaum H, Ivanova J, Connolly C, Kidolezi Y, Kuznik A.

**Costs associated with cardiovascular events in patients with hypertension in US managed care settings.**

*Publication:* Journal of the American Society of Hypertension 2009 11; 3(6): 403-415. doi: 10.1016/j.jash.2009.09.001.

*Authors:* Duh MS, Fulcher NM, White LA, Jayawant SS, Ramamurthy P, Moyneur E, Ong SH.

**Economic impact of switching from valsartan to other angiotensin II receptor blockers for nonmedical reasons in patients with hypertension.**

*Abstract:* AMCP's 2009 Educational Conference, San Antonio, TX Oct 7-9, 2009.

*Authors:* Wu EQ, Signorovitch J, Yu AP, Latremouille-Viau D, Dastani HB, Kahler K.

**Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.***Abstract:* ISPOR 12th Annual European Congress, Paris, France Oct 24-27, 2009.*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.**Healthcare costs and resource utilization of patients receiving combination treatments of angiotensin receptor blocker with chlorthalidone or with hydrochlorothiazide.***Abstract:* European Society of Cardiology, Barcelona, Spain Aug 29 - Sep 2, 2009.*Authors:* Sun S, Yu A, Chen K, Mattson M, Xu Y, Dabbous O.**The association of aspirin use on risk of hospitalization in CHF patients taking ace inhibitors: A retrospective analysis of a national cohort of veterans.***Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.*Authors:* Parikh NM, Shah DH, Deswal A, Ashton CM, Agarwal SJ, Chen H, Johnson M.**Cost trend associated with cardiovascular (CV) events in patients (pts) with hypertension (HTN) in US managed care settings.***Abstract:* 24th Annual Scientific Meeting and Exposition of the American Society of Hypertension, San Francisco, CA May 6-9, 2009.*Authors:* Jayawant SS, Fulcher N, Ramamurthy P, Moyneur E, Ong SH, Duh MS.**Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.***Publication:* Biostatistics 2009 04; 10(2): 275-281. doi: 10.1093/biostatistics/kxn034.*Authors:* Tian L, Cai T, Pfeffer MA, Piankov N, Cremieux PY, Wei LJ.**The risk of coronary heart disease and stroke among psoriasis patients.***Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.*Authors:* Kimball A, Guerin A, Mulani P, Gupta S.**Patient-reported health status in coronary heart disease in the United States: age, sex, racial, and ethnic differences.***Publication:* Circulation 2008 07; 118(5): 491-497. doi: 10.1161/CIRCULATIONAHA.107.752006.*Authors:* Xie J, Wu EQ, Zheng ZJ, Sullivan PW, Zhan L, Labarthe DR.**An evaluation of the effects of an angiotensin receptor blocker on health-related quality of life in patients with high-normal blood pressure (prehypertension) in the Trial of Preventing Hypertension (TROPHY).***Publication:* Journal of Clinical Hypertension (Greenwich, Conn.) 2008 06; 10(6): 436-442.*Authors:* Williams SA, Michelson EL, Cain VA, Yang M, Nesbitt SD, Egan BM, Julius S, Investigators TS.**Effect of Persistence with Drug Therapy On the Risk of Myocardial Re-infarction.***Publication:* P&T 2008 05; 33(5): 288-295.*Authors:* Shaya FT, Gu A, Yan X.**Delay in filling the initial prescription for a statin: A potential early indicator of medication nonpersistence.***Publication:* Clinical Therapeutics 2008 04; 30(4): 761-774. doi: 10.1016/j.clinthera.2008.04.015.*Authors:* Yu AP, Yu YF, Nichol MB, Gwady-Sridhar F.**Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction.***Publication:* Hypertension 2008 01; 51(1): 48-54. doi: 10.1161/HYPERTENSIONAHA.107.093682.*Authors:* Thune JJ, Signorovitch J, Kober L, Velazquez EJ, McMurray JJ, Califf RM, Maggioni AP, Rouleau JL, Howlett J, Zelenkofske S, Pfeffer MA, Solomon SD.

**Productivity costs associated with cardiometabolic risk factor clusters in the United States.**

*Publication:* Value in Health 2007 11; 10(6): 443-450. doi: 10.1111/j.1524-4733.2007.00199.x.

*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

**Impact of Single-Photon Emission Computed Tomography (SPECT) Use after Acute Myocardial Infarction (AMI) on Cardiac Procedures Rates and Hospital Length of Stay.**

*Abstract:* American Society of Nuclear Cardiology, San Diego, CA Sep 6-9, 2007.

*Authors:* Wu EQ, Persson B, Beaulieu N, White L, Spalding J, Mahmarian JJ.

**Prevalence, referral patterns, testing, and surgery in aortic valve disease: leaving women and elderly patients behind?**

*Publication:* Journal of Heart Valve Disease 2007 07; 16(4): 362-369.

*Authors:* Bach DS, Radeva JI, Birnbaum HG, Fournier AA, Tuttle EG.

**The economic impact of a partnership-measurement model of disease management: Improving Cardiovascular Outcomes in Nova Scotia (ICONS).**

*Publication:* Healthc Q 2007 05; 10(2): 38-46.

*Authors:* Cremieux PY, Fortin P, Meilleur MC, Montague T, Royer J.

**Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.**

*Publication:* Obesity (Silver Spring) 2007 02; 15(2): 511-521. doi: 10.1038/oby.2007.580.

*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

**The value of antihypertensive drugs: a perspective on medical innovation.**

*Publication:* Health Affairs 2007 01; 26(1): 97-110. doi: 10.1377/hlthaff.26.1.97.

*Authors:* Cutler DM, Long G, Berndt ER, Royer J, Fournier AA, Sasser A, Cremieux P.

**Antihypertensive drugs: a perspective on the value of improved blood pressure control in the USA.**

*Publication:* European Heart Journal Supplements 2007 9(suppl B): B19-B22.

*Authors:* Long G, Cutler DM, Berndt ER.

**Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States.**

*Publication:* Stroke 2006 10; 37(10): 2567-2572. doi: 10.1161/01.STR.0000240506.34616.10.

*Authors:* Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR.

**Economic evaluation of valsartan in patients with chronic heart failure: results from Val-HeFT adapted to The Netherlands.**

*Publication:* Journal of Medical Economics 2006 9(131): 121.

*Authors:* Boersma C, Ivanova J, Koopmanschap MA, Voors AA, Postma MJ.

**Economic burden and co-morbidities of atrial fibrillation in a privately insured population.**

*Publication:* Current Medical Research and Opinion 2005 10; 21(10): 1693-1699. doi: 10.1185/030079905X65475.

*Authors:* Wu EQ, Birnbaum HG, Mareva M, Tuttle E, Castor AR, Jackman W, Ruskin J.

**Assessing the economic impact of chronic conditions in postmenopausal women.**

*Publication:* Expert Opinion on Pharmacotherapy 2005 09; 6(11): 1803-1814. doi: 10.1517/14656566.6.11.1803.

*Authors:* Sasser AC, Taylor M, Birnbaum HG, Schoenfeld MJ, Oster EF, Rousculp M.

**Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT).**

*Publication:* American Heart Journal 2005 08; 150(2): 323-329. doi: 10.1016/j.ahj.2004.08.037.

*Authors:* Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, Valiant-Investigators.

**Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.**

*Publication:* Women's Health Issues 2005 05; 15(3): 97-108. doi: 10.1016/j.whi.2004.11.006.

*Authors:* Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D.

**Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation.**

*Publication:* Clinical Transplantation 2005 02; 19(1): 122-129. doi: 10.1111/j.1399-0012.2004.00312.x.

*Authors:* Radeva JI, Reed SD, Kalo Z, Kauf TL, Cantu E, 3rd, Cretin N, Schulman KA.

**Comparison of Alternative Strategies for the Diagnosis of Acute Cardiac Ischemia in Emergency Departments: Standard of Care versus BMIPP.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR).

*Authors:* Wu EQ, Birnbaum H, Cremieux P, Carpenter S, Borys N, Babich J.

**State-mandated continuing medical education and the use of proven therapies in patients with an acute myocardial infarction.**

*Publication:* Journal of the American College of Cardiology 2004 07; 44(1): 192-198. doi: 10.1016/j.jacc.2004.03.070.

*Authors:* Patel MR, Meine TJ, Radeva J, Curtis L, Rao SV, Schulman KA, Jollis JG.

**Cost and Comorbidities Associated with Atrial Fibrillation.**

*Abstract:* NASPE - Heart Rhythm Society.

*Authors:* Wu EQ, Howard BG, Mareva MN.

**PCV22 Cost and comorbidities associated with atrial fibrillation in different age groups.**

*Abstract:* ISPOR, 2004.

*Authors:* Wu E, Birnbaum H, Milena M.

**Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.**

*Publication:* Women's Health Issues 2003 11; 13(6): 204-213.

*Authors:* Birnbaum H, Leong S, Kabra A.

**Clinical and Economic Value of Cardiovascular Nuclear Medicine.**

*Publication:* Meniscus Health Care Communications 1996.

*Authors:* Mulhern C, Neels K.

## Dermatology

**Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.**

*Publication:* Acta Dermato-Venereologica 2019 09; 99(10): 851-857. e-pub ahead of print 2019/05/18; doi: 10.2340/00015555-3219.

*Authors:* Ariens LFM, Gadkari A, van Os-Medendorp H, Ayyagari R, Terasawa E, Kuznik A, Chen Z, Bego-Le Bagousse G, Lu Y, Rizova E, Graham NMH, Pirozzi G, De Bruin-Weller M, Eckert L.

**Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.**

*Publication:* Acta Dermato-Venereologica 2019 09; 99(10): 851-857. doi: 10.2340/00015555-3219.

*Authors:* Ariens LFM, Gadkari A, van Os-Medendorp H, Ayyagari R, Terasawa E, Kuznik A, Chen Z, Bego-Le Bagousse G, Lu Y, Rizova E, Graham NMH, Pirozzi G, De Bruin-Weller M, Eckert L.

**Impact of hidradenitis suppurativa on work loss, indirect costs and income.**

*Publication:* British Journal of Dermatology 2019 08; 181(1): 147-154. e-pub ahead of print 2018/08/19; doi: 10.1111/bjd.17101.

*Authors:* Tzellos T, Yang H, Mu F, Calimlim B, Signorovitch J.

**Calcipotriol plus betamethasone dipropionate aerosol foam vs. apremilast, methotrexate, acitretin or fumaric acid esters for the treatment of plaque psoriasis: a matching-adjusted indirect comparison.**

*Publication:* Journal of the European Academy of Dermatology and Venereology 2019 06; 33(6): 1107-1115. e-pub ahead of print 2018/11/26; doi: 10.1111/jdv.15369.

*Authors:* Bewley AP, Shear NH, Calzavara-Pinton PG, Hansen JB, Nyeland ME, Signorovitch J.

**Number needed to treat and cost per responder for flexible adalimumab dosing in the treatment of psoriasis in patients with suboptimal response to 40 mg every other week dosing.**

*Abstract:* 6th Congress of the Skin Inflammation and Psoriasis International Network, Paris, France Apr 25-27, 2019.

*Authors:* Savage LJ, Garcia-Horton V, Li J, Yin L, Betts KA, Calimlim B.

**The Comparative Efficacy for Novel Treatments of Moderate to Severe Plaque Psoriasis: A Network Meta-Analysis.**

*Abstract:* American Academy of Dermatology (AAD) Annual Meeting 2019, Washington, DC Mar 1-5, 2019.

*Authors:* Armstrong A, Puig L, Joshi A, Skup M, Kalabina S, Williams D, Li J, Garcia-Horton V, Betts K, Augustin M.

**Long-Term Safety Profile of Adalimumab versus Ustekinumab in Psoriasis - A Real World Matching-Adjusted Indirect Comparison (MAIC).**

*Abstract:* American Academy of Dermatology (AAD) Annual Meeting 2019, Washington, DC Mar 1-5, 2019.

*Authors:* Wu J, Singh R, Yang M, Li J, Bereswill M, Garcia-Horton V, Valdecantos W, Arikan D, Weiss S.

**The economic burden of psoriasis with high comorbidity among privately insured patients in the United States.**

*Publication:* Journal of Medical Economics 2019 02; 22(2): 196-203. e-pub ahead of print 2018/12/14; doi: 10.1080/13696998.2018.1557201.

*Authors:* Pilon D, Teeple A, Zhdanava M, Ladouceur M, Ching Cheung H, Muser E, Lefebvre P.

**Psy10 Opioid and Healthcare Resource Use among Privately Insured Moderate-to-Severe Psoriasis Patients in the Us.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Zhdanava M, Teeple A, Pilon D, Shak N, Fitzgerald T, Lefebvre P.

**Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa.**

*Publication:* Journal of the European Academy of Dermatology and Venereology 2018 12; 32(12): 2254-2256. e-pub ahead of print 2018/07/01; doi: 10.1111/jdv.15163.

*Authors:* Kimball AB, Ganguli A, Fleischer A.

**Adverse Medical Conditions Across Treatment Options in Patients With Psoriasis: A Claims-Based Analysis.**

*Publication:* J Drugs Dermatol 2018 11; 17(11): 1211-1218. e-pub ahead of print 2018/12/01.

*Authors:* Wu JJ, Armstrong A, Singh R, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Arikan D, Fleischer A, Guerin A, Ganguli A.

**Real-World Evidence of Disease Burden in Obese Patients Hospitalized With Acute Bacterial Skin and Skin-Structure Infections.**

*Publication:* Infectious Diseases in Clinical Practice 2018 11; 26(6): 333-338. doi: 10.1097/ipc.0000000000000688.

*Authors:* McGinnis E, Ayyagari R, Tan R-D, Tuttle E, Cammarata S, Tillotson G.

**The Comorbidity Burden of Hidradenitis Suppurativa in the United States: A Claims Data Analysis.**

*Publication:* Dermatol Ther (Heidelb) 2018 10. e-pub ahead of print 2018/10/12; doi: 10.1007/s13555-018-0264-z.

*Authors:* Kimball AB, Sundaram M, Gauthier G, Guerin A, Pivneva I, Singh R, Ganguli A.

**Incremental benefits on patient-reported outcomes for achieving PASI90 or PASI100 over PASI75 in patients with moderate to severe psoriasis.**

*Abstract:* European Academy of Dermatology and Venereology, Paris, France Sep 12-16, 2018.

*Authors:* Ryan C, Puig L, Zema C, Thompson E, Yang M, Wu EQ, Huang X, Skup M, Elewski B.

**Indirect economic burden associated with multiple and more complex surgical procedures for hidradenitis suppurativa (HS).**

*Abstract:* 27th EADV Congress, Paris, France Sept 12-16, 2018.

*Authors:* Kimball A, Singh R, Pivneva I, Fleischer Jr. A, Liu O, Guerin A.

**Patient-Reported Outcomes from the IMMVent Trial: Comparison of Risankizumab with Adalimumab in Moderate to Severe Psoriasis Patients.**

*Abstract:* European Academy of Dermatology and Venereology, Paris, France Sep 12-16, 2018.

*Authors:* Crowley J, Skup M, Huang X, Yang M, Wu EQ, Thompson E, Zema C, Reich K.

**Risankizumab Significantly Improves Patient-Reported Outcomes in Moderate to Severe Psoriasis in Two Phase III UtiMMA Trials.**

*Abstract:* European Academy of Dermatology and Venereology, Paris, France Sept 12-16, 2018.

*Authors:* Augustin M, Lambert J, Zema C, Thompson E, Yang M, Wu EQ, Geng Z, Valdes J, Skup M, Gordon M.

**Association of Inadequately Controlled Disease and Disease Severity With Patient-Reported Disease Burden in Adults With Atopic Dermatitis.**

*Publication:* JAMA Dermatol 2018 08; 154(8): 903-912. e-pub ahead of print 2018/07/05; doi: 10.1001/jamadermatol.2018.1572.

*Authors:* Simpson EL, Guttman-Yassky E, Margolis DJ, Feldman SR, Qureshi A, Hata T, Mastey V, Wei W, Eckert L, Chao J, Arnold RJG, Yu T, Vekeman F, Suarez-Farinas M, Gadkari A.

**Comparison of the efficacy of dupilumab vs. ciclosporin using Eczema Area and Severity Index thresholds in adult patients with moderate-to-severe atopic dermatitis.**

*Abstract:* 10th George Rajka International Symposium on Atopic Dermatitis, Utrecht, Netherlands April 11-13, 2018.

*Authors:* Ariens LFM, Gadkari AS, Os-Medendorp H, Rajeev A, Terasawa E, Kuznik A, Chen Z, Le-Bagousse-Bego G, Lu Y, Rizova E, Graham NNMH, Pirozzi G, Shumel B, Eckert L, De Bruin-Weller MS.

**Number needed to treat and costs per responder among biologic treatments for moderate-to-severe psoriasis: a network meta-analysis.**

*Publication:* Current Medical Research and Opinion 2018 07; 34(7): 1325-1333. e-pub ahead of print 2018/04/06; doi: 10.1080/03007995.2018.1457516.

*Authors:* Armstrong AW, Betts KA, Signorovitch JE, Sundaram M, Li J, Ganguli AX, Wu EQ.

**The risk of cardiovascular events in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus phototherapy: An observational cohort study.**

*Publication:* Journal of the American Academy of Dermatology 2018 07; 79(1): 60-68. doi:

<http://dx.doi.org/10.1016/j.jaad.2018.02.050>.

*Authors:* Wu JJ, Sundaram M, Cloutier M, Gauthier-Loiselle M, Guerin A, Singh R, Ganguli A.

**Health care burden and treatment patterns in commercially insured children with chronic idiopathic/spontaneous urticaria: A real-world study in the United States.**

*Publication:* Allergy and Asthma Proceedings 2018 05; 39(3): 201-211. e-pub ahead of print 2018/03/09; doi: 10.2500/aap.2018.39.4129.

*Authors:* Williams P, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Hernandez-Trujillo V.

**Real-world use of omalizumab in patients with chronic idiopathic/spontaneous urticaria in the United States.**

*Publication:* Allergy and Asthma Proceedings 2018 05; 39(3): 191-200. e-pub ahead of print 2018/02/21; doi: 10.2500/aap.2018.39.4132.

*Authors:* Eghrari-Sabet J, Sher E, Kavati A, Pilon D, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Bernstein JA.

**Economic outcomes associated with unsuitable immunosuppressant use in moderate-to-severe atopic dermatitis.**

*Abstract:* AMCP's 30th Annual Meeting, Boston, MA Apr 23–26, 2018.

*Authors:* Armstrong A, Chao J, Shah D, Garcia-Horton V, Macaulay D, Miao R, Mallya U.

**Treatment Patterns, Healthcare Resource Utilization, and Spending Among Medicaid-Enrolled Children with Chronic Idiopathic/Spontaneous Urticaria in the United States.**

*Publication:* Dermatol Ther (Heidelb) 2018 03; 8(1): 69-83. e-pub ahead of print 2018/02/13; doi: 10.1007/s13555-018-0225-6.

*Authors:* Williams PV, Kavati A, Pilon D, Xiao Y, Zhdanava M, Balp MM, Lefebvre P, Ortiz B, Hernandez-Trujillo V.

**Adverse Medical Conditions across Treatment Options in Patients with Psoriasis: A Claims-Based Analysis.**

*Abstract:* Annual Meeting of the American Academy of Dermatology, San Diego, CA Feb 16-20, 2018.

*Authors:* Wu JJ, Armstrong A, Singh R, Ganguli A, Arikian D, Fleishcher A, Cloutier M, Gauthier-Loiselle M.

**Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis.**

*Publication:* J Drugs Dermatol 2018 02; 17(2): 180-186. e-pub ahead of print 2018/02/21.

*Authors:* Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Ganguli A.

**Number needed to treat and costs per responder among biologic treatments for moderate-to-severe plaque psoriasis in Japan.**

*Publication:* Journal of Dermatological Treatment 2018 02; 29(1): 24-31. e-pub ahead of print 2017/06/14; doi: <http://dx.doi.org/10.1080/09546634.2017.1341607>.

*Authors:* Imafuku S, Nakano A, Dakeshita H, Li J, Betts KA, Guerin A.

**Prevalence of Psoriasis in Children and Adolescents in the United States: A Claims-Based Analysis.**

*Publication:* J Drugs Dermatol 2018 02; 17(2): 187-194. e-pub ahead of print 2018/02/21.

*Authors:* Paller AS, Singh R, Cloutier M, Gauthier-Loiselle M, Emond B, Guerin A, Ganguli A.

**Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.**

*Publication:* Value in Health 2018 01; 21(1): 1-8. e-pub ahead of print 2018/01/07; doi: 10.1016/j.jval.2017.05.025.

*Authors:* Papp KA, Yang M, Sundaram M, Jarvis J, Betts KA, Bao Y, Signorovitch JE.

**Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis.**

*Publication:* BMC Rheumatology 2018 01; 2 (1) (no pagination)(3). doi: <http://dx.doi.org/10.1186/s41927-018-0011-1>.

*Authors:* Strand V, Elaine Husni M, Betts KA, Song Y, Singh R, Griffith J, Beppu M, Zhao J, Ganguli A.

**Poor early response to methotrexate portends inadequate long-term outcomes in patients with moderate-to-severe psoriasis: Evidence from 2 phase 3 clinical trials.**

*Publication:* Journal of the American Academy of Dermatology 2017 12; 77(6): 1030-1037. e-pub ahead of print 2017/10/11; doi: 10.1016/j.jaad.2017.08.017.

*Authors:* Gordon KB, Betts KA, Sundaram M, Signorovitch JE, Li J, Xie M, Wu EQ, Okun MM.

**Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014.**

*Publication:* Journal of the American Academy of Dermatology 2017 07; 77(1): 55-62 e53. doi: 10.1016/j.jaad.2017.02.050.

*Authors:* Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB.

**Healthcare resource utilization, healthcare costs and dose escalation in psoriasis patients initiated on ustekinumab versus adalimumab: a retrospective claim study.**

*Publication:* Journal of Dermatological Treatment 2017 06; 28(4): 290-298. doi: 10.1080/09546634.2016.1247946.

*Authors:* Wu JJ, Guerin A, Gauthier G, Sundaram M.

**244 Risk of contraindication and drug-drug interaction (DDI) with use of systemic immunosuppressants (IMMs) in adult patients with atopic dermatitis (AD).**

*Abstract:* Society for Investigative Dermatology (SID) 2017 Annual Meeting, Portland, OR Apr 26–29, 2017.

*Authors:* Armstrong A, Wei W, Garcia-Horton V, Macaulay D, Schmerold L, Wu E, Shah D, Chao J.

**Drug cost per responder for the treatment of moderate-to-severe psoriasis and active psoriatic arthritis.**

*Abstract:* 75th Annual Meeting of the American Academy of Dermatology, Orlando, FL Mar 3-7, 2017.

*Authors:* Armstrong A, Merola J, Yang M, Li J, Zhao J, Sundaram M.

**Health-related quality of life and work productivity associated with HiSCR and NRS30 response among patients with moderate to severe hidradenitis suppurativa.**

*Abstract:* American Academy of Dermatology 75th Annual Meeting, Orlando, FL Mar 3-7, 2017.

*Authors:* Kimball A, Yang M, Song Y, Valdecantos W, Ganguli.

**High-Value Subpopulation for Skin Pain Improvement in Adalimumab-Treated Patients with Moderate to Severe Hidradenitis Suppurativa.**

*Abstract:* American Academy of Dermatology 75th Annual Meeting, Orlando, FL Mar 3-7, 2017.

*Authors:* Qureshi A, Yang M, Song Y, Zhang A, Sundaram M, Ganguli A.

**Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-alpha inhibitors versus methotrexate.**

*Publication:* Journal of the American Academy of Dermatology 2017 01; 76(1): 81-90. doi: 10.1016/j.jaad.2016.07.042.

*Authors:* Wu JJ, Guerin A, Sundaram M, Dea K, Cloutier M, Mulani P.

**Comparative efficacy and incremental cost per responder of methotrexate versus apremilast for methotrexate-naïve patients with psoriasis.**

*Publication:* Journal of the American Academy of Dermatology 2016 10; 75(4): 740-746. e-pub ahead of print 2016/08/02; doi: 10.1016/j.jaad.2016.05.040.

*Authors:* Armstrong AW, Betts KA, Sundaram M, Thomason D, Signorovitch JE.

**Patients' Willingness to Pay for a Subcutaneous Injection Device That Reduces Injection Site Pain in the Treatment of Psoriasis.**

*Abstract:* 25th European Academy of Dermatology and Venereology, Vienna, Austria Sep 28 - Oct 2, 2016.

*Authors:* Cividino A, Mittal M, Yang M, Signorovitch JE, M. S.



**Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured US population.**

*Publication:* Journal of Medical Economics 2016 07; 19(7): 649-654. e-pub ahead of print 2016/02/07; doi: 10.3111/13696998.2016.1151433.

*Authors:* Bradford Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M.

**What happens after a single surgical intervention for hidradenitis suppurativa? A retrospective claims-based analysis.**

*Publication:* Journal of Medical Economics 2016 07; 19(7): 710-717. doi: 10.3111/13696998.2016.1161636.

*Authors:* Jemec GB, Guerin A, Kaminsky M, Okun M, Sundaram M.

**Adalimumab Is Associated with Reduced Risk of Joint-related Signs and Symptoms Compared with Methotrexate in Patients with Moderate to Severe Psoriasis.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington DC March 4-8, 2016.

*Authors:* Merola J, Sundaram M, Yang M, Li J, Galebach P, Okun M.

**Cardiovascular (CV) event risk assessment in psoriasis (PS) patients treated with tumor necrosis factor-alpha inhibitors (TNFi) versus phototherapy.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Wu J, Cloutier M, Gauthier-Loiselle M, Guerin A, Sundaram M.

**Comparison of Outcomes between Psoriasis Patients who Switched from Etanercept to Adalimumab versus to Ustekinumab.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC March 4-8, 2016.

*Authors:* Jashin J, Wu J, Sundaram M, Guérin A, Gauthier G, Thompson-Leduc P.

**How is the severity of hidradenitis suppurativa measured in clinical practice?**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Sundaram M, Lin P, Thomason D, Signorovitch J.

**Numbers needed to treat and costs per responder for novel treatments of moderate to severe psoriasis.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Armstrong A, Betts K, Li J, Sundaram M, Wu E, Signorovitch J.

**Predicting PASI90 Response Among Adalimumab-Treated Patients with Moderate to Severe Psoriasis.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington DC March 4-8, 2016.

*Authors:* Ryan C, Sundaram M, Yang M, Goyal R, Zhou Z, Signorovitch J.

**Progression from a Milder to a More Severe Form of Hidradenitis Suppurativa is Associated with a Substantial Economic Burden.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC March 4-8, 2016.

*Authors:* Kimball A, Sundaram M, Gauthier G, Nitulescu R, Pivneva I, Guerin A.

**Progression from mild hidradenitis suppurativa (HS) to moderate-to-severe (m<sup>>2</sup>/s) HS is associated with a substantial economic burden.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Kimball A, Sundaram M, Gauthier G, Nitulescu R, Pivneva I, Guerin A.

**Psoriasis Plaque Resolution by Body Region and Plaque Signs with Adalimumab and Etanercept: an Indirect Comparison.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington DC March 4-8, 2016.

*Authors:* Papp K, Sundaram M, Yang M, Jarvis J, Signorovitch J.

**Relative efficacy and costs per responder for adalimumab versus secukinumab in the treatment of moderate to severe psoriasis.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Armstrong A, Betts K, Sundaram M, Li J, Wu E.

**Risk and economic burden of antibiotic failure in patients with moderate to severe hidradenitis suppurativa.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Kimball A, Sundaram M, Gauthier G, Pivneva I, Nitulescu R, Guerin A.

**Management of epidermal growth factor receptor inhibitor-associated rash: a systematic review.**

*Publication:* J Community Support Oncol 2016 01; 14(1): 21-28. e-pub ahead of print 2016/02/13; doi: 10.12788/jcso.0193.

*Authors:* Brown J, Su Y, Nelleson D, Shankar P, Mayo C.

**Healthcare resource utilization and work loss in dermatomyositis and polymyositis patients in a privately-insured population in the US.**

*Abstract:* AMCP Nexus 2015, Orlando, FL Oct 26-29, 2015.

*Authors:* Bradford Rice J, White A, Lopez A, Galebach P, Schepman P, Popelar B, Philbin M.

**Psoriasis and risk of diabetes-associated microvascular and macrovascular complications.**

*Publication:* Journal of the American Academy of Dermatology 2015 06; 72(6): 968-977 e962. doi: 10.1016/j.jaad.2015.02.1095.

*Authors:* Armstrong AW, Guerin A, Sundaram M, Wu EQ, Faust ES, Ionescu-Iltu R, Mulani P.

**Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis.**

*Publication:* Arthritis Care Res (Hoboken) 2015 05; 67(5): 708-717. doi: 10.1002/acr.22492.

*Authors:* Feldman SR, Zhao Y, Shi L, Tran MH, Lu J.

**Psoriasis Treatment Patterns: Phototherapy, Oral Nonbiologic, and Biologic Therapies.**

*Publication:* American Journal of Pharmacy Benefits 2015 05.

*Authors:* Kimball AB GG, Hiscock R, Zhang HF.

**Cost per Responder Associated with Biologic Therapies for Psoriasis.**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA Apr 7-10, 2015.

*Authors:* Liu Y, Reichmann W, Macaulay D.

**Comorbid psoriatic arthritis significantly impairs health-related quality of life in patients with moderate to severe psoriasis.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 20-24, 2015.

*Authors:* Kimball AB, Sundaram M, Signorovitch J, Yang M, Taska B.

**Comparative efficacy of methotrexate versus apremilast for methotrexate-naïve psoriasis patients: An indirect comparison.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology San Francisco, CA Mar 20-24, 2015.

*Authors:* Armstrong AW, Betts K, Sundaram M, Thomason D, Signorovitch J.

**Health care resource utilization, health care costs, and dose escalation in biologic-naïve psoriasis patients initiated on ustekinumab versus adalimumab.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology San Francisco, CA Mar 20-24, 2015.

*Authors:* Guerin A, Sundaram M, Gauthier G.

**Long-term Effect of Achieving PASI90 Compared with PASI75 Response on Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Ryan C, Sundaram M, Yang M, Goyal R, Signorovitch J.

**A practical model for early identification of response with methotrexate for moderate to severe psoriasis.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology San Francisco, CA Mar 20-24, 2015.

*Authors:* Gordon K, Sundaram M, Arunajadai S, Xie M, Signorovitch J, Betts K, Okun M.

**Rates and risk factors of PsA disease progression amongst newly diagnosed PsA patients.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 20-24, 2015.

*Authors:* Merolola J, Guerin A, Sundaram M, Jarvis J, Cummings AK, Ghorayeb E.

**Starting-dose trends over time in biologic-naïve and biologic-experienced psoriasis patients initiated on ustekinumab or adalimumab.**

*Abstract:* 73rd Annual Meeting of the American Academy of Dermatology San Francisco, CA Mar 20-24, 2015.

*Authors:* Guerin A, Sundaram M, Gauthier G.

**Comparative efficacy of biological treatments for moderate-to-severe psoriasis: a network meta-analysis adjusting for cross-trial differences in reference arm response.**

*Publication:* British Journal of Dermatology 2015 02; 172(2): 504-512. doi: 10.1111/bjd.13437.

*Authors:* Signorovitch JE, Betts KA, Yan YS, LeReun C, Sundaram M, Wu EQ, Mulani P.

**Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment.**

*Publication:* British Journal of Dermatology 2014 12; 171(6): 1434-1442. doi: 10.1111/bjd.13270.

*Authors:* Kimball AB, Jemec GB, Yang M, Kageleiry A, Signorovitch JE, Okun MM, Gu Y, Wang K, Mulani P, Sundaram M.

**Early identification of response with methotrexate for moderate-to-severe psoriasis.**

*Abstract:* 7th International Congress of Psoriasis: From Gene to Clinic, London, UK Dec 11-13, 2014.

*Authors:* Gordon K, Sundaram M, Arunajadai S, Xie M, Signorovitch J, Betts K, Okun M.

**Effects of briakinumab treatment for moderate to severe psoriasis on health-related quality of life and work productivity and activity impairment: results from a randomized phase III study.**

*Publication:* Journal of the European Academy of Dermatology and Venereology 2014 06; 28(6): 790-798. doi: 10.1111/jdv.12177.

*Authors:* Papp KA, Sundaram M, Bao Y, Williams DA, Gu Y, Signorovitch JE, Wang Y, Valdes JM, Mulani PM.

**Health care costs in psoriasis patients newly initiated on a biologic therapy or methotrexate.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Zhang F, Hiscock R.

**Severity, Healthcare Resource Use, and Costs of Patients Diagnosed with Hidradenitis Suppurativa in the United States: Evidence from a Large Administrative Claims Database. .**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Sundaram M, Guérin A, Styles A, M K.

**Higher health care costs and dose escalation rates in psoriasis patients treated with ustekinumab compared to adalimumab.**

*Abstract:* 72nd Annual Meeting of the American Academy of Dermatology Denver, CO Mar 21-25, 2014.

*Authors:* Guerin A, Wang K, Sundaram M.

**Incremental burden of psoriatic arthritis is substantial among patients with mild and moderate to severe psoriasis.**

*Abstract:* 72nd Annual Meeting of the American Academy of Dermatology, Denver, CO Mar 21-25, 2014.

*Authors:* Merola J, Guerin A, Jarvis JL, Wang K, Sundaram M.

**Nail psoriasis significantly impairs health-related quality of life among patients with chronic plaque psoriasis.**

*Abstract:* 72nd Annual Meeting of the American Academy of Dermatology Denver, CO Mar 21-25, 2014.

*Authors:* Okun M, Kageleiry A, Signorovitch J, Yang M, Sundaram M.

**Number needed to treat and cost per responder for biologic therapies for the treatment of moderate to severe psoriasis.**

*Abstract:* 72nd Annual Meeting of the American Academy of Dermatology, Denver, CO Mar 21-25, 2014.

*Authors:* Langley RG, Signorovitch J, Wang K, KA. B, Sundaram M, Mulani P, Yan S.

**Patient preferences and willingness to pay for enhancements to subcutaneous injection devices used to treat psoriasis.**

*Abstract:* 72nd Annual Meeting of the American Academy of Dermatology Denver, CO Mar 21-25, 2014.

*Authors:* Cividino A, Signorovitch JE, Skup M, Tundia N, Mulani P, Arulmani U, Bao Y.

**Economic and comorbidity burden of moderate-to-severe psoriasis.**

*Abstract:* Annual Maui Dermatology Conference, Maui, HI Jan 26-30, 2014.

*Authors:* Feldman S, Zhao Y, Tran MH, Shi L.

**Cost-effectiveness of biologic therapies for the treatment of moderate to severe psoriasis in the United Kingdom.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin, Ireland Nov 2-6, 2013.

*Authors:* Betts KA, Sundaram M, Mughal F, Yan SY, Signorovitch J, Wang K, Wu EQ.

**Characteristics of psoriasis patients with self-assessed limited disease control despite physician-assessed clear or minimal skin disease.**

*Abstract:* 71st Annual Meeting of the American Academy of Dermatology, Miami Beach, FL Mar 1-5, 2013.

*Authors:* Kimball AB, Signorovitch JE, Sundaram M, Samuelson T.

**Detecting undiagnosed depression in patients with moderate to severe psoriasis: Development and validation of a risk score for use in dermatology.**

*Abstract:* American Academy of Dermatology 71st Annual Meeting, Miami Beach, FL Mar 1-5, 2013.

*Authors:* Cather JC, Sundaram M, Horn EJ, Yang M, Signorovitch JE.

**Economic burden of hidradenitis suppurativa after a single surgical intervention: Assessment of unmet needs using a retrospective claims-based analysis.**

*Abstract:* 71st Annual Meeting of the American Academy of Dermatology, Miami Beach, FL Mar 3-5, 2013.

*Authors:* Jemec G, Guerin A, Okun M, Kaminsky M, Sundaram M.

**Prevalence and incidence of hidradenitis suppurativa in the United States: Evidence from large administrative claims databases.**

*Abstract:* 71st Annual Meeting of the American Academy of Dermatology, Miami Beach, FL Mar 1-5, 2013.

*Authors:* Sundaram M, Styles A, Guerin A, Aberki C, Okun M, Hayes O, Mulani P.

**Validation of the hidradenitis suppurativa clinical response as a clinical endpoint for hidradenitis suppurativa treatment evaluation.**

*Abstract:* 71st Annual Meeting of the American Academy of Dermatology Miami Beach, FL Mar 1-5, 2013.

*Authors:* Okun M, Yang M, Sundaram M, Gu Y.

**Validation of the physician's global assessment of psoriasis of the hands and/or feet as a clinical endpoint.**

*Abstract:* American Academy of Dermatology 71st Annual Meeting, Miami Beach, FL Mar 1-5, 2013.

*Authors:* Goldblum O, Sundaram M, Yang M, Thomason D.

**Sleep quality and other patient-reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open-label Phase IIIB trial.**

*Publication:* British Journal of Dermatology 2012 12; 167(6): 1374-1381. doi: 10.1111/bjd.12000.

*Authors:* Strober BE, Sobell JM, Duffin KC, Bao Y, Guerin A, Yang H, Goldblum O, Okun MM, Mulani PM.

**Cost-effectiveness of biologic therapies for the treatment of moderate to severe psoriasis in Germany.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Betts K, Yan Y, Sundaram M, Hengst N, Wolff M, Bensimon AG.

**Risks of developing psychiatric disorders in pediatric patients with psoriasis.**

*Publication:* Journal of the American Academy of Dermatology 2012 10; 67(4): 651-657 e651-652. doi: 10.1016/j.jaad.2011.11.948.

*Authors:* Kimball AB, Wu EQ, Guerin A, Yu AP, Tsaneva M, Gupta SR, Bao Y, Mulani PM.

**Characteristics of psoriasis patients with self-assessed limited disease control despite physician-assessed clear or minimal skin disease.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Kimball AB, Sundaram M, Samuelson TM, Signorovitch JE.

**Economic burden of hidradenitis suppurativa following a single surgical intervention: Assessment of unmet need using a retrospective claims-based analysis.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Jemec G, Guérin A, Sundaram M, Kaminsky MS, Okun MM.

**Indirect comparison suggests that adalimumab is associated with significantly more days of adverse event-free response versus etanercept.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Reich K, Signorovitch JE, Sundaram M, Mulani PM.

**Outcomes of switching to adalimumab vs. continuing methotrexate in patients with moderate to severe psoriasis stratified by initial response to methotrexate.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Reich K, Sundaram M, Signorovitch JE, Samuelson TM, Goldblum O, Fan L, Wu EQ, Mulani PM.

**Prevalence and incidence of hidradenitis suppurativa in the United States: Evidence from large administrative claims databases.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Sundaram M, Okun MM, Guérin A, Styles A, Hayes OA, Aberki C, Mulani PM.

**Psoriasis is significantly associated with lower rates of pregnancy and live births.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Cather JC, Horn EJ, Sundaram M, Latremouille-Viau D, Guérin A.

**Risk of developing micro- and macrovascular complications in diabetes patients with psoriasis.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Armstrong AW, Guérin A, Sundaram M, Faust E, Mulani PM.

**Treatment Patterns in Psoriasis Patients Newly Initiated on an Oral Conventional Systemic Therapy or on Phototherapy.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Zhang F, Guérin A, Hiscock R, Kimball A.

**Economic burden associated with workplace productivity losses (WPL) in patients with psoriasis in a population in the United States.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Zhang F, A G, Gauthier G, Day R, Khan Z.

**Economic burden of psoriasis (PSO) and obesity in patients with psoriasis in the United States.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

**Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Zhang F, Guerin A, Gauthier G, Day R, Khan Z.

**Quality-of-life effects of psoriasis skin symptoms affecting different body regions.**

*Abstract:* 3rd World Psoriasis and Psoriatic Arthritis Conference 2012: "Psoriasis - A Global Health Challenge" Stockholm, Sweden Jun 27-Jul 1, 2012.

*Authors:* Kimball AB, Sundaram M, Signorovitch J, Yang M, Mulani PM.

**Sex differences in health-related quality of life in patients with moderate to severe psoriasis.**

*Abstract:* 3rd World Psoriasis and Psoriatic Arthritis Conference 2012: "Psoriasis - A Global Health Challenge" Stockholm, Sweden Jun 27-Jul 1, 2012.

*Authors:* Cather JC, Horn EJ, Sundaram M, Yang M, Farooqui S, Mulani PM.

**Economic burden of psoriasis and obesity in patients with psoriasis in the United States.**

*Abstract:* 70th Annual Meeting of the American Academy of Dermatology, San Diego, CA Mar 16-20, 2012.

*Authors:* Zhang F, Guerin A, Latremouille-Viau D, Day R, Khan Z.

**Prevalence of autoimmune diseases and other comorbidities in patients with psoriasis in the United States.**

*Abstract:* 70th Annual Meeting of the American Academy of Dermatology, San Diego, CA Mar 16-20, 2012.

*Authors:* Guerin A, Zhang F, Gauthier G, Day R, Khan Z.

**Psoriasis is significantly associated with lower rates of pregnancy and live births.**

*Abstract:* 70th Annual Meeting of the American Academy of Dermatology, San Diego, CA Mar 16-20, 2012.

*Authors:* Cather JC, Latremouille-Viau D, Horn EJ, Bao Y.

**The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis.**

*Publication:* Journal of the American Academy of Dermatology 2012 02; 66(2): e67-76. doi: 10.1016/j.jaad.2010.10.020.

*Authors:* Kimball AB, Yu AP, Signorovitch J, Xie J, Tsaneva M, Gupta SR, Bao Y, Mulani PM.

**Treatment patterns of psoriasis patients and trends over time.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Zhang F, Guérin A, Gauthier G, Day R, Khan Z.

**ABT-874 versus methotrexate in moderate to severe psoriasis: Effects on health-related quality-of-life outcomes.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Reich K, Tsaneva M, Sundaram M, Bao Y.

**Achieving long-term sustained response is associated with improvements in patient-reported outcomes in patients with psoriasis treated with ABT-874.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Yu A, Sundaram M, Bao Y.

**Adalimumab provides health-related quality of life benefits for patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Duffin K, Menter A, Yang H, Gupta S.

**Comparison of psoriasis sign and symptom reduction and complete clearance with adalimumab versus etanercept.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Signorovitch J, Mulani P, Bao Y.

**Economic burden of comorbidities in patients with psoriasis is substantial.**

*Publication:* Journal of the European Academy of Dermatology and Venereology 2011 02; 25(2): 157-163. doi: 10.1111/j.1468-3083.2010.03730.x.

*Authors:* Kimball AB, Guerin A, Tsaneva M, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

**Effects of ABT-874 treatment on health-related quality of life and Work Productivity and Activity Impairment in patients with psoriasis.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Signorovitch J, Sundaram M, Bao Y.

**Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial.**

*Publication:* American Journal of Clinical Dermatology 2011 02; 12(1): 51-62. doi: 10.2165/11530640-000000000-00000.

*Authors:* Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, Bao Y, Gupta SR, Mulani PM.

**Fatigue outcomes following withdrawal from and retreatment with adalimumab among patients maintained on adalimumab for moderate to severe psoriasis.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Wu E, Goldblum O, Gupta S.

**Health care outcomes associated with continuous use of adalimumab versus continuous and intermittent use of etanercept in patients with psoriasis.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Latremouille-Viau D, Mulani P, Gupta S.

**Health-related quality of life in patients with moderate to severe psoriasis: Effects of treatment with ABT-874 versus etanercept or placebo.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Crowley J, Yang H, Sundaram M, Mulani P.

**Health-related quality of life outcomes in patients with moderate to severe psoriasis treated with ABT-874 versus etanercept or placebo.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Menter A, Signorovitch J, Sundaram M, Bao Y.

**Persistent impairment of work productivity and activity in patients with longer disease duration of psoriasis with hand/foot involvement.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA Feb 4-8, 2011.

*Authors:* Kimball A, Mulani P, Gupta S, Signorovitch J.

**Resource utilization and costs associated with adalimumab or etanercept for moderate to severe psoriasis in a real-world setting.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology, New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Guerin A, Gupta S, Bao Y.

**Resource utilization and costs associated with switching from etanercept to adalimumab versus dose escalating with etanercept in patients with psoriasis.**

*Abstract:* 69th Annual Meeting of the American Academy of Dermatology New Orleans, LA Feb 4-8, 2011.

*Authors:* Papp K, Guerin A, Mulani P, Gupta S.

**Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.**

*Publication:* Clinical Drug Investigation 2011 01; 31(1): 51-60. doi: 10.2165/11539360-000000000-00000.

*Authors:* Papp KA, Signorovitch J, Ramakrishnan K, Yu AP, Gupta SR, Bao Y, Mulani PM.

**Benefit-risk analysis of adalimumab versus methotrexate and placebo in the treatment of moderate to severe psoriasis: comparison of adverse event-free response days in the CHAMPION trial.**

*Publication:* Journal of the American Academy of Dermatology 2010 12; 63(6): 1011-1018. doi:

10.1016/j.jaad.2009.12.029.

*Authors:* Reich K, Signorovitch J, Ramakrishnan K, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

**Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trials.**

*Publication:* Dermatology 2010 11; 220(1): 1-7. doi: 10.1159/000260371.

*Authors:* Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

**ABT-874 versus etanercept or placebo treatment for moderate to severe psoriasis: Health-related quality of life.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Menter A, Signorovitch J, Parikh K, Yu A, Wu E, Yoo S, Gu Y, Valdes J, Sundaram M, Bao Y, Mulani P.

**Adalimumab improves sleep symptoms in patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Duffin K, Guérin A, Yang H, Wu E, Yu A, Gupta S, Goldblum O, Bao Y, Mulani P.



**Adalimumab provides health-related quality-of life benefits for patients with psoriasis with suboptimal response to etanercept methotrexate, or phototherapy.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Menter A, Guérin A, Yang H, Wu EQ, Yu AP, Gupta SR, Goldblum O, Bao Y, Mulani PM.

**Benefit-risk analysis of adalimumab for patients with psoriasis with suboptimal response to etanercept, methotrexate, or phototherapy.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Papp K, Guérin A, Parikh K, Signorovitch J, Yu AP, Wu EQ, Okun M, Gupta SR, Bao Y, Mulani PM.

**Effects of ABT-874 versus etanercept or placebo on health-related quality of life in patients with moderate to severe psoriasis.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Crowley J, Signorovitch J, Tsaneva M, Ramakrishnan K, Yu AP, Yoo S, Valdes J, Sundaram M, Bao Y, Mulani P.

**Longer disease duration of psoriasis with hand/foot involvement is independently associated with persistent impairment of work productivity and activity.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Kimball AB, Signorovitch J, Farooqui S, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani PM.

**Psoriasis treatment with ABT-874: Effects on health-related quality of life and work productivity and activity impairment.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Papp K, Signorovitch J, Yang H, Yu AP, Wu EQ, Yoo S, Gu Y, Williams D, Valdes J, Sundaram M, Bao Y, Mulani P.

**Resource utilization and costs in patients with moderate to severe psoriasis treated with adalimumab or etanercept in a real-world setting.**

*Abstract:* Congress of the European Academy of Dermatology and Venereology, Gothenburg, Sweden Oct 6-10, 2010.

*Authors:* Wu EQ, Guérin A, Latremouille-Viau D, Yu AP, Cloutier M, Gupta SR, Bao Y, Mulani PM.

**Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept.**

*Publication:* Pharmacoeconomics 2010 09; 28(10): 935-945. doi: 10.2165/11538370-000000000-00000.

*Authors:* Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, Gupta SR, Mulani PM.

**Burden of illness in patients with hidradenitis suppurativa.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL May 5-9, 2010.

*Authors:* Guerin A, Mulani P, Gupta S.

**The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.**

*Publication:* Journal of the American Academy of Dermatology 2010 05; 62(5): 812-818. doi: 10.1016/j.jaad.2009.07.022.

*Authors:* Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P.

**Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.**

*Publication:* American Journal of Medicine 2010 04; 123(4): 350-357. doi: 10.1016/j.amjmed.2009.08.022.

*Authors:* Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P.

**Adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol combination therapy: Effects on patient-reported outcomes in patients with psoriasis.**

*Abstract:* American Academy of Dermatology 68th Annual Meeting, Miami Beach, FL Mar 5-9, 2010.

*Authors:* Thaçi D, Xie J, Gupta S, Mulani P.

**Adalimumab versus ustekinumab treatment for psoriasis: Clinical efficacy, safety and cost per responder.**

*Abstract:* American Academy of Dermatology 68th Annual Meeting, Miami Beach, FL Mar 5-9, 2010.

*Authors:* Wu EQ, Signorovitch JE, Bao Y, Mulani PM.

**Comorbidity prevalence in psoriasis patients: A meta-analysis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Mrowietz U, Guerin A, Mulani P, Gupta S.

**Comorbidity risks increase over time in patients with psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Yu A, Mulani P, Bao Y.

**Comparative effectiveness of adalimumab versus ustekinumab treatment for psoriasis: Clinical efficacy, safety, and cost per responder.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Wu E, Signorovitch J, Mulani P, Bao Y.

**Comparison of benefit-risk profiles for adalimumab, methotrexate, and placebo in the treatment of moderate to severe psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Papp K, Signorovitch J, Mulani P, Bao Y.

**Comparison of response rates and drug costs during maintenance therapy with adalimumab versus ustekinumab in patients with moderate to severe psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Signorovitch J, Kantor E, Mulani P, Bao Y.

**Cost per responder for biologic treatment of psoriasis: Matching-adjusted comparison of adalimumab with etanercept, infliximab, and ustekinumab.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Signorovitch J, Mulani P, Gupta S, Bao Y.

**Cost-effectiveness of continuous adalimumab vs. continuous or intermittent etanercept for the treatment of psoriasis.**

*Abstract:* American Academy of Dermatology 68th Annual Meeting, Miami Beach, FL Mar 5-9, 2010.

*Authors:* Signorovitch J, Gupta SR, Bao Y, Mulan PM.

**Direct and indirect economic burden of employees with moderate to severe psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Reich K, Wu E, Mulani P, Gupta S.

**Economic burden of comorbidities in patients with psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Wu E, Mulani P, Bao Y.

**Effects of adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol combination therapy on patient-reported outcomes in psoriasis patients.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Thaci D, Xie J, Mulani P, Gupta S.

**Effects of adalimumab monotherapy versus adalimumab plus betamethasone/calcipotriol on patient-reported outcomes in patients with palmo-plantar, nail, or scalp psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Thaci D, Xie J, Mulani P, Gupta S.

**Increased cancer risks among patients with psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Guerin A, Mulani P, Bao Y.

**Increased economic burden associated with moderate to severe psoriasis compared with mild psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Yu A, Mulani P, Bao Y.

**Increased risk of psychiatric disorders in a pediatric population with psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Yu A, Mulani P, Gupta S.

**Longer psoriasis duration is independently associated with greater persistent functional impairment in patients with psoriatic arthritis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Signorovitch J, Mulani P, Bao Y.

**Potential drug-drug interactions of oral systemic therapies for psoriasis have adverse outcomes in a real-world setting.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Saurat JH, Guerin A, Mulani P, Gupta S.

**Psoriasis is associated with increased mortality risk.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Guerin A, Mulani P, Bao Y.

**Associated Resource Utilization and Costs of Patients with Psoriasis Switching from Etanercept to Adalimumab versus Dose Escalating with Etanercept.**

*Abstract:* American Academy of Dermatology 69th Annual Meeting, New Orleans, LA Feb 4-8, 2010.

*Authors:* Wu EQ GA, Lyon-Caen S, Latremouille-Viau D, Yu AP, Gupta SR, Bao Y.

**Healthcare Outcomes Associated with the Continuous Use of Adalimumab versus the Continuous and Intermittent Use of Etanercept in Patients with Psoriasis.**

*Abstract:* American Academy of Dermatology 69th Annual Meeting, New Orleans, LA Feb 4-8, 2010.

*Authors:* Wu EQ, Latremouille-Viau D, Guérin A, Cloutier M, Yu AP, Gupta SR, Bao Y.

**High prevalence of potential drug-drug interactions for psoriasis patients prescribed methotrexate or cyclosporine for psoriasis: associated clinical and economic outcomes in real-world practice.**

*Publication:* Dermatology 2010 02; 220(2): 128-137. doi: 10.1159/000275198.

*Authors:* Saurat JH, Guerin A, Yu AP, Latremouille-Viau D, Wu EQ, Gupta SR, Bao Y, Mulani PM.

**Economic burden of psoriasis compared to the general population and stratified by disease severity.**

*Publication:* Current Medical Research and Opinion 2009 10; 25(10): 2429-2438. doi: 10.1185/03007990903185557.

*Authors:* Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, Bao Y, Mulani PM.

**Risk-benefit analysis of adalimumab versus methotrexate and placebo for the treatment of moderate to severe psoriasis: Comparison of adverse event-free response days in the CHAMPION trial.**

*Abstract:* 39th Annual Meeting of the European Society for Dermatological Research, Budapest, Hungary Sep 9-12, 2009.

*Authors:* Reich K, Signorovitch J, Ramakrishnan K, Gupta S, Mulani P.

**Adalimumab reduces symptoms of depression in patients with moderate to severe psoriasis.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Menter A, Signorovitch J, Mulani P, Gupta S.

**Adalimumab reduces symptoms of psoriatic arthritis among psoriasis patients with comorbid psoriatic arthritis.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Mease P, Signorovitch J, Mulani P, Gupta S.

**Adalimumab treatment for moderate psoriasis reduces the risk of transitioning to severe psoriasis.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Papp K, Signorovitch J, Mulani P, Gupta S.

**Adalimumab's benefits for patient-reported outcomes in psoriasis patients are consistent across subgroups with different disease histories.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Kimball AB, Wu EQ, Mulani P, Gupta S.

**The benefits of adalimumab on clinical and patient-reported outcomes among moderate to severe psoriasis patients with comorbidities.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Kimball A, Chen L, Mulani P, Gupta S.

**Comorbidities of psoriasis have an independent effect on impairing patient health-related quality of life and work productivity.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Strober B, Guerin A, Mulani P, Gupta S.

**Discontinuation of adalimumab treatment for psoriasis following sustained response: Effects on health-related quality of life.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Menter A, Wu EQ, Mulani P.

**The effect of adalimumab on improving work productivity among moderate to severe psoriasis patients.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Kimball AB, Yu AP, Mulani P, Gupta S.

**The effect of adalimumab treatment for moderate to severe psoriasis on concurrent response for both psoriasis and psoriatic arthritis.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 3-10, 2009.

*Authors:* Mease P, Signorovitch J, Mulani P, Gupta S.

**Health-related quality of life and work productivity among psoriasis patients by disease severity.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Kimball A, Chen L, Mulani P, Gupta S.

**Risk-benefit analysis of adalimumab versus methotrexate and placebo for the treatment of moderate to severe psoriasis: Comparison of adverse event-free remission days in the CHAMPION trial.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Reich K, Yu AP, Mulani P, Gupta S.

**Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population.**

*Publication:* Current Medical Research and Opinion 2008 12; 24(12): 3493-3501. doi: 10.1185/03007990802551057.

*Authors:* Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK.

**The impact of psoriasis on health care costs and patient work loss.**

*Publication:* Journal of the American Academy of Dermatology 2008 11; 59(5): 772-780. doi:

10.1016/j.jaad.2008.06.043.

*Authors:* Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G.

**The direct and indirect cost burden of atopic dermatitis: an employer-payer perspective.**

*Publication:* Managed Care Interface 2007 10; 20(10): 26-32.

*Authors:* Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA, Kosicki G.

**Impact of Adalimumab (HUMIRA (R)) on Patient-Reported Outcomes.**

*Abstract:* American College of Gastroenterology, Philadelphia, PA Oct 12-17, 2007.

*Authors:* Loftus EV, Wu EQ, Yu AP.

**A survey-based assessment of the prevalence and severity of chronic hand dermatitis in a managed care organization.**

*Publication:* Cutis 2006 06; 77(6): 385-392.

*Authors:* Fowler JF, Duh MS, Chang J, Person J, Thorn D, Raut M, Ghosh A, Den E, Emani S.

**Impact of chronic hand dermatitis on quality of life, work productivity, activity impairment, and medical costs.**

*Publication:* Journal of the American Academy of Dermatology 2006 03; 54(3): 448-457. doi:

10.1016/j.jaad.2005.11.1053.

*Authors:* Fowler JF, Ghosh A, Sung J, Emani S, Chang J, Den E, Thorn D, Person J, Duh MS.

## Endocrine/Metabolic/Diabetes

**Comorbidities and Survival in Patients with Lipodystrophy: An International Chart Review Study.**

*Publication:* Journal of Clinical Endocrinology and Metabolism 2019 07. e-pub ahead of print 2019/07/18; doi:

10.1210/jc.2018-02730.

*Authors:* Akinci B, Oral EA, Neidert A, Rus D, Cheng WY, Thompson-Leduc P, Cheung HC, Bradt P, Foss de Freitas MC, Montenegro RM, Fernandes VO, Cochran E, Brown RJ.

**Clinical burden and healthcare resource utilization among patients with chronic hypoparathyroidism, overall and by adequately versus not adequately controlled disease: a multi-country chart review.**

*Publication:* Journal of Medical Economics 2019 05; 1. e-pub ahead of print 2019/05/28; doi:

10.1080/13696998.2019.1624081.

*Authors:* Chen K, Krasner A, Li N, Xiang CQ, Totev T, Xie J.

### **Management, Post-Discharge Admission, and Recurrence among Hyperkalemic Patients in the Emergency Department Setting.**

*Abstract:* NKF 2019 Spring Clinical Meeting, Boston, MA May 8-12, 2019.

*Authors:* Davis J, Israni R, Betts KA, Mu F, Cook E, Anzalone D, Szerlip H, Doctor T, Yin L, Uwaifo G, Wu E.

### **Outpatient Potassium Monitoring in Hyperkalemic Patients.**

*Abstract:* NKF 2019 Spring Clinical Meeting, Boston, MA May 8-12, 2019.

*Authors:* Davis J, Israni R, Betts KA, Mu F, Wang Y, Curhan GC, Anzalone D, Kinrich D, Pusch A, Uwaifo G, Fonseca V, Szerlip H.

### **Insights into the natural history of metachromatic leukodystrophy from interviews with caregivers.**

*Publication:* Orphanet Journal of Rare Diseases 2019 04; 14(1): 89. e-pub ahead of print 2019/05/01; doi: 10.1186/s13023-019-1060-2.

*Authors:* Harrington M, Whalley D, Twiss J, Rushton R, Martin S, Huynh L, Yang H.

### **Real-world impact of glyated hemoglobin reduction on treatment intensification and glyated hemoglobin goal attainment in type 2 diabetes mellitus patients initiated on a sodium glucose co-transporter 2 (SGLT2) inhibitor (SGLT2i).**

*Publication:* Current Medical Research and Opinion 2019 04: 1-8. e-pub ahead of print 2019/04/10; doi: 10.1080/03007995.2019.1605160.

*Authors:* Brunton S, Rozjabek HM, Pilon D, Lefeuvre MH, Kamstra R, Wynant W, Bookhart BK, Lefebvre P.

### **Management of Hyperkalemic Patients in the Inpatient Setting by Hyperkalemia Severity.**

*Abstract:* AMCP's 31st Annual Meeting, San Diego, CA Mar 25-28, 2019.

*Authors:* Davis J, Israni R, Betts K, Mu F, Cook E, Anzalone D, Szerlip H, Doctor T, Yin L, Uwaifo G, Fonseca V, Wu E.

### **Reduced Renin-Angiotensin-Aldosterone System Inhibitors (RAASi) Use after Hyperkalemia (HK)-Related Hospitalization.**

*Abstract:* AMCP's 31st Annual Meeting, San Diego, CA Mar 25-28, 2019.

*Authors:* Davis J, Betts K, Mu F, Wang Y, Wang Y.

### **Identifying solutions to psychological insulin resistance: An international study.**

*Publication:* Journal of Diabetes and its Complications. 2019 02. doi: <http://dx.doi.org/10.1016/j.jdiacomp.2019.01.001>.

*Authors:* Polonsky WH, Fisher L, Hessler D, Stuckey H, Snoek FJ, Tang T, Hermanns N, Mundet X, Silva M, Sturt J, Okazaki K, Hadjiyianni I, Cao D, Ivanova J, Desai U, Perez-Nieves M.

### **A real-world analysis of healthcare costs and relative risk of hyperprolactinemia associated with antipsychotic treatments in the United States.**

*Publication:* Journal of Medical Economics 2018 12; 21(12): 1183-1190. e-pub ahead of print 2018/09/07; doi: 10.1080/13696998.2018.1521415.

*Authors:* Cloutier M, Greene M, Touya M, Gagnon-Sanschagrin P, Guerin A.

### **Are some neighborhoods bad for your waistline? A test of neighborhood exposure effects on BMI.**

*Publication:* Journal of Health Economics 2018 11; 63: 52-63. e-pub ahead of print 2018/11/20; doi: 10.1016/j.jhealeco.2018.10.007.

*Authors:* Ou S.

### **Associated factors that influenced persistence with basal analog insulin therapy among people with type 2 diabetes: An exploratory analysis from a UK real-world sample.**

*Publication:* Primary Care Diabetes 2018 11. e-pub ahead of print 2018/11/28; doi: 10.1016/j.pcd.2018.09.002.

*Authors:* Idris I, Gulati K, Perez-Nieves M, Hadjiyianni I, Cao D, Tahbaz A, Ivanova J, Hassan SW.

**Attitudes among adults with type 2 diabetes affecting insulin initiation and discontinuation.**

*Abstract:* 54th Annual Meeting of the European Association for the Study Diabetes, EASD 2018, Berlin, Germany Oct 1-5, 2018.

*Authors:* Perez-Nieves M, Polonsky W, Fisher L, Snoek F, Hadjiyianni I, Cao D, Ivanova J, Desai U, Hessler D.

**Patient-level predictors of delay in insulin initiation and periods of insulin discontinuation among adults with type 2 diabetes.**

*Abstract:* 54th Annual Meeting of the European Association for the Study Diabetes, EASD 2018, Berlin, Germany Oct 1-5, 2018.

*Authors:* Fisher L, Polonsky W, Hessler D, Ivanova JI, Desai U, Cao D, Snoek FJ, Perez-Nieves M.

**Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes.**

*Publication:* Diabetes Care 2018 10; 41(10): 2096-2104. e-pub ahead of print 2018/08/23; doi: 10.2337/dc17-0662.

*Authors:* Desai U, Kirson NY, Kim J, Khunti K, King S, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.

**Predictors and clinical outcomes of treatment intensification in patients with type 2 diabetes uncontrolled on basal insulin in a real-world setting.**

*Publication:* Endocrine Practice 2018 09; 24(9): 805-814. doi: <http://dx.doi.org/10.4158/EP-2017-0261>.

*Authors:* Kallenbach L, Shui AM, Cheng WY, Fan T, Hu W, Zichlin ML, Duh MS, Ye F, Levin PA.

**Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data.**

*Publication:* Cardiovascular Diabetology 2018 08; 17(1): 118. e-pub ahead of print 2018/08/26; doi: 10.1186/s12933-018-0759-z.

*Authors:* Young JB, Gauthier-Loiselle M, Bailey RA, Manceur AM, Lefebvre P, Greenberg M, Lafeuille MH, Duh MS, Bookhart B, Wysham CH.

**Trends of insulin-like growth factor 1, growth hormone, and biochemical control of patients with acromegaly in Italy: A longitudinal retrospective chart review study.**

*Abstract:* 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic Aug 22-26, 2018.

*Authors:* Colao A, Grasso L, Di Cera M, Cheng WY, Thompson-Leduc P, Cheung HC, Duh MS, Neary MP, Pedroncelli AM, Maamari R, Pivonello R.

**Characteristics, Treatment Patterns, and Economic Outcomes of Patients Initiating Injectable Medications for Management of Type 2 Diabetes Mellitus in Japan: Results from a Retrospective Claims Database Analysis.**

*Publication:* Diabetes Therapy 2018 06; 9(3): 1125-1141. e-pub ahead of print 2018/04/18; doi: 10.1007/s13300-018-0407-3.

*Authors:* Suzuki S, Desai U, Strizek A, Ivanova J, Garcia-Horton V, Cai Z, Schmerold L, Liu X, Perez-Nieves M.

**Clinical Trajectories, Healthcare Resource Use, and Costs of Diabetic Nephropathy Among Patients with Type 2 Diabetes: A Latent Class Analysis.**

*Publication:* Diabetes Therapy 2018 06; 9(3): 1021-1036. e-pub ahead of print 2018/03/31; doi: 10.1007/s13300-018-0410-8.

*Authors:* Jiang R, Law E, Zhou Z, Yang H, Wu EQ, Seifeldin R.

**The prevalence of hyperkalemia in the United States.**

*Publication:* Current Medical Research and Opinion 2018 06; 34(6): 971-978. e-pub ahead of print 2018/01/26; doi: 10.1080/03007995.2018.1433141.

*Authors:* Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ.

**Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.**

*Publication:* Current Medical Research and Opinion 2018 06; 34(6): 1125-1133. e-pub ahead of print 2018/03/21; doi: 10.1080/03007995.2018.1454417.

*Authors:* Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P.

**Real-world evaluation of Hba1c, blood pressure, and weight loss among patients with type 2 diabetes mellitus treated with canagliflozin: an analysis of electronic medical records from a network of hospitals in Florida.**

*Publication:* Current Medical Research and Opinion 2018 06; 34(6): 1099-1115. e-pub ahead of print 2018/02/23; doi: 10.1080/03007995.2018.1444591.

*Authors:* Tanton D, Duh MS, Lafeuille MH, Lefebvre P, Pilon D, Zhdanova M, Emond B, Inman D, Bailey RA.

**Association between biochemical control and comorbidities and symptoms among patients with acromegaly in Italy: Stratified analyses by age and gender.**

*Publication:* Value in Health 2018 05; 21 (Supplement 1): S69-S70.

*Authors:* Colao A, Grasso L, Di Cera M, Cheng WY, Thompson-Leduc P, Cheung HC, Duh MS, Neary MP, Pedroncelli AM, Maamari R, Pivonello R.

**Healthcare costs associated with hyperprolactinemia in the United States.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Cloutier M, Greene M, Guerin A, Touya M, Gagnon-Sanschagrin P, Wu EQ.

**Initiation of Basal Insulin Analog Treatment for Type 2 Diabetes and Reasons Behind Patients' Treatment Persistence Behavior: Real-World Data from Germany.**

*Publication:* Experimental and Clinical Endocrinology and Diabetes 2018 05; 126(5): 287-297. e-pub ahead of print 2017/09/13; doi: 10.1055/s-0043-116386.

*Authors:* Moennig E, Perez-Nieves M, Hadjiyianni I, Cao D, Ivanova J, Klask R.

**Insulin non-persistence among people with type 2 diabetes: how to get your patients to stay on insulin therapy.**

*Publication:* Postgraduate Medicine 2018 05; 130(4): 394-401. e-pub ahead of print 2018/03/25; doi: 10.1080/00325481.2018.1457396.

*Authors:* Garnero TL, Davis NJ, Perez-Nieves M, Hadjiyianni I, Cao D, Ivanova JI, Peyrot M.

**Reduced Risk of Hyperprolactinemia Among Patients Treated With Atypical Antipsychotics that are Associated With Low or No Prolactin Elevation.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Cloutier M, Greene M, Guerin A, Touya M, Gagnon-Sanschagrin P, Wu E.

**Reduced risk of hyperprolactinemia among patients treated with atypical antipsychotics that are associated with low or no prolactin elevation.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Cloutier M, Greene M, Guerin A, Touya M, Gagnon-Sanschagrin P, Wu EQ.

**Comparison of 3-year estimated glomerular filtration rates between recombinant human parathyroid hormone (1-84) (RHPTH[1-84])-treated patients with chronic hypoparathyroidism and a historical control cohort.**

*Publication:* Endocrine Practice 2018 04; 24 (Supplement 1): 111. doi: <http://dx.doi.org/10.4158/1530-891X-24.s1.1>.

*Authors:* Chen K, Mu F, Swallow E, Zhao J, Wang J, Krasner A, Sherry N, Signorovitch J.



**Accepting insulin treatment for reluctant people with Type 2 diabetes: A global study to identify effective strategies (EMOTION): Results from the UK cohort.**

*Abstract:* 2018 Diabetes UK Professional Conference, London, UK Mar 14-16, 2018.

*Authors:* Sturt J, Fisher L, Ashraf N, Perez-Nieves M, Hadjiyianni I, Cao D, Balogh E, Ivanova J, Snoek F.

**Community health workers improve disease control and medication adherence among patients with diabetes and/or hypertension in Chiapas, Mexico: an observational stepped-wedge study.**

*Publication:* BMJ Glob Health 2018 03; 3(1): e000566. e-pub ahead of print 2018/03/13; doi: 10.1136/bmjgh-2017-000566.

*Authors:* Newman PM, Franke MF, Arrieta J, Carrasco H, Elliott P, Flores H, Friedman A, Graham S, Martinez L, Palazuelos L, Savage K, Tymeson H, Palazuelos D.

**The Cost of Hyperkalemia in the United States.**

*Publication:* Kidney Int Rep 2018 03; 3(2): 385-393. e-pub ahead of print 2018/05/05; doi: 10.1016/j.ekir.2017.11.003.

*Authors:* Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Wu EQ.

**Hba1c control and cost-effectiveness in patients with type 2 diabetes mellitus initiated on canagliflozin or a glucagon-like peptide 1 receptor agonist in a real-world setting.**

*Publication:* Endocrine Practice 2018 03; 24(3): 273-287. doi: <http://dx.doi.org/10.4158/EP-2017-0066>.

*Authors:* Wysham CH, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Lefebvre P.

**Treatment satisfaction with ITCA 650, a novel drug-device delivering continuous exenatide, versus twice-daily injections of exenatide in type 2 diabetics using metformin.**

*Publication:* Diabetes Obes Metab 2018 03; 20(3): 638-645. e-pub ahead of print 2017/10/21; doi: 10.1111/dom.13133.

*Authors:* Henry R, Rosenstock J, McCarthy JF, Carls G, Alessi T, Yee J, Baron M.

**Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy.**

*Publication:* Menopause 2018 25(11): 1297-1305. doi: <http://dx.doi.org/10.1097/GME.0000000000001232>.

*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

**Basal insulin initiation use and experience among people with type 2 diabetes mellitus with different patterns of persistence: results from a multi-national survey.**

*Publication:* Current Medical Research and Opinion 2017 10; 33(10): 1833-1842. e-pub ahead of print 2017/06/13; doi: 10.1080/03007995.2017.1341403.

*Authors:* Perez-Nieves M, Ivanova JI, Hadjiyianni I, Zhao C, Cao D, Schmerold L, Kalirai S, King S, DeLozier AM, Birnbaum HG, Peyrot M.

**Correlates of basal insulin persistence among insulin-naive people with type 2 diabetes: results from a multinational survey.**

*Publication:* Current Medical Research and Opinion 2017 10; 33(10): 1843-1851. e-pub ahead of print 2017/06/13; doi: 10.1080/03007995.2017.1341868.

*Authors:* Peyrot M, Perez-Nieves M, Ivanova J, Cao D, Schmerold L, Kalirai S, Hadjiyianni I.

**Patient characteristics of premix insulin users in china: An analysis of electronic medical record data.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Han S, Wang K, Hou J, Wang J, Wu EQ.

**Real-world persistence and HbA1c goal attainment in type 2 diabetes mellitus patients initiated on canagliflozin or a glucagon-like peptide-1.**

*Abstract:* 47th Annual Conference Endocrine Society of India, Kerala, India Oct 13-15, 2017.

*Authors:* Rajani A, Pfeifer M, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Wysham CH.

**Apolipoprotein C-III and High-Density Lipoprotein Subspecies Defined by Apolipoprotein C-III in Relation to Diabetes Risk.**

*Publication:* American Journal of Epidemiology 2017 09; 186(6): 736-744. doi: <http://dx.doi.org/10.1093/aje/kwx143>.

*Authors:* Aroner SA, Yang M, Li J, Furtado JD, Sacks FM, Tjonneland A, Overvad K, Cai T, Jensen MK.

**Glycaemic control, weight loss, and use of other antihyperglycaemics in patients with type 2 diabetes initiated on canagliflozin or sitagliptin: A real-world analysis.**

*Abstract:* 53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal Sep 11-15, 2017.

*Authors:* Ingham M, Lefebvre P, Pilon D, Lafeuille MH, Emond B, Kamstra R, Pfeifer M, Duh MS, Wysham C.

**Real-world persistence and HbA1c goal attainment in type 2 diabetes patients initiated on canagliflozin or a glucagon-like peptide-1.**

*Abstract:* 53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal Sep 11-15, 2017.

*Authors:* Pfeifer M, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Wysham C.

**Real-world weight change among patients treated with glucagon-like peptide-1 receptor agonist, dipeptidyl peptidase-4 inhibitor and sulfonylureas for type 2 diabetes and the influence of medication adherence.**

*Publication:* Obesity Science and Practice 2017 09; 3(3): 342-351. doi: <http://dx.doi.org/10.1002/osp4.116>.

*Authors:* Carls GS, Tan R, Zhu JY, Tuttle E, Yee J, Edelman SV, Polonsky WH.

**Renal outcomes with DPP-4 inhibitors compared with sulfonylurea as add-on to metformin among patients with type 2 diabetes.**

*Abstract:* 53rd Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal Sep 11-15, 2017.

*Authors:* Teh HH, Desai U, Kirson NY, Hellstern M, Leigh PS, Mukherjee J, Khunti K.

**Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014.**

*Publication:* Diabetes Therapy 2017 06. e-pub ahead of print 2017/06/25; doi: 10.1007/s13300-017-0280-5.

*Authors:* Carls G, Huynh J, Tuttle E, Yee J, Edelman SV.

**Healthcare Resource Use, Costs, and Disease Progression Associated with Diabetic Nephropathy in Adults with Type 2 Diabetes: A Retrospective Observational Study.**

*Publication:* Diabetes Therapy 2017 06; 8(3): 555-571. e-pub ahead of print 2017/04/01; doi: 10.1007/s13300-017-0256-5.

*Authors:* Zhou Z, Chaudhari P, Yang H, Fang AP, Zhao J, Law EH, Wu EQ, Jiang R, Seifeldin R.

**Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population.**

*Publication:* Current Medical Research and Opinion 2017 06; 33(6): 1105-1110. e-pub ahead of print 2017/03/16; doi: 10.1080/03007995.2017.1307173.

*Authors:* DerSarkissian M, Bhak RH, Huang J, Buchs S, Vekeman F, Smolarz BG, Brett J, Ganguly R, Duh MS.

**Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.**

*Publication:* BMC Endocrine Disorders 2017 06; 17(1): 32. e-pub ahead of print 2017/06/10; doi: 10.1186/s12902-017-0180-8.

*Authors:* Wysham CH, Lefebvre P, Pilon D, Ingham M, Lafeuille MH, Emond B, Kamstra R, Chow W, Pfeifer M, Duh MS.

**Systematic literature review of clinical, humanistic, and economic burden in cushing's disease.**

*Abstract:* 99th Annual Meeting and Expo of the Endocrine Society, Orlando, FL June 7, 2017.

*Authors:* Watchko S, Nellesen D, Neary MP.

**Reasons for different patterns of basal insulin persistence after initiation among people with type 2 diabetes (T2D).**

*Abstract:* Deutsche Diabetes Gesellschaft (DDG) Diabetes Kongress, Hamburg, Germany May 24-27, 2017.

*Authors:* Peyrot M, Ivanova J, Zao C, Schmerold L, King S, Birnbaum HG, DeLozier AM, Adjijanni IH, Kabul S, Cao D, Duan R, Perez-Nieves M.

**Insulin initiation experiences in people with Type 2 diabetes: Data from the UK.**

*Publication:* Diabetic Medicine 2017 03; 34: 189. doi: <http://dx.doi.org/10.1111/dme.13302>.

*Authors:* Hassan SW, Hadjiyanni I, Ivanova J, Cao D, Gulati K, Tahbaz A, Perez-Nieves M.

**Reasons for treatment persistence patterns in people with Type 2 diabetes after initiation of basal insulin: Data from UK patients.**

*Abstract:* Diabetes UK Professional Conference, Manchester, UK Mar 3-10, 2018.

*Authors:* Hassan SW, Gulati K, Hadjiyanni I, Cao D, Tahbaz A, Ivanova J, Perez-Nieves M.

**Basal Insulin Persistence, Associated Factors, and Outcomes after Treatment Initiation: A Retrospective Database Study Among People with Type 2 Diabetes Mellitus in Japan.**

*Publication:* Diabetes Therapy 2017 02; 8(1): 149-166. e-pub ahead of print 2016/12/04; doi: 10.1007/s13300-016-0215-6.

*Authors:* Hadjiyanni I, Desai U, Suzuki S, Ivanova JI, Cao D, Kirson NY, Chida D, Enloe C, Birnbaum HG, Perez-Nieves M.

**Understanding the Gap Between Efficacy in Randomized Controlled Trials and Effectiveness in Real-World Use of GLP-1 RA and DPP-4 Therapies in Patients With Type 2 Diabetes.**

*Publication:* Diabetes Care 2017 40(11): 1469-1478. doi: 10.2337/dc16-2725.

*Authors:* Carls GS, Tuttle E, Tan R-D, Huynh J, Yee J, Edelman SV, Polonsky WH.

**Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes.**

*Publication:* Journal of Endocrinological Investigation 2016 12; 39(12): 1391-1399. e-pub ahead of print 2016/06/12; doi: 10.1007/s40618-016-0495-8.

*Authors:* Bonora B, Maran A, Ciciliot S, Avogaro A, Fadini GP.

**The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure.**

*Abstract:* AMCP Nexus 2016, Baltimore, MD Oct 3-6, 2016.

*Authors:* Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhanian A, Wu E.

**The Prevalence of Hyperkalemia in the United States.**

*Abstract:* AMCP Nexus 2016, Baltimore, MD Oct 3-6, 2016.

*Authors:* Betts K, Woolley JM, Mu F, McDonald E, Tang W, Singhanian A, Pham H, Hollenack K, Wu EQ.

**A cloud-based electronic health records study of treatment intensification patterns in type 2 diabetes patients uncontrolled on >2 oral anti-diabetes drugs.**

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany Sep 12-16, 2016.

*Authors:* Kallenbach L, Pesuit J, Fan T, Hu W, Shui A, Cheng W, Duh M, Zichlin M, Levin P.

**Disease progression of diabetic nephropathy in adults with type 2 diabetes in the US.**

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany Sept 12-16, 2016.

*Authors:* Zhou Z, Yang H, Fang A, Zhao J, Wu E, Chaudhari P, Seifeldin R.

**The healthcare costs and utilisation associated with diabetic nephropathy in adult patients with type 2 diabetes in the US.**

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany Sept 12-16, 2016.

*Authors:* Yang H, Zhou Z, Zhao J, Fang A, Wu E, Chaudhari P, Seifeldin R.

**Real-world weight change among patients treated with GLP-1, SU, or DPP-4 therapy for type 2 diabetes and the influence of medication adherence.**

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany Sep 12-16, 2016.

*Authors:* Carls GS, Tan RD, Tuttle E, Yee J, Polonsky WH, Edelman SV.

**Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.**

*Publication:* Diabetes Therapy 2016 09; 7(3): 439-454. e-pub ahead of print 2016/08/10; doi: 10.1007/s13300-016-0189-4.

*Authors:* Thomas MC, Paldanius PM, Ayyagari R, Ong SH, Groop PH.

**Time to treatment intensification and its association with subsequent microvascular outcomes among patients with type 2 diabetes.**

*Abstract:* 52nd Annual Meeting of the European Association for the Study of Diabetes, Munich, Germany Sep 12-16, 2016.

*Authors:* Desai U, Kirson NY, Kim J, Khunti KK, King SB, Trieschman E, Hellstern M, Hunt PR, Mukherjee J.

**Real-world glycemic, blood pressure, and weight control in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health-record-based study.**

*Publication:* Current Medical Research and Opinion 2016 06; 32(6): 1151-1159. e-pub ahead of print 2016/04/27; doi: 10.1080/03007995.2016.1183604.

*Authors:* Lefebvre P, Pilon D, Robitaille MN, Lefeuille MH, Chow W, Pfeifer M, Duh MS.

**Venous thromboembolism and cardiovascular disease complications in menopausal women using transdermal versus oral estrogen therapy.**

*Publication:* Menopause 2016 06; 23(6): 600-610. doi: <http://dx.doi.org/10.1097/GME.0000000000000590>.

*Authors:* Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

**Maintenance of weight loss or stable weight in subjects with obesity: A retrospective longitudinal analysis of electronic medical record data.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Der Sarkissian M, Bhak R, Huang J, Buchs S, Vekeman F, Ganguly R, Duh MS.

**Real-world evaluation of weight loss in patients with type 2 diabetes mellitus treated with canagliflozin-an electronic health record-based study.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Lefebvre P, Chow W, Pilon D, Emond B, Lefeuille M, Pfeifer M, Rupnow MF, Duh MS.

**Basal insulin persistence, associated factors, and outcomes after treatment initiation among people with type 2 diabetes mellitus in the US.**

*Publication:* Current Medical Research and Opinion 2016 04; 32(4): 669-680. e-pub ahead of print 2015/12/26; doi: 10.1185/03007995.2015.1135789.

*Authors:* Perez-Nieves M, Kabul S, Desai U, Ivanova JI, Kirson NY, Cummings AK, Birnbaum HG, Duan R, Cao D, Hadjiyianni I.

**Budget impact of pasireotide LAR for the treatment of acromegaly, a rare endocrine disorder.**

*Publication:* Journal of Medical Economics 2016 04; 19(4): 374-385. doi: 10.3111/13696998.2015.1127816.

*Authors:* Zhang JJ, Nellesen D, Ludlam WH, Neary MP.

**Patterns of Weight Loss, Maintenance, and Gain in Patients with Obesity.**

*Abstract:* Endocrinology Society 2016, Boston, MA Apr 1-4, 2016.

*Authors:* Huang; J, Buchs; S, DerSarkissian; M, Bhak; R, Vekeman; F, Ganguly; R, Duh; MS.

**Safety and efficacy of insulin glargine 300 u/mL compared with other basal insulin therapies in patients with type 2 diabetes mellitus: a network meta-analysis.**

*Publication:* BMJ Open 2016 02; 6(2): e009421. e-pub ahead of print 2016/02/18; doi: 10.1136/bmjopen-2015-009421.

*Authors:* Freemantle N, Chou E, Frois C, Zhuo D, Lehmacher W, Vlajnic A, Wang H, Chung HW, Zhang Q, Wu E, Gerrits C.

**Real-world evaluation of weight loss in patients with type 2 diabetes mellitus (T2DM) treated with canagliflozin (CANA) - an electronic health-record (EHR)-based study.**

*Abstract:* Obesity Week, Los Angeles, CA Nov 2-6, 2015.

*Authors:* P; L, W; C, D; P, B; E, MH; L, M; P, MFT; R, MS; D.

**Retrospective Analysis of Dose Titration and Serum Testosterone Level Assessments in Patients Treated with Topical Testosterone.**

*Publication:* Am J Mens Health 2015 11; 9(6): 496-505. doi: 10.1177/1557988314551569.

*Authors:* Muram D, Kaltenboeck A, Boytsov N, Hayes-Larson E, Ivanova J, Birnbaum HG, Swindle R.

**Glycemic and Cholesterol Control versus Single-Goal Control in US Veterans with Newly Diagnosed Type 2 Diabetes: A Retrospective Observational Study.**

*Publication:* Diabetes Therapy 2015 09; 6(3): 339-355. doi: 10.1007/s13300-015-0122-2.

*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Zhang M, Wang Y, Fonseca VA.

**For a Step Change to Curb the Obesity Epidemic.**

*Publication:* Pharmacoeconomics 2015 07; 33(7): 613-617. doi: 10.1007/s40273-015-0303-x.

*Authors:* Frois C, Cremieux PY.

**Gap Between Evidence and Patient Access: Policy Implications for Bariatric and Metabolic Surgery in the Treatment of Obesity and its Complications.**

*Publication:* Pharmacoeconomics 2015 07; 33(7): 629-641. doi: 10.1007/s40273-015-0302-y.

*Authors:* Chawla AS, Hsiao CW, Romney MC, Cohen R, Rubino F, Schauer P, Cremieux P.

**Policy Makers' Views of Obesity-Related Challenges Around the World : An interview between Pierre Cremieux (of Analysis Group, Inc., and Guest Editor of this Special Issue) and policy makers from Brazil (Patricia Constante Jaime), Canada (Kimberly Elmslie), China (Bin Wang), France (Francois Cremieux), and the USA (Mark McClellan).**

*Publication:* Pharmacoeconomics 2015 07; 33(7): 619-628. doi: 10.1007/s40273-015-0290-y.

*Authors:* Cremieux P.

**Economic outcomes among Medicare patients receiving skin substitutes for treatment of diabetic foot ulcers.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Rice JB, Desai U, Ristovska L, Cummings AG, Birnbaum HG, Skornicki M, Margolis D, Parsons N.

**Glycated hemoglobin (Hba1c) control in patients with Type 2 Diabetes Mellitus (T2DM) treated with canagliflozin in a realworld setting.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 15-20, 2015.

*Authors:* Lefebvre P, Pilon D, Robitaille M, Lafeuille M, Chow W, Pfeifer M, Duh MS.

**Economic outcomes among Medicare patients receiving bioengineered cellular technologies for treatment of diabetic foot ulcers.**

*Publication:* Journal of Medical Economics 2015 04; 18(8): 586-595. doi: 10.3111/13696998.2015.1031793.

*Authors:* Rice JB, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Skornicki M, Margolis DJ, Parsons NB.

**Effect of adherence and insulin delivery system on clinical and economic outcomes among patients with type 2 diabetes initiating insulin treatment.**

*Publication:* Value in Health 2015 03; 18(2): 198-205. doi: 10.1016/j.jval.2014.12.016.

*Authors:* Ayyagari R, Wei W, Cheng D, Pan C, Signorovitch J, Wu EQ.

**Economic simulation of canagliflozin and sitagliptin treatment outcomes in patients with type 2 diabetes mellitus with inadequate glycemic control.**

*Publication:* Journal of Medical Economics 2015 02; 18(2): 113-125. doi: 10.3111/13696998.2014.980503.

*Authors:* Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

**Burden of diabetic foot ulcers for Medicare and private insurers.**

*Publication:* Diabetes Care 2014 11; 37(3): 651-658. doi: 10.2337/dc13-2176.

*Authors:* Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons NB.

**Daily dose and costs associated with maintenance therapy of topical testosterone agents among hypogonadal men.**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8 - 12, 2014.

*Authors:* Kaltenboeck A, Boytsov N, Hayes-Larson E, San Roman A, Ivanova J, Birnbaum H, Foster S, Vazquez J, Muram D, Swindle R.

**Which newly-diagnosed diabetics should receive dietary counseling services? Estimating individualized treatment allocations that optimize cost-effectiveness in real-world data.**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.

*Authors:* Signorovitch J, Betts KA, Meng X, Zhuo Y, Wu EQ, Shi L.

**The burden of "serial non-adherence" in type 2 diabetic patients.**

*Abstract:* 50th Annual Meeting of the European Association for the Study of Diabetes, Vienna, Austria Sept 15-19-2014.

*Authors:* Frois C, Dea K, Ling D, Dunn J, Baron M.

**Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis.**

*Publication:* Journal of Medical Economics 2014 09; 17(9): 646-657. doi: 10.3111/13696998.2014.925905.

*Authors:* Bron M, Guerin A, Latremouille-Viau D, Ionescu-Ittu R, Viswanathan P, Lopez C, Wu EQ.

**Treatment effectiveness of pasireotide on health-related quality of life in patients with Cushing's disease.**

*Publication:* European Journal of Endocrinology of the European Federation of Endocrine Societies 2014 07; 171(1): 89-98. doi: 10.1530/EJE-13-1013.

*Authors:* Webb SM, Ware JE, Forsythe A, Yang M, Badia X, Nelson LM, Signorovitch JE, McLeod L, Maldonado M, Zgliczynski W, de Block C, Portocarrero-Ortiz L, Gadelha M.

**Systematic Review of real-world evidence on treatment of Acromegaly.**

*Abstract:* 96th Annual Meeting and Expo of the Endocrine Society, Chicago, IL June 21-24, 2014.

*Authors:* Guérin A, Xu Y, Hiscock R, Begelman SM, Mu Y, Alaghband R, Wu EQ.

**Costs after initiating saxagliptin, sulfonyleurea, or sitagliptin in patients with T2DM.**

*Publication:* American Journal of Pharmacy Benefits 2014 05; 6(3): e60-e69.

*Authors:* Kaltenboeck A, Ivanova J, Birnbaum H, Yushkina Y, Schwiep F, Bell K, Thomas N.

**Daily dose and costs associated with maintenance therapy of topical testosterone agents among hypogonadal men.**

*Abstract:* 20th Annual Fall Scientific Meeting of the Sexual Medicine Society of North America, Miami, FL Nov 20-23, 2014.

*Authors:* Kaltenboeck A, Boytsov N, Hayes-Larson E, San Roman AM, Ivanova J, Birnbaum HG, Foster SA, Vazquez JA, Muram D, Swindle RW.

**Management of patients using combination therapy with pioglitazone and a dipeptidyl peptidase-4 inhibitor: an analysis of initial versus sequential combination therapy.**

*Publication:* Postgraduate Medicine 2014 05; 126(3): 47-55. doi: 10.3810/pgm.2014.05.2755.

*Authors:* Bron M, Ayyagari R, Sharma H, Chen K, Bozas A, Wu E.

**Units and costs per day per claim of comparable insulins supplied to Medicaid patients.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Ivanova JI, Foster S, Desai U, Hayes-Larson E, King S, Birnbaum HG, Swindle R.

**Budget impact of pasireotide for the treatment of Cushing's disease, a rare endocrine disorder associated with considerable comorbidities.**

*Publication:* Journal of Medical Economics 2014 04; 17(4): 288-295. doi: 10.3111/13696998.2013.877470.

*Authors:* Truong HL, Nellesen D, Ludlam WH, Neary MP.

**Estimating the incremental net health benefit of requirements for cardiovascular risk evaluation for diabetes therapies.**

*Publication:* Pharmacoepidemiology and Drug Safety 2014 03; 23(3): 268-277.

*Authors:* Chawla AJ, Mytelka DS, McBride SD, Nellesen D, Elkins BR, Ball DE, Kalsekar A, Towse A, Garrison LP.

**Opportunities for Improving Attainment of Quality Measures in Patients with Type 2 Diabetes Mellitus.**

*Publication:* American Journal of Managed Care 2014 01; 20(1).

*Authors:* Bailey R, Blonde L, Damaraju CV, Duh MS, Garber L, Gravel J, Grittner A, Lafeuille M, Lefebvre P, Martin S, Meininger G, Rupnow M.

**Quality measure attainment in patients with type 2 diabetes mellitus.**

*Publication:* American Journal of Managed Care 2014 01; 20(1 Suppl): s5-15.

*Authors:* Lafeuille MH, Grittner AM, Gravel J, Bailey RA, Martin S, Garber L, Sheng Duh M, Lefebvre P.

**Clinical and economic benefits associated with the achievement of both HbA1c and LDL cholesterol goals in veterans with type 2 diabetes.**

*Publication:* Diabetes Care 2013 10; 36(10): 3297-3304. doi: 10.2337/dc13-0149.

*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Fonseca VA.

**Venous thromboembolism and cardiovascular disease complications in women using transdermal versus oral menopausal estrogen therapy.**

*Abstract:* 24th Annual Meeting of the North American Menopause Society, Dallas, TX Oct 9-12, 2013.

*Authors:* Simon JA, Laliberte F, Duh MS, Pilon D, Kahler KH, Nyirady J, Davis PJ, Lefebvre P.

**Association of self-monitoring of blood glucose use on glycated hemoglobin and weight in newly diagnosed, insulin-naïve adult patients with type 2 diabetes.**

*Publication:* Journal of Diabetes Science and Technology 2013 09; 7(5): 1229-1242.

*Authors:* Virdi NS, Lefebvre P, Parise H, Duh MS, Pilon D, Laliberte F, Sundaresan D, Garber L, Dirani R.

**Cost predictors in type 2 diabetes mellitus: A retrospective claims database analysis.**

*Abstract:* 49th Annual Meeting of the European Association for the Study of Diabetes, Barcelona, Spain Sep 23-27, 2013.

*Authors:* Ionescu-Ittu R, Bron M, Latremouille-Viau D, Guerin A, Samp J, Wu E.

**Distribution of costs in patients with type 2 diabetes mellitus: A retrospective claims database analysis.**

*Abstract:* 49th Annual Meeting of the European Association for the Study of Diabetes, Barcelona, Spain Sep 23-27, 2013.

*Authors:* Bron M, Guerin A, Latremouille-Viau D, Ionescu-Ittu R, Lopez C, Viswanathan P, Wu E.

**Clinical characteristics, quality measure attainment, and diabetes-related healthcare costs in patients with type 2 diabetes mellitus (T2DM) receiving metformin (MET) and sulfonylurea (SU).**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Lafeuille MH, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

**Relative and attributable diabetes risk associated with hyperuricemia in US veterans with gout.**

*Publication:* QJM 2013 08; 106(8): 721-729. doi: 10.1093/qjmed/hct093.

*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu EQ, Tawk R, Liu J, Shi L.

**Effects of insulin adherence and delivery device on real world outcomes among patients with Type 2 Diabetes Mellitus (T2DM).**

*Abstract:* 73rd Scientific Sessions of the American Diabetes Association, Chicago, IL Jun 21-25, 2013.

*Authors:* Ayyagari R, Wei W, Cheng D, Pan C, Wu EQ.

**Clinical characteristics, quality measure attainment, and diabetes-related health care costs in elderly versus overall people living with type-2 diabetes mellitus (T2DM) receiving metformin (MET) and sulfonylurea (SU).**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Lafeuille MH, Gravel J, Bailey RA, Martin S, Garber L, Duh MS, Lefebvre P.

**Economic Outcomes Associated with Hba1c and Ldl-C Goal Achievement In Patients with Type 2 Diabetes Mellitu.**

*Abstract:* ISPOR, May 18-22, 2013.

*Authors:* Shi L, Ye X, Lu M, Wu E, Sharma H, Thomason D, Fonseca V.

**Health care resource use and costs in patients with type 2 diabetes mellitus after treatment initiation with saxagliptin or sitagliptin.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Kaltenboeck A, Ivanova J, Thomas N, Bell K, Yushkina Y, Schwiep FA, Birnbaum H.

**Medical, drug, and work-loss costs of diabetic foot ulcers.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

**Trend in economic burden of diabetes in urban china from 2009 to 2011.**

*Abstract:* ISPOR, May 18-22, 2013.

*Authors:* Wu E, Xie J, Du E, Liu M, Liu G.



**Hypoglycaemia and accident risk in people with type 2 diabetes mellitus treated with non-insulin antidiabetes drugs.**

*Publication:* Diabetes Obes Metab 2013 04; 15(4): 335-341. doi: 10.1111/dom.12031.

*Authors:* Signorovitch JE, Macaulay D, Diener M, Yan Y, Wu EQ, Gruenberger JB, Frier BM.

**Improved clinical outcomes associated with dual-goal (HBA1C and LDL-C) achievement in newly diagnosed type 2 diabetes mellitus.**

*Abstract:* American Heart Association's Epidemiology and Prevention/Physical Activity, Nutrition and Metabolism 2013 Scientific Sessions, New Orleans, LA Mar 3-22, 2013.

*Authors:* Shi L, Ye X, Lu M, Wu EQ, Sharma H, Thomason D, Kang AL, Fonseca VA.

**The importance of adjustment for placebo-arm effects in indirect comparisons of glycemic control in type 2 diabetes mellitus.**

*Abstract:* 1st American Diabetes Association Middle East Congress, Dubai, UAE Dec 4-6, 2012.

*Authors:* Ayyagari R, Ong SH, Signorovitch JE, Rikun A, Gruenberger JB.

**Clinical and resource utilization outcomes: Elderly type 2 diabetes patients initiating insulin pens versus vials.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Eby E, Frois C, Guerin A, Boggs JA, Nyhuis A, Swindle R.

**Hba1c reduction associated with initial versus sequential combination therapy with pioglitazone (PIO) and dipeptidyl peptidase-4 inhibitors (DPP4i) in patients with type 2 diabetes mellitus (T2DM).**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Bron M, Chen K, Ayyagari R, Sharma H, Wu EQ.

**Physician beliefs about insulin pens versus vials, therapy choice factors, and patient characteristics among elderly type 2 diabetes patients.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Eby E, Frois C, Guerin A, Boggs JA, Nyhuis A, Swindle R.

**Comparison of clinical and economic outcomes associated with DPP4i versus SU in combination with MET or PIO for the treatment of type 2 diabetes mellitus.**

*Abstract:* 48th Annual Meeting of the European Association for the Study of Diabetes, Berlin, Germany Oct 2-5, 2012.

*Authors:* Chen K, Wu E, Cheng D, Bensimon A, Bron M.

**Outcomes associated with post-discharge insulin continuity in US patients with type 2 diabetes mellitus initiating insulin in the hospital.**

*Publication:* Hosp Pract (1995) 2012 10; 40(4): 40-48. doi: 10.3810/hp.2012.10.1002.

*Authors:* Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T.

**The direct and indirect costs among U.S. privately insured employees with hypogonadism.**

*Publication:* Journal of Sexual Medicine 2012 09; 9(9): 2438-2447. doi: 10.1111/j.1743-6109.2012.02810.x.

*Authors:* Kaltenboeck A, Foster S, Ivanova J, Diener M, Bergman R, Birnbaum H, Kinchen K, Swindle R.

**Glycemic control and quality of life for patients with type 2 diabetes mellitus in China.**

*Abstract:* ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan (Republic of China) Sep 2-4, 2012.

*Authors:* Xie K, Wu J, Xie J, Zheng Y, Yang HY, Wu EQ.

**Outcomes associated with insulin therapy disruption after hospital discharge among patients with type 2 diabetes mellitus who had used insulin before and during hospitalization.**

*Publication:* Endocrine Practice 2012 09; 18(5): 651-659. doi: 10.4158/EP11314.OR.

*Authors:* Wu EQ, Zhou S, Yu A, Lu M, Sharma H, Gill J, Graf T.

**PDB17 Comparison of Clinical and Economic Outcomes Associated with Dpp4 Inhibitors (DPP4I) versus Sulfonylurea (SU) in Combination with Metformin (MET) or Pioglitazone (PIO) for the Treatment of Type 2 Diabetes Mellitus (T2DM).**

*Abstract:* ISPOR, Sep 2-4, 2012.

*Authors:* Bron M, Chen K, Cheng D, Bensimon A, Wu E.

**Predictors of reaching HbA1c goal in T2DM patients using dipeptidyl peptidase-4 inhibitors (DPP-4IS) combination therapy: A subgroup analysis.**

*Abstract:* ISPOR 5th Asia-Pacific Conference, Taipei, Taiwan (Republic of China) Sep 2-4, 2012.

*Authors:* Chen K, Bron M, Cheng D, Sharma H, Wu EQ.

**Risk of developing micro- and macrovascular complications in diabetes patients with psoriasis.**

*Abstract:* 21st European Academy of Dermatology and Venereology Congress, Prague, Czech Republic Sep 27-30, 2012.

*Authors:* Armstrong AW, Guérin A, Sundaram M, Faust E, Mulani PM.

**Assessment of Preferences and Willingness-to-Pay for a New Basal Insulin Across Insulin Naïve and Experienced Patients.**

*Abstract:* American Diabetes Association's 72nd Scientific Sessions, Philadelphia, PA June 8-10, 2012.

*Authors:* Yang M, Lin P, Wintfeld N, Frois C.

**A Discrete Choice Experiment to Evaluate Diabetes Patients Preferences and Willingness-to-Pay for a New Basal Insulin.**

*Abstract:* American Diabetes Association's 72nd Scientific Sessions, Philadelphia, PA June 8-10, 2012.

*Authors:* Yang M, Lin P, Wintfeld N, Frois C.

**Economic burden of type 2 diabetes mellitus in China.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Zheng Y, Wu EQ, Xie K, Zheng B, Yang HY, Xie J, Wu J.

**Effect of diabetes patient characteristics on the willingness-topay for a new basal insulin-a discrete choice experiment.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Yang M, Lin P, Wintfeld N, Frois C.

**Health utility for patients with type 2 diabetes mellitus in China.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Wu J, Xie J, Han R, Wang L, Yang HY, Wu EQ.

**Hypoglycaemia and accident risk in people with Type 2 diabetes treated with antidiabetes drugs without insulin.**

*Abstract:* Diabetes UK Professional Conference, Glasgow, UK Mar 7-9, 2012.

*Authors:* Chen S, Macaulay D, Xie J, Swallow E, Diener M, Farooqui S, Wu E.

**Hypoglycaemia and accident risk in people with Type 2 diabetes treated with antidiabetes drugs without insulin.**

*Abstract:* Diabetes UK Professional Conference 2012 Glasgow, UK Mar 7-9, 2012.

*Authors:* Signorovitch J, Macaulay D, Diener M, Wu EQ, Gruenberger JB, Frier BM.

**Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.**

*Publication:* Postgraduate Medicine 2012 01; 124(1): 124-132. doi: 10.3810/pgm.2012.01.2525.

*Authors:* Bron M, Marynchenko M, Yang H, Yu AP, Wu EQ.

**Cost and frequency of hypoglycemic events in adult and elderly diabetics from an insured managed care population in the U.S.**

*Abstract:* IDF World Diabetes Congress, Dubai, United Arab Emirates Dec 4-8, 2011.

*Authors:* Bron M, Yang HY, Yu AP, Marynchenko M, Fan L.

**Association between hypoglycemia and medication possession ratio among veterans with type 2 diabetes mellitus (T2DM).**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Zhao Y, Shi L, Fonseca V, Campbell C, Wu EQ.

**Economic burden of psoriasis and diabetes in patients with psoriasis in the United States.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Wu EQ, Guerin A, Latremouille-Viau D, Day R, Khan Z, Zhang F.

**Economic burden of psoriatic arthritis and diabetes in patients with psoriatic arthritis in the United States.**

*Abstract:* ACR/ARHP Annual Scientific Meeting, Chicago, IL Nov 4-9, 2011.

*Authors:* Guérin A, Gauthier G, Day R, Khan Z, Zhang F.

**Low lipoprotein cholesterol goal attainment in dyslipidemic patients with existing statin therapy: A chart extraction-based approach.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Ivanova J, Frois C, Bae JP, Boykin SD, McCracken R, Molife C, Waldman T, Zhao Z.

**Uncontrolled serum uric acid in veteran gout patients is associated with a higher risk of diabetes.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.

*Authors:* Pandya BJ, Marynchenko M, Sharma H, Yu A, Wu E, Shi L, Liu J.

**Comparison of hypoglycaemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus in a U.S. population.**

*Abstract:* 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal Sept 12-16, 2011.

*Authors:* Yang H, Marynchenko M, Bron M, Wu E, Yu AP.

**Does route of administration for estrogen hormone therapy and estradiol transdermal system dosage strength impact risk of venous thromboembolism.**

*Abstract:* 22nd Annual Meeting of the North American Menopause Society, Washington, DC Sept 21-24, 2011.

*Authors:* Kahler KH, Nyirady J, Beresford E, Laliberte F, Dea K, Sheng Duh M, Lefebvre P.

**Hypoglycaemia in adult vs. elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence in a U.S. population.**

*Abstract:* 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal Sep 12-16, 2011.

*Authors:* Bron M, Marynchenko M, Yang H, Yang Y, Wu E, Yu AP.

**Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during hospitalisation.**

*Abstract:* 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal Sept 12-16, 2011.

*Authors:* Zhou S, Wu E, Peng Yu A, Lu M, Sharma H, Graf T.

**Outcomes following insulin therapy disruption after hospital discharge in patients with type 2 diabetes.**

*Abstract:* 47th Annual Meeting of the European Association for the Study of Diabetes, Lisbon, Portugal Sep 12-16, 2011.

*Authors:* Wu E, Zhou S, Peng Yu A, Lu M, Sharma H, Graf T.

**Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes mellitus: a matching-adjusted indirect comparison of randomized trials.**

*Publication:* Clinical Drug Investigation 2011 08; 31(9): 665-674. doi: 10.2165/11592490-000000000-00000.

*Authors:* Signorovitch JE, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger JB.

**Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.**

*Abstract:* 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Chicago, IL Aug 14-17, 2011.

*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

**Comparison of hypoglycemia risk and cost between oral antidiabetic monotherapies in elderly patients with type 2 diabetes mellitus.**

*Abstract:* ADA 71st Scientific Session, San Diego, CA Jun 24-28, 2011.

*Authors:* Yang HY, Marynchenko M, Bron M, Wu EQ, Yu AP.

**Factors associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes initiated on insulin during a hospitalization.**

*Abstract:* 93rd Annual Meeting and Expo of the Endocrine Society, Boston, MA Jun 4-7, 2011.

*Authors:* Wu E, Zhou S, AP. Y, Lu M, Graf TR.

**Hypoglycemia in adult versus elderly type 2 diabetes mellitus patients: Risks, costs, and impact on treatment persistence.**

*Abstract:* ADA 71st Scientific Session, San Diego, CA Jun 24-28, 2011.

*Authors:* Bron M, Marynchenko M, Yang HY, Yang Y, Wu EQ, Yu AP.

**Hypoglycemia risk factors among veterans with type 2 diabetes treated with oral antidiabetic drugs.**

*Abstract:* ADA 71st Scientific Session, San Diego, CA Jun 24-28, 2011.

*Authors:* Shi L, Bron M, Zhao Y, Marynchenko M, Yu AP, Bensimon AG, Wu EQ.

**Outcomes associated with insulin therapy discontinuation after hospital discharge in patients with type 2 diabetes (T2D) initiated on insulin during hospitalization.**

*Abstract:* 93rd Annual Meeting and Expo of the Endocrine Society, Boston, MA Jun 4-7, 2011.

*Authors:* Wu E, Zhou S, Yu AP, Lu M, Graf TR.

**Outcomes associated with insulin therapy disruption after hospital discharge in patients with type 2 diabetes.**

*Abstract:* ADA 71st Scientific Session, San Diego, CA Jun 24-28, 2011.

*Authors:* Wu EQ, Zhou S, Yu AP, Lu M, Graf T.

**Short-term continuous subcutaneous insulin infusion decreases the plasma vaspin levels in patients with type 2 diabetes mellitus concomitant with improvement in insulin sensitivity.**

*Publication:* European Journal of Endocrinology of the European Federation of Endocrine Societies 2011 06; 164(6): 905-910. doi: 10.1530/EJE-10-1023.

*Authors:* Li K, Li L, Yang M, Liu H, Liu D, Yang H, Boden G, Yang G.

**Use of insulin during and after hospitalization and factors associated with therapy disruption after hospital discharge in type 2 diabetes patients.**

*Abstract:* ADA 71st Scientific Session, San Diego, CA Jun 24-28, 2011.

*Authors:* Wu EQ, Zhou S, Yu AP, Lu M, Graf T.

**The direct and indirect costs associated with hypogonadism among privately-insured employees in the United States.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Kaltenboeck A, Foster S, Thomas N, Ivanova J, Diener M, Bergman R, Birnbaum H, Swindle R.

**Direct healthcare and indirect workloss costs associated with the addition of rosiglitazone (RSG) versus sitagliptin (STG) therapy to metformin (MET).**

*Abstract:* ISPOR 16th Annual International Meeting Baltimore, MD May 21-25, 2011.

*Authors:* Lefebvre P, Sarda SP, Laliberte F, Ramamurthy P, Wei R, Arondekar B, Menditto L, Martin AA, Duh MS.

**Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system versus oral estrogen-only hormone therapy.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Laliberte F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P.

**Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus.**

*Publication:* Current Medical Research and Opinion 2011 01; 27(1): 189-195. doi: 10.1185/03007995.2010.536755.

*Authors:* Pandya BJ, Bron M, McCall T, Yu AP, Chen KS, Mattson ME, Wu EQ.

**Prevalence rates and costs of metabolic syndrome and associated risk factors using employees' integrated laboratory data and health care claims.**

*Publication:* Journal of Occupational Environmental Medicine 2011 01; 53(1): 27-33. doi:

10.1097/JOM.0b013e3181ff0594.

*Authors:* Birnbaum HG, Mattson ME, Kashima S, Williamson TE.

**Weighing the clinical benefits and economic impact of bariatric surgery in morbidly obese patients with diabetes.**

*Publication:* Canadian Journal of Diabetes 2011 35(2): 89-98.

*Authors:* Cremieux PY, Eapen S, Trask SW, Ghosh A.

**Estimating the effect of medication adherence on health outcomes among patients with type 2 diabetes--an application of marginal structural models.**

*Abstract:* ISPOR, Dec 2010.

*Authors:* Yu AP, Yu YF, Nichol MB.

**PDB5 Total and diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs from a large US managed care cohort.**

*Abstract:* ISPOR, Sep 5-7, 2010.

*Authors:* Bron M, Yu A, Marynchenko M, Sun S, Yang H, Wu E.

**Does route of administration for estrogen hormone therapy impact risk of venous thromboembolism: Estradiol transdermal system vs. oral estrogen-only hormone therapy.**

*Abstract:* 21st Annual Meeting of the North American Menopause Society, Chicago, IL Oct 6-9 2010.

*Authors:* Laliberte F, Dea K, Dub MS, Kahler KH, Rolli M, Lefebvre P.

**Economic effect of the clinical impact of bariatric surgery on morbidly obese patients with diabetes.**

*Abstract:* American Society for Healthcare Engineering 47th Annual Conference, Tampa, FL Jul 11-14, 2010.

*Authors:* Ghosh A, Crémieux PY, Klein S, Eapen S, McGavock T.

**The impact of bariatric surgery on comorbidities and medication use among obese patients.**

*Publication:* Obesity Surgery 2010 07; 20(7): 861-870. doi: 10.1007/s11695-010-0163-6.

*Authors:* Cremieux PY, Ledoux S, Clerici C, Cremieux F, Buessing M.

**Relationship of hypoglycemia with medication, discontinuation and costs in type 2 diabetes mellitus patients.**

*Abstract:* American Diabetes Association, 70th Scientific Sessions, Orlando, FL Jun 25-29, 2010.

*Authors:* Bron M, Yu AP, Marynchenko M, Yang H, Sun SX, Dabbous O.

**Diabetes-related costs associated with hypoglycemia in type 2 diabetes mellitus patients initiated on oral antidiabetic drugs.**

*Abstract:* AMCP's 22nd Annual Meeting, San Diego, CA Apr 7-10, 2010.

*Authors:* Bron M, Yu AP, Marynchenko M, Sun SX, Yang H, Wu EQ.

**Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: a retrospective database analysis.**

*Publication:* Diabetes Research and Clinical Practice 2010 01; 87(1): 108-116. doi: 10.1016/j.diabres.2009.09.023.

*Authors:* Lee LJ, Yu AP, Johnson SJ, Birnbaum HG, Atanasov P, Buesching DP, Jackson JA, Davidson JA.

**Medical costs in a US managed care cohort with oral antidiabetics maintenance therapy in type 2 diabetes patients who achieved HbA1c<7.0.**

*Abstract:* 45th EASD Annual Meeting of the European Association for the Study of Diabetes, Vienna, Austria Sep 30-Oct 2, 2009.

*Authors:* Pandya BJ, Bron M, Yu AP, Chen K, Wu E, Kaltenboeck A, Mattson M, Sun S.

**Anti-hypertensive drug use and risk of dementia in patients with diabetes mellitus (DM).**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Johnson ML, Parikh NM, Kunik M, Schulz P, Chen H, Aparasu R, Yadav R, Morgan R.

**Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.**

*Publication:* Journal of Managed Care Pharmacy 2009 05; 15(4): 312-322.

*Authors:* Laliberte F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

**Risk factors for dementia in elderly patients with diabetes mellitus.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Parikh NM, Morgan R, Kunik M, Schulz P, Chen H, Aparasu R, Yadav R, Johnson M.

**Impact of anemia on hospitalization rates and costs in a diabetic and a hypertensive cohort of chronic kidney disease patients.**

*Publication:* Journal of Managed Care Medicine 2009 (12 (3)): 41-50.

*Authors:* Laliberté F, Bookhart B, Corral M, Vekeman F, Duh M, Bailey R, Lefebvre P.

**Five Minutes with... The Economic Impact of Bariatric Surgery Study Investigators.**

*Publication:* Bariatric Times 2008 11.

*Authors:* Cremieux P, Buchwald H, Shikora S, Ghosh A, Yang E, Buessing M.

**Achieving Glycemic Goal with Initial Combination Therapy versus Sequential Augmentation Therapy using Metformin and Pioglitazone.**

*Abstract:* 44th EASD Meeting, Rome, Italy Sep 7-11, 2008.

*Authors:* Pandya BJ, Yu A, Wu EQ, Chen K, Kaltenboeck A, Seale J, Mattson M, Bron M, Baran RW.

**A study on the economic impact of bariatric surgery.**

*Publication:* American Journal of Managed Care 2008 09; 14(9): 589-596.

*Authors:* Cremieux PY, Buchwald H, Shikora SA, Ghosh A, Yang HE, Buessing M.

**Comparative Glycemic Goal Achievement among Type 2 Diabetes Mellitus Patients Treated with Oral Antidiabetic Monotherapies.**

*Abstract:* American Diabetes Association's 68th Scientific Sessions, San Francisco, CA Jun 6-10, 2008.

*Authors:* Wu EQ, Pandya BJ, Yu A, Chen K, Seale J, Kaltenboeck A, Mattson M, Bron M, Baran RW.

**Direct and indirect costs among employees with diabetic retinopathy in the United States.**

*Publication:* Current Medical Research and Opinion 2008 05; 24(5): 1549-1559. doi: 10.1185/030079908X297303.

*Authors:* Lee LJ, Yu AP, Cahill KE, Oglesby AK, Tang J, Qiu Y, Birnbaum HG.

**Drug utilization and costs of erythropoietic-stimulating agents in chronic kidney disease patients not receiving dialysis.**

*Publication:* Managed Care Interface 2007 12; 20 (12): 14-19.

*Authors:* Duh M, Mody S, Laliberté F, McKenzie R, Bookhart B, Lefebvre P.

**Productivity costs associated with cardiometabolic risk factor clusters in the United States.**

*Publication:* Value in Health 2007 11; 10(6): 443-450. doi: 10.1111/j.1524-4733.2007.00199.x.

*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

**Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France.**

*Publication:* Current Medical Research and Opinion 2007 09; 23(9): 2035-2042. doi: 10.1185/030079907X210516.

*Authors:* Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S.

**Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data.**

*Publication:* Current Medical Research and Opinion 2007 09; 23(9): 2157-2169. doi: 10.1185/0300799007X219544.

*Authors:* Yu AP, Wu EQ, Birnbaum HG, Emani S, Fay M, Pohl G, Wintle M, Yang E, Oglesby A.

**Impact of cardiometabolic risk factor clusters on health-related quality of life in the U.S.**

*Publication:* Obesity (Silver Spring) 2007 02; 15(2): 511-521. doi: 10.1038/oby.2007.580.

*Authors:* Sullivan PW, Ghushchyan V, Wyatt HR, Wu EQ, Hill JO.

**Cost-effectiveness of duloxetine versus routine treatment for U.S. patients with diabetic peripheral neuropathic pain.**

*Publication:* Journal of Pain 2006 06; 7(6): 399-407. doi: 10.1016/j.jpain.2006.01.443.

*Authors:* Wu EQ, Birnbaum HG, Mareva MN, Le TK, Robinson RL, Rosen A, Gelwicks S.

**HI1 Adult Economic Status and Obesity in the United States: 2000-2002.**

*Abstract:* ISPOR, 2006.

*Authors:* Wu E, Xie J, Crémieux P, Sullivan P.

**POB7 Obesity and quality of life in the united states: 2000-2002.**

*Abstract:* ISPOR, 2006.

*Authors:* Wu E, Xie J, Sullivan P.

**Prevalence of diabetic peripheral neuropathy and associated pain in French adults.***Publication:* Journal of Neurology 2006 05; 253: 108-108.*Authors:* Wu E, Borton J, Kahn E, Said G, Le T, Garcia-Cebrian A, Monz B.**Glycemic Control, Hypoglycemic Therapy and Subsequent Weight Change among Type 2 Diabetes Patients.***Abstract:* American Diabetes Association (ADA), 2006.*Authors:* Yu AP, Wu EQ, Birnbaum H, Emani S, Fay M, Oglesby A, Pohl G, Stockl K, Wintle M.**Obesity's Impact on Diabetes Patients' Health-Related Quality Of Life In The U.S.***Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia-Pacific, 2006.*Authors:* Cremieux P, Xie J, Greenberg P, Wu EQ, Castor A.**Short Term Economic Impact of Weight Change among Patients with Type 2 Diabetes.***Abstract:* American Diabetes Association.*Authors:* Wu EQ, Yu AP, Birnbaum H, Emani S, Fay M, Oglesby A, Pohl G, Stockl K, Wintle M, Yang E.**Employment and Income Associated with Obesity and Overweight in the US.***Abstract:* North American Association for the Study of Obesity (NAASO).*Authors:* Wu EQ, Xie J, Sullivan PW.**Employment and Income Associated with Obesity and Overweight in the US.***Abstract:* AMCP 2005.*Authors:* Colice G, Crivera C, Vearghese S, Faruqi R, Wu EQ, Birnbaum H, Daher M, Marynchenko MB.**Quality of Life of Obese Adults in the US.***Abstract:* International Society for Quality of Life Research.*Authors:* Wu EQ, Xie J, Hill JO, Wyatt H, Sullivan PW.**Cost-Effectiveness of Duloxetine versus Routine Treatment for Painful Diabetic Neuropathy in a Randomized Trial from a Societal Prospective.***Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR).*Authors:* Wu EQ, Birnbaum H, Mareva M, Le TK, Rosen A, Robinson R.**Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.***Publication:* Women's Health Issues 2003 11; 13(6): 204-213.*Authors:* Birnbaum H, Leong S, Kabra A.**PDB6: Factors associated with high-risk diabetic patients in the California Medicaid populations (medi-cal).***Abstract:* ISPOR, 2003.*Authors:* Chaikledkaew U, Wu E, Johnson K.**PDB10: A Methodology to identify high-risk patients with diabetes in the California Medicaid population (MEDI-CAL).***Abstract:* ISPOR, 2003.*Authors:* Chaikledkaew U, Wu E, Johnson K.**Productivity and medical costs of diabetes in a large employer population.***Publication:* Diabetes Care 2002 01; 25(1): 23-29.*Authors:* Ramsey S, Summers KH, Leong SA, Birnbaum HG, Kemner JE, Greenberg P.**Identification of Diabetes Patients Using Claims Data: An Economic Analysis.***Publication:* Drug Benefit Trends 2001 13: 28-33.*Authors:* Summers K, Leong S, Birnbaum H, Greenberg P, Kemner J, Ramsey S.



## Gastrointestinal

**Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.**

*Publication:* Journal of Medical Economics 2019 07: 1. e-pub ahead of print 2019/07/12; doi: 10.1080/13696998.2019.1642900.

*Authors:* Ueno F, Doi M, Kawai Y, Ukawa N, Cammarota J, Betts KA.

**Real-world incidence of inflammatory bowel disease among patients with other chronic inflammatory diseases treated with interleukin-17a or phosphodiesterase 4 inhibitors.**

*Publication:* Current Medical Research and Opinion 2019 05: 1-9. e-pub ahead of print 2019/05/21; doi: 10.1080/03007995.2019.1620713.

*Authors:* Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P.

**Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure.**

*Publication:* Journal of Parenteral and Enteral Nutrition. 2019 04. doi: <http://dx.doi.org/10.1002/jpen.1588>.

*Authors:* Chen K, Mu F, Xie J, Kelkar SS, Olivier C, Signorovitch J, Jeppesen PB.

**Factors associated with more frequent diagnostic tests and procedures in patients with irritable bowel syndrome.**

*Publication:* Therapeutic Advances in Gastroenterology 2019 01; 12(no pagination). doi: <http://dx.doi.org/10.1177/1756284818818326>.

*Authors:* Lacy B, Ayyagari R, Guerin A, Lopez A, Shi S, Luo M.

**Impact of anti-TNF treatment on extra-intestinal manifestations in patients with inflammatory bowel disease: Real-world data in Germany.**

*Abstract:* 14th Annual Congress of ECCO - Inflammatory Bowel Disease 2019, Copenhagen, Denmark Mar 6-9, 2019.

*Authors:* Bettenworth D, Lee WJ, Clark RS, Rath S, Yang M, Bensimon A, Vavricka S.

**Pgi2 Use of Different Statistical Approaches to Compare Real-World Outcomes Associated with Vedolizumab Versus Infliximab in Biologic-Naive Patients with Inflammatory Bowel Disease.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Latremouille-Viau D, Burne R, Shi S, Patel H.

**Incidence of catheter-related complications among Japanese patients with central venous catheters as well as patients with short bowel syndrome.**

*Publication:* Clinical and Experimental Gastroenterology 2018 12; 11: 439-445. e-pub ahead of print 2018/12/21; doi: 10.2147/CEG.S172430.

*Authors:* Wing VK, Song Y, Xiang C, Liu X, Macaulay D, Ponsillo M, Blumentals WA.

**Incidence of inflammatory bowel disease (IBD) among patients (PTS) with other chronic inflammatory diseases (CID) treated with interleukin-17A (IL-17A) or phosphodiesterase 4 (PDE4) inhibitors.**

*Abstract:* ACR/ARHP Annual Meeting, Chicago, IL Oct 19-24, 2018.

*Authors:* Emond B, Ellis LA, Chakravarty SD, Ladouceur M, Lefebvre P.

**Inflammatory bowel disease is associated with a substantial economic burden in patients with psoriatic arthritis and in patients with ankylosing spondylitis.**

*Abstract:* ACR/ARHP Annual Meeting, Chicago, IL Oct 19-24, 2018.

*Authors:* Bergman MJ, Zueger P, Song J, Pivneva I, Betts KA, Joshi AD.

**Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome.**

*Publication:* Therapeutics and Clinical Risk Management 2018 08; 14: 1267-1277. e-pub ahead of print 2018/08/14; doi: 10.2147/TCRM.S166081.

*Authors:* Chen KS, Xie J, Tang W, Zhao J, Jeppesen PB, Signorovitch JE.

**Real-world use of faecal calprotectin testing in patients with inflammatory bowel disease.**

*Abstract:* 13th Congress of European Crohn's and Colitis Organisation, Vienna, Austria Feb 14-17, 2018.

*Authors:* Rubin DT, Yang M, Wu EQ, Skup M, Lee WJ.

**Public health impact of Rotarix vaccination among commercially insured children in the United States.**

*Publication:* Vaccine 2017 09; 35(37): 5065-5072. e-pub ahead of print 2017/08/06; doi: 10.1016/j.vaccine.2017.06.034.

*Authors:* Krishnarajah G, Kageleiry A, Korves C, Lefebvre P, Duh MS.

**Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.**

*Publication:* Cancer Research and Treatment 2017 07; 49(3): 578-587. e-pub ahead of print 2016/09/14; doi: 10.4143/crt.2016.001.

*Authors:* Carter GC, Kaltenboeck A, Ivanova J, Liepa AM, San Roman A, Koh M, Rajan N, Cheng R, Birnbaum HG, Kim JS, Bang YJ.

**Realworld adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).**

*Abstract:* ASCO Annual Meeting, Chicago, IL June 2-6, 2017.

*Authors:* Patel AK, Duh MS, Barghout VE, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS.

**Association of clinical complications and surgery treatment on recurrence of acute diverticulitis.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Association of socio-demographics and clinical complications with future medical expenditures in diverticulitis.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Evaluation of age, multimorbidity and clinical complications as risk factors for urgent surgical treatment for diverticulitis.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Incremental expenditures associated with recurrence of diverticulitis.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Trajectories of expenditures associated with acute gastrointestinal diseases.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Kawatkar AA, Chu L, Nichol MB.

**Assessment of corticosteroid-related quality of care measures for ulcerative colitis and Crohn's disease in the United States: a claims data analysis.**

*Publication:* Current Medical Research and Opinion 2017 03; 33(3): 529-536. e-pub ahead of print Published online: 12 Jan 2017; doi: 10.1080/03007995.2016.1267616.

*Authors:* Rubin DT, Patel H, Shi S, Mody R.

**Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.**

*Abstract:* 12th Congress of the European Crohn's and Colitis Organisation, Barcelona, Spain February 15-18, 2017.

*Authors:* Sandborn W, Sakuraba A, Wang A, MacAulay D, Schemerold L, Yang M, Skup M.

**P676 Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.**

*Publication:* Journal of Crohn's & Colitis 2017 02; 11(suppl\_1): S426. e-pub ahead of print 2017/02/09; doi:

10.1093/ecco-jcc/jjx002.800.

*Authors:* Sandborn W, Sakuraba A, Wang A, Macaulay D, Schemerold L, Yang M, Skup M.

**Identifying higher-value subpopulations for treatment in heterogenous rare diseases: An example study of early responders to teduglutide for short bowel syndrome.**

*Abstract:* ISPOR 19th Annual European Congress, Vienna, Austria Oct 29 - Nov 2, 2016.

*Authors:* Chen K, Xie J, Tang C, Zhao J, Olivier C, Jeppesen PB, Signorovitch J.

**Direct Costs in Patients with Celiac Disease in the USA: A Retrospective Claims Analysis.**

*Publication:* Digestive Diseases and Sciences 2016 10; 61(10): 2823-2830. e-pub ahead of print 2016/07/16; doi:

10.1007/s10620-016-4219-x.

*Authors:* Guandalini S, Tundia N, Thakkar R, Macaulay D, Essenmacher K, Fuldeore M.

**Predictors of response to teduglutide among patients with parenteral nutrition-dependent short bowel syndrome.**

*Abstract:* 81st Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 21-26, 2016.

*Authors:* Seidner DL, Joly F, Gabe SM, Mu F, Xie J, Kelkar SS, Chen K, Olivier C.

**Predictors of response to teduglutide among patients with parenteral nutrition-dependent short bowel syndrome.**

*Abstract:* 24th United European Gastroenterology Week, Vienna, Austria Oct 15-19, 2016.

*Authors:* Joly F, Gabe SM, Seidner DL, Mu F, Xie J, Kelkar SS, Chen K, Olivier C.

**Comparison of real-world outcomes of adalimumab and infliximab for patients with ulcerative colitis in the United States.**

*Publication:* Current Medical Research and Opinion 2016 07; 32(7): 1233-1241. doi: 10.1185/03007995.2016.1168290.

*Authors:* Sandborn WJ, Sakuraba A, Wang A, Macaulay D, Reichmann W, Wang S, Chao J, Skup M.

**Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia and Mexico.**

*Publication:* Journal of Medical Economics 2016 07: 1-49. e-pub ahead of print 2016/07/05; doi:

10.1080/13696998.2016.1209508.

*Authors:* Tundia N, Gustavo Kotze P, Rojas Serrano J, Mendes de Abreu M, Skup M, Macaulay D, Signorovitch J, Chaves L, Chao J, Bao Y.

**Assessment of the real-world safety profile of vedolizumab using the united states food and drug administration adverse event reporting system (FAERS).**

*Abstract:* Digestive Disease Week, San Diego, CA May 21-24, 2016.

*Authors:* Cross R, Vekeman F, Xiao Y, Wu EQ, Chao J, Wang A.

**Diagnostic testing in IBS patients: Which factors are most strongly associated with more frequent diagnostic tests and procedures?**

*Abstract:* Digestive Disease Week, San Diego, CA May 21-24, 2016.

*Authors:* Luo M, Guerin A, Ayyagari R, Shi S, Lopez A, Lacy B.

**Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance.**

*Publication:* Human Vaccines & Immunotherapeutics 2016 05; 12(5): 1235-1243. e-pub ahead of print 2016/02/24; doi: 10.1080/21645515.2015.1136041.

*Authors:* Calnan M, Krishnarajah G, Duh MS, Haider BA, Yermakov S, Davis M, Yan S.

**Cost-analysis model of colonoscopy preparation using split-dose reduced-volume oral sulfate solution (OSS) and polyethylene glycol with electrolytes solution (PEG-ELS).**

*Publication:* Journal of Medical Economics 2016 04; 19(4): 356-363. e-pub ahead of print 2015/11/27; doi: 10.3111/13696998.2015.1125907.

*Authors:* Huynh L, Yermakov S, Davis M, Campbell R, Cleveland M, Farraye FA, Yenikomshian M.

**Variation in Care for Patients with Irritable Bowel Syndrome in the United States.**

*Publication:* PloS One 2016 04; 11(4): e0154258. e-pub ahead of print 2016/04/27; doi: 10.1371/journal.pone.0154258.

*Authors:* Lacy BE, Patel H, Guerin A, Dea K, Scopel JL, Alaghband R, Wu EQ, Mody R.

**Changes in Practice Patterns of Clopidogrel in Combination with Proton Pump Inhibitors after an FDA Safety Communication.**

*Publication:* PloS One 2016 01; 11(1): e0145504. doi: 10.1371/journal.pone.0145504.

*Authors:* Guerin A, Mody R, Carter V, Ayas C, Patel H, Lasch K, Wu E.

**Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States.**

*Publication:* PloS One 2016 01; 11(1): e0145977. e-pub ahead of print 2016/01/12; doi: 10.1371/journal.pone.0145977.

*Authors:* Krishnarajah G, Duh MS, Korves C, Demissie K.

**Economic Impact of Expanded Use of Biologic Therapy for Crohn's Disease In Latin American Countries.**

*Abstract:* ISPOR 5th Latin America Conference, Santiago, Chile Sept 6-8, 2015.

*Authors:* Kotze PG, Tundia N, Gumen A, Macaulay D, Chaves L, Bao Y.

**Comparison of real-world outcomes of adalimumab and infliximab for patients with moderate or severe ulcerative colitis in the United States.**

*Abstract:* ACG 2015 Annual Scientific Meeting & Post Graduate Course, Honolulu, HI Oct 10-21, 2015.

*Authors:* Sakuraba A, Sandborn W, Skup M, Macaulay D, Reichmann W, Chao J.

**Effect of adalimumab dose escalation on hospitalization risk in patients with moderately to severely active ulcerative colitis.**

*Abstract:* American College of Gastroenterology 80th Annual Meeting, Honolulu, HI Oct 16-21, 2015.

*Authors:* Feagan B, Skup M, Ozbay AB, Thakkar RB, Lazar A, Yang M, Macaulay D, Chao J, Sandborn W.

**A cost comparison of split-dose reduced-volume oral sulfate solution (OSS) and polyethylene glycol with electrolytes solution (PEG-ELS).**

*Abstract:* ISPE's 31st International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Boston, MA Aug 22-26, 2015.

*Authors:* Huynh L, Yermakov S, Davis M, Campbell R, Cleveland M, Farraye FA, Yenikomshian M.

**Direct and indirect healthcare resource utilization and costs associated with ulcerative colitis in a privately-insured employed population in the US.**

*Publication:* Journal of Medical Economics 2015 06; 18(6): 447-456. doi: 10.3111/13696998.2015.1021353.

*Authors:* Cohen R, Skup M, Ozbay AB, Rizzo J, Yang M, Diener M, Chao J.

**Direct costs in patients with celiac disease-a retrospective claims analysis.**

*Abstract:* 16th International Celiac Disease Symposium, Prague, Czech Republic Jun 21-24, 2015.

*Authors:* Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M.

**Prevalence of comorbidities in patients with celiac disease.**

*Abstract:* 16th International Celiac Disease Symposium, Prague, Czech Republic Jun 21-24, 2015.

*Authors:* Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M.

**A cost comparison of split-dose reduced-volume oral sulfate solution (OSS) and polyethylene glycol with electrolytes solution (PEG-ELS).**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Cleveland M, Yermakov S, Davis M, Campbell R, Huynh L, Farraye F, Yenikomshian M.

**Direct costs in patients with celiac disease-a retrospective claims analysis.**

*Abstract:* Digestive Disease Week, Washington, DC May 17-19, 2015.

*Authors:* Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M.

**Prevalence of comorbidities in patients with celiac disease.**

*Abstract:* Digestive Disease Week, Washington DC May 17-19, 2015.

*Authors:* Guandalini S, Tundia N, Thakkar R, Arunajadai S, Macaulay D, Essenmacher K, Fuldeore M.

**Cost of hospitalisations among moderate-to-severe Ulcerative Colitis patients treated with adalimumab and conventional non-biologic therapies.**

*Abstract:* 10th Congress of the European Crohn's and Colitis Organisation, Barcelona, Spain Feb 18-21, 2015.

*Authors:* Wang S, Yang H, Faust E, Bao Y.

**Prevalence and risk of developing comorbid conditions in patients with chronic constipation.**

*Publication:* Current Medical Research and Opinion 2014 12; 30(12): 2505-2513. doi: 10.1185/03007995.2014.964854.

*Authors:* Mody R, Guerin A, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ.

**Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States.**

*Publication:* Human Vaccines & Immunotherapeutics 2014 11; 10(8): 2255-2266. doi: 10.4161/hv.29511.

*Authors:* Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Sheng Duh M.

**Age-related health care disparities in patients with irritable bowel syndrome: Findings from a sample of commercially insured patients.**

*Abstract:* 79th Annual Scientific Meeting of the American College of Gastroenterology, Philadelphia, PA Oct 17-22, 2014.

*Authors:* Lacy B, Patel H, Guerin A, Dea K, Alaghband R, Wu EQ, Scopel J, Mody R.

**Comparison of cost per responder and remitter in patients with inflammatory bowel disease in the united states: An indirect comparison of adalimumab and vedolizumab.**

*Abstract:* 79th Annual Scientific Meeting of the American College of Gastroenterology Philadelphia, PA Oct 17-22, 2014.

*Authors:* Liu Y, Ozbay AB, Skup M, Reichmann W, Diener M, Chao J.

**Cost-effectiveness of adalimumab in moderately to severely active ulcerative colitis (sub-acute) in the UK. .**

*Abstract:* 22nd United European Gastroenterology Week, Vienna, Austria Oct 18-22, 2014.

*Authors:* Yang H, Curry A, Wang S, Yang M, Skup M, Chao J, Baofill Y.

**Gastrointestinal comorbidities associated with atrial fibrillation.**

*Publication:* Springerplus 2014 10; 3: 603. doi: 10.1186/2193-1801-3-603.

*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Schein JR, Lefebvre P.

**The impact of moderate-to-severe Crohn's Disease on employees' salary growth.**

*Publication:* Inflammatory Bowel Diseases 2014 10; 20(10): 1734-1738. doi: 10.1097/MIB.000000000000133.

*Authors:* Loftus EV, Jr., Skup M, Ozbay AB, Wu E, Guerin A, Chao J, Mulani P.

**Indirect comparison of adalimumab and vedolizumab in inflammatory bowel disease in the United Kingdom: cost per responder/remitter analysis.**

*Abstract:* 22nd Annual United European Gastroenterology Week, Vienna, Austria Oct 18-22, 2014.

*Authors:* Liu Y, Reichmann W, Wang S, Macaulay D, Skup M, Chao J, Bao Y.

**Regional variation of care for irritable bowel syndrome in the United States.**

*Abstract:* 79th Annual Scientific Meeting of the American College of Gastroenterology Philadelphia, PA Oct 17-22, 2014.

*Authors:* Lacy B, Patel H, Guerin A, Dea K, Alaghband R, Wu EQ, Scopel J, Mody R.

**The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population.**

*Publication:* Journal of Medical Economics 2014 08; 17(8): 577-586. doi: 10.3111/13696998.2014.919926.

*Authors:* Guerin A, Carson RT, Lewis B, Yin D, Kaminsky M, Wu E.

**Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation.**

*Publication:* Alimentary Pharmacology and Therapeutics 2014 07; 40(1): 83-92. doi: 10.1111/apt.12789.

*Authors:* Guerin A, Mody R, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ.

**Cost-effectiveness of adalimumab for the treatment of moderately to severely active ulcerative colitis in Canada.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Ghosh S, Desjardins O, Skup M, Wang S, Yang M, Yang H, Qi C, Bao Y, Chao J.

**A systematic review of the economic and humanistic burden of illness in irritable bowel syndrome and chronic constipation.**

*Publication:* Journal of Managed Care Pharmacy 2013 11; 19(9): 755-764.

*Authors:* Nellesen D, Yee K, Chawla A, Lewis BE, Carson RT.

**Association between adherence to adalimumab therapy and health care costs for patients with crohn's disease: Claims database analysis.**

*Abstract:* 78th Annual Scientific Meeting of the American College of Gastroenterology, San Diego, CA Oct 11-16, 2013.

*Authors:* Schifrien B, Yen E, Liu Y, Skup M, Tundia N, Ayyagari R, Yang H, Bao Y, Mulani P, Chao J.

**Impact of the FDA safety communication on prescription trends of clopidogrel in combination with proton pump inhibitors.**

*Abstract:* 78th Annual Scientific Meeting of the American College of Gastroenterology, San Diego, CA Oct 11-16, 2013.

*Authors:* Guerin A, Mody R, Carter V, Wu E.

**Indirect comparison of adalimumab and infliximab in ulcerative colitis: Cost per remitter analysis.**

*Abstract:* 78th Annual Scientific Meeting of the American College of Gastroenterology, San Diego, CA Oct 11-16, 2013.

*Authors:* Liu Y, Reichmann B, Yan S, Macaulay D, Skup M, Mulani P, Chao J.

**A health-related quality-of-life study comparing Vitala continence control device versus traditional pouch system only in patients with end colostomy.**

*Publication:* European Journal of Gastroenterology and Hepatology 2013 06; 25(6): 739-747. doi: 10.1097/MEG.0b013e32835d5f3c.

*Authors:* Hoch J, Yang M, Yan S, van den Broek N, Xie J, Warusavitarne J.

**Quality of life and life enjoyment: An analysis of end colostomy patients.**

*Abstract:* 12th European Council of Enterostomal Therapy, Paris, France June 23-26, 2013.

*Authors:* Yan S, Yang M, Hoch J, van den Broek N, Xie J, Warusavitarne J.

**Budgetary impact of linaclotide in the treatment of US adult patients with irritable bowel syndrome with constipation (IBS-C) or chronic constipation (CC).**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Taylor DCA, Carson RT, Xie J, Dean J, Du EX, Sarocco P, Blum SI.

**Su2017 Impact of Chronic Constipation Severity on the Risk of Developing Colorectal Cancer and Benign Neoplasm.**

*Abstract:* Digestive Disease Week, Orlando, FL May 18-21, 2013.

*Authors:* Guérin A, Mody R, Fok B, Wu EQ, Lasch K, Talley NJ.

**Medical costs associated with treatment failure with over-the-counter or prescription constipation treatments in patients with IBS-C in a Medicaid population.**

*Abstract:* AMCP's 25th Annual Meeting, San Diego, CA Apr 3-5, 2013.

*Authors:* Guérin A, Carson RT, Yin D, Kaminsky MS, Taylor DCA, Sarocco P, Wu EQ.

**Comorbidities in patients with irritable bowel syndrome with constipation or chronic idiopathic constipation: a review of the literature from the past decade.**

*Publication:* Postgraduate Medicine 2013 03; 125(2): 40-50. doi: 10.3810/pgm.2013.03.2640.

*Authors:* Nellesen D, Chawla A, Oh DL, Weissman T, Lavins BJ, Murray CW.

**High risk of leaving the workforce in US employees with ulcerative colitis.**

*Abstract:* 8th Congress of the European Crohn's and Colitis Organisation, Vienna, Austria Feb 14 - 16, 2013.

*Authors:* Cohen R, Rizzo J, Yang M, Skup M, Macaulay D, Behrer C, Fok B, Mulani PM, Chao J.

**Direct and indirect utilization and costs associated with ulcerative colitis.**

*Abstract:* 2012 Advances in Inflammatory Bowel Diseases Crohn's and Colitis Foundation's National Clinical and Research, Hollywood, FL Dec 13-15, 2012.

*Authors:* Cohen R, Rizzo J, Diener M, Yang M, Skup M, Mulani P, Chao J.

**Comparison of medical costs among patients using adalimumab and infliximab: a retrospective study (COMPAIRS).**

*Publication:* Inflammatory Bowel Diseases 2012 11; 18(11): 2043-2055. doi: 10.1002/ibd.22873.

*Authors:* Sussman DA, Kubiliun N, Mulani PM, Chao J, Gillis CA, Yang M, Lu M, M TA.

**Cost-effectiveness of adalimumab for treatment of CROHN's disease in Germany.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Yang M, Skup M, Zhou ZY, Hengst N, Wolff M, Mulani PM, Chao J.

**Comparative colorectal cancer risk in patients with ulcerative colitis treated with adalimumab versus conventional therapy.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Colombel JF, Thakkar R, Robinson A, Yang M, Skup M, Swallow E, Betts K, Chao J, Mulani P.

**Cost-effectiveness model of adalimumab for the treatment of moderate to severe ulcerative colitis in the United Kingdom.**

*Abstract:* 20th United European Gastroenterology Week, Amsterdam, Netherlands Oct 20-24, 2012.

*Authors:* Ali T, Yang M, Skup M, Yang M, Wu EQ, Chao J, Mulani PM.

**Cost-effectiveness of adalimumab in moderately to severely active ulcerative colitis in the US.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Ali T, Skup M, Yang M, Wu E, Mulani P, Chao J.

**Direct and indirect utilization and costs associated with ulcerative colitis.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Cohen R, Rizzo J, Diener M, Yang M, Skup M, Mulani P, Chao J.

**Prevalence and risk of developing gastrointestinal conditions in patients with chronic constipation.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Guerin A, Mody R, Fok B, Zhou Z, Wu E, Zhou W, Lasch K, Talley N.

**Prevalence and risk of developing non-gastrointestinal physical and mental comorbidities in patients with chronic constipation.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Guerin A, Mody R, Fok B, Zhou Z, Wu E, Zhou W, Lasch K, Talley NJ.

**Risk of developing colorectal cancer and benign neoplasm in patients with chronic constipation.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Mody R, Guerin A, Fok B, Zhou Z, Wu E, Brewer K, Zhou W, Lasch K, Talley N.

**Risk of malignancy, infection, serious infection, and acute health care use in patients with Crohn's disease treated with adalimumab vs. Immunosuppressants.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Colombel JF, Thakkar R, Castillo M, Robinson A, Skup M, Yang M, Swallow E, Sorg R, Chao J, Mulani P.

**Treatment benefit-risk preferences of patients with early Crohn's disease.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology Las Vegas, NV Oct 19-24, 2012.

*Authors:* Loftus E, Yang M, Skup M, Ivanova J, Sorg R, Chao J, Mulani P.

**Risk of gastrointestinal conditions among patients with atrial fibrillation.**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

**Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.**

*Publication:* Advances in Therapy 2012 07; 29(7): 620-634. doi: 10.1007/s12325-012-0035-7.

*Authors:* Liu Y, Wu EQ, Bensimon AG, Fan CP, Bao Y, Ganguli A, Yang M, Cifaldi M, Mulani P.



**The economic burden of unmet treatment needs in Medicaid patients with chronic constipation.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Carson RT, Guerin A, Lewis B, Yin D, Kaminsky M, Ramakrishnan K, Wu EQ.

**Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease.**

*Abstract:* Digestive Disorders Federation Meeting 2012, Liverpool, UK Jun 17-20, 2012.

*Authors:* Colombel JF, Rutgeerts PJ, Sandborn WJ, Reinisch W, Loftus Jr EV, Tang J, Pollack PF, Yang M, Patel SP, Huang B, Chao J, Mulani PM.

**Risk of gastrointestinal conditions among patients with atrial fibrillation.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Laliberte F, Dea K, Lamori JC, Mody SH, Jones JL, Arledge MD, Damaraju CV, Duh MS, Schein JR, Lefebvre P.

**Treatment patterns and indicators of unmet needs in Medicaid patients with irritable bowel syndrome with constipation and chronic constipation.**

*Abstract:* Digestive Disease Week, San Diego, CA May 19-22, 2012.

*Authors:* Carson R, Guérin A, Lewis B, Yin D, Kaminsky MS, Ramakrishnan K, Wu EQ.

**The economic burden of treatment failure in Medicaid patients with irritable bowel syndrome with constipation.**

*Abstract:* AMCP's 24th Annual Meeting, San Francisco, CA Apr 18-20, 2012.

*Authors:* Guérin A, Carson RT, Lewis B, Yin D, Kaminsky MS, Ramakrishnan K, Wu EQ.

**Gastrointestinal conditions among patients with atrial fibrillation.**

*Abstract:* 61th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, Chicago, IL Mar 24-27, 2012.

*Authors:* Laliberte F, Moore Y, Dea K, LaMori JC, Mody SH, Jones JL, Arledge M, Damaraju CV, Duh MS, Schein J, Lefebvre P.

**Adalimumab sustains deep remission for 3 years: Data from CHARM and ADHERE.**

*Abstract:* 7th Congress of ECCO European Crohn's and Colitis Organization, Barcelona, Spain Feb 16-18, 2012.

*Authors:* Sandborn WJ, Colombel J-F, Louis E, Panaccione R, Yang M, Chao J, Thakkar R, Robinson A, Pollack P, Mulani PM.

**Assessing preference for deep remission in patients with Crohn's disease.**

*Abstract:* 7th Congress of the European Crohn's and Colitis Organisation, Barcelona, Spain Feb 16-18, 2012.

*Authors:* Sandborn W, Colombel JF, Louis E, Panaccione R, Yang M, Wu E, Mulani P, Chao J.

**Development of three practical indices for mucosal healing among patients with moderate to severe Crohn's disease.**

*Abstract:* 7th Congress of ECCO European Crohn's and Colitis Organization, Barcelona, Spain Feb 16-18, 2012.

*Authors:* Sandborn WJ, Panaccione R, Colombel J-F, Louis E, Yang M, Thakkar R, Chao J, Mulani PM.

**Markov model projection of remission status for early vs. delayed step-up adalimumab use in moderate to severe Crohn's disease.**

*Abstract:* 2010 Advances in Inflammatory Bowel Diseases Crohn's and Colitis Foundation's National Clinical and Research Conference Hollywood, FL Dec 9-12, 2010.

*Authors:* Loftus EV, Chao J, Yang M, Pollack PF, Li Z, Thakkar RB, Mulani PM.

**C-reactive protein levels in moderate to severe crohn's disease patients decreased rapidly and significantly during adalimumab therapy.**

*Abstract:* 76th Annual Scientific Meeting of the American College of Gastroenterology Washington, DC Oct 28 - Nov 2, 2011.

*Authors:* Ghosh S, Wu E, Bensimon A, Mulani P, Yang M, Chao J.

**A retrospective comparison of health care outcomes in Crohn's disease patients with and without prolonged steroid monotherapy.**

*Abstract:* 19th United European Gastroenterology Week, Stockholm, Sweden Oct 22-26, 2011.

*Authors:* Siegel CA, Yang HY, Yu AP, Yang M, Mulani PM, Chao J.

**Increased risks of developing anxiety and depression in young patients with Crohn's disease.**

*Publication:* American Journal of Gastroenterology 2011 09; 106(9): 1670-1677. doi: 10.1038/ajg.2011.142.

*Authors:* Loftus EV, Jr., Guerin A, Yu AP, Wu EQ, Yang M, Chao J, Mulani PM.

**The economic and quality of life burden of illness in chronic constipation (CC) and irritable bowel syndrome (IBS): A systematic review.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Yee K, Nellesen D, Chawla A, Carson R, Lewis B.

**Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (Compairs).**

*Abstract:* Annual General Meeting of the British Society of Gastroenterology Conference, Birmingham, UK Mar 14-17, 2011.

*Authors:* Sussman DA, Kubiliun N, Chao J, Mulani PM, Gillis CA, Yang M, Lu M, Abreu MT.

**Markov model projection of remission status for early versus delayed step-up adalimumab use in moderate to severe crohn's disease.**

*Abstract:* Annual General Meeting of the British Society of Gastroenterology, Birmingham, UK Mar 14-17, 2011.

*Authors:* Loftus EV, Chao J, Yang M, Pollack PF, Li Z, Thakkar RB, Mulani PM.

**Racial differences in use of biologics for crohn's disease in a Medicaid population.**

*Abstract:* Annual General Meeting of the British Society of Gastroenterology Conference, Birmingham, UK Mar 14-17, 2011.

*Authors:* Flasar M, Mulani P, Yang M, Chao J, Lu M, Cross R.

**Impact of induction dosing on maintenance outcome with adalimumab in Crohn's disease.**

*Abstract:* 6th Congress of the European Crohn's and Colitis Organisation, Dublin, Ireland Feb 24-26, 2011.

*Authors:* Colombel J, Rutgeerts P, Sandborn WJ, Reinisch W, Loftus Jr EV, Tang J, Pollack PF, Yang M, Huang B, Chao J, Mulani PM.

**Risk-benefit analysis of adalimumab versus traditional non-biologic therapies for patients with Crohn's disease.**

*Publication:* Inflammatory Bowel Diseases 2011 01; 17(1): 127-140. doi: 10.1002/ibd.21341.

*Authors:* Loftus EV, Jr., Johnson SJ, Wang ST, Wu E, Mulani PM, Chao J.

**The CHOICE trial: adalimumab demonstrates safety, fistula healing, improved quality of life and increased work productivity in patients with Crohn's disease who failed prior infliximab therapy.**

*Publication:* Alimentary Pharmacology and Therapeutics 2010 11; 32(10): 1228-1239. doi: 10.1111/j.1365-2036.2010.04466.x.

*Authors:* Lichtiger S, Binion DG, Wolf DC, Present DH, Bensimon AG, Wu E, Yu AP, Cardoso AT, Chao J, Mulani PM, Lomax KG, Kent JD.

**Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (compairs).**

*Abstract:* 75th Annual Scientific Meeting of the American College of Gastroenterology, San Antonio, TX Oct 15-20, 2010.

*Authors:* Sussman D, Kubiliun N, Chao J, Mulani P, Gillis C, Yang M, Lu M, Abreu M.

**Markov model projection of remission status for early vs. delayed step-Up Adalimumab use in moderate to severe crohn's disease.**

*Abstract:* 75th Annual Scientific Meeting of the American College of Gastroenterology, San Antonio, TX Oct 15-20, 2010.

*Authors:* Loftus EV, Chao J, Yang M, Pollack PF, Li Z, Thakkar RB, Mulani PM.

**Racial differences in use of biologics for crohn's disease in a Medicaid population.**

*Abstract:* 75th Annual Scientific Meeting of the American College of Gastroenterology San Antonio, TX Oct 15-20, 2010.

*Authors:* Flasar M, Mulani P, Yang M, Chao J, Lu M, Cross R.

**T1065 Impact of Nighttime Symptoms (NTS) on Treatment Patterns and Healthcare Costs Among Gastroesophageal Reflux Disease (GERD) Patients.**

*Abstract:* Digestive Disease Week, New Orleans, LA Jun 1-6, 2010.

*Authors:* Mody R, Beaulieu N, Wu EQ, Dabbous F, McHale J, Chey WD.

**M1047 Quality-of-Life Benefits for Adalimumab-Treated Patients with Moderate to Severe Crohn's Disease are Predicted by Early Mucosal Healing Status.**

*Abstract:* Digestive Disease Week, New Orleans, Louisiana May 1-5, 2010.

*Authors:* Rutgeerts PJ, Thakkar R, Wu EQ, Kaltenboeck A, Yang M, Mulani P, Chao J.

**Systematic review: the costs of ulcerative colitis in Western countries.**

*Publication:* Alimentary Pharmacology and Therapeutics 2010 04; 31(7): 693-707. doi: 10.1111/j.1365-2036.2010.04234.x.

*Authors:* Cohen RD, Yu AP, Wu EQ, Xie J, Mulani PM, Chao J.

**Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease.**

*Publication:* European Journal of Gastroenterology and Hepatology 2009 11; 21(11): 1302-1309. doi: 10.1097/MEG.0b013e32832a8d71.

*Authors:* Loftus EV, Jr., Johnson SJ, Yu AP, Wu EQ, Chao J, Mulani PM.

**Healthcare costs of GERD and acid-related conditions in pediatric patients, with comparison between histamine-2 receptor antagonists and proton pump inhibitors.**

*Publication:* Current Medical Research and Opinion 2009 11; 25(11): 2703-2709. doi: 10.1185/03007990903307755.

*Authors:* Kothari S, Nelson SP, Wu EQ, Beaulieu N, McHale JM, Dabbous OH.

**Adalimumab Therapy is Associated with Improvements in Clinical Laboratory Parameters in Patients with Moderately to Severely Active Crohn's Disease.**

*Publication:* American Journal of Gastroenterology 2009 10; 104: S464-S465.

*Authors:* Rubin D, Ghosh S, Bensimon A, Yu A, Wu E, Pollack P, Chao J, Mulani P.

**Impact of compliance with proton pump inhibitors on NSAID treatment.**

*Publication:* American Journal of Managed Care 2009 10; 15(10): 681-688.

*Authors:* Duh MS, Gosselin A, Luo R, Lohoues H, Lewis BE, Crawley JA.

**Pediatric gastroesophageal reflux disease and acid-related conditions: trends in incidence of diagnosis and acid suppression therapy.**

*Publication:* Journal of Medical Economics 2009 10; 12(4): 348-355. doi: 10.3111/13696990903378680.

*Authors:* Nelson SP, Kothari S, Wu EQ, Beaulieu N, McHale JM, Dabbous OH.

**Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease.**

*Publication:* Pharmacoeconomics 2009 08; 27(7): 609-621. doi: 10.2165/11312710-000000000-00000.

*Authors:* Yu AP, Johnson S, Wang ST, Atanasov P, Tang J, Wu E, Chao J, Mulani PM.

**Treatment patterns and symptom control in patients with GERD: US community-based survey.**

*Publication:* Current Medical Research and Opinion 2009 08; 25(8): 1869-1878. doi: 10.1185/03007990903035745.

*Authors:* Chey WD, Mody RR, Wu EQ, Chen L, Kothari S, Persson B, Beaulieu N, Lu M.

**Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial.**

*Publication:* American Journal of Gastroenterology 2009 05; 104(5): 1170-1179. doi: 10.1038/ajg.2009.59.

*Authors:* Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM.

**Cost-effectiveness analysis of adalimumab vs. certolizumab maintenance therapies for moderate to severe Crohn's disease.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Jonasson S, Kaltenboeck A, Horn C, Mulani P, Majethia S, Chao J.

**Number-needed-to-treat (NNT) analysis: Remission rates for adalimumab vs. Infliximab in Crohn's disease.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Jonasson S, Kaltenboeck A, Horn C, Wu E, Majethia S, Mulani P, Chao J.

**S1030 Increased Risk of Psychiatric Disorders in Young Patients with Crohn's Disease.**

*Abstract:* Digestive Disease Week Annual Conference, Chicago, IL May 30 - Jun 4, 2009.

*Authors:* Loftus EV, Guérin A, Yu AP, Wu E, Chao J, Mulani P.

**S1136 Increased Risk of Clinical Relapse Is Associated with Longer Disease Duration in Crohn's Disease.**

*Abstract:* Digestive Disease Week Annual Conference, Chicago, IL May 30 - Jun 4, 2009.

*Authors:* Rubin DT, Bensimon AG, Yu AP, Wu E, Chao J, Mulani P.

**P246-Young patients with Crohn's disease are at increased risk for psychiatric disorders.**

*Abstract:* European Crohn's & Colitis Organisation 4th Congress, Hamburg, Germany Feb 5-7, 2009.

*Authors:* Loftus E, Guérin A, Yu A, Wu E, Chao J, Mulani P.

**Rate of dosage escalation in patients with crohn's disease treated with infliximab.**

*Abstract:* Canadian Digestive Diseases Week 2009, Banff, AB Canada Feb 27-Mar 2, 2009.

*Authors:* Plevy S, Wu E, Yu A, Chao J, Mulani P.

**The impact of proton pump inhibitor compliance on health-care resource utilization and costs in patients with gastroesophageal reflux disease.**

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research 2009.

*Authors:* Gosselin A, Luo R, Lohoues H, Toy E, Lewis B, Crawley J, Duh MS.

**Corrigendum: Effects of Adalimumab Maintenance Therapy on Health-Related Quality of Life of Patients with Crohn's Disease: Patient-Reported Outcomes of the CHARM Trial.**

*Publication:* The American Journal of Gastroenterology 2009 104(7).

*Authors:* Loftus EV, Feagan BG, Colombel J-F, Rubin DT, Wu EQ, Yu AP, Pollack PF, JINGDONG C, Mulani P.

**Adalimumab maintenance therapy for patients with Crohn's Disease is cost effective compared with nonbiologic maintenance therapy: P-0074.**

*Authors:* Feagan B, Loftus EJ, Johnson S, Wu E, Yu A, Chao J, Mulani P.

**Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial.**

*Publication:* American Journal of Gastroenterology 2008 12; 103(12): 3132-3141. doi: 10.1111/j.1572-0241.2008.02175.x.

*Authors:* Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, Pollack PF, Chao J, Mulani P.

**Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study.**

*Publication:* Gastroenterology 2008 11; 135(5): 1493-1499. doi: 10.1053/j.gastro.2008.07.069.

*Authors:* Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV, Jr., Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P.

**Adalimumab Treatment Significantly Reduces Hospitalization Risk for TNF-Antagonist-Naïve Patients with Crohn's Disease.**

*Abstract:* American College of Gastroenterology 2008 Annual Meeting, Orlando, FL Oct 3-8, 2008.

*Authors:* Loftus E, Feagan B, Colombel JF, Wu EQ, Yu A, Chao J, Mulani P.

**Health-Related Quality Of Life in TNF-Antagonist-Naïve Patients with Crohn's Disease during Short- and Long-Term Adalimumab Treatment.**

*Abstract:* American College of Gastroenterology 2008 Annual Meeting, Orlando, FL Oct 3-8, 2008.

*Authors:* Rubin D, Rutgeerts P, Colombel JF, Wu EQ, Yu A, Chao J, Mulani P.

**Infliximab Dosage-Increase Rate in Patients with Crohn's Disease.**

*Abstract:* American College of Gastroenterology 2008 Annual Meeting, Orlando, FL Oct 3-8, 2008.

*Authors:* Plevy S, Wu EQ, Yu A, Chao J, Mulani P.

**Loss of treatment response to infliximab maintenance therapy in Crohn's disease: a payor perspective.**

*Publication:* Value in Health 2008 10; 11(5): 820-829. doi: 10.1111/j.1524-4733.2008.00335.x.

*Authors:* Wu EQ, Mulani PM, Yu AP, Tang J, Pollack PF.

**Adalimumab maintenance therapy is cost effective for maintaining remission in patients with Crohn's disease.**

*Publication:* American Journal of Gastroenterology 2008 09; 103: S383-S383.

*Authors:* Feagan B, Loftus E, Johnson S, Wu E, Yu A, Chao J, Mulani P.

**Adherence to Infliximab Maintenance Therapy and Its Impact on Hospitalization of Patients with Crohn's Disease.**

*Abstract:* ISPOR 13th Annual International Meeting, Toronto, ON, Canada May 3-7, 2008.

*Authors:* Kane S, Wu EQ, Chen L, Yu A, Tsaneva M, Chao J, Mulani P.

**M1033 Nighttime Symptoms and Sleep Impairment Among Patients with Gastro-Esophageal Reflux Disease (GERD) Receiving Prescription (Rx) Proton Pump Inhibitors (PPIs).**

*Abstract:* Digestive Week, San Francisco, CA May 17-22, 2008.

*Authors:* Chey WD, Mody R, Chen L, Kothari S, Persson B, Wu E, Lu M.

**M1041 Are Proton Pump Inhibitors (PPIs) Sufficient in Controlling Symptoms of Gastro-Esophageal Reflux Disease (GERD)? A Community-Based US Survey Study.**

*Abstract:* Digestive Week, San Diego, CA May 17-22, 2008.

*Authors:* Chey WD, Mody R, Kothari S, Wu E, Chen L, Persson B, Beaulieu N, Lu M.

**T1061 Improvement in short inflammatory bowel disease questionnaire scores in adalimumab-treated Crohn's disease patients who failed infliximab (CHOICE trial).**

*Abstract:* Digestive Disease Week, San Diego, CA May 17-22, 2008.

*Authors:* Lichtiger S, Present DH, Wu E, Beaulieu N, Kent JD, Lomax KG, Chao J, Mulani P.

**T1062 Improvement in Work Productivity with Adalimumab in Crohn's Disease Patients Who Failed Prior Infliximab: An Analysis of the CHOICE Trial.**

*Abstract:* Digestive Disease Week, San Diego, CA May 17-22, 2008.

*Authors:* Lichtiger S, Present DH, Persson B, Wu E, Kent JD, Lomax KG, Chao J, Mulani P.

**T1197 A Risk-Benefit Analysis of Adalimumab vs. Standard of Care in Patients with Crohn's Disease.**

*Abstract:* Digestive Disease Week, San Diego, CA May 17-22, 2008.

*Authors:* Loftus EV, Colombel J-F, Johnson SJ, Wu E, Chao J, Mulani P.

**The costs of Crohn's disease in the United States and other Western countries: a systematic review.**

*Publication:* Current Medical Research and Opinion 2008 02; 24(2): 319-328. doi: 10.1185/030079908X260790.

*Authors:* Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J.

**An evaluation of adalimumab on the risk of hospitalization in patients with Crohn's disease, data from CHARM: O-007.**

*Publication:* Inflammatory Bowel Diseases 2008 01; 14: S2-S3.

*Authors:* Feagan B, Panaccione R, Sandborn W, D'Haens G, Schreiber S, Rutgeerts P, Loftus E, Lomax K, Wu E, Mulani P.

**Effect of sustained remission and clinical response on the risk of hospitalization in patients with Crohn's disease.**

*Publication:* Managed Care Interface 2008 21: 20-23.

*Authors:* Wu E, Yu A, Tang J, Atanasov P, Chao J, Mulani P.

**PGI17 Adherence to infliximab maintenance therapy and its impact on hospitalization of patients with crohn's disease.**

*Abstract:* ISPOR, 2008.

*Authors:* Kane S, Wu E, Chen L, Yu A, Tsaneva M, Chao J, Mulani P.

**Differences in Health Care Visits Coded for Potential Proxy Conditions/Symptoms of Gastroesophageal Reflux Disease (GERD) before and after a GERD Diagnosis: A Pediatric Database Study.**

*Abstract:* American College of Gastroenterology, Philadelphia, PA Oct 12-17, 2007.

*Authors:* Nelson SP, Kothari S, Wu EQ, Persson B, Beaulieu N, Arana M, Orenstein SR, El-Serag H.

**Healthcare Utilization and Cost in Pediatric Gastroesophageal Reflux Disease (GERD) Patients on Continuous vs. Intermittent Proton Pump Inhibitor (PPI) Treatment Regimens.**

*Abstract:* American College of Gastroenterology, Philadelphia, PA Oct 12-17, 2007.

*Authors:* Nelson SP, Kothari S, Wu EQ, Persson B, Beaulieu N, Arana M, Lu M.

**Impact of adalimumab (HUMIRA (R)) on Patient-Reported Outcomes among Patients with Fistulizing Crohn's Disease in the CHARM Trial.**

*Abstract:* American College of Gastroenterology, Philadelphia, PA Oct 12-17, 2007.

*Authors:* Colombel JF, Wu EQ, Yu AP.

**Lower Disease Activity And Clinical Remission Are Associated with Reduced Hospitalization Risk In Crohn's Disease.**

*Abstract:* ISPOR 12th Annual International Meeting, Arlington, VA May 19-23, 2007.

*Authors:* Wu EQ, Yu AP, Tang J, Atanasov PD, Chao J, Mulani PM.

**PGI13 Lower disease activity and clinical remission are associated with reduced hospitalization risk in crohn's disease.**

*Abstract:* ISPOR, 2007.

*Authors:* Wu E, Yu A, Atanasov P, Tang J, Pollack P, Lomax K, Mulani P.

**Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation.**

*Publication:* Pharmacoepidemiology and Drug Safety 2006 01; 15(1): 47-56. doi: 10.1002/pds.1118.

*Authors:* Sands BE, Duh MS, Cali C, Ajene A, Bohn RL, Miller D, Cole JA, Cook SF, Walker AM.

**Loss of Treatment Response among Crohn's Disease Patients Receiving Infliximab Maintenance Therapy.**

*Abstract:* AMCP's 18th Annual Meeting, Seattle, WA Apr 5-8, 2006.

*Authors:* Wu EQ, Yu A, Tang J, Yermakov S, Naeem A, Beaulieu N, Mulani P.

**Productivity loss due to irritable bowel syndrome—reply.**

*Publication:* Archives of Internal Medicine 2003 10; 163(18): 2249-2250. doi: 10.1001/archinte.163.18.2249-a.

*Authors:* Greenberg P, Birnbaum H, Leong S, Pike C, Ben-Hamadi R, Barghout V, Frech F, Ofman J.

**The economic consequences of irritable bowel syndrome: a US employer perspective.**

*Publication:* Archives of Internal Medicine 2003 04; 163(8): 929-935. doi: 10.1001/archinte.163.8.929.

*Authors:* Leong SA, Barghout V, Birnbaum HG, Thibeault CE, Ben-Hamadi R, Frech F, Ofman JJ.

**Alternative Management Strategies for Dyspepsia.**

*Abstract:* ISPOR, 2001.

*Authors:* Wu E, Hay J.

## Hematology

**Matching-adjusted indirect comparisons of annualized bleeding rate and utilization of BAY 94-9027 versus three recombinant factor VIII agents for prophylaxis in patients with severe hemophilia A.**

*Publication:* Journal of Blood Medicine 2019 08; 10: 147-159. e-pub ahead of print 2019/08/17; doi: 10.2147/JBM.S206806.

*Authors:* Batt K, Gao W, Ayyagari R, Deschaseaux C, Vashi PB, Yao Z, Wang Y, Kessabi S, Klamroth R.

**Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective.**

*Publication:* Leukemia and Lymphoma 2019 06; 60(6): 1476-1484. e-pub ahead of print 2019/01/23; doi: 10.1080/10428194.2018.1538510.

*Authors:* Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL.

**Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients.**

*Publication:* Current Medical Research and Opinion 2019 04; 35(4): 653-660. doi: <http://dx.doi.org/10.1080/03007995.2018.1530205>.

*Authors:* McHorney CA, Peterson ED, Ashton V, Laliberte F, Crivera C, Germain G, Sheikh N, Schein J, Lefebvre P.

**Influence of patient-reported outcomes on the treatment effect of deferasirox film-coated and dispersible tablet formulations in the ECLIPSE trial: A post hoc mediation analysis.**

*Publication:* American Journal of Hematology. 2019 02. doi: <http://dx.doi.org/10.1002/ajh.25408>.

*Authors:* Taher AT, Origa R, Perrotta S, Kouraklis A, Belhoul K, Huang V, Han J, Bruederle A, Bobbili P, Duh MS, Porter JB.

**Pin17 Rapid Initiation of Antiretroviral Treatment (Art) Following Diagnosis of Human Immunodeficiency Virus (Hiv) among Medicaid Beneficiaries: A Real-World Evaluation.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Benson C, Emond B, Romdhani H, Lefebvre P, Tandon N, Chow W, Dunn K.

**Model of short and long-term outcomes of emicizumab prophylaxis treatment for persons with hemophilia A.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Mahajerin A, Zhou ZY, Raimundo K, Patel A, Han S, Ji Y, Zhong J, Betts K.

**Adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.**

*Publication:* Current Medical Research and Opinion 2018 11; 34(11): 1959-1966. e-pub ahead of print 2018/04/28; doi: <http://dx.doi.org/10.1080/03007995.2018.1470500>.

*Authors:* Cheng WY, Said Q, Hao Y, Xiao Y, Vekeman F, Bobbili P, Duh MS, Nandal S, Blinder M.

**Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.**

*Publication:* American Journal of Hematology 2018 11. e-pub ahead of print 2018/11/13; doi: 10.1002/ajh.25348.

*Authors:* Khelif A, Saleh MN, Salama A, Portella M, Duh MS, Ivanova J, Grotzinger K, Roy AN, Bussel JB.

**Symptoms Following Discontinuation of Tyrosine Kinase Inhibitor (TKI) Therapy After Achieving an Adequate Response in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).**

*Abstract:* 20th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy Miami, FL Sept 13-16, 2018.

*Authors:* Ritchie EK, Sadek I, Pivneva I, Guerin A, Latremouille-Viau D, Ndife B, Joseph GJ, Atallah EL.

**Health care resource burden among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: A retrospective chart review study.**

*Abstract:* 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic Aug 22-26, 2018.

*Authors:* Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin J, Roy A, Duh MS, De Latour RP.

**Mediation by patient-reported outcomes of the association between filmcoated or dispersible formulations of deferasirox and serum ferritin reduction: A post hoc analysis of the eclipse trial.**

*Abstract:* 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic Aug 22-26, 2018.

*Authors:* Taher AT, Origa R, Perrotta S, Kouraklis A, Huang V, Han J, Bruederle A, Bobbili PJ, Cheng WY, Duh MS, Porter JB.

**Risk factors for self-reported cholera within HIV-affected households in rural Haiti.**

*Publication:* Open Forum Infectious Diseases 2018 07; 5(6). doi: <http://dx.doi.org/10.1093/ofid/ofy127>.

*Authors:* Richterman A, Cheung HC, Meiselbach MK, Jerome G, Ternier R, Ivers LC.



**Economic burden following allogeneic hematopoietic stem cell transplant in patients with diffuse large B-cell lymphoma.**

*Publication:* Leukemia and Lymphoma 2018 05; 59(5): 1133-1142. e-pub ahead of print 2017/09/22; doi: 10.1080/10428194.2017.1375100.

*Authors:* Maziarz RT, Hao Y, Guerin A, Gauthier G, Gauthier-Loiselle M, Thomas SK, Eldjerou L.

**Effectiveness and safety of anticoagulants for the treatment of venous thromboembolism in patients with cancer.**

*Publication:* American Journal of Hematology 2018 05; 93(5): 664-671. e-pub ahead of print 2018/02/06; doi: <http://dx.doi.org/10.1002/ajh.25059>.

*Authors:* Streiff MB, Milentijevic D, McCrae K, Yannicelli D, Fortier J, Nelson WW, Laliberte F, Crivera C, Lefebvre P, Schein J, Khorana AA.

**Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis.**

*Publication:* Critical Care Medicine 2018 05; 46(5): 691-698. e-pub ahead of print 2017/12/23; doi: 10.1097/CCM.0000000000002928.

*Authors:* Iankova I, Thompson-Leduc P, Kirson NY, Rice B, Hey J, Krause A, Schonfeld SA, DeBrase CR, Bozzette S, Schuetz P.

**Health resource burden among patients with severe aplastic anemia who have had insufficient response to immunosuppressive therapy: A retrospective chart review study.**

*Publication:* Value in Health 2018 05; 21 (Supplement 1): S259-S260.

*Authors:* Huynh L, Ivanova JI, Totev T, Bilginsoy M, Antin JH, Roy A, Bobbili PJ, Duh MS, Peffault De Latour R.

**Matching-adjusted indirect comparisons (MAICs) of efficacy and consumption of bay 94-9027 versus three recombinant factor VIII (RFVIII) for prophylaxis of severe hemophilia A.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Ayyagari R, Deschaseaux C, Vashi PB, Kessabi S, Gao W.

**Health care resource utilization and costs associated with treatment of acute bleeding events among patients with hemophilia A in the United States.**

*Abstract:* AMCP's 30th Annual Meeting, Boston, MA Apr 23-26, 2018.

*Authors:* Song J, Chamberlain C, Rokito A, Cammarota J, Ma E, Xu Y, Betts K.

**Value of transfusion independence in severe aplastic anemia from patients' perspectives – a discrete choice experiment.**

*Publication:* Journal of Patient-Reported Outcomes 2018 03; 2(1): 13. doi: 10.1186/s41687-018-0032-y.

*Authors:* Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Mühlbacher AC, Roy A, Duh MS.

**Bay 81-8973 prophylaxis frequency and long-term bleed outcomes in the leopold i extension study.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington DC Dec 9-12, 2017.

*Authors:* Saxena K, Sajeev G, Ayyagari R, Dua A, Church N, Sanabria M, Afonja OO.

**A retrospective chart review to assess burden of illness among patients with severe aplastic anemia with insufficient response to immunosuppressive therapy.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* De Latour RP, Huynh L, Ivanova JI, Bilginsoy M, Totev T, Antin JH, Roy A, Duh MS.

**Pharmacokinetic parameters, prophylaxis frequency and bleed outcomes of severe hemophilia A patients treated with BAY 81-8973.**

*Abstract:* 69th Annual National Hemophilia Foundation meeting Meeting, Chicago, IL Aug 24-26, 2017.

*Authors:* Sajeev G, Ayyagari R, Shah A, Wang Y, Church n, Guerin A, Afonja O.

**Achievement of Glycated Hemoglobin Goals in the US Remains Unchanged Through 2014.**

*Publication:* Diabetes Therapy 2017 06. e-pub ahead of print 2017/06/25; doi: 10.1007/s13300-017-0280-5.

*Authors:* Carls G, Huynh J, Tuttle E, Yee J, Edelman SV.

**Impact of U.S. FDA approval of lenalidomide maintenance therapy in the first-line treatment of multiple myeloma after autologous hematopoietic stem cell transplant on total healthcare costs.**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain June 22-25, 2017.

*Authors:* Parikh K, Xie J, Chen C, Yang C, Farrukh A, Cockrum P, Agarwal AB, Abouzaid S.

**Mediation by patient-reported outcomes on the association between film-coated versus dispersible formulations of deferasirox and serum ferritin reduction: A post hoc analysis of the eclipse trial.**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain Jun 22-25, 2017.

*Authors:* Taher AT, Origa R, Perrotta S, Kouraklis A, Belhoul K, Huang V, Han J, Bruederle A, Bobbili P, Duh MS, Porter JB.

**Real-world adherence to iron chelation therapy: Comparing a film-coated tablet versus dispersible tablet of deferasirox.**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain June 22-25, 2017.

*Authors:* Cheng W, Xiao Y, Bobbili P, Coe A, Hao Y, Paley C, Said Q, Huang V, Duh MS, Blinder M.

**Disease-stratified adherence to iron chelation therapy in patients who switched from deferasirox dispersible tablets to deferasirox film-coated tablets.**

*Publication:* Value in Health 2017 05; 20 (5): A232.

*Authors:* Cheng WY, Duh MS, Xiao Y, Coe A, Hao Y, Vekeman F, Bobbili PJ, Blinder M.

**Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products.**

*Publication:* Haemophilia 2017 05; 23(3): 408-416. doi: <http://dx.doi.org/10.1111/hae.13160>.

*Authors:* Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Yermakov S, Karner P.

**A Risk Score for Fluconazole Failure among Patients with Candidemia.**

*Publication:* Antimicrobial Agents and Chemotherapy 2017 05; 61(5). e-pub ahead of print 2017/03/08; doi: 10.1128/AAC.02091-16.

*Authors:* Ostrosky-Zeichner L, Harrington R, Azie N, Yang H, Li N, Zhao J, Koo V, Wu EQ.

**Value of transfusion independence in severe aplastic anemia from patients' perspectives-a discrete choice experiment.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Pickard AS, Huynh L, Ivanova JI, Totev T, Graham S, Muhlbacher AC, Roy A, Duh MS.

**Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption.**

*Publication:* Journal of Medical Economics 2017 04; 20(4): 337-344. doi:

<http://dx.doi.org/10.1080/13696998.2016.1265973>.

*Authors:* Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Yermakov S, Karner P.

**Pharmacokinetic parameters, prophylaxis frequency and bleed outcomes of severe hemophilia a patients treated with BAY 81-8973.**

*Publication:* Haemophilia 2017 04; 23: 34-36. doi: <http://dx.doi.org/10.1111/hae.13217>.

*Authors:* Sajeev G, Ayyagari R, Shah A, Wang Y, Church N, Guerin A, Afonja O.

**Epidemiologic and clinical characteristics of thalassemia (THAL) intermedia (TI) in the US.**

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland Aug 25-28, 2016.

*Authors:* Vichinsky E, Kwiatkowski JL, Giardina PJ, Paley C, Vekeman F, Cheng WY, Damron J, McCormick N, Sasane M, Qiu Y, Duh MS, Thompson A.

**Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A.**

*Publication:* Journal of Blood Medicine 2016 07; 7: 129-137. e-pub ahead of print 2016/07/23; doi: 10.2147/JBM.S104074.

*Authors:* Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Wu EQ, Xie J.

**Economic burden of hematologic adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US).**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C.

**Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.**

*Abstract:* European Association for the Study of the Liver, 50th International Liver Congress, Vienna, Austria Apr 22-26, 2015.

*Authors:* Fontana RJ, Brown RS, Jr., Moreno-Zamora A, Prieto M, Joshi S, Londono MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Ittu R, Emond B, Reddy KR.

**Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.**

*Publication:* Liver Transplantation 2016 04; 22(4): 446-458. doi: <http://dx.doi.org/10.1002/lt.24416>.

*Authors:* Fontana RJ, Brown RS, Moreno-Zamora A, Prieto M, Joshi S, Londono MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, Elsharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Ittu R, Emond B, Reddy KR.

**Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.**

*Publication:* Leukemia 2016 04; 30(4): 995-998. e-pub ahead of print 2015/08/15; doi: 10.1038/leu.2015.225.

*Authors:* Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV.

**Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.**

*Publication:* Journal of Medical Economics 2016 03; 19(3): 292-303. e-pub ahead of print 2015/12/01; doi: 10.3111/13696998.2015.1117979.

*Authors:* Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Qiu Y, Duh MS, Paley C, Adams-Graves P.

**Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.**

*Publication:* Journal of Comparative Effectiveness Research 2016 03; 5(2): 129-139. e-pub ahead of print 2015/09/22; doi: 10.2217/ce.15.49.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Mu F, Kim S, Noviello S, Signorovitch J.

**Bleed occurrence after bay 81-8973 injection and characteristics of patients who respond to prophylaxis: Analyses from leopold I and II.**

*Abstract:* 9th Annual Congress of the European Association for Haemophilia and Allied Disorders, Malmo, Sweden Feb 3-5, 2016.

*Authors:* Church N, Ayyagari R, Pocoski J, Sajeev G, Sneha K, Du EX, Shi S, Mass Enriquez M, Xie J.

**Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.**

*Publication:* Clinical Therapeutics 2016 02; 38(2): 404-412. doi: 10.1016/j.clinthera.2015.12.017.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Ackerman P, Signorovitch J.

**History of sucrose-formulated recombinant factor VIII (rFVIII-FS) Use and reduction in bleeds following bay 81-8973 prophylaxis in leopold I.**

*Abstract:* 9th Annual Congress of the European Association for Haemophilia and Allied Disorders, Malmo, Sweden Feb 2-5, 2016.

*Authors:* Pocoski J, Ayyagari R, Church N, Sajeev G, Shi S, Mass Enriquez M, Xie J.

**Matching-adjusted indirect comparisons (MAICS) of efficacy of bay 81-8973 vs. 2 Recombinant Factor VIII (rFVIII) for prophylaxis of severe hemophilia A.**

*Abstract:* 9th Annual Congress of the European Association for Haemophilia and Allied Disorders, Malmo, Sweden Feb 3-5, 2016.

*Authors:* Pocoski J, Li N, Ayyagari R, Church N, Maas Enriquez M, Xiang Q, Kelkar S, Du EX, Xie J.

**Characteristics of treatment-experienced HIV-1-infected patients switching from multi-tablet to single-tablet regimens in the veterans affairs health care system.**

*Authors:* Dersarkissian M, Schulman K, Zelt S, D'Amico R, Bhak R, Hellstern M, Altomare A, Ercolano E, Duh MS, Young-Xu Y.

**Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.**

*Publication:* Journal of Medical Economics 2016 19(4): 364-373. e-pub ahead of print 2015/12/02; doi: 10.3111/13696998.2015.1127252.

*Authors:* LaMori J, Tandon N, Laliberte F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

**Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure.**

*Publication:* Current Medical Research and Opinion 2015 12; 31(12): 2167-2173. e-pub ahead of print 2015/09/24; doi: 10.1185/03007995.2015.1096242.

*Authors:* McHorney CA, Crivera C, Laliberte F, Nelson WW, Germain G, Bookhart B, Martin S, Schein J, Lefebvre P, Deitelzweig S.

**Epidemiologic and clinical characteristics of thalassemia intermedia in the United States.**

*Abstract:* 57th American Society of Hematology Annual Meeting and Exposition, Orlando, FL Dec 6-8, 2015.

*Authors:* Vichinsky E, Kwiatkowski JL, Giardina PJ, Paley C, Vekeman F, Cheng WY, Damron J, McCormick N, Sasane M, Qiu Y, Duh MS, Thompson A.

**The healthcare resource utilization, costs, and predictors of progression among relapsed and refractory CLL patients.**

*Abstract:* 57th Annual Meeting of the American Society of Hematology, Orlando, FL Dec 5-8, 2015.

*Authors:* Guerin A, Ray S, Gauthier G, Hsu L.-I, Zhdanova M, Wu E.

**Patterns of prior treatment and bleeds among patients with severe hemophilia a: Impact on frequency of dosing with bay 81-8973 in the leopold I trial.**

*Abstract:* 57th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 3-6, 2016.

*Authors:* Church N, Ayyagari R, Pocoski J, Sajeev G, Kelkar SS, Du EX, Mass-Enriquez M, Xie J.

**Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin in patients with chronic hepatitis C coinfectd with HIV: A matching-adjusted indirect comparison.**

*Abstract:* 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015, San Francisco, CA Nov 13-17, 2015.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peebles M, Mu F, Noviello S, Signorovitch J.

**Comparisons of factor consumption for routine prophylaxis and bleeding during episodic therapy with recombinant factor VIII FC fusion protein and conventional recombinant factor VIII.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Iorio A, Krishnan S, Myren K, Lethagen S, McCormick N, Karner P.

**Factor consumption for prophylaxis and treatment of bleeding: Recombinant factor IX FC fusion protein compared with conventional recombinant factor IX.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Iorio A, Krishnan S, Myren K, Lethagen S, McCormick N, Karner P.

**Age-Related Emergency Department Reliance in Patients with Sickle Cell Disease.**

*Publication:* Journal of Emergency Medicine 2015 10; 49(4): 513-522 e511. doi: 10.1016/j.jemermed.2014.12.080.

*Authors:* Blinder MA, Duh MS, Sasane M, Trahey A, Paley C, Vekeman F.

**Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.**

*Publication:* Leukemia and Lymphoma 2015 10; 56(10): 2803-2811. doi: 10.3109/10428194.2015.1016933.

*Authors:* Vekeman F, Cheng WY, Sasane M, Huynh L, Duh MS, Paley C, Mesa RA.

**Direct and Indirect Cost Burden of Chronic Hepatitis C.**

*Publication:* The American Journal of Pharmacy Benefits 2015 07; 7(4): e90-e100.

*Authors:* Tandon N, Reddy K, Balart L, Fastenau J, Lefebvre P, Parisé H, Laliberté F, Pilon D, Duh M, Cho M, Prabhakar A.

**Costs and Resource Utilization Associated with Anemia and Rash in Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Agents in the United States.**

*Publication:* Clinical Therapeutics 2015 06. doi: 10.1016/j.clinthera.2015.05.503.

*Authors:* Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ.

**Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor IX FC fusion protein and other recombinant factor IX products.**

*Abstract:* 25th Congress of the International Society on Thrombosis and Haemostasis, Toronto, ON, Canada Jun 20-25, 2015.

*Authors:* Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Karner P.

**Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor VIII FC fusion protein and other recombinant factor VIII products.**

*Abstract:* 25th Congress of the International Society on Thrombosis and Haemostasis, Toronto, ON, Canada Jun 20-25, 2015.

*Authors:* Iorio A, Krishnan S, Myren KJ, Lethagen S, McCormick N, Karner P.

**Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with thalassemia.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Vekeman F, Sasane M, Cheng WY, Agnihotram RV, Fortier J, Duh MS, Paley C, Adams-Graves P.

**Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Tandon N, Laliberté F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

**Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis c genotype 3: A matching-adjusted indirect comparison.**

*Abstract:* 50th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress, Vienna, Austria Apr 22-26, 2015.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Noviello S, Signorovitch J.

**A descriptive analysis of a real-world population with chronic hepatitis C (CHC) treated with simeprevir (SMV)- and/or sofosbuvir (SOF)-based regimens: findings from a U.S. payer database.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA Apr 22-26, 2015.

*Authors:* Forlenza J, Fortier J, Laliberté F, Lefebvre P, Tandon N.

**Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.**

*Publication:* J Manag Care Spec Pharm 2015 04; 21(4): 308-318.

*Authors:* Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ.

**Comparative efficacy and tolerability of combination treatment with daclatasvir and asunaprevir versus peginterferon alpha ribavirin based regimens for patients infected with genotype 1B hepatitis C virus.**

*Abstract:* 24th Annual Conference of the Asian Pacific Association for the Study of the Liver, Istanbul, Turkey Mar 12-15, 2015.

*Authors:* Signorovitch J, Betts K, Song Y, Sorg R, Li J, Behl A, Kalsekar A.

**Multicenter COMPACT study of COMplications in patients with sickle cell disease and utilization of iron chelation therapy.**

*Publication:* Current Medical Research and Opinion 2015 03; 31(3): 513-523. doi: 10.1185/03007995.2014.998815.

*Authors:* Jordan L, Adams-Graves P, Kanter-Washko J, Oneal PA, Sasane M, Vekeman F, Bieri C, Magestro M, Marcellari A, Duh MS.

**Economic consequences of cytomegalovirus disease among stem cell transplant recipients.**

*Abstract:* 2015 BMT Tandem Meetings, San Diego, CA Feb 11-15, 2015.

*Authors:* Macalalad AR, Yang H, Zhou A, Wu EQ, Chaudhari P, Snyderman DR.

**Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications.**

*Publication:* Current Medical Research and Opinion 2015 31(10): 1889-1895. e-pub ahead of print 2015/07/28; doi: 10.1185/03007995.2015.1077213.

*Authors:* Crivera C, Nelson WW, Bookhart B, Martin S, Germain G, Laliberte F, Schein J, Lefebvre P.

**Reply: Essential need for research in hepatitis C.**

*Publication:* Journal of Medical Economics 2015 18(7): 514-515. e-pub ahead of print 2015/03/07; doi: 10.3111/13696998.2015.1017504.

*Authors:* Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

**Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease.**

*Abstract:* 56th Annual Meeting of the American Society of Hematology, San Francisco, CA Dec 6-9, 2014.

*Authors:* Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Duh MS, Paley C, Adams-Graves P.

**Associations between joint damage and quality of life among patients with severe hemophilia a in the 3-year spinart trial.**

*Abstract:* 56th Annual Meeting of the American Society of Hematology, San Francisco, CA Dec 6-9, 2014.

*Authors:* Pocoski J, Lin PL, Hong W, Kelkar SS, Jiao T, Du EX, Humphries TJ, Xie J.

**Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.**

*Publication:* Journal of Medical Economics 2014 12; 17(12): 862-871. doi: 10.3111/13696998.2014.964720.

*Authors:* Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

**Subcutaneous (SQ) bortezomib (BTZ) in patients (PTS) with relapsed mantle cell lymphoma (MCL): Retrospective, observational study of treatment patterns and outcomes in US community oncology practices.**

*Abstract:* 56th Annual Meeting of the American Society of Hematology, San Francisco, CA Dec 6-9, 2014.

*Authors:* Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, Ng Y, Van De Velde H, Dow E, Niculescu L, Bonthapally V, Goy A.

**Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.**

*Publication:* Clinical Lymphoma, Myeloma & Leukemia 2014 10; 14(5): 380-388. doi: 10.1016/j.clml.2014.03.005.

*Authors:* Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL.

**Demographics, Comorbidities, Clinical Characteristics, and Post-treatment Outcomes for Treated Patients with Chronic Hepatitis C (CHC): A Descriptive Analysis of Real-world U.S. Commercially-insured and Medicare Populations.**

*Abstract:* AASLD/EASL Special Conference on Hepatitis C, New York, NY Sep 12-13, 2014.

*Authors:* Forlenza JB, Fortier J, Laliberté F, Lefebvre P, Tandon N.

**A cost-analysis model for anticoagulant treatment in the hospital setting.**

*Publication:* Journal of Medical Economics 2014 07; 17(7): 492-498. doi: 10.3111/13696998.2014.914032.

*Authors:* Mody SH, Huynh L, Zhuo DY, Tran KN, Lefebvre P, Bookhart B.

**Associations between clinical outcomes, health care resources utilization, and quality of life among patients with severe hemophilia A.**

*Abstract:* World Federation of Hemophilia, World Congress Melbourne, VIC Australia May 11-15, 2014.

*Authors:* Lin PL, Pocoski J, Du EX, Kelkar SS, Silberman C, Xie J.

**High cost patients and cost patterns from pediatric to adult care in a Medicaid population with sickle cell disease.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Blinder MA, Sasane M, Fortier J, Paley CS, Duh MS, Vekeman F.

**High utilizers of health care resources: Results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Jordan L, Adams-Graves P, Kanter-Washko J, Oneal P, Sasane M, Magestro M, Marcellari A, Vekeman F, Bieri C, Adams A, Duh MS.

**Impact of chronic hepatitis C (CHC) treatment on post therapy healthcare cost.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

**An indirect comparison of the efficacy of prophylactic use of rF VIII Fc and other rFVIII products and model of the effect of compliance.**

*Abstract:* World Federation of Hemophilia, World Congress Melbourne, VIC Australia May 11-15, 2014.

*Authors:* Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

**An indirect comparison of the efficacy of prophylactic use of rFIXFc and other rFIX products and simulation of the effect of compliance on effectiveness.**

*Abstract:* World Federation of Hemophilia, Melbourne, VIC Australia May 11-15, 2014.

*Authors:* Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

**Indirect comparison of the efficacy of recombinant factor IX Fc fusion protein and other factor IX products for prophylaxis: Simulating the effect of compliance on real-world effectiveness.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

**Indirect comparison of the efficacy of recombinant factor VIII Fc fusion protein and other factor VIII products for prophylaxis modeling the effect of compliance.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S.

**Medical complications and resource utilization in blood transfusion-dependent patients with myelofibrosis by iron chelation therapy use.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Vekeman F, Huynh L, Sasane M, Cheng W, Duh MS, Paley C, Mesa R.

**Working title: Contraindications for HCV therapy in United States patients with untreated chronic hepatitis C (CHC).**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

**Comparable outcomes with bortezomib-cyclophosphamide-dexamethasone (VCD) and bortezomib-lenalidomide-dexamethasone (VRD) for initial treatment of newly diagnosed multiple myeloma (MM).**

*Abstract:* 55th Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 7-10, 2013.

*Authors:* Kumar SK, Enggbretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Yap M, Saravanan S, Pan I, Rembert D, Dhanda R, Niculescu L, Ba-Mancini A, Ma E, Quick M, Rajkumar SV.

**Impact chronic hepatitis C (CHC) treatment on post therapy healthcare cost.**

*Abstract:* HEP DART frontiers in drug development for viral hepatitis 2013, Big Island, Hawaii Dec 8-12, 2013.

*Authors:* Tandon N, Balart L, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

**Medical complications in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.**

*Abstract:* 55th Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 7-10, 2013.

*Authors:* Vekeman F, Cheng WY, Sasane M, Huynh L, Kaminsky M, Duh MS, Paley C, Mesa RA.

**Transition from pediatric to adult care of high cost patients in a Medicaid population with sickle cell disease.**

*Abstract:* 55th Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 7-10, 2013.

*Authors:* Blinder MA, Sasane M, Fortier J, Paley CS, Duh MS, Vekeman F.



**Age-related emergency department reliance (EDR) and healthcare resource utilization in patients with sickle cell disease (SCD).**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS.

**Final results from the multicenter compact study of complications in patients with sickle cell disease (SCD) and utilization of iron chelation therapy: A retrospective medical records review.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Jordan LB, Adams-Graves P, Kanter-Washko J, Oneal P, Vekeman F, Bieri C, Sasane M, Marcellari A, Magestro M, Gorn Z, Duh MS.

**Final results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy: A retrospective medical records review.**

*Abstract:* 18th Congress of the European Hematology Association, Stockholm, Sweden Jun 13-16, 2013.

*Authors:* L J, Adams-Graves P, Kanter-Washko J, Oneal P, Sasane M, Vekeman F, Bieri C, Marcellari A, Magestro M, Gorn Z, Duh M.

**Age-related emergency department reliance (EDR) and health care resource utilization in patients with sickle cell disease (SCD).**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Blinder M, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS.

**Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.**

*Publication:* Pediatric Blood & Cancer 2013 05; 60(5): 828-835. doi: 10.1002/pbc.24459.

*Authors:* Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Duh MS.

**Direct and indirect cost burden of chronic hepatitis c infection in privately-insured patients, stratified by liver disease severity.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Tandon N, Reddy KR, Lefebvre P, Parise H, Laliberte F, Pilon D, Duh MS, Prabhakar A, Cho M, Balart LA, Fastenau J.

**Direct and indirect cost burden of chronic hepatitis C stratified by liver disease severity in privately insured patients.**

*Abstract:* Digestive Disease Week, Orlando, FL May 18-21, 2013.

*Authors:* Tandon N, Reddy KR, Lefebvre P, Parisé H, Laliberté F, Pilon D, Duh MS, Prabhakar A, Cho M, Balart LA, Fastenau J.

**Key cost drivers in the cost of care for sickle cell disease patients: Results of a systematic literature search and a survey of payers and key opinion leaders.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Jordan L, Duh MS, Vekeman F, Matter S, Bieri C, Sasane M.

**Age-related emergency department reliance and healthcare resource utilization in patients with sickle cell disease.**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* Blinder MA, Vekeman F, Sasane M, Trahey A, Paley C, Magestro M, Duh MS.

**Dynamics of improvement in health-related quality of life (HRQoL) with long-term eltrombopag treatment in adults with chronic immune thrombocytopenia (ITP) in EXTEND.**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* Grotzinger KM, Bussel JB, Saleh MN, Bieri C, Orlova Y, Brainsky A.

**Final results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy: A retrospective medical records review.**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* Jordan LB, Adams-Graves P, Kanter-Washko J, Oneal PA, Vekeman F, Bieri C, Sasane M, Marcellari A, Magestro M, Gorn Z, Duh MS.

**Development and validation of a classification algorithm for prophylactic vs. on-demand factor VIII therapy in patients with hemophilia a.**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Vekeman F, Pocoski J, Cheng W, Trahey A, Sarda S, Valluri S, Preblich R, Duh MS.

**Development and validation of a classification algorithm for prophylactic versus on-demand factor VIII therapy in patients with hemophilia A.**

*Abstract:* 30th International Congress of the World Federation of Hemophilia, Paris France July 8-12, 2012.

*Authors:* Pocoski J, Vekeman F, Cheng W, Trahey A, Sarda S, Valluri S, Preblich R, Duh M.

**Development and validation of a classification algorithm for prophylactic versus on-demand factor VIII therapy in patients with hemophilia A.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Vekeman F, Pocoski J, Cheng W, Trahey A, Sarda SP, Valluri S, Preblich R, Duh MS.

**Improvement in health-related quality of life (HRQoL) with long-term eltrombopag treatment in adults with chronic immune thrombocytopenia (ITP): Results of extend from June 2006 to February 2011.**

*Abstract:* 17th Congress of the European Hematology Association, Amsterdam, Netherlands Jun 14-17, 2012.

*Authors:* Grotzinger K, Bieri C, Olney H, Saleh M, Sheng Duh M, Brainsky A.

**Interim results from the multicenter compact study of complications in patients with sickle cell disease and utilization of iron chelation therapy: A retrospective medical records review.**

*Abstract:* 17th Congress of the European Hematology Association, Amsterdam, Netherlands Jun 24-27, 2012.

*Authors:* Jordan L, Adams-Graves P, Kanter-Washko J, Lau H, Vekeman F, Bieri C, Sasane M, Marcellari A, Magestro M, Steele V, Bluett-Mills G, Gorn Z, Duh M.

**Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease.**

*Publication:* Journal of Clinical Pharmacy and Therapeutics 2012 04; 37(2): 173-181. doi: 10.1111/j.1365-2710.2011.01276.x.

*Authors:* Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

**Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia.**

*Publication:* Current Medical Research and Opinion 2012 01; 28(1): 79-87. doi: 10.1185/03007995.2011.644849.

*Authors:* Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM.

**Utilization and cost comparison of erythropoiesis-stimulating agents in inpatient and outpatient hospital settings.**

*Publication:* Journal of Medical Economics 2012 01; 15(2): 352-360. doi: 10.3111/13696998.2011.649326.

*Authors:* Lafeuille MH, Bailey RA, Vekeman F, Scott McKenzie R, Lefebvre P.

**Age-related blood transfusion patterns in patients with Sickle Cell Disease (SCD) and the association with sickle cell complications.**

*Abstract:* 53rd Annual Meeting of the American Society of Hematology, San Diego, CA Dec 10-13, 2013.

*Authors:* Blinder MA, Vekeman F, Trahey A, Sasane M, Paley CS, Duh MS.

**Age-related iron chelation utilization and healthcare costs in patients with Sickle Cell Disease (SCD).**

*Abstract:* 53rd Annual Meeting of the American Society of Hematology, San Diego, CA Dec 10-13, 2011.

*Authors:* Blinder MA, Vekeman F, Trahey A, Sasane M, Paley CS, Duh MS.

**Preoperative hemoglobin levels, characteristics, and resource utilization in total hip replacement patients with an anemia diagnosis versus without an anemia diagnosis: An electronic medical record analysis.**

*Abstract:* 53rd Annual Meeting of the American Society of Hematology, San Diego, CA Dec 10-13, 2011.

*Authors:* Forlenza JB, Ellis L, Parise H, Lafeuille MH, Lefebvre P.

**The economics of the hematopoietic growth factors.**

*Publication:* Cancer Treatment and Research 2011 11; 157: 403-418. doi: 10.1007/978-1-4419-7073-2\_22.

*Authors:* Eldar-Lissai A, Lyman GH.

**Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Lafeuille MH, Bailey RA, Senbetta M, McKenzie RS, Lefebvre P.

**Transfusional iron overload (TIO) monitoring and treatment: Findings from an electronic medical records review study at the moffitt cancer center and research institute.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Duh MS, Wetzstein G, Guo A, Sasane M, Sarda SP, Korves C, Wang ST, Wei R, Clinton B, Ray L.

**Risk of venous thromboembolism complications.**

*Abstract:* 2011 Annual Scientific Symposium of the Hemostasis and Thrombosis Research Society, Chicago, IL Apr 28-30, 2011.

*Authors:* Lefebvre P, Laliberte F, Nutescu E, Duh MS, Lamori J, Bookhart BK, Olson W, Dea K, Schein J, Kaatz S.

**Monitoring and treatment of transfusional iron overload: Findings from an electronic medical records review study at the Moffitt cancer center and research institute.**

*Abstract:* 52nd Annual Meeting of the American Society of Hematology, Orlando, FL Dec 4-7, 2010.

*Authors:* Ray LA, Wetzstein GA, Wang ST, Guo A, Korves C, Clinton B, Wei R, Duh MS.

**Monitoring and treatment among patients with trans-fusional iron overload: Preliminary findings from an electronic medical records review study at H. Lee moffitt cancer center and research institute.**

*Abstract:* 2010 Annual Meeting of the American College of Clinical Pharmacy, Austin, TX Oct 17-20, 2010.

*Authors:* Ray LA, Wetzstein GA, Korves C, Wang ST, Clinton B, Wei R, Corral M, Duh MS.

**Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.**

*Publication:* Consultant Pharmacist 2010 08; 25(8): 493-500. doi: 10.4140/TCP.n.2010.493.

*Authors:* Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P.

**Persistence and compliance of deferoxamine (DFO) versus deferasirox (DFX) in Medicaid patients with sickle-cell disease (SCD).**

*Abstract:* 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Brighton, UK Aug 19-22, 2010.

*Authors:* Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

**Persistence and compliance of deferoxamine versus deferasirox in Medicaid patients with sickle-cell disease (SCD).**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

**Comment: the impact of methodological approach on cost findings in comparison of epoetin alfa with darbepoetin alfa.**

*Publication:* Annals of Pharmacotherapy 2010 03; 44(3): 595; author reply 595-596. doi: 10.1345/aph.1L590a.

*Authors:* Lefebvre P, Vekeman F, Cremieux PY.

**Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.**

*Publication:* Journal of Cancer Research and Therapeutics 2010 01; 6(1): 31-35. doi: 10.4103/0973-1482.63570.

*Authors:* Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS.

**Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.**

*Publication:* Transfusion 2010 01; 50(1): 190-199. doi: 10.1111/j.1537-2995.2009.02361.x.

*Authors:* Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.

**The cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Wang ST, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, Van De Velde H, Esseltine DL, Garrison L.

**Persistence and compliance of deferoxamine versus deferasirox in medicaid patients with sickle-cell disease.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Jordan LB, Vekeman F, Sengupta A, Corral M, Guo A, Duh MS.

**Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.**

*Publication:* Cancer 2009 10; 115(20): 4839-4848. doi: 10.1002/cncr.24535.

*Authors:* Heaney ML, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Duh MS.

**Comparison of infection-related hospitalization risk among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

**Pattern of utilization of pegfilgrastim (PEGFIL) in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Skarin AT, Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS.

**Association of health-related quality of life (HRQoL), bleeding, and platelet levels in chronic idiopathic thrombocytopenic purpura (itp): Results from RAISE and EXTEND.**

*Abstract:* 14th Congress of the European Hematology Association, Berlin, Germany June 4-7, 2009.

*Authors:* Bussel J, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Brainsky A.

**Improvement in fatigue and health-related quality of life (HRQoL) with long-term Eltrombopag therapy in chronic idiopathic thrombocytopenic purpura: results of phase 3, double-blind study(raise).**

*Abstract:* 14th Congress of the European Hematology Association, Berlin, Germany Jun 4-7, 2009.

*Authors:* Provan D, Bussel JB, Cheng G, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Aivado M.

**Improvement in fatigue and health-related quality of life with long-term Eltrombopag treatment in adults with chronic idiopathic thrombocytopenic purpura: The EXTEND study.**

*Abstract:* 14th Congress of the European Hematology Association, Berlin, Germany Jun 4-7, 2009.

*Authors:* Bussel J, Saleh M, Salama A, Grotzinger KM, Duh M, Signorovitch J, Stone NL, Aivado M.

**Budget impact analysis of sargramostim use in patients with chemotherapy-induced neutropenia.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Toy EL, Porter CL, Books P, Vekeman F, Barghout V, Duh M, Skarin AT.

**Comparison of infection-related hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

**Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.**

*Publication:* Transfusion 2009 05; 49(5): 895-902. doi: 10.1111/j.1537-2995.2008.02072.x.

*Authors:* Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, Lefebvre P.

**Pattern of utilization of pegfilgrastim in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS, Skarin AT.

**Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: Data from multi-center clinical practices.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Raptis A, Duh MS, Wang ST, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel N, Corral M, Scott J.

**Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.**

*Publication:* Journal of Medical Economics 2009 03; 12(1): 1-8. doi: 10.3111/13696990802648167.

*Authors:* Vekeman F, McKenzie RS, Bookhart BK, Laliberte F, Duh MS, Tak Piech C, Lefebvre P.

**An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.**

*Publication:* Cancer 2009 02; 115(4): 706-715. doi: 10.1002/cncr.24090.

*Authors:* Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V.

**Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis.**

*Publication:* Annals of Hematology 2008 07; 87(7): 527-536. doi: 10.1007/s00277-008-0450-7.

*Authors:* Moyo V, Lefebvre P, Duh MS, Yektashenas B, Mundle S.

**Anaemia and the risk of injurious falls in a community-dwelling elderly population.**

*Publication:* Drugs and Aging 2008 04; 25(4): 325-334.

*Authors:* Duh MS, Mody SH, Lefebvre P, Woodman RC, Buteau S, Piech CT.

**Cost analytic model to determine the least costly inpatient erythropoiesis stimulating therapy regimen.**

*Publication:* Annals of Pharmacotherapy 2008 01; 42(1): 16-23. doi: 10.1345/aph.1K061.

*Authors:* Sikand H, Decter A, Greco T, Watson SH, Kang YJ, Mody SH, Piech CT, Duh MS, Naeem A.

**Management of anaemia: a critical and systematic review of the cost effectiveness of erythropoiesis-stimulating agents.**

*Publication:* Pharmacoeconomics 2008 01; 26(2): 99-120.

*Authors:* Duh MS, Weiner JR, White LA, Lefebvre P, Greenberg PE.

**Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: An employer's perspective.**

*Publication:* Journal of Health & Productivity 2007 10: 309.

*Authors:* Moyneur E BB, Mody SH, Fournier A, Mallet D, Duh MS.

**Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.**

*Publication:* American Journal of Health-System Pharmacy 2007 09; 64(18): 1943-1949. doi: 10.2146/ajhp060585.

*Authors:* Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS.

**Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?**

*Publication:* Hepatology 2007 07; 46(1): 283; author reply 283-284. doi: 10.1002/hep.21707.

*Authors:* Wu WK, Duh MS, Lefebvre P.

**Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study.**

*Publication:* Critical Care (London, England) 2007 06; 11(3): R63. doi: 10.1186/cc5934.

*Authors:* Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF.

**Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.**

*Publication:* Drugs and Aging 2006 12; 23(12): 969-976.

*Authors:* Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.

**Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease.**

*Publication:* Journal of the American Society of Nephrology 2006 12; 17(12): 3497-3502. doi: 10.1681/ASN.2006030289.

*Authors:* Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH.

**Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies.**

*Publication:* Clinical Therapeutics 2006 10; 28(10): 1701-1708. doi: 10.1016/j.clinthera.2006.10.009.

*Authors:* Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS.

**Impact and treatment of anemia in the elderly: clinical, epidemiological and economic perspectives.**

*Publication:* Expert Review of Pharmacoeconomics & Outcomes Research 2006 10; 6(5): 577-590. doi: 10.1586/14737167.6.5.577.

*Authors:* Duh MS, Latypova A, Greenberg P.

**Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.**

*Publication:* Current Medical Research and Opinion 2006 10; 22(10): 1929-1937. doi: 10.1185/030079906X132541.

*Authors:* Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY.

**Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application.**

*Publication:* Journal of Oncology Pharmacy Practice 2006 09; 12(3): 165-178. doi: 10.1191/1078155206069925.

*Authors:* Cremieux P, Vekeman F, Lefebvre P.

**Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.**

*Publication:* Clinical Therapeutics 2006 09; 28(9): 1443-1450. doi: 10.1016/j.clinthera.2006.09.020.

*Authors:* Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.

**Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.**

*Publication:* Current Medical Research and Opinion 2006 09; 22(9): 1623-1631. doi: 10.1185/030079906X120968.

*Authors:* Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS.

**Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.**

*Publication:* Journal of Supportive Oncology 2006 05; 4(5): 243-250.

*Authors:* Chu E, Einhorn LH, Lefebvre P.

**Economic evaluation of weekly epoetin alfa versus biweekly darbepoetin alfa for chemotherapy-induced anaemia: evidence from a 16-week randomised trial.**

*Publication:* Pharmacoeconomics 2006 05; 24(5): 479-494.

*Authors:* Reed SD, Radeva JI, Daniel DB, Mody SH, Forlenza JB, McKenzie RS, Schulman KA.

**Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer.**

*Publication:* P AND T 2006 31(10): 594.

*Authors:* Gosselin A, McKenzie R, Lefebvre P, Mody S, Piech C, Duh M.

**Health-Related Quality Of Life of Anemia Patients in the U.S.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia-Pacific.

*Authors:* Cremieux P, Xie J, Wu EQ, Castor A.

**Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.**

*Publication:* Journal of the National Comprehensive Cancer Network 2005 11; 3(6): 807-816.

*Authors:* Campos SM, Duh MS, Lefebvre P, Rosberg J.

**The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.**

*Publication:* Current Medical Research and Opinion 2005 10; 21(10): 1677-1682. doi: 10.1185/030079905X65501.

*Authors:* Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.

**Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia.**

*Publication:* Current Medical Research and Opinion 2005 10; 21(10): 1527-1533. doi: 10.1185/030079905X65394.

*Authors:* Reed SD, Radeva JI, Daniel DB, Fastenau JM, Williams D, Schulman KA.

**Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia.**

*Publication:* Expert Review of Pharmacoeconomics & Outcomes Research 2005 08; 5(4): 383-394. doi:

10.1586/14737167.5.4.383.

*Authors:* Duh MS, L Mark T.

**Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve.**

*Publication:* Oncologist 2005 06; 10(6): 438-448. doi: 10.1634/theoncologist.10-6-438.

*Authors:* Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ.

**Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia : a meta-analysis.**

*Publication:* Clinical Drug Investigation 2005 25(1): 33-48.

*Authors:* Rosberg JH, Ben-Hamadi R, Cremieux PY, Fastenau JM, Piech CT.

**Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia.**

*Publication:* Journal of Managed Care Pharmacy 2004 11; 10(6): 531-537.

*Authors:* Cremieux PY, Fastenau JM, Kosicki G, Piech CT, Fendrick AM.

**Red blood cell transfusion and ventilator-associated pneumonia: A potential link?**

*Publication:* Critical Care Medicine 2004 03; 32(3): 666-674. e-pub ahead of print 2004/04/20.

*Authors:* Shorr AF, Duh MS, Kelly KM, Kollef MH.

**The CRIT Study: Anemia and blood transfusion in the critically ill--current clinical practice in the United States.**

*Publication:* Critical Care Medicine 2004 01; 32(1): 39-52. doi: 10.1097/01.CCM.0000104112.34142.79.

*Authors:* Corwin HL, Gettinger A, Pearl RG, Fink MP, Levy MM, Abraham E, MacIntyre NR, Shabot MM, Duh MS, Shapiro MJ.

**PCN6: Dose conversion of erythropoietic agents in chemotherapy-induced anemia: A meta-analysis.**

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research 2003, 2003.

*Authors:* Rosberg J, Oster E, Wu E, Fastenau J, Piech C.

**Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.**

*Publication:* Cancer 2002 08; 95(4): 888-895. doi: 10.1002/cncr.10763.

*Authors:* Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA.

**Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy.**

*Publication:* Journal of Clinical Oncology 2002 06; 20(11): 2757-2758.

*Authors:* Gabrilove JL, Sarokhan B, Cremieux P.

**Anemia-related costs for cancer patients.**

*Publication:* Journal of Managed Care Medicine 2002 6(1): 20-28.

*Authors:* Barnett A, Cremieux P, Fendrick A, George M, Slavin M.

**Cost Effectiveness of rHuEPO in Oncology.**

*Publication:* Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology: Scientific and Clinical Aspects of Anemia in Cancer 2002.

*Authors:* Cremieux P, Dial E, Gustafson M, Saraokhan B, Slavin M.

**Costs Associated with Anemia and Cancer.**

*Publication:* ONE: Oncology Economics 2000 1(11): 1-7.

*Authors:* Cremieux PY GM, Holland M, Slavin MB.



**Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.**

*Publication:* Pharmacoeconomics 1999 11; 16(5 Pt 1): 459-472.

*Authors:* Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB.

## Infectious Diseases

**Assessing Patient Preferences for Treatment Decisions for New Direct Acting Antiviral (DAA) Therapies for Chronic Hepatitis C Virus Infections.**

*Publication:* Advances in Therapy 2019 06. e-pub ahead of print 2019/06/27; doi: 10.1007/s12325-019-01012-6.

*Authors:* Welzel TM, Yang M, Sajeev G, Chen YJ, Pinsky B, Bao Y, Wu EQ, Dieterich D.

**Clinical and Economic Burden of Patients with Chronic Hepatitis C with Versus Without Antiviral Treatment in Japan: An Observational Cohort Study Using Hospital Claims Data.**

*Publication:* Infect Dis Ther 2019 06; 8(2): 285-299. e-pub ahead of print 2019/02/17; doi: 10.1007/s40121-019-0234-5.

*Authors:* Yamazaki K, Macaulay D, Song Y, Sanchez Gonzalez Y.

**The role of provider characteristics on the hepatitis A and B vaccination status of adults in the United States during 2007-2015.**

*Publication:* Prev Med Rep 2019 06; 14 (no pagination)(100833). doi: <http://dx.doi.org/10.1016/j.pmedr.2019.100833>.

*Authors:* Ghaswalla PK, Patterson BJ, Cheng WY, Duchesneau E, Macheca M, Duh MS, Trofa AF.

**Beyond multidrug resistance: Leveraging rare variants with machine and statistical learning models in Mycobacterium tuberculosis resistance prediction.**

*Publication:* EBioMedicine 2019 04. e-pub ahead of print 2019/05/03; doi: 10.1016/j.ebiom.2019.04.016.

*Authors:* Chen ML, Doddi A, Royer J, Freschi L, Schito M, Ezewudo M, Kohane IS, Beam A, Farhat M.

**Substantial declines in HIV, syphilis, genital ulcers and urethral discharge over two decades, with recent increases in sexually transmitted infection (STI) prevalence in an STI clinic in urban Haiti.**

*Abstract:* HIV and Hepatitis in the Americas, Bogota, Columbia April 4-6, 2019.

*Authors:* Liautaud B, Koenig S, Greenberg M, Serra E, Hilaire G, Marcelin A, Bernadin J, Macheca M, Pape J.

**Trends in CD4 cell count at diagnosis of HIV and initiation of ART in Haiti (2004 to 2016).**

*Abstract:* HIV and Hepatitis in the Americas, Bogota, Columbia April 4-6, 2019.

*Authors:* Dua A, Bousleiman S, Marcelin A, Rivera V, Koenig S, Cremieux P, Deschamps M, Pape J.

**Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.**

*Publication:* The American journal of tropical medicine and hygiene 2019 02; 100(2): 392-398. doi: <http://dx.doi.org/10.4269/ajtmh.18-0493>.

*Authors:* Walsh KF, Souroutzidis A, Vilbrun SC, Peebles M, Joissaint G, Delva S, Widmann P, Royal G, Pry J, Bang H, Pape JW, Koenig SP.

**Outcomes with continuation of tenofovir-lamivudine versus switching to zidovudine-lamivudine in second-line antiretroviral therapy in Haiti.**

*Abstract:* HIV and Hepatitis in the Americas, Bogotá, Colombia Apr 4-6, 2019.

*Authors:* Pierre S, Bocharova I, Nguyen C, Cremieux P, Koenig S, Pape J.

**Pin17 Rapid Initiation of Antiretroviral Treatment (Art) Following Diagnosis of Human Immunodeficiency Virus (Hiv) among Medicaid Beneficiaries: A Real-World Evaluation.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Benson C, Emond B, Romdhani H, Lefebvre P, Tandon N, Chow W, Dunn K.

**Early treatment with direct-acting antivirals (DAAs) saves medical costs in non-cirrhotic patients with chronic hepatitis C (CHC) virus infection in the United States (US).**

*Abstract:* 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), San Francisco, CA Nov 9-13, 2018.

*Authors:* Cacoub P, Gonzalez YS, Ionescu-Iltu R, Bondin M, Macaulay D.

**Risk Factors, Health Care Resource Utilization, and Costs Associated with Nonadherence to Antiretrovirals in Medicaid-Insured Patients with HIV.**

*Publication:* Journal of Managed Care & Specialty Pharmacy 2018 10; 24(10): 1040-1051. doi: <http://dx.doi.org/10.18553/jmcp.2018.17507>.

*Authors:* Dunn K, Lafeuille MH, Jiao X, Romdhani H, Emond B, Woodruff K, Pesa J, Tandon N, Lefebvre P.

**A Successful Model of Expedited Antiretroviral Therapy for Clinically Stable Patients Living With HIV in Haiti.**

*Publication:* Journal of acquired immune deficiency syndromes (1999) 2018 09; 79(1): 70-76. doi: <http://dx.doi.org/10.1097/QAI.0000000000001725>.

*Authors:* Guiteau Moise C, Rivera VR, Hennessey KA, Bellot C, Nicholas C, Fang AP, Verdier RI, Severe P, Sainvil A, Charles B, Dorval D, St Amour J, Pape JW, Koenig SP.

**Relationship between patient copayments in Medicare Part D and vaccination claim status for herpes zoster and tetanus-diphtheria-acellular pertussis.**

*Publication:* Current Medical Research and Opinion 2018 07; 34(7): 1261-1269. e-pub ahead of print 2017/12/13; doi: 10.1080/03007995.2017.1416347.

*Authors:* Yan S, DerSarkissian M, Bhak RH, Lefebvre P, Duh MS, Krishnarajah G.

**Risk factors for self-reported cholera within HIV-affected households in rural Haiti.**

*Publication:* Open Forum Infectious Diseases 2018 07; 5(6). doi: <http://dx.doi.org/10.1093/ofid/ofy127>.

*Authors:* Richterman A, Cheung HC, Meiselbach MK, Jerome G, Ternier R, Ivers LC.

**Adherence to antiretrovirals in medicaid-insured patients living with hiv: Predictors and economic consequences.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Dunn K, Lafeuille M, Jiao X, Romdhani H, Emond B, Woodruff K, Pesa J, Tandon N, Lefebvre P.

**Comorbidity and treatment burden among HIV-infected patients in a US medicaid population.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Der Sarkissian M, Bhak R, Oglesby AK, Priest J, Gao E, Macheca M, Sharperson C, Laliberte F, Duh MS.

**Efficacy and Safety of Procalcitonin Guidance in Patients With Suspected or Confirmed Sepsis: A Systematic Review and Meta-Analysis.**

*Publication:* Critical Care Medicine 2018 05; 46(5): 691-698. e-pub ahead of print 2017/12/23; doi: 10.1097/CCM.0000000000002928.

*Authors:* Iankova I, Thompson-Leduc P, Kirson NY, Rice B, Hey J, Krause A, Schonfeld SA, DeBrase CR, Bozzette S, Schuetz P.

**A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population.**

*Publication:* Infect Dis Ther 2018 05. e-pub ahead of print 2018/05/16; doi: 10.1007/s40121-018-0201-6.

*Authors:* Chawla A, Wang C, Patton C, Murray M, Puneekar Y, de Ruiter A, Steinhart C.

**Can food help retention in HIV care: A cohort study of adults initiating ART in Haiti.**

*Publication:* Topics in Antiviral Medicine 2018 04; 26 (Supplement 1): 504s-505s.

*Authors:* Reiff J, Galbaud S, Dua A, Mathon JE, Joseph P, Marcelin A, Julma P, Koenig S, Cremieux P, Pape JW, McNairy M.

**The Impact of a Community-Based Intervention Including a Monthly Food Ration on Food Insecurity Among HIV-Positive Adults During the First Year of Antiretroviral Therapy.**

*Publication:* AIDS and Behavior 2018 01; 22(1): 154-163. e-pub ahead of print 2017/08/30; doi: 10.1007/s10461-017-1897-0.

*Authors:* Rothman J, Kayigamba F, Hills V, Gupta N, Machara F, Niyigena P, Franke MF.

**Diagnostic yield of active case finding for tuberculosis and HIV at the household level in slums in Haiti.**

*Publication:* International Journal of Tuberculosis and Lung Disease 2017 11; 21(11): 1140-1146. e-pub ahead of print 2017/10/19; doi: 10.5588/ijtld.17.0049.

*Authors:* Rivera VR, Jean-Juste MA, Gluck SC, Reeder HT, Sainristil J, Julma P, Peck M, Joseph P, Ocheretina O, Perodin C, Secours R, Duran-Mendicuti M, Hashiguchi L, Cremieux PY, Koenig SP, Pape JW.

**Retention in Care among Patients with Early HIV Disease in Haiti.**

*Publication:* J Int Assoc Provid AIDS Care 2017 11; 16(6): 523-526. e-pub ahead of print 2017/12/01; doi: 10.1177/2325957417742670.

*Authors:* Hennessey KA, Leger TD, Rivera VR, Marcelin A, McNairy ML, Guiteau C, Devieux JG, Marcelin Y, Charles B, Cremieux PY, Koenig SP, Pape JW.

**Assessing patient preferences for and relative importance of features of new direct acting antiviral (DAA) treatments for chronic hepatitis C virus (HCV) infections.**

*Abstract:* 68th Annual Meeting of the American Association for the Study of Liver Diseases, Washington, DC Oct 20-24, 2017.

*Authors:* Welzel TM, Yang M, Sajeev G, Pinsky B, Mehta D, Bao Y, Wu E, Chen YJ.

**Real-world burden of care for patients with chronic hepatitis C before, during and after treatment with novel direct-acting antiviral agents (DAAs).**

*Abstract:* AMCP Nexus 2017, Dallas, TX Oct 16-19, 2017.

*Authors:* Yang M, Mu F, Macaulay D, Kort JJ, Chen YJ.

**Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial.**

*Publication:* PLoS Medicine 2017 07; 14 (7) (no pagination)(e1002357). doi: <http://dx.doi.org/10.1371/journal.pmed.1002357>.

*Authors:* Koenig SP, Dorvil N, Devieux JG, Hedt-Gauthier BL, Riviere C, Faustin M, Lavoile K, Perodin C, Apollon A, Duverger L, McNairy ML, Hennessey KA, Souroutzidis A, Cremieux PY, Severe P, Pape JW.

**A claims-based analysis of hepatitis a, b, and a/b vaccination series completion and compliance among US adults.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Patterson BJ, Cheng WY, Trofa AF, Duchesneau ED, Macheca M, Masseria C, Duh MS.

**Prevalence and economic burden of extrahepatic manifestations of hepatitis C virus are underestimated but can be improved with therapy.**

*Publication:* Hepatology Communications 2017 05; 1(5): 439-452. doi: <http://dx.doi.org/10.1002/hep4.1049>.

*Authors:* Reau N, Vekeman F, Wu E, Bao Y, Gonzalez YS.

**The cumulative prevalence and incidence of extra-hepatic manifestations in patients with hepatitis C virus infection: Real-world evidence from the United States.**

*Abstract:* International Liver Congress 2017 - 52nd Annual Meeting of the European Association for the Study of the Liver, Amsterdam, Netherlands Apr 19-23, 2017.

*Authors:* Reau N, Vekeman F, Wu E, Bao C, Gonzalez YS.

**Cost-Effectiveness Analysis of Isavuconazole vs. Voriconazole as First-Line Treatment for Invasive Aspergillosis.**

*Publication:* Advances in Therapy 2017 01; 34(1): 207-220. e-pub ahead of print 2016/12/04; doi: 10.1007/s12325-016-0443-1.

*Authors:* Harrington R, Lee E, Yang H, Wei J, Messali A, Azie N, Wu EQ, Spalding J.

**Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study.**

*Publication:* BMC Infectious Diseases 2016 12; 16(1): 730. e-pub ahead of print 2016/12/03; doi: 10.1186/s12879-016-2023-z.

*Authors:* Kontoyiannis DP, Yang H, Song J, Kelkar SS, Yang X, Azie N, Harrington R, Fan A, Lee E, Spalding JR.

**Daclatasvir +asunaprevir versus sofosbuvir/ledipasvir for the treatment of chronic hepatitis c genotype 1 in Japanese patients: A matching-adjusted indirect comparison.**

*Abstract:* 18th European Congress of the International Society for Pharmacoeconomics and Outcomes Research, Milan, Italy Nov 7-11, 2015.

*Authors:* Swallow E, Kelley C, Ristovska L, Signorovitch JE, McPhee F, Wygant G.

**Comparative hepatotoxicity of echinocandins in hospitalized patients (pts): A retrospective cohort study.**

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland Aug 25-28, 2016.

*Authors:* Vekeman F, Weiss LS, Aram J, Ionescu-Iltu R, Moosavi S, Xiao Y, Cheng WY, Bhak R, Tawadrous M, Duh MS.

**Same-day HIV testing and antiretroviral therapy initiation results in higher rates of treatment initiation and retention in care.**

*Abstract:* 21st International AIDS Conference, Durban, South Africa Jul 18-22, 2016.

*Authors:* Koenig S, Dorvil N, Severe P, Riviere C, Faustin M, Perodin C, Paul C, Apollon A, Saintil G, Duverger L, Dumont E, Hedt-Gauthier B, Hennessey K, Rivera V, Devieux J, Pape JW.

**Drug-Drug Interaction Associated with Mold-Active Triazoles among Hospitalized Patients.**

*Publication:* Antimicrobial Agents and Chemotherapy 2016 06; 60(6): 3398-3406. e-pub ahead of print 2016/03/24; doi: 10.1128/AAC.00054-16.

*Authors:* Andes D, Azie N, Yang H, Harrington R, Kelley C, Tan RD, Wu EQ, Franks B, Kristy R, Lee E, Khandelwal N, Spalding J.

**Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.**

*Publication:* Journal of Comparative Effectiveness Research 2016 05; 5(3): 273-279. e-pub ahead of print 2016/01/23; doi: 10.2217/ce.15.69.

*Authors:* Swallow E, Kelley C, Signorovitch J, Wygant G, McPhee F.

**Rotavirus vaccination in a Medicaid infant population from four US states: compliance, vaccination completion rate, and predictors of compliance.**

*Publication:* Human Vaccines & Immunotherapeutics 2016 05; 12(5): 1235-1243. e-pub ahead of print 2016/02/24; doi: 10.1080/21645515.2015.1136041.

*Authors:* Calnan M, Krishnarajah G, Duh MS, Haider BA, Yermakov S, Davis M, Yan S.

**Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.**

*Abstract:* European Association for the Study of the Liver, 50th International Liver Congress, Vienna, Austria Apr 22-26, 2015.

*Authors:* Fontana RJ, Brown RS, Jr., Moreno-Zamora A, Prieto M, Joshi S, Londono MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Ittu R, Emond B, Reddy KR.

**Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection.**

*Publication:* Liver Transplantation 2016 04; 22(4): 446-458. doi: <http://dx.doi.org/10.1002/lt.24416>.

*Authors:* Fontana RJ, Brown RS, Moreno-Zamora A, Prieto M, Joshi S, Londono MC, Herzer K, Chacko KR, Stauber RE, Knop V, Jafri SM, Castells L, Ferenci P, Torti C, Durand CM, Loiacono L, Lionetti R, Bahirwani R, Weiland O, Mubarak A, ElSharkawy AM, Stadler B, Montalbano M, Berg C, Pellicelli AM, Stenmark S, Vekeman F, Ionescu-Ittu R, Emond B, Reddy KR.

**High rate of linkage to care and antiretroviral therapy initiation in Haiti and improvements over time.**

*Abstract:* Congress of the HIV and Hepatitis in the Americas 2016.

*Authors:* Dorvil N, Hennessey K, Guiteau C, Rivera V, Devieux J, McNairy M, Severe P, Marcelin A, Julma P, Attwood S, Koenig S, Pape JW.

**Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison.**

*Publication:* Journal of Comparative Effectiveness Research 2016 03; 5(2): 129-139. e-pub ahead of print 2015/09/22; doi: 10.2217/ce.15.49.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Mu F, Kim S, Noviello S, Signorovitch J.

**Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.**

*Publication:* Clinical Therapeutics 2016 02; 38(2): 404-412. doi: 10.1016/j.clinthera.2015.12.017.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Ackerman P, Signorovitch J.

**Indirect comparison of daclatasvir+asunaprevir vs sofosbuvir/ledipasvir for HCV in Japanese patients.**

*Abstract:* 25th APASL Conference, Tokyo, Japan Feb 20-24, 2016.

*Authors:* Swallow E, Kelley C, Signorovitch J, McPhee F, Wygant G.

**Predictors of CD4 count recovery in the CIPRA HT-001 trial of early ART.**

*Abstract:* 23rd Conference on Retroviruses and Opportunistic Infections, Boston, MA Feb 22 - 25, 2016.

*Authors:* Collins SE, Calnan M, Juste MAJ, Severe P, Secours R, Bernard D, Batavia A, Fitzgerald DW, Koenig SP, Pape JW.

**Public Health Impact of Complete and Incomplete Rotavirus Vaccination among Commercially and Medicaid Insured Children in the United States.**

*Publication:* PLoS One 2016 01; 11(1): e0145977. e-pub ahead of print 2016/01/12; doi: 10.1371/journal.pone.0145977.

*Authors:* Krishnarajah G, Duh MS, Korves C, Demissie K.

**Characteristics of patients hospitalized for acute bacterial skin and skin structure infections (ABSSSI) from 2009 to 2013.**

*Abstract:* ID Week 2016, New Orleans, LA Oct 26-30, 2016.

*Authors:* McGinnis E, Cammarata S, Tan RD, Barrett M, Tuttle E.

**Characteristics of treatment-experienced HIV-1-infected patients switching from multi-tablet to single-tablet regimens in the veterans affairs health care system.**

*Authors:* Dersarkissian M, Schulman K, Zelt S, D'Amico R, Bhak R, Hellstern M, Altomare A, Ercolano E, Duh MS, Young-Xu Y.

**Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.**

*Publication:* Journal of Medical Economics 2016 19(4): 364-373. e-pub ahead of print 2015/12/02; doi: 10.3111/13696998.2015.1127252.

*Authors:* LaMori J, Tandon N, Laliberte F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

**Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.**

*Publication:* Journal of Comparative Effectiveness Research 2015 11; 4(6): 593-605. doi: 10.2217/ce.15.33.

*Authors:* Signorovitch JE, Betts KA, Song Y, Sorg RA, Li J, Behl AS, Kalsekar A.

**Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin in patients with chronic hepatitis C coinfecting with HIV: A matching-adjusted indirect comparison.**

*Abstract:* 66th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2015, San Francisco, CA Nov 13-17, 2015.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Noviello S, Signorovitch J.

**A second look at the association between gender and mortality on antiretroviral therapy.**

*Publication:* PLoS One 2015 11; 10 (11) (no pagination)(e0142101). doi:

<http://dx.doi.org/10.1371/journal.pone.0142101>.

*Authors:* Koenig SP, Bornstein A, Severe K, Fox E, Devieux JG, Severe P, Joseph P, Marcelin A, Bright DA, Pham N, Cremieux P, Pape JW.

**Effect of Cumulating Exposure to Abacavir on the Risk of Cardiovascular Disease Events in Patients From the Swiss HIV Cohort Study.**

*Publication:* Journal of Acquired Immune Deficiency Syndromes 2015 08; 69(4): 413-421. doi:

10.1097/QAI.0000000000000662.

*Authors:* Young J, Xiao Y, Moodie EE, Abrahamowicz M, Klein MB, Bernasconi E, Schmid P, Calmy A, Cavassini M, Cusini A, Weber R, Bucher HC, Swiss HIVCS.

**Direct and Indirect Cost Burden of Chronic Hepatitis C.**

*Publication:* The American Journal of Pharmacy Benefits 2015 07; 7(4): e90-e100.

*Authors:* Tandon N, Reddy K, Balart L, Fastenau J, Lefebvre P, Parisé H, Laliberté F, Pilon D, Duh M, Cho M, Prabhakar A.

**Simulations Show Diagnostic Testing For Malaria In Young African Children Can Be Cost-Saving Or Cost-Effective.**

*Publication:* Health Affairs 2015 07; 34(7): 1196-1203. doi: 10.1377/hlthaff.2015.0095.

*Authors:* Phillips V, Njau J, Li S, Kachur P.

**Costs and Resource Utilization Associated with Anemia and Rash in Chronic Hepatitis C Patients Treated with Direct-Acting Antiviral Agents in the United States.**

*Publication:* Clinical Therapeutics 2015 06. doi: 10.1016/j.clinthera.2015.05.503.

*Authors:* Le TK, Macaulay D, Kalsekar A, Yuan Y, Sorg RA, Wei J, Wu EQ.

**Association of Obesity with 30-day readmission rates among patients Hospitalized with Acute Bacterial Skin and Skin-Structure Infections (ABSSI).**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Ayyagari R, Revol C, Tang W, Faust E, Tuttle EG.

**Predictors of high healthcare resource utilization and liver disease progression among patients with chronic hepatitis C.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Tandon N, Laliberté F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

**Comparative efficacy and tolerability of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for hepatitis c genotype 3: A matching-adjusted indirect comparison.**

*Abstract:* 50th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress, Vienna, Austria Apr 22-26, 2015.

*Authors:* Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Noviello S, Signorovitch J.

**Daclatasvir (DCV) combined with sofosbuvir (SOF) or simeprevir (SMV) in liver transplant (LT) recipients with severe recurrent HCV genotype 1 infection.**

*Abstract:* 50th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress, Vienna, Austria Apr 22-26, 2015.

*Authors:* Fontana RJ, Brown Jr R, Herzer J, Stauber K, Moreno-Zamora RE, Londono A, Prieto MC, Castells M, Chacko L, Ferenci K, Jafri P, Knop SM, Bahirwani V, Durand R, Lionetti C, Loiacono R, Berg L, Joshi C, Montalbano S, Mubarak M, Pellicelli A, Elsharkawy A, Stenmark A, Torti S, Vekeman C, Ionescu-Ittu F, Edmond R, Reddy B.

**A descriptive analysis of a real-world population with chronic hepatitis C (CHC) treated with simeprevir (SMV)- and/or sofosbuvir (SOF)-based regimens: findings from a U.S. payer database.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA Apr 22-26, 2015.

*Authors:* Forlenza J, Fortier J, Laliberté F, Lefebvre P, Tandon N.

**Treatment patterns, health care resource utilization, and costs in U.S. patients diagnosed with chronic hepatitis C infection who received telaprevir or boceprevir.**

*Publication:* J Manag Care Spec Pharm 2015 04; 21(4): 308-318.

*Authors:* Le TK, Kalsekar A, Macaulay D, Yuan Y, Sorg RA, Behrer CR, Wei J, Wu EQ.

**Comparative efficacy and tolerability of combination treatment with daclatasvir and asunaprevir versus peginterferon alpha ribavirin based regimens for patients infected with genotype 1B hepatitis C virus.**

*Abstract:* 24th Annual Conference of the Asian Pacific Association for the Study of the Liver, Istanbul, Turkey Mar 12-15, 2015.

*Authors:* Signorovitch J, Betts K, Song Y, Sorg R, Li J, Behl A, Kalsekar A.

**Economic consequences of cytomegalovirus disease among stem cell transplant recipients.**

*Abstract:* 2015 BMT Tandem Meetings, San Diego, CA Feb 11-15, 2015.

*Authors:* Macalalad AR, Yang H, Zhou A, Wu EQ, Chaudhari P, Snyderman DR.

**The epidemiology of herpes zoster and its complications in Medicare cancer patients.**

*Publication:* BMC Infectious Diseases 2015 02; 15: 106. doi: 10.1186/s12879-015-0810-6.

*Authors:* Yenikomshian MA, Guignard AP, Haguinet F, LaCasce AS, Skarin AT, Trahey A, Karner P, Duh MS.

**CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001.**

*Publication:* International Journal of Tuberculosis and Lung Disease 2015 01; 19(1): 50-57. doi: 10.5588/ijtld.14.0217.

*Authors:* Collins SE, Jean Juste MA, Koenig SP, Secours R, Ocheretina O, Bernard D, Riviere C, Calnan M, Dunning A, Hurtado Rua SM, Johnson WD, Jr., Pape JW, Fitzgerald DW, Severe P.

**Reply: Essential need for research in hepatitis C.**

*Publication:* Journal of Medical Economics 2015 18(7): 514-515. e-pub ahead of print 2015/03/07; doi: 10.3111/13696998.2015.1017504.

*Authors:* Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

**Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.**

*Publication:* Journal of Medical Economics 2014 12; 17(12): 862-871. doi: 10.3111/13696998.2014.964720.

*Authors:* Tandon N, Balart LA, Laliberte F, Pilon D, Lefebvre P, Germain G, Prabhakar A.

**Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States.**

*Publication:* Human Vaccines & Immunotherapeutics 2014 11; 10(8): 2255-2266. doi: 10.4161/hv.29511.

*Authors:* Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Sheng Duh M.

**Demographics and clinical characteristics associated with high healthcare resource utilization (hru) and costs among chronic hepatitis c (chc) patients.**

*Abstract:* American Association for the Study of Liver Diseases Annual Meeting, Boston, MA Nov 7-11, 2014.

*Authors:* LaMori J, Tandon N, Laliberte F, Germain G, Pilon D, Lefebvre P, Prabhakar A.

**The pharmacoconomics review of 7-valent pneumococcal conjugate vaccination in Asian-pacific region.**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.

*Authors:* Zhu L.

**Cost burden of cytomegalovirus (CMV) disease among solid organ transplant recipients.**

*Abstract:* 54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC Sep 5-9, 2014.

*Authors:* Yang H, Zhuo D, Zhou Z, Wu EQ, Chaudhari P, Snyderman DR.

**Demographics, Comorbidities, Clinical Characteristics, and Post-treatment Outcomes for Treated Patients with Chronic Hepatitis C (CHC): A Descriptive Analysis of Real-world U.S. Commercially-insured and Medicare Populations.**

*Abstract:* AASLD/EASL Special Conference on Hepatitis C, New York, NY Sep 12-13, 2014.

*Authors:* Forlenza JB, Fortier J, Laliberté F, Lefebvre P, Tandon N.

**Contraindications for HCV therapy in U.S. patients with untreated chronic hepatitis C.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

**Cost-effectiveness of single versus multiple tablet regimens for treatment of HIV-1 infection.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Sweet DE, Zhuo DY, Macalalad AR, Signorovitch J.

**Impact of chronic hepatitis C (CHC) treatment on post therapy healthcare cost.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Tandon N, Balart LA, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

**Real-world persistence with single versus multiple tablet regimens for HIV-1 treatment.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Sweet DE, Kim Y, Song J, Zhong Y, Signorovitch J.

**Treatment patterns, health care resource utilization and costs in united states patients diagnosed with chronic hepatitis C infection.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Arunajadai SG, Wei J, Wu EQ.



**Working title: Contraindications for HCV therapy in United States patients with untreated chronic hepatitis C (CHC).**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Le TK, Kalsekar A, Yuan Y, Macaulay D, Sorg RA, Behrer CR, Wei J, Wu EQ.

**Budget impact analysis of liposomal amphotericin B and amphotericin B lipid complex in the treatment of invasive fungal infections in the United States.**

*Publication:* Appl Health Econ Health Policy 2014 02; 12(1): 85-93. doi: 10.1007/s40258-013-0072-7.

*Authors:* Yang H, Chaudhari P, Zhou ZY, Wu EQ, Patel C, Horn DL.

**Impact chronic hepatitis C (CHC) treatment on post therapy healthcare cost.**

*Abstract:* HEP DART frontiers in drug development for viral hepatitis 2013, Big Island, Hawaii Dec 8-12, 2013.

*Authors:* Tandon N, Balart L, Laliberté F, Pilon D, Lefebvre P, Prabhakar A.

**Infective endocarditis in children with congenital heart disease: cumulative incidence and predictors.**

*Publication:* Circulation 2013 09; 128(13): 1412-1419. doi: 10.1161/CIRCULATIONAHA.113.001827.

*Authors:* Rushani D, Kaufman JS, Ionescu-Iltu R, Mackie AS, Pilote L, Therrien J, Marelli AJ.

**The epidemiology of herpes zoster (HZ) and its complications in Medicare cancer patients.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Yenikomshian MA, La Casce AS, AT. S, Trahey A, Guignard A, Haguinet FF, Karner PE, Duh MS.

**Budget impact analysis of liposomal amphotericin b and amphotericin b lipid complex for treating invasive fungal infections in hospitalized patients.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Chaudhari P, Yang H, Zhou ZY, Patel C, Wu EQ.

**Direct and indirect cost burden of chronic hepatitis c infection in privately-insured patients, stratified by liver disease severity.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Tandon N, Reddy KR, Lefebvre P, Parise H, Laliberte F, Pilon D, Duh MS, Prabhakar A, Cho M, Balart LA, Fastenau J.

**Direct and indirect cost burden of chronic hepatitis C stratified by liver disease severity in privately insured patients.**

*Abstract:* Digestive Disease Week, Orlando, FL May 18-21, 2013.

*Authors:* Tandon N, Reddy KR, Lefebvre P, Parisé H, Laliberté F, Pilon D, Duh MS, Prabhakar A, Cho M, Balart LA, Fastenau J.

**Matching-adjusted indirect comparison of lipid profile at 48 weeks among treatment naive HIV-1 patients treated with atazanavir/ritonavir versus darunavir/ritonavir.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Xie J, Juday TR, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

**Direct and indirect cost burden is higher in HCV infection compared with a matched nonHCV infected cohort in a privately-insured population.**

*Abstract:* 48th Annual Meeting of the European Association for the Study of the Liver, International Liver Congress, Amsterdam, Netherlands Apr 24-28, 2013.

*Authors:* Tandon N, Reddy KR, Lefebvre P, Parise H, Laliberte F, Pilon D, Duh MS, Prabhakar A, Cho M, Balart LA, Fastenau J.

**Comparative efficacy at 48 weeks of atazanavir/ritonavir versus darunavir/ritonavir in treatment naive HIV-1 patients: A matching adjusted indirect comparison of randomized trials.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Xie J, Juday T, Swallow E, Du X, Uy J, Hebden T, Signorovitch J.

**Current trends in utilization and dosage patterns of micafungin and caspofungin in the United States.**

*Abstract:* American Society for Microbiology Conference on Candida and Candidiasis, San Francisco, CA Mar 29 - Apr 2, 2012.

*Authors:* Wu EQ, Chaudhari P, Sharma H, Macalalad AR, Horn D.

**PIH14 Rates and Predictors of Chlamydia re-Screening among Privately insured Patients with Chlamydia in 2007-2009.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Shi L, Liu J, Kissinger P, Khan M, Wu E.

**Prevalence of pseudomonas aeruginosa infection and antibiotic resistance by age group in the CFF patient registry in 2003 and 2008.**

*Abstract:* 25th Annual North American Cystic Fibrosis Conference, Anaheim, CA Nov 3-5, 2011.

*Authors:* Latremouille-Viau D, Zhang J, DeBonnett L, Signorovitch J, Von Wartbu M, Wu EQ, Shi L.

**Rates and predictors of gonorrhea re-screening among privately insured patients with gonorrhea in 2007-2009.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Shi L, Liu J, Kissinger P, Khan M, Wu EQ.

**Removal of opioid/acetaminophen combination prescription pain medications: assessing the evidence for hepatotoxicity and consequences of removal of these medications.**

*Publication:* Pain Medicine 2010 03; 11(3): 369-378. doi: 10.1111/j.1526-4637.2010.00811.x.

*Authors:* Michna E, Duh MS, Korves C, Dahl JL.

**Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?**

*Publication:* Hepatology 2007 07; 46(1): 283; author reply 283-284. doi: 10.1002/hep.21707.

*Authors:* Wu WK, Duh MS, Lefebvre P.

**Lower respiratory tract infections: impact on the workplace.**

*Publication:* Pharmacoeconomics 2003 06; 21(10): 749-759.

*Authors:* Birnbaum H, Morley M, Leong S, Greenberg P, Colice G.

**Economic burden of respiratory infections in an employed population.**

*Publication:* Chest 2002 08; 122(2): 603-611.

*Authors:* Birnbaum HG, Morley M, Greenberg PE, Colice GL.

## Neurology

**A Phase 1b/2 study of RG6206(BMS-986089)in boys with Duchenne muscular dystrophy: 72-week update.**

*Abstract:* 61th Annual Meeting of the Japanese Society of Child Neurology. Japan, Nagoya, Japan May 31 - Jun 2, 2019.

*Authors:* Dreggici R, Wagner KR, Wong BL, Byrne BJ, Tian C, Jacobsen LK, Tirucherai GS, Rabbia M, Kletzl H, Yen K, Sajeev G, Signorovitch J, Ward SJ, Krishnan M.

**The long-term direct and indirect economic burden among Parkinson's disease caregivers in the United States.***Publication:* Movement Disorders 2019 12; 34(2): 236-245. e-pub ahead of print 2018/12/28; doi: 10.1002/mds.27579.*Authors:* Martinez-Martin P, Macaulay D, Jalundhwala YJ, Mu F, Ohashi E, Marshall T, Sail K.**Real-world outcomes post-transition to once-every-3-months paliperidone palmitate in patients with schizophrenia within US commercial plans.***Publication:* Current Medical Research and Opinion. 2019 12. doi: <http://dx.doi.org/10.1080/03007995.2018.1560220>.*Authors:* Emond B, El Khoury AC, Patel C, Pilon D, Morrison L, Zhdanava M, Lefebvre P, Tandon N, Joshi K.**Trends in health service use and potentially avoidable hospitalizations before Alzheimer's disease diagnosis: A matched, retrospective study of US Medicare beneficiaries.***Publication:* Alzheimers Dement (Amst) 2019 12; 11: 125-135. e-pub ahead of print 2019/02/23; doi:

10.1016/j.dadm.2018.12.005.

*Authors:* Desai U, Kirson NY, Ye W, Mehta NR, Wen J, Andrews JS.**Burden of treatment-resistant depression in Medicare: A retrospective claims database analysis.***Publication:* PloS One 2019 10; 14(10): e0223255. e-pub ahead of print 2019/10/11; doi:

10.1371/journal.pone.0223255.

*Authors:* Pilon D, Joshi K, Sheehan JJ, Zichlin ML, Zuckerman P, Lefebvre P, Greenberg PE.**Is clinician impression of depression symptom severity associated with incremental economic burden in privately insured US patients with treatment resistant depression?***Publication:* Journal of Affective Disorders 2019 08; 255: 50-59. doi: <http://dx.doi.org/10.1016/j.jad.2019.04.100>.*Authors:* Pilon D, Sheehan JJ, Szukis H, Morrison L, Zhdanava M, Lefebvre P, Joshi K.**The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.***Publication:* Current Medical Research and Opinion 2019 07; 35(7): 1205-1214. e-pub ahead of print 2019/01/15; doi:<http://dx.doi.org/10.1080/03007995.2019.1569871>.*Authors:* McEvoy J, Park T, Schilling T, Terasawa E, Ayyagari R, Carroll B.**The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.***Publication:* Current Medical Research and Opinion 2019 07; 35(7): 1205-1214. e-pub ahead of print 2019/01/15; doi:

10.1080/03007995.2019.1569871.

*Authors:* McEvoy J, Park T, Schilling T, Terasawa E, Ayyagari R, Carroll B.**Migraine-related healthcare resource use in the emergency department setting: a panel-based chart review in France, Germany, Italy, and Spain.***Publication:* Journal of Medical Economics 2019 07; 1-7. e-pub ahead of print 2019/06/27; doi:

10.1080/13696998.2019.1636052.

*Authors:* Vo P, Gao W, Zichlin ML, Fuqua E, Fadli E, Aguirre Vazquez M, Tarancon T, Mahieu N, Maier-Peuschel M, Rossi S, Naclerio M, Ritrovato D, Swallow E.**Risk assessment and prediction of TD incidence in psychiatric patients taking concomitant antipsychotics: a retrospective data analysis.***Publication:* BMC Neurology 2019 07; 19(1): 174. e-pub ahead of print 2019/07/22; doi: 10.1186/s12883-019-1385-4.*Authors:* Patterson-Lomba O, Ayyagari R, Carroll B.**Adherence, Healthcare Resource Utilization, and Costs in Medicaid Beneficiaries with Schizophrenia Transitioning from Once-Monthly to Once-Every-3-Months Paliperidone Palmitate.***Publication:* PharmacoEconomics - Open 2019 06; 3(2): 177-188. doi: <http://dx.doi.org/10.1007/s41669-018-0089-9>.*Authors:* Emond B, Joshi K, Khoury ACE, Lafeuille MH, Pilon D, Tandon N, Romdhani H, Lefebvre P.

**Initiation of antidepressant medication and risk of incident stroke: using the Adult Changes in Thought cohort to address time-varying confounding.**

*Publication:* Annals of Epidemiology. 2019 06. doi: <http://dx.doi.org/10.1016/j.annepidem.2019.04.010>.

*Authors:* Glymour MM, Gibbons LE, Gilsanz P, Gross AL, Mez J, Brewster PW, Marden J, Zahodne LB, Nho K, Hamilton J, Li G, Larson EB, Crane PK.

**Mild traumatic brain injury in the United States: demographics, brain imaging procedures, health-care utilization and costs.**

*Publication:* Brain Injury 2019 06; 33(9): 1151-1157. e-pub ahead of print 2019/06/27; doi: 10.1080/02699052.2019.1629022.

*Authors:* Pavlov V, Thompson-Leduc P, Zimmer L, Wen J, Shea J, Beyhaghi H, Toback S, Kirson N, Miller M.

**US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study.**

*Publication:* PharmacoEconomics Open 2019 06. e-pub ahead of print 2019/06/30; doi: 10.1007/s41669-019-0154-z.

*Authors:* Pilon D, Szukis H, Joshi K, Singer D, Sheehan JJ, Wu JW, Lefebvre P, Greenberg P.

**Impact of Antipsychotic Treatment Switching in Patients With Schizophrenia, Bipolar Disorder, And Major Depressive Disorder.**

*Abstract:* American Academy of Neurology 71st Annual Meeting, Philadelphia, PA May 4-10, 2019.

*Authors:* Carroll B, Ayyagari R, Thomason D, Fan Mu P, Philbin M.

**Economic burden of relapse/recurrence in patients with major depressive disorder.**

*Publication:* J Drug Assess 2019 04; 8(1): 97-103. e-pub ahead of print 2019/06/14; doi: 10.1080/21556660.2019.1612410.

*Authors:* Gauthier G, Mucha L, Shi S, Guerin A.

**Medicaid spending burden among beneficiaries with treatment-resistant depression.**

*Publication:* Journal of Comparative Effectiveness Research 2019 04; 8(6): 381-392. e-pub ahead of print 2019/02/09; doi: 10.2217/ce-2018-0140.

*Authors:* Pilon D, Sheehan JJ, Szukis H, Singer D, Jacques P, Lejeune D, Lefebvre P, Greenberg PE.

**Development of a classifier to identify patients with probable Lennox-Gastaut syndrome in health insurance claims databases via random forest methodology.**

*Publication:* Current Medical Research and Opinion 2019 03: 1-6. e-pub ahead of print 2019/03/15; doi: 10.1080/03007995.2019.1595552.

*Authors:* Vekeman F, Pina-Garza JE, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Sheng Duh M, Shen V, Saurer TB, Montouris GD, Isojarvi J.

**The humanistic burden of postpartum depression: a systematic literature review.**

*Publication:* Current Medical Research and Opinion 2019 03; 35(3): 383-393. e-pub ahead of print 2018/11/24; doi: 10.1080/03007995.2018.1552039.

*Authors:* Moore Simas TA, Huang MY, Patton C, Reinhart M, Chawla AJ, Clemson C, Eldar-Lissai A.

**Level of Care Dependency and Functional Status Among Patients with Alzheimer's Disease and Agitation/Aggression Symptoms.**

*Abstract:* American Association for Geriatric Psychiatry (AAGP) 2019 Annual Meeting, Atlanta, GA Mar 1-4, 2019.

*Authors:* Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Sanon M.

**Real-world Utilization of Non-Pharmacological Therapy Prior to Initiation of Antipsychotic Treatment in the Management of Agitation in Patients with Dementia: Findings from a Large Retrospective Chart Review.**

*Abstract:* American Association for Geriatric Psychiatry (AAGP) 2019 Annual Meeting, Atlanta, GA Mar 1-4, 2019.

*Authors:* Sanon M, Gauthier-Loiselle M, Ladouceur M, Guerin A, Hartry A, Baker RA, Grundman M, Duffy R, Gwin K, Mergel V, Fillit H, Cloutier M.

**Severity of Agitation in Alzheimer's Disease: Proportion of Individuals Transitioning to Long-Term Residential Care using US National Alzheimer's Coordinating Center Data.**

*Abstract:* American Association for Geriatric Psychiatry (AAGP) 2019 Annual Meeting, Atlanta, GA Mar 1-4, 2019.

*Authors:* Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Sanon M.

**Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3years: a retrospective US claims database analysis.**

*Publication:* Journal of the Neurological Sciences 2019 01; 398: 163-170. e-pub ahead of print 2019/02/08; doi: 10.1016/j.jns.2019.01.036.

*Authors:* Fox E, Vieira MC, Johnson K, Peebles M, Bensimon AG, Signorovitch J, Herrera V.

**Pmh14 Cost Efficiency of Esketamine Nasal Spray Versus Standard of Care for Treatment Resistant Depression.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Desai U, Kirson NY, Guglielmo A, Le H, Spittle T, Tseng-Tham J, Shawi M, Sheehan JJ.

**Pmh22 Is Increased Severity Status Associated with Incremental Economic Burden in Privately Insured Us Patients with Treatment Resistant Depression?**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Zhdanava M, Pilon D, Szukis H, Sheehan J, Morrison L, Lefebvre P, Joshi K.

**The prospective economic impact of once monthly paliperidone palmitate versus oral atypical antipsychotics in Medicaid patients with schizophrenia.**

*Publication:* Current Medical Research and Opinion. 2018 12. doi: <http://dx.doi.org/10.1080/03007995.2018.1558195>.

*Authors:* El Khoury AC, Pilon D, Morrison L, Shak N, Vermette-Laforme M, Amos TB, Kim E, Lefebvre P.

**Ambulatory Function in Duchenne Muscular Dystrophy (Dmd): The Characteristic Trajectory and Variation across Individuals.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Signorovitch J, Muntoni F, Sajeev G, Yao Z, Ward SJ, Abrams KR.

**The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.**

*Abstract:* 2017 Neuroscience Education Institute Psychopharmacology Congress, NEI 2017, Colorado Springs, CO Nov 8-12, 2017.

*Authors:* McEvoy J, Park T, Schilling T, Terasawa E, Ayyagari R, Carroll B.

**Hospital utilization rates following antipsychotic dose reductions among patients with schizophrenia.**

*Abstract:* 2017 Neuroscience Education Institute Psychopharmacology Congress, NEI 2017, Colorado Springs, CO Nov 8-12, 2017.

*Authors:* Caroff SN, Mu F, Ayyagari R, Schilling T, Abler V, Carroll B.

**Patient Characteristics and Outcomes Associated with Receiving an Earlier Versus Later Diagnosis of Probable Alzheimer's Disease.**

*Publication:* Journal of Alzheimer's Disease 2018 11; 61(1): 295-307. e-pub ahead of print 2017/11/21; doi: 10.3233/JAD-170078.

*Authors:* Kirson NY, Scott Andrews J, Desai U, King SB, Schonfeld S, Birnbaum HG, Ball DE, Kahle-Wroblewski K.

**Short-term rehospitalizations in young adults with schizophrenia treated with once-monthly paliperidone palmitate or oral atypical antipsychotics: a retrospective analysis.**

*Publication:* Current Medical Research and Opinion 2018 09; 1-9. e-pub ahead of print 2018/08/15; doi: 10.1080/03007995.2018.1512477.

*Authors:* Pilon D, Amos TB, Kamstra R, Manceur AM, El Khoury AC, Lefebvre P.

**Epilepsy treatment patterns among patients with tuberous sclerosis complex.**

*Publication:* Journal of the Neurological Sciences 2018 08; 391: 104-108. e-pub ahead of print 2018/08/15; doi: 10.1016/j.jns.2018.06.011.

*Authors:* Song J, Swallow E, Said Q, Peebles M, Meiselbach M, Signorovitch J, Kohrman M, Korf B, Krueger D, Wong M, Sparagana S.

**Health Care Resource Utilization and Costs Associated with Transitioning to 3-Month Paliperidone Palmitate Among US Veterans.**

*Publication:* Clinical Therapeutics 2018 08; 40(9): 1496-1508. e-pub ahead of print 2018/08/27; doi: 10.1016/j.clinthera.2018.07.011.

*Authors:* DerSarkissian M, Lefebvre P, Joshi K, Brown B, Lafeuille MH, Bhak RH, Hellstern M, Bobbili P, Shiner B, El Khoury AC, Young-Xu Y.

**Mild traumatic brain injury in United States. Timing and modalities of brain imaging.**

*Abstract:* 3rd Joint Symposium of the International and National Neurotrauma Societies and AANS/CNS Section on Neurotrauma and Critical Care, Toronto, Canada Aug 11-16, 2018.

*Authors:* Pavlov V, Thompson-Leduc P, Toback S, Wen J, Shea J, Berdugo M, Zimmer L, Kirson N, Miller M.

**Treatment patterns and Medicaid spending in comorbid schizophrenia populations: once-monthly paliperidone palmitate versus oral atypical antipsychotics.**

*Publication:* Current Medical Research and Opinion 2018 08; 34(8): 1377-1388. e-pub ahead of print 2018/02/18; doi: 10.1080/03007995.2018.1442822.

*Authors:* Kamstra R, Pilon D, Lefebvre P, Emond B, Joshi K.

**Concomitant Use of Psychotropic Medication With Stimulants for the Treatment of ADHD in Children and Adolescents: A Retrospective Insurance Claims Study in the United States.**

*Publication:* J Atten Disord 2018 07; 1087054718784668. e-pub ahead of print 2018/07/12; doi: 10.1177/1087054718784668.

*Authors:* Zhou Z, Betts KA, Bocharova I, Kinrich D, Spalding WM.

**Development of a prognostic model for 1-year change in timed 4 stair-climb in duchenne patients.**

*Abstract:* 15th International Congress on Neuromuscular Diseases, ICNMD 2018, Vienna, Austria Jul 6-10, 2018.

*Authors:* Goemans N, Vanden Hauwe M, Signorovitch J, Sajeev G, Yao Z, Jenkins M, McDonald E, Dieye I, Ward SJ.

**Efficacy of antiepileptic drugs in the adjunctive treatment of refractory partial-onset seizures: Meta-analysis of pivotal trials.**

*Publication:* Epilepsy Research 2018 07; 143: 120-129. e-pub ahead of print 2018/05/23; doi: 10.1016/j.epilepsyres.2017.10.004.

*Authors:* Slater J, Chung S, Huynh L, Duh MS, Gorin B, McMicken C, Ziemann A, Isojarvi J.

**Treatment patterns among adults with ADHD receiving long-acting therapy.**

*Publication:* American Journal of Managed Care 2018 07; 24(8 Spec No.): Sp329-sp337. e-pub ahead of print 2018/07/19.

*Authors:* Zhou Z, Zhou ZY, Kellar SS, Sikirica V, Xie J, Grebla R.

**Examining a Statewide Educational Consulting Program for Pediatric Brain Injury.**

*Publication:* Clinical Pediatrics 2018 06; 57(6): 645-655. e-pub ahead of print 2017/09/22; doi: 10.1177/0009922817732146.

*Authors:* Myers RK, Eagan-Brown BL, Conway AT, Nagele DA, Vaccaro MJ, Kendi S, Zonfrillo MR.

**The humanistic burden of postpartum depression: A systematic literature review.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Reinhart M, Patton C, Chawla A, Clemson C, Huang M.

**Outcomes among medicaid recipients with schizophrenia treated with once-every-three month paliperidone palmitate.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Joshi K, Lafeuille M, Pilon D, Emond B, Romdhani H, Lefebvre P, El Khoury AC.

**Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis.**

*Publication:* Journal of the Neurological Sciences 2018 05; 388: 168-174. e-pub ahead of print 2018/04/09; doi: 10.1016/j.jns.2018.03.018.

*Authors:* Kantor D, Johnson K, Vieira MC, Signorovitch J, Li N, Gao W, Koo V, Duchesneau E, Herrera V.

**Treatment patterns and medicaid spending in comorbid schizophrenia populations: Once-monthly paliperidone palmitate vs oral atypical antipsychotics.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Kamstra R, Pilon D, Lefebvre P, Emond B, Joshi K.

**Medication use in adults with attention deficit/hyperactivity disorder in a commercially-insured population in the United States.**

*Publication:* Current Medical Research and Opinion 2018 04; 34(4): 585-592. e-pub ahead of print 2017/12/01; doi: 10.1080/03007995.2017.1411792.

*Authors:* Zhou Z, Zhou ZY, Kelkar SS, Sikirica V, Xie J, Grebla R.

**One-Year Effect of the Medicare Annual Wellness Visit on Detection of Cognitive Impairment: A Cohort Study.**

*Publication:* Journal of the American Geriatrics Society 2018 04. e-pub ahead of print 2018/04/03; doi: 10.1111/jgs.15330.

*Authors:* Fowler NR, Campbell NL, Pohl GM, Munsie LM, Kirson NY, Desai U, Trieschman EJ, Meiselbach MK, Andrews JS, Boustani MA.

**Direct and Indirect Cost Burden and Change of Employment Status in Treatment-Resistant Depression: A Matched-Cohort Study Using a US Commercial Claims Database.**

*Publication:* Journal of Clinical Psychiatry 2018 03; 79(2). e-pub ahead of print 2018/02/24; doi: 10.4088/JCP.17m11725.

*Authors:* Amos TB, Tandon N, Lefebvre P, Pilon D, Kamstra RL, Pivneva I, Greenberg PE.

**Reliability of coded data to identify earliest indications of cognitive decline, cognitive evaluation and Alzheimer's disease diagnosis: a pilot study in England.**

*Publication:* BMJ Open 2018 03; 8(3): e019684. e-pub ahead of print 2018/03/24; doi: 10.1136/bmjopen-2017-019684.

*Authors:* Dell'Agnello G, Desai U, Kirson NY, Wen J, Meiselbach MK, Reed CC, Belger M, Lenox-Smith A, Martinez C, Rasmussen J.

**Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.**

*Publication:* Journal of Medical Economics 2018 02; 21(2): 135-143. e-pub ahead of print 2017/09/13; doi: 10.1080/13696998.2017.1379413.

*Authors:* Pilon D, Alcusky M, Xiao Y, Thompson-Leduc P, Lafeuille MH, Lefebvre P, Benson C.

**A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.**

*Publication:* Eur J Health Econ 2018 01; 19(1): 21-35. e-pub ahead of print 2017/01/18; doi: 10.1007/s10198-016-0864-4.

*Authors:* Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA.

**The economic burden of bipolar I disorder in the United States in 2015.**

*Publication:* Journal of Affective Disorders 2018 01; 226: 45-51. e-pub ahead of print 2017/09/30; doi: 10.1016/j.jad.2017.09.011.

*Authors:* Cloutier M, Greene M, Guerin A, Touya M, Wu E.

**A systematic literature review and meta-analysis of prevalence estimates in migraine.**

*Abstract:* 11th European Headache Federation Congress Jointly with 31st Congress of the Italian Society for the Study of Headaches, Rome, Italy Dec 1-3, 2017.

*Authors:* Bilitou A, Vo P, Lopez-Leon S, Kelkar S, Cheung C, Gao E, Betts KA, Zhou Z.

**Adherence and Persistence on Long-acting Monotherapy and Combination Therapy in Adults with Attention-Deficit Hyperactivity Disorder (ADHD) in the US.**

*Abstract:* AMCP Nexus 2017, Dallas, TX Oct 16-19, 2017.

*Authors:* Zhou Z, ZY Zhou, Kelkar SS, Xie J, Grebla R.

**Baseline characteristics and treatment patterns of patients with schizophrenia initiated on once-every-three-months paliperidone palmitate in a real-world setting.**

*Publication:* Current Medical Research and Opinion 2017 10; 33(10): 1763-1772. e-pub ahead of print 2017/07/26; doi: 10.1080/03007995.2017.1359516.

*Authors:* Joshi K, Lafeuille MH, Brown B, Wynant W, Emond B, Lefebvre P, Tandon N.

**Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?**

*Publication:* Cns Drugs 2017 10; 31(10): 899-910. e-pub ahead of print 2017/09/01; doi: 10.1007/s40263-017-0462-8.

*Authors:* Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S.

**Cost-effectiveness analysis of ocrelizumab versus subcutaneous interferon beta-1a for the treatment of relapsing multiple sclerosis.**

*Publication:* Journal of Medical Economics 2017 10; 20(10): 1056-1065. e-pub ahead of print 2017/07/14; doi: 10.1080/13696998.2017.1355310.

*Authors:* Yang H, Duchesneau E, Foster R, Guerin A, Ma E, Thomas NP.

**Deflazacort or prednisone treatment for duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Signorovitch JE, Sajeev G, McDonnell E, Yao Z.

**Health care resource utilization before and after perampanel initiation among patients with epilepsy in the United States.**

*Publication:* Epilepsia 2017 10; 58(10): 1742-1748. e-pub ahead of print 2017/07/26; doi: 10.1111/epi.13857.

*Authors:* Faught E, Laliberte F, Wang Z, Barghout V, Haider B, Lejeune D, Germain G, Choi J, Wagh A, Duh MS.



**Impact of ocrelizumab vs. interferon beta-1a in delaying the deterioration of patients' daily functions and associated costs in relapsing-remitting multiple sclerosis.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Yang H, Duchesneau ED, Guerin A, Ma E, Thomas NP.

**Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.**

*Publication:* Current Medical Research and Opinion 2017 10; 33(10): 1891-1900. e-pub ahead of print 2017/06/08; doi: 10.1080/03007995.2017.1339674.

*Authors:* Weir MR, Berger JS, Ashton V, Laliberte F, Brown K, Lefebvre P, Schein J.

**Treatment Patterns, Health Care Resource Utilization, and Spending in Medicaid Beneficiaries Initiating Second-generation Long-acting Injectable Agents Versus Oral Atypical Antipsychotics.**

*Publication:* Clinical Therapeutics 2017 10; 39(10): 1972-1985 e1972. e-pub ahead of print 2017/09/19; doi: 10.1016/j.clinthera.2017.08.008.

*Authors:* Pilon D, Tandon N, Lafeuille MH, Kamstra R, Emond B, Lefebvre P, Joshi K.

**The Burden of Tardive Dyskinesia Secondary to Antipsychotic Medication Use among Patient with Mental Disorders.**

*Abstract:* The 30th Annual Psych Congress, New Orleans, LA Sept 16-19, 2017.

*Authors:* McEnvoy J, Park T, Schilling T, Terasawa E, Ayyagari R, Carroll B.

**Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator.**

*Publication:* Journal of Stroke and Cerebrovascular Diseases 2017 09; 26(9): 1996-2003. e-pub ahead of print 2017/07/12; doi: 10.1016/j.jstrokecerebrovasdis.2017.06.010.

*Authors:* Betts KA, Hurley D, Song J, Sajeev G, Guo J, Du EX, Paschoalin M, Wu EQ.

**Stroke and myocardial infarction risk among newly diagnosed heart failure patients with reduced, borderline, and preserved left ventricle ejection fraction.**

*Abstract:* 21st Annual Scientific Meeting of the Heart Failure Society of America, Grapevine, TX Sept 16-19, 2017.

*Authors:* Fonarow GC, Peterson ED, Greenberg B, Berger JS, Laliberte F, Zhao Q, Germain G, Lejeune D, Lefebvre P.

**Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome.**

*Publication:* Epilepsy & Behavior 2017 08; 73: 46-50. e-pub ahead of print 2017/06/14; doi: 10.1016/j.yebeh.2017.05.021.

*Authors:* Pina-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Duh MS, Shen V, Saurer TB, Isojarvi J.

**Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.**

*Publication:* European Child and Adolescent Psychiatry 2017 08; 26(8): 875-897. e-pub ahead of print 2017/03/05; doi: 10.1007/s00787-017-0962-6.

*Authors:* Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V.

**Health care resource utilization before and after perampanel initiation for the treatment of epilepsy in the United States.**

*Abstract:* 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Montreal, QC, Canada Aug 26-30, 2017.

*Authors:* Faught E, Laliberte F, Wang Z, Barghout V, Choi J, Haider B, Lejeune D, Germain G, Duh MS.

**Health Services Utilization Among Fee-for-Service Medicare and Medicaid Patients Under Age 65 with Behavioral Health Illness at an Urban Safety Net Hospital.**

*Publication:* J Manag Care Spec Pharm 2017 07; 23(7): 781-788. e-pub ahead of print 2017/06/27; doi: 10.18553/jmcp.2017.23.7.781.

*Authors:* Cancino RS, Jack BW, Jarvis J, Cummings AK, Cooper E, Cremieux PY, Burgess JF, Jr.

**Impact of Paliperidone Palmitate Versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans With Schizophrenia and Comorbid Substance Abuse.**

*Publication:* Clinical Therapeutics 2017 07; 39(7): 1380-1395 e1384. e-pub ahead of print 2017/06/24; doi: 10.1016/j.clinthera.2017.05.356.

*Authors:* Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak RH, Duh MS, Shiner B, Young-Xu Y.

**Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis.**

*Publication:* J Manag Care Spec Pharm 2017 07; 23(7): 771-780. e-pub ahead of print 2017/06/27; doi: 10.18553/jmcp.2017.23.7.771.

*Authors:* Guo A, Niyazov A, Macaulay D, Terasawa E, Schmerold L, Wu EQ, Krieger S.

**Is the annual wellness visit adequate to impact cognitive care?**

*Abstract:* Alzheimer's Association International Conference, London, UK July 14-20, 2017.

*Authors:* Fowler NR, Campbell NL, Pohl GM, Munsie LM, Kirson NY, Desai U, Trieschman EJ, Meiselbach MK, Andrews JS, Tanaka Y, Boustani MA.

**Trends in health service use and potentially avoidable hospitalizations prior to Alzheimer's disease diagnosis: A matched, retrospective study of U.S. medicare beneficiaries.**

*Abstract:* Alzheimer's Association International Conference, London, UK July 16-20, 2017.

*Authors:* Desai U, Kirson NY, Mehta N, Wen J, Sheng Y, Ye W, Andrews JS.

**A systematic literature review and meta-analysis of epidemiologic studies in chronic and episodic migraine.**

*Abstract:* 3rd Congress of the European Academy of Neurology, Amsterdam, Netherlands June 24-27, 2017.

*Authors:* Bilitou A, Vo P, Lopez S, Kelkar S, Cheung C, Gao E, Betts K, Zhou Z.

**Treatment patterns, healthcare resource utilization, and costs following first-line antidepressant treatment in major depressive disorder: a retrospective US claims database analysis.**

*Publication:* BMC Psychiatry 2017 06; 17(1): 222. e-pub ahead of print 2017/06/21; doi: 10.1186/s12888-017-1385-0.

*Authors:* Gauthier G, Guerin A, Zhdanova M, Jacobson W, Nomikos G, Merikle E, Francois C, Perez V.

**Healthcare costs among patients with lennox-gastaut syndrome treated with clobazam.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Pina-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Shen Y, Duh MS, Chatamra K, Kymes SM.

**Healthcare resource utilization and costs among adult schizophrenia patients using once-monthly versus twice-monthly long-acting antipsychotics.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Benson C, Alcusky M, Pilon D, Durkin M, Xiao Y, Thompson-Leduc P, Lafeuille M, Lefebvre P.

**Assessing Preferences for Attributes of Disease-Modifying Therapies among Patients with Relapsing-Form of Multiple Sclerosis: A Discrete Choice Study.**

*Abstract:* American Academy of Neurology 69th Annual Meeting, Boston, MA Apr 22-28, 2017.

*Authors:* Ye X, Kantor D, Barbato LM, Wakeford C, Yang M, Macaulay D, Marshall T.

**Healthcare resource utilization among patients with lennox-gastaut syndrome treated with clobazam.**

*Abstract:* 69th American Academy of Neurology Annual Meeting, Boston, MA April 22-28, 2017.

*Authors:* Pina-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Shen Y, Sheng Duh M, Isojarvi J, Kymes S, Saurer TB.

**Stroke risk reduction outweighed bleeding risk increase from vitamin K antagonist treatment among nonvalvular atrial fibrillation patients with high stroke risk and low bleeding risk.**

*Publication:* Current Medical Research and Opinion 2017 04; 33(4): 631-638. doi: 10.1080/03007995.2016.1275936.

*Authors:* Nelson WW, Laliberte F, Patel AA, Germain G, Pilon D, McCormick N, Lefebvre P.

**Treatment persistence and hospitalization rates among patients with schizophrenia: a quasi-experiment to evaluate a patient information program.**

*Publication:* Current Medical Research and Opinion 2017 04; 33(4): 713-721. doi: 10.1080/03007995.2016.1277989.

*Authors:* Pilon D, Amos TB, Germain G, Lafeuille MH, Lefebvre P, Benson CJ.

**Economic burden of illness for patients with traumatic brain injury resulting in chronic motor impairment.**

*Abstract:* 12th World Congress on Brain Injury of the International Brain Injury Association, New Orleans, LA Mar 29-Apr 1, 2017.

*Authors:* Swallow E, Liu WJ, Wen J, Fang A, Kirson N, Birnbaum H, Bates D.

**Incremental risk of ischemic stroke over time in newly diagnosed heart failure patients without atrial fibrillation.**

*Abstract:* 66th Annual Scientific Session of the American College of Cardiology and i2 Summit: Innovation in Intervention, Washington, DC Mar 17-19, 2017.

*Authors:* Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir M.

**Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.**

*Publication:* J Clin Mov Disord 2017 03; 4: 3. e-pub ahead of print 2017/03/08; doi: 10.1186/s40734-017-0051-5.

*Authors:* Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D.

**Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.**

*Publication:* Patient Preference and Adherence 2017 03; 11: 619-629. doi: <http://dx.doi.org/10.2147/PPA.S127623>.

*Authors:* Pilon D, Joshi K, Tandon N, Lafeuille MH, Kamstra RL, Emond B, Lefebvre P.

**Functional limitations and health care resource utilization for individuals with cognitive impairment without dementia: Findings from a United States population-based survey.**

*Publication:* Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring 2017 02; 6: 65-74. doi: <http://dx.doi.org/10.1016/j.dadm.2016.11.005>.

*Authors:* Desai U, Kirson NY, Enloe CJ, Ristovska L, King S, Birnbaum HG.

**Real-world costs of ischemic stroke by discharge status.**

*Publication:* Current Medical Research and Opinion 2017 02; 33(2): 371-378. e-pub ahead of print 2016/11/09; doi: 10.1080/03007995.2016.1257979.

*Authors:* Mu F, Hurley D, Betts KA, Messali AJ, Paschoalin M, Kelley C, Wu EQ.

**Adherence to QD vs. BID medications in nvaf patients is associated with reduced risk of ischemic stroke: A modeling study using rct and claims data.**

*Abstract:* American Heart Association's 2016 Scientific Sessions and Resuscitation Science Symposium, Nov 2016.

*Authors:* McHorney CA, Peterson E, Ashton V, Laliberte F, Crivera C, Sheikh N, Germain G, Schein J, Xiao Y, Lefebvre P.

**Risk of ischemic stroke in newly diagnosed heart failure patients.**

*Abstract:* American Heart Association's 2016 Scientific Sessions and Resuscitation Science Symposium, New Orleans, LA Nov 12-14, 2016.

*Authors:* Berger JS, Peterson E, Laliberte F, Germain G, Lejeune D, Schein J, Lefebvre P, Zhao Q, Weir M.

**Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia.**

*Publication:* Am Health Drug Benefits 2016 10; 9(7): 399-410. e-pub ahead of print 2016/12/21.

*Authors:* Lafeuille MH, Frois C, Cloutier M, Duh MS, Lefebvre P, Pesa J, Clancy Z, Fastenau J, Durkin M.

**Impact of Paliperidone Palmitate versus Oral Atypical Antipsychotics on Health Care Resource Use and Costs in Veterans with Schizophrenia.**

*Publication:* Journal of Clinical Psychiatry 2016 10; 77(10): e1332-e1341. e-pub ahead of print 2016/08/31; doi: 10.4088/JCP.16m10745.

*Authors:* Young-Xu Y, Duh MS, Muser E, DerSarkissian M, Faust E, Kageleiry A, Bhak RH, Fu DJ, Lefebvre P, Shiner B.

**Indirect comparison of tolerability of deutetrabenazine and tetrabenazine in the first-HD and tetra-HD trials.**

*Abstract:* 141st Annual Meeting of the American Neurological Association, Baltimore, MD Oct 16-18, 2016.

*Authors:* Claassen DO, Carroll B, De Boer LM, Wu E, Ayyagari R, Gandhi S, Stamler D.

**Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.**

*Publication:* PloS One 2016 10; 11(10): e0164684. e-pub ahead of print 2016/10/14; doi: 10.1371/journal.pone.0164684.

*Authors:* Goemans N, Vanden Hauwe M, Signorovitch J, Swallow E, Song J, Collaborative Trajectory Analysis P.

**Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.**

*Publication:* Neuromuscular Disorders 2016 09; 26(9): 576-583. e-pub ahead of print 2016/07/18; doi: 10.1016/j.nmd.2016.05.016.

*Authors:* Mercuri E, Signorovitch JE, Swallow E, Song J, Ward SJ, Group DMDI, Trajectory Analysis P.

**Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare resource use and costs in veterans with schizophrenia with limited antipsychotic exposure in the prior 12 months.**

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland Aug 25-28, 2016.

*Authors:* Lefebvre P, Muser E, Joshi K, DerSarkissian M, Bhak R, Kageleiry A, Duh MS, Shiner B, Young-Xu Y.

**Assessing the economic burden of Alzheimer's disease patients first diagnosed by specialists.**

*Publication:* BMC Geriatrics 2016 07; 16: 138. e-pub ahead of print 2016/07/13; doi: 10.1186/s12877-016-0303-5.

*Authors:* Kirson NY, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Ye W, Andrews JS, Ball D, Kahle-Wroblewski K.

**Prognostic model for 1-year change in 6-minute walk distance (6MWD) in patients with duchenne muscular dystrophy (DMD).**

*Abstract:* 14th International Congress on Neuromuscular Diseases, Toronto, CA July 5-9, 2016.

*Authors:* Goemans NM, Signorovitch J, Swallow E, Song J, Ward SJ.

**The Economic Burden of Schizophrenia in the United States in 2013.**

*Publication:* Journal of Clinical Psychiatry 2016 06; 77(6): 764-771. e-pub ahead of print 2016/05/03; doi: 10.4088/JCP.15m10278.

*Authors:* Cloutier M, Aigbogun MS, Guerin A, Nitulescu R, Ramanakumar AV, Kamat SA, DeLucia M, Duffy R, Legacy SN, Henderson C, Francois C, Wu E.

**Non-motor symptoms in advanced Parkinson's disease patients treated with levodopa/carbidopa intestinal gel, deep brain stimulation, or continuous subcutaneous apomorphine: A systematic literature review and pooled analysis.**

*Abstract:* 20th International Congress of Parkinson's Disease and Movement Disorders, Berlin, Germany Jun 19-23, 2016.

*Authors:* Chaudhuri KR, Terasawa E, Jalundhwala Y, Macaulay D, Ayyagari R, Zhou ZY, Marshall T, Chatamra K, Yucel A, Sail K.

**Can indirect comparison methods mitigate evolving trial populations in adjunctive antiepileptic drug trials? A propensity score matched indirect comparison of brivaracetam and levetiracetam.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S.

**Excess Costs Associated with Possible Misdiagnosis of Alzheimer's Disease Among Patients with Vascular Dementia in a UK CPRD Population.**

*Publication:* Journal of Alzheimer's Disease 2016 05; 53(1): 171-183. doi: 10.3233/JAD-150685.

*Authors:* Happich M, Kirson NY, Desai U, King S, Birnbaum HG, Reed C, Belger M, Lenox-Smith A, Price D.

**A life-course assessment of medication use and medical costs of lennox-gastaut syndrome (LGS).**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Montouris G, Pina-Garza JE, Vekeman F, Cheng WY, Tuttle EG, Giguere-Duval P, Duh MS, Isojarvi J.

**Real-world costs of ischemic stroke by discharge status.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Mu F, Hurley D, Betts K, Messali A, Paschoalin M, Wu EQ.

**Association of Rescue Medication Use with Clinical Outcomes and Health Care Costs in Patients with Seizure Clusters.**

*Abstract:* AMCP's 28th Annual Meeting, San Francisco, CA Apr 19-22, 2016.

*Authors:* Vazquez B, Hesdorffer D, Wu E, Macaulay D, Sorg R, Squillacote D, Sidovar M, Guo A.

**Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database.**

*Publication:* Pharmacoepidemiology and Drug Safety 2016 04; 25(4): 413-421. e-pub ahead of print 2016/02/19; doi: 10.1002/pds.3975.

*Authors:* Quinlan SC, Cheng WY, Ishihara L, Irizarry MC, Holick CN, Duh MS.

**Persistent use of dalfampridine extended release on healthcare resource utilization and cost in multiple sclerosis: A claims database analysis.**

*Abstract:* 68th American Academy of Neurology Annual Meeting, Vancouver, BC, Canada Apr 15-21, 2016.

*Authors:* Krieger S, Niyazov A, Macaulay D, Terasawa E, Wu E, Aupperle P, Guo A.

**Persistent use of dalfampridine extended release on healthcare resource utilization and cost in multiple sclerosis: A claims database analysis.**

*Publication:* Neurology, 2016 2016 04; 86(16 SUPPL. 1). e-pub ahead of print April 8, 2016.

*Authors:* Krieger S, Niyazov A, Macaulay D, Terasawa E, Wu E, Aupperle P, Guo A.

**Real-world durability of long-term relapse rates among patients with multiple sclerosis receiving fingolimod therapy: A retrospective US claims database analysis.**

*Abstract:* 68th American Academy of Neurology Annual Meeting, Vancouver, BC, Canada Apr 15-21, 2016.

*Authors:* Fox E, Johnson K, Lin F, Signorovitch J, Li N, Peebles M, Ristovska L, Souroutzidis A, Hong W, Herrera V.

**Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective.**

*Publication:* Current Medical Research and Opinion 2016 03; 32(3): 405-416. e-pub ahead of print 2015/11/14; doi: 10.1185/03007995.2015.1119678.

*Authors:* Nazareth T, Li N, Marynchenko M, Zhou Z, Chopra P, Signorovitch J, Wu E, Ahmed S, Marvel J, Sasane R.

**Treatment outcomes after methylphenidate in adults with attention-deficit/hyperactivity disorder treated with lisdexamfetamine dimesylate or atomoxetine.**

*Publication:* Patient Prefer Adherence 2016 03; 10: 391-405. doi: 10.2147/PPA.S98498.

*Authors:* Joseph A, Cloutier M, Guerin A, Nitulescu R, Sikirica V.

**Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.**

*Publication:* Current Medical Research and Opinion 2016 02; 32(4): 759-769. e-pub ahead of print 2016/01/12; doi: 10.1185/03007995.2016.1140634.

*Authors:* Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.

**Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review.**

*Publication:* Neurological Sciences 2016 02; 37(2): 165-179. e-pub ahead of print 2015/11/06; doi: 10.1007/s10072-015-2400-1.

*Authors:* Vollmer T, Huynh L, Kelley C, Galebach P, Signorovitch J, DiBernardo A, Sasane R.

**Development of a classifier to identify patients with Lennox-Gastaut syndrome in health insurance claims databases via the random forest methodology.**

*Abstract:* 69th Annual Meeting of the American Epilepsy Society, Philadelphia, PA Dec 4-8, 2015.

*Authors:* Vekeman F, Piña-Garza JE, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Isojarvi J, Montouris GD.

**A life-course assessment of treatment patterns and healthcare costs of Lennox-Gastaut syndrome.**

*Abstract:* 69th Annual Meeting of the American Epilepsy Society, Philadelphia, PA; Dec 4-8, 2015.

*Authors:* Montouris GD, Piña-Garza JE, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Duh MS, Shen V, Isojarvi J.

**Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.**

*Publication:* Journal of Neurology 2015 11; 262(11): 2425-2432. doi: 10.1007/s00415-015-7853-x.

*Authors:* Tauhid S, Chu R, Sasane R, Glanz BI, Neema M, Miller JR, Kim G, Signorovitch JE, Healy BC, Chitnis T, Weiner HL, Bakshi R.

**Impact of paliperidone palmitate versus oral atypical antipsychotics on healthcare outcomes in schizophrenia patients.**

*Publication:* Journal of Comparative Effectiveness Research 2015 11; 4(6): 579-592. doi: 10.2217/CER.15.34.

*Authors:* Xiao Y, Muser E, Lafeuille MH, Pesa J, Fastenau J, Duh MS, Lefebvre P.

**The natural history of brain volume loss among patients with multiple sclerosis: a systematic literature review and meta-analysis.**

*Publication:* Journal of the Neurological Sciences 2015 10; 357(1-2): 8-18. doi: 10.1016/j.jns.2015.07.014.

*Authors:* Vollmer T, Signorovitch J, Huynh L, Galebach P, Kelley C, DiBernardo A, Sasane R.

**Systematic Literature Review of the Methods Used to Compare Newer Second-Generation Agents for the Management of Schizophrenia: A focus on Health Technology Assessment.**

*Publication:* Pharmacoeconomics 2015 10; 33(10): 1049-1067. doi: 10.1007/s40273-015-0285-8.

*Authors:* Kruse G, Wong BJ, Duh MS, Lefebvre P, Lafeuille MH, Fastenau JM.

**Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.**

*Abstract:* ISPOR, Sep 2015.

*Authors:* Setyawan J, Yang H, Cheng D, Cai X, Signorovitch J, Xie J, Erder MH.

**Patient and Caregiver Burden Associated with Fragile X Syndrome in the United States.**

*Publication:* American Journal on Intellectual and Developmental Disabilities 2015 09; 120(5): 444-459. doi: 10.1352/1944-7558-120.5.444.

*Authors:* Vekeman F, Gauthier-Loiselle M, Faust E, Lefebvre P, Lahoz R, Duh MS, Sacco P.

**Predicting factors for reaching stabilized maintenance with once-monthly paliperidone almitate in Medicaid patients with schizophrenia.**

*Abstract:* US Psychiatric & Mental Health Congress, San Diego, CA Sep 10-13, 2015.

*Authors:* Muser E, Pilon D, Emond B, Xiao Y, Amos T, Lefebvre P, Benson C.

**Treatment patterns in schizophrenia patients reaching stabilized maintenance therapy with once-monthly paliperidone palmitate.**

*Abstract:* US Psychiatric & Mental Health Congress, San Diego, CA Sep 10-13, 2015.

*Authors:* Amos T, Pilon D, Muser E, Emond B, Xiao Y, Lefebvre P, Benson C.

**Functional limitations and healthcare resource utilization for individuals with cognitive impairment without dementia: Findings from a U.S. population-based survey.**

*Abstract:* 2015 Alzheimer's Association International Conference, Washington, DC Jul 18-23, 2015.

*Authors:* Andrews JS, Kirson NY, Desai U, Enloe CJ, L. R, King S, Birnbaum HG, Fleisher AS, Ye W, Wroblewski KK.

**Medical costs of Alzheimer's disease misdiagnosis among US Medicare beneficiaries.**

*Publication:* Alzheimers Dement 2015 07. doi: 10.1016/j.jalz.2015.06.1889.

*Authors:* Hunter CA, Kirson NY, Desai U, Cummings AK, Faries DE, Birnbaum HG.

**Development of a risk score to guide individualized treatment selection in attention-deficit/hyperactivity disorder.**

*Abstract:* 16th International Congress of European Society for Child and Adolescent Psychiatry, Madrid, Spain Jun 20-24, 2015.

*Authors:* Grebla R, Setyawan J, Yang H, Cheng D, Cai X, Signorovitch J, Xie J, Erder M.

**Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder.**

*Publication:* Journal of Medical Economics 2015 06; 18(11): 919-929. doi: 10.3111/13696998.2015.1061534.

*Authors:* Zhou ZY, Sun S, Chopra P, Zhong Y, Totev T, Signorovitch J.

**Impact of increasing adherence to disease-modifying therapies on healthcare resource utilization and direct medical and indirect work loss costs for patients with multiple sclerosis.**

*Publication:* Journal of Medical Economics 2015 06; 18(9): 711-720. doi: 10.3111/13696998.2015.1044276.

*Authors:* Yermakov S, Davis M, Calnan M, Fay M, Cox-Buckley B, Sarda S, Duh MS, Iyer R.

**Systematic literature review and mixed treatment comparison of guanfacine extended release (GXR) versus other pharmacotherapies in children and adolescents with attention deficit/hyperactivity disorder (ADHD).**

*Abstract:* 16th International Congress of European Society for Child and Adolescent Psychiatry, Madrid, Spain Jun 20-24, 2015.

*Authors:* Joseph A, Xie J, Bischof M, Zhanabekova Z, Cai S, Zhuo Y, Huss M, Sikirica V.

**Bone pain, skeletal related events and opioid use in patients with prostate cancer and bone metastases.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Valderrama A, Eapen S, Hennessey KA, Jones C, Wen L, Germino J, Duh MS.

**The burden of treatment switch in patients with major depression: A US retrospective administrative claims analysis.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Perez V, Gauthier G, Guerin A, Francois C, Merikle E.

**Description of prophylactic drug utilization patterns in migraine patients.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Shei A, Woolley JM, Desai PR, Enloe CJ, Kirson NY, Birnbaum HG, Corey-Lisle PK, Sapra S.

**Healthcare resource utilization associated with rescue medication use in adult patients with seizure clusters: A retrospective chart review.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Vazquez B, Sidovar M, Squillacote D, Wu E, Macaulay D, Sorg R, Guo A.

**Healthcare Utilization and costs among Adults with Major depressive Disorder treated with Vilazodone vs. Other selective Serotonin Reuptake Inhibitors.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Zhou Z, Sun SX, Chopra P, Zhong Y, Totev T, Signorovitch JE.

**Predictors of receiving at least 5 claims for once monthly paliperidone palmitate among Medicaid patients with schizophrenia.**

*Abstract:* American Psychiatric Association Convention 168th Annual Meeting, Toronto, ON, Canada May 16-20, 2015.

*Authors:* Lafeuille MH, Xiao Y, Muser E, Pesa J, Fastenau J, Duh MS, Lefebvre P.

**Real-world treatment outcomes in adults with attention deficit/hyperactivity disorder treated with lisdexamfetamine versus atomoxetine following methylphenidate treatment.**

*Abstract:* World Congress of ADHD, Glasgow, Scotland May 28-31, 2015.

*Authors:* A. Joseph, M. Cloutier, A. Guérin, R. Nitulescu, V. Sikirica.

**Relative efficacy and tolerability of vortioxetine versus approved antidepressants for major depressive disorder: A meta-regression of clinical trials.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Diamand F, Danchenko N, Brignone M, Rive B, Perez V, Ereshefsky L, Francois C, Merikle E.

**Treatment patterns among chronic users of immediate-release oxycodone initiating treatment with extended-release opioids.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Pergolizzi JV, Kirson NY, Bell J, Jones C, Mantovanelli F, Cummings AG, Birnbaum HG, Ben-Joseph R.

**Comparison of Medicaid spending in schizoaffective patients treated with once monthly paliperidone palmitate or oral atypical antipsychotics.**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA Apr 7-10, 2015.

*Authors:* Xiao Y, Muser E, Fu DJ, Lafeuille MH, Pilon D, Emond B, Wu A, Duh MS, Lefebvre P.

**Development of a claims-based classifier to identify Lennox-Gastaut Syndrome.**

*Abstract:* 67th Annual Meeting of the American Academy of Neurology, Washington, DC Apr 18-25, 2015.

*Authors:* Pina-Garza EJ, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Duh MS, Shen V, Isojarvi J, Montouris GD.



**Comparison of rehospitalization rates and associated costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics.**

*Publication:* American Journal of Health-System Pharmacy 2015 03; 72(5): 378-389. doi: 10.2146/ajhp140219.

*Authors:* Lafeuille MH, Grittner AM, Fortier J, Muser E, Fasteneau J, Duh MS, Lefebvre P.

**The economic burden of adults with major depressive disorder in the United States (2005 and 2010).**

*Publication:* Journal of Clinical Psychiatry 2015 02; 76(2): 155-162. doi: 10.4088/JCP.14m09298.

*Authors:* Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC.

**The Growing Economic Burden of Depression in the U.S. .**

*Publication:* Scientific American MIND Guest Blog 2015 02.

*Authors:* Greenberg P.

**A systematic review and network meta-analysis of eslicarbazepine acetate and other recently-approved anti-epileptic drugs for adjunctive treatment of partial-onset seizures in adults.**

*Abstract:* 68th Annual Meeting of the American Epilepsy Society, Seattle, WA Dec 5-9, 2014.

*Authors:* Betts K, Bollu V, De G, Blum D, Velez F.

**Clinical characteristics and treatment pattern in cluster seizures: A preliminary chart review analysis.**

*Abstract:* 68th Annual Meeting of the American Epilepsy Society, Seattle, WA Dec 5-9, 2014.

*Authors:* Vazquez B, Wu E, Macaulay D, Sidovar M, Roberts H, Squillacote D, Rabinowicz AL, Guo A.

**The economic burden of central nervous system events among patients with partial onset seizures treated with antiepileptic drugs.**

*Abstract:* 2013 Annual Meeting of the American Epilepsy Society, Washington, DC Dec 6-10, 2013.

*Authors:* Velez F, Bollu V, M. C, Guerin A, Carter V, Heroux J, Nitulescu R, Wu EQ.

**Impact of treatment-associated adverse events on healthcare resource utilization and costs among patients with partial onset seizures: A longitudinal analysis.**

*Abstract:* 2013 Annual Meeting of the American Epilepsy Society, Washington, DC Dec 6-10, 2013.

*Authors:* Bollu V, Velez F, Cloutier M, Guerin A, Carter V, Heroux J, Dea K, Wu EQ.

**Pulse pressure and stroke risk: development and validation of a new stroke risk model.**

*Publication:* Current Medical Research and Opinion 2014 12; 30(12): 2453-2460. doi: 10.1185/03007995.2014.971357.

*Authors:* Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

**Systematic literature review and mixed treatment comparison of GXR versus other treatments in children and adolescents with attention deficit hyperactivity disorder (ADHD).**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.

*Authors:* Joseph A, Ayyagari R, Bischof M, Cai S, Xie M, Zhanabekova Z, Sikirica V.

**Treatment patterns, resource use, and economic outcomes associated with atypical antipsychotic prescriptions in children and adolescents with attention-deficit hyperactivity disorder in quebec.**

*Publication:* Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie 2014 11; 59(11): 597-608.

*Authors:* Lachaine J, De G, Sikirica V, Van Stralen J, Hodgkins P, Yang H, Heroux J, Ben Amor L.

**Comparison of re-hospitalization and emergency room visit patterns among patients with schizophrenia receiving paliperidone palmitate or oral atypical antipsychotics in an inpatient setting.**

*Abstract:* 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Taipei, Taiwan (Republic of China) Oct 24-27, 2014.

*Authors:* Lafeuille MH, Grittner A, Muser E, Fastenau J, Duh MS, Lefebvre P.

**Healthcare resource utilization preceeding first diagnosis for fragile x syndrome (fxs).***Abstract:* ANA 2014 Annual Meeting, Baltimore, MD Oct 12-14, 2014.*Authors:* Nazareth T, Marynchenko M, Chopra P, Li N, Zhou Z, Signorovitch J, Wu E, Marvel J, Ahmed S, Sasane R.**Medical specialists involved in caring for patients with fragile x syndrome (FXS): a Medicaid perspective.***Abstract:* ANA 2014 Annual Meeting, Baltimore, MD Oct 12-14, 2014.*Authors:* Nazareth T, Marynchenko M, Li N, Chopra P, Zhou Z, Signorovitch J, Wu EQ, Ahmed S MJ, Sasane R. .**Pulse pressure and stroke risk: Development and validation of a new stroke risk model.***Abstract:* 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Taipei, Taiwan (Republic of China) Oct 24-27, 2014.*Authors:* Vekeman F, Ayyagari R, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.**Assessing the impact of time-dependent treatment with once-monthly paliperidone palmitate or oral atypical antipsychotics on healthcare resource utilization and Medicaid spending among patients with schizophrenia using marginal structural models.***Abstract:* US Psych 27th Annual Meeting, Orlando, FL Sep 20-23, 2014.*Authors:* Muser E, Lafeuille M, Xiao Y, Lefebvre P, Pesa J, Fastenau J, Duh MS.**Brain MRI lesions and atrophy are associated with employment status in patients with multiple sclerosis.***Abstract:* 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting Boston, MA Sept 9-13, 2014.*Authors:* Tauhid S, Chu R, Sasane R, Glanz BI, Neema M, Miller JR, Kim G, Sigornivich JE, Healy BC, Chitnis T, Weiner HL, Bakshi R.**Combination and switching of stimulants in children and adolescents with attention deficit/hyperactivity disorder in Quebec.***Publication:* Journal of the Canadian Academy of Child and Adolescent Psychiatry. Journal de l'Académie Canadienne de Psychiatrie de L'enfant et de l'Adolescent 2014 09; 23(3): 157-166.*Authors:* Ben Amor L, Sikirica V, Cloutier M, Lachaine J, Guerin A, Carter V, Hodgkins P, van Stralen J.**Comparison of healthcare resource utilization and Medicaid spending among patients with schizophrenia treated with once monthly paliperidone palmitate or oral atypical antipsychotics using the inverse probability of treatment weighting approach.***Abstract:* US Psych 27th Annual Meeting, Orlando, FL Sep 20-23, 2014.*Authors:* Muser E, Lafeuille M, Xiao Y, Lefebvre P, Pesa J, Fastenau J, Duh MS.**Impact of atypical antipsychotic use among adolescents with attention-deficit/hyperactivity disorder.***Publication:* American Journal of Managed Care 2014 09; 20(9): 711-721.*Authors:* Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson TM, Xie J, Erder MH, Dammerman RS, Robertson B, Wu EQ.**Impact of improved adherence to disease-modifying therapies on healthcare resource utilization and medical costs for patients with multiple sclerosis.***Abstract:* 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting, Boston, MA Sep 10-13, 2014.*Authors:* Yermakov S, Davis M, Calnan M, Fay M, Buckley B, Sarda S, Duh MS, Iyer R.

**The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis.**

*Abstract:* 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting, Boston, MA Sep 10-13, 2014.

*Authors:* Vollmer T, Signorovitch JE, Huynh L, Galebach P, Kelley C, Marvel J, Di Bernardo A, Sasane R.

**Real-world titration of disease modifying therapies in the treatment of multiple sclerosis: Findings from a survey of neurologists.**

*Abstract:* 2014 Joint Americas Committee for Treatment and Research in Multiple Sclerosis ACTRIMS - European Committee for Treatment and Research in Multiple Sclerosis ECTRIMS Meeting, Boston, MA Sep 10-13, 2014.

*Authors:* Nazareth T, Marvel J, Sikirica S, Xie J, Reichmann W, Zhao C, Sasane R.

**Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review.**

*Publication:* Neuropsychiatric Disease Treatments 2014 08; 10: 1543-1569. doi: 10.2147/NDT.S65721.

*Authors:* Gajria K, Lu M, Sikirica V, Greven P, Zhong Y, Qin P, Xie J.

**Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia.**

*Publication:* Current Medical Research and Opinion 2014 08; 30(8): 1643-1655. doi: 10.1185/03007995.2014.915211.

*Authors:* Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

**Assessing the economic burden of Alzheimer's disease patients treated by specialists within three months of preliminary diagnosis of cognitive decline.**

*Abstract:* Alzheimer's Association International Conference, Copenhagen, Denmark July 12-17, 2014.

*Authors:* Hunter CA, Kirson NY, Desai U, Ristovska L, Cummings AK, Birnbaum HG, Kahle-Wroblewski K, Ye W, Andrews JS.

**Excess costs associated with possible misdiagnosis of Alzheimer's disease among patients with vascular dementia in a UK CPRD population.**

*Abstract:* Alzheimer's Association International Conference, Copenhagen, Denmark Jul 12-17, 2014.

*Authors:* Happich M, Kirson NY, Desai U, King S, Birnbaum HG, Price D, Belger M, Hunter CA, Lenox-Smith AJ, Reed CC.

**Period prevalence of concomitant psychotropic medication usage among children and adolescents with attention-deficit/hyperactivity disorder during 2009.**

*Publication:* Journal of Child and Adolescent Psychopharmacology 2014 06; 24(5): 260-268. doi: 10.1089/cap.2013.0107.

*Authors:* Betts KA, Sikirica V, Hodgkins P, Zhou Z, Xie J, DeLeon A, Erder MH, Wu EQ.

**Comparison of re-hospitalization, emergency room visits, and hospital costs among patients with schizophrenia receiving paliperidone palmitate or oral antipsychotics in an inpatient setting.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Lafeuille MH, Grittner AM, Fortier J, Muser E, Fastenau J, Duh MS, Lefebvre P.

**Effect of improving adherence to disease-modifying agents on health care resource utilization and medical costs in patients with multiple sclerosis.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Yermakov S, Davis M, Calnan M, Fay M, Duh M, Iyer R.

**Factors associated with performance on the Medicaid HEDIS measure: Continuity of antipsychotic (AP) medications for treatment of schizophrenia.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Lafeuille MH, Frois C, Cloutier M, Duh MS, Lefebvre P, Pesa JA, Clancy Z, Fastenau J, Durkin M.

**Healthcare resource utilization prior to first diagnosis in patients with newly diagnosed fragile x syndrome (FXS): A multi-state Medicaid perspective.**

*Abstract:* APA 167th Annual Meeting, New York, NY May 3-7, 2014.

*Authors:* Signorovitch J, Wu E, Li N, Chopra P.

**Medication use, medical services and comorbidities associated with fragile x syndrome (FXS): A multi-state Medicaid perspective.**

*Abstract:* APA 167th Annual Meeting, New York, NY May 3-7, 2014.

*Authors:* Signorovitch J, Wu E, Li N, Chopra P.

**Systematic review of long-acting injectables (LAI) versus oral atypical antipsychotics (OA) on hospitalization in schizophrenia.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Lafeuille MH, Cloutier M, Fortier J, Duh MS, Fastenau J, Dirani R, Lefebvre P.

**Treatment patterns of patients receiving paliperidone palmitate in an inpatient setting.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Lafeuille MH, Fortier J, Grittner AM, Muser E, Fastenau J, Duh MS, Lefebvre P.

**Burden of schizophrenia on selected comorbidity costs.**

*Publication:* Expert Review of Pharmacoeconomics & Outcomes Research 2014 04; 14(2): 259-267. doi: 10.1586/14737167.2014.894463.

*Authors:* Lafeuille MH, Dean J, Fastenau J, Panish J, Olson W, Markowitz M, Duh MS, Lefebvre P.

**HD-PRO-TRIAD Validation: A Patient-reported Instrument for the Symptom Triad of Huntington's Disease.**

*Publication:* Tremor Other Hyperkinet Mov (N Y) 2014 04; 4: 223. doi: 10.7916/D8PN93NZ.

*Authors:* Carlozzi NE, Victorson D, Sung V, Beaumont JL, Cheng W, Gorin B, Duh MS, Samuelson D, Tulskey D, Gutierrez S, Nowinski CJ, Mueller A, Shen V, Frank S.

**Identifying Motor, Emotional-Behavioral, and Cognitive Deficits that Comprise the Triad of HD Symptoms from Patient, Caregiver, and Provider Perspectives.**

*Publication:* Tremor Other Hyperkinet Mov (N Y) 2014 04; 4: 224. doi: 10.7916/D8JW8BWS.

*Authors:* Victorson D, Carlozzi NE, Frank S, Beaumont JL, Cheng W, Gorin B, Duh MS, Samuelson D, Tulskey D, Gutierrez S, Nowinski CJ, Mueller A, Shen V, Sung V.

**Implications of early treatment among Medicaid patients with Alzheimer's disease.**

*Publication:* Alzheimers Dement 2014 03; 10(2): 214-224. doi: 10.1016/j.jalz.2013.01.015.

*Authors:* Geldmacher DS, Kirson NY, Birnbaum HG, Eapen S, Kantor E, Cummings AK, Joish VN.

**The effectiveness of hydrotherapy in the treatment of social and behavioral aspects of children with autism spectrum disorders: a systematic review.**

*Publication:* Journal of Multidisciplinary Healthcare 2014 02; 7: 93-104. doi: 10.2147/JMDH.S55345.

*Authors:* Mortimer R, Privopoulos M, Kumar S.

**Cost utility of hub-and-spoke telestroke networks from societal perspective.**

*Publication:* American Journal of Managed Care 2013 12; 19(12): 976-985.

*Authors:* Demaerschalk BM, Switzer JA, Xie J, Fan L, Villa KF, Wu EQ.

**Comparative efficacy of guanfacine extended release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: applying matching-adjusted indirect comparison methodology.**

*Publication:* Cns Drugs 2013 11; 27(11): 943-953. doi: 10.1007/s40263-013-0102-x.

*Authors:* Sikirica V, Findling RL, Signorovitch J, Erder MH, Dammerman R, Hodgkins P, Lu M, Xie J, Wu EQ.

**Glioblastoma treatment patterns and outcomes and resource use in the united states.**

*Abstract:* 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in Conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology, San Francisco, CA Nov 21-24, 2013.

*Authors:* Girvan A, Carter G, Li L, Kaltenboeck A, Chawla A, Ivanova J, Koh M, Stevens J, Lahn M.

**Health care resource use and direct costs associated with fragile x syndrome (FXS) in the United States.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin, Ireland Nov 2-6, 2013.

*Authors:* Vekeman F, Gauthier-Loiselle M, Faust E, Lefebvre P, Lahoz R, Duh MS, Sacco P.

**Health care resource utilization and costs associated with atypical antipsychotics use in children and adolescents with attention deficit/hyperactivity disorder in Quebec, Canada.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin Ireland Nov 2-6, 2013.

*Authors:* Lachaine J, Sikirica V, De G, Van Stralen J, BenAmor L, Hodgkins P, Yang H, Heroux J.

**Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.**

*Publication:* Journal of Medical Economics 2013 11; 16(11): 1290-1299. doi: 10.3111/13696998.2013.841705.

*Authors:* Lafeuille MH, Gravel J, Lefebvre P, Fastenau J, Muser E, Doshi D, Duh MS.

**Treatment persistence in attention deficit/hyperactivity disorder: a retrospective analysis of patients initiated on lisdexamfetamine vs other medications.**

*Publication:* Journal of Medical Economics 2013 11; 16(11): 1275-1289. doi: 10.3111/13696998.2013.839947.

*Authors:* Setyawan J, Guerin A, Hodgkins P, Gauthier G, Cloutier M, Wu E, Erder MH.

**Comparison of therapy augmentation and deviation rates from the recommended once-daily dosing regimen between LDX and commonly prescribed long-acting stimulants for the treatment of ADHD in youth and adults.**

*Publication:* Journal of Medical Economics 2013 10; 16(10): 1203-1215. doi: 10.3111/13696998.2013.832258.

*Authors:* Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder MH.

**Costs of Parkinson's disease in a privately insured population.**

*Publication:* Pharmacoeconomics 2013 09; 31(9): 799-806. doi: 10.1007/s40273-013-0075-0.

*Authors:* Johnson SJ, Kaltenboeck A, Diener M, Birnbaum HG, Grubb E, Castelli-Haley J, Siderowf AD.

**Impact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysis.**

*Publication:* BMC Psychiatry 2013 09; 13: 221. doi: 10.1186/1471-244X-13-221.

*Authors:* Lafeuille MH, Laliberte-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS.

**Pulse pressure and stroke risk: Development and validation of a stroke risk equation.**

*Abstract:* ISPOR 4th Latin America Conference, Buenos Aires, Argentina Sep 12-14, 2013.

*Authors:* Ayyagari R, Vekeman F, Lefebvre P, Ong SH, Faust E, Trahey A, Machnicki G, Duh MS.

**Development and validation of a claims-based algorithm to identify urinary retention in patients receiving antiepileptic drugs.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Duh MS, Ishihara L, Cheng W, Quinlan SC, Zhao Y, Irizarry M.

**Incidence of stimulant augmentation among children and adolescents with attention/deficit hyperactivity disorder (ADHD) during 2010.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Betts KA, Sikirica V, Hodgkins P, Du E, Zhou Z, Erder HM, Wu EQ.

**Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Lefeuille MH, Gravel J, Lefebvre P, Fasteneau J, Muser E, Doshi D, Duh MS.

**Period prevalence of therapy combination and switching among children and adolescents with attention deficit/hyperactivity disorder (ADHD) treated with stimulants in the Canadian province of Quebec.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Lachaine J, Sikirica V, Cloutier M, BenAmor L, Hodgkins P, Van Stralen J, Carter V, Guerin A.

**Pre-diagnosis excess acute care costs in Alzheimer's patients among a US Medicaid population.**

*Publication:* Appl Health Econ Health Policy 2013 08; 11(4): 407-413. doi: 10.1007/s40258-013-0038-9.

*Authors:* Geldmacher DS, Kirson NY, Birnbaum HG, Eapen S, Kantor E, Cummings AK, Joish VN.

**Comparing treatment adherence of lisdexamfetamine and other medications for the treatment of attention deficit/hyperactivity disorder: a retrospective analysis.**

*Publication:* Journal of Medical Economics 2013 07; 16(7): 962-975. doi: 10.3111/13696998.2013.800524.

*Authors:* Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu EQ, Erder MH.

**Direct and indirect cost burden associated with multiple sclerosis relapses: excess costs of persons with MS and their spouse caregivers.**

*Publication:* Journal of the Neurological Sciences 2013 07; 330(1-2): 71-77. doi: 10.1016/j.jns.2013.04.007.

*Authors:* Parise H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B.

**Excess costs associated with misdiagnosis of Alzheimer's disease among u.s. Medicare beneficiaries with vascular dementia or parkinson's disease.**

*Abstract:* Alzheimer's Association International Conference, Boston, MA Jul 13-18, 2013.

*Authors:* Kirson N, Hunter C, Desai U, Cummings A, San Roman A, Faries D, Hardwick C, Birnbaum H.

**Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.**

*Publication:* Journal of Clinical Psychiatry 2013 06; 74(6): 568-575. doi: 10.4088/JCP.12r08167.

*Authors:* Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJ.

**Therapy combination: a prevalent pattern among children and adolescents with attention-deficit/hyperactivity disorder treated with stimulants in the Canadian province of Quebec. .**

*Abstract:* World Congress on ADHD, Milan, Italy June 6-9, 2013.

*Authors:* BenAmor L, Sikirica V, De G, Lachaine J, Cloutier M, van Stralen J, Héroux J, Yang H, Hodgkins P.

**Assessing the impact of a Medicaid prior authorization (PA) policy for duloxetine on antipsychotic use among patients with depression.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Birnbaum HG, Ivanova JI, Waldman T, Swallow E, Cummings AK, Clark T, Peng X, Swindle R.

**Burden of schizophrenia on selected comorbidities costs.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Lafeuille MH, Dean J, Fastenau J, Panish JM, Olson WH, Markowitz M, Duh MS, Lefebvre P.

**A meta-analysis of efficacy and safety of prescription opioids, including formulations with tamper-resistant technologies, in non-cancer pain management.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Michna E, Cheng W, Korves C, Schaaf D, Andrews R, Zhou Z, Mardekian J, Joshi AV, Birnbaum H, Duh MS.

**Patterns of relapse and associated cost burden in schizophrenia patients receiving atypical antipsychotics.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Lafeuille MH, Gravel J, Lefebvre P, Fasteneau J, Muser E, Doshi D, Duh MS.

**Guanfacine immediate release vs. Guanfacine extended release: Comparative medication adherence, resource utilization, and healthcare costs among children and adolescents with attention-deficit/hyperactivity disorder (ADHD).**

*Abstract:* 16th Annual Meeting of the College of Psychiatric and Neurologic Pharmacists, Colorado Springs, CO Apr 21-24, 2013.

*Authors:* Sikirica V, Xie J, He TL, Erder MH, Hodgkins P, Yang H.

**Detecting undiagnosed depression in patients with moderate to severe psoriasis: Development and validation of a risk score for use in dermatology.**

*Abstract:* American Academy of Dermatology 71st Annual Meeting, Miami Beach, FL Mar 1-5, 2013.

*Authors:* Cather JC, Sundaram M, Horn EJ, Yang M, Signorovitch JE.

**An economic model of Parkinson's disease: implications for slowing progression in the United States.**

*Publication:* Movement Disorders 2013 03; 28(3): 319-326. doi: 10.1002/mds.25328.

*Authors:* Johnson SJ, Diener MD, Kaltenboeck A, Birnbaum HG, Siderowf AD.

**An economic model of improved acute stroke care in the management of acute ischemic stroke from a state Medicaid perspective.**

*Abstract:* 2013 International Stroke Conference and Nursing Symposium of the American Heart Association/American Stroke Association, Honolulu, HI Feb 6-8, 2013.

*Authors:* Zhou ZY, Fan L, Chen E, Xie J, Wu EQ.

**Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke from the hospitals' perspectives.**

*Publication:* Circulation: Cardiovascular Quality and Outcomes 2013 01; 6(1): 18-26. doi: 10.1161/CIRCOUTCOMES.112.967125.

*Authors:* Switzer JA, Demaerschalk BM, Xie J, Fan L, Villa KF, Wu EQ.

**Characteristics, clinical and economic outcomes in Medicaid pediatric vagus nerve stimulation (VNS) therapy patients for the treatment of refractory epilepsy.**

*Abstract:* 65th Annual Meeting of the American Epilepsy Society, Baltimore, MD Dec 2-6, 2011.

*Authors:* Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

**Comparative treatment patterns, resource utilization, and costs in stimulant-treated children with ADHD who require subsequent pharmacotherapy with atypical antipsychotics versus non-antipsychotics.**

*Publication:* Journal of Managed Care Pharmacy 2012 11; 18(9): 676-689.

*Authors:* Sikirica V, Pliszka SR, Betts KA, Hodgkins P, Samuelson T, Xie J, Erder H, Dammerman R, Robertson B, Wu EQ.

**Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparison.**

*Publication:* Appl Health Econ Health Policy 2012 11; 10(6): 381-395. doi: 10.2165/11641870-000000000-00000.

*Authors:* Erder MH, Xie J, Signorovitch JE, Chen KS, Hodgkins P, Lu M, Wu EQ, Sikirica V.

**Differences in short-term radiographic progression following early response to adalimumab plus methotrexate vs. methotrexate alone.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012, Washington, DC Nov 9-14,, 2012.

*Authors:* Van Vollenhoven RF, Shaw JW, Cifaldi MA, Signorovitch J, Wu EQ, Samuelson T, Faust E, Emery P.

**Economic value of screening for early parkinson's disease in a european setting.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Johnson S, Birnbaum HG, Kaltenboeck A, Diener M, Siderowf A.

**Economic value of slowing Parkinson's disease in Germany: Modeling progression through Hoehn and Yahr stages.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Johnson S, Birnbaum HG, Kaltenboeck A, Diener M, Siderowf A.

**Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization.**

*Publication:* Neurology 2012 10; 79(18): 1908-1916. doi: 10.1212/WNL.0b013e318271f77e.

*Authors:* Manjunath R, Paradis PE, Parise H, Lafeuille MH, Bowers B, Duh MS, Lefebvre P, Faught E.

**A comparison of rates and reasons for urgent care utilization among children with ADHD treated with atypical antipsychotics vs. nonantipsychotics.**

*Abstract:* Institute of Psychiatric Services Meeting, New York, NY Oct 4-7, 2012.

*Authors:* Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodgkins PS, Samuelson TM, Xie J, Robertson B, Wu EQ, Erder MH.

**Direct and indirect costs of patients treated with extended-release oxycodone HCl or controlled-release oxycodone HCl.**

*Publication:* Journal of Medical Economics 2012 10; 15(1): 87-95. e-pub ahead of print 2011/10/29; doi: 10.3111/13696998.2011.629261.

*Authors:* Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Peterson K, Ben-Joseph RH, Berner T, Summers KH.

**Impact of the frequency of multiple sclerosis relapses on the direct and indirect cost burden of family caregivers.**

*Abstract:* 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Lyon, France Oct 10-13, 2012.

*Authors:* Parise H, Laliberte F, Lefebvre P, Duh MS, Kim E, Agashivala N, Abouzaid S, Weinstock-Guttman B.

**Period prevalence of stimulant augmentation among pediatric attention deficit/hyperactivity disorder (ADHD) patients during 2009: A retrospective analysis of a managed care population.**

*Abstract:* 59th AACAP Annual Meeting, San Francisco, CA Oct 23-28, 2012.

*Authors:* Sikirica V, DiBello J, Betts KA, Hodgkins PS, Zhou ZY, Xie J, DeLeon A, Erder MH, EQ W.

**Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy.**

*Publication:* European Journal of Paediatric Neurology 2012 09; 16(5): 449-458. doi: 10.1016/j.ejpn.2012.01.001.

*Authors:* Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.



**Economic value of screening for early parkinson's disease in a european setting.**

*Abstract:* 16th Congress of the European Federation of Neurological Societies, Stockholm, Sweden Sep 8-11, 2012.

*Authors:* Johnson S, Siderowf AD.

**Economic value of slowing parkinson's disease in germany: Modelling progression through hoehn and yahr stages.**

*Abstract:* 16th Congress of the European Federation of Neurological Societies, Stockholm, Sweden Sep 8-11, 2012.

*Authors:* Johnson SJ, Birnbaum HG, Siderowf AD.

**Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.**

*Publication:* Pain Pract 2012 09; 12(7): 533-540. doi: 10.1111/j.1533-2500.2011.00526.x.

*Authors:* Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R.

**Cost effectiveness of guanfacine extended release as an adjunctive therapy to a stimulant compared with stimulant monotherapy for the treatment of attention-deficit hyperactivity disorder in children and adolescents.**

*Publication:* Pharmacoeconomics 2012 08; 30(8): e1-15. doi: 10.2165/11632920-000000000-00000.

*Authors:* Sikirica V, Haim Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu EQ.

**The impact of long-acting injectable vs oral antipsychotics on hospitalization rates in patients with schizophrenia: A systematic review and meta-analysis.**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

**Impact of long-acting injectable vs. oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients.**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Lafeuille MH, Laliberte-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS.

**Comparison of discontinuation risk in patients initiated on lisdexamfetamine dimesylate (LDX) vs. other medications for the treatment of attention deficit/hyperactivity disorder (ADHD): A retrospective claims analysis.**

*Abstract:* 20th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions, Paris France Jul 21-25, 2012.

*Authors:* Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder MH.

**Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review.**

*Publication:* Cns Drugs 2012 07; 26(7): 581-600. doi: 10.2165/11633900-000000000-00000.

*Authors:* Wu EQ, Hodgkins P, Ben-Hamadi R, Setyawan J, Xie J, Sikirica V, Du EX, Yan SY, Erder MH.

**Prevalence, comorbidity burden and treatment of alzheimer's disease among the elderly in the united states.**

*Abstract:* Alzheimer's Association International Conference, Vancouver, BC, Canada Jul 14-19, 2012.

*Authors:* Ivanova J, Birnbaum H, Desai U, Kirson N, Cummings A, San Roman A, Rao S, Andrews R, Doan Q, Zachry W.

**An application of group-based modeling approach for trajectory recognition: The developmental courses of hyperactivity and inattentive symptoms.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Cheng W, Goodwin R, Wu P, Vitaro F, Tremblay R.

**Economic value of screening for early parkinson's disease.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Johnson S, Siderowf A.

**Economic value of slowing parkinson's disease to payers and patients: Modeling progression through hoehn and Yahr stages.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Johnson S, Diener M, Kaltenboeck A, Birnbaum H, Grubb E, Siderowf A.

**The impact of long-acting injectable versus oral antipsychotics on hospitalization rates in patients with schizophrenia: A systematic review and meta-analysis.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Lafeuille MH, Dean J, Carter V, Duh MS, Fastenau J, Dirani R, Lefebvre P.

**Impact of long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Lafeuille MH, Laliberte-Auger F, Lefebvre P, Frois C, Fastenau J, Duh MS.

**Incremental clinical and economic burden of uncontrolled partial-onset seizures in a privately-insured population.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Paradise PE, Parise H, Duh MS, Bowers BW, Faught E.

**Model of rasagiline versus standard of care for parkinson's disease: Comparison of progression effects.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Johnson S, Wang ST, Birnbaum H, Grubb E.

**Treatment patterns, resource utilization and costs associated with guanfacine immediate release versus guanfacine extended release among children and adolescents with attention deficit/hyperactivity disorder (ADHD).**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* DiBello J, Sikirica V, Samuelson T, Xie J, He T, Erder MH.

**Associations of hypertension with risk of cardiovascular events among chinese stroke patients in the US.**

*Abstract:* American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition, New York, NY May 19-22, 2012.

*Authors:* Fung G, Kahler K, Xie J, Marynchenko M, Wu E, Kam I, Yang W.

**Characteristics and use patterns of chronic hydrocodone users.**

*Abstract:* 31st Annual Scientific Meeting of the American Pain Society, Honolulu, HI May 16-19, 2012.

*Authors:* Rice J, Samuelson T, Birnbaum H, Katz N.

**Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder.**

*Publication:* Pharmacoepidemiology and Drug Safety 2012 05; 21 Suppl 2: 130-137. doi: 10.1002/pds.3246.

*Authors:* Signorovitch J, Erder MH, Xie J, Sikirica V, Lu M, Hodgkins PS, Wu EQ.

**A comparison of rates and reasons for urgent care utilization among children with ADHD treated with atypical antipsychotics vs. nonantipsychotics.**

*Abstract:* 165th APA Annual Meeting, Philadelphia, PA May 5-9, 2012.

*Authors:* Betts KA, Pliszka SR, Sikirica V, Dammerman R, Hodgkins PS, Samuelson TM, Xie J, Robertson B, Wu EQ, Erder MH.

**Direct costs and survival of Medicare beneficiaries with early and advanced Parkinson's disease.**

*Publication:* Parkinsonism & Related Disorders 2012 05; 18(4): 321-326. doi: 10.1016/j.parkreldis.2011.11.015.

*Authors:* Kaltenboeck A, Johnson SJ, Davis MR, Birnbaum HG, Carroll CA, Tarrants ML, Siderowf AD.

**Risk of cardiovascular events associated with hypertension among chinese and caucasian stroke patients in the US.**

*Abstract:* American Society of Hypertension, Inc. 27th Annual Scientific Meeting and Exposition, New York, NY May 19-22, 2012.

*Authors:* Fung G, Kahler K, Xie J, Liu N, Wu E, Kam I, Yang W.

**Urgent care utilization for adolescents treated with atypical antipsychotics or nonantipsychotics: A comparison of rates and reasons.**

*Abstract:* 165th APA Annual Meeting, Philadelphia, PA May 5-9, 2012.

*Authors:* Pliszka SR, Sikirica V, Betts K, Hodgkins PS, Samuelson TM, Xie J, Dammerman R, Robertson B, Wu EQ, Erder MH.

**Cost implications of early treatment among patients with alzheimer's disease - A Medicaid perspective.**

*Abstract:* 64th American Academy of Neurology Annual Meeting, New Orleans, LA Apr 21-28, 2015.

*Authors:* Geldmacher D, Kirson N, Birnbaum H, Eapen S, Cummings K, A, Joish V.

**Cost-effectiveness of hub-and-spoke telestroke networks for the management of acute ischemic stroke.**

*Abstract:* 64th American Academy of Neurology Annual Meeting, New Orleans, LA Apr 21-28, 2012.

*Authors:* Switzer J, Demaerschalk B, Xie J, Fan L, Villa K, Wu E.

**Cost-utility analysis of hub-and-spoke telestroke networks for the management of acute ischemic stroke from a societal perspective.**

*Abstract:* 64th American Academy of Neurology Annual Meeting, New Orleans, LA Apr 21-28, 2012.

*Authors:* Demaerschalk B, Switzer J, Xie J, Fan L, Villa K, Wu E.

**Atypical antipsychotics versus non-antipsychotics: Comparative treatment patterns, resource utilization, and costs in stimulant-treated adolescents with adhd who require subsequent pharmacotherapy.**

*Abstract:* AMCP's 24th Annual Meeting, San Francisco, CA Apr 18-20, 2012.

*Authors:* Sikirica V, Pliszka SR, Betts K, Hodgkins P, Samuelson T, Xie J, Dammerman R.

**Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis in the US.**

*Publication:* Journal of Medical Economics 2012 03; 15(3): 601-609. doi: 10.3111/13696998.2012.667027.

*Authors:* Ivanova JI, Bergman RE, Birnbaum HG, Phillips AL, Stewart M, Meletiche DM.

**Validating Migraine-Specific Quality of Life Questionnaire v2.1 in episodic and chronic migraine.**

*Publication:* Headache 2012 03; 52(3): 409-421. doi: 10.1111/j.1526-4610.2011.01997.x.

*Authors:* Bagley CL, Rendas-Baum R, Maglinte GA, Yang M, Varon SF, Lee J, Kosinski M.

**Treatment persistence & health care costs of adult MDD patients treated with escitalopram vs. citalopram in a Medicaid population.**

*Publication:* Managed Care 2012 01; 21(1): 49-58.

*Authors:* Wu EQ, Ben-Hamadi R, Lu M, Beaulieu N, Yu AP, Erder MH.

**PMH65 Comparison of Deviation Rates from the Labeled Daily Average Consumption in Patients Initiated on Stimulant Medication for the Treatment of Attention-Deficit/Hyperactivity Disorder.**

*Abstract:* 2012 International Society for Pharmacoeconomics and Outcomes Research, 2012.

*Authors:* Setyawan J, Hodgkins P, Guerin A, Gauthier G, Cloutier M, Wu E, Erder M.

**Characteristics and clinical and economic outcomes in Medicaid patients receiving vagus nerve stimulation (VNS) therapy for the treatment of refractory epilepsy.**

*Abstract:* 64th Annual Meeting of the American Epilepsy Society and 3rd Biennial North American Regional Epilepsy Congress, San Antonio, TX Dec 3-7, 2010.

*Authors:* Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Faught E.

**Economic Outcomes of Switching Treatment in Major Depressive Disorder Patients.**

*Publication:* American Journal of Pharmacy Benefits 2011 12; 3(6): e111-e120. e-pub ahead of print Dec 6, 2011.

*Authors:* Marynchenko M YA, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Blum S, Erder HM, Bose A. .

**Comparison of treatment adherence in patients initiated on lisdexamfetamine dimesylate vs. other medications for the treatment of attention deficit/ hyperactivity disorder: A retrospective study.**

*Abstract:* The American Professional Society of ADHD and Related Disorders, Current Concepts and Future Developments Conference, Philadelphia, PA Nov 19, 2011.

*Authors:* Setyawan J, Hodgkins PS, Wu EQ, Guérin A, Gauthier G, Cloutier M, Erder MH.

**Early retirement and income loss in patients with early and advanced Parkinson's disease.**

*Publication:* Appl Health Econ Health Policy 2011 11; 9(6): 367-376. doi: 10.2165/11596900-000000000-00000.

*Authors:* Johnson S, Davis M, Kaltenboeck A, Birnbaum H, Grubb E, Tarrants M, Siderowf A.

**Effect of treatment timing on risk of institutionalization among patients with Alzheimer's disease.**

*Abstract:* ISPOR 14th Annual European Congress, Madrid, Spain Nov 5-8, 2011.

*Authors:* Geldmacher DS, Kirson NY, Birnbaum HG, Kantor E, Eapen S, Joish VN.

**PIH23 Cost-Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Psychostimulant Compared to Psychostimulant Monotherapy for the Treatment of Attention Deficit/Hyperactivity Disorder in Children and Adolescents.**

*Abstract:* 2011 International Society for Pharmacoeconomics and Outcomes Research, Nov 5-8, 2011.

*Authors:* Sikirica V, Erder M, Xie J, Macaulay D, Diener M, Hodgkins P, Wu E.

**Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy.**

*Publication:* Epilepsy & Behavior 2011 10; 22(2): 370-375. doi: 10.1016/j.yebeh.2011.07.020.

*Authors:* Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

**Comparative efficacy of guanfacine extended release and atomoxetine for the treatment of oppositional symptoms in children with attention deficit/ hyperactivity disorder (ADHD) and comorbid oppositional defiant disorder (ODD).**

*Abstract:* CADDRA 2011 Annual ADHD Conference, Toronto, ON, Canada Oct 14-16, 2011.

*Authors:* Signorovitch JE, Sikirica V, Lu M, Xie J, Wu EQ, Erder MH.

**Comparison of treatment adherence in patients initiated on lisdexamfetamine dimesylate (LDX) vs. other medications for the treatment of ADHD: A retrospective study.**

*Abstract:* AACAP/CACAP Joint Annual Meeting, Toronto, ON, Canada Oct 18-23, 2011.

*Authors:* Setyawan J, Hodgkins PS, Wu EQ, Guérin A, Gauthier G, Cloutier M, Erder MH.

**Treatment patterns, resource utilization, and costs associated with atypical antipsychotics vs. non-antipsychotics added to or switched from stimulants among children with attention deficit/ hyperactivity disorder (ADHD).**

*Abstract:* AMCP's 2011 Educational Conference, Atlanta, GA Oct 19-21, 2011.

*Authors:* Sikirica V, Betts KA, Erder MH, Xie J, Samuelson TM, Hodgkins PS, Wu EQ.

**Characteristics, clinical and economic outcomes in Medicaid patients 17 years and younger receiving vagus nerve stimulation (VNS) therapy for the treatment of refractory epilepsy.**

*Abstract:* 29th International Epilepsy Congress, Rome, Italy Aug 28-Sept 1, 2011.

*Authors:* Helmers SL, Duh MS, Guirin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

**Cost of post-traumatic stress disorder vs major depressive disorder among patients covered by Medicaid or private insurance.**

*Publication:* American Journal of Managed Care 2011 08; 17(8): e314-323.

*Authors:* Ivanova JI, Birnbaum HG, Chen L, Duhig AM, Dayoub EJ, Kantor ES, Schiller MB, Phillips GA.

**Impact of vagus nerve stimulation (VNS) therapy on clinical outcomes and costs in Medicaid patients with drug-resistant epilepsy.**

*Abstract:* 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Chicago, IL Aug 14-17, 2011.

*Authors:* Duh MS, Faught E, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Helmers SL.

**Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs.**

*Publication:* Journal of Medical Economics 2011 06; 14(4): 508-515. doi: 10.3111/13696998.2011.593602.

*Authors:* Yu AP, Ben-Hamadi R, Wu EQ, Kaltenboeck A, Bergman R, Xie J, Blum S, Erder MH.

**Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors.**

*Publication:* Current Medical Research and Opinion 2011 06; 27(6): 1089-1096. doi: 10.1185/03007995.2011.567255.

*Authors:* Signorovitch J, Ramakrishnan K, Ben-Hamadi R, Yu AP, Wu EQ, Dworak H, Erder MH.

**Assessment of parkinson's disease progression rates by stage of disease.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Johnson SJ, Kaltenboeck A, Diener M, Tarrant M, Birnbaum H.

**Comparison of real-world health care costs after the initiation of second-line duloxetine or generic selective serotonin reuptake inhibitors in patients with major depressive disorder.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Swindle R, Ivanova JI, Birnbaum HG, Cummings AK, Kantor E, Schiller M, Clark T, Reed C.

**The cost-effectiveness of guanfacine extended release (GXR) versus atomoxetine (ATX) for the treatment of attention-deficit/ hyperactivity disorder (ADHD) in children and adolescents.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Erder M, Chen K, Wu EQ, Hodgkins P, Sikirica V.

**Direct and indirect costs of privately-insured patients treated with oxycodone extended-release or oxycodone controlled-release tablets.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Kirson NY, White AG, Birnbaum HG, Schiller M, Waldman T, Ben-Joseph RH, Berner T, KH S.

**Impact of vagus nerve stimulation (VNS) therapy on clinical outcomes and costs in Medicaid patients with drug-resistant epilepsy.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Duh MS, Faught E, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Helmers SL.

**Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.**

*Abstract:* 30th Annual Scientific Meeting of the American Pain Society, Austin, TX May 19-21, 2011.

*Authors:* Swindle R, Birnbaum H, Ivanova J, Schiller M, Waldman T, Mullen R, Reed C.

**Uncontrolled epilepsy in a Medicaid population.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Mishagina N, Parise H, Rovba L, Lefebvre P, Faught E.

**Burden of uncontrolled epilepsy in a privately insured population.**

*Abstract:* 63rd Annual Meeting of the American Academy of Neurology, Honolulu, HI Apr 9-16, 2011.

*Authors:* Manjunath R, Faught E, Paradis PE, Parise H, Lafeuille MH, Lefebvre P, Duh MS.

**Economic impact of therapeutic substitution of a brand selective serotonin reuptake inhibitor with an alternative generic selective serotonin reuptake inhibitor in patients with major depressive disorder.**

*Publication:* Annals of Pharmacotherapy 2011 04; 45(4): 441-451. doi: 10.1345/aph.1P482.

*Authors:* Wu EQ, Yu AP, Lauzon V, Ramakrishnan K, Marynchenko M, Ben-Hamadi R, Blum S, Erder MH.

**Relationship between adherence to diseasemodifying drugs and severe relapses, direct and indirect costs among employees with multiple sclerosis.**

*Abstract:* 63rd Annual Meeting of the American Academy of Neurology, Honolulu, HI Apr 9-16, 2011.

*Authors:* Philips AL, Ivanova JI, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM.

**Switch to generic SSRIs may boost costs in MDD.**

*Publication:* PharmacoEconomics & Outcomes News 2011 04; 625: 2.

*Authors:* Wu E.

**Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram.**

*Publication:* Am Health Drug Benefits 2011 03; 4(2): 78-87.

*Authors:* Wu EQ, Greenberg PE, Ben-Hamadi R, Yu AP, Yang EH, Erder MH.

**Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine.**

*Publication:* Cephalalgia 2011 02; 31(3): 357-367. doi: 10.1177/0333102410379890.

*Authors:* Yang M, Rendas-Baum R, Varon SF, Kosinski M.

**Physicians' decisions to prescribe antidepressant therapy in older patients with depression in a US managed care plan.**

*Publication:* Drugs and Aging 2011 01; 28(1): 51-62. doi: 10.2165/11539900-000000000-00000.

*Authors:* Ivanova JI, Bienfait-Beuzon C, Birnbaum HG, Connolly C, Emani S, Sheehy M.

**Economic outcomes of switching to another generic SSRI, escitalopram, or an SNRI among MDD patients treated with generic SSRI therapy.**

*Publication:* American Journal of Pharmacy Benefits 2011.

*Authors:* Marynchenko M, Yu AP, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Blum S, Erder MH, Bose A.

**Perceptions and prescribing considerations among US psychiatrists regarding drug-drug interactions associated with oral atypical antipsychotics.**

*Publication:* Current Medical Research and Opinion 2010 12; 26(12): 2735-2744. doi: 10.1185/03007995.2010.530159.

*Authors:* Frois C, Guerin A, Saraogi A, Panish J, Dirani R.

**A novel approach to estimate the minimally important difference for the Fatigue Impact Scale in multiple sclerosis patients.**

*Publication:* Quality of Life Research 2010 11; 19(9): 1349-1358. doi: 10.1007/s11136-010-9704-7.

*Authors:* Rendas-Baum R, Yang M, Cattelin F, Wallenstein GV, Fisk JD.

**Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.**

*Publication:* Drugs and Aging 2010 11; 27(11): 903-913. doi: 10.2165/11584290-000000000-00000.

*Authors:* Scharre DW, Vekeman F, Lefebvre P, Mody-Patel N, Kahler KH, Duh MS.

**Compliance and persistence to single-tablet levodopa/ carbidopa/entacapone compound versus levodopa/carbidopa in idiopathic parkinson's disease.**

*Abstract:* 2010 Annual Meeting of the American College of Clinical Pharmacy, Austin, TX Oct 17-20, 2010.

*Authors:* Stacy MA, Laliberte F, Kulkarni AS, Somogyi M, Vekeman F, Duh MS, Lefebvre P.

**Direct and indirect costs of employees with treatment-resistant and non-treatment-resistant major depressive disorder.**

*Publication:* Current Medical Research and Opinion 2010 10; 26(10): 2475-2484. doi: 10.1185/03007995.2010.517716.

*Authors:* Ivanova JI, Birnbaum HG, Kidolezi Y, Subramanian G, Khan SA, Stensland MD.

**Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study.**

*Publication:* Journal of Medical Economics 2010 10; 13(4): 599-609. doi: 10.3111/13696998.2010.521736.

*Authors:* Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Blum S, Haim Erder M.

**Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.**

*Publication:* Journal of Medical Economics 2010 08; 13(3): 482-491. doi: 10.3111/13696998.2010.506176.

*Authors:* Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Puenpatom RA, Ben-Joseph RH, Summers KH.

**Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%.**

*Publication:* Journal of Medical Economics 2010 08; 13(3): 472-481. doi: 10.3111/13696998.2010.499819.

*Authors:* Kirson NY, Ivanova JI, Birnbaum HG, Wei R, Kantor E, Amy Puenpatom R, Ben-Joseph RH, Summers KH.

**Economic burden associated with the use of generic antiepileptic drugs in the United States.**

*Publication:* Epilepsy & Behavior 2010 08; 18(4): 437-444. e-pub ahead of print 2010/06/29; doi:

10.1016/j.yebeh.2010.05.015.

*Authors:* Helmers SL, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latremouille-Viau D, Lefebvre P, Labiner DM.

**Economic burden of epilepsy among the privately insured in the US.**

*Publication:* Pharmacoeconomics 2010 07; 28(8): 675-685. doi: 10.2165/11535570-000000000-00000.

*Authors:* Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S.

**Cost of illness of post-traumatic stress disorder compared with major depressive disorder.**

*Abstract:* ISPOR 15th Annual International Meeting Atlanta, GA May 15-19, 2010.

*Authors:* Ivanova J, Birnbaum H, Chen L, Dayoub E, Kantor E, Phillips G.

**Descriptive profile of Medicaid patients with post herpetic neuralgia treated and untreated with lidocaine patch 5%.**

*Abstract:* 29th Annual Scientific Meeting of the American Pain Society, Baltimore, MD May 6-8, 2010.

*Authors:* Kirson N, Puenpatom R, Ivanova J, Birnbaum H, Wei R, Kantor E, Schiller M, Summers K.

**Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States.**

*Publication:* Epilepsia 2010 05; 51(5): 838-844. doi: 10.1111/j.1528-1167.2009.02422.x.

*Authors:* Ivanova JI, Birnbaum HG, Kidolezi Y, Qiu Y, Mallett D, Caleo S.

**Economic value of lidocaine patch 5% vs. gabapentin or pregabalin in Medicaid patients with post herpetic neuralgia.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Ivanova JI, Puenpatom RA, Kirson NY, Birnbaum HG, Wei R, Kantor E, Summers K.

**The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial.**

*Publication:* Journal of the American Academy of Dermatology 2010 05; 62(5): 812-818. doi:

10.1016/j.jaad.2009.07.022.

*Authors:* Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, Mulani P.

**Generic antiepileptic drugs and associated medical resource utilization in the United States.**

*Publication:* Neurology 2010 05; 74(20): 1566-1574. doi: 10.1212/WNL.0b013e3181df091b.

*Authors:* Labiner DM, Paradis PE, Manjunath R, Duh MS, Lafeuille MH, Latremouille-Viau D, Lefebvre P, Helmers SL.

**Healthcare utilization and costs incurred by patients with major depression after being switched from escitalopram to another SSRI for non-medical reasons.**

*Publication:* Journal of Medical Economics 2010 05; 13(2): 314-323. doi: 10.3111/13696998.2010.488985.

*Authors:* Wu EQ, Ben-Hamadi R, Yu AP, Tang J, Haim Erder M, Bose A.

**Impact of medication adherence to disease-modifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Ivanova JI, Phillips AL, Bergman RE, Birnbaum HG, Stewart M, Meletiche DM.

**Age differences in the prevalence and co-morbidity of DSM-IV major depressive episodes: results from the WHO World Mental Health Survey Initiative.**

*Publication:* Depression and Anxiety 2010 04; 27(4): 351-364. doi: 10.1002/da.20634.

*Authors:* Kessler RC, Birnbaum HG, Shahly V, Bromet E, Hwang I, McLaughlin KA, Sampson N, Andrade LH, de Girolamo G, Demyttenaere K, Haro JM, Karam AN, Kostyuchenko S, Kovess V, Lara C, Levinson D, Matschinger H, Nakane Y, Browne MO, Ormel J, Posada-Villa J, Sagar R, Stein DJ.

**Coronary heart disease and stroke risk in patients with psoriasis: retrospective analysis.**

*Publication:* American Journal of Medicine 2010 04; 123(4): 350-357. doi: 10.1016/j.amjmed.2009.08.022.

*Authors:* Kimball AB, Guerin A, Latremouille-Viau D, Yu AP, Gupta S, Bao Y, Mulani P.

**Economic value of lidocaine patch 5% versus gabapentin or pregabalin in Medicaid patients with post-herpetic neuralgia.**

*Abstract:* AMCP's 22nd Annual Meeting, San Diego, CA Apr 7-10, 2010.

*Authors:* Ivanova J, Puenpatom A, Kirson NY, Birnbaum HG, Wei R, Kantor E, Summers K.



**Impact of medication adherence to diseasemodifying drugs on severe relapse, and direct and indirect costs among employees with multiple sclerosis.**

*Abstract:* 62nd American Academy of Neurology Annual Meeting, Toronto, ON, Canada Apr 10-17, 2010.

*Authors:* Phillips A, Ivanova J, Bergman R, Birnbaum H, Stewart M, Meletiche D.

**Increased risk of psychiatric disorders in a pediatric population with psoriasis.**

*Abstract:* 68th Annual Meeting of the American Academy of Dermatology, Miami, FL Mar 5-9, 2010.

*Authors:* Kimball A, Yu A, Mulani P, Gupta S.

**Assessing the relationship between compliance with antidepressant therapy and employer costs among employees in the United States.**

*Publication:* Journal of Occupational Environmental Medicine 2010 02; 52(2): 115-124. doi: 10.1097/JOM.0b013e3181cb5b10.

*Authors:* Birnbaum HG, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Kantor E, Cremieux PY, Greenberg PE.

**The risks and costs of multiple-generic substitution of topiramate (author reply).**

*Publication:* Neurology 2010 02; 74(8): 701-702; author reply 701-702. doi: 10.1212/WNL.0b013e3181c7770b.

*Authors:* Sethi NK, Torgovnick J, Sethi PK, Arsura E, Emmanuel Paradis P, Duh MS, Durkin MB, Wan GJ.

**Impact of levodopa/carbidopa/entacapone compound versus levodopa/carbidopa on hospitalization rates in patients with idiopathic parkinson's disease.**

*Abstract:* 2010 Annual Meeting of the American College of Clinical Pharmacy, Austin, TX Jan 17-20, 2010.

*Authors:* Stacy MA, Laliberte F, Kulkarni AS, Somogyi M, Vekeman F, Duh MS, Lefebvre P.

**Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance.**

*Publication:* Depression and Anxiety 2010 27(1): 78-89. doi: 10.1002/da.20580.

*Authors:* Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE.

**Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version.**

*Publication:* Cephalalgia 2009 11; 29(11): 1180-1187.

*Authors:* Cole JC, Lin P, Rupnow MF.

**Economic consequence of switching to citalopram after its generic entry among major depressive disorder patients treated with escitalopram.**

*Abstract:* AMCP's 2009 Educational Conference San Antonio, TX Oct 7-9, 2009.

*Authors:* Yu AP, Xie J, Bensimon A, Parikh K, Wu EQ, Ben-Hamadi R, Erder H.

**Economic impact of generic entry of topiramate in Germany: Conversion of the canadian experience into the settings of Germany.**

*Abstract:* ISPOR 12th Annual European Congress, Paris, France Oct 24-27, 2009.

*Authors:* Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

**The economic implications of generic substitution of antiepileptic drugs: a review of recent evidence.**

*Publication:* Expert Opinion on Pharmacotherapy 2009 10; 10(14): 2317-2328. doi: 10.1517/14656560903140525.

*Authors:* Duh MS, Cahill KE, Paradis PE, Cremieux PY, Greenberg PE.

**The Economic Outcomes of Early Education with Second Generation Antidepressants among Adolescents with Depression.**

*Abstract:* AMCP's 2009 Educational Conference, San Antonio, TX Oct 7-9, 2009.

*Authors:* Yu AP, Kaltenboeck A, Bergman R, Xie J, Ben-Hamadi R, Wu EQ, Erder H.

**The potential economic impact of generic substitution of topiramate on health care costs in the G4 European countries.**

*Abstract:* ISPOR 12th Annual European Congress, Paris, France Oct 24-27, 2009.

*Authors:* Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

**Impact of generic substitution of topiramate for patients with epilepsy.**

*Abstract:* 13th Congress of the EFNS, Florence, Italy Sep 12 - 15, 2009.

*Authors:* Paradis PE, Latremouille-Viau D, Lefebvre P, Lafeuille MH, Mishagina N, Moore Y, Gaudig M, Duh MS.

**The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US.**

*Publication:* Pharmacoeconomics 2009 08; 27(8): 681-691. doi: 10.2165/11314700-000000000-00000.

*Authors:* Ivanova JI, Birnbaum HG, Samuels S, Davis M, Phillips AL, Meletiche D.

**Evaluation of cardiovascular diseases (CVDs) risk in French patients receiving milnacipran (MLN) relative to patients receiving other antidepressants therapies.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Mease PJ, Duh MS, Vekeman F, Guerin A, Boerstoeel-Streefland M, Jiang W, Lefebvre P, Zimetbaum PJ.

**Resource utilization and costs of schizophrenia patients treated with olanzapine versus quetiapine in a Medicaid population.**

*Abstract:* 2009 International Society for Pharmacoeconomics and Outcomes Research, Aug 2009.

*Authors:* Yu AP, Atanasov P, Ben-Hamadi R, Birnbaum H, Stensland MD, Philips G.

**Compliance, persistence, and outcomes in patients with Alzheimer's disease treated with oral cholinesterase inhibitors.**

*Abstract:* Alzheimer's Association International Conference, Vienna, Austria July 11-16, 2009.

*Authors:* Mody-Patel N, Vekeman F, Laliberte F, Kahler KH, Duh MS, Lefebvre P.

**Determinants of direct cost differences among US employees with major depressive disorders using antidepressants.**

*Publication:* Pharmacoeconomics 2009 07; 27(6): 507-517. doi: 10.2165/00019053-200927060-00006.

*Authors:* Birnbaum HG, Ben-Hamadi R, Greenberg PE, Hsieh M, Tang J, Reygrobellet C.

**Projected economic impact of clinical findings of generic entry of topiramate on G4 European countries.**

*Publication:* Current Medical Research and Opinion 2009 07; 25(7): 1793-1805. doi: 10.1185/03007990903044374.

*Authors:* Paradis PE, Latremouille-Viau D, Moore Y, Mishagina N, Lafeuille MH, Lefebvre P, Gaudig M, Duh MS.

**Clinical consequences of generic substitution of topiramate.**

*Abstract:* 28th International Epilepsy Congress, Budapest, Hungary Jun 28-Jul 2, 2009.

*Authors:* Paradis P, Dominick L, Patrick L, Marie-Helene L, Natalia M, Moore Y, Gaudig M, Duh M.

**Economic impact of generic entry of topiramate in Germany.**

*Abstract:* 6th Joint Meeting of the German, Austrian, and Swiss Sections of the International League Against Epilepsy, 2009.

*Authors:* Paradis P, Mishagina N, Moore Y, Lefebvre P, Gaudig M, Duh MS.

**Impact of generic substitution of topiramate for patients with epilepsy.**

*Abstract:* 6th Joint Meeting of the German, Austrian, and Swiss Sections of the International League Against Epilepsy.

*Authors:* Paradis P, Latremouille-Viau D, Lefebvre P, Lafeuille M, Mishagina N, Moore Y, Gaudig M, Duh MS.

**The impact of generic substitution of topiramate on healthcare costs: Conversion of the Canadian experience into the settings of Germany.**

*Abstract:* 6th Joint Meeting of the German, Austrian, and Swiss Sections of the International League Against Epilepsy, 2009.

*Authors:* Paradis P, Latremouille-Viau D, Lafeuille M, Lefebvre P, Gaudig M, Duh MS.

**The risks and costs of multiple-generic substitution of topiramate.**

*Publication:* Neurology 2009 06; 72(24): 2122-2129. doi: 10.1212/WNL.0b013e3181aa5300.

*Authors:* Duh MS, Paradis PE, Latremouille-Viau D, Greenberg PE, Lee SP, Durkin MB, Wan GJ, Rupnow MF, LeLorier J.

**Treatment persistence, healthcare utilisation and costs in adult patients with major depressive disorder: a comparison between escitalopram and other SSRI/SNRIs.**

*Publication:* Journal of Medical Economics 2009 06; 12(2): 124-135. doi: 10.3111/13696990903093537.

*Authors:* Wu EQ, Greenberg PE, Yang E, Yu AP, Ben-Hamadi R, Erder MH.

**Antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine versus donepezil: Evidence from health claims data.**

*Abstract:* ISPOR 14th Annual International Meeting Orlando, FL May 16-20, 2009.

*Authors:* Lefebvre P, Vekeman F, Kahler K, Mody-Patel N, Duh MS, Scharre DW.

**Comparison of hospitalizations and health care costs of elderly major depressive disorder (MDD) patients treated with escitalopram, generic SSRIs, or SNRIs.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Wu EQ, Cahill KE, Bieri C, Ben-Hamadi R, Yu AP, Erder MH.

**Compliance and persistence of oral cholinesterase inhibitors in patients with Alzheimer's disease.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Vekeman F, Laliberte F, Kahler K, Mody-Patel N, Lefebvre P, Duh MS.

**Direct costs in older patients with depression treated and untreated with antidepressant therapy.**

*Abstract:* ISPOR 14th Annual International Meeting Orlando, FL May 16-20, 2009.

*Authors:* Ivanova J, Birnbaum HG, Samuels S, Emani S, Sheehy M, Cattelin F.

**Direct costs of patients with treatment resistant and non-treatment resistant major depressive disorder.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Ivanova J, Birnbaum HG, Kidolezi Y, Subramanian G, Stensland MD, Khan SA.

**Economic assessment of second-line treatment: Switching from a generic SSRI to escitalopram, an SNRI, or another generic SSRI by patients with major depressive disorder (MDD).**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Marynchenko M, Yu AP, Lauzon V, Ramakrishnan K, Wu EQ, Ben-Hamadi R, Erder MH, Bose A.

**Economic impact of generic entry of topiramate in the G4 European countries.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Paradis PE, Mishagina N, Moore Y, Lefebvre P, Gaudig M, Duh M.

**The economic impact of generic switching for patients with major depressive disorder (MDD) treated with escitalopram or a patented SSRI.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Lauzon V, Kaltenboek A, Yu AP, Ramakrishnan K, Marynchenko M, Wu EQ, Ben-Hamadi R, Erder MH, Bose A.

**Economic implication of dose escalation in depressed patients treated with escitalopram or venlafaxine XR.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Yu AP, Bensimon AG, Wu EQ, Ben-Hamadi R, Bourezak A, Erder MH.

**The impact of generic substitution of topiramate on health care costs: Conversion of the Canadian experience into the settings of G4 European countries.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Paradis PE, Latremouille-Viau D, Lafeuille MH, Lefebvre P, Gaudig M, Duh M.

**Physicians' attitude to prescribing antidepressant therapy in older patients with depression.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Ivanova JI, Birnbaum HG, Connolly C, Emani S, Sheehy M, Bienfait-Beuzon C.

**Economic impact of multiple sclerosis disease-modifying drugs in an employed population: direct and indirect costs.**

*Publication:* Current Medical Research and Opinion 2009 04; 25(4): 869-877. doi: 10.1185/03007990902743869.

*Authors:* Birnbaum HG, Ivanova JI, Samuels S, Davis M, Cremieux PY, Phillips AL, Meletiche D.

**Antidepressant treatment patterns and costs among US employees.**

*Publication:* Journal of Medical Economics 2009 03; 12(1): 36-45. doi: 10.3111/13696990902757389.

*Authors:* Birnbaum H, Greenberg PE, Tang J, Hsieh M, Wu EQ, Amand C, Ben-Hamadi R.

**Comparing the treatment patterns of patients with schizophrenia treated with olanzapine and quetiapine in the Pennsylvania Medicaid population.**

*Publication:* Current Medical Research and Opinion 2009 03; 25(3): 755-764. doi: 10.1185/03007990802683579.

*Authors:* Yu AP, Ben-Hamadi R, Birnbaum HG, Atanasov P, Stensland MD, Philips G.

**Impact of nonadherence to antiepileptic drugs on health care utilization and costs: findings from the RANSOM study.**

*Publication:* Epilepsia 2009 03; 50(3): 501-509. doi: 10.1111/j.1528-1167.2008.01794.x.

*Authors:* Faught RE, Weiner JR, Guerin A, Cunningham MC, Duh MS.

**The risk of coronary heart disease and stroke among psoriasis patients.**

*Abstract:* 67th Annual Meeting of the American Academy of Dermatology, San Francisco, CA Mar 6-10, 2009.

*Authors:* Kimball A, Guerin A, Mulani P, Gupta S.

**Assessing the relationship between compliance with antidepressant therapy and costs among employees in the United States.**

*Abstract:* 17th European Psychiatric Association Congress, Lisbon, Portugal Jan 24-28, 2009.

*Authors:* Birnbaum H, Ben-Hamadi R, Kelley D, Hsieh M, Seal B, Cremieux P, Greenberg P.

**Healthcare resource utilization and costs of mild, moderate, and severe depression in the workforce in the united states.**

*Abstract:* 17th European Psychiatric Association Congress, Lisbon, Portugal Jan 24-28, 2009.

*Authors:* Birnbaum H, Kessler R, Joish V, Kelley D, Ben-Hamadi R, M. H, Greenberg P.

**Nonadherence to antiepileptic drugs and increased mortality: findings from the RANSOM Study.**

*Publication:* Neurology 2008 11; 71(20): 1572-1578. doi: 10.1212/01.wnl.0000319693.10338.b9.

*Authors:* Faught E, Duh MS, Weiner JR, Guerin A, Cunningham MC.

**Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants.**

*Publication:* Current Medical Research and Opinion 2008 10; 24(10): 2805-2813. doi: 10.1185/03007990802336780.

*Authors:* Wu E, Greenberg P, Yang E, Yu A, Ben-Hamadi R, Erder MH.

**Antipsychotic medication utilization trends among Texas veterans: 1997-2002.**

*Publication:* Annals of Pharmacotherapy 2008 09; 42(9): 1229-1238. doi: 10.1345/aph.1L155.

*Authors:* Yang M, Barner JC, Lawson KA, Rascati KL, Wilson JP, Crismon ML, Worchel J, Mascarenas CA.

**Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population.**

*Publication:* Current Medical Research and Opinion 2008 09; 24(9): 2587-2595. doi: 10.1185/03007990802303525.

*Authors:* Wu E, Greenberg PE, Yang E, Yu A, Erder MH.

**Health care utilization and costs of depressed patients treated with escitalopram versus SNRIs.**

*Abstract:* 21st ECNP Congress Barcelona, Spain Aug 30 - Sep 3, 2008.

*Authors:* Erder MH, Wu E, Ben-Hamadi R, Beaulieu N, Lu M.

**Treatment compliance and health care costs of Medicaid depressed adult patients treated with escitalopram versus citalopram.**

*Abstract:* 21st ECNP Congress, Barcelona, Spain Aug 30 - Sep 03, 2008.

*Authors:* Erder MH, Wu E, Lu M, Ben-Hamadi R, Beaulieu N.

**Clinical consequences of generic substitution of lamotrigine for patients with epilepsy.**

*Publication:* Neurology 2008 05; 70(22 Pt 2): 2179-2186. e-pub ahead of print 2008/05/30; doi: 10.1212/01.wnl.0000313154.55518.25.

*Authors:* LeLorier J, Duh MS, Paradis PE, Lefebvre P, Weiner J, Manjunath R, Sheehy O.

**Health Care Resource Utilization and Costs Comparison For MDD Patients on 10mg Escitalopram Who Increased to 20mg Dose vs. Those Who Were Switched to SNRI.**

*Abstract:* ISPOR 13th Annual International Meeting, Toronto, ON, Canada May 3-7, 2008.

*Authors:* Wu EQ, Yu A, Buessing M, Ben-Hamadi R, Tang J, Seale J, Erder M, Bose A.

**Economic impact of generic substitution of lamotrigine: projected costs in the US using findings in a Canadian setting.**

*Publication:* Current Medical Research and Opinion 2008 04; 24(4): 1069-1081. doi: 10.1185/030079908X280572.

*Authors:* LeLorier J, Duh MS, Paradis PE, Latremouille-Viau D, Lefebvre P, Manjunath R, Sheehy O.

**Antidepressant Treatment Patterns and Related Costs among U.S. Employees.**

*Abstract:* Institute on Psychiatric Services (APA-I), New Orleans, LA Oct 11-14, 2007.

*Authors:* Birnbaum H, Greenberg P, Tang J, Hsieh M, Wu EQ, Reygrobellet C, Ben-Hamadi R.

**Comparing Treatment Compliance, Hospitalizations, and Costs of Elderly MDD Patients on Escitalopram and Citalopram.**

*Abstract:* Institute on Psychiatric Services (APA-I), New Orleans, LA Oct 11-14, 2007.

*Authors:* Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

**Estimated prevalence of peripheral neuropathy and associated pain in adults with diabetes in France.**

*Publication:* Current Medical Research and Opinion 2007 09; 23(9): 2035-2042. doi: 10.1185/030079907X210516.

*Authors:* Wu EQ, Borton J, Said G, Le TK, Monz B, Rosilio M, Avoinet S.

**Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies.**

*Publication:* Journal of Managed Care Pharmacy 2007 09; 13(7): 561-569.

*Authors:* Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D.

**The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.**

*Publication:* Disease Management 2007 08; 10(4): 216-225. doi: 10.1089/dis.2007.104649.

*Authors:* Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY.

**Comparing Treatment Compliance, Hospitalization, and Costs of Elderly MDD Patients on Escitalopram and Citalopram.**

*Abstract:* International Health Economics Association, Copenhagen, Denmark Jul 8-11, 2007.

*Authors:* Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

**Comparing Treatment Compliance and Hospitalization of Elderly MDD Patients on Escitalopram and Other SSRI/SNRI.**

*Abstract:* New Clinical Drug Evaluation Unit (NCDEU), Boca Raton, FL Jun 13-16, 2007.

*Authors:* Wu EQ, Elaine Y, Greenberg P, Erder M.H., Yu A.

**Factors related to antipsychotic oversupply among Central Texas Veterans.**

*Publication:* Clinical Therapeutics 2007 06; 29(6): 1214-1225. doi: 10.1016/j.clinthera.2007.06.013.

*Authors:* Yang M, Barner JC, Worchel J.

**Health care costs and resource use in patients with major depressive disorder: a comparison between escitalopram and other antidepressants (SSRI/SNRI).**

*Abstract:* ISPOR 12th Annual International Meeting, Arlington, VA May 19-23, 2007.

*Authors:* Wu EQ, Yang E, Greenberg P, Erder MH, Yu A, Buessing M.

**Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication.**

*Publication:* Archives of General Psychiatry 2007 05; 64(5): 543-552. doi: 10.1001/archpsyc.64.5.543.

*Authors:* Merikangas KR, Akiskal HS, Angst J, Greenberg PE, Hirschfeld RM, Petukhova M, Kessler RC.

**MH2 Comparison of health care costs and hospitalization days of elderly major depressive disorder patients treated with escitalopram and other antidepressants.**

*Abstract:* 2007 International Society for Pharmacoeconomics and Outcomes Research, May 19-23, 2007.

*Authors:* Wu E, Yang E, Greenberg P, Erder M, Yu A, Buesing M.

**Treatment Compliance of Adult Depressed Patients on Escitalopram and Citalopram.**

*Abstract:* European College of Neuropsychopharmacology (ECNP) Regional Meeting, Sofia, Bulgaria Apr 27-29, 2007.

*Authors:* Wu EQ, Yang E, Greenberg P, Erder MH, Buessing M.

**Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes.**

*Publication:* Epilepsia 2007 03; 48(3): 464-469. doi: 10.1111/j.1528-1167.2007.01007.x.

*Authors:* Andermann F, Duh MS, Gosselin A, Paradis PE.

**Considering the costs of bipolar depression.**

*Publication:* Behav Healthc 2007 01; 27(1): 45-47.

*Authors:* Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg PE, Hirschfeld RM, Wang PS.

**Health Economics Impact in the Treatment of Depression.**

*Abstract:* 2007 National Association of Managed Care Physicians (NAMCP), 2007.

*Authors:* Navarro R, Wu EQ.

**Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach.**

*Publication:* Psychological Medicine 2006 11; 36(11): 1535-1540. doi: 10.1017/S0033291706008191.

*Authors:* Wu EQ, Shi L, Birnbaum H, Hudson T, Kessler R.

**Impact of stroke on health-related quality of life in the noninstitutionalized population in the United States.**

*Publication:* Stroke 2006 10; 37(10): 2567-2572. doi: 10.1161/01.STR.0000240506.34616.10.

*Authors:* Xie J, Wu EQ, Zheng ZJ, Croft JB, Greenlund KJ, Mensah GA, Labarthe DR.

**Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers.**

*Publication:* American Journal of Psychiatry 2006 09; 163(9): 1561-1568. doi: 10.1176/appi.ajp.163.9.1561.

*Authors:* Kessler RC, Akiskal HS, Ames M, Birnbaum H, Greenberg P, Hirschfeld RM, Jin R, Merikangas KR, Simon GE, Wang PS.

**MH4 Medical costs and hospitalization of adults diagnosed with attention-deficit/hyperactivity disorder who received alternative therapies.**

*Abstract:* 2006 International Society for Pharmacoeconomics and Outcomes Research, 2006.

*Authors:* Wu E, Birnbaum H, Zhang H, Radeva J, Yang E, Castor A.

**Employer Burden for Adults Diagnosed with Attention-Deficit/Hyperactivity Disorder who Received Alternative Therapies.**

*Abstract:* 2006 American Psychiatric Association.

*Authors:* Wu EQ, Birnbaum H, Zhang HF, Radeva J, Yang E, Castor A.

**Health-Related Quality Of Life of Stroke Survivors in the U.S.**

*Abstract:* 2006 International Society for Pharmacoeconomics & Outcomes Research (ISPOR) Asia- Pacific.

*Authors:* Xie J, Wu EQ, Zheng ZJ, Croft JB, Mensah GA, Labarthe D.

**Patterns of Antidepressant Treatment Response in an Employed Population.**

*Abstract:* 2006 American Psychiatric Association.

*Authors:* Wu EQ, Birnbaum H, Ben-Hamadi R, Tang J, Greenberg P, Gilloteau I, Smadja E.

**PMH7 Annual costs associated with patterns of antidepressant treatment response among employees.**

*Abstract:* 2006 International Society for Pharmacoeconomics and Outcomes Research, 2006.

*Authors:* Wu E, Birnbaum H, Ben-Hamadi R, Yu A, Tang J, Greenberg P, Gilloteau I, Smadja E.

**Unemployment drives high cost of schizophrenia in the US.**

*Publication:* Pharmacoeconomics & Outcomes News 2005 12; 493: 17.

*Authors:* Wu E.

**PMH37 The economic burden of schizophrenia in the united states in 2002.**

*Abstract:* 2005 International Society for Pharmacoeconomics and Outcomes Research, 2005.

*Authors:* Wu E, Birnbaum H, Shi L, Ball D, Kessler R, Moulis M, Aggarwal J.

**The prevalence and correlates of nonaffective psychosis in the National Comorbidity Survey Replication (NCS-R).**

*Publication:* Biological Psychiatry 2005 10; 58(8): 668-676. doi: 10.1016/j.biopsych.2005.04.034.

*Authors:* Kessler RC, Birnbaum H, Demler O, Falloon IR, Gagnon E, Guyer M, Howes MJ, Kendler KS, Shi L, Walters E, Wu EQ.

**Economic burden of illness for employees with painful conditions.**

*Publication:* Journal of Occupational and Environmental Medicine 2005 09; 47(9): 884-892. e-pub ahead of print 2005/09/13.

*Authors:* White AG, Birnbaum HG, Mareva MN, Henckler AE, Grossman P, Mallett DA.

**The economic burden of schizophrenia in the United States in 2002.**

*Publication:* Journal of Clinical Psychiatry 2005 09; 66(9): 1122-1129.

*Authors:* Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J.

**Costs of schizophrenia have shifted.**

*Publication:* PharmacoEconomics & Outcomes News 2005 06; 480: 18.

*Authors:* Wu E.

**The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers.**

*Publication:* Journal of Occupational Environmental Medicine 2005 06; 47(6): 565-572.

*Authors:* Kessler RC, Adler L, Ames M, Barkley RA, Birnbaum H, Greenberg P, Johnston JA, Spencer T, Ustun TB.

**PMH49 Estimating annual US prevalence of schizophrenia in 2002.**

*Abstract:* 2005 International Society for Pharmacoeconomics and Outcomes Research, 2005.

*Authors:* Wu E, Birnbaum H, Aggarwal J, Moulis M.

**The economic burden of depression in the US: societal and patient perspectives.**

*Publication:* Expert Opinion on Pharmacotherapy 2005 03; 6(3): 369-376. doi: 10.1517/14656566.6.3.369.

*Authors:* Greenberg PE, Birnbaum HG.

**Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000.**

*Publication:* Current Medical Research and Opinion 2005 02; 21(2): 195-206. doi: 10.1185/030079904X20303.

*Authors:* Birnbaum HG, Kessler RC, Lowe SW, Secnik K, Greenberg PE, Leong SA, Swensen AR.

**Direct Health Care Costs of Schizophrenia in the United States: 2002.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR).

*Authors:* Wu EQ, Birnbaum H, Kessler R, Beaulieu N, Daher M, Aggarwal J, Svanum H, Shi L.

**Economic Burden of Lost Productivity due to Schizophrenia in the United States: 2002.**

*Abstract:* American Psychiatric Association.

*Authors:* Wu EQ, Birnbaum H, Kessler R, Shi L, Ball D.

**Using Claims Data to Estimate the Annual Prevalence of Schizophrenia in the United States, 2002.**

*Abstract:* 2005 International Society for Pharmacoeconomics & Outcomes Research (ISPOR) European, 2005.

*Authors:* Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J.

**Incidence and costs of accidents among attention-deficit/hyperactivity disorder patients.**

*Publication:* Journal of Adolescent Health 2004 10; 35(4): 346 e341-349.

*Authors:* Swensen A, Birnbaum HG, Ben Hamadi R, Greenberg P, Cremieux PY, Secnik K.

**Economic implications of treatment-resistant depression among employees.**

*Publication:* PharmacoEconomics 2004 04; 22(6): 363-373.

*Authors:* Greenberg P, Corey-Lisle PK, Birnbaum H, Marynchenko M, Claxton A.



**Comorbidities and Cost Associated with Bipolar Disorder.**

*Abstract:* 2004 American Public Health Association.

*Authors:* Parece A, Wu EQ, Birnbaum H, Greenberg P, Huang Z, Victor T, Kessler RC.

**Cost and Comorbidities Associated with Bipolar Disorder.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR).

*Authors:* Parece A, Wu EQ, Birnbaum HG, Greenberg P, Huang Z, Victor T, Kessler RC.

**Drug Treatment Patterns of Bipolar Disorder and Associated Costs.**

*Abstract:* 2004 National Institute of Mental Health's (NIMH) New Clinical Drug Evaluation Unit (NCDEU) Meeting.

*Authors:* Wu EQ, Birnbaum H, Greenberg P, Huang Z, Kessler R, Parece A, T. V.

**What's so different about anxiety disorders (such as phobias).**

*Publication:* WPA series evidence and experience in psychiatry 2004 7.

*Authors:* Greenberg P, Birnbaum H, Sisitsky T.

**Attention-deficit/hyperactivity disorder: increased costs for patients and their families.**

*Publication:* Journal of the American Academy of Child and Adolescent Psychiatry 2003 12; 42(12): 1415-1423. doi: 10.1097/00004583-200312000-00008.

*Authors:* Swensen AR, Birnbaum HG, Secnik K, Marynchenko M, Greenberg P, Claxton A.

**The economic burden of depression in the United States: how did it change between 1990 and 2000?**

*Publication:* Journal of Clinical Psychiatry 2003 12; 64(12): 1465-1475.

*Authors:* Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, Corey-Lisle PK.

**Economic consequences of not recognizing bipolar disorder patients: a cross-sectional descriptive analysis.**

*Publication:* Journal of Clinical Psychiatry 2003 10; 64(10): 1201-1209.

*Authors:* Birnbaum HG, Shi L, Dial E, Oster EF, Greenberg PE, Mallett DA.

**Economic impact of olanzapine plus fluoxetine combination therapy among patients treated for depression: a pilot study.**

*Publication:* Psychopharmacology Bulletin 2003 08; 37(3): 90-98.

*Authors:* Corey-Lisle PK, Birnbaum H, Greenberg P, Marynchenko M, Dube S.

**PNP16: The comparison of different methods for determining the impact of migraine prophylaxis on costs.**

*Abstract:* 2003 International Society for Pharmacoeconomics and Outcomes Research, 2003.

*Authors:* Barlev A, Globe D, Wu E, Yu W, Johnson K.

**The economic burden of depression with painful symptoms.**

*Publication:* Journal of Clinical Psychiatry 2003 05; 64 Suppl 7: 17-23.

*Authors:* Greenberg PE, Leong SA, Birnbaum HG, Robinson RL.

**The economics of women and depression: an employer's perspective.**

*Publication:* Journal of Affective Disorders 2003 03; 74(1): 15-22.

*Authors:* Birnbaum HG, Leong SA, Greenberg PE.

**Identification of a claims data "signature" and economic consequences for treatment-resistant depression.**

*Publication:* Journal of Clinical Psychiatry 2002 08; 63(8): 717-726.

*Authors:* Corey-Lisle PK, Birnbaum HG, Greenberg PE, Marynchenko MB, Claxton AJ.

**An analysis of the diffusion of new antidepressants: variety, quality, and marketing efforts.**

*Publication:* Journal of Mental Health Policy and Economics 2002 03; 5(1): 3-19.

*Authors:* Berndt ER, Bhattacharjya A, Mishol DN, Arcelus A, Lasky T.

**The economic burden of anxiety and stress disorders.**

*Publication:* Neuropsychopharmacology: The fifth generation of progress 2002 67: 982-992.

*Authors:* Kessler RC, Greenberg PE.

**Cost of depression: current assessment and future directions.**

*Publication:* Expert Review of Pharmacoeconomics & Outcomes Research 2001 10; 1(1): 69-76. doi: 10.1586/14737167.1.1.69.

*Authors:* Greenberg PE, Birnbaum SA.

**Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD.**

*Publication:* Neurology 2001 09; 57(6): 957-964.

*Authors:* Neumann PJ, Araki SS, Arcelus A, Longo A, Papadopoulos G, Kosik KS, Kuntz KM, Bhattacharjya A.

**Assessing the economic impact of psychiatric disorders: where to begin?**

*Publication:* Expert Opinion on Pharmacotherapy 2001 04; 2(4): 641-652. doi: 10.1517/14656566.2.4.641.

*Authors:* Greenberg PE, Leong SA, Birnbaum HG.

**Depression and work productivity: the comparative costs of treatment versus nontreatment.**

*Publication:* Journal of Occupational Environmental Medicine 2001 01; 43(1): 2-9.

*Authors:* Simon GE, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Wang PS, Kessler RC.

**Survival and Nursing Home Free Survival (NHFS) of Alzheimer's Disease (AD) Patients.**

*Abstract:* 2001 International Society for Pharmacoeconomics & Outcomes Research (ISPOR), 2001.

*Authors:* Wu EQ, Hay J.

**The impact of antidepressant use on social functioning: reboxetine versus fluoxetine.**

*Publication:* International Clinical Psychopharmacology 2000 09; 15(5): 279-289.

*Authors:* Venditti LN, Arcelus A, Birnbaum H, Greenberg P, Barr CE, Rowland C, Williamson T.

**The Economics of Anxiety Disorders.**

*Publication:* Psychiatric Times' Mental Health Economics: Practical Information on Changes in the U.S. Health Care System 2000.

*Authors:* Greenberg P, Sisitsky T.

**The Impact of an Over-the-Counter Migraine Medication on Quality of Life.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research.

*Authors:* Burk C, Nichol MB, Wu EQ, Gilderman A, Salas J.

**Management of major depression in the workplace.**

*Publication:* Disease Management and Health Outcomes 2000 7(3): 163-171.

*Authors:* Birnbaum HG, Cremieux PY, Greenberg PE, Kessler RC.

**The workplace burden of depression: underlying causes, recent empirical findings, and future directions.**

*Publication:* TEN 2000 2(6): 37-40.

*Authors:* Greenberg P, Birnbaum H.

**Depression in the workplace: effects on short-term disability.**

*Publication:* Health Affairs 1999 09; 18(5): 163-171.

*Authors:* Kessler RC, Barber C, Birnbaum HG, Frank RG, Greenberg PE, Rose RM, Simon GE, Wang P.

**The economic burden of anxiety disorders in the 1990s.**

*Publication:* Journal of Clinical Psychiatry 1999 07; 60(7): 427-435.

*Authors:* Greenberg PE, Sisitsky T, Kessler RC, Finkelstein SN, Berndt ER, Davidson JR, Ballenger JC, Fyer AJ.

**Workplace burden of depression: a case study in social functioning using employer claims data.***Publication:* Drug Benefits Trends 1999 11: 6BH-12BH.*Authors:* Birnbaum H, Greenberg P, Barton M, Kessler R, Rowland C, Williamson T.**Workplace performance effects from chronic depression and its treatment.***Publication:* Journal of Health Economics 1998 10; 17(5): 511-535.*Authors:* Berndt ER, Finkelstein SN, Greenberg PE, Howland RH, Keith A, Rush AJ, Russell J, Keller MB.**Improvement in subjective work performance after treatment of chronic depression: some preliminary results. Chronic Depression Study Group.***Publication:* Psychopharmacology Bulletin 1996 01; 32(1): 33-40.*Authors:* Finkelstein SN, Berndt ER, Greenberg PE, Parsley RA, Russell JM, Keller MB.**Depression in the workplace: an economic perspective.***Publication:* Selective Serotonin Re-Uptake Inhibitors: Advances in Basic Research and Clinical Practice. 2nd ed. New York, NY: John Wiley & Sons 1996: 327-363.*Authors:* Greenberg PE, Kessler RC, Nells TL, Finkelstein SN, Berndt ER.**The effectiveness of surgery on the treatment of acute spinal cord injury and its relation to pharmacological treatment.***Publication:* Neurosurgery 1994 08; 35(2): 240-248; discussion 248-249.*Authors:* Duh MS, Shepard MJ, Wilberger JE, Bracken MB.**The Economics of Clinical Depression.***Publication:* MIT Management Magazine 1994 Spring.*Authors:* Greenberg P.**Depression: a neglected major illness.***Publication:* Journal of Clinical Psychiatry 1993 11; 54(11): 419-424.*Authors:* Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER.**The economic burden of depression in 1990.***Publication:* Journal of Clinical Psychiatry 1993 11; 54(11): 405-418.*Authors:* Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER.

## Oncology

**Adverse Events Associated with Cumulative Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.***Publication:* Drug Safety 2019 10. e-pub ahead of print 2019/10/07; doi: 10.1007/s40264-019-00867-6.*Authors:* Schultz NM, Penson DF, Wilson S, Song Y, Yang H, Ramaswamy K, Lowentritt B.**Grade 3/4 adverse event (AE) costs of nivolumab versus dabrafenib + trametinib as adjuvant treatment in patients with stage III BRAF-mutated cutaneous melanoma.***Abstract:* 15th International Congress of the Society for Melanoma Research, SMR 2018, Manchester, England Oct 24-27, 2018.*Authors:* Freeman M, Jiang S, Betts KA, Du EX, Rao S, Shoushtari A.**Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America.***Publication:* Advances in Therapy 2019 10. e-pub ahead of print 2019/10/21; doi: 10.1007/s12325-019-01109-y.*Authors:* Queiroz Muniz D, Ratto B, Yang H, Zhao J, Jenkins M, Signorovitch J, Dezzani L, Salman P, Lema Medina M, Lopera D, Lerzo G, Del Castillo C, Chacon M, Martin A, Campos-Gomez S.

**Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer.**

*Publication:* Future Oncology (London, England) 2019 10. e-pub ahead of print 2019/09/24; doi: 10.2217/fon-2019-0282.

*Authors:* Bobbili P, Ryan K, Duh MS, Dua A, Fernandes AW, Pavilack M, Gomez JE.

**Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence.**

*Publication:* Oncologist 2019 10. e-pub ahead of print 2019/10/04; doi: 10.1634/theoncologist.2019-0244.

*Authors:* Klemptner SJ, Fabrizio D, Bane S, Reinhart M, Peoples T, Ali SM, Sokol ES, Frampton G, Schrock AB, Anhorn R, Reddy P.

**Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data.**

*Publication:* Advances in Therapy 2019 08.

*Authors:* Freeman M, Betts KA, Jiang S, Du EX, Gupte-Singh K, Lu Y, Rao S, Shoushtari AN.

**Patient and Oncologist Preferences for the Treatment of Adults with Advanced Soft Tissue Sarcoma: A Discrete Choice Experiment.**

*Publication:* Patient 2019 08; 12(4): 393-404. e-pub ahead of print 2019/01/20; doi: 10.1007/s40271-019-00355-0.

*Authors:* Ivanova J, Hess LM, Garcia-Horton V, Graham S, Liu X, Zhu Y, Nicol S.

**Second-line rituximab-bendamustine versus rituximab-gemcitabine-oxaliplatin in diffuse large B-cell lymphoma in the real world.**

*Publication:* Journal of Comparative Effectiveness Research 2019 08. e-pub ahead of print 2019/08/28; doi: 10.2217/ce-2019-0062.

*Authors:* Ionescu-Ittu R, Shang A, Velde NV, Guerin A, Lin Y, Shi L, Shi S, Qayum N.

**Systematic literature review of clinical trials of endocrine therapies for premenopausal women with metastatic HR+ HER2- breast cancer.**

*Publication:* Breast Journal. 2019 07. doi: <http://dx.doi.org/10.1111/tbj.13345>.

*Authors:* Patterson-Lomba O, Dalal AA, Ayyagari R, Liu O, Dervishi E, Platt E, Chandiwana D, O'Shaughnessy JA.

**Economic Impact of Next-Generation Sequencing Versus Single-Gene Testing to Detect Genomic Alterations in Metastatic Non-Small-Cell Lung Cancer Using a Decision Analytic Model.**

*Publication:* JCO Precision Oncology 2019 06; (3): 1-9. doi: 10.1200/po.18.00356.

*Authors:* Pennell NA, Mutebi A, Zhou Z-Y, Ricculi ML, Tang W, Wang H, Guerin A, Arnhart T, Dalal A, Sasane M, Wu KY, Culver KW, Otterson GA.

**Effectiveness of first-line treatments in metastatic squamous non-small-cell lung cancer.**

*Publication:* Current Oncology (Toronto, Ont.) 2019 06; 26(3): e300-e308. e-pub ahead of print 2019/07/10; doi: 10.3747/co.26.4485.

*Authors:* Levy BP, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Parisi M.

**Health Care Resource Utilization and Costs Associated with Corticosteroid Use in Patients with Castration-Resistant Prostate Cancer: An Administrative Claims Analysis.**

*Publication:* Journal of Managed Care & Specialty Pharmacy 2019 06: 1-10. doi: <http://dx.doi.org/10.18553/jmcp.2019.19109>.

*Authors:* Schultz NM, Penson DF, Wilson SD, Song Y, Yang H, Ramaswamy K, Lowentritt B.

**Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.**

*Publication:* Melanoma Research 2019 06; 29(3): 301-310. e-pub ahead of print 2018/09/25; doi: 10.1097/CMR.0000000000000504.

*Authors:* Gbate S, Ionescu-Ittu R, Burne R, Ndife B, Laliberte F, Nakasato A, Duh MS.

**Tyrosine kinase inhibitor therapy treatment and discontinuation in patients with chronic myeloid leukemia in chronic phase in the United States: a clinical practice perspective.**

*Publication:* Leukemia and Lymphoma 2019 06; 60(6): 1476-1484. e-pub ahead of print 2019/01/23; doi: 10.1080/10428194.2018.1538510.

*Authors:* Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah EL.

**Clinical events associated with cumulative corticosteroid use in patients with castration-resistant prostate cancer: An administrative claims analysis.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2019, Chicago, IL May 31 - Jun 4, 2019.

*Authors:* Lowentritt BH, Penson DF, Wilson SC, Song Y, Yang H, Ramaswamy K, Schultz NM.

**Comparison of real-world treatment patterns, persistence, healthcare resource utilization (HRU) and costs between octreotide and lanreotide for the treatment of neuroendocrine tumors (NET).**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2019, Chicago, IL May 31 - Jun 4, 2019.

*Authors:* Huynh L, Cai B, Sharperson C, Lejeune D, Duh MS, Kim MK.

**Consideration of Potential Drug-Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer.**

*Publication:* American Journal of Therapeutics 2019 05; 26(3): e422-e424. doi: <http://dx.doi.org/10.1097/MJT.0000000000000693>.

*Authors:* Pilon D, Ellis LA, Xiao Y, Behl AS, Lefebvre P.

**Economic burden of select adverse events (AEs) in patients (Pts) with advanced urothelial cancer (aUC) treated with first-line (1L) systemic therapy.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2019, Chicago, IL May 31 - Jun 4, 2019.

*Authors:* Grivas P, Laliberte F, Doleh Y, O'Connor C, Duh MS, Shenolikar R.

**Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.**

*Publication:* Journal of Medical Economics 2019 05; 1. doi: <http://dx.doi.org/10.1080/13696998.2019.1620752>.

*Authors:* Streiff M, Milentijevic D, McCrae KR, Laliberte F, Lejeune D, Lefebvre P, Schein J, Khorana AA.

**Real-world adherence, costs, and treatment dosage of patients with neuroendocrine tumors (NET) treated with octreotide or lanreotide.**

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research (ISPOR), New Orleans, LA May 18-22, 2019.

*Authors:* Huynh L, Cai B, Lejeune D, Bhak R, Cheng M, Lax A, Duh MS, Kim MK.

**Real-world assessment of clinical outcomes among first-line (1L) sunitinib (SUN) patients (pts) with metastatic renal cell carcinoma (mRCC) by the international mRCC database consortium (IMDC) risk group.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2019, Chicago, IL May 31 - Jun 4, 2019.

*Authors:* Savard MF, Wells JC, Graham J, Steinharter JA, McGregor BA, Donskov F, Bjarnason GA, Vaishampayan UN, Hansen AR, Iafolla MAJ, Zanotti G, Huynh L, Duh MS, Heng DYC.

**Real-world clinical outcomes of pazopanib immediately following immunotherapy discontinuation for the treatment of advanced renal cell carcinoma.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2019, Chicago, IL May 31 - Jun 4, 2019.

*Authors:* Cao X, Tang D, Ratto BE, Poole A, Ravichandran S, Jin L, Gao W, Swallow E, Vogelzang NJ.

**Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A single institution retrospective study.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2019, Chicago, IL May 31 - Jun 4, 2019.

*Authors:* Patel AK, Ng K, Duh MS, Barghout VE, Huynh L, Yenikomshian MA, Sharperson C, Brais LK, Fuchs CS.

**A budget impact analysis of the introduction of copanlisib for treatment of relapsed follicular lymphoma in the United States.**

*Publication:* Journal of Managed Care and Specialty Pharmacy 2019 04; 25(4): 437-446b.

*Authors:* Appukkuttan S, Yaldo A, Gharibo M, Babajanyan S, Duchesneau E, Zichlin ML, Bhak RH, Duh MS.

**Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.**

*Publication:* Journal of Medical Economics 2019 04; 1. e-pub ahead of print 2019/04/24; doi:

10.1080/13696998.2019.1609485.

*Authors:* Bensimon AG, Zhou ZY, Jenkins M, Song Y, Gao W, Signorovitch J, Krepler C, Liu FX, Wang J, Aguiar-Ibanez R.

**Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: A medical chart study.**

*Publication:* European Journal of Haematology 2019 04; 102(4): 341-350. e-pub ahead of print 2018/12/24; doi:

10.1111/ejh.13205.

*Authors:* Griffin JD, Yang H, Song Y, Kinrich D, Shah MV, Bui CN.

**Assessment of change in quality of life, carcinoid syndrome symptoms and healthcare resource utilization in patients with carcinoid syndrome.**

*Publication:* BMC Cancer 2019 03; 19(1): 274. e-pub ahead of print 2019/03/30; doi: 10.1186/s12885-019-5459-x.

*Authors:* Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak RH, Narkhede S, Totev T, Duh MS, Neary MP, Cella D.

**Patients' preferences for treatment attributes associated with ribociclib and abemaciclib in women with advanced or metastatic breast cancer (mBC): a discrete choice experiment.**

*Abstract:* AMCP's 31st Annual Meeting, San Diego, CA Mar 25-28, 2019.

*Authors:* Dalal AA, Gauthier G, Caria N, Gauthier-Loiselle M, Shohoudi A, Guerin A.

**Treatment duration and response among pre/perimenopausal women with HR+HER2- metastatic breast cancer: a chart review study in the US.**

*Abstract:* Miami Breast Cancer Conference 36th Annual Meeting, Miami, FL Mar 7-10 2019.

*Authors:* Dalal A, Goldschmidt D, Romdhani H, Guerin A, Costa O, O'Shaughnessy J.

**Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.**

*Publication:* Journal of Medical Economics 2019 02; 22(2): 140-150. e-pub ahead of print 2018/11/16; doi:

10.1080/13696998.2018.1549056.

*Authors:* Signorovitch J, Zhou Z, Ryan J, Anhorn R, Chawla A.

**Comparative Effectiveness of Non-cisplatin First-line Therapies for Metastatic Urothelial Carcinoma: Phase 2 IMvigor210 Study Versus US Patients Treated in the Veterans Health Administration.**

*Publication:* Eur Urol Oncol 2019 02; 2(1): 12-20. e-pub ahead of print 2019/04/02; doi: 10.1016/j.euo.2018.07.003.

*Authors:* Vander Velde N, Guerin A, Ionescu-Iltu R, Shi S, Wu EQ, Lin SW, Hsu LI, Saum KU, de Ducla S, Wang J, Li S, Thastrom A, Liu S, Shi L, Leppert JT.

**Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States.**

*Publication:* Pharmacoeconomics. 2019 02; 37(2): 239-253. e-pub ahead of print 2018/11/02; doi: <http://dx.doi.org/10.1007/s40273-018-0732-4>.

*Authors:* Stein E, Xie J, Duchesneau E, Bhattacharyya S, Vudumula U, Ndife B, Bonifacio G, Guerin A, Li N, Joseph G.

**Cost Offsets in the Treatment Journeys of Patients With Relapsed/Refractory Multiple Myeloma.**

*Publication:* Clinical Therapeutics 2019 02. e-pub ahead of print 2019/02/19; doi: 10.1016/j.clinthera.2019.01.009.

*Authors:* Ailawadhi S, DerSarkissian M, Duh MS, Lafeuille MH, Posner G, Ralston S, Zagadailov E, Ba-Mancini A, Rifkin R.

**Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective.**

*Publication:* Journal of Managed Care & Specialty Pharmacy 2019 02; 25(2): 246-259. doi: <http://dx.doi.org/10.18553/jmcp.2019.25.2.246>.

*Authors:* Frois C, Howe A, Jarvis J, Grice K, Wong K, Zacker C, Sasane R.

**Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia.**

*Publication:* Advances in Therapy 2019 02. e-pub ahead of print 2019/02/14; doi: 10.1007/s12325-019-0873-7.

*Authors:* Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman Z, Belton L, Franklin J, Palmer S.

**Stage III melanoma incidence and impact of transitioning to the 8th AJCC staging system: a US population-based study.**

*Publication:* Future Oncology (London, England) 2019 02; 15(4): 359-370. e-pub ahead of print 2018/10/16; doi: 10.2217/fon-2018-0671.

*Authors:* Tarhini A, Gbate S, Ionescu-Iltu R, Shi S, Nakasato A, Ndife B, Laliberte F, Burne R, Duh MS.

**Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls.**

*Publication:* Current Medical Research and Opinion 2019 01; 35(1): 105-111. doi: <http://dx.doi.org/10.1080/03007995.2018.1541443>.

*Authors:* Li J, Knoll S, Bocharova I, Tang W, Signorovitch J.

**Real-World Treatment Patterns and Clinical Outcomes in Advanced Gastrointestinal Neuroendocrine Tumors (GI NET): A Multicenter Retrospective Chart Review Study.**

*Publication:* Oncologist 2019 01. e-pub ahead of print 2019/01/05; doi: 10.1634/theoncologist.2018-0519.

*Authors:* Kulke MH, Benson AB, Dasari A, Huynh L, Cai B, Totev T, Roesner N, Duh MS, Neary MP, Maurer VE, Shih BE, Dagohoy CG, Chan J, Bergsland EK.

**Treatment Patterns and Clinical Outcomes in Advanced Lung Neuroendocrine Tumors in Real-World Settings: A Multicenter Retrospective Chart Review Study.**

*Publication:* Oncologist 2019 01. e-pub ahead of print 2019/01/06; doi: 10.1634/theoncologist.2018-0520.

*Authors:* Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Dagohoy CG, Shih BE, Maurer VE, Chan J, Kulke MH.

**Adjuvant Therapy versus Watch-and-Wait Post Surgery for Stage III Melanoma: A Multi-Country Retrospective Chart Review.**

*Publication:* Melanoma Management 2019.

*Authors:* Peter Mohr, Felix Kiecker, Virtudes Soriano Teruel, Olivier Dereure, Karmele Mujika, Philippe Saiag, Jochen Utikal, Rama Koneru, Caroline Robert, Florencia Cuadros, Matias Chacón, Rodrigo Villarroel, Yana G. Najjar, Lisa Kottschade, Eva Muñoz Couselo, Roy Koruth, Annie Guérin, Rebecca Burne, Raluca Ionescu-Iltu, Maurice Perrinjaquet, Jonathan S. Zager.

**Evaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy.**

*Abstract:* ESMO Breast Cancer 2019, Berlin, Germany May 2-5, 2019.

*Authors:* Huang M, Qi CZ, Ramsey S, Briggs A, Zhao J, Haiderali A, Karantza V, Xie J, Gu C, Fasching PA.

**Pcn22 Clinical Heterogeneity among First-Line Sunitinib Patients with Metastatic Renal Cell Carcinoma (Mrcc) Categorized as Intermediate Risk (Ir) Group According to the International Mrcc Database Consortium (Imdc) Risk Model.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Huynh L, Wells JC, Graham J, Steinharter J, McGregor B, Donskov F, Bjarnason GA, Vaishampayan U, Hansen A, Iafora M, Zanotti G, Chang R, Cheng WY, Duh MS, Heng DYC.

**Pcn33 Matching-Adjusted Indirect Comparison of Efficacy and Safety of Acalabrutinib Versus Ibrutinib in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Telford C, Kabadi S, Abhyankar S, Song J, Signorovitch J, Zhao J, Yao Z.

**Pcn48 Economic Burden Associated with Severe Adverse Events in Patients with Metastatic Non-Small Cell Lung Cancer Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Lejeune D, Pavilack M, Dersarkissian M, Fernandes A, Duh MS, Subramanian J.

**Pcn109 Real-World Adherence, Costs, and Treatment Dosage of Patients with Neuroendocrine Tumors (Net) Treated with Octreotide or Lanreotide.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Huynh L, Cai B, Lejeune D, Bhak R, Cheng M, Lax A, Duh MS, Kim M.

**Pcn130 Real-World Demographics and Clinical Characteristics of Patients Diagnosed with Primary Mediastinal B-Cell Lymphoma (Pmbcl).**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Laliberte F, Yang X, Germain G, Raut M, Duh MS, Sen S, Lejeune D, Yee C, Desai K, Armand P.

**Pmu62 Us Care Pathways: Continued Focus on Oncology and Outstanding Challenges.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Chawla A, Westrich K, Dai A, Mantels S, Dubois RW.

**Consensus grading of cytokine release syndrome (CRS) in adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) treated with tisagenlecleucel on the juliet study.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Schuster SJ, Maziarsz RT, Ericson SG, Rusch ES, Signorovitch J, Romanov VV, Locke FL, Maloney DG.

**Cost-effectiveness analysis of lenalidomide for maintenance therapy after autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) patients: A united states payer perspective.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Zhou ZY, Parikh K, Chai X, Rokito A, Udeze C, Xie J, Agarwal A.

**Front-line ibrutinib treatment is associated with longer time to next treatment, net total cost reduction, and lower healthcare resource utilization compared to chemoimmunotherapy in patients with chronic lymphocytic leukemia.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Wang S, Emond B, Romdhani H, Lefebvre P, Sundaram M, Mato AR.



**Grading of neurotoxicity in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) receiving tisagenlecleucel treatment in the juliet study.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Maziarz RT, Schuster SJ, Romanov VV, Rusch ES, Signorovitch J, Ericson SG, Maloney DG, Locke FL.

**Healthcare costs in patients with cancer increase with increasing risk of venous thromboembolism.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Streiff MB, McCrae KR, Kuderer NM, Milentijevic D, Germain G, Laliberte F, Le N, Lefebvre P, Lyman GH, Khorana AA.

**Healthcare resource utilization in adult patients with b-cell precursor acute lymphoblastic leukemia in first hematologic complete remission with and without minimal residual disease.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Rose D, Shah S, Despiegel N, Tibrewala S, Chawla A, Cong Z.

**Healthcare resource utilization in patients with metastatic melanoma receiving first-line therapy with dabrafenib + trametinib versus nivolumab or pembrolizumab monotherapy.**

*Publication:* Current Medical Research and Opinion 2018 12; 34(12): 2169-2176. e-pub ahead of print 2018/07/17; doi: 10.1080/03007995.2018.1501351.

*Authors:* Ghathe SR, Ionescu-Ittu R, Burne R, Ndife B, Laliberte F, Nakasato A, Duh MS.

**Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.**

*Publication:* Melanoma Research 2018 12; 28(6): 618-628. e-pub ahead of print 2018/09/15; doi: 10.1097/CMR.0000000000000507.

*Authors:* Tarhini A, Ghathe SR, Ionescu-Ittu R, Manceur AM, Ndife B, Jacques P, Laliberte F, Nakasato A, Burne R, Duh MS.

**The rate of venous thromboembolism in cancer patients varies by khorana risk category.**

*Abstract:* 60th Annual Meeting of the American Society of Hematology, San Diego, CA Dec 1-4, 2018.

*Authors:* Khorana AA, Kuderer NM, McCrae KR, Milentijevic D, Germain G, Laliberte F, Le N, Lefebvre P, Lyman GH, Streiff MB.

**Cost-Effectiveness of Tisagenlecleucel for Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma : A Canadian Societal Perspective.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Yang H, Qi C, Zhang J, El Ouagari K.

**Cost-Effectiveness of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Canadian Societal Perspective.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Yang H, Zhang J, Hampe M.

**Impact of carcinoid syndrome symptoms and long-term use of somatostatin analogs on quality of life in patients with carcinoid syndrome: A survey study.**

*Publication:* Medicine (Baltimore) 2018 11; 97(47): e13390. e-pub ahead of print 2018/11/22; doi: 10.1097/MD.00000000000013390.

*Authors:* Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak RH, Duh MS, Neary MP, Cella D.

**Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Chowdhury S, Oudard S, Hadaschik BA, Uemura H, Joniau S, Pilon D, Ladouceur M, Behl A, Liu J, Dearden L, Sermon J, Van Sanden S, Diels J.

**Observational study of characteristics and clinical outcomes of Dutch patients with tuberous sclerosis complex and renal angiomyolipoma treated with everolimus.**

*Publication:* PloS One 2018 11; 13(11): e0204646. e-pub ahead of print 2018/11/16; doi: 10.1371/journal.pone.0204646.

*Authors:* Zonnenberg BA, Neary MP, Duh MS, Ionescu-Iltu R, Fortier J, Vekeman F.

**Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.**

*Publication:* Urologic Oncology 2018 11; 36(11): 500 e501-500 e509. e-pub ahead of print 2018/09/12; doi: 10.1016/j.urolonc.2018.08.002.

*Authors:* Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP.

**The risk of recurrent VTE and major bleeding in a commercially-insured population of cancer patients treated with anticoagulation.**

*Publication:* American Journal of Hematology 2018 11. e-pub ahead of print 2018/11/27; doi: 10.1002/ajh.25361.

*Authors:* Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff MB.

**Comparative Effectiveness of nab-Paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Retrospective Nationwide Chart Review in the United States.**

*Publication:* Advances in Therapy 2018 10; 35(10): 1564-1577. e-pub ahead of print 2018/09/14; doi: 10.1007/s12325-018-0784-z.

*Authors:* Kim S, Signorovitch JE, Yang H, Patterson-Lomba O, Xiang CQ, Ung B, Parisi M, Marshall JL.

**Correction to: Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.**

*Publication:* BMC Urology 2018 10; 18(1): 84. e-pub ahead of print 2018/10/05; doi: 10.1186/s12894-018-0397-5.

*Authors:* Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

**Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial.**

*Publication:* Cancer 2018 10; 124(20): 4032-4043. e-pub ahead of print 2018/09/12; doi: 10.1002/cncr.31680.

*Authors:* Dimopoulos MA, Lonial S, Betts KA, Chen C, Zichlin ML, Brun A, Signorovitch JE, Makenbaeva D, Mekan S, Sy O, Weisel K, Richardson PG.

**A time and motion study of patients treated with Pembrolizumab and Nivolumab in Australia.**

*Abstract:* Society for Melanoma Research 2017 Congress. Australia, Brisbane, Australia October 18-21, 2017.

*Authors:* Pivneva I, Kothari S, Van Koeveerden P, Pellissier J, Stone S, Herawati L, Guerin A.

**Treatment Duration, Healthcare Resource Utilization, and Costs Among Chemotherapy-Naïve Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate: A Retrospective Claims Analysis.**

*Publication:* Advances in Therapy 2018 10; 35(10): 1639-1655. e-pub ahead of print 2018/09/08; doi: 10.1007/s12325-018-0774-1.

*Authors:* Schultz NM, Flanders SC, Wilson S, Brown BA, Song Y, Yang H, Lechpammer S, Kassabian V.

**Antiepileptic Drug Titration and Related Health Care Resource Use and Costs.**

*Publication:* J Manag Care Spec Pharm 2018 09; 24(9): 929-938. e-pub ahead of print 2018/02/28; doi: 10.18553/jmcp.2018.17337.

*Authors:* Fishman J, Kalilani L, Song Y, Swallow E, Wild I.

**Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States.**

*Publication:* Health Qual Life Outcomes 2018 09; 16(1): 193. e-pub ahead of print 2018/09/23; doi: 10.1186/s12955-018-1013-9.

*Authors:* Stein EM, Yang M, Guerin A, Gao W, Galebach P, Xiang CQ, Bhattacharyya S, Bonifacio G, Joseph GJ.

**Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials.**

*Publication:* BMC Urology 2018 09; 18(1): 77. e-pub ahead of print 2018/09/08; doi: 10.1186/s12894-018-0387-7.

*Authors:* Schultz NM, Shore ND, Chowdhury S, Klotz LH, Concepcion RS, Penson DF, Karsh LI, Yang H, Brown BA, Barlev A, Flanders SC.

**Progression-free survival with endocrine-based therapies following progression on non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer: a network meta-analysis.**

*Publication:* Current Medical Research and Opinion 2018 09; 34(9): 1645-1652. e-pub ahead of print 2018/05/22; doi: <http://dx.doi.org/10.1080/03007995.2018.1479246>.

*Authors:* Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA.

**Real-world Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib.**

*Publication:* Clinical Colorectal Cancer 2018 09; 17(3): e531-e539. e-pub ahead of print 2018/05/29; doi: <http://dx.doi.org/10.1016/j.clcc.2018.04.002>.

*Authors:* Patel AK, Duh MS, Barghout V, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS.

**Symptoms Following Discontinuation of Tyrosine Kinase Inhibitor (TKI) Therapy After Achieving an Adequate Response in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).**

*Abstract:* 6th Annual Meeting of the Society of Hematologic Oncology (SOHO 2018), Houston, TX Sept 12-15, 2018.

*Authors:* Ritchie E, Sadek I, Pivneva I, Guerin A, Latremouille-Viau D, Ndife B, Joseph G, Atallah E.

**Symptoms Following Discontinuation of Tyrosine Kinase Inhibitor (TKI) Therapy After Achieving an Adequate Response in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP).**

*Abstract:* 20th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy Miami, FL Sept 13-16, 2018.

*Authors:* Ritchie EK, Sadek I, Pivneva I, Guerin A, Latremouille-Viau D, Ndife B, Joseph GJ, Atallah EL.

**Treatment and Monitoring Patterns Among Premenopausal Women with HR+/HER2- Advanced Breast Cancer.**

*Publication:* Advances in Therapy 2018 09; 35(9): 1356-1367. e-pub ahead of print 2018/08/15; doi: 10.1007/s12325-018-0764-3.

*Authors:* Dalal AA, Gauthier G, Gagnon-Sanschagrin P, Burne R, Guerin A, Niravath P, Small T.

**Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.**

*Publication:* Advances in Therapy 2018 08; 35(10): 1671-1685. e-pub ahead of print 2018/08/30; doi: 10.1007/s12325-018-0772-3.

*Authors:* Seiter K, Latremouille-Viau D, Guerin A, Ndife B, Habucky K, Tang DH, Pivneva I, Gagnon-Sanschagrin P, Joseph GJ.

**Chemoradiotherapy treatment patterns and 1-year survival rate among patients with unresectable, stage III non-small cell lung cancer: Time trends from 2009 to 2014.**

*Abstract:* 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic Aug 22-26, 2018.

*Authors:* Bobbili PJ, Ryan K, Duh MS, Fernandez A, DerSarkissian M, Dua A, Pavilack M, Gomez JE.

**Deep molecular response in chronic phase-Chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: A multi-country retrospective chart review study.**

*Abstract:* 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic Aug 22-26, 2018.

*Authors:* Cortes J, Huynh L, Mendelson E, Brandt P, Dalal D, Der Sarkissian M, Cortina D, Narkhede S, Duh MS.

**Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.**

*Publication:* BMJ Open 2018 08; 8(8): e021642. e-pub ahead of print 2018/08/20; doi: 10.1136/bmjopen-2018-021642.

*Authors:* Li J, Sasane M, Zhang J, Zhao J, Ricculi ML, Yao Z, Redhu S, Signorovitch J.

**Monitoring of Hematologic, Cardiac, and Hepatic Function in Post-Menopausal Women with HR+/HER2-Metastatic Breast Cancer.**

*Publication:* Advances in Therapy 2018 08; 35(8): 1251-1264. e-pub ahead of print 2018/06/28; doi: 10.1007/s12325-018-0740-y.

*Authors:* Guerin A, Goldschmidt D, Small T, Gagnon-Sanschagrin P, Romdhani H, Gauthier G, Kelkar S, Wu EQ, Niravath P, Dalal AA.

**Real-world analysis of treatment patterns and long-term effectiveness among patients with advanced neuroendocrine tumors of lung origin: A multicenter study.**

*Abstract:* 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic Aug 22-26, 2018.

*Authors:* Huynh L, Totev T, Dasari A, Bergsland EK, Benson AB, Cai B, Shea J, Duh MS, Neary MP, Kulke MH.

**Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis.**

*Publication:* Advances in Therapy 2018 07; 35(7): 1035-1048. e-pub ahead of print 2018/06/28; doi: 10.1007/s12325-018-0734-9.

*Authors:* Li J, Sasane M, Zhao J, Horton VG, Zhang P, Ricculi ML, Zhou ZY, Signorovitch J.

**Drivers of treatment patterns in patients with chronic lymphocytic leukemia stopping ibrutinib or idelalisib therapies.**

*Publication:* Cancer Biology & Therapy 2018 07; 19(7): 636-643. e-pub ahead of print 2018/03/28; doi: 10.1080/15384047.2018.1449616.

*Authors:* Mato AR, Samp JC, Gauthier G, Terasawa E, Brander DM.

**Economic analysis of BRAF gene mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.**

*Publication:* Journal of Medical Economics 2018 07; 21(7): 649-655. e-pub ahead of print 2018/03/09; doi: 10.1080/13696998.2018.1450261.

*Authors:* Dalal AA, Guerin A, Mutebi A, Culver KW.

**Overall survival and health care costs of Medicare patients with previously treated chronic lymphocytic leukemia.**

*Publication:* Journal of Cancer Therapy 2018 07.

*Authors:* Reyes C, Gauthier G, Shi S, Guerin A.

**Assessing the Value of Nivolumab (NIVO) versus Placebo (PBO) and Ipilimumab (IPI) as Adjuvant Therapy for Resected Melanoma.**

*Abstract:* American Society of Clinical Oncology, Chicago, IL June 1-5, 2018.

*Authors:* Freeman M, Shoushtari A, Betts KA, Gupte-Singh K, Du EX, Ritchings C, Rao S.

**Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.**

*Publication:* Journal of Medical Economics 2018 06; 21(6): 577-586. e-pub ahead of print 2018/02/21; doi: 10.1080/13696998.2018.1443111.

*Authors:* Zhou ZY, Mutebi A, Han S, Bensimon AG, Louise Ricculi M, Xie J, Dalal A, Culver K.

**Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2- Metastatic Breast Cancer.**

*Publication:* Advances in Therapy 2018 06; 35(6): 768-778. e-pub ahead of print 2018/06/06; doi: 10.1007/s12325-018-0701-5.

*Authors:* Dalal AA, Gagnon-Sanschagrin P, Burne R, Guerin A, Gauthier G, Small T, Niravath P.

**Economic burden of treatment failure in chronic lymphocytic leukemia patients.**

*Publication:* Current Medical Research and Opinion 2018 06; 34(6): 1135-1142. e-pub ahead of print 2018/04/14; doi: 10.1080/03007995.2018.1464904.

*Authors:* Wang S, Lefeuvre MH, Lefebvre P, Romdhani H, Emond B, Senbetta M.

**Economic impact of next generation sequencing vs sequential single-gene testing modalities to detect genomic alterations in metastatic non-small cell lung cancer using a decision analytic model.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2018, Chicago, IL Jun 1-5, 2018.

*Authors:* Pennell NA, Mutebi A, Zhou ZY, Ricculi ML, Tang W, Wang H, Guerin A, Arnhart T, Culver KW, Otterson GA.

**Indirect treatment comparison of blinatumomab versus inotuzumab ozogamicin for the treatment of adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2018, Chicago, IL Jun 1-5, 2018.

*Authors:* Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman ZF, Belton L, Franklin J, Palmer S.

**Indirect treatment comparison of blinatumomab vs inotuzumab ozogamicin for treating adult patients with relapsed or refractory acute lymphoblastic leukemia receiving zero or one prior salvage therapy.**

*Abstract:* 23rd Congress of the European Hematology Association, EHA 2018, Stockholm, Sweden Jun 14-17, 2018.

*Authors:* Song J, Ma Q, Gao W, Cong Z, Xie J, Zimmerman Z, Belton L, Franklin J, Palmer S.

**Indirect treatment comparison of nivolumab versus placebo as an adjuvant therapy for resected melanoma.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2018, Chicago, IL June 1-5, 2018.

*Authors:* Shoushtari AN, Freeman ML, Betts KA, Gupte-Singh K, Du EX, Ritchings C, Rao S.

**Novel treatment (TX) use and associated outcomes among African American patients (PTS) with multiple myeloma (MM): A SEERMedicare analysis.**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2018, Chicago, IL June 1-5, 2018.

*Authors:* Parikh K, Clancy Z, Zhou ZY, Tang W, Cheung C, Zhou Z, Xie J, Ailawadhi S.

**Predictors of overall survival (OS) in veterans with non-metastatic castration resistant prostate cancer (nmCRPC).**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2018, Chicago, IL June 1-5, 2018.

*Authors:* Fuld AD, Young-Xu Y, Li S, Pilon D, Bhak R, Duchesneau E, Hellstern M, Kamstra R, Behl AS, Lefebvre P, Freedland SJ.

**Real-world adherence in patients with metastatic colorectal cancer (mCRC) treated with trifluridine/tipiracil (FTD/TPI) or regorafenib (REG).**

*Abstract:* American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL Jun 1-5, 2018.

*Authors:* Patel AK, Barghout V, Yenikomshian MA, Germain G, Jacques P, Laliberte F, Duh MS.

**Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data.**

*Publication:* J Manag Care Spec Pharm 2018 06; 24(6): 525-533. e-pub ahead of print 2018/05/26; doi:

10.18553/jmcp.2018.24.6.525.

*Authors:* Vogelzang NJ, Pal SK, Ghatge SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.

**Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers.**

*Publication:* Journal of Medical Economics 2018 06; 21(6): 543-552. e-pub ahead of print 2018/01/04; doi:

<http://dx.doi.org/10.1080/13696998.2017.1423488>.

*Authors:* Chawla A, Peeples M, Li N, Anhorn R, Ryan J, Signorovitch J.

**A seer-medicare analysis of novel treatment use and associated outcomes among african american patients with multiple myeloma.**

*Abstract:* 23rd Congress of the European Hematology Association, EHA 2018, Stockholm, Sweden June 14-17, 2018.

*Authors:* Ailawadhi S, Clancy Z, Zhou ZY, Tang W, Cheung C, Zhou Z, Xie J, Parikh K.

**Symptoms following TKI therapy discontinuation after achieving an adequate response in patients with chronic myeloid leukemia in chronic phase (CML-CP).**

*Abstract:* Annual Meeting of the American Society of Clinical Oncology, ASCO 2018, Chicago, IL June 1-5, 2018.

*Authors:* Ritchie EK, Sadek I, Pivneva I, Guerin A, Latremouille-Viau D, Ndife B, Joseph GJ, Atallah EL.

**Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations.**

*Publication:* Journal of Medical Economics 2018 06; 21(6): 556-563. e-pub ahead of print 2018/01/07; doi:

10.1080/13696998.2018.1425209.

*Authors:* Stein EM, Bonifacio G, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Joseph GJ.

**Adherence to national comprehensive cancer network guidelines for BRCA testing among breast cancer patients.**

*Publication:* Journal of Clinical Oncology. Conference 2018 05; 36(15 Supplement 1). doi:

<http://dx.doi.org/10.1200/JCO.2018.36.15-suppl.e13624>.

*Authors:* Tung NM, Bobbili PJ, Olufade TO, DerSarkissian M, Bhak R, Reiff J, Briceno JM, Yu H, Shenolikar R, Duh MS.

**Assessment of change in quality of life (QoL), carcinoid syndrome (CS) symptoms, and health care resource utilization (HRU) in CS patients treated with somatostatin analogs (SSA)-results from longitudinal patient surveys.**

*Publication:* Value in Health 2018 05; 21 (Supplement 1): S38-S39.

*Authors:* Huynh L, Bhak R, Narkhede S, Beaumont JL, Halperin DM, Cai B, Duh MS, Neary MP, Chang R, Cella D.

**Comparison of healthcare resource utilization (HRU) and costs related to pleural effusion (PE) between patients newly diagnosed with chronic myeloid leukemia (CML) treated with dasatinib or nilotinib as first-line therapy in the United States.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Seiter K, Latremouille-Viau D, Guerin A, Ndife B, Habucky K, Joseph GJ, Pivneva I, Gagnon-Sanschagrin P, Tang DH.

**Cost-effectiveness of ceritinib in previously untreated ALK-positive non-small cell lung cancer in the United Kingdom.**

*Publication:* Value in Health 2018 05; 21 (Supplement 1): S29.

*Authors:* Xie J, Knoll S, Slowley A, Bensimon A, Vieira J, Chilcott J, Paisley S, Zhou Z.

**Overall survival in patients with glioblastoma before and after bevacizumab approval.**

*Publication:* Current Medical Research and Opinion 2018 05; 34(5): 813-820. e-pub ahead of print 2017/10/14; doi: 10.1080/03007995.2017.1392294.

*Authors:* Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Ittu R, Shi S, Macalalad A, Uhm JH.

**Patterns of treatment and recurrence in patients with non-metastatic melanoma who underwent lymph node dissection surgery.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Ndife B, Tarhini A, Ionescu-Ittu R, Manceur AM, Jacques P, Laliberte F, Duh MS, Nakasato A, Gbate SR.

**Real-world analysis of treatment patterns and long-term effectiveness among patients with advanced neuroendocrine tumors of lung origin (lung NET): A multicenter study.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Dasari A, Bergsland EK, Benson AB, Cai B, Huynh L, Totev T, Shea J, Duh MS, Neary MP, Kulke MH.

**Reimbursement landscape for molecular testing in non-small cell lung cancer (NSCLC) in the United States.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Nellesen D, Patton C, Mutebi A, Culver KW.

**Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy.**

*Publication:* Lung Cancer 2018 05; 119: 112-119. e-pub ahead of print 2018/04/17; doi: 10.1016/j.lungcan.2018.02.011.

*Authors:* Borghaei H, Yim YM, Guerin A, Pivneva I, Shi S, Gandhi M, Ionescu-Ittu R.

**Surrogate Outcomes in Oncology: How can they be used to predict overall survival in clinical practice and payer decision making?**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Ayyagari R, Xie J, Wu E, Song J.

**Systematic literature review of treatments for patients with untreated advanced or metastatic non-small cell lung cancer (NSCLC).**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Song J, Huang M, Kelkar SS, Zhou Z, Zhang Y.

**Treatment patterns, clinical and economic outcomes of patients with anaplastic lymphoma kinase-positive non-small cell lung cancer receiving ceritinib: a retrospective observational claims analysis.**

*Publication:* J Drug Assess 2018 05; 7(1): 21-27. e-pub ahead of print 2018/05/01; doi: 10.1080/21556660.2018.1445092.

*Authors:* Dalal AA, Guerin A, Mutebi A, Culver KW.

**The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.**

*Publication:* J Manag Care Spec Pharm 2018 04; 24(4): 335-343. e-pub ahead of print 2018/03/27; doi: 10.18553/jmcp.2018.24.4.335.

*Authors:* Swallow E, Messali A, Gbate S, McDonald E, Duchesneau E, Perez JR.

**Assessment of costs associated with adverse events in patients with cancer.**

*Publication:* PloS One 2018 04; 13(4): e0196007. e-pub ahead of print 2018/04/14; doi: 10.1371/journal.pone.0196007.

*Authors:* Wong W, Yim YM, Kim A, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A.

**Characteristics of patients diagnosed de novo with AJCC7 stage III or regionally advanced cutaneous melanoma and trends in adjuvant therapy: An analysis of the SEER cancer registry in the United States.**

*Abstract:* Annual Meeting of the American Association for Cancer Research, AACR 2018, Chicago, IL April 14-18, 2018.

*Authors:* Tarhini A, Gbate S, Nakasato A, Ionescu-Iltu R, Shi S, Ndife B, Burne R, Laliberte F, Duh MS.

**Current Treatment Patterns Among Postmenopausal Women with HR+/HER2- Metastatic Breast Cancer in US Community Oncology Practices: An Observational Study.**

*Publication:* Advances in Therapy 2018 04; 35(4): 482-493. e-pub ahead of print 2018/03/28; doi: 10.1007/s12325-018-0676-2.

*Authors:* Goldschmidt D, Dalal AA, Romdhani H, Kelkar S, Guerin A, Gauthier G, Wu EQ, Niravath P, Small T.

**Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women.**

*Publication:* Advances in Therapy 2018 04; 35(4): 503-514. e-pub ahead of print 2018/03/21; doi: 10.1007/s12325-018-0689-x.

*Authors:* Gauthier G, Gagnon-Sanschagrin P, Guerin A, Burne R, Small T, Niravath P, Dalal AA.

**Efficacy of Ponatinib Versus Earlier Generation Tyrosine Kinase Inhibitors for Front-line Treatment of Newly Diagnosed Philadelphia-positive Acute Lymphoblastic Leukemia.**

*Publication:* Clinical Lymphoma, Myeloma & Leukemia 2018 04; 18(4): 257-265. e-pub ahead of print 2018/03/10; doi: 10.1016/j.clml.2018.02.010.

*Authors:* Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, O'Brien S, Ravandi F, Kantarjian HM.

**Epidemiologic and clinical characteristics of nontransfusion-dependent thalassemia in the United States.**

*Publication:* Pediatric Blood & Cancer 2018 04; 65(7): e27067. e-pub ahead of print 2018/04/11; doi: 10.1002/pbc.27067.

*Authors:* Vichinsky E, Cohen A, Thompson AA, Giardina PJ, Lal A, Paley C, Cheng WY, McCormick N, Sasane M, Qiu Y, Kwiatkowski JL.

**Healthcare Resource Utilization (HRU) and Cost Comparison of Infection-Related Complications During Therapy With Dasatinib or Nilotinib in Patients (pts) With Chronic Myeloid Leukemia.**

*Abstract:* AMCP's 30th Annual Meeting, Boston, MA Apr 23-26, 2018.

*Authors:* Seiter K, Latremouille-Viau D, Guerin A, Ndife B, Habucky K, Joseph G, Pivneva R, Gagnon-Sanschagrin P, Tang D.



**Healthcare Resource Utilization and Costs among Premenopausal Women with HR+/HER2- Metastatic Breast Cancer.**

*Abstract:* AMCP's 30th Annual Meeting, Boston, MA Apr 23–26, 2018.

*Authors:* Dalal A, Gagnon-Sanschagrin P, Burne R, Guerin A, Gauthier G, Small T, Niravath P.

**Incidence of AJCC7 stage III or regionally advanced cutaneous melanoma in the United States.**

*Abstract:* Annual Meeting of the American Association for Cancer Research, AACR 2018, Chicago, IL April 14-18, 2018.

*Authors:* Tarhini AM, Ghathe SR, Nakasato A, Ionescu-Iltu R, Shi S, Ndife B, Burne R, Laliberte F, Duh MS.

**Patterns of BRAF testing and treatment in patients with metastatic melanoma presumed BRAF positive.**

*Abstract:* Annual Meeting of the American Association for Cancer Research Chicago, IL Apr 14-18, 2018.

*Authors:* Ghathe S, Nakasato A, Ionescu-Iltu R, Shi S, Ndife B, Burne R, Laliberte F, Duh MS.

**Patterns of treatment with immune check point inhibitors and targeted therapy in patients with metastatic melanoma presumed BRAF V600 positive.**

*Abstract:* Annual Meeting of the American Association for Cancer Research, AACR 2018, Chicago, IL April 14-18, 2018.

*Authors:* Ghathe S, Nakasato A, Ionescu-Iltu R, Shi S, Ndife B, Burne R, Laliberte F, Duh MS.

**Progression-free Survival With First-line Endocrine-based Therapies Among Postmenopausal Women With HR+/HER2- Metastatic Breast Cancer:: A Network Meta-analysis.**

*Publication:* Clinical Therapeutics 2018 04; 40(4): 628-639 e623. e-pub ahead of print 2018/04/04; doi: 10.1016/j.clinthera.2018.03.004.

*Authors:* Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Chandiwana D, Dalal AA, Niravath PA.

**Real-world comparative effectiveness of treatment sequences in metastatic non-small cell lung cancer with squamous histology.**

*Abstract:* 8th European Lung Cancer Congress, Geneva, Switzerland Apr 11-14, 2018.

*Authors:* Yang H, Levy BP, Signorovitch JE, Patterson-Lomba O, Xiang CQ, Parisi M.

**Dosing patterns and economic burden of drug wastage among postmenopausal women with HR+/HER2- metastatic breast cancer receiving palbociclib.**

*Abstract:* 14th Annual Meeting for the Hematology/Oncology Pharmacy Association, Denver, CO Mar 21-24, 2018.

*Authors:* Dalal A, Gagnon-Sanschagrin P, Burne R, Guerin A, Gauthier G, Small T.

**Factors associated with the number and size of renal angiomyolipomas in sporadic angiomyolipoma (sAML): a study of adult patients with sAML managed in a Dutch tertiary referral center.**

*Publication:* International Urology and Nephrology 2018 03; 50(3): 459-467. doi: <http://dx.doi.org/10.1007/s11255-017-1766-9>.

*Authors:* Ruud Bosch JLH, Vekeman F, Duh MS, Neary M, Magestro M, Fortier J, Karner P, Ionescu-Iltu R, Zonnenberg BA.

**Hematologic, cardiac, and hepatic function monitoring among post-menopausal women with HR+/HER2- metastatic breast cancer.**

*Abstract:* 2018 National Comprehensive Cancer Network 23rd Annual Conference, Orlando, FL Mar 22-24, 2018.

*Authors:* Dalal AA, Goldschmidt D, Romdhani H, Kelkar S, Guerin A, Gauthier G, Small T, Niravath P.

**A model estimating work productivity loss due to premature death associated with hepatic veno-occlusive disease/sinusoidal obstruction syndrome among hematopoietic stem cell transplant patients in the united states.**

*Abstract:* 14th Annual Meeting for the Hematology/Oncology Pharmacy Association, Denver, CO Mar 21-24, 2018.

*Authors:* Zhou ZY, Tang W, Villa K.

**Treatment and monitoring patterns among premenopausal women with HR+/HER2- metastatic breast cancer.***Abstract:* 2018 National Comprehensive Cancer Network 23rd Annual Conference, Orlando, FL Mar 22-24, 2018.*Authors:* Guerin A, Dalal AA, Gagnon-Sanschagrin P, Burne R, Gauthier G, Small T, Niravath P.**Treatment patterns among post-menopausal women with HR+/HER2- metastatic breast cancer: a chart review study.***Abstract:* 2018 National Comprehensive Cancer Network 23rd Annual Conference, Orlando, FL Mar 22-24, 2018.*Authors:* Dalal AA, Goldschmidt D, Romdhani H, Kelkar S, Guerin A, Gauthier G, Small T, Niravath P.**Increased Prevalence of Cancer in Adult Patients With Psoriasis in the United States: A Claims Based Analysis.***Publication:* J Drugs Dermatol 2018 02; 17(2): 180-186. e-pub ahead of print 2018/02/21.*Authors:* Kimball AB, Sundaram M, Cloutier M, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Guerin A, Ganguli A.**Real-world Characteristics and Outcomes of Patients With Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy Versus Androgen Receptor-targeted Therapy After Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting.***Publication:* Clinical Genitourinary Cancer 2018 02; 16(1): 50-57. doi: <http://dx.doi.org/10.1016/j.clgc.2017.06.004>.*Authors:* Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.**Reimbursement Landscape for Molecular Testing in Non-Small Cell Lung Cancer.***Publication:* American Journal of Managed Care 2018 02.*Authors:* Nellesen D, Dea K, Guerin A, Culver K, Mutebi A, Dalal A.**Comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in metastatic pancreatic cancer: A nationwide chart review in the United States.***Abstract:* Gastrointestinal Cancers Symposium, San Francisco, CA Jan 18-20, 2018.*Authors:* Kim SS, Signorovitch J, Yang H, Patterson-Lomba O, Xiang C, Ung B, Parisi M, Marshall J.**Comparative effectiveness of non-cisplatin (cis)-based first-line (1L) regimens in patients with metastatic urothelial carcinoma (mUC): Veterans Affairs control cohorts vs. IMvigor210.***Abstract:* Genitourinary Cancers Symposium, San Francisco, CA Jan 18-20, 2018.*Authors:* Vander Velde NS, Guerin A, Ionescu-Ittu R, Shi S, Wu E, Lin SW, Hsu LI, Saum KU, Ducla SD, Wang J, Li S, Derleth CL, Liu S, Shi L, Leppert J.**Comparison of enzalutamide and bicalutamide in patients with non-metastatic castration-resistant prostate cancer: Number needed to treat to achieve one additional patient free of clinical progression events.***Abstract:* Genitourinary Cancers Symposium, San Francisco, CA Jan 18-20, 2018.*Authors:* Karsh LI, Penson DF, Concepcion R, Flanders S, Brown BA, Yang H, Ramaswamy K, Schultz NM.**Comparison of the real-world adherence and compliance patterns with trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).***Abstract:* Gastrointestinal Cancers Symposium, San Francisco, CA Jan 18-20, 2018.*Authors:* Patel AK, Duh MS, Barghout V, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS.**Health care resource utilization and costs in metastatic castration-resistant prostate cancer patients treated with enzalutamide or abiraterone acetate.***Abstract:* Genitourinary Cancers Symposium, San Francisco, CA Jan 18-20, 2018.*Authors:* Kassabian V, Flanders S, Wilson S, Brown BA, Song Y, Yang H, Lechpammer S, Schultz NM.**Improvement of carcinoid syndrome (CS) symptoms and quality of life (QoL) in CS patients treated with somatostatin analogs (SSAs): Results from longitudinal patient surveys.***Abstract:* Gastrointestinal Cancers Symposium, San Francisco, CA Jan 18-20, 2018.*Authors:* Halperin DM, Huynh L, Beaumont JL, Cai B, Bhak R, Narkhede S, Duh MS, Neary M, Cella D.

**Real-world analysis of treatment patterns and persistence of octreotide LAR and other agents in patients with advanced gastrointestinal neuroendocrine tumors (GI NET): A multicenter study.**

*Abstract:* Gastrointestinal Cancers Symposium, San Francisco, CA Jan 18-20, 2018.

*Authors:* Kulke MH, Benson AB, Huynh ADL, Cai B, Totev T, Roesner N, Duh MS, Neary M, Bergsland EK.

**Time to first-line (1L) therapy discontinuation in metastatic melanoma (MM).**

*Abstract:* ASCO-SITC Clinical Immuno-Oncology Symposium, San Francisco, CA Jan 25-27, 2018.

*Authors:* Luke JJ, Ghate S, Ionescu-Iltu R, Ndife B, Burne R, Laliberte F, Duh MS.

**Treatment duration and utilization patterns in metastatic castration-resistant prostate cancer patients receiving enzalutamide or abiraterone acetate.**

*Abstract:* Genitourinary Cancers Symposium, San Francisco, CA Jan 18-20, 2018.

*Authors:* Kassabian V, Flanders S, Wilson S, Brown BA, Song Y, Yang H, Lechpammer S, Schultz NM.

**Comparison of Adverse Event Costs of Nivolumab combined with Ipilimumab versus Sunitinib for Previously Untreated Metastatic Renal Cell Carcinoma.**

*Abstract:* American Society of Clinical Oncology, Chicago, IL (abstract accepted as online presentation) June 1-5, 2018.

*Authors:* Betts KA, Yang S, Du EX, Johansen J, Rao S.

**First-line nivolumab plus ipilimumab is associated with lower costs per responder versus sunitinib among patients with advanced renal cell carcinoma.**

*Abstract:* 33rd Annual Meeting and Pre Conference Programs of the Society for Immunotherapy of Cancer, SITC, Washington, D.C. Nov 7-11, 2018.

*Authors:* Choueiri T, Betts K, Yang S, Du E, Rao S, George S.

**Treatment patterns and sequences among pre-menopausal women with HR+/HER2-metastatic breast cancer: A chart review study.**

*Abstract:* San Antonio Breast Cancer Symposium Annual Meeting, San Antonio, TX Dec 4-8, 2018.

*Authors:* Dalal AA, Goldschmidt D, Romdhani H, Kelkar S, Guerin A, Wang H, Caria N, Sawhney A, O'Shaughnessy J.

**Clinical benefits of achieving deep remission to second-line therapy in patients with relapse/refractory (R/R) chronic lymphocytic leukemia (CLL) - A real-world study.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Wierda WG, Gauthier G, Meissner B, Guerin A, Samp JC.

**Comparison of Healthcare Resource Utilization and Costs Related to Infections between Patients Newly Diagnosed with Chronic Myeloid Leukemia Treated with Dasatinib and Nilotinib as First-line and Second-line Therapy in the United States.**

*Abstract:* American Society of Hematology Annual Meeting, Atlanta, GA December 9-12, 2017.

*Authors:* Seiter K, Latremouille-Viau D, Guerin A, Ndife B, Habucky K, Joseph G, Pivneva R, Gagnon-Sanschagrin P, Tang D.

**Comparison of healthcare resource utilization and costs related to infections between patients newly diagnosed with chronic myeloid leukemia treated with dasatinib and nilotinib as first-line therapy in the United States.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington DC Dec 9-12, 2017.

*Authors:* Seiter K, Latremouille-Viau D, Guerin A, Ndife B, Habucky K, Joseph GJ, Pivneva I, Gagnon-Sanschagrin P, Tang DH.

**Cost offsets in the treatment journeys of patients with relapsed/refractory multiple myeloma (RRMM).**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 9-12, 2017.

*Authors:* Ailawadhi S, DerSarkissian M, Duh MS, Lafeuille MH, Posner G, Ralston S, Zagadailov E, Ba-Mancini A, Rifkin RM.

**Cost-effectiveness analysis of CTL019 for the treatment of pediatric and young adult patients with relapsed or refractory b-cell acute lymphoblastic leukemia in the united states.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington DC Dec 9-12, 2017.

*Authors:* Hao Y, Eldjerou LK, Yang H, Qi C, Globe D.

**Cost-effectiveness of midostaurin in the treatment of newly diagnosed FLT3-mutated acute myeloid leukemia in the United States.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Stein EM, Xie J, Duchesneau E, Bhattacharyya S, Ndife B, Bonifacio G, Joseph GJ.

**Drivers of treatment patterns in patients with chronic lymphocytic leukemia (CLL) treated with B cell receptor inhibitors (BCRIs) - A medical chart review study.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec. 9-12, 2017.

*Authors:* Mato AR, Samp JC, Gauthier G, Terasawa E, Brander DM.

**First-line treatment disruption among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.**

*Publication:* Current Medical Research and Opinion 2017 12; 33(12): 2137-2143. e-pub ahead of print 2017/10/11; doi: 10.1080/03007995.2017.1390447.

*Authors:* Tang DH, Li N, Du EX, Peebles M, Chu L, Xie J, Barghout V.

**Managing acute myeloid leukemia in older patients: Are we making progress? an analysis of treatment patterns and healthcare resource utilization.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Lafeuille MH, Sundaram M, Hoehn D, Emond B, Romdhani H, Lefebvre P.

**Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: A seer-medicare analysis.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington DC Dec 9-12, 2017.

*Authors:* Ailawadhi S, Parikh K, Zhou Z, Tang W, Clancy Z, Cheung C, Zhou ZY, Xie J, Abouzaid S.

**Real-world outcomes among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.**

*Abstract:* San Antonio Breast Cancer Symposium, San Antonio, TX Dec 6-10, 2016.

*Authors:* Li N, Du EX, Peebles M, Chu L, Xie J, Barghout V, Tang DH.

**Systematic Literature Review of the Impact of Endocrine Monotherapy and in Combination with Targeted Therapy on Quality of Life of Postmenopausal Women with HR+/HER2- Advanced Breast Cancer.**

*Publication:* Advances in Therapy 2017 12; 34(12): 2566-2584. e-pub ahead of print 2017/11/17; doi: 10.1007/s12325-017-0644-2.

*Authors:* Zhou Z, Tang DH, Xie J, Ayyagari R, Wu E, Niravath PA.

**Treatment characteristics and deep molecular response in chronic phase-chronic myeloid leukemia patients treated with second-line nilotinib or dasatinib: A multi-country retrospective chart review study.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington DC Dec 9-12, 2017.

*Authors:* Cortes JE, Huynh L, Mendelson E, Brandt P, Dalal D, Dersarkissian M, Cortina D, Narkhede S, Duh MS.

**Treatment patterns and healthcare resource utilization in patients with FLT3-mut and FLT3-wt acute myeloid leukemia: A multi-country medical chart study.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington DC Dec 9-12, 2017.

*Authors:* Griffin JD, Yang H, Song Y, Kinrich D, Bui CN.

**Treatment patterns in patients with chronic myeloid leukemia in chronic phase in US clinical practice, with a focus on tyrosine kinase inhibitor therapy discontinuation.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington DC Dec 9-12, 2017.

*Authors:* Ritchie EK, Latremouille-Viau D, Guerin A, Pivneva I, Habucky K, Ndife B, Joseph GJ, Atallah E.

**Treatment patterns of hypomethylating agents in older ( $\geq 65$  Years) acute myeloid leukemia patients who did not receive intensive chemotherapy: A retrospective claims database analysis.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Sundaram M, Lafeuille MH, Hoehn D, Emond B, Romdhani H, Lefebvre P.

**VTE recurrence and safety of anticoagulants among patients with cancer treated for venous thromboembolism.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff MB.

**Who is receiving novel therapies for relapsed/refractory follicular lymphoma? A retrospective chart review of recent real-world practice.**

*Abstract:* 59th Annual Meeting of the American Society of Hematology, Washington, DC Dec 9-12, 2017.

*Authors:* Signorovitch J, Garcia-Horton V, Ricculi ML, McGuire M.

**Access to Cancer Specialist Care and Treatment in Patients With Advanced Stage Lung Cancer.**

*Publication:* Clinical Lung Cancer 2017 11; 18(6): 640-650 e642. e-pub ahead of print 2017/05/20; doi: 10.1016/j.clcc.2017.04.010.

*Authors:* Ganti AK, Hirsch FR, Wynes MW, Ravelo A, Ramalingam SS, Ionescu-Iltu R, Pivneva I, Borghaei H.

**Anticoagulant treatment patterns for cancer-associated thrombosis in a commercial insurance population.**

*Abstract:* Resuscitation Science Symposium, Anaheim, CA Nov 11-15, 2017.

*Authors:* Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff M.

**Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis.**

*Publication:* Advances in Therapy 2017 11; 34(11): 2452-2465. e-pub ahead of print 2017/10/28; doi: 10.1007/s12325-017-0628-2.

*Authors:* Vogelzang NJ, Pal SK, Ghatge SR, Swallow E, Li N, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.

**Comparing the cost of treatment with octreotide long-acting release versus lanreotide in patients with metastatic gastrointestinal neuroendocrine tumors.**

*Publication:* American Health and Drug Benefits 2017 11; 10(8): 408-415.

*Authors:* Ayyagari R, Neary M, Li S, Rokito A, Yang H, Xie J, Benson AB.

**Dabrafenib and trametinib combination therapy versus docetaxel in previously treated metastatic NSCLC: An adjusted indirect comparison.**

*Abstract:* 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL Sep 14-16, 2017.

*Authors:* Sasane M, Li J, Zhang P, Zhao J, Ricculi ML, Signorovitch J.

**Healthcare resource utilization associated with venous thromboembolism in cancer patients treated with anticoagulants in a commercial insurance population.**

*Abstract:* Resuscitation Science Symposium, Anaheim, CA Nov 11-15, 2017.

*Authors:* Khorana AA, McCrae K, Milentijevic D, McCormick N, Laliberte F, Crivera C, Lefebvre P, Lejeune D, Rozjabek H, Schein J, Streiff M.

**Patient preferences in advanced soft tissue sarcoma: A discrete choice experiment.**

*Abstract:* The Connective Tissue Oncology Society (CTOS) 2017 Annual Meeting, Maui, HI Nov 8–11, 2017.

*Authors:* Armstrong A, Wei W, Garcia-Horton V, Macaulay D, Schmerold L, Wu E, Shah D, Chao J.

**Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA.**

*Publication:* Medical Oncology 2017 11; 34(12): 193. e-pub ahead of print 2017/11/06; doi: 10.1007/s12032-017-1049-4.

*Authors:* Ivanova JI, Saverno KR, Sung J, Duh MS, Zhao C, Cai S, Vekeman F, Peevyhouse A, Dhawan R, Fuchs CS.

**Assessment of the association between the burden of carcinoid syndrome symptoms and the quality of life among patients with carcinoid syndrome in the united states based on the FACT-G instrument.**

*Abstract:* 10th Annual Meeting of the North American Neuroendocrine Tumor Society, Philadelphia, PA Oct 19-21, 2017.

*Authors:* Huynh L, Totev T, Cai B, Beaumont JL, Halperin DM, Neary MP, Bhak R, Vekeman F, Duh MS, Cella D.

**Budget impact analysis of dabrafenib and trametinib combination therapy in the treatment of BRAF V600E-mutant advanced non-small cell lung cancer in the United States.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Zhou Z, Bensimon A, Cheng J, Dalal A.

**Budget impact analysis of first-line ceritinib in the treatment of ALK+ metastatic non-small cell lung cancer (NSCLC) in the United States.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Mutebi A, Zhou Z, Ricculi ML, Han S, Xie J, Dalal A, Culver K.

**Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea.**

*Publication:* Asia-Pacific Journal of Clinical Oncology 2017 10; 13(5): e239-e245. e-pub ahead of print 2017/04/19; doi: 10.1111/ajco.12645.

*Authors:* Lim SH, Yoh KA, Lee JS, Ahn MJ, Kim YJ, Kim SH, Zhang J, Patel D, Swallow E, Kageleiry A, Galebach P, Lee D, Stein K, Degun R, Park K.

**Cost consequence analysis of different gene mutation testing modalities for BRAFV600E mutation in advanced non-small cell lung cancer using a decision analytic model.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Dalal A, Zhou Z, Tang W, Ricculi ML, Guerin A, Sasane M, Wu K, Culver K, Otterson G, Pennell N.

**Cost-effectiveness of ceritinib in previously untreated alk-positive non-small cell lung cancer in the united states**

*Abstract:* AMCP Nexus 2017, Dallas, TX Oct 16-19, 2017.

*Authors:* Zhou ZY, Mutebi A, Han S, Bensimon A, Ricculi ML, Xie J, Dalal AA, Culver KW.

**Costs associated with disease progression in advanced melanoma-a claims analysis using a novel staging algorithm.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Song J, Goldschmidt D, Driver M, Buchanan J, Murugappan S.

**Overall survival in patients with metastatic urothelial cancer by first-line therapy.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Vander Velde NS, Guerin A, Ionescu-Ittu R, Shi S, Wu E, Lin S, De Ducla S, Wang J, Li S, Derleth C, Leppert JT, Liu S, Shi L.

**Real world treatment patterns in metastatic and/or unresectable gastric cancer patients in Russia.***Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.*Authors:* Tjulandin SA, Sholokhova E, Ivanova JI, Cheng WY, Schmerold LM, Thompson-Leduc P, Novick D.**Systematic literature review for treatment outcomes (including immuno-oncology treatment) among patients with stage 3 unresectable non-small cell lung cancer (NSCLC).***Abstract:* ISPOR 20th Annual European Congress Glasgow, UK Nov 4-8, 2017.*Authors:* Zhou Z, Song J, Ouwens MJ, Huhn M, Jiang H, Zhang Y, Dalevi D.**Using FACT-G and PROMIS-29 to evaluate the association between duration of somatostatin analog use and quality of life in patients with carcinoid syndrome in the United States.***Publication:* Quality of Life Research 2017 10; 26 (1 Supplement 1): 131-132. doi: <http://dx.doi.org/10.1007/s11136-017-1658-6>.*Authors:* Beaumont J, Huynh L, Halperin DM, Cai B, Totev T, Bhak R, Duh MS, Neary MP, Cella D.**Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.***Publication:* Journal of Medical Economics 2017 09; 20(9): 945-951. e-pub ahead of print 2017/06/01; doi: 10.1080/13696998.2017.1337019.*Authors:* Huynh L, Totev T, Vekeman F, Neary MP, Duh MS, Benson AB.**Economic analysis of molecular mutation testing in real world practice using claims data: costs of single gene versus panel tests in patients with lung cancer.***Abstract:* 5th Annual NASP Annual Meeting and Educational Conference, Washington, DC Sept 18-20, 2017.*Authors:* Dalal A, Dea K, Guerin A, Culver K.**Impact of symptomatic skeletal events on health-care resource utilization and quality of life among patients with castration-resistant prostate cancer and bone metastases.***Publication:* Prostate Cancer and Prostatic Diseases 2017 09; 20(3): 276-282. e-pub ahead of print 2017/02/22; doi: 10.1038/pcan.2017.4.*Authors:* McKay R, Haider B, Duh MS, Valderrama A, Nakabayashi M, Fiorillo M, Ristovska L, Wen L, Kantoff P.**What are the treatment patterns and overall survival (OS) in patients with metastatic triple-negative breast cancer (mTNBC) in US clinical practice?***Abstract:* ESMO 2017 Congress, Madrid, Spain Sept 8-12, 2017.*Authors:* Bajaj P, Latremouille-Viau D, Guerin A, Reyes C, Kurian A, Stein A, Cortazar P.**Overall Survival In Patients with Glioblastoma Before and After Bevacizumab Approval.***Abstract:* 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management Montreal, QC, Canada Aug 26-30, 2017.*Authors:* Johnson DR, Omuro AM, Ravelo A, Sommer N, Geuerin A, Ionescu-Iltu R, Shi S, Uhm JH.**Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation.***Publication:* Cancer 2017 08; 123(15): 2875-2880. e-pub ahead of print 2017/04/08; doi: 10.1002/cncr.30558.*Authors:* Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, Kantarjian HM, Cortes JE.**Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.***Publication:* Medical Oncology 2017 08; 34(9): 160. e-pub ahead of print 2017/08/11; doi: 10.1007/s12032-017-1014-2.*Authors:* Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.

**Real-world palbociclib dosing patterns and implications for drug costs in the treatment of HR+/HER2-metastatic breast cancer.**

*Publication:* Expert Opinion on Pharmacotherapy 2017 08; 18(12): 1167-1178. e-pub ahead of print 2017/07/13; doi: 10.1080/14656566.2017.1351947.

*Authors:* Li N, Du EX, Chu L, Peeples M, Xie J, Barghout V, Tang DH.

**Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.**

*Publication:* Clinical Genitourinary Cancer 2017 08; 15(4): e573-e582. e-pub ahead of print 2017/02/01; doi: 10.1016/j.clgc.2016.12.005.

*Authors:* Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ.

**Severe Adverse Events Impact Overall Survival and Costs In Elderly Patients with Advanced NSCLC On Second-Line Therapy.**

*Abstract:* 33rd International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Montreal, QC, Canada Aug 26-30, 2017.

*Authors:* Borghaei H, YimYM, Guerin A, Gandhi M, Pivneva I, S S, Ionescu-Iltu R.

**Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices.**

*Publication:* Leukemia and Lymphoma 2017 08; 58(8): 1968-1972. e-pub ahead of print 2017/01/18; doi: 10.1080/10428194.2016.1272688.

*Authors:* Skarbnik AP, Ma E, Lafeuille MH, Fortier J, Feldman T, Duh MS, van de Velde H, Niculescu L, Bonthapally V, Goy A.

**Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014.**

*Publication:* Journal of the American Academy of Dermatology 2017 07; 77(1): 55-62 e53. doi: 10.1016/j.jaad.2017.02.050.

*Authors:* Migden M, Xie J, Wei J, Tang W, Herrera V, Palmer JB.

**Monitoring for and Characterizing Crizotinib Progression: A Chart Review of ALK-Positive Non-Small Cell Lung Cancer Patients.**

*Publication:* Advances in Therapy 2017 07; 34(7): 1673-1685. e-pub ahead of print 2017/06/05; doi: 10.1007/s12325-017-0551-6.

*Authors:* Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guerin A.

**Real-World Treatment Patterns among Patients with Advanced Gastric Cancer in South Korea.**

*Publication:* Cancer Research and Treatment 2017 07; 49(3): 578-587. e-pub ahead of print 2016/09/14; doi: 10.4143/crt.2016.001.

*Authors:* Carter GC, Kaltenboeck A, Ivanova J, Liepa AM, San Roman A, Koh M, Rajan N, Cheng R, Birnbaum HG, Kim JS, Bang YJ.

**Association between Duration of Somatostatin Analogs (SSAs) Use and Quality of Life in Patients with Carcinoid Syndrome in the United States Based on the FACT-G Instrument.**

*Abstract:* ASCO 2017, Chicago, IL June 2-6, 2017.

*Authors:* Halperin DM, Huynh L, Beaumont J, Cai B, Totev t, Bhak R, Duh MS, Vekeman F, Neary M, Cella D.

**Burden of illness in patients with acute myeloid leukemia aged 65 years ineligible for intensive chemotherapy.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Lafeuille MH, Sundaram M, Lefebvre P, Emond B, Romdhani H, Senbetta M.



**Comparative efficacy with endocrine-based combination versus monotherapy among postmenopausal women with HR+/ HER2- metastatic breast cancer: A network metaanalysis.**

*Abstract:* ASCO Annual Meeting, Chicago, IL June 2-6, 2017.

*Authors:* Tang D, Ayyagari R, Patterson-Lomba O, Zhou Z, Xie J, Niravath PA.

**Comprehensive genomic profiling (CGP) versus conventional molecular diagnostic testing of patients with advanced non-small cell lung cancer (NSCLC): Overall survival (OS) and cost in a U.S. Health plan population.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 2-6, 2017.

*Authors:* Signorovitch J, Zhou Z, Ryan J, Chawla A.

**Cost burden of first-line antineoplastic treatment failure in patients with chronic lymphocytic leukemia.**

*Abstract:* ASCO Annual Meeting, Chicago, IL June 2-6, 2017.

*Authors:* Senbetta M, Lafeuille MH, Lefebvre P, Romdhani H, Emond B, Wang S.

**Estimated cost of anticancer therapy directed by comprehensive genomic profiling (CGP) in a single-center study.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 2-6, 2017.

*Authors:* Signorovitch J, Janku F, Wheler JJ, Miller VA, Ryan J, Zhou Z, Chawla A.

**Healthcare cost of Medicare patients with previously treated chronic lymphocytic leukemia.**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain June 22-25, 2017.

*Authors:* Reyes C, Gauthier G, Schmerold L, Guerin A.

**Impact of FDA approval of lenalidomide maintenance therapy in the firstline treatment of multiple myeloma after autologous stem cell transplant on total healthcare costs.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 2-6, 2017.

*Authors:* Xie J, Parikh K, Chen C, Yang C, Farrukh A, Cockrum P, Agarwal AB, Abouzaid S.

**Multi-country retrospective chart audit study to examine deep molecular response (MR4.5) associated with second-line tyrosine kinase inhibitors in chronic phase - Chronic myelogenous leukemia (CML-CP).**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain June 22-25, 2017.

*Authors:* Cortes J, Huynh L, Brandt P, DerSarkissian M, Zaccardelli G, Dalal D, Hussein J, Duh MS.

**Predictors of clinical outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone acetate or placebo: An exploratory posthoc analysis of COU-AA-302 trial data.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 2-6, 2017.

*Authors:* Pilon D, Behl AS, Kamstra R, Xiao Y, Lafeuille MH, Lefebvre P, Freedland SJ.

**Progression-free survival and overall survival in patients with chronic lymphocytic leukemia - Clinical benefits of achieving a deep response to first-line therapy.**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain June 22-25, 2017.

*Authors:* Samp J, Guerin A, Foster R, Meissner B, Rokito A, Enschede SH, Gauthier G.

**Prostate-specific antigen (PSA) trajectories correlate with overall survival (OS) in men treated with abiraterone acetate plus prednisone (AA+P) or placebo plus prednisone: A post-hoc analysis of COU-AA-301 trial data  
Dominic Pilon.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 2-6, 2017.

*Authors:* Behl AS, Kamstra R, Xiao Y, Lafeuille MH, Lefebvre P, Freedland SJ.

**Realworld adherence and treatment discontinuation with trifluridine/tipiracil (FTD-TPI) compared with regorafenib (REG) for the treatment of metastatic colorectal cancer (mCRC).**

*Abstract:* ASCO Annual Meeting, Chicago, IL June 2-6, 2017.

*Authors:* Patel AK, Duh MS, Barghout VE, Yenikomshian MA, Xiao Y, Wynant W, Tabesh M, Fuchs CS.

**Real-world Characteristics and Outcomes of Patients with Metastatic Castration-resistant Prostate Cancer Receiving Chemotherapy versus Androgen Receptor-targeted Therapy after Failure of First-line Androgen Receptor-targeted Therapy in the Community Setting.**

*Publication:* Clinical Genitourinary Cancer 2017 06. e-pub ahead of print 2017/07/22; doi: 10.1016/j.clgc.2017.06.004.

*Authors:* Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.

**Reduced healthcare resource utilization in patients with chronic lymphocytic leukemia achieving complete remission to first-line therapy.**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain June 22-25, 2017.

*Authors:* Heitner Enschede S, Samp J, Guerin A, Foster R, Meissner B, Rokito A, Gauthier G.

**Relative progression-free survival over time of novel triplet regimens for the treatment of relapsed/refractory multiple myeloma.**

*Abstract:* 22th Congress of the European Hematology Association, Madrid, Spain June 22-25, 2017.

*Authors:* Betts K, Chen C, Zichlin M, Brun A, Signorovitch J, Makenbaeva D.

**Treatment patterns in patients with advanced gastric cancer in Taiwan.**

*Publication:* Asia-Pacific Journal of Clinical Oncology 2017 06; 13(3): 185-194. doi:

<http://dx.doi.org/10.1111/ajco.12497>.

*Authors:* Cuyun Carter G, Kaltenboeck A, Ivanova J, Liepa AM, San Roman A, Koh M, Rajan N, Cheng R, Birnbaum H, Chen JS.

**Tyrosine kinase inhibitor (TKI) therapy discontinuation in patients with CML in chronic phase: A US clinical practice perspective.**

*Abstract:* ASCO Annual Meeting, Chicago, IL June 2-6, 2017.

*Authors:* Ritchie EK, Wolff JE, Latremouille-Viau D, Guerin A, Pivneva I, Briggs O, Joseph GJ, Atallah EL.

**Assessing utility values for treatment-related health states of acute myeloid leukemia in the United States.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Stein EM, Yang M, Gao W, Galebach P, Xiang CQ, Bhattacharyya S, Bonifacio G, Joseph GJ.

**Assessment of costs associated with adverse events in patients with cancer.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Cloutier M, Yim YM, Wong W, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Kim A, Guerin A.

**Assessment of real-world central nervous system events in patients with advanced prostate cancer using abiraterone acetate, bicalutamide, enzalutamide, or chemotherapy.**

*Publication:* American Health and Drug Benefits 2017 05; 10(3): 143-152.

*Authors:* Pilon D, Behl AS, Ellis LA, Robitaille MN, Lefebvre P, Dawson NA.

**Assessment of the association between the burden of carcinoid syndrome symptoms and the quality of life among patients with carcinoid syndrome in the United States based on the FACT-G instrument.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Huynh L, Totev T, Cai B, Beaumont JL, Halperin DM, Neary MP, Bhak R, Vekeman F, Duh MS, Cella D.

**Association between time to progression and subsequent survival in previously treated BRAF V600E-mutant metastatic non-small cell lung cancer.**

*Abstract:* 7th European Lung Cancer Conference, Geneva, Switzerland May 5-8, 2017.

*Authors:* Sasane M, Li J, Zhang J, Zhao J, Ricculi ML, Redhu S, Signorovitch J.

**A meta-analysis and meta-regression of the efficacy of front-line treatment combinations with ponatinib versus 1st- and 2nd-generation tyrosine kinase inhibitors for ph+ acute lymphoblastic leukemia.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Jabbour E, DerSarkissian M, Duh MS, McCormick N, Cheng WY, McGarry L, Souroutzidis A, Huang H, O'Brien S, Ravandi-Kashani F, Kantarjian HM.

**Progression-free survival with endocrine-based therapies following progression on a non-steroidal aromatase inhibitor among postmenopausal women with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A network meta-analysis.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Ayyagari R, Tang D, Patterson-Lomba O, Zhou Z, Xie J, Niravath PA.

**Real-world outcomes among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (ARCC): A retrospective analysis of Medicare data.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Vogelzang NJ, Ghatge SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N.

**Real-world treatment patterns and costs in Medicare beneficiaries newly diagnosed with acute myeloid leukemia.**

*Abstract:* ISPOR 22nd Annual International Meeting, Boston, MA May 20-24, 2017.

*Authors:* Stein EM, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Bonifacio G, Joseph G.

**Real-world treatment patterns and costs in patients with newly diagnosed acute myeloid leukemia.**

*Abstract:* AMCP's 29th Annual Meeting, Denver, CO Mar 27-30, 2017.

*Authors:* Stein EM, Latremouille-Viau D, Guerin A, Shi S, Gagnon-Sanschagrin P, Briggs O, Bonifacio G, Joseph GJ.

**Real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: perspectives from an academic tertiary center and community oncology practices.**

*Publication:* Medical Oncology 2017 05; 34(5): 88. e-pub ahead of print 2017/04/11; doi: 10.1007/s12032-017-0927-0.

*Authors:* Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary M, Bergsland E.

**Role of Cost-Sharing Subsidies on the Initiation of and Adherence to Tyrosine Kinase Inhibitor Therapy by Medicare Beneficiaries With Chronic Myeloid Leukemia.**

*Publication:* Journal of Clinical Oncology 2017 05; 35(15): 1744-1745. e-pub ahead of print 2017/05/20; doi: 10.1200/JCO.2016.72.0011.

*Authors:* Ritchie EK, Guerin A, Wolff J, Joseph G.

**Treatment Patterns and Early Outcomes of ALK-Positive Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.**

*Publication:* Advances in Therapy 2017 05; 34(5): 1145-1156. e-pub ahead of print 2017/04/14; doi: 10.1007/s12325-017-0527-6.

*Authors:* Bendaly E, Dalal AA, Culver K, Galebach P, Bocharova I, Foster R, Sasane M, Macalalad AR, Guerin A.

**Assessment of Evidence-Based Standards in the Treatment of Advanced Prostate Cancer in a Community Practice.**

*Publication:* Urology Practice. 2017 04; 4(3): 218-224. doi: <http://dx.doi.org/10.1016/j.urpr.2016.06.004>.

*Authors:* Pilon D, Ellis LA, Behl AS, Gozalo L, Emond B, Lefebvre P, Calabrese R, Prime H, Gaylis F.

**Budget impact of everolimus for the treatment of progressive, well-differentiated, non-functional neuroendocrine tumors of gastrointestinal or lung origin that are advanced or metastatic.**

*Publication:* Journal of Medical Economics 2017 04; 20(4): 395-404. e-pub ahead of print 2016/12/17; doi: 10.1080/13696998.2016.1273228.

*Authors:* Rose DB, Nellesen D, Neary MP, Cai B.

**Nilotinib versus dasatinib as second-line therapy in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase who are resistant or intolerant to imatinib: a cost-effectiveness analysis based on real-world data.**

*Publication:* Journal of Medical Economics 2017 04; 20(4): 328-336. doi: 10.1080/13696998.2016.1261032.

*Authors:* Li N, Yang X, Fan L, Totev T, Guerin A, Chen L, Bhattacharyya S, Joseph G.

**Patterns of care among patients receiving sequential targeted therapies for advanced renal cell carcinoma: A retrospective chart review in the USA.**

*Publication:* International Journal of Urology 2017 04; 24(4): 272-278. e-pub ahead of print 2017/03/03; doi: 10.1111/iju.13314.

*Authors:* Pal SK, Signorovitch JE, Li N, Zichlin ML, Liu Z, Ghate SR, Perez JR, Vogelzang NJ.

**Utility values associated with advanced or metastatic non-small cell lung cancer: data needs for economic modeling.**

*Publication:* Expert Review of Pharmacoeconomics & Outcomes Research 2017 04; 17(2): 153-164. e-pub ahead of print 2017/03/25; doi: 10.1080/14737167.2017.1311210.

*Authors:* Brown J, Cook K, Adamski K, Lau J, Bargo D, Breen S, Chawla A.

**Association between duration of somatostatin analogs (SSAS) use and quality of life in patients with carcinoid syndrome in the United States based on the FACT-G instrument.**

*Abstract:* 10th Annual Meeting of the North American Neuroendocrine Tumor Society, Philadelphia, PA Oct 19-21, 2017.

*Authors:* Halperin DM, Huynh L, Beaumont JL, Cai B, Totev T, Bhak R, Duh MS, Vekeman F, Neary MP, Cella D.

**Evaluation of the impact of the burden of carcinoid syndrome symptoms on quality of life among treated patients with carcinoid syndrome in the United States based on the PROMIS-29 instrument.**

*Abstract:* 10th Annual Meeting of the North American Neuroendocrine Tumor Society, Philadelphia, PA Oct 19-21, 2017.

*Authors:* Neary MP, Huynh L, Totev T, Cai B, Beaumont JL, Halperin DM, Bhak R, Duh MS, Cella D.

**Oncologist preferences in advanced soft tissue sarcoma: A discrete choice experiment.**

*Abstract:* ASCO Quality Care Symposium, Orlando, FL Mar 3-4, 2017.

*Authors:* Hess LM, Ivanova JI, Horton VG, Graham S, Liu O, Zhu Y, Lorenzo M, Nicol SJ.

**Potential drug-drug interaction events in patients treated with abiraterone acetate plus prednisone or enzalutamide.**

*Abstract:* ASCO Quality Care Symposium, Orlando, FL Mar 3-4, 2017.

*Authors:* Pilon D, Behl AS, Emond B, Xiao Y, Lefebvre P, Kane CJ.

**Real-world economic outcomes during time on treatment among patients who initiated pazopanib or sunitinib as first targeted therapy for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.**

*Abstract:* AMCP's 29th Annual Meeting, Denver, CO Mar 27-30, 2017.

*Authors:* Nicholas J. Vogelzang, Sameer R. Ghate, Nanxin Li, Elyse Swallow, Miranda Peebles, Miriam Zichlin, Mark Meiselbach, Jose Ricardo Perez, Neeraj Agarwal.

**Real-world palbociclib dosing patterns and potential wastage associated with dose modifications among postmenopausal women with HR-positive/HER2-negative metastatic breast cancer (mBC).**

*Abstract:* ASCO Quality Care Symposium Orlando, FL Mar 3-7, 2017.

*Authors:* Li N, Du EX, Chu L, Peebles M, Xie J, Barghout VE, Tang DH.

**Duration of treatment in prostate cancer patients treated with abiraterone acetate or enzalutamide.**

*Publication:* Journal of Managed Care and Specialty Pharmacy 2017 02; 23(2): 225-235. doi: <http://dx.doi.org/10.18553/jmcp.2016.16233>.

*Authors:* Pilon D, Behl AS, Ellis LA, Emond B, Lefebvre P, Dawson NA.

**Health care resource utilization and costs in patients with chronic myeloid leukemia with better adherence to tyrosine kinase inhibitors and increased molecular monitoring frequency.**

*Publication:* Journal of Managed Care and Specialty Pharmacy 2017 02; 23(2): 214-224. doi: <http://dx.doi.org/10.18553/jmcp.2017.23.2.214>.

*Authors:* Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ.

**Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer.**

*Publication:* Journal of Medical Economics 2017 02; 20(2): 121-128. doi: 10.1080/13696998.2016.1229670.

*Authors:* Massoudi M, Balk M, Yang H, Bui CN, Pandya BJ, Guo J, Song Y, Wu EQ, Brown B, Barlev A, Flanders S.

**Real-world economic outcomes among patients (pts) who initiated sunitinib or pazopanib as first targeted therapy (TT) for advanced renal cell carcinoma (aRCC): A retrospective analysis of Medicare data.**

*Abstract:* Genitourinary Cancers Symposium, Orlando, FL Feb 16-18, 2017.

*Authors:* Vogelzang NJ, Pal SK, Ghate S, Li N, Swallow E, Peeples M, Zichlin M, Meiselbach M, Perez JR, Agarwal N.

**Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) chemotherapy (CT) vs alternative androgen receptor-targeted agents (ARTA) after lack of response to first-line (1L) ARTA in US community oncology practices.**

*Abstract:* Genitourinary Cancers Symposium, Orlando, FL Feb 16-18, 2017.

*Authors:* Oh WK, Cheng WY, Miao R, Vekeman F, Gauthier-Loiselle M, Duh MS, Drea E, Szatrowski TP.

**Refill gaps and dose reductions in patients treated with abiraterone acetate plus prednisone (AA+P) or enzalutamide (ENZ).**

*Abstract:* 2017 Genitourinary Cancers Symposium, Orlando, FL Feb 16-18, 2017.

*Authors:* Pilon D, Behl AS, Emond B, Xiao Y, Lefebvre P, Kane CJ.

**Treatment Disruption of First-line Endocrine and Chemotherapy among Post-Menopausal Women with HR+/HER2- Metastatic Breast Cancer (mBC).**

*Abstract:* NCCN Annual Conference General Poster Session, Orlando, FL Mar 23-24, 2017.

*Authors:* Li N, Du EX, Peeples M, Chu L, Xie J, Barghout V, Tang DH.

**The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.**

*Publication:* Journal of Medical Economics 2017 01; 20(1): 54-62. e-pub ahead of print 2016/09/08; doi: 10.1080/13696998.2016.1225577.

*Authors:* Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C.

**Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.**

*Publication:* Journal of Medical Economics 2017 01; 20(1): 63-71. e-pub ahead of print 2016/09/08; doi: 10.1080/13696998.2016.1225578.

*Authors:* Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon PS, Joseph GJ, Chen L.

**Access to Biomarker Testing in Patients with Advanced Non-Small Cell Lung Cancer.**

*Abstract:* 17th World Conference on Lung Cancer, Vienna, Austria Dec 4-7, 2016.

*Authors:* Ganti AK, Hirsch F, Wynes MW, Ravelo A, Ramalingam S, Ionescu-Ittu R, Pivneva I, Borghaei H.

**Ceritinib Dosing Patterns and Outcomes of Patients with ALK+ NSCLC in a Real-World Practice in the United States.**

*Abstract:* Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL Sep 22-24, 2016.

*Authors:* Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, Struebbe G, Guerin A.

**Cost per month of overall survival and progression-free survival: Everolimus compared with cabozantinib, nivolumab, and axitinib for metastatic renal cell carcinoma.**

*Abstract:* 15th International Kidney Cancer Symposium, Miami, FL Nov 4-5, 2016.

*Authors:* Swallow E, Ghate S, Messali A, McDonald E, Duchesneau E, Perez JR.

**Monitoring for and Characteristics of Crizotinib Progression: A Chart Review of ALK+ Non-Small Cell Lung Cancer Patients.**

*Abstract:* 17th World Conference on Lung Cancer, Vienna, Austria Dec 4-7, 2016.

*Authors:* Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, Struebbe G, Guerin A.

**Real-world survival outcomes and prognostic factors among patients receiving first targeted therapy for advanced renal cell carcinoma: A SEER-Medicare database analysis.**

*Abstract:* 15th International Kidney Cancer Symposium, Miami, FL Dec, 2016.

*Authors:* Vogelzang N, Pal S, Ghate S, Li N, Swallow E, Peebles M, Zichlin M, Perez JR, Agarwal N.

**Severe adverse events impact overall survival (OS) and costs in elderly patients with advanced NSCLC on second-line therapy.**

*Abstract:* 17th World Conference on Lung Cancer, Vienna, Austria Dec 4-7, 2016.

*Authors:* Borghaei H, Yim YM, Guerin A, Gandhi M, Pivneva I, Shi S, Ionescu-Iltu R.

**Time on treatment of everolimus versus endocrine monotherapy or chemotherapy for early-line treatment of HR+/HER2- metastatic breast cancer: A retrospective chart review study in the US.**

*Abstract:* SABCS 2016 Annual Meeting, San Antonio, TX Dec 6-10, 2016.

*Authors:* Li N, Ohashi E, Koo V, Xie J, Hao Y, Tang DH.

**Treatment Patterns and Early Outcomes of ALK+ Non-Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study.**

*Abstract:* IASLC 17th World Conference on Lung Cancer, Vienna, Austria Dec 4-7, 2016.

*Authors:* Bendaly E, Dalal A, Culver K, Galebach P, Bocharova I, Foster R, Struebbe G, Guerin A.

**Association between time to progression and subsequent survival in ceritinib-treated patients with advanced ALK-positive non-small-cell lung cancer.**

*Publication:* Current Medical Research and Opinion 2016 11; 32(11): 1911-1918. e-pub ahead of print 2016/08/05; doi: 10.1080/03007995.2016.1220934.

*Authors:* Liu G, Zhang J, Zhou ZY, Li J, Cai X, Signorovitch J.

**An Evaluation of Treatment Patterns and Outcomes in Elderly Patients Newly Diagnosed with Acute Myeloid Leukemia: A Retrospective Analysis of Electronic Medical Records from US Community Oncology Practices.**

*Publication:* Clinical Lymphoma, Myeloma & Leukemia 2016 11; 16(11): 625-636 e623. e-pub ahead of print 2016/10/01; doi: 10.1016/j.clml.2016.08.006.

*Authors:* Ma E, Bonthapally V, Chawla A, Lefebvre P, Swords R, Lafeuille MH, Fortier J, Emond B, Duh MS, Dezube BJ.

**Physician preference and experience with nivolumab and cabozantinib in the treatment of advanced renal cell carcinoma (aRCC) in the United States (US): A physician survey.**

*Abstract:* 15th International Kidney Cancer Symposium, Miami, FL Nov 4-5, 2016.

*Authors:* Ghate S, Li N, Swallow E, Zichlin M, Duchesneau E, Kang B, Perez JR.

**PS01.70: Ceritinib Dosing Patterns and Outcomes of Patients with ALK+ NSCLC in a Real-World Practice in the United States: Topic: Medical Oncology.**

*Publication:* Journal of Thoracic Oncology 2016 11; 11(11s): S314-s315. e-pub ahead of print 2016/12/15; doi: 10.1016/j.jtho.2016.09.105.

*Authors:* Bendaly E, Dalal A, Culver K, Galebach PJ, Bocharova I, Foster R, Struebbe G, Guerin A.

**Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis.**

*Abstract:* IKCS 2016 Annual Meeting, Miami, FL Nov 4-5, 2016.

*Authors:* Nicholas J. Vogelzang, Sumanta K. Pal, Sameer Ghatge, Nanxin Li, Elyse Swallow, Miranda Peeples, Miriam Zichlin, Jose Ricardo Perez, Neeraj Agarwal.

**Clinical outcomes and dosing patterns of 2nd targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.**

*Abstract:* 41st European Society for Medical Oncology Congress, Copenhagen, Denmark Oct 7-11, 2016.

*Authors:* Heng D, Park J, Signorovitch JE, Yang H, Song J, Weiss J, Dezzani L, Powles TB.

**Impact of severe adverse events during second-line therapy on healthcare costs in patients with advanced non-small cell lung cancer (aNSCLC).**

*Abstract:* 41st European Society for Medical Oncology Congress, Copenhagen, Denmark Oct 7-11, 2016.

*Authors:* Yim YM, Gandhi M, Guerin A, Ionescu-Iltu R, Pivneva I, Shi S, Wu E.

**Economic burden of relapsed/refractory chronic lymphocytic leukemia.**

*Abstract:* 16th International Workshop on Chronic Lymphocytic Leukaemia, Sydney, Australia Sept 6-9, 2015.

*Authors:* Guerin A, Ray S, Gauthier G, Hsu LI, Zhdanova M, Heroux J, Wu E.

**Economic evaluation of octreotide LAR versus lanreotide depot in the treatment of metastatic gastrointestinal neuroendocrine tumors.**

*Abstract:* 8th Annual Meeting of the North American NeuroEndocrine Tumor Society, Jackson, WY Sept 30 - Oct 1, 2016.

*Authors:* Ayyagari R, Neary M, Li S, Zhao C, Higuchi K, Xie J, Benson AB.

**Five-year direct costs of acute lymphoblastic leukemia pediatric patients undergoing allogeneic stem cell transplant.**

*Publication:* International Journal of Hematologic Oncology 2016 09; 5(2): 63-75. doi: <http://dx.doi.org/10.2217/ijh-2016-0001>.

*Authors:* Maziarz RT, Guerin A, Gauthier G, Heroux J, Zhdanova M, Wu EQ, Thomas SK, Chen L.

**Real-world treatment patterns in advanced Pancreatic neuroendocrine tumors in the era of targeted therapy: Perspectives from an academic tertiary center and community oncology practices.**

*Abstract:* 8th Annual Meeting of the North American NeuroEndocrine Tumor Society, Jackson, WY Sept 30 - Oct 1, 2016.

*Authors:* Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary MP, Bergsland E.

**Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.**

*Publication:* Lung Cancer 2016 08; 98: 9-14. e-pub ahead of print 2016/07/10; doi: 10.1016/j.lungcan.2016.05.004.

*Authors:* Cadranell J, Park K, Arrieta O, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Swallow E, Galebach P, Kageleiry A, Stein K, Degun R, Zhang J.

**Cost per median overall survival month associated with abiraterone acetate and enzalutamide for treatment of patients with metastatic castration-resistant prostate cancer.**

*Publication:* Journal of Medical Economics 2016 08; 19(8): 777-784. doi: 10.3111/13696998.2016.1173042.

*Authors:* Pilon D, Queener M, Lefebvre P, Ellis LA.

**Epidemiological assessment of real-world treatment patterns in advanced pancreatic neuroendocrine tumors in the era of targeted therapy: Perspectives from an academic tertiary center and community oncology practices.**

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland Aug 25-28, 2016.

*Authors:* Huynh L, Herring M, Duh MS, Vekeman F, Tiew A, Neary MP, Bergsland E.

**Patient characteristics and Overall Survival (OS) in the post-docetaxel Metastatic Castration-Resistant Prostate Cancer (mCRPC) community setting.**

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland Aug 25-28, 2016.

*Authors:* Cheng WY, Miao R, Duh MS, Vekeman F, Sung J, Gauthier-Loiselle M, Fortier J, Dhawan R, Oh WK.

**Access to biomarker testing in patients with advanced nonsmall cell lung cancer.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Borghaei H, Hirsch FR, Wynes M, Ravelo A, Ramalingam SS, Ionescu-Iltu R, Pivneva I, Ganti AK.

**Access to specialist care and treatment in patients with advanced non-small cell lung cancer.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Ganti AK, Borghaei H, Hirsch FR, Wynes M, Ravelo A, Ionescu-Iltu R, Pivneva I, Ramalingam SS.

**Disparities in treatment patterns and outcomes between caucasian and African American patients with multiple myeloma (MM).**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Safiya Abouzaid, Kejal Parikh, Zheng-Yi Zhou, Zhou Zhou, nxi Tang, Jipan Xie, Manali I. Patel.

**Economic burden of hematologic adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US).**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C.

**Efficacy of front-line treatment combinations with ponatinib versus 1st-and 2nd-generation tyrosine kinase inhibitors for Ph+ acute lymphoblastic leukemia: A meta-analysis and meta-regression.**

*Publication:* Haematologica 2016 06; 101: 33.

*Authors:* Jabbour E, DerSarkissian M, McCormick N, Cheng WY, McGarry LJ, Souroutzidis A, Huang H, Duh MS.

**Overall Survival in Patients with Glioblastoma Before and After Bevacizumab Approval.**

*Abstract:* ASCO Annual Meeting, Chicago, Illinois Jun 3-7, 2016.

*Authors:* Johnson DR, Omuro AMP, Ravelo A, Sommer N, Guerin A, Ionescu-Iltu R, Macalalad AR, Shi S, Uhm JH.

**Quality of life by smoking status in patients with metastatic or advanced NSCLC from Phase 2 clinical trial of veliparib with carboplatin and paclitaxel.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Bonnet P, Cloutier M, McKee MD, Loiselle MG, Qian J, Mu F, Qin QQ, Guerin A, Wu EQ, Giranda VL.



**Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2-Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy.**

*Publication:* Advances in Therapy 2016 06; 33(6): 983-997. doi: 10.1007/s12325-016-0328-3.

*Authors:* Hao Y, Li N, Fang AP, Koo V, Peeples M, Kageleiry A, Wu EQ, Guerin A.

**Reduction in hospital visits in patients with chronic myeloid leukemia (CML) with better adherence to tyrosine kinase inhibitors (TKI) and increased molecular monitoring frequency.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Latremouille-Viau D, Guerin A, Gagnon-Sanschagrin P, Dea K, Cohen BG, Joseph GJ.

**Temporal trends in overall survival and disease-specific survival among patients with advanced renal cell carcinoma during the targeted therapy era: A SEER-Medicare analysis.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2016.

*Authors:* Vogelzang NJ, Signorovitch JE, Swallow E, Peeples M, Koo V, Perez JR, Gbate S, Pal SK.

**Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study.**

*Publication:* Expert Opinion on Pharmacotherapy 2016 06; 17(9): 1189-1196. e-pub ahead of print 2016/04/08; doi: 10.1080/14656566.2016.1176148.

*Authors:* Guerin A, Hao Y, Tang D, Peeples M, Fang A, Kageleiry A, Koo V, Li N, Wu EQ.

**Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK-Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls.**

*Abstract:* International Association for the Study of Lung Cancer, Chicago, IL May 29 - Jun 2, 2015.

*Authors:* Tan DS, Araujo A, Zhang J, Signorovitch J, Zhou ZY, Cai X, Liu G.

**Cost-effectiveness of ceritinib in patients previously treated with crizotinib in anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer in Canada.**

*Publication:* Journal of Medical Economics 2016 05; 1-17. doi: 10.1080/13696998.2016.1187151.

*Authors:* Hurry M, Zhou ZY, Zhang J, Zhang C, Liangyi F, Rebeira M, Xie J.

**Delay in initiation of adjuvant trastuzumab therapy leads to decreased overall survival and relapse-free survival in patients with HER2-positive non-metastatic breast cancer.**

*Publication:* Breast Cancer Research and Treatment 2016 05; 157(1): 145-156. e-pub ahead of print 2016/04/25; doi: 10.1007/s10549-016-3790-3.

*Authors:* Gallagher CM, More K, Kamath T, Masaquel A, Guerin A, Ionescu-Iltu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Butts E, Wu EQ, Barnett B.

**The economic burden of brain metastasis among lung cancer patients in the United States.**

*Publication:* Journal of Medical Economics 2016 05; 19(5): 526-536. doi: 10.3111/13696998.2016.1138962.

*Authors:* Guerin A, Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Macalalad AR.

**Economic model to examine the cost benefit associated with resolution or improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotidelar in patients with neuroendocrine tumors based on data from a retrospective chart review study at three large tertiary oncology centers in the United States.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Huynh L, Totev T, Vekeman F, Neary M, Duh MS, Kulke M, Benson A.

**Real-world analysis of medical costs and healthcare resource utilization in elderly women with HR+/HER2-metastatic breast cancer receiving everolimus-based therapy or chemotherapy.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Hao Y, Li N, Fang A, Koo V, Peeples M, Kageleiry A.

**Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.**

*Publication:* Journal of Medical Economics 2016 05; 19(5): 462-468. doi: 10.3111/13696998.2015.1131705.

*Authors:* Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ.

**Real-world treatment patterns of everolimus + exemestane in patients with hormone-receptor-positive, human epidermal growth factor receptor-negative advanced breast cancer by line of therapy: A global chart review.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Costanzo V, Zarba J, Michelotti A, Livi L, Villanueva C, Bordonaro R, Sherstnev V, Kowalyszyn R, Marinsek N, Zhou Z, Macalalad AR, Koo V, Trieschman E, Xie J, Signorovitch J, Petracci F, Korbenfeld E, Ratto B, Higuchi K, Saghatchian M.

**Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.**

*Publication:* Current Medical Research and Opinion 2016 05; 32(5): 817-827. e-pub ahead of print 2016/01/09; doi: 10.1185/03007995.2016.1140030.

*Authors:* Smith BD, Liu J, Latremouille-Viau D, Guerin A, Fernandez D, Chen L.

**Treatment sequences, patient characteristics, and overall survival of patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* Oh WK, Miao R, Duh MS, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Fortier J, Dhawan R.

**142PD: The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer.**

*Publication:* Journal of Thoracic Oncology 2016 04; 11(4): S119-S120. doi: <http://dx.doi.org/10.1016/S1556-0864%2816%2930252-0>.

*Authors:* Zhang J, Song Y, Zhou ZY, Zhang C, Signorovitch J.

**178P: Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC.**

*Publication:* Journal of Thoracic Oncology 2016 04; 11(4): S134-S135. doi: <http://dx.doi.org/10.1016/S1556-0864%2816%2930288-X>.

*Authors:* Tan D, Liu G, Kim DW, Thomas M, Felip E, Signorovitch J, Zhang J, Szczudlo T, Shaw AT.

**Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.**

*Publication:* Current Medical Research and Opinion 2016 04; 32(4): 741-747. doi: 10.1185/03007995.2016.1140028.

*Authors:* Vogelzang NJ, Pal SK, Signorovitch JE, Reichmann WM, Li N, Yang C, Liu Z, Perez JR, Jonasch E.

**Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis.**

*Publication:* Journal of Medical Economics 2016 04; 19(4): 414-423. doi: 10.3111/13696998.2015.1131704.

*Authors:* Li N, Hao Y, Koo V, Fang A, Peeples M, Kageleiry A, Wu EQ, Guerin A.

**Continuation of ceritinib beyond disease progression is associated with prolonged post-progression survival (PPS) in ALK+ NSCLC.**

*Abstract:* 6th European Lung Cancer Conference, Geneva, Switzerland Apr 13-16, 2016.

*Authors:* Daniel Shao-Weng Tan, Geoffrey Liu, Dong-Wan Kim, Michael Thomas, Enriqueta Felip, James Signorovitch, Jie Zhang, Tomek Szczudlo, Alice Shaw, et al.

**Economic Benefits Associated with Resolution or Improvement of Carcinoid Syndrome Symptoms Following Treatment with Above-Standard Dose of Octreotide LAR in Patients with Neuroendocrine Tumors: Data From a Multicenter Chart Review Study.**

*Abstract:* AMCP's 28th Annual Meeting, San Francisco, CA Apr 19-22, 2016.

*Authors:* Huynh L, Totev T, Vekeman F, Neary M, Duh MS, Kulke M, Benson A.

**Effectiveness of Everolimus versus Endocrine Monotherapy or Chemotherapy Among HR+/HER2- mBC Patients with Multiple Metastatic Sites.**

*Publication:* Clinical Therapeutics 2016 04; 38(4): 905-917. e-pub ahead of print 2016/03/08; doi: 10.1016/j.clinthera.2016.02.009.

*Authors:* Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.

**The impacts on work productivity from ceritinib compared with chemotherapy for crizotinib-experienced ALK+ non-small cell lung cancer.**

*Abstract:* 6th European Lung Cancer Conference, Geneva, Switzerland Apr 13-16, 2016.

*Authors:* Jie Zhang, Yan Song, Zheng-Yi Zhou, Chenxue Zhang, James Signorovitch.

**Number needed to treat and associated incremental costs to achieve one additional patient free of event: indirect comparison of enzalutamide and abiraterone + prednisone in chemotherapy-naïve metastatic castration-resistant prostate cancer.**

*Abstract:* AMCP's 28th Annual Meeting, San Francisco, CA Apr 19-22, 2016.

*Authors:* Bui C, Massoudi M, Balk M, Guo J, Song Y, Brown B, Barlev A, Pandya BJ, H. Y.

**Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.**

*Publication:* Clinical Genitourinary Cancer 2016 04; 14(2): 160-167 e163. doi: 10.1016/j.clgc.2015.11.011.

*Authors:* Pal SK, Signorovitch JE, Reichmann WM, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ.

**Real-World Treatment Patterns and Brain Metastases Development in ALK-Positive Non-Small Cell Lung Cancer.**

*Abstract:* AMCP's 28th Annual Meeting, San Francisco, CA Apr 19-22, 2016.

*Authors:* Betts K, Song J, Guo J, Wong W, Ravelo A, M. S.

**Treatment outcomes, health-care resource utilization and costs of bortezomib and dexamethasone, with cyclophosphamide or lenalidomide, in newly diagnosed multiple myeloma.**

*Publication:* Leukemia 2016 04; 30(4): 995-998. e-pub ahead of print 2015/08/15; doi: 10.1038/leu.2015.225.

*Authors:* Kumar SK, Ma E, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille MH, Lefebvre P, Cheng WY, Dea K, Rembert D, Patt D, Niculescu L, Quick M, Rajkumar SV.

**Treatment patterns and healthcare costs in newly diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States: A retrospective claims database analysis.**

*Abstract:* AMCP's 28th Annual Meeting, San Francisco, CA Apr 19-22, 2016.

*Authors:* Latremouille-Viau D, Guerin A, Nitulescu R, Gagnon-Sanschagrin P, Chen L.

**Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus-based therapy or chemotherapy: A US claims study. .**

*Abstract:* NCCN 21st Annual Conference, Hollywood, FL Mar 31 - Apr 2, 2016.

*Authors:* Li N, Hao Y, Tang D, Koo V, Fang A, Peeples M, Kageleiry A.

**Economic burden of common adverse events (AEs) associated with metastatic colorectal cancer (mCRC) treatment in the United States (US).**

*Publication:* Journal of Clinical Oncology 2016 03; 34(7\_suppl): 21-21. e-pub ahead of print 2017/02/06; doi: 10.1200/jco.2016.34.7\_suppl.21.

*Authors:* Latremouille-Viau D, Chang J, Guerin A, Shi S, Wang E, Yu J, Ngai C.

**Factors and treatment patterns associated with everolimus use among post-menopausal women with HR+/HER2- metastatic breast cancer.**

*Abstract:* NCCN 21st Annual Conference, Hollywood, FL Mar 31 - Apr 2, 2016.

*Authors:* Hao Y, Tang D, Li N, Peebles M, Fang A, Kageleiry A, V K.

**Survival in patients with non-metastatic breast cancer treated with adjuvant trastuzumab in clinical practice.**

*Publication:* Springerplus 2016 03; 5: 395. e-pub ahead of print 2016/04/06; doi: 10.1186/s40064-016-2008-9.

*Authors:* Gallagher CM, More K, Masaquel A, Kamath T, Guerin A, Ionescu-Iltu R, Nitulescu R, Gauthier-Loiselle M, Sicignano N, Butts E, Wu EQ, Barnett B.

**Treatment patterns and key factors associated with high treatment costs among commercially insured patients with advanced basal cell carcinoma.**

*Abstract:* 74th Annual Meeting of the American Academy of Dermatology, Washington, DC Mar 4-8, 2016.

*Authors:* Migden M, Wei J, Tang W, Herrera V, Xie J, Palmer J.

**Physician experiences and preferences in the treatment of HR+/HER2- metastatic breast cancer in the United States: a physician survey.**

*Publication:* Cancer Med 2016 02; 5(2): 209-220. doi: 10.1002/cam4.580.

*Authors:* Lin PL, Hao Y, Xie J, Li N, Zhong Y, Zhou Z, Signorovitch JE, Wu EQ.

**Survival and Tumor Response Outcomes in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): A Systematic Literature Review.**

*Abstract:* Multidisciplinary Head and Neck Cancer Symposium, Scottsdale, AZ Feb 18-20, 2016.

*Authors:* Signorovitch J, Li N, Zhang C, Shaw J, Dastani H, Orsini L.

**Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: A retrospective claims study in the US.**

*Publication:* Current Medical Research and Opinion 2016 02; 32(2): 385-394.

*Authors:* Li N, Hao Y, Kageleiry A, Peebles M, Fang A, Koo V, Wu EQ, Guerin A.

**Impact of symptomatic skeletal events on healthcare resource utilization, health-related quality of life and pain among patients with castration-resistant prostate cancer and bone metastases.**

*Abstract:* Genitourinary Cancers Symposium, San Francisco, CA Jan 7-9, 2016.

*Authors:* McKay RR, Haider B, Duh MS, Valdarrama A, Nakabayashi M, Fiorillo M, Ristovska L, Wen LK, Kantoff PW.

**Outcomes of second targeted therapy in metastatic renal carcinoma: A retrospective chart review in the EU.**

*Abstract:* Genitourinary Cancers Symposium, San Francisco, CA Jan 7-9, 2016.

*Authors:* Heng DYC, Park J, Signorovitch JE, Yang H, Song J, Patel D, Lin C, Powles T.

**Assessment of Multiple Myeloma Patient Preferences on Treatment Choices: An International Discrete Choice Study.**

*Abstract:* 57th American Society of Hematology Annual Meeting and Exposition, Orlando, FL Dec 5-8, 2015.

*Authors:* Leleu X, Mateos M-V, Delforge M, Lewis P, Schindler T, Gibson CJ, Yang M, Weisel K.

**A chart review of patient characteristics, treatment patterns and response in metastatic breast cancer patients treated with ado-trastuzumab emtansine in first-line therapy and beyond.**

*Abstract:* San Antonio Breast Cancer Symposium, San Antonio, TX December 8-12, 2015.

*Authors:* Gauthier G, Guerin A, Zhdanava M, Wu E.

**Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites.**

*Abstract:* 2015 San Antonio Breast Cancer Symposium, San Antonio, TX December 8-12, 2015.

*Authors:* Xie J, Hao Y, Li N, Lin P, Ohashi E, Koo V, Wu E.

**Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.**

*Publication:* Experimental Hematology & Oncology 2015 12; 4(31): 31. doi: 10.1186/s40164-015-0023-0.

*Authors:* Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Wu EQ.

**Five-year direct cost of pediatric patients with acute lymphoblastic leukemia (ALL) undergoing allogeneic stem cell transplantation (HSCT): An analysis from US payers' perspective.**

*Abstract:* 57th Annual Meeting of the American Society of Hematology, Orlando, FL Dec 5-8, 2016.

*Authors:* Maziarz RT, Guerin A, Gauthier G, Heroux J, Zhdanava M, Wu EQ, Thomas SK, Chen L.

**The healthcare resource utilization, costs, and predictors of progression among relapsed and refractory CLL patients.**

*Abstract:* 57th Annual Meeting of the American Society of Hematology, Orlando, FL Dec 5-8, 2015.

*Authors:* Guerin A, Ray S, Gauthier G, Hsu L-I, Zhdanava M, Wu E.

**The impact of ponatinib versus allogeneic stem cell transplant (SCT) on outcomes in patients with chronic myeloid leukemia (CML) or philadelphia chromosome-positive acute lymphoblastic leukemia (PH+ ALL) with the T315i mutation.**

*Abstract:* 57th Annual Meeting of the American Society of Hematology, Orlando, FL Dec 3-6, 2015.

*Authors:* Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes TP, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Kageleiry A, Yang M, Huang H, McGarry LJ, Kantarjian HM, Cortes JE.

**Nilotinib vs Dasatinib as Second-Line Therapy in Patients with Philadelphia-Positive Chronic Myeloid Leukemia in Chronic Phase (Ph+ CML-CP) Who Are Resistant or Intolerant to Imatinib: A Cost-Effectiveness Analysis (CEA) based on Real-World Data.**

*Abstract:* 57th Annual Meeting of the American Society of Hematology, Orlando, FL December 5-8, 2015.

*Authors:* Li N, Yang C, Fan L, Totev T, Guerin A, Chen L.

**Real-world effectiveness of everolimus subsequent to different first targeted therapies (TTs) for the treatment of advanced renal cell carcinoma (aRCC): Synthesis of three retrospective chart reviews.**

*Abstract:* 14th International Kidney Cancer Symposium Miami, FL Nov 6-7, 2015.

*Authors:* Pal SK, Signorovitch JE, Li N, Koo V, Liu Z, Perez JR, Vogelzang NJ.

**Real-world effectiveness of Everolimus versus endocrine monotherapy or chemotherapy in HR+/HER2- metastatic breast cancer patients with liver metastasis or multiple metastatic sites.**

*Abstract:* 2015 San Antonio Breast Cancer Symposium, San Antonio, TX December 8-12, 2015.

*Authors:* Li N, Hao Y, Lin P, Koo V, Ohashi E, Wu E, Xie J.

**Time on treatment of everolimus, fulvestrant, and capecitabine for the treatment of HR+/HER2- metastatic breast cancer: A retrospective claims study in the US.**

*Abstract:* 2015 San Antonio Breast Cancer Symposium, San Antonio, TX December 8-12, 2015.

*Authors:* Li N, Hao Y, Kageleiry A, Peeples M, Fang A, Koo V, Guerin A.

**Utilization, Costs, and Predictors of Progression Among Relapsed and Refractory CLL Patients.**

*Abstract:* 57th Annual Meeting of the American Society of Hematology, Orlando, FL Dec 5-8, 2015.

*Authors:* Guerin A, Ray S, Gauthier G, Hsu Ling-I, Zhdanava M, Wu EQ.

**What are the real-world treatment patterns and medical costs in patients with metastatic breast cancer treated with ado-trastuzumab emtansine?**

*Abstract:* 2015 San Antonio Breast Cancer Symposium, San Antonio, TX December 8-12, 2015.

*Authors:* Cloutier M, Guerin A, Heroux J, Emond B, Wu E.

**Adherence and Persistence Among Chronic Myeloid Leukemia Patients During Second-Line Tyrosine Kinase Inhibitor Treatment.**

*Publication:* J Manag Care Spec Pharm 2015 11; 21(11): 1088. doi: 10.18553/jmcp.2015.21.11.1088.

*Authors:* Chen L, Wu EQ.

**Comparative efficacy of treatments for previously treated advanced or metastatic non-small cell lung cancer (NSCLC): a network meta-analysis.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Zhang J, Zhou Z, Cai X, J. S.

**Cost-effectiveness of ceritinib in previously treated patients with crizotinib in anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer in Canada.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Zhou Z, Hurry M, Jhang J, Fan L, Zhang C, J. X.

**Cost-effectiveness of ceritinib in the treatment of previously treated anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer in Canada.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Zhou Z, Jhang J, Fan L, Zhang C, J. X.

**Overall Survival (Os) and Quality-of-Life (QoL) Outcomes in Recurrent Or Metastatic Squamous Cell Carcinoma of the Head And Neck (Scchn): A Systematic Literature Review.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Signorovitch J, Li N, Zhong Y, Shaw J, Dastani H, L. O.

**Overall Survival (Os), Quality of Life (QoL), and Neurocognitive Function (Nf) in Recurrent Glioblastoma Multiforme (Gbm): A Systematic Literature Review.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Signorovitch J, Li N, Ohashi E, Dastani H, Shaw J, L. O.

**Patient relevant outcomes in recurrent glioblastoma: a systematic literature review.**

*Abstract:* Society for Neuro-Oncology Annual Scientific Meeting and Education Day, San Antonio, TX Nov 19-22, 2015.

*Authors:* Signorovitch J, Li N, Kim S, Dastani H, Shaw J, Orsini L.

**Real-world effectiveness, dosing, and drug costs of everolimus (EVE) and axitinib (AXI) as second targeted therapies (TTs) for advanced renal cell carcinoma (aRCC) in the US: A retrospective chart review.**

*Abstract:* 14th International Kidney Cancer Symposium, Miami, FL Nov 6-7, 2015.

*Authors:* Jonasch E, Pal SK, Signorovitch JE, Li N, Liu Z, Perez JR, Vogelzang NJ.

**Economic Benefits Associated with Resolution or Improvement of Carcinoid Syndrome Symptoms Following Treatment with Above-Standard Dose of Octreotide LAR in Patients with Neuroendocrine Tumors: Assessment Based on Data from a Multicenter Retrospective Chart Review Study.**

*Abstract:* 12th Annual Meeting of the International Society of Gastrointestinal Oncology, Arlington, VA Oct 22-23, 2015.

*Authors:* Huynh L, Totev T, Vekeman F, Neary M, Duh MS, Kulke MH, Benson AB.

**Economic evaluation of octreotide LAR versus lanreotide depot in the treatment of metastatic gastrointestinal neuroendocrine tumors (GI-NETs).**

*Abstract:* 2015 NANETS Symposium,, Austin, TX Oct 15-17, 2015.

*Authors:* Ayyagari R, Neary M, Li iS, Zhao C, Higuchi K, Xie J, Benson A B.

**Economic Evaluations of Everolimus versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer from a US Payer Perspective.**

*Publication:* Clinical Breast Cancer 2015 10; 15(5): e263-276. doi: 10.1016/j.clbc.2015.04.001.

*Authors:* Xie J, Hao Y, Zhou ZY, Qi CZ, De G, Gluck S.

**Real-world effectiveness of everolimus-based therapy versus endocrine monotherapy and chemotherapy in patients of HR+/HER2- breast cancer with liver metastasis in the USA.**

*Publication:* Expert Opinion on Pharmacotherapy 2015 10; 16(14): 2101-2111. doi: 10.1517/14656566.2015.1074182.

*Authors:* Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ.

**Real-world treatment patterns in advanced Pancreatic neuroendocrine tumors in the era of targeted therapy: Perspectives from an academic tertiary center and community oncology practices.**

*Abstract:* 8th Annual Meeting of the North American NeuroEndocrine Tumor Society, Austin, TX Oct 14-18, 2015.

*Authors:* Herring M, Huynh L, Duh MS, Vekeman F, Tiew A, Neary MP, Bergsland E.

**Real-World Treatment Patterns of Everolimus for Advanced Breast Cancer: A Multicountry Chart Review Study.**

*Abstract:* AMCP Nexus 2015, Orlando, FL Oct 26-29, 2015.

*Authors:* Hamm C, Zarba J, Xie J, Higuchi K, Macalalad AR, Zhou Z, Schraa S, Signorovitch J, Marinsek N, Villanueva C, Livi L, Lerzo G, Ratto B, Vega N, Sherstnev V, Los M.

**Access to cancer directed therapies and cancer specialists in patients with metastatic lung cancer.**

*Abstract:* 16th World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.

*Authors:* A.K. Ganti, F.R. Hirsch, M. Wynes, A. Ravelo, S.S. Ramalingam, R. Ionescu-Ittu, I. Pivneva, P. Lin, H. Borghaei.

**Characteristics and treatment patterns of ALK+ NSCLC patients who receive second-generation ALK inhibitors: A chart review study.**

*Abstract:* European Cancer Congress 2015, Vienna, Austria Sept 25-29, 2015.

*Authors:* Cadranell J, Park K, Pless M, Bendaly E, Patel D, Sasane M, Swallow E, Galebach P, Stein K, Marinsek N, Zhang J.

**Characteristics of non-small cell lung cancer (NSCLC) patients who underwent curative-intent surgical resections in China.**

*Publication:* Journal of Thoracic Oncology 2015 09; 10(9 SUPPL. 2): S380.

*Authors:* Zhou J, Han S, Yang F, Wu E.Q, Xie J, Wang X, Li H, Wang J.

**Clinical Outcomes with First-line Endocrine Therapy or Chemotherapy in Postmenopausal HR+/HER2- Metastatic Breast Cancer.**

*Publication:* Breast Cancer (Auckl) 2015 09; 9: 67-72. doi: 10.4137/BCBCR.S30771.

*Authors:* Song Y, Hao Y, Macalalad AR, Lin PL, Signorovitch JE, Wu EQ.

**Diverse characteristics of ALK+ NSCLC patients in the United States.**

*Abstract:* 16th World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.

*Authors:* Bendaly E, Sasane M, Zhang J, Swallow E, Macalalad AR, Patel D, Kageleiry A, Galebach P, Kercheval J, Stein K, Guérin A.

**Is there a difference in outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) who receive chemotherapy (CT) vs androgen receptor-targeted therapy (ART) after 1st-line ART in the community setting?**

*Abstract:* European Cancer Congress, Vienna, Austria Sep 25-29, 2015.

*Authors:* Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Fortier J, Dhawan R, Hennessy D, Duh MS.

**Patient outcomes following curative-intent lung resection among non-small cell lung cancer (NSCLC) patients in China.**

*Publication:* Journal of Thoracic Oncology 2015 09; 10(9 SUPPL. 2): S677.

*Authors:* Zhou J, Wu E.Q, Yang F, Xie J, Han S, Wang X, Song H, Wang J.

**Physician decision-making on modifying or discontinuing crizotinib in ALK+ NSCLC: A survey of U.S. physicians.**

*Abstract:* 16th World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.

*Authors:* Guérin A, Sasane M, Zhang J, Swallow E, Macalalad AR, Stein K, Kageleiry A, Galebach P, Kercheval J, Patel D, Bendaly E.

**Physician Underestimation of the Risk of Gastrointestinal Stromal Tumor Recurrence after Resection.**

*Publication:* JAMA Oncol 2015 09; 1(6): 797-805. doi: 10.1001/jamaoncol.2015.2407.

*Authors:* Guerin A, Sasane M, Keir CH, Gauthier G, Macalalad AR, Wu EQ, Conley AP.

**Real-world characteristics and outcomes for ALK+ NSCLC in Korea.**

*Abstract:* 16th World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.

*Authors:* Lim SH, Yoh KA, Lee JS, Ahn M, Kim YJ, Kim SH, Zhang J, Patel D, Swallow E, Kageleiry A, Yi H, Stein K, Degun R, Park K.

**Real-world patterns of access to cancer specialist care among patients with lung cancer in the United States: A claims database analysis.**

*Abstract:* 16th World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.

*Authors:* A.K. Ganti, H. Borghaei, F.R. Hirsch, M. Wynes, A. Ravelo, R. Ionescu-Iltu, I. Pivneva, P. Lin, S. Ramalingam.

**Symptoms of bone and liver metastases in patients with ALK+ Non-Small Cell Lung Cancer (NSCLC).**

*Abstract:* 16th World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.

*Authors:* Guerin A, Sasane M, Nitulescu R, Zhang J, Culver K, Wu EQ, Macalalad A.

**Testing and treatment practice of oncologists managing ALK+ NSCLC: International physician survey across four regions.**

*Abstract:* European Cancer Congress, Vienna, Austria Sep 25-29, 2015.

*Authors:* Arrieta O, Cadranell J, Park K, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Macalalad AR, Kercheval J, Stein K, Weiss J, Zhang J.

**Time to Progression and Post-Progression Survival in ALK+ Ceritinib-Treated NSCLC.**

*Abstract:* 16th World Conference on Lung Cancer, Denver, CO Sep 6-9, 2015.

*Authors:* Geoffrey Liu, J Zhang, Zheng-Yi Zhou, Junlong Li, Xiaopeng Cai, James Signorovitch.



**Treatment patterns and best response in a contemporary cohort of patients with relapsed / refractory chronic lymphocytic leukemia with 17p deletion.**

*Abstract:* Leukemia and Lymphoma Conference, Sydney, NSW Australia Sep 6-9, 2015.

*Authors:* Lamanna N, Hurst D, Latremouille-Viau D, Ionescu-Ittu, Guerin A, Yim YM, Reyes C.

**Treatment patterns and survival among ALK+ non-small cell lung cancer (NSCLC) patients: A chart review study.**

*Abstract:* European Cancer Congress Vienna, Austria Sep 25-29, 2015.

*Authors:* Park K, Cadranell J, Arrieta O, Pless M, Bendaly E, Patel D, Sasane M, Nosal A, Guerin A, Kageleiry A, Stein K, Marinsek N, Zhang J.

**What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses.**

*Abstract:* European Cancer Congress, Vienna, Austria Sep 25-29, 2015.

*Authors:* Vale C, Rydzewska LH, Tierney JF, Albiges L, Clarke NW, Fisher DJ, Fizazi K, James ND, Mason MD, Parmar MK, Sweeney CJ, Sydes MR, Tombal B, Burdett S.

**Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting.**

*Publication:* Current Medical Research and Opinion 2015 08; 31(8): 1561-1572. doi: 10.1185/03007995.2015.1062356.

*Authors:* Toy EL, Vekeman F, Lewis MC, Oglesby AK, Duh MS.

**Everolimus use and associated factors among post-menopausal women with hormonal receptor positive/human epidermal growth factor receptor 2 negative metastatic breast cancer.**

*Publication:* Current Medical Research and Opinion 2015 08; 31(8): 1573-1582. e-pub ahead of print 2015/06/16; doi: 10.1185/03007995.2015.1062358.

*Authors:* Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ.

**Real-world effectiveness of everolimus-based therapy versus fulvestrant monotherapy in HR(+)/HER2(-) metastatic breast cancer.**

*Publication:* Journal of Comparative Effectiveness Research 2015 08; 4(4): 315-326. e-pub ahead of print 2015/08/15; doi: 10.2217/ce.15.25.

*Authors:* Hao Y, Lin PL, Xie J, Li N, Koo V, Ohashi E, Wu EQ, Rogerio J.

**Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.**

*Publication:* Cancer Med 2015 08; 4(8): 1205-1213. doi: 10.1002/cam4.475.

*Authors:* Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Abhyankar S, Reyes C, Guerin A, Yim YM.

**Treatment, overall survival, and costs in patients with ALK-positive non-small-cell lung cancer after crizotinib monotherapy.**

*Publication:* Current Medical Research and Opinion 2015 08; 31(8): 1587-1597. doi: 10.1185/03007995.2015.1057115.

*Authors:* Guerin A, Sasane M, Wakelee H, Zhang J, Culver K, Dea K, Nitulescu R, Galebach P, Macalalad AR.

**ALK rearrangement testing and treatment patterns for patients with ALK-positive non-small cell lung cancer.**

*Publication:* Cancer Epidemiology 2015 06; 39(3): 307-312. doi: 10.1016/j.canep.2015.04.005.

*Authors:* Guerin A, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Culver K, Wu EQ, Wakelee H.

**Comparative effectiveness of everolimus-based therapy versus endocrine monotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review in community oncology practices in the US.**

*Publication:* Current Medical Research and Opinion 2015 06; 31(6): 1095-1103. e-pub ahead of print 2015/05/15; doi: 10.1185/03007995.2015.1021906.

*Authors:* Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ, Yardley DA.

**Median overall survival meta-analysis comparing brentuximab vedotin with other therapies in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant.**

*Abstract:* 13th International Conference on Malignant Lymphoma, Lugano, Switzerland Jun 17-20, 2015.

*Authors:* Bonthapally V, Yang H, Ayyagari R, Tan R, Cai S, Wu E, Gautam A, Chi A, Huebner D.

**Real-world outcomes of patients with relapsed or refractory chronic lymphocytic leukemia with 17p deletion.**

*Abstract:* 20th Congress of the European Hematology Association, Vienna, Austria Jun 11-14, 2015.

*Authors:* Lamanna N, Hurst D, Latremouille-Viau D, Ionescu-Ittu R, Guerin A, Yim YM, Reyes C.

**Treatment Sequences and Pharmacy Costs of 2 New Therapies for Metastatic Castration-Resistant Prostate Cancer.**

*Publication:* Am Health Drug Benefits 2015 06; 8(4): 185-195.

*Authors:* Ellis LA, Lafeuille MH, Gozalo L, Pilon D, Lefebvre P, McKenzie S.

**Assessing the prognostic impact of intermediate outcomes on survival time in relapsed/refractory multiple myeloma (RRMM) patients (pts) via a robust and clinically interpretable quantitative procedure.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - June 2, 2015.

*Authors:* Ayyagari R, Cheng WY, Cai X, Jones C, Ma E, Bonthapally V, Zhu Y, Lefebvre P, Wei LJ, Duh MS.

**Association between duration of treatment (DOT) and healthcare costs in multiple myeloma (MM) patients receiving initial therapy with bortezomib.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29-June 2, 2015.

*Authors:* Xiao Y, Wong BJ, Lefebvre P, Fortier J, Ma E, Bonthapally V, Duh MS.

**Brentuximab vedotin compared with other therapies in relapsed/refractory Hodgkin lymphoma post autologous stem cell transplant: median overall survival meta-analysis.**

*Publication:* Current Medical Research and Opinion 2015 05; 31(7): 1377-1389. doi: 10.1185/03007995.2015.1048208.

*Authors:* Bonthapally V, Yang H, Ayyagari R, Tan RD, Cai S, Wu E, Gautam A, Chi A, Huebner D.

**Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data.**

*Publication:* Current Medical Research and Opinion 2015 05; 31(5): 993-1001. doi: 10.1185/03007995.2015.1030378.

*Authors:* Bonthapally V, Wu E, Macalalad A, Yang H, Shonukan O, Liu Y, Chi A, Huebner D.

**Budgetary impact analysis of abiraterone acetate plus prednisone (AA+P) versus enzalutamide (ENZ) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).**

*Abstract:* AVBCC 5th Annual Conference, Washington, DC May 3-6, 2015.

*Authors:* Ellis L, Pilon D, Lefebvre P.

**Changes in treatment patterns among patients receiving at least two targeted therapies for metastatic renal cell carcinoma (mRCC) in the US: A comparison of retrospective chart reviews conducted in 2012 and 2014.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - Jun 2, 2015.

*Authors:* Perez JR, Pal SK, Signorovitch JE, Reichmann WM, Li N, Liu Z, Jonasch E, Vogelzang NJ.

**Clinical features and overall survival (OS) in patients (pts) with post-docetaxel (DTX) metastatic castration-resistant prostate cancer (mCRPC) receiving second-line (2L) therapy in the community setting.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - Jun 2, 2015.

*Authors:* Oh WK, Miao R, Duh MS, Vekeman F, Sung J, Cheng WY, Hennessy D, Gauthier-Loiselle M, Fortier J, Dhawan R.

**Comparative effectiveness of everolimus and axitinib as second targeted therapy of metastatic renal cell carcinoma in the United States: a retrospective chart review.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - June 2, 2015.

*Authors:* Signorovitch JE, Pal SK, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ, Jonasch E.

**Comparative effectiveness of everolimus versus chemotherapies among post-menopausal women with HR+/HER2-metastatic breast cancer: A retrospective chart review of community oncology practices in the US.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - Jun 2, 2015.

*Authors:* Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.

**Comparative effectiveness of everolimus versus endocrine monotherapies among post-menopausal women with HR+/HER2-metastatic breast cancer: A retrospective chart review of community oncology practices in the US.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - Jun 2, 2015.

*Authors:* Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, Signorovitch JE, Wu EQ.

**Comparative effectiveness of everolimus vs. fulvestrant monotherapy among postmenopausal women with HR+/HER2-metastatic breast cancer.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Lin PL, Hao Y, Xie J, Li N, Ohashi E, Koo V, Wu EQ.

**Comparative efficacy of ceritinib and crizotinib in previously treated crizotinib-naïve anaplastic lymphoma kinase-positive (ALK+) advanced or metastatic non-small cell lung cancer (NSCLC): An adjusted indirect comparison.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - Jun 2, 2015.

*Authors:* Tan DSW, Araujo A, Zhang J, Signorovitch JE, Zhou ZY, Cai X, Liu G.

**Cost-effectiveness of octreotide LAR versus lanreotide depot in the treatment of metastatic gastrointestinal neuroendocrine tumors (GI-NETs).**

*Abstract:* Association of Value-Based Cancer Care, Fifth Annual Conference, Washington, DC, May 3-6, 2015.

*Authors:* Ayyagari R, Neary M, Li S, Zhao C, Higuchi K, Xie J, Benson AB.

**Economic burden of relapsed/refractory chronic lymphocytic leukemia.**

*Abstract:* ASCO Annual Meeting, Chicago, IL May 29-Jun 2, 2015.

*Authors:* Guerin A, Ray S, Gauthier G, Hsu L, Zhdanova M, Heroux J, Wu EQ.

**Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2- Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study.**

*Publication:* International Journal of Breast Cancer 2015 05; 2015: 240750. doi: 10.1155/2015/240750.

*Authors:* Li N, Hao Y, Xie J, Lin PL, Koo V, Ohashi E, Wu EQ.

**The evolving treatment patterns in multiple myeloma (MM): Retrospective database analyses of U.S. community oncology electronic medical records and administrative claims.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29 - Jun 2, 2015.

*Authors:* MS D, Lefebvre P, Fortier J, Ma E, Bonthapally V, Wong BJ.

**Overall survival in post-menopausal women with HR+/HER2-metastatic breast cancer treated with 1st-line endocrine therapy vs. Chemotherapy.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Vekeman F, Hao Y, Cheng WY, Fortier J, Robitaille M, Duh MS.

**Realworld treatment patterns and effectiveness among patients with metastatic colorectal cancer (mCRC) treated with zivafibercept (Z) in community oncology practices in the United States (US).**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29-Jun 2, 2015.

*Authors:* Ivanova JI, Saverno K, Sung J, Sheng Duh M, Zhao C, Cai X, Vekeman F, Peevyhouse A, Dhawan R, Fuchs CS.

**Systematic literature review (SLR) of clinical and realworld observational studies of octreotide LAR for treatment of neuroendocrine tumors (NETs).**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29-Jun 2, 2015.

*Authors:* Sorg R, Neary M, Tang C, Song C, Xie J.

**Treatment patterns and characteristics of post-menopausal women with HR+/HER2-metastatic breast cancer receiving everolimus.**

*Abstract:* 2015 ASCO Annual Meeting, Chicago, IL May 29-Jun 2, 2015.

*Authors:* Vekeman F, Hao Y, Cheng W, Fortier J, Robitaille MN, Duh MS.

**Treatment patterns of endocrine therapy and chemotherapy among post-menopausal women with HR+/HER2-Metastatic Breast Cancer.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Lin PL, Hao Y, Signorovitch JE, Kelley C, Macalalad AR, Ohashi E, Zhou Z, Wu EQ.

**Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden.**

*Publication:* Journal of Medical Economics 2015 04; 18(4): 312-322. doi: 10.3111/13696998.2014.1003644.

*Authors:* Guerin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R, Wu EQ.

**Overall survival with first line endocrine therapy or chemotherapy among postmenopausal women with HR+/HER2- metastatic breast cancer: a retrospective chart review study in the US.**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA Apr 7-10, 2015.

*Authors:* Xie J, Hao Y, Li N, Lin PL, Koo V, Ohashi E, Wu EQ.

**Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.**

*Publication:* Expert Opinion on Pharmacotherapy 2015 04; 16(6): 805-819. doi: 10.1517/14656566.2015.1020298.

*Authors:* Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Wang X, Liu Z, Culver K, Scott JA, George DJ, Vogelzang NJ.

**Real-World Dosing and Drug Costs with Everolimus (EVE) and Axitinib (AXI) as 2nd Targeted Therapies (TTs) for Metastatic Renal Cell Carcinoma (mRCC): A Retrospective Chart Review.**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA Apr 7-10, 2015.

*Authors:* Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Li N, Liu Z, Perez JR, Vogelzang NJ.

**Real-world dosing and drug costs with everolimus (EVE) and axitinib (AXI) as second targeted therapies (TT s) for metastatic renal cell carcinoma (mRCC): A retrospective chart review.**

*Abstract:* 27th Annual Meeting and Expo of the Academy of Managed Care Pharmacy, San Diego, CA Apr 7-10, 2015.

*Authors:* Pal S, Jonasch E, Signorovitch J, Reichmann W, Li N, Liu Z, Perez J, Vogelzang N.

**Treatment sequences and pharmacy costs observed for abiraterone and enzalutamide: considerations for U.S. payors.**

*Abstract:* AMCP's 27th Annual Meeting, San Diego, CA Apr 7-10, 2015.

*Authors:* Ellis L, Lafeuille MH, Gozalo L, Pilon D, Lefebvre P, McKenzie S.

**Current treatment characteristics in postmenopausal women with HR+/HER2- metastatic breast cancer.**

*Abstract:* NCCN 20th Annual Conference, Hollywood, FL Mar 12-14, 2015.

*Authors:* Vekeman F, Hao Y, Cheng WY, Fortier J, Robitaille MN, Duh MS.

**The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.**

*Publication:* Current Medical Research and Opinion 2015 03; 31(3): 537-545. doi: 10.1185/03007995.2015.1008131.

*Authors:* Macalalad AR, McAuliffe M, Yang H, Kageleiry A, Zhong Y, Wu EQ, Shonukan O, Bonthapally V.

**Glioblastoma treatment patterns, survival, and healthcare resource use in real-world clinical practice in the USA.**

*Publication:* Drugs Context 2015 03; 4. doi: 10.7573/dic.212274.

*Authors:* Girvan AC, Carter GC, Li L, Kaltenboeck A, Ivanova J, Koh M, Stevens J, Hayes-Larson E, Lahn MM.

**A retrospective chart review of drug treatment patterns and clinical outcomes among patients with metastatic or recurrent soft tissue sarcoma refractory to one or more prior chemotherapy treatments.**

*Publication:* BMC Cancer 2015 03; 15(175): 175. e-pub ahead of print 2015/04/18; doi: 10.1186/s12885-015-1182-4.

*Authors:* Wagner MJ, Amodu LI, Duh MS, Korves C, Solleza F, Manson SC, Diaz J, Neary MP, Demetri GD.

**Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: A retrospective chart review.**

*Abstract:* 2015 Genitourinary Cancers Symposium, Orlando, FL Feb 26-28, 2015.

*Authors:* Vogelzang NJ, Pal SK, Signorovitch JE, Reichmann WM, Chopra P, Liu Z, Perez JR, Jonasch E.

**The epidemiology of herpes zoster and its complications in Medicare cancer patients.**

*Publication:* BMC Infectious Diseases 2015 02; 15: 106. doi: 10.1186/s12879-015-0810-6.

*Authors:* Yenikomshian MA, Guignard AP, Haguinet F, LaCasce AS, Skarin AT, Trahey A, Karner P, Duh MS.

**Treatment patterns and duration in post-menopausal women with HR+/HER2- metastatic breast cancer in the US: a retrospective chart review in community oncology practices (2004-2010).**

*Publication:* Current Medical Research and Opinion 2015 02; 31(02): 263-273. doi: 10.1185/03007995.2014.980885.

*Authors:* Macalalad AR, Hao Y, Lin PL, Signorovitch JE, Wu EQ, Ohashi E, Zhou Z, Kelley C.

**Treatment patterns of recently approved therapies for metastatic castration resistant prostate cancer (mCRPC): Real world evidence from three datasets.**

*Abstract:* ASCO Genitourinary Cancers Symposium, Orlando, FL Feb 26-28, 2015.

*Authors:* Ellis L, Lafeuille MH, Gozalo L, P L, Malangone-Monaco E, Wilson K, McKenzie S.

**Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies.**

*Publication:* PloS One 2014 12; 9(12): e114264. doi: 10.1371/journal.pone.0114264.

*Authors:* Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Qin P, Zhuo DY, Wang X, Park J, Stergiopoulos S, Kollmannsberger C.

**Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.**

*Publication:* Lung Cancer 2014 12; 86(3): 350-357. doi: 10.1016/j.lungcan.2014.09.017.

*Authors:* Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S.

**Comparison of Survival, Healthcare Resource Use and Costs of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as a Second-Line Therapy.**

*Abstract:* American Society of Hematology, San Francisco, CA Dec 6-9, 2014.

*Authors:* Smith D, Liu J, Latremouille-Viau D, Zhou Z, Guerin A, Fernandex D, Yi D, Wang X, Wu EQ, Mhatre SK, Keir C, Chen L.

**Comparison of Treatment Patterns of Elderly Patients with Chronic Myeloid Leukemia Receiving Dasatinib or Nilotinib as a Second-Line Therapy. .**

*Abstract:* American Society of Hematology, San Francisco, CA Dec 6-9, 2014.

*Authors:* Smith D, Liu J, Latremouille-Viau D, Zhou Z, Guerin A, Fernandex D, Yi D, Wang X, Wu EQ, Mhatre SK, Keir C, Chen L.

**Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.**

*Publication:* Journal of Medical Economics 2014 12; 17(12): 837-845. doi: 10.3111/13696998.2014.959589.

*Authors:* Campone M, Yang H, Faust E, Kageleiry A, Signorovitch JE, Zhang J, Gao H.

**Delay in Trastuzumab Initiation Leads to Decreased Overall Survival in Patients with HER2+ Early Stage Breast Cancer.**

*Abstract:* 2014 San Antonio Breast Cancer Symposium, San Antonio, TX Dec 9-13, 2014.

*Authors:* Gallagher CM, More KF, Sicignano N, Masaquel A, Barnett B, Kamath T, Guérin A, Ionescu-Iltu R, Gauthier-Louiselle M, Nitulescu R, Wu EQ.

**Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population.**

*Publication:* Melanoma Research 2014 12; 24(6): 602-610. doi: 10.1097/CMR.0000000000000097.

*Authors:* Vekeman F, Cloutier M, Yermakov S, Amonkar MM, Arondekar B, Duh MS.

**The economic burden of gastrointestinal stromal tumor (GIST) recurrence in patients who have received adjuvant imatinib therapy.**

*Publication:* Journal of Medical Economics 2014 12; 1-8. doi: 10.3111/13696998.2014.991787.

*Authors:* Guerin A, Sasane M, Gauthier G, Keir CH, Zhdavana M, Wu EQ.

**Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries.**

*Publication:* Cancer Med 2014 12; 3(6): 1517-1526. doi: 10.1002/cam4.302.

*Authors:* Porta C, Levy A, Hawkins R, Castellano D, Bellmunt J, Nathan P, McDermott R, Wagstaff J, Donnellan P, McCaffrey J, Vekeman F, Neary MP, Diaz J, Mehmud F, Duh MS.

**Impact of visceral metastases on treatment patterns for hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC).**

*Abstract:* 2014 SAN ANTONIO BREAST CANCER SYMPOSIUM, San Antonio, TX Dec 9-13, 2014.

*Authors:* Signorovitch J, Wang J, Tan R, Thomason D, Kageleiry A, Swallow E.

**Real-world treatment durations without chemotherapy (CT) for hormone-receptorpositive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) metastatic breast cancer (mBC).**

*Abstract:* 2014 SAN ANTONIO BREAST CANCER SYMPOSIUM, San Antonio, TX Dec 9-13, 2014.

*Authors:* Swallow E, Wang J, Thomason D, Tan R, Kageleiry A, Signorovitch J.

**A retrospective analysis of treatment patterns in elderly patients with chronic myeloid leukemia receiving dasatinib or nilotinib as second-line therapy after imatinib.**

*Abstract:* 56th Annual Meeting of the American Society of Hematology, San Francisco, CA Dec 6-9, 2014.

*Authors:* Smith BD, Liu J, Latremouille-Viau D, Zhou Z, Guerin A, Fernandez D, Yi D, Wang X, Wu EQ, Mhatre SK, Keir CH, Chen L.

**Treatment patterns, prescribing decision drivers, and predictors of complete response following disease recurrence in gastrointestinal stromal tumor patients-a chart extract-based approach.**

*Publication:* Journal of Gastrointestinal Cancer 2014 12; 45(4): 431-440. doi: 10.1007/s12029-014-9600-4.

*Authors:* Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

**Twelve-month cost per responder (CPR) analysis of nilotinib and dasatinib as front-line therapy in patients with philadelphia chromosome-positive (PH+) chronic myeloid leukemia in chronic phase (CML-CP).**

*Abstract:* 56th Annual Meeting of the American Society of Hematology, San Francisco, CA Dec 6-9, 2014.

*Authors:* Guerin A, Revol C, Ramanakumar AV, Foster R, Wu EQ, Mhatre SK, Chen L.

**Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: synthesis of findings from two multi-practice chart reviews in the United States.**

*Publication:* Current Medical Research and Opinion 2014 11; 30(11): 2343-2353. doi: 10.1185/03007995.2014.949645.

*Authors:* Signorovitch JE, Vogelzang NJ, Pal SK, Lin PL, George DJ, Wong MK, Liu Z, Wang X, Culver K, Scott JA, Jonasch E.

**Impact of low-grade adverse events on health-related quality of life in adult patients receiving imatinib or nilotinib for newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase.**

*Publication:* Current Medical Research and Opinion 2014 11; 30(11): 2317-2328. doi: 10.1185/03007995.2014.944973.

*Authors:* Guerin A, Chen L, Ionescu-Ittu R, Marynchenko M, Nitulescu R, Hiscock R, Keir C, Wu EQ.

**One-year and long-term molecular response to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison.**

*Publication:* Current Medical Research and Opinion 2014 11: 1-8. doi: 10.1185/03007995.2014.977992.

*Authors:* Signorovitch JE, Betts KA, Reichmann WM, Thomason D, Galebach P, Wu EQ, Chen L, DeAngelo DJ.

**Overall survival in patients with HER2+ early stage breast cancer patients treated with trastuzumab in the US department of defense practice setting.**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.

*Authors:* Gallagher CM, More K, Masaquel AS, Kamath T, Guerin A, Ionescu-Ittu R, Gauthier-Loiselle M, Nitulescu R, Sicignano N, Barnett B, Wu EQ.

**Symptomatic and economic burden of brain metastases in patients with ALK+ NSCLC.**

*Abstract:* 19th Annual Scientific Meeting of the Society for Neuro-Oncology Conference, Miami, FL Nov 13-16, 2014.

*Authors:* Macalalad A, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, Wu E, Guerin A.

**Above standard dose of octreotide-lar in patients with neuroendocrine tumors (NET) for control of carcinoid syndrome symptoms: A multi-center retrospective chart review study.**

*Abstract:* 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Taipei, Taiwan (Republic of China) Oct 24-27, 2014.

*Authors:* Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH.

**Cost Effectiveness of Everolimus plus Exemestane for the Treatment of Advanced HR+, HER2- Breast Cancer in the United States. .**

*Abstract:* AMCP Nexus 2014, Boston, MA Oct 7-10, 2014.

*Authors:* Xie J, Hao Y, Zhou J, Qi C, De G, S G.

**Cost of treatment failure in patients with chronic lymphocytic leukemia: results of a large U.S. observational study.**

*Abstract:* AMCP Nexus 2014, Boston, MA Oct 7-10, 2014.

*Authors:* Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.

**Description of ALK+ NSCLC patient characteristics and ALK testing patterns.**

*Abstract:* 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology Chicago, IL Oct 30 - Nov 1, 2014.

*Authors:* Wakelee HA, Sasane M, Zhang J, Macalalad AR, Galebach P, Jarvis J, Kageleiry A, Huang Q, Culver K, Wu EQ, Guerin A.

**Economic burden and treatments of progression to metastatic disease in ALK+ NSCLC patients.**

*Abstract:* 2014 Chicago Multidisciplinary Symposium in Thoracic Oncology, Chicago, IL Oct 30 - Nov 01, 2014.

*Authors:* Guerin A, Sasane M, Zhang J, Culver K, Macalalad A, Nitulescu R, Wu E, Dea K.

**Economic burden of brain metastases among lung cancer patients.**

*Abstract:* AMCP Nexus 2014, Boston, MA Oct 7-10, 2014.

*Authors:* Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, Wu EQ, Guérin A.

**Meta-analysis of the efficacy and safety of bortezomib re-treatment in patients with multiple myeloma.**

*Publication:* Clinical Lymphoma, Myeloma & Leukemia 2014 10; 14(5): 380-388. doi: 10.1016/j.clml.2014.03.005.

*Authors:* Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-Mancini A, Ma E, Shi H, Comenzo RL.

**Treatment patterns in metastatic renal cell carcinoma in the US: A retrospective chart review.**

*Abstract:* 13th International Kidney Cancer Symposium, Chicago, IL Oct 24-25, 2014.

*Authors:* Pal SK, Jonasch E, Signorovitch JE, Reichmann WM, Liu Z, Perez JR, Vogelzang NJ.

**Treatment patterns in metastatic renal cell carcinoma: a retrospective review of medical records from US community oncology practices.**

*Publication:* Current Medical Research and Opinion 2014 10; 30(10): 2041-2050. doi: 10.1185/03007995.2014.938730.

*Authors:* Jonasch E, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Vogelzang NJ.

**Association between Risk of Recurrence Assessment and Adjuvant Treatment (Tx) Duration in Patients (Pts) with Resected Gastrointestinal Stromal Tumors.**

*Abstract:* ESMO 2014 Congress, Madrid, Spain Sep 26-30, 2014.

*Authors:* Guérin A, Sasane M, Keir C, Gauthier G, Macalalad A, Wu EQ, Conley AP.

**Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.**

*Publication:* Oncologist 2014 09; 19(9): 930-936. doi: 10.1634/theoncologist.2014-0120.

*Authors:* Strosberg JR, Benson AB, Huynh L, Duh MS, Goldman J, Sahai V, Rademaker AW, Kulke MH.

**Cost of treatment failure in patients with mantle cell lymphoma: results of a large U.S. observational study.**

*Abstract:* SOHO Annual Meeting, Houston, TX Sep 17-20, 2014.

*Authors:* Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.

**Investigation of adverse-event-related costs for patients with metastatic breast cancer in a real-world setting.**

*Publication:* Oncologist 2014 09; 19(9): 901-908. doi: 10.1634/theoncologist.2014-0059.

*Authors:* Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Latremouille Viau D, Wu EQ, Lalla D.

**Predictors of treatment (tx) response and progression in BRAF V600E metastatic melanoma (mM) patients (pts) with brain metastases (BM) receiving vemurafenib (vem) in a real-world setting.**

*Abstract:* 2014 European Society for Medical Oncology Congress, Sep 26-30, 2014 Sep 26-30, 2014.

*Authors:* Gibney GT, Gauthier G, Ayas C, Galebach P, Wu EQ, Yeun MY, Sarang A, Reyes C, Guerin A.



**Treatment failure patterns in patients with mantle cell lymphoma: results of a large U.S. observational study.**

*Abstract:* ESMO Congress, Madrid, Spain Sep 26-30, 2014.

*Authors:* Senbetta M, Robitaille M, McKenzie RS, Lefebvre P.

**Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012.**

*Publication:* Current Medical Research and Opinion 2014 08; 30(8): 1537-1545. doi: 10.1185/03007995.2014.908829.

*Authors:* Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J.

**Association between regular molecular monitoring and tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.**

*Publication:* Current Medical Research and Opinion 2014 07; 30(7): 1345-1352. doi: 10.1185/03007995.2014.904281.

*Authors:* Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL.

**Risk of developing colorectal cancer and benign colorectal neoplasm in patients with chronic constipation.**

*Publication:* Alimentary Pharmacology and Therapeutics 2014 07; 40(1): 83-92. doi: 10.1111/apt.12789.

*Authors:* Guerin A, Mody R, Fok B, Lasch KL, Zhou Z, Wu EQ, Zhou W, Talley NJ.

**Impact of timely switching from imatinib to a second-generation tyrosine kinase inhibitor after 12-month complete cytogenetic response failure: a chart review analysis.**

*Publication:* Clinical Lymphoma, Myeloma & Leukemia 2014 06; 14(3): 245-251. doi: 10.1016/j.clml.2013.12.002.

*Authors:* DeAngelo DJ, Chen L, Guerin A, Styles A, Giguere-Duval P, Wu EQ.

**Incidence of hepatic resection among colorectal cancer patients with liver metastases.**

*Abstract:* 16th World Congress on Gastrointestinal Cancer, Barcelona, Spain Jun 25-28, 2014.

*Authors:* Betts K, Lu M, Zhuo D, Sharma H, Morlock R, Sommer N, Ogale S.

**Real-world treatment patterns among patients with advanced gastric cancer in Taiwan.**

*Abstract:* 16th World Congress on Gastrointestinal Cancer, Barcelona, Spain Jun 25-28, 2014.

*Authors:* Gebra CC, Anna K, Jasmina I, Astra L, Alexandra SR, Maria K, Helen LHJ, Howard B, Narayan R, Shaila B, Rebecca C, Jen-Shi C.

**Treatments and clinical burden among hodgkin lymphoma patients at high risk of relapse after autologous stem cell transplant: A literature review.**

*Abstract:* 19th Congress of the European Hematology Association, Milan, Italy Jun 12-15, 2014.

*Authors:* Bonthapally V, Ayyagari R, Yang H, Wu EQ, Shonukan O.

**Adherence patterns for abiraterone acetate and concomitant prednisone use in patients with prostate cancer.**

*Publication:* J Manag Care Spec Pharm 2014 05; 20(5): 477-484. doi: 10.18553/jmcp.2014.20.5.477.

*Authors:* Lafeuille MH, Grittner AM, Lefebvre P, Ellis L, McKenzie RS, Slaton T, Kozma C.

**Characteristics, treatment, and outcomes of patients with de novo HR+/HER2- advanced breast cancer: A retrospective chart review of community-based oncology practices.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Lin PL, Macalalad AR, Hao Y, Signorovitch JE, Wu EQ, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA.

**Comparable outcomes and lower total healthcare cost with bortezomib-cyclophosphamidedexamethasone (VCd) compared to bortezomiblenalidomide-dexamethasone (VRd) for initial treatment of newly diagnosed multiple myeloma (MM).**

*Abstract:* AVBCC 3rd Annual Conference, Hollywood, FL May 6-9, 2014.

*Authors:* Kumar SK, Engebretson AE, Buadi FK, Lacy MQ, Dispenzieri A, Duh MS, Lafeuille M, Lefebvre P, Cheng W, Dea K, Yap M, Saravanan S, Rembert D, Patt D, Niculescu L, Ma E, Quick M, Rajkumar SV.

**Comparison of treatment patterns and economic outcomes in metastatic breast cancer patients initiated on trastuzumab versus lapatinib: a retrospective analysis.**

*Publication:* Springerplus 2014 05; 3: 236. doi: 10.1186/2193-1801-3-236.

*Authors:* Guerin A, Lalla D, Gauthier G, Styles A, Wu EQ, Masaquel A, Brammer MG.

**Description of ALK+ NSCLC patient characteristics and ALK testing patterns.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30 - Jun 3, 2014.

*Authors:* Wakelee HA, Sasane M, Zhang J, Macalalad AR, Galebach PJ, Jarvis J, Kageleiry AJ, Huang Q, Culver KW, Wu EQ, Guerin A.

**Impact of underestimation of risk on treatment duration and recurrence in GIST patients.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30 - Jun 2014.

*Authors:* Guerin A, Conley AP, Sasane M, Macalalad AR, Huang Q, Schwiep FA, Keir CH, Wu EQ.

**One-year and longer-term molecular responses to nilotinib and dasatinib for newly diagnosed chronic myeloid leukemia: A matching-adjusted indirect comparison.**

*Abstract:* ASCO 50th Annual Meeting, Chicago, IL May 30 - June 3, 2014.

*Authors:* Chen L, Signorovitch JE, Wu EQ, Betts KA, Reichmann WM, Thomason D, Galebach PJ.

**Patient characteristics, treatment, and outcomes in recurrent HR+/HER2- advanced breast cancer after adjuvant therapy: A retrospective chart review of community-based practice.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Hao Y, Lin PL, Macalalad AR, Signorovitch JE, Wu EQ, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA.

**Physician treatment preferences for HR+/HER2- advanced breast cancer patients: A survey of community oncology practices in the United States.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Wu EQ, Hao Y, Signorovitch JE, Lin PL, Macalalad AR, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA.

**Prescribing and monitoring patterns for HR+/HER2- advanced breast cancer: A survey of community-based oncologists.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Lin PL, Hao Y, Signorovitch JE, Macalalad AR, Wu EQ, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA.

**Relapse impact on overall survival in trastuzumab-treated women with HER2+ early-stage breast cancer.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Gallagher CM, More K, Masaquel A, Kamath T, Guerin A, Ionescu-Iltu R, Gauthier-Loiselle M, Nitulescu R, Wu EQ, Sicignano N, Butts E, Barnett B.

**Retrospective analysis of treatment patterns and outcomes with subcutaneous (SQ) bortezomib (BTZ) in patients (pts) with relapsed mantle cell lymphoma (MCL).**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Bonthapally V, Lafeuille MH, Fortier J, Duh MS, Ng Y, Van De Velde H, Niculescu L, Ma E, Goy A.

**Symptomatic and economic burden of brain metastases in patients with ALK+ NSCLC.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30 - June 3, 2014.

*Authors:* Guerin A, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, Wu EQ, Macalalad AR.

**Treatment and survival patterns among ALK+ NSCLC patients following crizotinib discontinuation.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Guerin A, Wakelee H, Sasane M, Zhang J, Galebach P, Jarvis J, Kageleiry A, Huang Q, Culver K, Wu EQ, Macalalad AR.

**Treatment patterns and outcomes in BRAF V600E mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Gibney GT, Marynchenko M, Galebach PJ, Ayas C, Liu NS, Wu EQ, Yim YM, Abhyankar SS, Reyes CM, Guerin A.

**Treatment sequencing and duration among HR+/HER2- advanced breast cancer patients in community-based oncology practices.**

*Abstract:* 2014 ASCO Annual Meeting, Chicago, IL May 30-Jun 3, 2014.

*Authors:* Hao Y, Signorovitch JE, Macalalad AR, Wu EQ, Lin PL, Zhou Z, Song J, Ohashi E, Kelley C, Massarweh SA.

**Brain Metastases in Patients with ALK+ Non-Small Cell Lung Cancer: Treatment Patterns and Economic Burden.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Macalalad AR, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, Guérin A.

**Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.**

*Publication:* Current Medical Research and Opinion 2014 04; 30(4): 537-545. doi: 10.1185/03007995.2013.871243.

*Authors:* Wong MK, Yang H, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi CZ, George DJ.

**Comparative overall survival with treatment sequences for metastatic renal cell carcinoma: A systematic review and meta-analysis of real-world observational studies.**

*Abstract:* 29th Annual Congress of the European Association of Urology, Stockholm, Sweden Apr 11-15, 2015.

*Authors:* Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Wang X, Moonis M, Cattaneo A, Stergiopoulos S, Kollmannsberger C.

**Duration of treatment by line of therapy among post-menopausal women with HR+/HER2- metastatic breast cancer.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Macalalad AR, Hao Y, Signorovitch JE, Kelley C, Lin PL, Ohashi E, Zhou Z, Wu EQ.

**Economic burden of bone and liver metastases in patients with ALK+ non-small cell lung cancer.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Guerin A, Sasane M, Nitulescu R, Zhang J, Culver K, Wu EQ.

**Monitoring of multifunctional nanocomplex containing gold coated iron oxide particles in human prostate tumoral cells through MRI.**

*Abstract:* 2014 World Molecular Imaging Congress, Seoul, South Korea Sep 17-20, 2014.

*Authors:* Oghabian MA, Montazerabadi A, Delavari HH, Irajirad R, Muhammadnejad S.

**Overall survival following initiation of first-line treatment with a non-steroidal aromatase inhibitor or fulvestrant among post-menopausal women with recurrent HR+/HER2- metastatic breast cancer.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Song Y, Hao Y, Macalalad A, Lin PL, Signorovitch JE, Wu EQ.

**Robust feature selection and gene committee predictor for breast cancer patient survival prediction.**

*Abstract:* 105th Annual Meeting of the American Association for Cancer Research, San Diego, CA Apr 5-9, 2014.

*Authors:* Yang HH, Lee MP.

**Symptoms of bone and liver metastases in patients with anaplastic lymphoma kinase positive (ALK+) non-small cell lung cancer (NSCLC).**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Guerin A, Sasane M, Nitulescu R, Zhang J, Culver KW, Macalalad AR, Wu EQ.

**Treatment and Costs Post Crizotinib Monotherapy in Patients with ALK+ Non-Small Cell Lung Cancer: A Retrospective Claims Database Analysis. .**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Guérin A, Sasane M, Zhang J, Culver K, Dea K, Nitulescu R, Macalalad AR.

**Treatment patterns and predictors of everolimus use among post-menopausal women with HR+/HER2-metastatic breast cancer in the US.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Li N, Hao Y, Xie J, Lin PL, Zhou Z, Zhong Y, Signorovitch JE, Wu EQ.

**Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: a network meta-analysis.**

*Publication:* Cancer Treatment Reviews 2014 03; 40(2): 285-292. doi: 10.1016/j.ctrv.2013.09.004.

*Authors:* Signorovitch J, Ayyagari R, Reichmann WM, Wu EQ, Chen L.

**Underestimation of the Risk of Recurrence in Patients with Primary Resected Gastrointestinal Stromal Tumors.**

*Abstract:* NCCN 19th Annual Conference, Hollywood, FL Mar 13-15, 2014.

*Authors:* Conley AP, Sasane M, Guérin A, Macalalad AR, Huang Q, Schwiep F, Wu E.

**Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia.**

*Publication:* Journal of Medical Economics 2014 02; 17(2): 89-98. doi: 10.3111/13696998.2013.862251.

*Authors:* Guerin A, Chen L, Dea K, Wu EQ, Goldberg SL.

**Assessment and management of the risk of recurrence of resected gastrointestinal stromal tumors.**

*Abstract:* 2014 Gastrointestinal Cancers Symposium, San Francisco, CA Jan 16-18, 2014.

*Authors:* Conley AP, Sasane M, Pelletier CL, Guerin A, Macalalad AR, Huang Q, Wu EQ.

**Prostate cancer patients demonstrate adherence to medication use while on abiraterone acetate (AA) therapy.**

*Abstract:* ASCO- Genitourinary Cancers Symposium, San Francisco, CA Jan 30-Feb 1, 2014.

*Authors:* Kozma C, Slaton TS, Ellis LA, McKenzie RS, Lafeuille M, Grittner AM, Lefebvre P.

**Real-world corticosteroid utilization in prostate cancer patients treated with two new oral agents.**

*Abstract:* ASCO- Genitourinary Cancers Symposium, San Francisco, CA Jan 30-Feb 1, 2014.

*Authors:* Lafeuille M, Ellis LA, McKenzie RS, Grittner AM, Lefebvre P.

**Real-world treatment patterns among patients with advanced gastric cancer in South Korea.**

*Abstract:* 2014 Gastrointestinal Cancers Symposium, San Francisco, CA Jan 16-18, 2014.

*Authors:* Carter GC, Kaltenboeck A, Ivanova J, Liepa AM, Roman AS, Koh M, Lee HJ, Rajan N, Ballal S, Birnbaum H, Bang YJ.

**Cost of treatment failure in patients with chronic lymphocytic leukemia: Results of a large U.S. observational study.**

*Publication:* Journal of Clinical Oncology 2014 32(30\_suppl): 22-22. doi: 10.1200/jco.2014.32.30\_suppl.22.

*Authors:* Senbetta M, Robitaille M-N, McKenzie RS, Lefebvre P.

**Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States (Re.).**

*Publication:* Journal of Medical Economics 2013 12; 16(2): 260-262. doi: 10.3111/13696998.2012.752738.

*Authors:* Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

**Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population.**

*Publication:* Sarcoma 2013 12; 2013: 947413. doi: 10.1155/2013/947413.

*Authors:* Duh MS, Hackshaw MD, Ivanova JI, Kruse G, Miller LA, Lefebvre P, Karner P, Wong B.

**Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison.**

*Publication:* Experimental Hematology & Oncology 2013 12; 2(1): 32. doi: 10.1186/2162-3619-2-32.

*Authors:* Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, Devine B, Metrakos P.

**Impact of low-grade adverse events (AES) on health-related quality of life (HRQOL) in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase (PH+ CML-CP) from the enestnd trial: 48-month follow-up.**

*Abstract:* 55th Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 7-10, 2013.

*Authors:* Chen L, Guerin A, Marynchenko M, Ionescu-Iltu R, Hiscock R, Nitulescu R, Pooja C, Hsu LI, Keir C, Wu EQ.

**Multi-center experience with CELLSEARCH circulating tumor cell kit on patients with metastatic breast cancer.**

*Abstract:* 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX Dec 10-14, 2013.

*Authors:* Montero AJ, Eapen S, Tran KN, Gorin B, Adler P.

**Budget impact analysis of everolimus for the treatment of hormone receptor positive, human epidermal growth factor receptor-2 negative (HER2-) advanced breast cancer in the United States.**

*Publication:* Journal of Medical Economics 2013 11; 16(2): 278-288. doi: 10.3111/13696998.2012.749788.

*Authors:* Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M.

**Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin, Ireland Nov 2-6, 2013.

*Authors:* Campone M, Yang H, Faust E, Kageleiry A, Signorovitch J, Zhang J, Gao H.

**Economic burden of dermatologic adverse drug reactions in the treatment of colorectal, non-small cell lung, and head and neck cancers with epidermal growth factor receptor inhibitors.**

*Publication:* Journal of Medical Economics 2013 11; 16(2): 221-230. doi: 10.3111/13696998.2012.749789.

*Authors:* Ray S, Bonthapally V, Holen KD, Gauthier G, Wu EQ, Cloutier M, Guerin A.

**Efficacy of brentuximab vedotin and other treatments in patients with relapsed or refractory (RR) systemic anaplastic large-cell lymphoma (SALCL): A systematic review.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin, Ireland Nov 2-6, 2013.

*Authors:* Bonthapally V, Yang H, Macalalad AR, Wu EQ, Lutes R, Shonukan O, Chi A, Huebner D.

**Glioblastoma treatment patterns and outcomes and resource use in the united states.**

*Abstract:* 4th Quadrennial Meeting of the World Federation of Neuro-Oncology held in Conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology, San Francisco, CA Nov 21-24, 2013.

*Authors:* Girvan A, Carter G, Li L, Kaltenboeck A, Chawla A, Ivanova J, Koh M, Stevens J, Lahn M.

**Above Standard Dose of Octreotide-LAR in Patients with Neuroendocrine Tumors (NET).**

*Abstract:* 2013 International Society of Gastrointestinal Oncology, Arlington, VA Oct 19, 2013.

*Authors:* Goldman J, Hulke MH, Strosberg JR, Huynh L, Duh MS, Sahai V, Rademaker A, Benso AB.

**Antitumor activity of brentuximab vedotin in patients with relapsed or refractory (RR) Hodgkin Lymphoma (HL) following autologous stem cell transplant (ASCT): Meta-analysis comparison.**

*Abstract:* 9th International Symposium on Hodgkin Lymphoma Conference, Cologne, Germany Oct 12-15, 2013.

*Authors:* Bonthapally V, Wu E, Macalalad A, Yang H, Shonukan O, Liu Y, Chi A, Huebner D.

**Association between guideline-adherent imaging and overall survival following 2nd-line targeted therapy for metastatic renal cell carcinoma.**

*Abstract:* 12th International Kidney Cancer Symposium, Chicago, IL Oct 25-26, 2013.

*Authors:* Lin PL, Pal SK, Jonasch E, Signorovitch JE, Liu Z, Culver K, Scott JA, Vogelzang NJ.

**Comparative effectiveness of 2nd-line targeted therapies for metastatic renal cell Carcinoma: Analysis of two practice-based chart reviews.**

*Abstract:* 12th International Kidney Cancer Symposium Chicago, IL Oct 25-26, 2013.

*Authors:* Signorovitch JE, Vogelzang NJ, Pal SK, Lin P, George DJ, Wong MK, Liu Z, Wang X, Culver K, Scott JA, Jonasch E.

**Dose-Escalation of Octreotide-LAR in Patients with Neuroendocrine Tumors (NET).**

*Abstract:* NANETS 2013 Annual Conference, Charleston, SC Oct 4-5, 2013.

*Authors:* Kulke MH, Strosberg JR, Huynh L, Duh MS, Sahai V, Rademaker AW, Benson AB.

**Impact of regular molecular monitoring on tyrosine kinase inhibitor therapy adherence in chronic myelogenous leukemia in the chronic phase.**

*Abstract:* 2013 Annual Meeting of the American College of Clinical Pharmacy, Albuquerque, NM Oct 13-16, 2013.

*Authors:* Guerin A, Chen L, Wu EQ, Dea K, Goldberg SL.

**Overall survival and hospitalization rates in Medicare patients diagnosed with advanced NSCLC treated with bevacizumab-paclitaxel-carboplatin vs paclitaxel-carboplatin: A retrospective cohort study.**

*Abstract:* 15th World Conference on Lung Cancer, Sydney, Australia Oct 27-30, 2013.

*Authors:* Langer CJ, Ravelo A, Hazard S, Guerin A L-VD, Ionescu-Ittu R, Wu EQ, Ramalingam SS.

**Survival advancements in advanced non-small cell lung cancer in the past 20 years: A story of hope.**

*Abstract:* 15th World Conference on Lung Cancer, Sydney, NSW Australia Oct 27-30, 2013.

*Authors:* Ravelo A, Guerin A, Latremouille-Viau D, Ionescu-Ittu R, Wu EQ.

**Survival following initiation of everolimus for 2nd-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials.**

*Abstract:* 12th International Kidney Cancer Symposium, Chicago, IL Oct 25-26, 2013.

*Authors:* Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Liu Z, Wang X, Culver K, Scott JA, George DJ, Vogelzang NJ.

**Análisis Costo-Efectividad De Everolimus Más Exemestano Para Pacientes Con Cáncer De Mama Avanzado Con Receptores Hormonales Positivos (RE+), HER2-, Que Fallaron a Los Inhibidores De Aromatasa No Esteroideos (IANES) En México.**

*Abstract:* ISPOR 4th Latin America Conference, Buenos Aires, Argentina Sep 12-14, 2013.

*Authors:* Zhang J, Pramanik A, Fuentes-Albuero A, Anaya P, Tinajero-Ayala B, Zhou ZY, Xie J, Signorovitch J, Fan L.

**Association between molecular monitoring and long-term outcomes in chronic myelogenous leukemia patients treated with first line imatinib.**

*Publication:* Current Medical Research and Opinion 2013 09; 29(9): 1075-1082. doi: 10.1185/03007995.2013.812034.

*Authors:* Goldberg SL, Chen L, Guerin A, Macalalad AR, Liu N, Kaminsky M, Ericson SG, Wu EQ.

**Study of imatinib treatment patterns and outcomes among US veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia.**

*Publication:* Journal of Oncology Practice 2013 09; 9(5): e212-219. doi: 10.1200/JOP.2012.000822.

*Authors:* Vander Velde N, Chen L, Guo A, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang H, Shi L.

**Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.**

*Publication:* Cancer 2013 08; 119(16): 2990-2998. e-pub ahead of print 2013/05/31; doi: 10.1002/cncr.28102.

*Authors:* Nakabayashi M, Hayes J, Taplin ME, Lefebvre P, Lafeuille MH, Pomerantz M, Sweeney C, Duh MS, Kantoff PW.

**Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM).**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28 2013.

*Authors:* Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

**Evaluating the utility of existing patient-reported outcome scales in novel patient populations with pancreatic cancer, lung cancer, and myeloproliferative neoplasms using Medicare current beneficiary survey data.**

*Publication:* Patient 2013 07; 6(3): 189-200. doi: 10.1007/s40271-013-0018-z.

*Authors:* Ivanova JI, Mytelka DS, Duh MS, Birnbaum HG, Cummings AK, San Roman AM, Price GL, Swindle RW.

**Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases.**

*Publication:* Am Health Drug Benefits 2013 07; 6(6): 307-316.

*Authors:* Lafeuille MH, Gravel J, Grittner A, Lefebvre P, Ellis L, McKenzie RS.

**Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.**

*Publication:* Current Medical Research and Opinion 2013 06; 29(6): 623-631. doi: 10.1185/03007995.2013.789012.

*Authors:* Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Ionescu-Ittu R, Wu EQ.

**Comparison of the long-term risk of recurrence and other clinical outcomes in GIST patients receiving imatinib as adjuvant therapy--a retrospective chart extract-based approach.**

*Publication:* Journal of Gastrointestinal Cancer 2013 06; 44(2): 190-198. doi: 10.1007/s12029-012-9467-1.

*Authors:* Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

**The economic burden of pleural effusions in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.**

*Publication:* Journal of Medical Economics 2013 06; 16(1): 125-133. doi: 10.3111/13696998.2012.693896.

*Authors:* Guerin A, Wu EQ, Bollu VK, Williams D, Guo A, de Leon DP, Quintas-Cardama A.

**Predictors of complete response following disease recurrence in gastrointestinal stromal tumor (GIST) patient: A retrospective patient chart review analysis.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31-Jun 4, 2013.

*Authors:* Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep FA, Keir CH, Magestro M, Wu EQ.

**Association between guideline-adherent imaging and overall survival following second-line targeted therapy for metastatic renal cell carcinoma.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31-June 4, 2013.

*Authors:* Lin PL, Pal SK, Jonasch E, Signorovitch JE, Liu Z, Culver KW, Scott JA, Vogelzang NJ.

**Comparative effectiveness of second-line targeted therapies for metastatic renal cell carcinoma: Analysis of two practice-based chart reviews.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31 - Jun 4, 2013.

*Authors:* Signorovitch JE, Vogelzang NJ, Pal SK, Lin PL, George DJ, Wong MKK, Liu Z, Wang X, Culver KW, Scott JA, Jonasch E.

**Comparison of discontinuation, health care resource utilization (HRU), and costs between metastatic breast cancer (mBC) patients (pts) who received trastuzumab (T) in an office clinic versus outpatient hospital setting.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31-Jun 4, 2013.

*Authors:* Brammer M, Lalla D, Gauthier G, Guerin A, Giguere-Duval P, Wu EQ, Santos E.

**Do oncology patients in an outpatient hospital receive the same care as patients in an office/clinic setting? A case study evaluating patients with non-metastatic HER2+ breast cancer (BC) receiving adjuvant trastuzumab.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL Jun 4, 2013.

*Authors:* Lalla D, Brammer M, Guerin A, Gauthier G, Giguere-Duval P, Wu EQ, Santos E.

**Economic benefits of adequate molecular monitoring in patients with chronic myelogenous leukemia (CML).**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31 - Jun 4, 2013.

*Authors:* Chen L, Guerin A, Wu EQ, Dea K, Goldberg SL.

**The economic burden of metastatic castration-resistant prostate cancer: U.S. Medicare perspective.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31 - Jun 4, 2013.

*Authors:* Eapen S, Andrews R, Gorin B, Higano CS.

**Health care resource utilization and cost of Medicare patients with non-small cell lung cancer (NSCLC).**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Yenikomshian M, Hackshaw M, Cai X, Trahey A, Arondekar B, Knoll S, Duh MS.

**Incremental cost of brain metastases among patients with metastatic melanoma.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Vekeman F, Cloutier M, Yermakov S, Amonkar M, Arondekar B, Duh MS.

**Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM).**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

**Observed abiraterone acetate utilization by prostate cancer (PC) patients in a large administrative claims database in the united states.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Lafeuille MH, Dean J, Lefebvre P, Ellis L, Senbetta M.

**Prescribing decision drivers in patients with recurrent gastrointestinal stromal tumor (GIST) previously treated with adjuvant imatinib: A retrospective chart extract-based approach.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31-Jun 4, 2013.

*Authors:* Guerin A, Sasane M, Gauthier G, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP.

**A single-center experience with CELLSEARCH system circulating tumor cell test on patients with metastatic breast cancer.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31-Jun 4, 2013.

*Authors:* Montero AJ, Eapen S, Andrews RM, Gorin B.



**Su2017 Impact of Chronic Constipation Severity on the Risk of Developing Colorectal Cancer and Benign Neoplasm.**

*Abstract:* Digestive Disease Week, Orlando, FL May 18-21, 2013.

*Authors:* Guérin A, Mody R, Fok B, Wu EQ, Lasch K, Talley NJ.

**Survival following initiation of everolimus for second-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31-Jun 4, 2013.

*Authors:* Wong MK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Liu Z, Wang X, Culver K, Scott JA, George DJ, Vogelzang NJ.

**Tumor characteristics and treatment (trt) patterns following disease recurrence in gastrointestinal stromal tumor (GIST) patients (pts) who received adjuvant imatinib (IM) as primary trt: A retrospective chart extract-based approach.**

*Abstract:* 2013 ASCO Annual Meeting, Chicago, IL May 31-Jun 4, 2013.

*Authors:* Gauthier G, Sasane M, Guerin A, Schwiep FA, Keir CH, Magestro M, Wu EQ, Conley AP.

**Comparison of healthcare resource utilization and costs between patients who received trastuzumab in an outpatient hospital vs. office clinic setting for the treatment of breast cancer.**

*Abstract:* AMCP's 25th Annual Meeting, San Diego, CA Apr 3-5, 2013.

*Authors:* Brammer M, Lalla D, Gauthier G, Guérin A, Giguere-Duval P, Wu EQ, Santos E.

**Meta-analysis of the efficacy and safety of bortezomib (BTZ) retreatment in patients (PTS) with multiple myeloma (MM).**

*Abstract:* 14th International Myeloma Workshop Conference, Kyoto, Japan Apr 3-7, 2013.

*Authors:* Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

**Outcomes of second-targeted therapy for mRCC: A retrospective chart review of community practices in the United States.**

*Abstract:* 2013 Genitourinary Cancers Symposium, Orlando, FL Feb 14-16, 2013.

*Authors:* Jonasch E, Signorovitch JE, Lin P, Liu Z, Culver KW, Pal SK, Scott JA, Vogelzang NJ.

**Sequential use of targeted therapies for metastatic renal cell carcinoma: A physician survey and chart review of community oncology practices in the United States.**

*Abstract:* 2013 Genitourinary Cancers Symposium, Orlando, FL Feb 14-16, 2013.

*Authors:* Vogelzang NJ, Signorovitch JE, Lin PL, Liu Z, Culver KW, Scott JA, Pal SK, Jonasch E.

**The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.**

*Publication:* Oncologist 2013 01; 18(1): 27-36. doi: 10.1634/theoncologist.2011-0380.

*Authors:* Garrison LP, Jr., Wang ST, Huang H, Ba-Mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, van de Velde H, Corzo D, Duh MS.

**Re.: Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.**

*Publication:* Journal of Medical Economics 2013 16(2): 260-262. doi: 10.3111/13696998.2012.752738.

*Authors:* Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

**Benefits of early switching from imatinib to a second-generation tyrosine kinase inhibitor following 12 month complete cytogenetic response failure: A chart review analysis.**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* DeAngelo DJ, Chen L, Guerin A, Styles A, Aberki C, Giguere-Duval P, Wu EQ.

**Budget impact analysis of everolimus for estrogen receptor positive, human epidermal growth factor receptor-2 negative metastatic breast cancer patients in the United States.**

*Abstract:* 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX Dec 4-8, 2012.

*Authors:* Xie J, Diener M, De G, Yang H, Wu EQ, Namjoshi M.

**Characteristics of patients with chronic myelogenous leukemia in chronic phase switched to nilotinib or dasatinib as second-line therapy.**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* Macalalad AR, Chen L, Guerin A, Luo J, Wu EQ, Griffin JD.

**Chemotherapy Treatment Patterns in Elderly Patients Initially Diagnosed with Advanced Ovarian Cancer.**

*Publication:* Clinical Ovarian and Other Gynecologic Cancer 2012 12; 5(2): 67-77. e61.

*Authors:* Johnson SJ, Sorg RA, Borker RD, Duh MS.

**Comparison of disease outcomes for patients with chronic myelogenous leukemia in chronic phase switched to nilotinib or dasatinib as second-line therapy.**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* Griffin JD, Guerin A, Chen L, Macalalad AR, Luo J, Wu EQ.

**Comparison of treatment changes for patients with chronic myelogenous leukemia in chronic phase switched from imatinib to nilotinib or dasatinib as second-line therapy.**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* Macalalad AR, Chen L, Guerin A, Luo J, Wu EQ, Griffin JD.

**Comparison of treatment patterns and outcomes in metastatic breast cancer patients initiated on trastuzumab vs. lapatinib; A retrospective analysis.**

*Abstract:* 35th Annual CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX Dec 4-8, 2012.

*Authors:* Gauthier G, Guerin A, Styles AL, Wu EQ, Masaquel A, Brammer MG, Lalla D.

**Frequency of molecular monitoring correlates with long term outcomes in chronic phase chronic myelogenous leukemia treated with first-line imatinib: Results of a community survey.**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* Goldberg SL, Chen L, Ericson SG, Macalalad AR, Guerin A, Liu N, Kaminsky M, Wu EQ.

**Meta-analysis of the efficacy and safety of bortezomib retreatment in patients with multiple myeloma (MM).**

*Abstract:* 54th Annual Meeting of the American Society of Hematology, Atlanta, GA Dec 8-11, 2012.

*Authors:* Knopf KB, Duh MS, Lafeuille MH, Gravel J, Lefebvre P, Niculescu L, Ba-mancini A, Ma E, Shi H, Comenzo RL.

**Re: Stopeck A, Rader M, Henry D, et al. Cost-effectiveness of denosumab vs. zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.**

*Publication:* Journal of Medical Economics 2012 12.

*Authors:* Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

**Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first and second-line chemotherapies.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Hurvitz SA, Guerin A, Brammer M, Guardino E, Zhou ZY, Kaminsky MS, Wu EQ, Lalla D.

**Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study.**

*Publication:* Urologic Oncology 2012 11; 30(6): 848-855. doi: 10.1016/j.urolonc.2010.07.009.

*Authors:* Choueiri TK, McDermott D, Sheng Duh M, Sarda SP, Neary MP, Oh WK.

**Investigation of gastrointestinal stromal tumor (GIST) care management in GIST patients (pts) receiving short-term versus long-term imatinib (IM) adjuvant therapy: A chart review analysis.**

*Abstract:* ASCO's Quality Care Symposium, San Diego, CA Nov 30-Dec 1, 212.

*Authors:* Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

**Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis.**

*Publication:* Current Medical Research and Opinion 2012 11; 28(11): 1831-1839. doi: 10.1185/03007995.2012.741577.

*Authors:* Chen L, Guerin A, Xie J, Wu EQ, Yu AP, Ericson SG, Jabbour E.

**Review of national institute for health and clinical excellence (NICE) recommendations for anti-cancer agents across multiple drug-indication combinations.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Chawla A, Oza A, Nellesen D, Brown J, Liepa AM, Price G, Nash-Smyth E, Cuyun Carter G, Boye ME.

**A systematic review of the heterogeneity of treatment effect in ovarian cancer (OC)-Are there implications for outcomes research?**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Chawla A, Nellesen D, Yee K, Brown J, Boye ME.

**Risk of developing colorectal cancer and benign neoplasm in patients with chronic constipation.**

*Abstract:* 77th Annual Scientific Meeting of the American College of Gastroenterology, Las Vegas, NV Oct 19-24, 2012.

*Authors:* Mody R, Guerin A, Fok B, Zhou Z, Wu E, Brewer K, Zhou W, Lasch K, Talley N.

**Treatment patterns in metastatic renal cell carcinoma in the US: A retrospective chart review in community oncology practices.**

*Abstract:* 11th International Kidney Cancer Symposium Annual Meeting Proceedings, Chicago, IL Oct 5-6, 2012.

*Authors:* Vogelzang NJ, Signorovitch JE, Lin PL, Liu Z, Culver K, Pal SK, Scott JA, Jonasch E.

**Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia in chronic phase (CML-CP).**

*Abstract:* ESH-iCML International Conference, Baltimore, MD Sep 20-23, 2012.

*Authors:* Vander Velde NS, Chen L, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang HY, Guo A, Shi L.

**Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases.**

*Publication:* Clinical Breast Cancer 2012 08; 12(4): 247-258. doi: 10.1016/j.clbc.2012.04.001.

*Authors:* Xie J, Diener M, Sorg R, Wu EQ, Namjoshi M.

**Beyond the Abstract - Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.**

*Publication:* UroToday.com 2012 07.

*Authors:* Xie J.

**The economic burden of metastatic breast cancer: a U.S. managed care perspective.**

*Publication:* Breast Cancer Research and Treatment 2012 07; 134(2): 815-822. doi: 10.1007/s10549-012-2097-2.

*Authors:* Montero AJ, Eapen S, Gorin B, Adler P.

**Re: Ulcickas Yood M, Oliveria SA, Cziraky M, et al. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia. Curr Med Res Opin 2012, 28(2): 213-19.**

*Publication:* Current Medical Research and Opinion 2012 07; 28(7): 1164; author reply 1164-1165. doi: 10.1185/03007995.2012.703135.

*Authors:* Wu E, Chen L.

**A retrospective analysis of therapy adherence in imatinib resistant or intolerant patients with chronic myeloid leukemia receiving nilotinib or dasatinib in a real-world setting.**

*Publication:* Current Medical Research and Opinion 2012 07; 28(7): 1155-1162. doi: 10.1185/03007995.2012.705264.

*Authors:* Guerin A, Chen L, Wu EQ, Ponce de Leon D, Griffin JD.

**Budget impact analysis of everolimus for ER+, HER2-metastatic breast cancer patients in the United States.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Xie J, Diener M, De G, Wu EQ, Namjoshi M.

**Characteristics of gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib (IM) adjuvant therapy: A chart review analysis.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL June 1-5, 2012.

*Authors:* Guerin A, Conley AP, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

**Comparison of treatment patterns and outcomes in metastatic breast cancer (MBC) patients initiated on trastuzumab versus lapatinib: A retrospective analysis.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Gauthier G, Guerin A, Styles A, Wu EQ, Brammer MG, Lalla D.

**Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first- and second-line chemotherapies.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Hurvitz SA, Guerin A, Brammer MG, Guardino E, Zhou ZY, Kaminsky MS, Wu EQ, Lalla D.

**Comprehensive investigation of adverse event (AE)-related costs in patients with metastatic breast cancer (MBC) treated with first-and second-line chemotherapies.**

*Abstract:* 2012 International MASCC/ISOO Symposium: Supportive Care in Cancer, New York ,NY Jun 28-30- 2012.

*Authors:* Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Kaminsky M, Wu EQ, Lalla D.

**Drug treatment (tx) patterns and survival among patients (pts) with metastatic or recurrent soft tissue sarcoma (m/rSTS) refractory to at least one prior therapy.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Wagner M, Amodu L, Duh MS, Korves C, Solleza F, Mykletun A, Manson S, Diaz J, Neery MP, Demetri GD.

**Economic burden of hepatocellular carcinoma in China.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Wu EQ, Wu J, Yang HY, Zheng Y, Xie K, Yu R, Xie J.

**Health care utilization and economic burden of dermatologic adverse drug reactions (ADRs) in patients with NSCLC treated with an epidermal growth factor receptor inhibitor (EGFRI).**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Bonthapally V, Guerin A, Wu EQ, Gauthier G, Cloutier M, Holen KD, Ray S.

**Lifetime costs to Medicare of providing care to patients with chronic lymphocytic leukemia.**

*Publication:* Leukemia and Lymphoma 2012 06; 53(6): 1146-1154. doi: 10.3109/10428194.2011.643405.

*Authors:* Lafeuille MH, Vekeman F, Wang ST, Kerrigan M, Menditto L, Duh MS.

**Monitoring and switching patterns in chronic myelogenous leukemia (CML) pts treated with imatinib (IM): A chart review analysis.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Chen L, Guerin A, Aberki C, Wu EQ, Ericson S, Jabbour E.

**Overall and progression-free survival with everolimus, temsirolimus, or sorafenib as second targeted therapies for metastatic renal cell carcinoma: A retrospective U.S. chart review.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Yang H, Wong MKK, Signorovitch JE, Wang X, Liu Z, Liu NS, Qi Z, George DJ.

**Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison of randomized trials.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Signorovitch JE, Swallow E, Kantor E, Wang X, Hass T, Klimovsky J, Metrakos P.

**PCN42 Health Care Utilization and Costs Among Lung Cancer Patients in China.**

*Abstract:* ISPOR, Jun 2-6, 2012.

*Authors:* Zheng Y, Wu J, Xie J, Xie K, Yang H, Liu J, Wu E.

**Real-world study of imatinib treatment patterns and outcomes among veteran patients with chronic myeloid leukemia in chronic phase.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Vander Velde NS, Chen L, Sharma H, Marynchenko M, Wu EQ, Liu J, Yang HY, Guo A, Shi L.

**Risk of disease recurrence and mortality in gastrointestinal stromal tumor (GIST) patients receiving short-term versus long-term imatinib adjuvant therapy: A chart review analysis.**

*Abstract:* 2012 ASCO Annual Meeting, Chicago, IL Jun 1-5, 2012.

*Authors:* Conley AP, Guerin A, Sasane M, Gauthier G, Schwiep F, Keir CH, Wu EQ.

**Safety and treatment patterns of angiogenesis inhibitors in patients with metastatic renal cell carcinoma: evidence from US community oncology clinics.**

*Publication:* Medical Oncology 2012 06; 29(2): 786-794. doi: 10.1007/s12032-011-9922-z.

*Authors:* Feinberg BA, Jolly P, Wang ST, Fortner B, Scott J, Gilmore J, Neary MP, Duh MS.

**Number needed to treat and risk benefit analysis of denosumab versus zoledronic acid in the treatment of castrate-resistant prostate cancer patients with bone metastases.**

*Abstract:* American Urological Association Annual Meeting, Atlanta, GA May 19-23, 2012.

*Authors:* Xie J, Diener M, Wu EQ, Sorg R, Yu AP, Namjoshi M.

**Bioevaluation study of 32P-CP-PLLA particle brachytherapy in a rabbit VX2 lung tumor model.**

*Publication:* Applied Radiation and Isotopes 2012 04; 70(4): 583-588. doi: 10.1016/j.apradiso.2011.12.047.

*Authors:* Xu Y, Yang M, Pan D, Wang L, Liu L, Huang P, Shao G.

**Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer.**

*Publication:* Chemother Res Pract 2012 04; 2012: 913848. doi: 10.1155/2012/913848.

*Authors:* Pike CT, Birnbaum HG, Muehlenbein CE, Pohl GM, Natale RB.

**Treatment patterns and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients.**

*Publication:* Journal of Medical Economics 2012 04; 15(4): 786-795. doi: 10.3111/13696998.2012.682632.

*Authors:* Kim Le T, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ.

**Comparison of adherence patterns with second-line nilotinib and dasatinib in patients with Chronic Myeloid Leukemia (CML).**

*Abstract:* 8th Annual Meeting of the Hematology/Oncology Pharmacy Association, Orlando, FL Mar 21-24, 2012.

*Authors:* Chen L, Guerin A, Guo A, Stepner M, Griffin JD, Wu EQ.

**Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.**

*Publication:* Current Medical Research and Opinion 2012 02; 28(2): 213-219. doi: 10.1185/03007995.2011.649849.

*Authors:* Yood MU, Oliveria SA, Cziraky M, Hirji I, Hamdan M, Davis C.

**Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomised phase III trial.**

*Publication:* European Journal of Cancer 2012 02; 48(3): 311-323. doi: 10.1016/j.ejca.2011.05.017.

*Authors:* Cella D, Pickard AS, Duh MS, Guerin A, Mishagina N, Antras L, Neary MP, McCann L, Hodge R, Sternberg CN.

**Health care utilization and economic burden of dermatologic adverse drug reactions (ADRs) in patients with colorectal cancer treated with an epidermal growth factor receptor inhibitor (EGFRI).**

*Abstract:* 2012 Gastrointestinal Cancers Symposium, San Francisco, CA Jan 19-21, 2012.

*Authors:* Bonthapally V, Guerin A, Wu EQ, Gauthier G, Holen KD, Ray S.

**Re: Economic Evaluation of Denosumab Compared with Zoledronic Acid in Hormone-Refractory Prostate Cancer Patients with Bone Metastases.**

*Publication:* European Urology 2012 61(2): 427-428.

*Authors:* XIE J, NAMJOSHI M, WU E.

**Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia.**

*Abstract:* 53rd Annual Meeting of the American Society of Hematology, San Diego, CA Dec 10-13, 2011.

*Authors:* Guerin A, Bollu VK, Guo A, Stepner M, Griffin JD, Wu EQ.

**The economics of the hematopoietic growth factors.**

*Publication:* Cancer Treatment and Research 2011 11; 157: 403-418. doi: 10.1007/978-1-4419-7073-2\_22.

*Authors:* Eldar-Lissai A, Lyman GH.

**Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases.**

*Abstract:* 2011 Breast Cancer Symposium Chicago, IL Nov 30 - Dec 3, 2011.

*Authors:* Wu EQ, Xie J, Signorovitch J, Diener M, Sorg R, Namjoshi M.

**Predictors of response to sequential sunitinib and the impact of prior VEGF-targeted drug washout in patients with metastatic clear-cell renal cell carcinoma.**

*Publication:* Urologic Oncology 2011 11; 29(6): 756-763. doi: 10.1016/j.urolonc.2010.01.008.

*Authors:* Elfiky AA, Cho DC, McDermott DF, Rosenberg JE, Fortner B, Antras L, Chen K, Sheng Duh M, Jayawant SS, Oh WK, Atkins MB, Choueiri TK.

**Adherence patterns and dose adjustments with second-line nilotinib and dasatinib in patients with chronic myeloid leukemia: Evaluation in a real-world setting.**

*Abstract:* 2011 Annual Meeting of the American College of Clinical Pharmacy Conference, Pittsburgh, PA Oct 16-19, 2011.

*Authors:* Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu E.

**Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases.**

*Publication:* Journal of Managed Care Pharmacy 2011 10; 17(8): 621-643.

*Authors:* Xie J, Namjoshi M, Wu EQ, Parikh K, Diener M, Yu AP, Guo A, Culver KW.

**5002 ORAL Complications Associated with Chemotherapy in Patients with Metastatic Breast Cancer.**

*Publication:* European Journal of Cancer 2011 09; 47: S330.

*Authors:* Brammer M, Lalla D, Guerin A, Latremouille-Viau D, Yu A, Wu E, Hurvitz S.

**The association between treatment (TX) modifications due to adverse events (AES) and overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with sunitinib and sorafenib: Results from a multi-country study in europe.**

*Abstract:* 2011 European Multidisciplinary Cancer Congress, Stockholm, Sweden Sept 23-27, 2011.

*Authors:* Oudard S, Porta C, Castellano D, McDermott R, Nathan P, McCaffrey J, Neary MP, Korves C, Dial Suthoff E, Duh M.

**Comparing early intervention with zoledronic acid to no bisphosphonate (BP) therapy in patients with metastatic prostate cancer to bone: A study of the US Veterans Affairs (VA) population.**

*Abstract:* 10th International Conference on Cancer-Induced Bone Disease Conference, Sheffield, UK Sept 22-25, 2010.

*Authors:* Wu EQ, Guo A, Shi L, Lu M, Yu AP, Sharma H, Fan CPS, Vander Velde N.

**Complications associated with chemotherapy in patients with metastatic breast cancer.**

*Abstract:* 2011 European Multidisciplinary Cancer Congress, Stockholm, Sweden Sept 23-27, 2011.

*Authors:* Brammer M, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Hurvitz S.

**Number needed to treat and risk benefit analysis of denosumab versus zoledronic acid in the treatment of castrate-resistant prostate cancer patients with bone metastases.**

*Abstract:* 2011 Annual Meeting of the American Society for Bone and Mineral Research, San Diego, CA Sept 16-20, 2011.

*Authors:* Yu AP, Diener M, Wu EQ, Namjoshi M.

**Number needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases.**

*Abstract:* 2011 Breast Cancer Symposium San Francisco, CA Sep 8-10, 2011.

*Authors:* Wu EQ, Xie J, Signorovitch J, Diener M, Sorg R, Namjoshi M.

**A pan-european study of treatment (TRX) patterns and toxicity of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC).**

*Abstract:* 2011 European Multidisciplinary Cancer Congress Stockholm, Sweden Sep 23-27, 2011.

*Authors:* Levy A, Porta C, Hawkins R, Bellmunt J, Wagstaff J, Donnellan P, Neary MP, Sarda SP, Vekeman F, Duh MS.

**Comparison of skeletal complications and treatment patterns associated with early vs. delayed zoledronic acid therapy in multiple myeloma.**

*Publication:* Clinical Lymphoma, Myeloma & Leukemia 2011 08; 11(4): 326-335. doi: 10.1016/j.clml.2011.04.004.

*Authors:* Wu EQ, Bensimon AG, Marynchenko M, Namjoshi M, Guo A, Yu AP, Ericson SG, Raje N.

**Sunitinib (SU) treatment (Trx) patterns and toxicity in patients (Pts) with advanced renal cell carcinoma (RCC) in United Kingdom (UK).**

*Abstract:* 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Chicago, IL Aug 14-17, 2011.

*Authors:* Hawkins R, Wagstaff J, Nathan P, Sarda SP, Vekeman F, Korves C, Dasgupta S, O'Mara S, Fitton S, Hayers J, Tham C, Luka A, Wei R, Mykletun A, Neary MP, Duh MS.

**Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.**

*Publication:* Journal of Medical Economics 2011 07; 14(5): 542-552. doi: 10.3111/13696998.2011.596600.

*Authors:* Yang H, Yu AP, Wu EQ, Yim YM, Yu E.

**Chemotherapy-related complication burden in patients with metastatic breast cancer in a real-world setting.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Hurvitz SA, Lalla D, Guerin A, Latremouille-Viau D, Yu AP, Wu EQ, Brammer M.

**Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.**

*Publication:* Current Medical Research and Opinion 2011 06; 27(6): 1263-1271. doi: 10.1185/03007995.2011.576238.

*Authors:* Signorovitch JE, Wu EQ, Betts KA, Parikh K, Kantor E, Guo A, Bollu VK, Williams D, Wei LJ, DeAngelo DJ.

**Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Guerin A, Lalla D, Latremouille-Viau D, Yu AP, Wu EQ, Brammer M, Hurvitz SA.

**Economic evaluation of denosumab compared with zoledronic acid in patients with hormone-refractory prostate cancer with bone metastases.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Yu AP, Namjoshi M, Xie J, Parikh K, Wu EQ, Guo A, Culver KW.

**Health-related quality of life in patients with advanced renal cell carcinoma receiving pazopanib or placebo in a randomized phase III trial.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Pickard A, Cella D, Duh M, Guerin A, Mishagina N, Antras L, Neary M, McCann L, Hodge R, Sternberg C.

**Impact of pleural effusion (PE) on treatment adherence, discontinuation, switching, and dose modification in patients with chronic myelogenous leukemia (CML).**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Wu EQ, Guerin A, Bollu VK, Guo A, Cloutier M, Ponce de Leon Barido D, Ericson S, Quintas-Cardama A.

**Patterns of treatment (trx) and safety of angiogenesis inhibitors in patients (pts) with advanced renal cell carcinoma (RCC) in France.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Gross-Goupil M, Oudard S, Levy A, Elaidi R, Scotte F, Duh MS, Sarda SP, Korves C, Goglia R, Ramamurthy P, Neary M, Escudier B.

**Sunitinib (SU) treatment (trx) patterns and toxicity in patients (pts) with advanced renal cell carcinoma (RCC) in United Kingdom (UK).**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Wagstaff J, Hawkins RE, Nathan PD, Sarda SP, Vekeman F, Korves C, Dasgupta S, O'Mara S, Fitton S, Hayers J, Tham C, Luka A, Wei R, Mykletun A, Neary M, Duh MS.

**Treatment (trx) of metastatic renal cell carcinoma (mRCC) with angiogenesis inhibitors (AIs): Safety and treatment patterns observed in Taiwanese patients.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 3-7, 2011.

*Authors:* Chang Y, Ou Y, Huang C, Chiang P, Chuang C, Kina S, Vekeman F, Goglia R, Neary M, Duh MS.



**The cost-effectiveness of bortezomib plus melphalan and prednisone versus lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment for the initial treatment of multiple myeloma in the united states.**

*Abstract:* ISPOR 16th Annual International Meeting Baltimore, MD May 21-25, 2011.

*Authors:* Wang ST, Huang H, Ba-mancini A, Shi H, Chen K, Korves C, Dhawan R, Cakana A, Van De Velde H, Duh MS.

**Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Lafeuille MH, Bailey RA, Senbetta M, McKenzie RS, Lefebvre P.

**Health care resource utilization and economic burden of metastatic and recurrent locally-advanced head and neck cancer patients.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Le TK, Winfree KB, Yang H, Marynchenko M, Yu AP, Frois C, Wu EQ.

**New methods to adjust for selective crossover in survival analysis: In assessments of costeffectiveness of cancer therapies.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Delea TE, Duh MS, Wei LJ, Robins J.

**Patterns of angiogenesis inhibitor treatment in patients with metastatic renal cell carcinoma (MRCC) in Ireland.**

*Abstract:* ISPOR 16th Annual International Meeting Baltimore, MD May 21-25, 2011.

*Authors:* McDermott R, Donnellan P, McCaffery J, Keane F, Sarda SP, Korves C, Luka A, Wei R, Neary MP, Hanley R, Duh MS.

**Real world clinical resource utilization of metastatic prostate cancer patients in the United States: Results from two large claims databases.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Senbetta M LM, Dean J, McKenzie RS, Lefebvre P.

**Safety and treatment patterns of angiogenesis inhibitors in patientswith metastatic renal cell carcinoma (MRCC) in the United Kingdom: Preliminary results of an ongoing charts reviewstudy.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Hawkins R, Wagstaff J, Nathan P, Sarda SP, Vekeman F, Korves C, Dasgupta S, O'Mara S, Fitton S, Hayers J, Tham C, Wei R, Luka A, Neary MP, Duh MS.

**Treatment patterns and healthcare resource utilization of metastatic prostate cancer patients by physician specialty.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Senbetta M, Lafeuille MH, Dean J, McKenzie RS, Lefebvre P.

**Health care resource utilization and costs associated with bevacizumab versus cetuximab in second-line treatment of metastatic colorectal cancer patients.**

*Abstract:* AMCP's 23rd Annual Meeting, Minneapolis, MN Apr 27-29, 2011.

*Authors:* Yang H, Yu A, Yim Y, Yu E, Wu E.

**The benefits of timely intervention with zoledronic acid in patients with metastatic prostate cancer to bones: a retrospective study of the US Veterans Affairs population.**

*Publication:* Prostate Cancer and Prostatic Diseases 2011 03; 14(1): 79-84. doi: 10.1038/pcan.2010.49.

*Authors:* Velde NV, Wu EQ, Guo A, Lu M, Yu AP, Sharma H, Liu J, Fan CP, Shi L.

**Safety and treatment patterns of multikinase inhibitors in patients with metastatic renal cell carcinoma at a tertiary oncology center in Italy.**

*Publication:* BMC Cancer 2011 03; 11: 105. doi: 10.1186/1471-2407-11-105.

*Authors:* Porta C, Paglino C, Imarisio I, Canipari C, Chen K, Neary M, Duh MS.

**Treatment (trx) patterns and toxicity of angiogenesis inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) in United Kingdom (UK).**

*Abstract:* 26th Annual Congress of the European Association of Urology, Vienna, Austria Mar 18-22, 2011.

*Authors:* Hawkins R, Wagstaff J, Nathan P, Sarda SP, Vekeman F, Korves C, Dasgupta S, O'Mara S, Fitton S, Hayers J, Tham C, Wei R, Luka A, Duh MS, Neary MP.

**Treatment (trx) patterns of angiogenesis inhibitors in patients (pts) with metastatic renal cell carcinoma (mRCC) in Ireland.**

*Abstract:* 2011 Genitourinary Symposium., Orlando, FL Feb 17-19, 2011.

*Authors:* McDermott RS, Donnellan PP, McCaffery J, Sarda SP, Korves C, Luka A, Wei R, Neary M, Hanley R, Duh MS.

**Treatment patterns and health care resource utilization of metastatic colorectal cancer (mCRC) patients who received bevacizumab or cetuximab in second-line regimen.**

*Abstract:* 2011 Gastrointestinal Cancers Symposium San Francisco, CA Jan 20-22, 2011.

*Authors:* Yang H, Yu AP, Yim Y, Yu E, Wu E.

**Comparison of adherence between nilotinib and dasatinib as second-line therapies in chronic myeloid leukemia.**

*Abstract:* 52nd Annual Meeting of the American Society of Hematology, Orlando, FL Dec 4-7, 2010.

*Authors:* Guerin A, Bollu V, Guo A, Griffin JD, Yu AP, Wu EQ.

**The economic burden of pleural effusions (PE) in patients with chronic myeloid leukemia (CML).**

*Abstract:* 52nd Annual Meeting of the American Society of Hematology, Orlando, FL Dec 4-7, 2010.

*Authors:* Wu EQ, Guerin A, Bollu V, Williams D, Guo A, De Leon Barido DP, Yu AP, Quintas-Cardama A.

**Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.**

*Publication:* Current Medical Research and Opinion 2010 12; 26(12): 2861-2869. doi: 10.1185/03007995.2010.533648.

*Authors:* Wu EQ, Guerin A, Yu AP, Bollu VK, Guo A, Griffin JD.

**Comparison of skeletal complications and treatment patterns associated with early versus delayed zoledronic acid therapy in multiple myeloma.**

*Abstract:* 52nd Annual Meeting of the American Society of Hematology, Orlando, FL Dec 4-7, 2010.

*Authors:* Yu AP, Bensimon AG, Marynchenko M, Wu EQ, Namjoshi M, Guo A, Ericson SG, Raje N.

**Healthcare costs of second-line (2L) metastatic colorectal cancer (mCRC) patients treated with bevacizumab (BV) versus cetuximab (CX).**

*Abstract:* 35th ESMO Congress, Milan, Italy Oct 8-12, 2010.

*Authors:* Yim Y, Wu EQ, Yu AP, Yang HY, Yu E.

**Tolerability, efficacy, and safety of pegylated liposomal Doxorubicin in combination with Carboplatin versus gemcitabine-Carboplatin for the treatment of platinum-sensitive recurrent ovarian cancer: a systematic review.**

*Publication:* Oncologist 2010 10; 15(10): 1073-1082. doi: 10.1634/theoncologist.2009-0331.

*Authors:* Holloway RW, Grendys EC, Lefebvre P, Vekeman F, McMeekin S.

**Active dose re-escalation of nilotinib following dose reduction is associated with improved efficacy in patients with chronic phase chronic myeloid Leukemia (CML-CP) who fail imatinib.**

*Abstract:* 15th Congress of the European Hematology Association, Barcelona, Spain Jun 10-13, 2010.

*Authors:* Nicolini F, Kim DW, Turkina A, Alimena G, Al-Ali HK, Shen Z, Jootar S, Smith G, De Souza C, Dorlhiac-Llacer P, Rizzieri D, Lyon-Caen S, Berton M, Szczudlo T, Le Coutre P.

**Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review.**

*Publication:* BJU International 2010 05; 105(9): 1247-1254. doi: 10.1111/j.1464-410X.2009.08972.x.

*Authors:* Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy AG, Antras L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK.

**Costs of treatment with angiogenesis inhibitors (AIS) in patients with metastatic renal cell carcinoma (MRCC): Results from a medical chart review study.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Oh WK, McDermott DF, Duh MS, Antras L, Chen K, Sarda SP, Luka A, Whittemore S, Ramamurthy P, Neary MP, Choueiri TK.

**Costs to Medicare of treating chronic lymphocytic leukemia patients with alemtuzumab.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Lafeuille MH, Vekeman F, Kerrigan M, Wang ST, Duh MS.

**Health care costs associated with angiogenesis inhibitors (AIS) and mtor inhibitors (MTORS) in patients with metastatic renal cell carcinoma (MRCC) treated at US community oncology clinics.**

*Abstract:* ISPOR 15th Annual International Meeting Atlanta, GA May 15-19, 2010.

*Authors:* Chen K, SP S, Antras L, Whittemore S, Luka A, Ramamurthy P, Scott J, Fortner B, Neary MP, Duh MS, Jolly P.

**Health care costs associated with multikinase inhibitors (MKIS) for treatment of metastatic renal cell carcinoma (MRCC) in a clinical practice setting in Italy.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Paglino C, Porta C, Canipari C, Antras L, Chen K, Whittemore S, Luka A, Ramamurthy P, Neary MP, Duh MS.

**Incidence and cost of adverse events (AEs) in patients with renal cell carcinoma (RCC) treated with angiogenesis inhibitors (AIs).**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Dial E, Duh MS, Antras L, Rodermund D, Neary MP, Choueiri TK, Oh WK.

**Lower health care resource utilization associated with managing nilotinib related adverse events in chronic myeloid leukemia (CML) patients: Evidence from a clinical practice setting study.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Guerin A, Bollu V, Williams D.

**Modeling the cost-effectiveness of bortezomib for the initial treatment of multiple myeloma in the United States.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Wang ST, Huang H, Shi H, Duh MS, Chen K, Chang E, Korves C, Dhawan R, Cakana A, Van De Velde H, Esseltine DL, Garrison L.

**Non-adherence to imatinib in chronic myeloid leukemia (cml) patients is associated with short-and long-term negative impacts on health care resource utilization and costs.**

*Abstract:* Cited from Google Scholar, May 15-19, 2010.

*Authors:* Guerin A, Bollu V, Guo A, Wu E, Yu A, Sirulnik L, Griffin J.

**PCN47 Comparison of health care resource utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia (CML).**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Wu E, Bollu V, Guo A, Guerin A, Tsaneva M, Williams D, Griffin J.

**Puk1 incidence and cost of adverse events (AES) in patients with renal cell carcinoma (RCC) treated with angiogenesis inhibitors (AIS).**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Dial E, Duh MS, Antras L, Rodermund D, Neary MP, Choueiri TK, Oh WK.

**Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.**

*Publication:* Current Medical Research and Opinion 2010 01; 26(1): 61-69. doi: 10.1185/03007990903396469.

*Authors:* Wu EQ, Johnson S, Beaulieu N, Arana M, Bollu V, Guo A, Coombs J, Feng W, Cortes J.

**Comparison of healthcare utilization and costs between nilotinib and dasatinib as second line therapies in chronic myeloid leukemia.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Wu EQ, Bollu VK, Guo A, Guerin A, Tsaneva M, Williams D, Griffin JD.

**Costs to Medicare of treating chronic lymphocytic leukemia patients with alemtuzumab.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Lafeuille MH, Vekeman F, Kerrigan M, Wang ST, Duh M.

**Efficacy and safety of nilotinib in elderly patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): A sub-analysis of the ENACT (expanding nilotinib access in clinical trials) study.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Le Coutre PD, Turkina A, Kim DW, Ceglarek B, Alimena G, Al-Ali HK, Shen Z, Jootar S, Smith G, De Souza CA, Dorlhiac-Llacer PE, Rizzieri DA, Szczudlo T, Berton M, Wang J, Wang ST, Nicolini FE.

**Impact of prior therapy and suboptimal response to imatinib on the efficacy and safety of nilotinib among 1,422 patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) in chronic phase (CP): Sub-analyses of the ENACT (expanding nilotinib access in clinical trials) study.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Nicolini FE, Kim DW, Ceglarek B, Turkina A, Alimena G, Al-Ali HK, Shen Z, Jootar S, Smith G, De Souza CA, Dorlhiac-Llacer PE, Rizzieri DA, Szczudlo T, Berton M, Wang J, Bieri C, Le Coutre PD.

**Lower healthcare resource utilization associated with managing nilotinib related adverse events in chronic myeloid leukemia (CML) patients - Evidence from a clinical practice setting study.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Guerin A, Bollu VK, Williams D.

**Molecular response, efficacy and safety analysis of 168 adult french patients with chronic myeloid leukemia (CML) in chronic phase (CP) from the ENACT (expanding nilotinib access in clinical trials) study.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Nicolini FI, Etienne G, Bordessoule D, Caillot D, Belanger C, Cayuela JM, Charbonnier A, Coiteux V, Guerci-Bresler A, Dubruielle V, Lamy T, Huguet F, Rousselot P, Tulliez M, Cahn JY, Gardembas-Pain M, Legros L, Maloisel F, Rea D, Johnson-Ansah H, Lenain P, Delmer A, Berger M, Szczudlo T, Wang J, Duh MS, Guilhot F.

**Non-adherence to imatinib in chronic myeloid leukemia patients is associated with a short term and long term negative impact on healthcare utilization and costs.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Wu EQ, Bollu VK, Guo A, Guerin A, Yu AP, Sirulnik A, Griffin JD.

**Patterns and management of selected adverse events of adult patients with imatinib-resistant or -intolerant chronic myeloid leukemia (CML) from the enact (expanding nilotinib access in clinical trials) study.**

*Abstract:* 51st Annual Meeting of the American Society of Hematology, New Orleans, LA Dec 5-8, 2009.

*Authors:* Le Coutre PD, Ceglarek B, Turkina A, Kim DW, Alimena G, Al-Ali HK, Shen Z, Jootar S, Smith G, De Souza CA, Rizzieri DA, Szczudlo T, Berton M, Wang J, Dial E, Nicolini FE.

**Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.**

*Publication:* Cancer 2009 10; 115(20): 4839-4848. doi: 10.1002/cncr.24535.

*Authors:* Heaney ML, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Duh MS.

**Safety and treatment (trx) patterns of angiogenesis inhibitors (AIs) in patients (pts) with metastatic renal cell carcinoma (mRCC): Evidence from US community oncology clinics.**

*Abstract:* Joint ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin, Germany Sep 20-24, 2009.

*Authors:* Wang S, Ivanova J, Antras L, Chang E, Ramamurthy P, Whittemore S, Fortner B, Scott J, Neary M, Duh M.

**Safety and treatment (trx) patterns of multikinase inhibitors (MKI) in patients (pts) with metastatic renal cell carcinoma (mRCC) in Italy.**

*Abstract:* Joint ECCO 15 - 34th ESMO Multidisciplinary Congress, Berlin, Germany Sep 20-24, 2009.

*Authors:* Di Cesare P, Porta C, Lasagna A, Ferraris E, Imarisio I, Paglino C, Antras L, Chen K, Neary MP, Duh MS.

**Comparison of infection-related hospitalization risk among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

**Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis.**

*Publication:* Current Medical Research and Opinion 2009 08; 25(8): 2081-2090. doi: 10.1185/03007990903084800.

*Authors:* Duh MS, Dial E, Choueiri TK, Fournier AA, Antras L, Rodermund D, Neary MP, Oh WK.

**Patients (Pts) with metastatic Renal Cell Carcinoma (mRCC) receiving Angiogenesis Inhibitor (AI) therapies: Treatment efficacy and safety in clinical practice.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* McDermott D, Choueiri TK, Clement J, Brick AJ, Kwabi C, Shah K, Antras L, Jayawant SS, Wang ST, Luka A, Duh MS, Neary M, Oh WK.

**Pattern of utilization of pegfilgrastim (PEGFIL) in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Skarin AT, Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS.

**Treatment (Tx) and dosing patterns for Angiogenesis Inhibitor (AI) therapies in patients (Pts) with metastatic Renal Cell Carcinoma (mRCC).**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Choueiri TK, Brick AJ, McDermott D, Clement J, Kwabi C, Shah K, Antras L, Chen K, Jayawant SS, Duh MS, Luka A, Neary M, Oh WK.

**Adverse events associated with imatinib dose escalation versus switching to dasatinib in patients with chronic myelogenous leukemia.**

*Abstract:* ASCO Annual Meeting, Orlando, FL May 29 - Jun 2, 2009.

*Authors:* Morgan JA, Guo A, Williams D, Guérin A, Latremouille-Viau D, Tsnaeva M, Yu P, Wu EQ, Signorovitch J, Demetri GD.

**A pilot study: Impact of Chemotherapy-associated peripheral neuropathy on chemotherapy related treatment patterns in metastatic breast and non-small cell lung cancer patients.**

*Abstract:* 2009 International MASCC/ISOO Symposium Rome, Italy Jun 25-27, 2009.

*Authors:* Pike C, Birnbaum H, Kaufman R, Muehlenbein C, Pohl G, Natale R.

**Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.**

*Publication:* Supportive Care in Cancer 2009 06; 17(6): 719-725. doi: 10.1007/s00520-008-0553-7.

*Authors:* Diel IJ, Weide R, Koppler H, Antras L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.

**Adverse events associated with escalating imatinib versus switching to dasatinib in patients with chronic myelogenous leukemia.**

*Publication:* J Clin Oncol (Meeting Abstracts) 2009 05; 27(15S): 7092.

*Authors:* Wu E, Guo A, Williams D, Guérin A, Yu A, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin J, Bollu V.

**Budget impact analysis of sargramostim use in patients with chemotherapy-induced neutropenia.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Toy EL, Porter CL, Books P, Vekeman F, Barghout V, Duh M, Skarin AT.

**Comparison of infection-related hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Duh MS, Toy EL, Vekeman F, Laliberte F, Dority BL, Perlman D, Barghout V, Heaney ML.

**Direct health care and workloss burden of chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and non-small cell lung cancer.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Pike C, Birnbaum HG, Kaufman R, Muehlenbein CE, Pohl G, Natale R.

**Health care resource utilization associated with escalating imatinib versus switching to dasatinib in patients with chronic myelogenous leukemia.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Yu AP, Guo A, Guerin A, Latremouille-Viau D, Tsaneva M, Xie J, Signorovitch J, Williams D, Wu E.

**Impact of limiting erythropoiesis-stimulating agent use for chemotherapy-induced anemia on the United States blood supply margin.**

*Publication:* Transfusion 2009 05; 49(5): 895-902. doi: 10.1111/j.1537-2995.2008.02072.x.

*Authors:* Vekeman F, Bookhart BK, White J, McKenzie RS, Duh MS, Piech CT, Lefebvre P.

**Pattern of utilization of pegfilgrastim in patients with chemotherapy-induced neutropenia: A retrospective analysis of administrative claims data.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Vekeman F, Laliberte F, Afonja O, Lafeuille MH, Barghout V, Duh MS, Skarin AT.

**Real world treatment patterns of gastrointestinal stromal tumor patients.**

*Abstract:* ASCO Annual Meeting, Orlando, FL May 29 - Jun 2, 2009.

*Authors:* Wu EQ.

**Treatment patterns of chronic myelogenous leukemia patients who initiated their treatment on imatinib.**

*Abstract:* ASCO Annual Meeting, Orlando, FL May 29 - June 2, 2009.

*Authors:* Guérin A, Guo A, Williams D, Yu AP, Wu EQ, Latremouille-Viau D, Tsaneva M, Signorovitch J, Griffin JD.

**Drug utilization and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database.**

*Publication:* Journal of Medical Economics 2009 03; 12(1): 1-8. doi: 10.3111/13696990802648167.

*Authors:* Vekeman F, McKenzie RS, Bookhart BK, Laliberte F, Duh MS, Tak Piech C, Lefebvre P.

**An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.**

*Publication:* Cancer 2009 02; 115(4): 706-715. doi: 10.1002/cncr.24090.

*Authors:* Mundle S, Lefebvre P, Vekeman F, Duh MS, Rastogi R, Moyo V.

**Symptom assessment in relapsed small cell lung cancer: cross-validation of the patient symptom assessment in lung cancer instrument.**

*Abstract:* International Association for the Study of Lung Cancer 2008.

*Authors:* Chen L, Antras L, Duh MS, Neary M, O'Brien ME.

**Patients (PTS) with metastatic renal cell carcinoma (MRCC) receiving angiogenesis inhibitor (AIS) therapies: Treatment efficacy and safety in clinical practice.**

*Abstract:* 34th Congress of the European Society for Medical Oncology Conference Stockholm, Sweden Sep 12-16, 2008.

*Authors:* McDermott D, Choueiri TK, Clement J, Brick AJ, Kwabi C, Shah K, Banerjee A, Duh MS, Neary MP, Oh WK.

**Treatment and dosing patterns for angiogenesis inhibitor (AIS) therapies in patients with metastatic renal cell carcinoma (MRCC).**

*Abstract:* 34th Congress of the European Society for Medical Oncology, Stockholm, Sweden Sep 12-16, 2008.

*Authors:* Choueiri TK, Brick AJ, McDermott D, Clement J, Kwabi C, Shah K, Chen K, Duh MS, Neary MP, Oh WK.

**Costs associated with intravenous chemotherapy administration in patients with small cell lung cancer: a retrospective claims database analysis.**

*Publication:* Current Medical Research and Opinion 2008 04; 24(4): 967-974. doi: 10.1185/030079908X280464.

*Authors:* Duh MS, Reynolds Weiner J, Lefebvre P, Neary M, Skarin AT.

**Psychometric validation of the Patient Symptom Assessment in Lung Cancer instrument for small cell lung cancer.**

*Publication:* Current Medical Research and Opinion 2007 11; 23(11): 2741-2752. doi: 10.1185/030079907X233331.

*Authors:* Chen L, Antras L, Duh MS, Levy N, Neary M, O'Brien ME, von Pawel J.

**Dose and cost comparison of erythropoietic agents in the inpatient hospital setting.**

*Publication:* American Journal of Health-System Pharmacy 2007 09; 64(18): 1943-1949. doi: 10.2146/ajhp060585.

*Authors:* Vekeman F, McKenzie RS, Lefebvre P, Watson SH, Mody SH, Piech CT, Duh MS.

**Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients.**

*Publication:* Value in Health 2007 09; 10(5): 408-414. doi: 10.1111/j.1524-4733.2007.00195.x.

*Authors:* Wu EQ, Mulani P, Farrell MH, Sleep D.

**Is there a difference in the cost-effectiveness of erythropoietic therapies for the treatment of anemia in patients receiving HCV combination therapy?**

*Publication:* Hepatology 2007 07; 46(1): 283; author reply 283-284. doi: 10.1002/hep.21707.

*Authors:* Wu WK, Duh MS, Lefebvre P.

**Medical Costs Associated with Imatinib Non-compliance in Chronic Myeloid Leukemia Patients,.**

*Abstract:* ASCO Annual Meeting, Chicago, IL Jun 1-5, 2007.

*Authors:* Wu EQ, Feng W, Johnson S, Beaulieu N, Cremieux P, Cortes J.

**The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.**

*Publication:* Cancer 2007 03; 109(6): 1090-1096. doi: 10.1002/cncr.22504.

*Authors:* Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antras L, Smith M, Neary MP, Duh MS.

**Drug administration frequency and provider office visit patterns for oncology patients during treatment with erythropoietic agents: an analysis of four observational studies.**

*Publication:* Clinical Therapeutics 2006 10; 28(10): 1701-1708. doi: 10.1016/j.clinthera.2006.10.009.

*Authors:* Gosselin A, Pashos CL, Harley C, Mark TL, McKenzie RS.

**Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application.**

*Publication:* Journal of Oncology Pharmacy Practice 2006 09; 12(3): 165-178. doi: 10.1191/1078155206069925.

*Authors:* Cremieux P, Vekeman F, Lefebvre P.

**Dosing patterns, treatment costs, and frequency of physician visits in adults with cancer receiving erythropoietic agents in managed care organizations.**

*Publication:* Current Medical Research and Opinion 2006 09; 22(9): 1623-1631. doi: 10.1185/030079906X120968.

*Authors:* Lefebvre P, Gosselin A, McKenzie RS, Mody SH, Piech CT, Duh MS.

**Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors.**

*Publication:* Clinical Breast Cancer 2006 06; 7(2): 127-132. doi: 10.3816/CBC.2006.n.021.

*Authors:* Mincey BA, Duh MS, Thomas SK, Moyneur E, Marynchenko M, Boyce SP, Mallett D, Perez EA.

**Alkaline phosphatase predicts survival in patients with metastatic neuroendocrine tumors.**

*Publication:* Digestive Diseases and Sciences 2006 05; 51(5): 877-884. doi: 10.1007/s10620-006-9345-4.

*Authors:* Clancy TE, Sengupta TP, Paulus J, Ahmed F, Duh MS, Kulke MH.

**Clinical benefits of once-weekly epoetin alfa in anemic patients with colorectal cancer receiving chemotherapy.**

*Publication:* Journal of Supportive Oncology 2006 05; 4(5): 243-250.

*Authors:* Chu E, Einhorn LH, Lefebvre P.

**PCN33 Mapping FACT-P and EORTC QLQ-C30 to the EQ-5D health utility in metastatic hormone-refractory prostate cancer patients.**

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research 2006, 2006.

*Authors:* Wu E, Mulani P, Farrell M, Sleep D.



**Assessing the risk of clinical fracture in men with non-metastatic prostate cancer receiving gonadotropin-releasing hormone agonist therapy.**

*Publication:* Journal of Urology 2006 01; 175(1): 136-139.

*Authors:* Smith M, Boyce S, Moyneur E, Duh MS, Raut M, Brandman J.

**Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.**

*Publication:* Journal of Urology 2006 01; 175(1): 136-139; discussion 139. doi: 10.1016/S0022-5347(05)00033-9.

*Authors:* Smith MR, Boyce SP, Moyneur E, Duh MS, Raut MK, Brandman J.

**Dose-conversion ratio for epoetin alfa and darbepoetin alfa in chemotherapy patients with anemia and cancer.**

*Publication:* P AND T 2006 31(10): 594.

*Authors:* Gosselin A, McKenzie R, Lefebvre P, Mody S, Piech C, Duh M.

**Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia.**

*Publication:* Journal of the National Comprehensive Cancer Network 2005 11; 3(6): 807-816.

*Authors:* Campos SM, Duh MS, Lefebvre P, Rosberg J.

**The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia.**

*Publication:* Current Medical Research and Opinion 2005 10; 21(10): 1677-1682. doi: 10.1185/030079905X65501.

*Authors:* Ben-Hamadi R, Duh MS, Aggarwal J, Henckler A, McKenzie RS, Tak Piech C.

**Early hemoglobin response and alternative metrics of efficacy with erythropoietic agents for chemotherapy-related anemia.**

*Publication:* Current Medical Research and Opinion 2005 10; 21(10): 1527-1533. doi: 10.1185/030079905X65394.

*Authors:* Reed SD, Radeva JI, Daniel DB, Fastenau JM, Williams D, Schulman KA.

**Cost-effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia.**

*Publication:* Expert Review of Pharmacoeconomics & Outcomes Research 2005 08; 5(4): 383-394. doi:

10.1586/14737167.5.4.383.

*Authors:* Duh MS, L Mark T.

**Assessing the clinical benefits of erythropoietic agents using area under the hemoglobin change curve.**

*Publication:* Oncologist 2005 06; 10(6): 438-448. doi: 10.1634/theoncologist.10-6-438.

*Authors:* Duh MS, Lefebvre P, Fastenau J, Piech CT, Waltzman RJ.

**Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.**

*Publication:* Women's Health Issues 2005 05; 15(3): 97-108. doi: 10.1016/j.whi.2004.11.006.

*Authors:* Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D.

**Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anaemia : a meta-analysis.**

*Publication:* Clinical Drug Investigation 2005 25(1): 33-48.

*Authors:* Rosberg JH, Ben-Hamadi R, Cremieux PY, Fastenau JM, Piech CT.

**Cost-minimization analysis of once-weekly versus thrice-weekly epoetin alfa for chemotherapy-related anemia.**

*Publication:* Journal of Managed Care Pharmacy 2004 11; 10(6): 531-537.

*Authors:* Cremieux PY, Fastenau JM, Kosicki G, Piech CT, Fendrick AM.

**PCN6: Dose conversion of erythropoietic agents in chemotherapy-induced anemia: A meta-analysis.**

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research 2003, 2003.

*Authors:* Rosberg J, Oster E, Wu E, Fastenau J, Piech C.

**Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy.**

*Publication:* Cancer 2002 08; 95(4): 888-895. doi: 10.1002/cncr.10763.

*Authors:* Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA.

**Statistical explanations for a community-based study of once-weekly epoetin alfa therapy in patients receiving chemotherapy.**

*Publication:* Journal of Clinical Oncology 2002 06; 20(11): 2757-2758.

*Authors:* Gabrilove JL, Sarokhan B, Cremieux P.

**Anemia-related costs for cancer patients.**

*Publication:* Journal of Managed Care Medicine 2002 6(1): 20-28.

*Authors:* Barnett A, Cremieux P, Fendrick A, George M, Slavin M.

**Cost Effectiveness of rHuEPO in Oncology.**

*Publication:* Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology: Scientific and Clinical Aspects of Anemia in Cancer 2002.

*Authors:* Cremieux P, Dial E, Gustafson M, Saraokhan B, Slavin M.

**The costs of cancer: cancer-related conditions can add dramatically to overall costs of care.**

*Publication:* Journal of Managed Care Medicine 2002 6(1): 12-19.

*Authors:* Cremieux P, Slavin M, Fendrick A, Hiriak T, Kosicki G.

**The costs of cancer to a major employer in the United States: a case-control analysis.**

*Publication:* American Journal of Managed Care 2000 11; 6(11): 1243-1251.

*Authors:* Barnett A, Birnbaum H, Cremieux PY, Fendrick AM, Slavin M.

**Cost of outpatient blood transfusion in cancer patients.**

*Publication:* Journal of Clinical Oncology 2000 07; 18(14): 2755-2761.

*Authors:* Cremieux PY, Barrett B, Anderson K, Slavin MB.

**Costs Associated with Anemia and Cancer.**

*Publication:* ONE: Oncology Economics 2000 1(11): 1-7.

*Authors:* Cremieux PY GM, Holland M, Slavin MB.

**Understanding the Pharmacoeconomic profile of cancer.**

*Publication:* ONE: Oncology Economics 2000 1(10): 36-39.

*Authors:* Cremieux PY BH, Greenberg PE.

**Cost effectiveness, quality-adjusted life-years and supportive care. Recombinant human erythropoietin as a treatment of cancer-associated anaemia.**

*Publication:* Pharmacoeconomics 1999 11; 16(5 Pt 1): 459-472.

*Authors:* Cremieux PY, Finkelstein SN, Berndt ER, Crawford J, Slavin MB.

## Renal

### **The Economic Burden of Nocturia on the U.S. Health Care System and Society: A National Health and Nutrition Examination Survey Analysis.**

*Publication:* Journal of Managed Care & Specialty Pharmacy 2019 09; 0(0): 1-13. doi: 10.18553/jmcp.2019.19191.

*Authors:* Jhaveri J, Gauthier-Loiselle M, Gagnon-Sanschagrin P, Wu EQ.

### **Economic and clinical benefits of early identification of acute kidney injury using a urinary biomarker.**

*Publication:* Journal of Medical Economics 2019 07: 1-9. e-pub ahead of print 2019/06/27; doi:

10.1080/13696998.2019.1636053.

*Authors:* Berdugo MA, Kirson NY, Zimmer L, Beyhaghi H, Toback S, Scarpatti LM, Stone MN, Dember R, Tseng-Tham J, Wen J, Miller M.

### **Healthcare resource utilization and associated costs of cytomegalovirus management among solid organ transplant recipients.**

*Abstract:* 2019 American Transplant Congress, ATC 2019, Boston, MA Jun 1-5, 2019.

*Authors:* Cheng WY, Thompson-Leduc P, Cheung H, Avery R, Bo T, Chavan S, Duh M, Hirji I.

### **Prevalence and Factors Associated with Undiagnosed Chronic Kidney Disease in Diabetes Mellitus.**

*Abstract:* NKF 2019 Spring Clinical Meetings, Boston, MA May 8-12, 2019.

*Authors:* Bakris G, Coresh J, Vassalotti J, Weir M, Pilon D, Bailey R, Blais J, Durkin M.

### **Puk10 Societal Burden of Autosomal Dominant Polycystic Kidney Disease (Adpkd) in the United States: Beyond Healthcare Costs.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Cloutier M, Manceur AM, Guerin A, Sanon M, Oberdhan D, Gauthier-Loiselle M.

### **Societal Burden of Autosomal Dominant Polycystic Kidney Disease (ADPKD) in the United States: Beyond Healthcare Costs.**

*Abstract:* ISPOR 24th Annual International Meeting, New Orleans, LA May 18-22, 2019.

*Authors:* Cloutier M, Manceur AM, Guerin A, Sanon MA, Oberdhan D, Gauthier-Loiselle M.

### **Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review.**

*Publication:* Journal of Medical Economics 2019 02: 1-12. e-pub ahead of print 2019/03/01; doi:

10.1080/13696998.2019.1588738.

*Authors:* Spinowitz B, Pecoits-Filho R, Winkelmayer WC, Pergola PE, Rochette S, Thompson-Leduc P, Lefebvre P, Shafai G, Bozas A, Sanon M, Krasa HB.

### **Pcn22 Clinical Heterogeneity among First-Line Sunitinib Patients with Metastatic Renal Cell Carcinoma (Mrcc) Categorized as Intermediate Risk (Ir) Group According to the International Mrcc Database Consortium (Imdc) Risk Model.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Huynh L, Wells JC, Graham J, Steinharter J, McGregor B, Donskov F, Bjarnason GA, Vaishampayan U, Hansen A, lafolla M, Zanolli G, Chang R, Cheng WY, Duh MS, Heng DYC.

### **Economic and humanistic burden of dialysisdependent patients with chronic kidney diseaserelated anemia: A systematic review.**

*Abstract:* 55th Annual Congress of the European Renal Association-European Dialysis and Transplant Association, Copenhagen, Denmark May 24-27, 2018.

*Authors:* Spinowitz B, Pecoits-Filho R, Winkelmayer W, Rochette S, Thompson-Leduc P, Lefebvre P, Bozas A, Krasa H.

**Impact of renal function on ischemic stroke and major bleeding rates in nonvalvular atrial fibrillation patients treated with warfarin or rivaroxaban: a retrospective cohort study using real-world evidence.**

*Publication:* Current Medical Research and Opinion 2017 10; 33(10): 1891-1900. e-pub ahead of print 2017/06/08; doi: 10.1080/03007995.2017.1339674.

*Authors:* Weir MR, Berger JS, Ashton V, Laliberte F, Brown K, Lefebvre P, Schein J.

**The burden of hepatorenal syndrome among commercially insured and Medicare patients in the United States.**

*Publication:* Current Medical Research and Opinion 2017 08; 33(8): 1473-1480. e-pub ahead of print 2017/05/17; doi: 10.1080/03007995.2017.1331211.

*Authors:* Rice JB, White AG, Galebach P, Korenblat KM, Wagh A, Lovelace B, Wan GJ, Jamil K.

**Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.**

*Publication:* J Manag Care Spec Pharm 2016 10; 22(10): 1204-1214. doi: 10.18553/jmcp.2016.22.10.1204.

*Authors:* DerSarkissian M, Xiao Y, Duh MS, Lefebvre P, Swensen AR, Bell CF.

**The economic burden of hyperkalemia among patients with chronic kidney disease and/or heart failure.**

*Abstract:* AMCP Nexus 2016, Baltimore, MD Oct 3-6, 2016.

*Authors:* Betts KA, Woolley JM, Mu F, Xiang C, Tang W, Pham H, Hollenack K, Singhanian A, Wu E.

**Systematic Literature Review of DPP-4 Inhibitors in Patients with Type 2 Diabetes Mellitus and Renal Impairment.**

*Publication:* Diabetes Therapy 2016 09; 7(3): 439-454. e-pub ahead of print 2016/08/10; doi: 10.1007/s13300-016-0189-4.

*Authors:* Thomas MC, Paldanius PM, Ayyagari R, Ong SH, Groop PH.

**Resource utilization of adult patients with sporadic angiomyolipoma in the Netherlands.**

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland Aug 25-28, 2016.

*Authors:* Vekeman F, Magestro M, Karner P, Fortier J, Duh MS, Zonnenberg BA.

**Natural history for adult patients with sporadic angiomyolipoma in the Netherlands.**

*Abstract:* 53rd ERA-EDTA Congress, Vienna, Austria May 21-24, 2016.

*Authors:* Vekeman F, Magestro M, Karner P, Fortier J, Duh MS, Zonnenberg BA.

**Development and validation of an algorithm for identifying urinary retention in a cohort of patients with epilepsy in a large US administrative claims database.**

*Publication:* Pharmacoepidemiology and Drug Safety 2016 04; 25(4): 413-421. e-pub ahead of print 2016/02/19; doi: 10.1002/pds.3975.

*Authors:* Quinlan SC, Cheng WY, Ishihara L, Irizarry MC, Holick CN, Duh MS.

**Kidney involvement in tuberous sclerosis complex: The impact on health care resource use and costs in The Netherlands.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Zonnenberg BA.

**Kidney involvement in tuberous sclerosis complex: The impact on healthcare resource use and costs.**

*Publication:* Journal of Medical Economics 2015 01; 18(12): 1060-1070. doi:

<http://dx.doi.org/10.3111/13696998.2015.10759953>.

*Authors:* Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

**Healthcare resource use and costs of privately insured patients who switch, discontinue, or persist on anti-muscarinic therapy for overactive bladder.**

*Publication:* Journal of Medical Economics 2014 10; 17(10): 741-750. doi: 10.3111/13696998.2014.941066.

*Authors:* Ivanova JI, Hayes-Larson E, Sorg RA, Birnbaum HG, Berner T.

**The healthcare cost impacts of switching antimuscarinic agents among patients with overactive bladder in a privately insured population.**

*Abstract:* AUGS/IUGA Scientific Meeting, Washington, DC Jul 22-26, 2014.

*Authors:* Ivanova J, Hayes-Larson E, Sorg R, Birnbaum H.

**Health care costs among patients who continue therapy or switch antimuscarinic agents for overactive bladder.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Ivanova J, Hayes-Larson E, Sorg RA, Birnbaum HG, Fitzmartin J, Berner T.

**Healthcare costs among patients who continue therapy or switch antimuscarinic agents for overactive bladder.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Ivanova JI, Hayes-Larson E, Sorg RA, Birnbaum HG, Berner G.

**Kidney dysfunction and healthcare resource utilization in tuberous sclerosis complex patients in the Netherlands.**

*Abstract:* 51st ERA-EDTA Congress, Amsterdam, Netherlands May 31-Jun 3, 2014.

*Authors:* Magestro M, Vekeman F, Nichols T, Karner P, Duh MS, Srivastava B, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

**Development and validation of a claims-based algorithm to identify urinary retention in patients receiving antiepileptic drugs.**

*Abstract:* 29th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Montreal, QC, Canada Aug 25-28, 2013.

*Authors:* Duh MS, Ishihara L, Cheng W, Quinlan SC, Zhao Y, Irizarry M.

**Development and validation of a new chronic kidney disease risk equation: The role of pulse pressure.**

*Abstract:* European Society of Cardiology, Amsterdam, Netherlands Aug 31 - Sep 4, 2013.

*Authors:* Ayyagari R, Vekeman F, Faust E, Ong S, Trahey A, Lefebvre P, Machnicki G, Duh M.

**Serum urate and incidence of kidney disease among veterans with gout.**

*Publication:* Journal of Rheumatology 2013 07; 40(7): 1166-1172. doi: 10.3899/jrheum.121061.

*Authors:* Krishnan E, Akhras KS, Sharma H, Marynchenko M, Wu E, Tawk RH, Liu J, Shi L.

**Vitala™ Continence Control Device vs. Traditional Pouch System: A Comparison of Health-Related Quality-of-Life.**

*Abstract:* 12th European Council of Enterostomal Therapy Congress, Paris, France June 23-26, 2013.

*Authors:* Yan S, Warusavitarne J, Yang M, van den Broek N, Wu EQ, Thomason D, Hoch J.

**Impact of mirabegron treatment and symptom severity on work productivity and activity impairment in patients with overactive bladder.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* De G, Yang H, Runken M, Yan Y, Kelkar S, Bui C, Xie J, Wu E.

**Cost-effectiveness analysis of mirabegron versus tolterodine extended release in the treatment of patients with overactive bladder in the United States.**

*Abstract:* ISPOR 15th Annual European Congress, Berlin, Germany Nov 3-7, 2012.

*Authors:* Xie J, Zhou ZY, Bui CN, Yan Y, De G, Runken MC, Wu EQ.

**Uncontrolled serum uric acid is associated with an increased risk of developing renal disease in veterans with gout.**

*Abstract:* Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals, Chicago, IL Nov 4-9, 2011.

*Authors:* Krishnan E, Sharma H, Pandya BJ, Marynchenko M, Yu A, Wu E, Liu J.

**Clinical and economic impact of vagus nerve stimulation therapy in patients with drug-resistant epilepsy.**

*Publication:* Epilepsy & Behavior 2011 10; 22(2): 370-375. doi: 10.1016/j.yebeh.2011.07.020.

*Authors:* Helmers SL, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E.

**Dosing pattern and cost comparison of epoetin alfa and darbepoetin alfa in chronic kidney disease and chemotherapy-induced anemia inpatients.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Lafeuille MH, Bailey RA, Senbetta M, McKenzie RS, Lefebvre P.

**Healthcare costs associated with nephrology care in pre-dialysis chronic kidney disease patients.**

*Publication:* Journal of Medical Economics 2010 11; 13(4): 673-680. doi: 10.3111/13696998.2010.529032.

*Authors:* Vekeman F, Yameogo ND, Lefebvre P, Bailey RA, McKenzie RS, Piech CT.

**Drug utilization and cost for erythropoiesis-stimulating agents in a long-term care resident population with chronic kidney disease.**

*Publication:* Consultant Pharmacist 2010 08; 25(8): 493-500. doi: 10.4140/TCP.n.2010.493.

*Authors:* Lafeuille MH, Bailey RA, Vekeman F, Kilpatrick BS, Senbetta M, Piech CT, Lefebvre P.

**Assessment of recent erythropoiesis-stimulating agent guidelines changes on dosing patterns in chronic kidney disease patients not on dialysis.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19 2010.

*Authors:* Lafeuille MH, Bailey RA, Laliberte F, Senbetta M, Vekeman F, McKenzie RS, Blacksmith A, Lefebvre P.

**Erythropoiesis-stimulating agent dosing and hemoglobin trends over time in chronic kidney disease patients not on dialysis.**

*Abstract:* ISPOR 15th Annual International Meeting Atlanta, GA May 15-19, 2010.

*Authors:* Lafeuille MH, Bailey RA, Laliberte F, Senbetta M, Vekeman F, McKenzie RS, Dea K, Lefebvre P.

**Seven year trends of pharmacy benefit erythropoiesisstimulating agent utilization and cost considerations of chronic kidney disease patients not on dialysis.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Vekeman F, Bailey RA, Laliberte F, Senbetta M, McKenzie RS, Lefebvre P.

**Renal toxicity in patients with multiple myeloma receiving zoledronic acid vs. ibandronate: a retrospective medical records review.**

*Publication:* Journal of Cancer Research and Therapeutics 2010 01; 6(1): 31-35. doi: 10.4103/0973-1482.63570.

*Authors:* Weide R, Koppler H, Antras L, Smith M, Chang MP, Green J, Wintfeld N, Neary MP, Duh MS.

**Risk of renal impairment after treatment with ibandronate versus zoledronic acid: a retrospective medical records review.**

*Publication:* Supportive Care in Cancer 2009 06; 17(6): 719-725. doi: 10.1007/s00520-008-0553-7.

*Authors:* Diel IJ, Weide R, Koppler H, Antras L, Smith M, Green J, Wintfeld N, Neary M, Duh MS.

**Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.**

*Publication:* Journal of Managed Care Pharmacy 2009 05; 15(4): 312-322.

*Authors:* Laliberte F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

**Erythropoietin therapy and left ventricular mass index in CKD and ESRD patients: a meta-analysis.**

*Publication:* Clinical Journal of the American Society of Nephrology 2009 04; 4(4): 755-762. doi: 10.2215/CJN.02730608.

*Authors:* Parfrey PS, Lauve M, Latremouille-Viau D, Lefebvre P.

**The economic impact of pre-dialysis epoetin alpha on health care and work loss costs in chronic kidney disease: an employer's perspective.**

*Publication:* Disease Management 2008 02; 11(1): 49-58. doi: 10.1089/dis.2008.111715.

*Authors:* Moyneur E, Bookhart BK, Mody SH, Fournier AA, Mallett D, Duh MS.

**Medical and work loss burden of pre-dialysis chronic kidney disease and related anemia: An employer's perspective.**

*Publication:* Journal of Health & Productivity 2007 10: 309.

*Authors:* Moyneur E BB, Mody SH, Fournier A, Mallet D, Duh MS.

**Comment on: The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.**

*Publication:* Current Medical Research and Opinion 2007 07; 23(7): 1571-1573; author reply 1573-1574. doi: 10.1185/030079907X199655.

*Authors:* Einarson T, Machado M, Walker J, Iskedjian M.

**The economic impact of epoetin alfa therapy on delaying time to dialysis in elderly patients with chronic kidney disease.**

*Publication:* Disease Management 2007 02; 10(1): 37-45. doi: 10.1089/dis.2006.626.

*Authors:* Lefebvre P, Duh MS, Mody SH, Bookhart B, Piech CT.

**Dosing patterns and treatment costs of erythropoietic agents in elderly patients with pre-dialysis chronic kidney disease in managed care organisations.**

*Publication:* Drugs and Aging 2006 12; 23(12): 969-976.

*Authors:* Duh MS, Mody SH, McKenzie RS, Lefebvre P, Gosselin A, Bookhart BK, Piech CT.

**Medical costs of untreated anemia in elderly patients with predialysis chronic kidney disease.**

*Publication:* Journal of the American Society of Nephrology 2006 12; 17(12): 3497-3502. doi: 10.1681/ASN.2006030289.

*Authors:* Lefebvre P, Duh MS, Buteau S, Bookhart B, Mody SH.

**The relative dosing of epoetin alfa and darbepoetin alfa in chronic kidney disease.**

*Publication:* Current Medical Research and Opinion 2006 12; 22(12): 2329-2336. doi: 10.1185/030079906X154024.

*Authors:* Cremieux PY, Van Audenrode M, Lefebvre P.

**Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin alfa.**

*Publication:* Current Medical Research and Opinion 2006 10; 22(10): 1929-1937. doi: 10.1185/030079906X132541.

*Authors:* Lefebvre P, Vekeman F, Sarokhan B, Enny C, Provenzano R, Cremieux PY.

**Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations.**

*Publication:* Clinical Therapeutics 2006 09; 28(9): 1443-1450. doi: 10.1016/j.clinthera.2006.09.020.

*Authors:* Duh MS, Mody SH, Scott McKenzie R, Lefebvre P, Gosselin A, Tak Piech C.

**A retrospective claims database analysis to assess patterns of interstitial cystitis diagnosis.**

*Publication:* Current Medical Research and Opinion 2006 03; 22(3): 495-500. doi: 10.1185/030079906X80431.

*Authors:* Wu EQ, Birnbaum H, Kang YJ, Parece A, Mallett D, Taitel H, Evans RJ.

**Comorbidity contributes to high treatment cost of interstitial cystitis.**

*Publication:* Pharmacoeconomics & Outcomes News 2006 02; (497): 6.

*Authors:* Wu E.

**Interstitial Cystitis: Cost, treatment and co-morbidities in an employed population.**

*Publication:* Pharmacoeconomics 2006 02; 24(1): 55-65.

*Authors:* Wu EQ, Birnbaum H, Mareva M, Parece A, Huang Z, Mallett D, Taitel H.

**Employees with overactive bladder: work loss burden.**

*Publication:* Journal of Occupational Environmental Medicine 2005 05; 47(5): 439-446.

*Authors:* Wu EQ, Birnbaum H, Marynchenko M, Mareva M, Williamson T, Mallett D.

**PUK9 Interstitial Cystitis Costs, Treatment and Comorbidities in an Employed Population.**

*Publication:* Value in Health 2005 8(3): 415-416. doi: 10.1016/S1098-3015(10)63135-X.

*Authors:* Wu EQ, Birnbaum H, Parece A, Kang YJ, Mareva MN, Taitel H.

**Cost of stress urinary incontinence: a claims data analysis.**

*Publication:* Pharmacoeconomics 2004 01; 22(2): 95-105.

*Authors:* Birnbaum HG, Leong SA, Oster EF, Kinchen K, Sun P.

**Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence.**

*Publication:* Women's Health Issues 2003 11; 13(6): 204-213.

*Authors:* Birnbaum H, Leong S, Kabra A.

**Dose conversion from epoetin alfa to darbepoetin alfa for patients with chronic kidney disease receiving hemodialysis.**

*Publication:* Pharmacotherapy 2003 05; 23(5): 690-693; discussion 693-694.

*Authors:* Barnett AL, Cremieux PY.

## Respiratory

**Medication adherence and persistence in chronic obstructive pulmonary disease patients receiving triple therapy in a USA commercially insured population.**

*Publication:* International Journal of Chronic Obstructive Pulmonary Disease 2019 12; 14: 343-352. e-pub ahead of print 2019/03/14; doi: 10.2147/COPD.S184653.

*Authors:* Bogart M, Stanford RH, Laliberte F, Germain G, Wu JW, Duh MS.

**Characterizing Real-World Use Of Tiotropium In Asthma In The USA.**

*Publication:* J Asthma Allergy 2019 10; 12: 309-321. e-pub ahead of print 2019/10/22; doi: 10.2147/jaa.S216932.

*Authors:* Averell CM, Laliberte F, Duh MS, Wu JW, Germain G, Faison S.

**Medication adherence in patients with asthma using once-daily versus twice-daily ICS/LABAs.**

*Publication:* Journal of Asthma 2019 10; 1-10. e-pub ahead of print 2019/10/15; doi: 10.1080/02770903.2019.1663429.

*Authors:* Averell CM, Stanford RH, Laliberte F, Wu JW, Germain G, Duh MS.

**Characteristics and Management of Patients Following Pulmonary Embolism: A Focus on Screening for Chronic Thromboembolic Pulmonary Hypertension.**

*Abstract:* ISHLT 39th Annual Meeting and Scientific Sessions, Orlando, FL Apr 3-6, 2019.

*Authors:* Kanwar M, Cole M, Gauthier-Loiselle M, Manceur AM, Lickert C, Greenberg M, Lefebvre P, Drake W, Benza R.



**Comorbidity and Economic Burden of Peanut Allergy in Privately-Insured Patients in the United States.**

*Abstract:* AMCP's 31st Annual Meeting, San Diego, CA Mar 25-28, 2019.

*Authors:* Tilles S, Birchwood C, Robison D, Damle V, Norrett K, Hass S, Guerin A, Latremouille-Viau D.

**Healthcare Resource Utilization and Direct Healthcare Cost Related to Peanut Allergy in Medicaid Patients.**

*Abstract:* AMCP's 31st Annual Meeting, San Diego, CA Mar 25-28, 2019.

*Authors:* Tilles S, Birchwood C, Robison D, Damle V, Norrett K, Hass S, Guerin A, Latremouille-Viau D.

**Biomarkers and Outcomes in Omalizumab-Treated Patients with Allergic Asthma: A Real-World Study in a Large Allergy Practice in the United States (US).**

*Abstract:* 2019 AAAAI Annual Meeting, San Francisco, CA Feb 22-25, 2019.

*Authors:* Ortiz B, Kavati A, Zhdanava M, Lecocq J, Schiffman B, Pilon D, Ho H, Stone BD.

**Long-Term Outcomes of Omalizumab in Chronic Idiopathic Urticaria (CIU): Evidence from a Large Allergy Practice in the United States (US).**

*Abstract:* 2019 AAAAI Annual Meeting, San Francisco, CA Feb 22-25, 2019.

*Authors:* Lecocq J, Kavati A, Zhdanava M, Ortiz B, Schiffman B, Cheung HC, Lefebvre P, Stone BD.

**Omaliuzumab Treatment Patterns in Chronic Idiopathic Urticaria (CIU): Evidence from a Large Allergy Practice in the United States (US).**

*Abstract:* 2019 AAAAI Annual Meeting, San Francisco, CA Feb 22-25, 2019.

*Authors:* Stone BD, Kavati A, Zhdanava M, Ortiz B, Lecocq J, Schiffman B, Cheung HC, Lefebvre P.

**Clinical burden of asynchrony in patients with asthma when using metered-dose inhalers for control.**

*Publication:* Allergy and Asthma Proceedings 2019 01; 40(1): 21-31. doi: <http://dx.doi.org/10.2500/aap.2019.40.4192>.

*Authors:* Ferro TJ, Sundaresan AS, Pitcavage JM, Ivanova JI, Schmerold L, Ariely R, Parikh R, Cheng WY.

**Health characteristics of patients with asthma, COPD and asthma-COPD overlap in the NHANES database.**

*Publication:* International Journal of Chronic Obstructive Pulmonary Disease 2018 09; 13: 2859-2868. e-pub ahead of print 2018/09/27; doi: 10.2147/COPD.S167379.

*Authors:* Llanos JP, Ortega H, Germain G, Duh MS, Lafeuille MH, Tiggelaar S, Bell CF, Hahn B.

**Burden of disease associated with a COPD eosinophilic phenotype.**

*Publication:* International Journal of Chronic Obstructive Pulmonary Disease 2018 08; 13: 2425-2433. e-pub ahead of print 2018/08/28; doi: 10.2147/COPD.S170995.

*Authors:* Ortega H, Llanos JP, Lafeuille MH, Germain G, Duh MS, Bell CF, Sama SR, Hahn B.

**Effects of Systemic Corticosteroids on Blood Eosinophil Counts in Asthma: Real-World Data.**

*Publication:* Journal of Asthma 2018 08; 1-26. e-pub ahead of print 2018/08/22; doi: 10.1080/02770903.2018.1502301.

*Authors:* Ortega H, Llanos JP, Lafeuille MH, Duh MS, Germain G, Lejeune D, Sama S, Bell C, Hahn B.

**Health care resource utilization of conjunctivitis in the general population and in patients with prior antibiotic-resistant infection: A retrospective US claims-based analysis.**

*Abstract:* 34th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Prague, Czech Republic Aug 22-26, 2018.

*Authors:* Cheng W, McCormick N, Duh MS, Cheung HC, Bobbili P, Joseph C, Sarda S.

**Characterizing real-world use of lamas in asthma in the US.**

*Abstract:* American Thoracic Society International Conference, ATS, San Diego, CA May 18-23, 2018.

*Authors:* Averell CM, Laliberte F, Duh M, Wu JW, Germain G, Katial R, Faison S.

**Do blood eosinophils play a role in burden of illness in patients with COPD?**

*Abstract:* American Thoracic Society International Conference, ATS, San Diego, CA May 18-23, 2018.

*Authors:* Hahn B, Ortega H, Bell C, Lafeuille M, Duh M, Germain G, Llanos J.

**Healthcare resource utilization of conjunctivitis in the general population and in patients with prior antibiotic-resistant infection: A retrospective us claims-based analysis.**

*Publication:* Value in Health 2018 05; 21 (Supplement 1): S243.

*Authors:* Cheng WY, McCormick N, Duh MS, Cheung HC, Bobbili PJ, Joseph C, Sarda SP.

**Medication adherence and persistence in chronic obstructive pulmonary disease (COPD) patients on triple therapy in a us commercially-insured population.**

*Abstract:* American Thoracic Society International Conference, ATS, San Diego, CA May 18-23, 2018.

*Authors:* Bogart M, Laliberte F, Duh MS, Wu JW, Germain G, Stanford RH.

**Procalcitonin guidance in patients with lower respiratory tract infections: a systematic review and meta-analysis.**

*Publication:* Clinical Chemistry and Laboratory Medicine 2018 05; 56(8): 1200-1209. e-pub ahead of print 2018/05/02; doi: 10.1515/cclm-2018-0126.

*Authors:* Hey J, Thompson-Leduc P, Kirson NY, Zimmer L, Wilkins D, Rice B, Iankova I, Krause A, Schonfeld SA, DeBrase CR, Bozzette S, Schuetz P.

**Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab.**

*Publication:* Allergy and Rhinology 2018 04; 9(no pagination). doi: <http://dx.doi.org/10.1177/2152656718763387>.

*Authors:* Kavati A, Pilon D, Ortiz B, Paknis B, Vegesna A, Schiffman B, Zhdanava M, Lefebvre P, Stone B.

**Asthma control, lung function, symptoms, and corticosteroid sparing after omalizumab initiation in patients with allergic asthma.**

*Publication:* Allergy and Asthma Proceedings 2018 03; 39(2): 127-135. e-pub ahead of print 2017/12/07; doi: 10.2500/aap.2018.39.4111.

*Authors:* Pilon D, Kavati A, Ortiz B, Paknis B, Vegesna A, Schiffman B, Zhdanava M, Lefebvre P, Stone B.

**Claims-based risk model for first severe COPD exacerbation.**

*Publication:* American Journal of Managed Care 2018 02; 24(2): e45-e53. e-pub ahead of print 2018/02/21.

*Authors:* Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M, Merrigan JFP, Duh MS.

**A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.**

*Publication:* International Journal of Chronic Obstructive Pulmonary Disease 2017 06; 12: 1825-1836. e-pub ahead of print 2017/07/08; doi: 10.2147/COPD.S129007.

*Authors:* Mapel D, Laliberte F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.

**A prospective assessment of healthcare utilization and costs associated with symptom burden measured by mmrc and cat.**

*Abstract:* American Thoracic Society International Conference, Washington, DC May 19-24, 2017.

*Authors:* Stanford RH, Mapel D, Roberts M, Pilon D, Laliberte F, Lefebvre P, Sama S, Emond B, Duh M.

**Readmission Risk in Chronic Obstructive Pulmonary Disease Patients: Comparative Study of Nebulized beta2-Agonists.**

*Publication:* Drugs Real World Outcomes 2017 03; 4(1): 33-41. e-pub ahead of print 2016/11/20; doi: 10.1007/s40801-016-0097-y.

*Authors:* Bollu V, Guerin A, Gauthier G, Hiscock R, Wu EQ.

**Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.**

*Publication:* Hospital Practice 2017 02; 45(1): 1-8. e-pub ahead of print 2017/01/10; doi: 10.1080/21548331.2017.1279012.

*Authors:* Llop CJ, Tuttle E, Tillotson GS, LaPlante K, File TM, Jr.

**Comparative efficacy of long-acting beta2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.**

*Publication:* International Journal of Chronic Obstructive Pulmonary Disease 2017 02; 12: 367-381. e-pub ahead of print 2017/02/09; doi: 10.2147/copd.s119908.

*Authors:* Donohue JF, Betts KA, Du EX, Altman P, Goyal P, Keininger DL, Gruenberger JB, Signorovitch JE.

**Burden of systemic glucocorticoid-related complications in severe asthma.**

*Publication:* Current Medical Research and Opinion 2017 01; 33(1): 57-65. e-pub ahead of print 2016/09/15; doi: 10.1080/03007995.2016.1233101.

*Authors:* Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA.

**Patient Characteristics, Clinical Outcomes and Healthcare Resource Utilization Among IPF Patients Stratified by Lung Function at Diagnosis.**

*Publication:* American Journal of Respiratory and Critical Care Medicine 2017: A1133-A1133. doi: 10.1164/ajrccm-conference.2017.195.1\_MeetingAbstracts.A1133.

*Authors:* Nathan S, Macaulay D, Garcia Horton V, Terasawa E, Yu Y.

**Characteristics and outcomes of patients with hospital-acquired pneumonia (HAP).**

*Abstract:* ISPOR 19th Annual European Congress, Vienna, Austria Oct 29 - Nov 2, 2016.

*Authors:* Han S, Xie J, Song H, Zhang C, Wu EQ.

**Feasibility of matching-adjusted indirect comparison (MAIC) of omalizumab (OMA) vs. mepolizumab (MEPO) in moderate-to-severe asthma.**

*Abstract:* ISPOR 19th Annual European Congress, Vienna, Austria Oct 29 - Nov 2, 2016.

*Authors:* Ayyagari R, Alvares L, Mu F, Hacking V, Martinez R, Signorovitch JE.

**Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma.**

*Publication:* J Manag Care Spec Pharm 2016 07; 22(7): 833-847. doi: 10.18553/jmcp.2016.22.7.833.

*Authors:* Dalal AA, Duh MS, Gozalo L, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Lefebvre P.

**Validation of a New Risk Measure for Chronic Obstructive Pulmonary Disease Exacerbation Using Health Insurance Claims Data.**

*Publication:* Ann Am Thorac Soc 2016 07; 13(7): 1067-1075. e-pub ahead of print 2016/04/14; doi: 10.1513/AnnalsATS.201508-493OC.

*Authors:* Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Vekeman F, Gauthier-Loiselle M, Duh MS, Merrigan JF, Schatz M.

**Spectrum of idiopathic pulmonary fibrosis severity in clinical practice: implications for clinical trial feasibility and design.**

*Abstract:* American Thoracic Society International Conference, San Francisco, CA May 13-18, 2016.

*Authors:* Macaulay D, Nathan SD, Terasawa E, Yu Y.

**Acute and chronic systemic corticosteroid-related complications in patients with severe asthma.**

*Publication:* Journal of Allergy and Clinical Immunology 2015 12; 136(6): 1488-1495. e-pub ahead of print 2015/09/29; doi: 10.1016/j.jaci.2015.07.046.

*Authors:* Lefebvre P, Duh MS, Lafeuille MH, Gozalo L, Desai U, Robitaille MN, Albers F, Yancey S, Ortega H, Forshag M, Lin X, Dalal AA.

**Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization.**

*Publication:* Respiratory Medicine 2015 12; 109(12): 1582-1588. doi: 10.1016/j.rmed.2015.11.001.

*Authors:* Yu YF, Macaulay DS, Reichmann WM, Wu EQ, Nathan SD.

**Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.**

*Publication:* BMC Pulmonary Medicine 2015 12; 15(167): 167. doi: 10.1186/s12890-015-0161-5.

*Authors:* Reichmann WM, Yu YF, Macaulay D, Wu EQ, Nathan SD.

**Clinical and Economic Burden of Pulmonary Exacerbations In Patients with Cystic Fibrosis Who are Homozygous for the F508del Mutation.**

*Publication:* International Society for Pharmacoeconomics and Outcomes Research 2015 11; 18(7): A658-659. e-pub ahead of print 2015/11/05; doi: 10.1016/j.jval.2015.09.2386.

*Authors:* O'Sullivan AK, Signorovitch JE, Fang A, Wagener J, Hodgkins P.

**Inpatient Burden Among Patients with Cystic Fibrosis Who Are Homozygous for the F508del Mutation.**

*Abstract:* ISPOR 18th Annual European Congress, Milan, Italy Nov 7-11, 2015.

*Authors:* Hodgkins P, Ayyagari R, Guo J, Wagener J, O'Sullivan AK.

**Association of change in forced vital capacity with healthcare resource utilization in patients with newly diagnosed idiopathic pulmonary fibrosis.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Reichmann WM, Yu Y, Macaulay D, Nathan SD.

**Change in forced vital capacity and clinical outcomes in newly diagnosed idiopathic pulmonary fibrosis patients.**

*Abstract:* American Thoracic Society International Conference, Denver, CO May 15-20, 2015.

*Authors:* Nathan SD, Reichmann WM, Macaulay D, Yu YF.

**Cost and resource utilization in hospital-treated cap patients.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Tuttle EG, Llop CJ.

**Economic and clinical burden of acute and chronic systemic corticosteroid-related complications in asthma patients Respiratory Disease.**

*Abstract:* American Thoracic Society International Conference, Denver, CO May 15-20, 2015.

*Authors:* Lefebvre P, Mei Sheng D, Lafeuille MH, Gozalo L, Desai U, Albers F, Yancey S, Ortega HG, Forshag M, Lin X, Dalal AA.

**Impact of suspected idiopathic pulmonary fibrosis acute exacerbations on clinical and healthcare resource utilization outcomes.**

*Abstract:* American Thoracic Society International Conference, Denver, CO May 15-20, 2015.

*Authors:* Nathan SD, Reichmann WM, Macaulay D, Yu YF.

**Time to treatment augmentation among patients with chronic obstructive pulmonary disease (COPD) newly initiated on long acting muscarinic agents (LAMA) or inhaled corticosteroid (ICS) and long acting beta-2 agonist (LABA) combination therapy.**

*Abstract:* American Thoracic Society International Conference Denver, CO May 15-20, 2015.

*Authors:* Patel J, Mapel DW, Roberts MH, Sama S, Gilmore J, Sundaresan D, Laliberte F, Pilon D, Lefebvre P, Duh M.

**Impact of a telehealth and care management program for patients with chronic obstructive pulmonary disease.**

*Publication:* Ann Am Thorac Soc 2015 03; 12(3): 323-331. doi: 10.1513/AnnalsATS.201501-042OC.

*Authors:* Au DH, Macaulay DS, Jarvis JL, Desai US, Birnbaum HG.

**Assessment of time to clinical response, a proxy for discharge readiness, among hospitalized patients with community-acquired pneumonia who received either ceftaroline fosamil or ceftriaxone in two phase III FOCUS trials.**

*Publication:* Antimicrobial Agents and Chemotherapy 2015 02; 59(2): 1119-1126. doi: 10.1128/AAC.03643-14.

*Authors:* Lodise TP, Anzueto AR, Weber DJ, Shorr AF, Yang M, Smith A, Zhao Q, Huang X, File TM.

**Budget impact model of ORALAIR® for the treatment of grass pollen-induced allergic rhinitis with or without conjunctivitis in adults and children.**

*Abstract:* AMCP Nexus 2014, Boston, MA Oct 7-10, 2014.

*Authors:* Ivanova J, Diener M, Kelkar S, Bean S, King S, Birnbaum HG, Hocker S, Johnson M, Phipps R, Lankow R.

**Pulmonary medication adherence and health-care use in cystic fibrosis.**

*Publication:* Chest 2014 07; 146(1): 142-151. doi: 10.1378/chest.13-1926.

*Authors:* Quittner AL, Zhang J, Marynchenko M, Chopra PA, Signorovitch J, Yushkina Y, Riekert KA.

**Assessment of COPD exacerbation risk: Utilizing health claims data to develop and validate a risk equation.**

*Abstract:* American Thoracic Society International Conference, San Diego, CA May 16-21, 2014.

*Authors:* Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M, Merrigan J, Duh M.

**Risk assessment of first severe COPD exacerbation using predictive models based on health claims data.**

*Abstract:* American Thoracic Society International Conference, San Diego, CA May 16-21, 2014.

*Authors:* Stanford RH, Nag A, Mapel DW, Lee TA, Rosiello R, Schatz M, Vekeman F, Gauthier-Loiselle M, Merrigan P, Duh M.

**Burden of illness of patients with allergic asthma versus non-allergic asthma.**

*Publication:* Journal of Asthma 2013 10; 50(8): 900-907. doi: 10.3109/02770903.2013.810244.

*Authors:* Lafeuille MH, Gravel J, Figliomeni M, Zhang J, Lefebvre P.

**Development and validation of a claims-based prediction model for COPD severity.**

*Publication:* Respiratory Medicine 2013 10; 107(10): 1568-1577. doi: 10.1016/j.rmed.2013.05.012.

*Authors:* Macaulay D, Sun SX, Sorg RA, Yan SY, De G, Wu EQ, Simonelli PF.

**A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care.**

*Publication:* Pediatric Pulmonology 2013 10; 48(10): 954-961. doi: 10.1002/ppul.22741.

*Authors:* Sawicki GS, Ayyagari R, Zhang J, Signorovitch JE, Fan L, Swallow E, Latremouille-Viau D, Wu EQ, Shi L.

**Risk of Hospital Readmissions in Patients with Chronic Obstructive Pulmonary Disease Receiving Arformoterol Tartrate versus Nebulized Short-Acting Beta2-Agonists Following Hospital Discharge.**

*Abstract:* COPD8USA Conference, Chicago, IL June 14-15, 2013.

*Authors:* Bollu VK, Guérin A, Gauthier G, Hiscock R, Wu EQ.

**Impact of integrated telehealth and care management program on resource utilization in Medicare beneficiaries with chronic obstructive pulmonary disease.**

*Abstract:* American Thoracic Society International Conference, Philadelphia, PA May 17-22, 2013.

*Authors:* Au DH, Jarvis J, Macaulay D, Birnbaum HG.

**Re-hospitalization risk in patients with chronic obstructive pulmonary disease (COPD) initiating nebulized long-acting vs. Short-acting beta2-agonists.**

*Abstract:* American Thoracic Society International Conference, Philadelphia, PA May 17-22, 2013.

*Authors:* Bollu V, Guerin A, Karafilidis J, Gauthier G, Hiscock R, Wu E.

**Association between consistent omalizumab treatment and asthma control.**

*Publication:* The Journal of Allergy and Clinical Immunology: In Practice 2013 1(1): 51-57.

*Authors:* Lafeuille M-H, Gravel J, Zhang J, Gorsh B, Figliomeni M, Lefebvre P.

**Annual healthcare costs for patients with cystic fibrosis from a Medicaid perspective.**

*Abstract:* 26th Annual North American Cystic Fibrosis Conference Orlando, FL Oct 11-13, 2012.

*Authors:* Zhang J, Marynchenko M, Chopra P, Ohashi E, Signorovitch J, Wu E.

**Lower adherence to chronic pulmonary medications is associated with increased health service utilization in patients with cystic fibrosis.**

*Abstract:* 26th Annual North American Cystic Fibrosis Conference, Orlando, FL Oct 11-13, 2012.

*Authors:* Quittner AL, Zhang J, Marynchenko M, Chopra P, Signorovitch J, Rieker KA.

**Pulmonary medication adherence among individuals with cystic fibrosis.**

*Abstract:* 26th Annual North American Cystic Fibrosis Conference Orlando, FL Oct 11-13, 2012.

*Authors:* Rieker KA, Zhang J, Marynchenko M, Chopra P, Signorovitch J, Quittner AL.

**A validated claims-based prediction model for COPD severity.**

*Abstract:* CHEST 2012 Atlanta, GA Oct 20-25, 2012.

*Authors:* Macaulay D, Sun S, Sorg R, Yan S, De G, Wu E, Simonelli P.

**Impact of omalizumab initiation on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids and long-acting beta2-agonists Respiratory Disease.**

*Abstract:* 28th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Barcelona, Spain Aug 23-26, 2012.

*Authors:* Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

**Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.**

*Publication:* Annals of Allergy, Asthma, and Immunology 2012 07; 109(1): 59-64. doi: 10.1016/j.janai.2012.04.015.

*Authors:* Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

**Association of allergic rhinitis with asthma exacerbations and health care costs in asthma patients Respiratory Disease.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Ivanova JI, Desai U, Birnbaum HG, Cummings AK, Bornstein A, Karafilidis J, Spalding W.

**Comparisons of patient characteristics and health care costs by quartile among patients with allergic rhinitis.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Desai U, Ivanova JI, Birnbaum HG, Cummings AK, Bornstein A, Karafilidis J, Spalding W.

**Development of a pulmonary exacerbation risk score among cf patients not receiving recommended therapies for pulmonary care.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Sawicki G, Ayyagari R, Zhang J, Signorovitch J, Fan L, Latremouille-viau D, Shi L.

**Economic burden associated with acute exacerbations of chronic obstructive pulmonary disease in China.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Yang HY, Wu J, Zheng Y, Xie K, Jin L, Xie J, Wu EQ.

**Impact of omalizumab on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids Respiratory Disease.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

**Assessment of a pulmonary exacerbation risk score among cystic fibrosis patients free of recent exacerbations and not receiving recommended therapies for pulmonary care.**

*Abstract:* American Thoracic Society International Conference, San Francisco, CA May 18-23, 2015.

*Authors:* Sawicki G, Ayyagari R, Zhang J, Signorovitch J, Fan L, Swallow E, Shi L.

**Effect of asthma exacerbations on health care costs among asthmatic patients with moderate and severe persistent asthma.**

*Publication:* Journal of Allergy and Clinical Immunology 2012 05; 129(5): 1229-1235. doi: 10.1016/j.jaci.2012.01.039.

*Authors:* Ivanova JI, Bergman R, Birnbaum HG, Colice GL, Silverman RA, McLaurin K.

**Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis.**

*Publication:* Journal of Medical Economics 2012 04; 15(2): 219-224. doi:

<http://dx.doi.org/10.3111/13696998.2011.638954>.

*Authors:* Sangsiry SS, Joish VN, Boklage S, Goyal RK, Chopra P, Sethi S.

**Impact of omalizumab on emergency-department visits, hospitalizations and corticosteroid use in patients with uncontrolled asthma using high-dose inhaled corticosteroids Respiratory Disease.**

*Abstract:* 2012 Annual Meeting of the American Academy of Allergy, Asthma and Immunology, Orlando, FL Mar 2-6, 2012.

*Authors:* Lafeuille MH, Dean J, Zhang J, Duh MS, Gorsh B, Lefebvre P.

**Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.**

*Publication:* Pediatric Pulmonology 2012 01; 47(1): 44-52. doi: 10.1002/ppul.21521.

*Authors:* Sawicki GS, Signorovitch JE, Zhang J, Latremouille-Viau D, von Wartburg M, Wu EQ, Shi L.

**Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD.**

*Publication:* Respiratory Medicine 2011 12; 105(12): 1861-1871. doi: 10.1016/j.rmed.2011.07.001.

*Authors:* Yu AP, Guerin A, de Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, Blum SI, Setyawan J.

**Concomitant asthma medication use in patients receiving omalizumab: results from three large insurance claims databases.**

*Publication:* Journal of Asthma 2011 11; 48(9): 923-930. doi: 10.3109/02770903.2011.618568.

*Authors:* Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Swensen A, Lefebvre P.

**Development of a pulmonary exacerbation risk score among CF patients not receiving recommended therapies for pulmonary care.**

*Abstract:* 25th Annual North American Cystic Fibrosis Conference Anaheim, CA Nov 3-5, 2011.

*Authors:* Sawicki GS, Ayyagari R, Zhang J, Signorovitch J, Fan L, Latremouille-Viau D, Shi L.

**Effect of tobramycin inhalation solution on mortality in subgroups of patients with cystic fibrosis.**

*Abstract:* 25th Annual North American Cystic Fibrosis Conference Anaheim, CA Nov 3-5, 2011.

*Authors:* Latremouille-Viau D, Sawicki GS, Zhang J, Von Wartburg M, Signorovitch J, Wu EQ, Shi L.

**Excess costs associated with patients with chronic thromboembolic pulmonary hypertension in a US privately insured population.**

*Publication:* Appl Health Econ Health Policy 2011 11; 9(6): 377-387. doi: 10.2165/11592440-000000000-00000.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

**Prevalence of pseudomonas aeruginosa infection and antibiotic resistance by age group in the CFF patient registry in 2003 and 2008.**

*Abstract:* 25th Annual North American Cystic Fibrosis Conference, Anaheim, CA Nov 3-5, 2011.

*Authors:* Latremouille-Viau D, Zhang J, DeBonnett L, Signorovitch J, Von Wartbu M, Wu EQ, Shi L.

**Cost-effectiveness analysis of roflumilast/tiotropium combination therapy vs. tiotropium monotherapy in patients with severe to very severe COPD.**

*Abstract:* 2011 Annual Meeting of the American College of Clinical Pharmacy Pittsburgh, PA Oct 16-19, 2011.

*Authors:* Yu AP, Sun S, Marynchenko M, Banerjee R, Mocarski M, Yin D, Wu E.

**Cost-effectiveness analysis of roflumilast/tiotropium therapy versus tiotropium monotherapy for treating severe-to-very severe COPD.**

*Publication:* Journal of Medical Economics 2011 10; 14(6): 805-815. doi: 10.3111/13696998.2011.623204.

*Authors:* Sun SX, Marynchenko M, Banerjee R, Cheng D, Mocarski M, Yin D, Yu AP, Wu EQ.

**Excess costs associated with patients with pulmonary arterial hypertension in a US privately insured population.**

*Publication:* Appl Health Econ Health Policy 2011 09; 9(5): 293-303. doi: 10.2165/11592430-000000000-00000.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

**Prevalence of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension in the United States.**

*Publication:* Current Medical Research and Opinion 2011 09; 27(9): 1763-1768. doi: 10.1185/03007995.2011.604310.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Waldman T, Joish V, Williamson T.

**Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases Respiratory Disease.**

*Abstract:* 27th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Chicago, IL Aug 14-17, 2011.

*Authors:* Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Lefebvre P.

**Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers.**

*Publication:* Journal of Medical Economics 2011 06; 14(4): 486-496. doi: 10.3111/13696998.2011.594123.

*Authors:* Yu AP, Guerin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J.



**Concomitant asthma medication use in patients usingomalizumab: Results from three large insurance claims databases Respiratory Disease.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Lafeuille MH, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Lefebvre P.

**PRS7 Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis.**

*Abstract:* ISPOR, May 21-25, 2011.

*Authors:* Signorovitch J, Sawicki G, Zhang J, Latremouille-Viau D, Wu E, von Wartburg M, Lizheng S.

**Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis.**

*Publication:* Journal of Medical Economics 2011 04; 14(3): 315-323. doi: 10.3111/13696998.2011.576295.

*Authors:* Yu AP, Yang H, Wu EQ, Setyawan J, Mocarski M, Blum S.

**Concomitant asthma medication use in patients using omalizumab: Results from three large insurance claims databases Respiratory Disease.**

*Abstract:* 2011 American Academy of Allergy, Asthma and Immunology Annual Meeting San Francisco, CA Mar 18-22, 2011.

*Authors:* Lafeuille M, Duh MS, Zhang J, Wertz D, Gu T, Tang J, Swensen A, Stanley EL, Lefebvre P.

**Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs.**

*Publication:* Respiratory Medicine 2011 03; 105(3): 435-441. doi: 10.1016/j.rmed.2010.09.006.

*Authors:* Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat CA, Swensen A, Duh MS.

**Association between private-to-Medicaid change in health insurance & healthcare utilization & outcomes among children with cystic fibrosis.**

*Abstract:* 24th Annual North American Cystic Fibrosis Conference Baltimore, MD Oct 21-23, 2010.

*Authors:* Zhivan N, Campbell CR, Signorovitch J, Zhang J, Shi L.

**Comparison of drug costs & clinical outcomes with tobramycin solution for inhalation & aztreonam lysine for inhalation in cystic fibrosis.**

*Abstract:* 24th Annual North American Cystic Fibrosis Conference, Baltimore, MD Oct 21-23, 2010.

*Authors:* Signorovitch J, Latremouille-Viau D, Dea K, Wu E, Zhang J.

**Persistence and adherence in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.**

*Abstract:* CHEST 2010 Annual Meeting, Vancouver, BC, Canada Oct 30-Nov 4, 2010.

*Authors:* Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI.

**Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.**

*Abstract:* Chest 2010 Meeting, Vancouver, BC, Canada Oct 30 - Nov 4, 2010.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

**Resource utilization and costs in patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.**

*Abstract:* CHEST 2010 Annual Meeting, Vancouver, BC, Canada Oct 30-Nov 4, 2010.

*Authors:* Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Xie J, Wu EQ, Setyawan J, Dembiski M, Blum SI.

**Risk of exacerbations among patients with chronic obstructive pulmonary disease (COPD) treated with multiple vs single long-acting inhalers.**

*Abstract:* CHEST 2010 Annual Meeting Vancouver, BC, Canada Oct 30-Nov 4, 2010.

*Authors:* Yu AP, Guerin A, De Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI.

**Use of inhaled tobramycin is associated with reduced mortality in patients with cystic fibrosis.**

*Abstract:* 24th Annual North American Cystic Fibrosis Conference Baltimore, MD Oct 21-23, 2010.

*Authors:* Sawicki GS, Signorovitch J, Latremouille-Viau D, Von Wartburg M, Wu E, Zhang J, Shi L.

**The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review.**

*Publication:* COPD 2010 06; 7(3): 214-228. doi: 10.3109/15412555.2010.481697.

*Authors:* Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS.

**Cost comparison among moderate or severe persistent asthma patients with and without asthma exacerbations Respiratory Disease.**

*Abstract:* American Thoracic Society International Conference, New Orleans, LA May 14-19, 2010.

*Authors:* Ivanova JI, Bergman RE, Birnbaum HG, Colice GL, Silverman R, McLaurin KK.

**Economic burden of exacerbations in chronic obstructive pulmonary disease.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Yu A, Yang H, Wu EQ, Dembiski M, Blum S, Setyawan J.

**Relationship between daily dosing frequency, compliance, health care resource use, and costs: Evidence from the treatment of chronic obstructive pulmonary disease (COPD).**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Toy EL, Beaulieu NU, McHale JM, Welland TR, Plauschinat C, Swensen A, Duh MS.

**Hospital visits and costs following outpatient treatment of CAP with levofloxacin or moxifloxacin.**

*Publication:* Current Medical Research and Opinion 2010 02; 26(2): 355-363. doi: 10.1185/03007990903482418.

*Authors:* Signorovitch JE, Sheng Duh M, Sengupta A, Gu A, Grant R, Raut M, Mody SH, Schein J, Fisher AC, Ng D.

**Persistence and Adherence in Patients with Chronic Obstructive Pulmonary Disease (COPD) Treated with Multiple vs Single Long-Acting Inhalers.**

*Publication:* CHEST Journal 2010 138(4\_MeetingAbstracts): 482A-482A.

*Authors:* Yu AP, Guérin A, de Leon Barido DP, Ramakrishnan K, Wu EQ, Setyawan J, Dembiski M, Blum SI.

**Inhaled corticosteroids or long-acting beta-agonists alone or in fixed-dose combinations in asthma treatment: a systematic review of fluticasone/budesonide and formoterol/salmeterol.**

*Publication:* Clinical Therapeutics 2009 12; 31(12): 2779-2803. doi: 10.1016/j.clinthera.2009.12.021.

*Authors:* Frois C, Wu EQ, Ray S, Colice GL.

**Chronic thromboembolic pulmonary hypertension (CTEPH) cost of illness in the privately-insured population in the United States.**

*Abstract:* ISPOR 12th Annual European Congress, Paris, France Oct 24-27, 2009.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

**Chronic thromboembolic pulmonary hypertension (CTEPH) cost of illness in the privately-insured population in the United States.**

*Abstract:* Chest 2010 Meeting, Vancouver, BC, Canada Oct 30 - Nov 4, 2010.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

**Pulmonary arterial hypertension (PAH) cost of illness in the U.S. Privately-insured population.**

*Abstract:* ISPOR 12th Annual European Congress, Paris, France Oct 24-27, 2009.

*Authors:* Kirson NY, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Williamson T.

**The direct economic impact of exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A review of the literature.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Toy EL, Gallagher KF, Stanley EL, Duh MS.

**The risk of hospitalization or emergency care following outpatient treatment of community-acquired pneumonia (CAP) with levofloxacin versus moxifloxacin.**

*Abstract:* 25th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Providence, RI Aug 16-19, 2009.

*Authors:* Signorovitch JE, Gu A, Sengupta A, Raut M, Mody SH, Grant R, Schein J, Fisher AC, Ng D, Duh MS.

**The direct economic impact of exacerbations of chronic obstructive pulmonary disease (COPD): A review of the literature.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Toy EL, Gallagher KF, Stanley EL, Duh MS.

**Comparability of the Asthma Control Test telephone interview administration format with self-administered mail-out mail-back format.**

*Publication:* Current Medical Research and Opinion 2009 03; 25(3): 717-727. doi: 10.1185/03007990802711602.

*Authors:* Kosinski M, Kite A, Yang M, Rosenzweig JC, Williams A.

**Asthma severity categorization using a claims-based algorithm or pulmonary function testing.**

*Publication:* Journal of Asthma 2009 02; 46(1): 67-72. doi: 10.1080/02770900802503099.

*Authors:* Birnbaum HG, Ivanova JI, Yu AP, Hsieh M, Seal B, Emani S, Rosiello R, Colice GL.

**Adherence to inhaled corticosteroid use and local adverse events in persistent asthma.**

*Publication:* American Journal of Managed Care 2008 12; 14(12): 801-809.

*Authors:* Ivanova JI, Birnbaum HG, Hsieh M, Yu AP, Seal B, van der Molen T, Emani S, Rosiello RA, Colice GL.

**Costs and resource use of mild persistent asthma patients initiated on controller therapy.**

*Publication:* Journal of Asthma 2008 05; 45(4): 293-299. doi: 10.1080/02770900801911178.

*Authors:* Colice GL, Yu AP, Ivanova JI, Hsieh M, Birnbaum HG, Lage MJ, Brewster C.

**Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature.**

*Publication:* Expert Opinion on Pharmacotherapy 2008 04; 9(5): 751-766. doi: 10.1517/14656566.9.5.751.

*Authors:* Weiner JR, Toy EL, Sacco P, Duh MS.

**Use of inhaled corticosteroids and healthcare costs in mild persistent asthma.**

*Publication:* Journal of Asthma 2007 07; 44(6): 479-483. doi: 10.1080/02770900701424124.

*Authors:* Colice G, Wu EQ, Birnbaum H, Daher M, Maryna BM.

**Red blood cell transfusions and the risk of acute respiratory distress syndrome among the critically ill: a cohort study.**

*Publication:* Critical Care (London, England) 2007 06; 11(3): R63. doi: 10.1186/cc5934.

*Authors:* Zilberberg MD, Carter C, Lefebvre P, Raut M, Vekeman F, Duh MS, Shorr AF.

**Development of a COPD severity score.**

*Publication:* Current Medical Research and Opinion 2006 09; 22(9): 1679-1687. doi: 10.1185/030079906X115621.

*Authors:* Wu EQ, Birnbaum HG, Cifaldi M, Kang Y, Mallet D, Colice G.

**Healthcare and workloss costs associated with patients with persistent asthma in a privately insured population.**

*Publication:* Journal of Occupational Environmental Medicine 2006 08; 48(8): 794-802. doi: 10.1097/01.jom.0000229819.26852.0e.

*Authors:* Colice G, Wu EQ, Birnbaum H, Daher M, Marynchenko MB, Varghese S.

**Inpatient and Emergency Department Utilization of Persistent Asthma Patients.**

*Abstract:* American Thoracic Society.

*Authors:* Colice G, Crivera C, Wu EQ, Birnbaum HG, Daher M, Marynchenko MB, Faruqi R, Varghese ST.

**PRS3 Acute exacerbation of chronic bronchitis (AECB) treatment effectiveness: Comparison of macrolides to fluoroquinolones.**

*Abstract:* ISPOR, 2005.

*Authors:* Wu E, Birnbaum H, Cifaldi M, Kang Y, Colice G.

**Development of a COPD Severity Score in ClaimsDatabase,.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR) European.

*Authors:* Wu EQ, Birnbaum H, Cifaldi M, Colice G, Kang Y.

**Healthcare Costs of Patients with Persistent Asthma.**

*Abstract:* AMCP's 2005 Educational Conference, Nashville, TN Oct 5-8, 2005.

*Authors:* Colice G, Crivera C, Varghese S, Faruqi R, Wu EQ, Birnbaum H, Daher M, Marynchenko MB.

**Treatment costs of community-acquired pneumonia in an employed population.**

*Publication:* Chest 2004 06; 125(6): 2140-2145.

*Authors:* Colice GL, Morley MA, Asche C, Birnbaum HG.

**Red blood cell transfusion and ventilator-associated pneumonia: A potential link?**

*Publication:* Critical Care Medicine 2004 03; 32(3): 666-674. e-pub ahead of print 2004/04/20.

*Authors:* Shorr AF, Duh MS, Kelly KM, Kollef MH.

**Lower respiratory tract infections: impact on the workplace.**

*Publication:* Pharmacoeconomics 2003 06; 21(10): 749-759.

*Authors:* Birnbaum H, Morley M, Leong S, Greenberg P, Colice G.

**PRP13: Assessing the cost implications of combined pharmacotherapy in the long term management of asthma.**

*Abstract:* ISPOR, 2003.

*Authors:* Wu E, Johnson K, Nichol M.

**Assessing the Cost Implication of Combined Pharmacotherapy in the Long Term Management of Asthma.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR).

*Authors:* Wu EQ, Johnson KA, Nichol MB.

**Economic burden of respiratory infections in an employed population.**

*Publication:* Chest 2002 08; 122(2): 603-611.

*Authors:* Birnbaum HG, Morley M, Greenberg PE, Colice GL.

**Direct and indirect costs of asthma to an employer.**

*Publication:* Journal of Allergy and Clinical Immunology 2002 02; 109(2): 264-270.

*Authors:* Birnbaum HG, Berger WE, Greenberg PE, Holland M, Auerbach R, Atkins KM, Wanke LA.

**Economic burden of pneumonia in an employed population.**

*Publication:* Archives of Internal Medicine 2001 12; 161(22): 2725-2731.

*Authors:* Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL.

**Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients.**

*Publication:* Annals of Allergy, Asthma, and Immunology 2000 11; 85(5): 356-361. e-pub ahead of print 2000/12/02; doi: 10.1016/S1081-1206(10)62545-8.

*Authors:* Duh MS, Walker AM, Lindmark B, Laties AM.

**Savings in direct medical costs from the use of tobramycin solution for inhalation in patients with cystic fibrosis.**

*Publication:* Clinical Therapeutics 2000 01; 22(1): 140-151.

*Authors:* LeLorier J, Perreault S, Birnbaum H, Greenberg P, Sheehy O.

**Lack of Intraocular Pressure Effect of Budesonide Inhalation Therapy in a Mixed Asthmatic Population.**

*Publication:* Annals of Asthma, Allergy & Immunology 2000: 356-361.

*Authors:* Duh M, Walker A, Lindmark B, Laties A.

## Substance Abuse

**Modelling the potential impact of abuse-deterrent opioids on medical resource utilization.**

*Publication:* Journal of Medical Economics 2019 07; 1. e-pub ahead of print 2019/07/18; doi: 10.1080/13696998.2019.1645680.

*Authors:* Yenikomshian MA, White AG, Carson ME, Jia ZB, Mendoza MR, Roland CL.

**Assessment of Workplace Productivity Loss and Costs Associated with Opioid Abuse: A Retrospective Claims Analysis.**

*Publication:* Postgraduate Medicine 2018 08; 130(sup1): 1-91. e-pub ahead of print 2018/08/24; doi: 10.1080/00325481.2018.1512253.

*Authors:* White AG, Spittle T, Fernan C, Marrett E, Kwong WJ, Rossiter LF.

**The Economic Burden of Abuse of Prescription Opioids: A Systematic Literature Review from 2012 to 2017.**

*Publication:* Appl Health Econ Health Policy 2018 08; 16(5): 609-632. e-pub ahead of print 2018/07/22; doi: 10.1007/s40258-018-0402-x.

*Authors:* Reinhart M, Scarpatti LM, Kirson NY, Patton C, Shak N, Erensen JG.

**Assessment of work loss and costs associated with opioid abuse: A retrospective claims analysis.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* White AG, Spittle T, Fernan C, Marrett E, Kwong J, Rossiter LF.

**Opioid Abuse: A Detailed Examination of Cost Drivers over a 24-Month Follow-up Period.**

*Publication:* J Manag Care Spec Pharm 2017 11; 23(11): 1110-1115. e-pub ahead of print 2017/10/31; doi: 10.18553/jmcp.2017.17019.

*Authors:* Scarpatti LM, Kirson NY, Jia ZB, Wen J, Howard J.

**Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.**

*Publication:* Journal of Opioid Management 2017 09; 13(5): 291-301. e-pub ahead of print 2017/12/05; doi: 10.5055/jom.2017.0398.

*Authors:* Yenikomshian MA, White AG, Carson ME, Garrison LP, Oderda GM, Biskupiak JE, Hlavacek PR, Roland CL.

**Drivers of excess costs of opioid abuse among a commercially insured population.**

*Publication:* American Journal of Managed Care 2017 05; 23(5): 276-282. e-pub ahead of print 2017/07/26.

*Authors:* Scarpati LM, Kirson NY, Zichlin ML, Jia ZB, Birnbaum HG, Howard JC.

**The Economic Burden of Opioid Abuse: Updated Findings.**

*Publication:* Journal of Managed Care and Specialty Pharmacy 2017 04; 23(4): 427-445. doi: 10.18553/jmcp.2017.16265.

*Authors:* Kirson NY, Scarpati LM, Enloe CJ, Dincer AP, Birnbaum HG, Mayne TJ.

**A harm reduction model to quantify potential misuse/abuse reduction and misuse/abuse-related events avoided from extended-release abuse deterrent opioids.**

*Abstract:* 36th Annual Scientific Meeting of the American Pain Society, Pittsburgh, PA May 17-20, 2017.

*Authors:* White A, Spittle T, Niebler W, Brown C, Dayno J, Katz N.

**The costs and cost drivers of opioid misuse by diagnosis: Abuse, dependence, and overdose/poisoning.**

*Abstract:* 2016 Pain Week Conference, Las Vegas, NV Sept 6-10, 2016.

*Authors:* Howard J, Kirson N, Scarpati L, Dincer A, Hanway J, Zichlin M, Birnbaum H.

**The economic burden of opioid abuse and its drivers: Evidence from a payer perspective.**

*Abstract:* 2016 Pain Week Conference, Sept 6-10, 2016.

*Authors:* Howard J, Kirson N, Scarpati L, Dincer A, Hanway J, Zichlin M, Birnbaum H.

**A model to quantify potential medical events avoided and cost savings from abuse deterrent opioids.**

*Abstract:* Annual Scientific Meeting of the American Pain Society, Austin, TX May 11-14, 2016.

*Authors:* White AG, Yenikomshian M, Carson M, Masters ET, Roland CL.

**Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.**

*Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.

*Authors:* White AG, Yenikomshian M, Carson ME, Garrison LP, Oderda G, Biskupiak JE, Hlavacek P, Roland CL.

**(263) A model to quantify potential medical events avoided and cost savings from abuse deterrent opioids.**

*Publication:* The Journal of Pain 2016 04; 17(4): S41. e-pub ahead of print 2017/02/07; doi: 10.1016/j.jpain.2016.01.168.

*Authors:* White A, Yenikomshian M, Carson M, Masters E, Roland C.

**The Burden of Undiagnosed Opioid Abuse Among Commercially Insured Individuals.**

*Publication:* Pain Medicine 2015 07; 16(7): 1325-1332. doi: 10.1111/pme.12768.

*Authors:* Kirson NY, Shei A, Rice JB, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

**Positive subjective measures in abuse liability studies and real-world nonmedical use: Potential impact of abuse-deterrent opioids on rates of nonmedical use and associated healthcare costs.**

*Publication:* Journal of Opioid Management 2015 05; 11(3): 199-210. e-pub ahead of print 2015/05/20; doi: 10.5055/jom.2015.0269.

*Authors:* White AG, LeCates J, Birnbaum HG, Cheng W, Roland CL, Mardekian J.

**Sources of prescription opioids among diagnosed opioid abusers.**

*Publication:* Current Medical Research and Opinion 2015 04; 31(4): 779-784. doi: 10.1185/03007995.2015.1016607.

*Authors:* Shei A, Rice JB, Kirson NY, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

**A model to estimate the health system burden of prescription opioid abuse in Europe.**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.

*Authors:* Shei A, Hirst M, Kirson NY, Enloe CJ, Birnbaum HG, Dunlop W.

**Examining the use of ICD-9-CM diagnosis codes for opioid abuse and opioid dependence in commercial claims data.**

*Abstract:* AMCP Nexus 2014, Boston, MA Oct 7-10, 2014.

*Authors:* Shei A, Rice B, Kirson NY, Bodnar K, Cummings AKG, Birnbaum HG, Holly P, Ben-Joseph R.

**Comparing the prevalence and healthcare costs of opioid abuse using two commercial claims databases.**

*Abstract:* PAINWeek Conference, Las Vegas, NV Sep 2-6, 2014.

*Authors:* Rice B, Kirson NY, Shei A, Enloe CJ, Cummings AK, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

**Medical resource use and costs among pain patients with potential opioid-tolerability issues.**

*Publication:* Journal of Opioid Management 2014 09; 10(5): 305-310. doi: 10.5055/jom.2014.0220.

*Authors:* Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R, Michna E.

**Methods to estimate the prevalence and healthcare costs of undiagnosed opioid abuse among commercially-insured individuals.**

*Abstract:* PAINWeek Conference, Las Vegas, NV Sep 2-6, 2014.

*Authors:* Shei A, Rice B, Kirson NY, Enloe CJ, Bodnar K, Birnbaum HG, Holly P, Ben-Joseph R.

**Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.**

*Publication:* Pain Medicine 2014 09; 15(9): 1450-1454. e-pub ahead of print 2014/07/22; doi: 10.1111/pme.12489.

*Authors:* Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Rossiter LF, Michna E.

**Estimating the costs of opioid abuse and dependence from an employer perspective: a retrospective analysis using administrative claims data.**

*Publication:* Appl Health Econ Health Policy 2014 08; 12(4): 435-446. doi: 10.1007/s40258-014-0102-0.

*Authors:* Rice JB, Kirson NY, Shei A, Cummings AK, Bodnar K, Birnbaum HG, Ben-Joseph R.

**Use of prescription opioids with abuse-deterrent technology to address opioid abuse.**

*Publication:* Current Medical Research and Opinion 2014 08; 30(8): 1589-1598. doi: 10.1185/03007995.2014.915803.

*Authors:* Michna E, Kirson NY, Shei A, Birnbaum HG, Ben-Joseph R.

**The economic burden of diagnosed opioid abuse among commercially insured individuals.**

*Publication:* Postgraduate Medicine 2014 07; 126(4): 53-58. doi: 10.3810/pgm.2014.07.2783.

*Authors:* Rice JB, Kirson NY, Shei A, Enloe CJ, Cummings AK, Birnbaum HG, Holly P, Ben-Joseph R.

**Medical resource use and costs among pain patients with potential opioid tolerability issues.**

*Abstract:* ICOO 2014, Boston, MA Jun 8-10, 2014.

*Authors:* Birnbaum H, Kirson N, Shei A.

**The burden of opioid abuse among commercially-insured patients.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Rice JB, Kirson NY, Shei A, Enloe C, Cummings AK, Birnbaum HG, Ben-Joseph R.

**Differences between high-cost and low-cost patients diagnosed with opioid abuse.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Rice JB, Kirson NY, Bodnar K, Shei A, Birnbaum HG, Holly P, Ben-Joseph R.

**Characteristics of high-cost patients diagnosed with opioid abuse.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Birnbaum H, Kirson N, Shei A.

**Estimating the prevalence and healthcare costs of diagnosed opioid abuse in a large commercial claims database.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Birnbaum H, Kirson N, Shei A.

**Medical cost savings associated with an extended-release opioid with abuse-deterrent technology in the US.**

*Publication:* Journal of Medical Economics 2014 04; 17(4): 279-287. e-pub ahead of print 2014/02/25; doi: 10.3111/13696998.2014.897628.

*Authors:* Rossiter LF, Kirson NY, Shei A, White AG, Birnbaum HG, Ben-Joseph R, Michna E.

**Opioid utilization and abuse rates following the introduction of an abuse-deterrent formulation.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Birnbaum H, Kirson N, Shei A.

**The relationship between positive subjective measures in abuse liability studies and real-world non-medical use: potential impact of abuse deterrent opioids on rates of non-medical use and associated healthcare costs.**

*Abstract:* American Academy of Pain Medicine's 30th Annual Meetin, Phoenix, AZ Mar 6-9, 2014.

*Authors:* White AG, LeCates J, Cheng W, Roland CL, Schaaf D, Mardekian J.

**Systematic literature review and meta-analysis of the efficacy and safety of prescription opioids, including abuse-deterrent formulations, in non-cancer pain management.**

*Publication:* Pain Medicine 2014 01; 15(1): 79-92. doi: 10.1111/pme.12233.

*Authors:* Michna E, Cheng WY, Korves C, Birnbaum H, Andrews R, Zhou Z, Joshi AV, Schaaf D, Mardekian J, Sheng M.

**The prevalence and economic impact of prescription opioid-related side effects among patients with chronic noncancer pain.**

*Publication:* Journal of Opioid Management 2013 07; 9(4): 239-254. doi: 10.5055/jom.2013.0165.

*Authors:* Ivanova JI, Birnbaum HG, Yushkina Y, Sorg RA, Reed J, Merchant S.

**Estimating the payer-specific excess medical costs of opioid abuse in the United States.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Michna E, Kirson NH, Shei A, White A, Birnbaum HG, Ben-Joseph R, Rossiter LF.

**Prescription opioid abuse: challenges and opportunities for payers.**

*Publication:* American Journal of Managed Care 2013 04; 19(4): 295-302. e-pub ahead of print 2013/06/04.

*Authors:* Katz NP, Birnbaum H, Brennan MJ, Freedman JD, Gilmore GP, Jay D, Kenna GA, Madras BK, McElhaney L, Weiss RD, White AG.

**A model to identify patients at risk for prescription opioid abuse, dependence, and misuse.**

*Publication:* Pain Medicine 2012 09; 13(9): 1162-1173. e-pub ahead of print 2012/08/01; doi: 10.1111/j.1526-4637.2012.01450.x.

*Authors:* Rice JB, White AG, Birnbaum HG, Schiller M, Brown DA, Roland CL.

**Characteristics and use patterns of chronic hydrocodone users.**

*Abstract:* 31st Annual Scientific Meeting of the American Pain Society, Honolulu, HI May 16-19, 2012.

*Authors:* Rice J, Samuelson T, Birnbaum H, Katz N.

**A systematic literature review of the efficacy and safety of abuse-deterrent formulation and non-abuse-deterrent formulation prescription opioids in non-cancer pain management.**

*Abstract:* 31st Annual Scientific Meeting of the American Pain Society, Honolulu, HI May 16-19, 2012.

*Authors:* Michna E, Cheng W, Korves C, Sarda S, Schaaf D, Andrews R, Zhou Z, Mardekian J, Joshi A, Birnbaum H, Duh M.



**Identifying predictors of chronic hydrocodone use.**

*Abstract:* 28th Annual Meeting of the American Academy of Pain Medicine, Palm Springs, CA Feb 23-26, 2012.

*Authors:* Rice JB, Samuelson TM, Birnbaum HG, Katz N.

**Economic impact of opioid abuse, dependence, and misuse.**

*Publication:* American Journal of Pharmacy Benefits 2011 05; 3(3): e59-e70.

*Authors:* White AG, Birnbaum HG, Schiller M, Waldman T, Cleveland JM, Roland CL.

**Societal costs of prescription opioid abuse, dependence, and misuse in the United States.**

*Publication:* Pain Medicine 2011 04; 12(4): 657-667. e-pub ahead of print 2011/03/12; doi: 10.1111/j.1526-4637.2011.01075.x.

*Authors:* Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL.

**Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications.**

*Publication:* Pain Medicine 2010 11; 11(11): 1718-1725. doi: 10.1111/j.1526-4637.2010.00979.x.

*Authors:* Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei RS, Stangle BE, Lafeuille MH, Michna E, Greenberg PE.

**Risk of hepatotoxicity-related hospitalizations among patients treated with opioid/acetaminophen combination prescription pain medications.**

*Abstract:* 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE) Brighton, UK Aug 19-22, 2010.

*Authors:* Duh MS, Vekeman F, Korves C, Lefebvre P, Dial E, Latremouille-Viau D, Wei RS, Stangle BE, Lafeuille MH, Michna E, Greenberg PE.

**Societal Costs of Prescription Opioid Abuse, Dependence, and Misuse in the United States.**

*Abstract:* ISPOR 15th Annual International Meeting Atlanta, GA May 15-19, 2010.

*Authors:* Birnbaum H, White A, Schiller M, Waldman T, Cleveland JM, Setnik BS, Pixton GC, Roland CL.

**Analytic models to identify patients at risk for prescription opioid abuse.**

*Publication:* American Journal of Managed Care 2009 12; 15(12): 897-906. e-pub ahead of print 2009/12/17.

*Authors:* White AG, Birnbaum HG, Schiller M, Tang J, Katz NP.

**Health care and work loss burden of prescription opioid abuse, dependence, and misuse.**

*Abstract:* AMCP's 2009 Educational Conference, San Antonio, TX Oct 7-9, 2009.

*Authors:* White AG, Birnbaum H, Schiller M, Waldman T, Cleveland JM, Setnik B, Roland CL.

**Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extraction.**

*Publication:* Appl Health Econ Health Policy 2009 06; 7(1): 61-70. e-pub ahead of print 2009/06/30; doi: 10.2165/00148365-200907010-00006.

*Authors:* White AG, Birnbaum HG, Rothman DB, Katz N.

**Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective.**

*Publication:* Clinical Journal of Pain 2006 10; 22(8): 667-676. e-pub ahead of print 2006/09/22; doi: 10.1097/01.ajp.0000210915.80417.cf.

*Authors:* Birnbaum HG, White AG, Reynolds JL, Greenberg PE, Zhang M, Vallow S, Schein JR, Katz NP.

**Geographic variation in the prescription of schedule II opioid analgesics among outpatients in the United States.**

*Publication:* Health Services Research 2006 06; 41(3 Pt 1): 837-855. doi: 10.1111/j.1475-6773.2006.00511.x.

*Authors:* Curtis LH, Stoddard J, Radeva JI, Hutchison S, Dans PE, Wright A, Woosley RL, Schulman KA.

**Direct costs of opioid abuse in an insured population in the United States.**

*Publication:* Journal of Managed Care Pharmacy 2005 07; 11(6): 469-479. e-pub ahead of print 2005/07/07; doi: 10.18553/jmcp.2005.11.6.469.

*Authors:* White AG, Birnbaum HG, Mareva MN, Daher M, Vallow S, Schein J, Katz N.

**Other Diseases & Conditions****Economic burden of spinal muscular atrophy in the United States: a contemporary assessment.**

*Publication:* Journal of Medical Economics 2019 07; 1. e-pub ahead of print 2019/07/20; doi: 10.1080/13696998.2019.1646263.

*Authors:* Droege M, Sproule D, Arjunji R, Gauthier-Loiselle M, Cloutier M, Dabbous O.

**Burden of Illness of Spinal Muscular Atrophy: An Update.**

*Abstract:* ISPOR 24th Annual International Meeting, New Orleans, LA May 18-22, 2019.

*Authors:* Droege M, Dabbous O, Arjunji R, Gauthier-Loiselle M, Cloutier M, Sproule D.

**Number needed to treat (NNT) in spinal muscular atrophy type 1 (SMA1) with AVXS-101 relative to nusinersen.**

*Abstract:* American Academy of Neurology (AAN), Philadelphia, PA May 4-11, 2019.

*Authors:* Droege M DO, Cloutier M, Guerin A, Pivneva I, Wu E Q, Sproule D M.

**Pro22 Burden of Illness of Spinal Muscular Atrophy: An Update.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Droege M, Dabbous O, Arjunji R, Gauthier-Loiselle M, Cloutier M, Sproule DM.

**Ro2 Assessing the Relationship between Lifelong Value and Pricing for Orphan Drugs in Ultra-Rare Diseases.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Dabbous O, Zhou ZY, Tang C, Harvey M, Wu EQ, Arjunji R.

**Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.**

*Abstract:* Medizinisch-Wissenschaftlichen Beirates der Deutschen Gesellschaft für Muskelkranke - 24 Kongress, Göttingen, Germany May 9-11, 2019.

*Authors:* Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner DE, Sproule DM.

**Comparaison de la survie, de la fonction motrice et des étapes de développement moteur de l'AVXS-101 et du nusinersen dans le traitement des nourrissons atteints d'amyotrophie spinale de type 1 (ASI-1).**

*Abstract:* Journées de Neurologie de Langue Française - 2019 Congrès, Lille, France Apr 16-19, 2019.

*Authors:* Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner DE, Sproule DM.

**Outcomes comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1 (SMA1).**

*Abstract:* Muscular Dystrophy Association - 1st Clinical and Research Conference, Orlando, FL Apr 16-19, 2019.

*Authors:* Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guérin A, Pivneva I, Wu EQ, Arjunji R, Feltner DE, Sproule DM.

**Survival, motor function, and motor milestones comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1 (SMA1).**

*Abstract:* Journée de Neurologie de Langue Française (JNLF), Lille, France Apr 16-19, 2019.

*Authors:* Dabbous O MB, Jansen J P, Lorenzi M, Cloutier M, Guerin A, Pivneva I, Wu E Q, Arjunji R, Feltner D, Sproule D M.

**Number needed to treat in spinal muscular atrophy type 1 (SMA1) with AVXS-101 relative to nusinersen.**

*Abstract:* Association Francaise contre les Myopathies Telethon (AFMT), Bordeaux, France Mar 25-28, 2019.

*Authors:* Dabbous O CM, Guerin A, Pivneva I, Wu E Q, Droeghe M, Sproule D M.

**Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.**

*Publication:* Advances in Therapy 2019 03. doi: <http://dx.doi.org/10.1007/s12325-019-00923-8>.

*Authors:* Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guerin A, Pivneva I, Wu EQ, Arjunji R, Feltner D, Sproule DM.

**Survival, Motor Function, and Motor Milestones: Comparison of AVXS-101 Relative to Nusinersen for the Treatment of Infants with Spinal Muscular Atrophy Type 1.**

*Abstract:* AMCP's 31st Annual Meeting, San Diego, CA Mar 25-28, 2019.

*Authors:* Dabbous O, Maru B, Jansen JP, Lorenzi M, Cloutier M, Guerin A, Pivneva I, Wu EQ, Arjunji R, Feltner DE, Sproule DM.

**Dry eye disease ranking among common reasons for seeking eye care in a large US claims database.**

*Publication:* Clinical Ophthalmology (Auckland, N.Z.) 2019 02; 13: 225-232. e-pub ahead of print 2019/02/19; doi: 10.2147/OPHTH.S188314.

*Authors:* Bradley JL, Ozer Stillman I, Pivneva I, Guerin A, Evans AM, Dana R.

**Economic Burden of Non-Infectious Inflammatory Eye Disease (NIIED) in a Commercially-Insured Population in the United States.**

*Publication:* Ocular Immunology and Inflammation 2019 02: 1-11. e-pub ahead of print 2019/02/23; doi: 10.1080/09273948.2018.1560476.

*Authors:* Albin TA, Rice JB, White AG, Johnson M, Reiff J, Lima AF, Bartels-Peculis L, Ciepielewska G, Nelson WW.

**Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care System.**

*Publication:* American Journal of Ophthalmology 2019 02. e-pub ahead of print 2019/02/06; doi: 10.1016/j.ajo.2019.01.026.

*Authors:* Dana R, Bradley JL, Guerin A, Pivneva I, Stillman IO, Evans AM, Schaumberg DA.

**Pih15 Comorbidity and Economic Burden of Peanut Allergy in Privately-Insured Pediatric Patients in the United States.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Tilles S, Birchwood C, Robison DR, Damle V, Norrett KE, Hass S, Guerin A, Latremouille-Viau D.

**Pih25 Healthcare Resource Utilization and Direct Healthcare Cost Related to Peanut Allergy in Pediatric Medicaid Patients.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Tilles S, Birchwood C, Robison DR, Damle V, Norrett KE, Hass S, Guerin A, Latremouille-Viau D.

**Psy24 Early Predictors of Sjogren's Syndrome: A Machine Learning Approach.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Royer J, Signorovitch J, Pivneva I, Huber W, Capkun G.

**Indirect costs associated with premature mortality among those with veno-occlusive disease/sinusoidal obstruction syndrome with multiorgan dysfunction post-hematopoietic stem-cell-transplant.**

*Publication:* Clinicoecon Outcomes Res 2018 12; 11: 13-22. e-pub ahead of print 2018/12/28; doi: 10.2147/ceor.S184883.

*Authors:* Zhou ZY, Tang W, Villa KF.

**Number needed to treat in patients with spinal muscular atrophy type 1 treated with AVXS-101 relative to nusinersen.**

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Dabbous O CM, Guerin A, Pivneva I, Wu E Q, Sproule D M.

**Real-World Experience of Generalized Lipodystrophy Patients Enrolled in the Metreleptin Early Access Program: Initial Results.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Cook K, Stears A, Araujo-Vilar D, Santini F, O'Rahilly S, Ceccarini G, Frois C, Bradt P, Savage D.

**Burden of illness associated with generalised lipodystrophy (GL) in leptin replacement therapy-naïve patients: A longitudinal medical chart review study.**

*Abstract:* 54th Annual Meeting of the European Association for the Study Diabetes, EASD 2018, Berlin, Germany Oct 1-5, 2018.

*Authors:* Akinci B, Oral E, Neidert A, Rus D, Cheng W, Thompson-Leduc P, Salinardi T, Cochran E, Brown R.

**Comorbidities and Prescribed Medications in Patients With or Without Dry Eye Disease: A Population-Based Study.**

*Publication:* American Journal of Ophthalmology 2018 10. e-pub ahead of print 2018/10/13; doi: 10.1016/j.ajo.2018.10.001.

*Authors:* Dana R, Bradley JL, Guerin A, Pivneva I, Evans AM, Stillman IO.

**Number Needed to Treat in Patients with Spinal Muscular Atrophy Type 1.**

*Abstract:* 23rd International Annual Congress of the World Muscle Society, Mendoza, Argentina Oct 2-6, 2018

*Authors:* Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu EQ, Sproule DM.

**Number needed to treat in patients with spinal muscular atrophy type 1 with AVXS-101 relative to nusinersen**

*Abstract:* AMCP Nexus 2018, Orlando, FL Oct 22-25, 2018.

*Authors:* Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu EQ, Droegge M, Sproule DM.

**Number needed to treat in spinal muscular atrophy type 1 with AVXS-101 relative to nusinersen.**

*Abstract:* European Society of Gene & Cell Therapy (ESGCT), Lausanne, Switzerland Oct 16-19, 2018.

*Authors:* Dabbous O CM, Guerin A, Pivneva I, Wu E Q, Droegge M, Sproule D M.

**The burden of non-infectious intraocular inflammatory eye diseases: a systematic literature review.**

*Publication:* Current Medical Research and Opinion 2018 09; 34(12): 2095-2103. e-pub ahead of print 2018/08/17; doi: 10.1080/03007995.2018.1512961.

*Authors:* Rice JB, White AG, Scarpati LM, Wan GJ, Nelson WW.

**Disability burden in patients with tenosynovial giant cell tumors in the United States from employer perspective.**

*Abstract:* ASCO Quality Care Symposium, Phoenix, AZ Sept 28-29, 2018.

*Authors:* Lin FI-I, R; Pivneva, I; Wynant, W; Shi, S; Shohudi Mojdehi, A; Wu, E.Q; Kwong, J; Abraham, J.A.

**Comparison of Characteristics of Benign Prostatic Hyperplasia (BPH) Patients Treated with Finasteride and Alpha Blocker Combination Therapy Versus Alpha Blocker Monotherapy in China: An Analysis of Electronic Medical Record Data.**

*Publication:* Advances in Therapy 2018 08; 35(8): 1191-1198. doi: <http://dx.doi.org/10.1007/s12325-018-0748-3>.

*Authors:* Fu Y, Han S, Wang L, Gao W, Wu E, Cao X, Wang J.

**Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication.**

*Publication:* BMC Infectious Diseases 2018 08; 18(1): 438. e-pub ahead of print 2018/08/31; doi: 10.1186/s12879-018-3333-0.

*Authors:* Vekeman F, Weiss L, Aram J, Ionescu-Ittu R, Moosavi S, Xiao Y, Cheng WY, Bhak RH, Tawadrous M, Capparella MR, Montravers P, Duh MS.

**Number Needed to Treat in Patients with Spinal Muscular Atrophy Type 1 Treated with AVXS-101 Relative to Nusinersen.**

*Abstract:* International Congress on Neuromuscular Diseases Vienna, Austria Jul 6-10, 2018

*Authors:* Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu E, Sproul D.

**Number needed to treat in spinal muscular atrophy type 1 with AVXS-101 relative to nusinersen.**

*Abstract:* 15th International Congress on Neuromuscular Diseases, ICNMD 2018, Vienna, Austria Jul 6-10, 2018.

*Authors:* Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu EQ, Sproule DM.

**Disability burden in patients with tenosynovial giant cell tumors in the United States from employer perspective.**

*Abstract:* American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, IL Jun 1-5, 2018.

*Authors:* Lin F, Ionescu-Ittu R, Pivneva I, Wynant W, Shi S, Mojdehi AS, Wu E, Kwong J, Abraham JA.

**Number needed to treat in patients with spinal muscular atrophy type 1 treated with AVXS-101 relative to nusinersen.**

*Abstract:* ISPOR 23rd Annual International Meeting, Baltimore, MD May 19-23, 2018.

*Authors:* Dabbous O, Cloutier M, Guerin A, Pivneva I, Wu EQ, Sproule DM.

**Tuberous Sclerosis Complex (TSC) and epilepsy manifestations: The impact of refractory epilepsy on health-related quality of life (HRQoL).**

*Abstract:* 70th Annual Meeting of the American Academy of Neurology, Apr 21-27, 2018.

*Authors:* Vergeer M, De Ranitz-Greven WL, Neary MP, Ionescu-Ittu R, Emond B, Duh MS, Sonnenberg B.

**Corticosteroid-Related Adverse Events Systematically Increase with Corticosteroid Dose in Noninfectious Intermediate, Posterior, or Panuveitis: Post Hoc Analyses from the VISUAL-1 and VISUAL-2 Trials.**

*Publication:* Ophthalmology 2017 12; 124(12): 1799-1807. e-pub ahead of print 2017/07/12; doi: 10.1016/j.ophtha.2017.06.017.

*Authors:* Suhler EB, Thorne JE, Mittal M, Betts KA, Tari S, Camez A, Bao Y, Joshi A.

**Dry eye symptoms and treatment satisfaction with ophthalmic cyclosporine: results of a claims database survey.**

*Abstract:* American Academy of Ophthalmology, Chicago, IL Nov 11-14, 2017.

*Authors:* Bradley JL, Özer-Stillman I, Pivneva I, Guerin A, Evans AM, Dana R.

**Treatment Patterns, Complications, and Health Care Utilization Among Endometriosis Patients Undergoing a Laparoscopy or a Hysterectomy: A Retrospective Claims Analysis.**

*Publication:* Advances in Therapy 2017 11; 34(11): 2436-2451. e-pub ahead of print 2017/10/19; doi: 10.1007/s12325-017-0619-3.

*Authors:* Surrey ES, Soliman AM, Yang H, Du EX, Su B.

**Dry eye disease ranking among common reasons for seeking eye care in a United States claims database.**

*Abstract:* American Academy of Optometry, Chicago, IL Oct 11-14, 2017.

*Authors:* Bradley JL, Özer-Stillman I, Pivneva I, Guerin A, Evans AM, Dana R.

**Liver damage in lipodystrophy and impact of metreleptin: Experience from a large retrospective review.**

*Abstract:* 68th Annual Meeting of the American Association for the Study of Liver Diseases, Washington DC Oct 20-24, 2017.

*Authors:* Akinci B, Oral EA, Neidert A, Rus D, Cheng W, Yang M, Salinardi T, Cochran E, Brown RJ.

**Engagement in health and wellness: An online incentive-based program.**

*Publication:* Prev Med Rep 2017 09; 7: 86-90. e-pub ahead of print 2017/06/20; doi: 10.1016/j.pmedr.2017.05.013.

*Authors:* Gibson TB, Maclean JR, Carls GS, Moore BJ, Ehrlich ED, Fener V, Goldberg J, Mechanic E, Baigel C.

**Ranking of dry eye disease among common reasons for seeking eye care in a United States claims database.**

*Abstract:* Kongress der Deutschen Ophthalmologischen Gesellschaft (DOG) Berlin, Germany Sep 28 - Oct 1, 2017.

*Authors:* Özer-Stillman I, Bradley JL, Pivneva I, Guerin A, Evans AM, Dana R.

**Attributes of nuclear imaging centers impacting physician referrals for single-photon emission computed tomography myocardial perfusion imaging tests.**

*Publication:* Journal of Medical Economics 2017 08; 20(8): 777-785. e-pub ahead of print 2017/04/14; doi: 10.1080/13696998.2017.1314969.

*Authors:* Li J, Houle CR, Spalding JR, Yang H, Xiang CQ, Kitt TM, Kristy RM, Wu EQ.

**A comparison of comorbidities among patients with and without dry eye disease in a large US healthcare system.**

*Abstract:* Congress of the European Society of Ophthalmology Symposium & Congress, Barcelona, Spain June 10-13, 2017.

*Authors:* Dana R, Bradley JL, Guerin A, Pivneva I, Dea K, Evans AM, Özer-Stillman I.

**Effect of Adalimumab on Visual Functioning in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials.**

*Publication:* JAMA Ophthalmol 2017 06; 135(6): 511-518. doi: 10.1001/jamaophthalmol.2017.0603.

*Authors:* Sheppard J, Joshi A, Betts KA, Hudgens S, Tari S, Chen N, Skup M, Dick AD.

**HPR predicting the future development of spondyloarthritis among patients with idiopathic acute anterior uveitis using real-world data.**

*Abstract:* Annual European Congress of Rheumatology, Madrid, Spain June 14-17, 2017.

*Authors:* Haroon M, Betts KA, Mu F, Skup M, Anderson JK, Joshi AD.

**Incidence and prevalence of dry eye disease: Estimates from claims database analysis in a large United States health care system.**

*Abstract:* Congress of the European Society of Ophthalmology Symposium & Congress, Ottawa, ON, Canada June 28-30, 2017.

*Authors:* Özer-Stillman I, Bradley JL, Guerin A, Pivneva I, Evans AM, Dana R, Schaumberg DA.

**Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas.**

*Publication:* Urology 2017 06; 104: 110-114. e-pub ahead of print 2017/03/07; doi: 10.1016/j.urology.2017.02.036.

*Authors:* Swallow E, King S, Song J, Peeples M, Signorovitch JE, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Sparagana S.

**Retreatment Rates Among Endometriosis Patients Undergoing Hysterectomy or Laparoscopy.**

*Publication:* J Womens Health (Larchmt) 2017 06; 26(6): 644-654. doi: 10.1089/jwh.2016.6043.

*Authors:* Soliman AM, Du EX, Yang H, Wu EQ, Haley JC.

**Treatment patterns and clinical characteristics among patients with tuberous sclerosis complex related angiomyolipomas.**

*Abstract:* 2017 International Research Conference on TSC & LAM, Washington, DC June 22-24, 2017.

*Authors:* Swallow E, Song J, Peeples M, Meiselbach M, Signorovitch J, Said Q, Prestifilippo J, Wong M, Northrup H, Frost M, Korf B, Sparagana S.

**Comorbidities among patients with dry eye disease in a large US healthcare system.**

*Abstract:* American Society of Cataract and Refractive Surgery•American Society of Ophthalmic Administrators Symposium & Congress, Los Angeles, CA May 5–9, 2017.

*Authors:* Dana R, Bradley JL, Guerin A, Pivneva I, Dea K, Evans AM, Özer-Stillman I.

**Out-of-pocket medical costs and third-party healthcare costs for children with Down syndrome.**

*Publication:* American Journal of Medical Genetics. Part A 2017 03; 173(3): 627-637. e-pub ahead of print 2016/12/15; doi: 10.1002/ajmg.a.38050.

*Authors:* Kageleiry A, Samuelson D, Duh MS, Lefebvre P, Campbell J, Skotko BG.

**Estimates of incidence and prevalence of dry eye disease across age groups in the US using data from a large healthcare system.**

*Abstract:* American Academy of Optometry 95th Annual Meeting, Anaheim, CA Nov 9-12, 2016

*Authors:* Bradley JL, Guerin A, Pivneva I, Evans AM, Özer-Stillman I, Dana R, Schaumberg DA.

**Prevalence of Noninfectious Uveitis in the United States: A Claims-Based Analysis.**

*Publication:* JAMA Ophthalmol 2016 11; 134(11): 1237-1245. e-pub ahead of print 2016/09/09; doi: 10.1001/jamaophthalmol.2016.3229.

*Authors:* Thorne JE, Suhler E, Skup M, Tari S, Macaulay D, Chao J, Ganguli A.

**Adherence and persistence with cyclosporine ophthalmic emulsion for treatment of dry eye disease in a large US healthcare System.**

*Abstract:* 2016 Annual Meeting of the American College of Clinical Pharmacy, Hollywood, FL Oct 23-26, 2016.

*Authors:* Schaumberg DA, Bradley J, Guerin A, Pivneva I, Evans A, Stillman IO, Dana R.

**Incidence and prevalence of dry eye disease in a large US healthcare system across a wide range of ages.**

*Abstract:* American Academy of Ophthalmology, Chicago, IL Oct 15-18, 2016

*Authors:* Dana R, Bradley JL, Guerin A, Pivneva I, Evans AM, Özer-Stillman I, Schaumberg DA.

**Direct and indirect resource use, healthcare costs and work force absence in patients with non-infectious intermediate, posterior or panuveitis.**

*Publication:* Acta Ophthalmol 2016 08; 94(5): e331-339. e-pub ahead of print 2016/03/05; doi: 10.1111/aos.12987.

*Authors:* Thorne JE, Skup M, Tundia N, Macaulay D, Revol C, Chao J, Joshi A, Dick AD.

**Impact of the introduction of newer Long Acting Reversible Contraceptive (LARC) methods on LARC use in a commercially insured population.**

*Abstract:* 32nd International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland Aug 25-28, 2016.

*Authors:* Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS.

**Retrospective analysis of the impact of increasing access to long acting reversible contraceptives in a commercially insured population.**

*Publication:* Reprod Health 2016 08; 13(1): 96. e-pub ahead of print 2016/08/24; doi: 10.1186/s12978-016-0211-3.

*Authors:* Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS.

**Development of a Risk Score for Fluconazole Failure among Patients with Invasive Candidiasis.***Abstract:* ASM 2016 | ICAAC 2016, Boston, MA Jun 16-20, 2016.*Authors:* Ostrosky-Zeichner L, Harrington R, Azie N, Yang H, Li N HY, Xie J, Lin PL, Ohashi E, Koo V, Wu EQ, Zhao J, Koo V, Wu E.**Comorbidities and symptoms among endometriosis patients: A systematic literature review.***Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.*Authors:* Soliman AM, Yang H, Du EX, Wu EQ, Castelli-Haley J, Winkel C.**Impact of the introduction of newer long acting reversible contraceptive (LARC) methods on LARC use in a commercially insured population.***Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.*Authors:* Law A, Pilon D, Lynen R, Laliberte F, Gozalo L, Lefebvre P, Duh MS.**Income growth trajectory for parents of children with down syndrome in the United States.***Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.*Authors:* Samuelson D, Kageleiry A, Duh MS, Lefebvre P, Campbell JY, DerSarkissian M, Haider BA, Skotko BG.**Measuring opportunities to improve health outcomes via individualized treatment assignment.***Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.*Authors:* Patterson-Lomba O, Signorovitch J.**Rates of subsequent endometriosis-related surgeries following an initial laparoscopy or hysterectomy: A longitudinal analysis of commercially insured endometriosis patient in the united states.***Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.*Authors:* Soliman AM, Yang H, Du EX, Wu EQ, Castelli-Haley J, Winkel C.**A systematic literature review of comorbidities and symptoms among uterine fibroids patients between 2000 and 2013.***Abstract:* ISPOR 21st Annual International Meeting, Washington, DC May 21-25, 2016.*Authors:* Soliman AM, Yang H, Du EX, Kelkar S, Winkel C.**Comparison of Annual Treatment Costs for Patients Treated with Infusion versus Injectable Biologics.***Abstract:* Academy of Managed Care & Specialty Pharmacy Annual Meeting, San Francisco, CA Apr 19-22, 2016.*Authors:* Skup M, Macaulay D, Wei J, Terasawa E, Chao J.**The direct and indirect costs associated with endometriosis: a systematic literature review.***Publication:* Human Reproduction 2016 04; 31(4): 712-722. e-pub ahead of print 2016/02/07; doi: 10.1093/humrep/dev335.*Authors:* Soliman AM, Yang H, Du EX, Kelley C, Winkel C.**Epilepsy treatment patterns among patients with tuberous sclerosis complex.***Abstract:* 68th Annual Meeting of the American Academy of Neurology Annual Meeting, Vancouver, BC, Canada Apr 15-21, 2016.*Authors:* Sparagana S, Swallow E, Song J, King S, Peeples M, Signorovitch J, Liu Z, Prestifilippo J, Kohrman M, Korf B, Krueger D, Wong M.**Subependymal giant cell astrocytoma treatment patterns among patients with tuberous sclerosis complex.***Abstract:* 68th American Academy of Neurology Annual Meeting, Vancouver, BC, Canada Apr 15-21, 2016.*Authors:* Krueger D, Song J, Swallow E, King S, Peeples M, Signorovitch J, Liu Z, Prestifilippo J, Korf B, Sparagana S, Wong M, Kohrman M.



**Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis.**

*Publication:* Ophthalmology 2016 03; 123(3): 655-662. e-pub ahead of print 2015/12/30; doi: 10.1016/j.ophtha.2015.10.028.

*Authors:* Dick AD, Tundia N, Sorg R, Zhao C, Chao J, Joshi A, Skup M.

**The Economic Burden Associated with Zygomycosis-Related Hospitalizations in the U.S.**

*Abstract:* IDSA IDWeek annual meeting, San Diego, CA Oct 7-11, 2015.

*Authors:* Yang H, Song J, Yang C, Kelkar S, Lee E, Fan A, Azie N, Spalding J.

**Demographic and Clinical Characteristics of Patients with Tuberous Sclerosis Complex in a TSC Patient Database.**

*Abstract:* International TSC Research Conference, Windsor, UK Sep 10-12, 2015.

*Authors:* Swallow E, King S, Song J, Peeples M, Signorovitch J, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Northrup H, Sparagana S.

**Monitoring testing patterns among patients with tuberous sclerosis complex-related angiomyolipomas.**

*Abstract:* International TSC Research Conference, Windsor, UK Sept 10-12, 2015.

*Authors:* Swallow E, King S, Song J, Peeples M, Signorovitch J, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Northrup H, Sparagana S.

**The direct and indirect costs of uterine fibroid tumors: a systematic review of the literature between 2000 and 2013.**

*Publication:* American Journal of Obstetrics and Gynecology 2015 08; 213(2): 141-160. doi: 10.1016/j.ajog.2015.03.019.

*Authors:* Soliman AM, Yang H, Du EX, Kelkar SS, Winkel C.

**Cellular rejuvenation and ageing-proteome by Ginsenoside 20(S)-Rg3.**

*Abstract:* 40th FEBS Congress: The Biochemical Basis of Life, Berlin, Germany July 4-9, 2015.

*Authors:* Kim YR, Baek SJ, Kang YM, Oh KS, Kwon J, Choi JS.

**Using ClinicalTrials.gov to supplement information in ophthalmology conference abstracts about trial outcomes: A comparison study.**

*Publication:* PloS One 2015 06; 10 (6) (no pagination)(e0130619). doi: <http://dx.doi.org/10.1371/journal.pone.0130619>.

*Authors:* Scherer RW, Huynh L, Ervin AM, Dickersin K.

**Kidney involvement in tuberous sclerosis complex: The impact on health care resource use and costs in The Netherlands.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Zonnenberg BA.

**Out-of-pocket medical costs for parents with children with down syndrome in the united states.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Kageleiry A, Samuelson D, Duh MS, Lefebvre P, DerSarkissian M, Campbell JY, Skotko BG.

**Treatment patterns of women diagnosed with uterine fibroids 5 years pre and post diagnosis: A longitudinal retrospective claims analysis of a commercially insured population in the US.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C.

**Incremental direct and indirect costs of untreated vasomotor symptoms.**

*Publication:* Menopause 2015 03; 22(3): 260-266. doi: 10.1097/GME.0000000000000320.

*Authors:* Sarrel P, Portman D, Lefebvre P, Lefeuvre MH, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM.

**Healthcare utilization and costs among women diagnosed with uterine fibroids: A longitudinal evaluation for 5 years pre and post diagnosis.**

*Publication:* Current Medical Research and Opinion 2015 01; (0): 1-38.

*Authors:* Fuldeore M, Yang H, Soliman AM, Winkel C.

**Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases.**

*Publication:* Fertility and Sterility 2015 01; 103(1): 163-171. doi: 10.1016/j.fertnstert.2014.10.011.

*Authors:* Fuldeore M, Yang H, Du EX, Soliman AM, Wu EQ, Winkel C.

**Kidney involvement in tuberous sclerosis complex: The impact on healthcare resource use and costs.**

*Publication:* Journal of Medical Economics 2015 01; 18(12): 1060-1070. doi:

<http://dx.doi.org/10.3111/13696998.2015.10759953>.

*Authors:* Vekeman F, Magestro M, Karner P, Duh MS, Nichols T, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

**The Clinical Burden Associated With Zygomycosis-Related Hospitalizations in the United States.**

*Publication:* Open Forum Infectious Diseases 2015 2(suppl\_1): 460-460. doi: 10.1093/ofid/ofv133.335.

*Authors:* Yang H, Song J, Yang C, Kelkar S, Lee E, Fan A, Azie N, Spalding J, Kontoyiannis D.

**Clinical and economic burden of vasomotor symptoms among untreated menopausal women.**

*Abstract:* ICPE 30th Annual Meeting, Taipei, Taiwan (Republic of China) Oct 24-27, 2014.

*Authors:* Sarrel P, Lefebvre P, Lafeuille M, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM, Portman D.

**Incremental direct and indirect cost of untreated vasomotor symptoms (VMS).**

*Abstract:* 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management Taipei, Taiwan (Republic of China) Oct 24-27, 2014.

*Authors:* Sarrel P, Lefebvre P, Lafeuille MH, Gravel J, Sheng Duh M, Aupperle PM, Portman D.

**A longitudinal retrospective claims analysis of healthcare costs incurred by uterine fibroids patients.**

*Abstract:* 70th Annual Meeting of the American Society for Reproductive Medicine, Honolulu, HI Oct 18-22, 2014.

*Authors:* Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C.

**Treatment patterns among US women diagnosed with endometriosis: A retrospective claims analyses pre-and post-diagnosis.**

*Abstract:* 70th Annual Meeting of the American Society for Reproductive Medicine, Honolulu, HI Oct 18-22, 2014.

*Authors:* Soliman AM, Fuldeore M, Yang H, Du EX, Wu EQ, Winkel C.

**Diagnosis and treatment patterns among patients with tuberous sclerosis complex-related angiomyolipomas.**

*Abstract:* World TSC Conference, Washington, DC July 3-6, 2014.

*Authors:* Sparagana S, Krueger D, Swallow E, Nichols T, King S, Signorovitch J, Liu Z, Prestifilippo J, Nakagawa JA, Roberds S, Kohrman M, Frost M.

**Duloxetine use in employees with low back pain: treatment patterns and direct and indirect costs.**

*Publication:* Pain Medicine 2014 06; 15(6): 1015-1026. doi: 10.1111/pme.12362.

*Authors:* Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW.

**Significant Economic Burden Among Endometriosis Patients before and after Diagnosis: A Retrospective Claims Database Analysis.**

*Abstract:* 96th Annual Meeting and Expo of the Endocrine Society, Chicago, IL June 21-24, 2014.

*Authors:* Soliman AM, Fuldeore MJ, Yang H, Du EX, Wu EQ, Winkel CA.

**Burden of venous leg ulcers in the United States.**

*Publication:* Journal of Medical Economics 2014 05; 17(5): 347-356. doi: 10.3111/13696998.2014.903258.

*Authors:* Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

**Kidney dysfunction and healthcare resource utilization in tuberous sclerosis complex patients in the Netherlands.**

*Abstract:* 51st ERA-EDTA Congress, Amsterdam, Netherlands May 31-Jun 3, 2014.

*Authors:* Magestro M, Vekeman F, Nichols T, Karner P, Duh MS, Srivastava B, Van Waalwijk Van Doorn-Khosrovani SB, Zonnenberg BA.

**Risk of leaving the workforce in non-infectious uveitis.**

*Abstract:* Association for Research in Vision and Ophthalmology, Orlando, FL May 4-8, 2014.

*Authors:* Tundia N, Skup M, Sorg R, Macaulay D, Chao J, Mulani P, Thorne JE.

**Risk of ocular complications in non-infectious uveitis.**

*Abstract:* Association for Research in Vision and Ophthalmology, Orlando, FL May 4-8, 2014.

*Authors:* Skup M, Tundia N, Sorg R, Chao J, Mulani P, Dick A.

**Clinical and economic burden of vasomotor symptoms among untreated menopausal women.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Sarrel P, Lefebvre P, Lafeuille M, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM, Portman D.

**Direct and indirect resource use and costs associated with non-infectious non-anterior uveitis.**

*Abstract:* 2014 Annual Meeting of the Association for Research in Vision and Ophthalmology, Orlando, FL May 4-8, 2014.

*Authors:* Thorne JE, Tundia N, Skup M, Macaulay D, Revol C, Chao J, Mulani P, Dick AD.

**Medicaid spending on contraceptive coverage and pregnancy-related care.**

*Publication:* Reprod Health 2014 03; 11(1): 20. doi: 10.1186/1742-4755-11-20.

*Authors:* Laliberte F, Lefebvre P, Law A, Duh MS, Pocoski J, Lynen R, Darney P.

**Assessing the impact of substandard copy medicines in developing countries: the experience with imatinib copies.**

*Publication:* Expert Review of Clinical Pharmacology 2013 11; 6(6): 691-701. doi: 10.1586/17512433.2013.843450.

*Authors:* Kaltenboeck A, Long G, Hayes-Larson E, Lopes Gde L.

**Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA.**

*Publication:* Journal of ophthalmic inflammation and infection 2013 11; 3(1): 64.

*Authors:* Chu DS, Johnson SJ, Mallya UG, Davis MR, Sorg RA, Duh MS.

**Systematic literature review of the costs of pregnancy in the US.**

*Publication:* Pharmacoeconomics 2013 11; 31(11): 1005-1030. doi: 10.1007/s40273-013-0096-8.

*Authors:* Huynh L, McCoy M, Law A, Tran KN, Knuth S, Lefebvre P, Sullivan S, Duh MS.

**Direct and indirect costs for women with vasomotor symptoms (VMS) receiving lower-versus higher-dose paroxetine.**

*Abstract:* 24th Annual Meeting of the North American Menopause Society, Dallas, TX Oct 9-12, 2013.

*Authors:* Portman D, Lafeuille MH, Lefebvre P, Gravel J, Duh MS, Aupperle PM, Sarrel P.

**Incremental direct and indirect cost of untreated vasomotor symptoms (VMS).**

*Abstract:* 24th Annual Meeting of the North American Menopause Society, Dallas, TX Oct 9-12, 2013.

*Authors:* Sarrel P, Lefebvre P, Lafeuille MH, Gravel J, Sheng Duh M, Aupperle PM, Portman D.

**Actuarial analysis of Medicaid spending for contraception and pregnancy care.**

*Abstract:* 1st Global Conference on Contraception, Reproductive and Sexual Health, Copenhagen, Denmark May 22-25, 2013.

*Authors:* Laliberte F, Lefebvre P, Law A, Sheng Duh M, Lynen R, Darney P.

**Medicaid spending for users of contraceptives and pregnancy-related care.**

*Abstract:* 1st Global Conference on Contraception, Reproductive and Sexual Health, Copenhagen, Denmark May 22-25, 2013.

*Authors:* Laliberte F, Lefebvre P, Law A, Sheng Duh M, Lynen R, Darney P.

**Medical, drug, and work-loss costs of venous leg ulcers.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Rice JB, Desai U, Cummings AK, Birnbaum HG, Skornicki M, Parsons N.

**Actuarial analysis of Medicaid spending for contraception and pregnancy care.**

*Abstract:* 21st Annual Women's Health Congress, Washington, DC April 22-24, 2013.

*Authors:* Laliberte F, Lefebvre P, Law A, Duh MS, Lynen R, Darney P.

**Medical resource use and costs associated with chylomicronemia.**

*Publication:* Journal of Medical Economics 2013 03; 16(5): 657-666. doi: 10.3111/13696998.2013.779277.

*Authors:* Gaudet D, Signorovitch J, Swallow E, Fan L, Tremblay K, Brisson D, Meyers C, Gruenberger JB.

**Pain relief and tolerability balance of immediate release tapentadol or oxycodone treatment for patients with moderate to severe osteoarthritis or low back pain.**

*Publication:* Pain Medicine 2012 09; 13(9): 1110-1120. doi: 10.1111/j.1526-4637.2012.01454.x.

*Authors:* Kavanagh S, Kwong W, Hammond G, Nelson W, Upmalis D, Yang M.

**Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.**

*Publication:* Pain Pract 2012 09; 12(7): 533-540. doi: 10.1111/j.1533-2500.2011.00526.x.

*Authors:* Reed C, Birnbaum HG, Ivanova JI, Schiller M, Waldman T, Mullen RE, Swindle R.

**Duloxetine use in chronic low back pain: treatment patterns and costs.**

*Publication:* Pharmacoeconomics 2012 07; 30(7): 595-609. doi: 10.2165/11598130-000000000-00000.

*Authors:* Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle RW.

**Health care costs and utilization for privately insured patients treated for non-infectious uveitis in the United States.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Johnson S, Duh MS, Mallya U, Diener M, Sorg R, Chu D.

**Cost burden and treatment patterns associated with management of heavy menstrual bleeding.**

*Publication:* J Womens Health (Larchmt) 2012 05; 21(5): 539-547. doi: 10.1089/jwh.2011.3147.

*Authors:* Jensen JT, Lefebvre P, Laliberte F, Sarda SP, Law A, Pocoski J, Duh MS.

**Economic burden and quality of life of vulvodynia in the United States.**

*Publication:* Current Medical Research and Opinion 2012 04; 28(4): 601-608. doi: 10.1185/03007995.2012.666963.

*Authors:* Xie Y, Shi L, Xiong X, Wu E, Veasley C, Dade C.

**Effects of quinestron and levonorgestrel on populations of plateau pikas, Ochotona curzoniae, in the Qinghai-Tibetan Plateau.**

*Publication:* Pest Manag Sci 2012 04; 68(4): 592-601. doi: 10.1002/ps.2302.

*Authors:* Liu M, Qu J, Yang M, Wang Z, Wang Y, Zhang Y, Zhang Z.

**Direct and indirect costs associated with Dupuytren's contracture.**

*Publication:* Journal of Medical Economics 2012 03; 15(4): 664-671. doi: 10.3111/13696998.2012.670678.

*Authors:* Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P.

**Prevalence and costs of osteoporotic patients with subsequent non-vertebral fractures in the US.**

*Publication:* Osteoporosis International 2011 10; 22(10): 2611-2621. doi: 10.1007/s00198-010-1494-9.

*Authors:* Pike CT, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET.

**A qualitative study on feasibility of a web-based Women's Health Portal and Information System.**

*Publication:* Patient 2011 07; 4(1): 67-68. doi: 10.2165/11586790-000000000-00000.

*Authors:* Yang M, Kosinski M, Boulanger R.

**Direct and indirect costs associated with dupuytren's contracture.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Macaulay D, Ivanova J, Birnbaum H, Sorg R, Skodny P.

**Health care resource utilization and costs in females with newly diagnosed heavy menstrual bleeding: An employer's perspective.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-24, 2011.

*Authors:* Jensen JT, Lefebvre P, Laliberte F, Sarda SP, Law A, Pocoski J, MS. D.

**New methods to adjust for selective crossover in survival analysis: In assessments of costeffectiveness of cancer therapies.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Delea TE, Duh MS, Wei LJ, Robins J.

**Real-world role of tricyclic antidepressants in the treatment of fibromyalgia.**

*Abstract:* 30th Annual Scientific Meeting of the American Pain Society, Austin, TX May 19-21, 2011.

*Authors:* Swindle R, Birnbaum H, Ivanova J, Schiller M, Waldman T, Mullen R, Reed C.

**Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.**

*Publication:* Journal of Medical Economics 2011 04; 14(3): 324-334. doi: 10.3111/13696998.2011.578698.

*Authors:* Vekeman F, LaMori JC, Laliberte F, Nutescu E, Duh MS, Bookhart BK, Schein J, Dea K, Olson WH, Lefebvre P.

**Analysis of genetic diversity of gemplasm of *Pinellia ternata* based on SRAP.**

*Publication:* China Journal of Chinese Materia Medica 2011 02; 36(3): 334-337.

*Authors:* Yang M, Chen K.

**Economic burden of privately insured non-vertebral fracture patients with osteoporosis over a 2-year period in the US.**

*Publication:* Osteoporosis International 2011 01; 22(1): 47-56. doi: 10.1007/s00198-010-1267-5.

*Authors:* Pike C, Birnbaum HG, Schiller M, Swallow E, Burge RT, Edgell ET.

**Real-world use of duloxetine for chronic low back pain: Treatment pattern and costs.**

*Abstract:* ISPOR 13th Annual European Congress, Prague Czech Republic Nov 6-9, 2010.

*Authors:* Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Swindle R.

**Evaluation of cardiovascular diseases (CVDs) risk for patients with fibromyalgia syndrome in the United States.**

*Abstract:* 26th International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE),

Brighton, UK Aug 19-22, 2010.

*Authors:* Mease PJ, Duh MS, Vekeman F, Lefebvre P, Laliberte F, Boerstoeel-Streefland M, Jiang W, Zimetbaum PJ.

**Real-world use of duloxetine for low back pain and chronic low back pain: Treatment pattern, direct and indirect costs.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Ivanova JI, Birnbaum HG, Kantor E, Schiller M, Johnstone B, Faries D, Risser R, Swindle R.

**Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.**

*Publication:* Pharmacoeconomics 2010 04; 28(5): 395-409. doi: 10.2165/11531040-000000000-00000.

*Authors:* Pike C, Birnbaum HG, Schiller M, Sharma H, Burge R, Edgell ET.

**Cost-effectiveness analysis of treatments for premenstrual dysphoric disorder.**

*Publication:* Appl Health Econ Health Policy 2010 02; 8(2): 129-140. doi: 10.2165/11532210-000000000-00000.

*Authors:* Rendas-Baum R, Yang M, Gricar J, Wallenstein GV.

**Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference.**

*Publication:* Current Medical Research and Opinion 2009 10; 25(10): 2487-2494. doi: 10.1185/03007990903167415.

*Authors:* Yang M, Morin CM, Schaefer K, Wallenstein GV.

**Comparison of health care use and costs in newly diagnosed and established patients with fibromyalgia.**

*Publication:* Journal of Pain 2009 09; 10(9): 976-983. doi: 10.1016/j.jpain.2009.03.012.

*Authors:* White LA, Robinson RL, Yu AP, Kaltenboeck A, Samuels S, Mallett D, Birnbaum HG.

**The costs of non-vertebral osteoporotic fractures in the United States.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Birnbaum HG, Pike C, Schiller M, Sharma H, Gu A, Burge RT, Edgell ET.

**Real-world use of duloxetine for low back pain.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Ivanova J, Birnbaum HG, Schiller M, Kantor E, Waldman T, Johnstone BM, Faries D, Risser R, Swindle R.

**Clinical and Economic Outcomes among Women Using Levonorgestrel-Releasing Intrauterine System (LNG-IUS).**

*Abstract:* ISPOR 13th Annual International Meeting, Toronto, ON, Canada May 3-7, 2008.

*Authors:* Yu A, Wu EQ, Perrson B, Chang J, Costales C, Gricar J.

**WH3 Clinical and economic outcomes among women using levonorgestrel-releasing intrauterine system (LNG-IUS).**

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research 2008, May 3-7, 2008.

*Authors:* Yu A, Wu E, Perrson B, Chang J, Costales A, Gricar J.

**Burden of premenstrual dysphoric disorder on health-related quality of life.**

*Publication:* J Womens Health (Larchmt) 2008 01; 17(1): 113-121. doi: 10.1089/jwh.2007.0417.

*Authors:* Yang M, Wallenstein G, Hagan M, Guo A, Chang J, Kornstein S.

**Employees with fibromyalgia: medical comorbidity, healthcare costs, and work loss.**

*Publication:* Journal of Occupational Environmental Medicine 2008 01; 50(1): 13-24. doi:

10.1097/JOM.0b013e31815cff4b.

*Authors:* White LA, Birnbaum HG, Kaltenboeck A, Tang J, Mallett D, Robinson RL.

**Actual versus predicted first-year utilization patterns of teriparatide in patients with employer-sponsored health insurance.**

*Publication:* Current Medical Research and Opinion 2007 12; 23(12): 3215-3222. doi: 10.1185/030079907X242908.

*Authors:* Meadows ES, Rousculp M, Sasser AC, Birnbaum HG, Moyneur E, Mallet D, Johnston JA.

**Mapping MOS Sleep Scale scores to SF-6D utility index.**

*Publication:* Current Medical Research and Opinion 2007 09; 23(9): 2269-2282. doi: 10.1185/030079907X210796.

*Authors:* Yang M, Dubois D, Kosinski M, Sun X, Gajria K.

**The direct and indirect cost burden of clinically significant and symptomatic uterine fibroids.**

*Publication:* Journal of Occupational Environmental Medicine 2007 05; 49(5): 493-506. doi: 10.1097/JOM.0b013e31805f6cf2.

*Authors:* Lee DW, Ozminkowski RJ, Carls GS, Wang S, Gibson TB, Stewart EA.

**Hemodynamic changes induced by positive pressure capnothorax during thoracoscopic thymectomy.**

*Publication:* Chirurgia 2007 05; 102(3): 263-270.

*Authors:* Tomescu D, Grigorescu B, Nitulescu R, Tomulescu V, Popescu I, Tulbure D.

**Annual costs associated with diagnosis of uterine leiomyomata.**

*Publication:* Obstetrics and Gynecology 2006 10; 108(4): 930-937. doi: 10.1097/01.AOG.0000234651.41000.58.

*Authors:* Hartmann KE, Birnbaum H, Ben-Hamadi R, Wu EQ, Farrell MH, Spalding J, Stang P.

**Annual Costs Associated with Diagnosis of Uterine Fibroids.**

*Abstract:* The American College of Obstetricians and Gynecologists.

*Authors:* Hartmann KE, Birnbaum H, Wu EQ, Ben-Hamadi R, Spalding J, Stang P.

**Lifetime Costs of Patients with Clinically Detected Uterine Fibroids: An Employer's Perspective.**

*Publication:* Drug Benefit Trends 2006 18(7): 405.

*Authors:* Wu E, Ben-Hamadi R, Birnbaum H, Farrell M, Spalding J, Stang P, Hartmann K.

**Lifetime Costs of Patients with Clinically-Detected Uterine Fibroids: An Employer Perspective.**

*Abstract:* The American College of Obstetricians and Gynecologists.

*Authors:* Wu EQ, Birnbaum H, Farrell MH, Spalding J, Stang P, Hartmann KE.

**Assessing the economic impact of chronic conditions in postmenopausal women.**

*Publication:* Expert Opinion on Pharmacotherapy 2005 09; 6(11): 1803-1814. doi: 10.1517/14656566.6.11.1803.

*Authors:* Sasser AC, Taylor M, Birnbaum HG, Schoenfeld MJ, Oster EF, Rousculp M.

**Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.**

*Publication:* Women's Health Issues 2005 05; 15(3): 97-108. doi: 10.1016/j.whi.2004.11.006.

*Authors:* Sasser AC, Rousculp MD, Birnbaum HG, Oster EF, Lufkin E, Mallet D.

**POS1 Using a budget impact model to predict first-year use of a new osteoporosis therapy.**

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research 2005, 2005.

*Authors:* Sasser A, Rousculp M, Birnbaum H, Moyneur E, Wu E, Marcus R.

**Validation of a Budget Impact Model in Predicting First-Year Use of a New Osteoporosis Therapy.**

*Abstract:* AMCP 2005.

*Authors:* Rousculp MD, Sasser AC, Birnbaum HG, Moyneur E, Wu EQ, Mallet D, Marcus R.

**Depression and fibromyalgia: treatment and cost when diagnosed separately or concurrently.**

*Publication:* Journal of Rheumatology 2004 08; 31(8): 1621-1629.

*Authors:* Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Wolfe F.

**Economic Impact Analysis: Proposition 71 - California Stem Cell Research and Cures Initiative.**

*Publication:* Report Commissioned by Californians for Stem Cell Research and Cures 2004.

*Authors:* Baker L, Deal B.

**Economic cost and epidemiological characteristics of patients with fibromyalgia claims.***Publication:* Journal of Rheumatology 2003 06; 30(6): 1318-1325.*Authors:* Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ.**The effects of chronic medical conditions on work loss and work cutback.***Publication:* Journal of Occupational Environmental Medicine 2001 03; 43(3): 218-225.*Authors:* Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS.**Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts.***Publication:* Pharmacoepidemiology and Drug Safety 1999 07; 8(4): 275-283. doi: 10.1002/(SICI)1099-1557(199907)8:4<275::AID-PDS427>3.0.CO;2-D.*Authors:* Duh MS, Walker AM, Kronlund KH, Jr.**Calculating the workplace cost of chronic disease.***Publication:* Business and Health 1995 09; 13(9): 27-28, 30.*Authors:* Greenberg PE, Finkelstein SN, Berndt ER.**An alternative in terminal care: results of the National Hospice Study.***Publication:* Journal of Chronic Diseases 1986 01; 39(1): 9-26.*Authors:* Greer DS, Mor V, Morris JN, Sherwood S, Kidder D, H. B.**An Alternative in Terminal Care: Results of the National Advice on Hospice Care for Benefits Design.***Publication:* Business and Health 1985.*Authors:* Birnbaum H.

## Other (Health Policy, Market Access, and other topics)

**The Development of Health Technology Assessment in Asia: Current Status and Future Trends.***Publication:* Value Health Reg Issues 2019 10; 21: 39-44. e-pub ahead of print 2019/10/22; doi: 10.1016/j.vhri.2019.08.472.*Authors:* Liu G, Wu EQ, Ahn J, Kamae I, Xie J, Yang H.**Transparency in Health Economic Modeling: Options, Issues and Potential Solutions.***Publication:* Pharmacoeconomics 2019 10. e-pub ahead of print 2019/10/09; doi: 10.1007/s40273-019-00842-0.*Authors:* Wu EQ, Zhou ZY, Xie J, Metallo C, Thokala P.**Validation of an ambient measurement system (AMS) for physical activities in a paediatric population.***Publication:* Journal of Medical Engineering and Technology 2019 07: 1-8. e-pub ahead of print 2019/07/16; doi: 10.1080/03091902.2019.1640308.*Authors:* Varsanik JS, Kimmel ZM, Laforet GA, Ricotti V, Sajeev G, Signorovitch J, Quiroz JA, Chevalier TW.**College affirmative action bans and smoking and alcohol use among underrepresented minority adolescents in the United States: A difference-in-differences study.***Publication:* PLoS Medicine 2019 06; 16(6): e1002821. doi: <http://dx.doi.org/10.1371/journal.pmed.1002821>.*Authors:* Venkataramani AS, Cook E, O'Brien RL, Kawachi I, Jena AB, Tsai AC.**Economic Impact of Non-Medical Switching from Originator Biologics to Biosimilars: A Systematic Literature Review.***Publication:* Advances in Therapy 2019 06. e-pub ahead of print 2019/06/07; doi: 10.1007/s12325-019-00998-3.*Authors:* Liu Y, Yang M, Garg V, Wu EQ, Wang J, Skup M.



**Federal government-interest patent disclosures for recent top-selling drugs.**

*Publication:* Journal of Medical Economics 2019 06: 1-7. e-pub ahead of print 2019/06/14; doi: 10.1080/13696998.2019.1631832.

*Authors:* Long G.

**Pmu87 Matching Adjusted Indirect Comparisons: Recommendation for the Selection of Baseline Characteristics Used for Matching.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Gao W, Patterson-Lomba O, Signorovitch J, Wu EQ, Ayyagari R.

**Beyond multidrug resistance: Leveraging rare variants with machine and statistical learning models in Mycobacterium tuberculosis resistance prediction.**

*Publication:* EBioMedicine 2019 04. e-pub ahead of print 2019/05/03; doi: 10.1016/j.ebiom.2019.04.016.

*Authors:* Chen ML, Doddi A, Royer J, Freschi L, Schito M, Ezewudo M, Kohane IS, Beam A, Farhat M.

**Combining the Power of Artificial Intelligence with the Richness of Healthcare Claims Data: Opportunities and Challenges.**

*Publication:* PharmacoEconomics. 2019 03. doi: <http://dx.doi.org/10.1007/s40273-019-00777-6>.

*Authors:* Thesmar D, Sraer D, Pinheiro L, Dadson N, Veliche R, Greenberg P.

**Development of a classifier to identify patients with probable Lennox-Gastaut syndrome in health insurance claims databases via random forest methodology.**

*Publication:* Current Medical Research and Opinion 2019 03: 1-6. e-pub ahead of print 2019/03/15; doi: 10.1080/03007995.2019.1595552.

*Authors:* Vekeman F, Pina-Garza JE, Cheng WY, Tuttle E, Giguere-Duval P, Oganisian A, Damron J, Sheng Duh M, Shen V, Saurer TB, Montouris GD, Isojarvi J.

**P445 Prevalence rates of biosimilar discontinuation and switchback to originator biologics following non-medical switching: a meta-analysis of real-world studies.**

*Abstract:* 14th Annual Congress of the ECCO - Inflammatory Bowel Disease 2019, Copenhagen, Denmark Mar 6-9, 2019.

*Authors:* Yifei L, Skup M, Yang M, Qi C, Doctor T.

**Potentially High Number of Ineffective Drugs with the Standard Shorter Course Regimen for Multidrug-Resistant Tuberculosis Treatment in Haiti.**

*Publication:* The American journal of tropical medicine and hygiene 2019 02; 100(2): 392-398. doi: <http://dx.doi.org/10.4269/ajtmh.18-0493>.

*Authors:* Walsh KF, Souroutzidis A, Vilbrun SC, Peeples M, Joissaint G, Delva S, Widmann P, Royal G, Pry J, Bang H, Pape JW, Koenig SP.

**Comment on "The price of abandoning diagnostics testing for cell-free fetal DNA screening".**

*Publication:* Prenatal Diagnosis 2019 01; 39(2): 130. doi: <http://dx.doi.org/10.1002/pd.5331>.

*Authors:* Skotko BG, Samuelson D, Kageleiry A, Lefebvre P, Hellstern M, Campbell J.

**Pns196 Use of Machine Learning in Health Economics and Outcomes Research (Heor): Optimizing Predictive Models.**

*Abstract:* ISPOR 2019: Rapid. Disruptive. Innovative: A New Era in HEOR, New Orleans, LA May 18-22, 2019.

*Authors:* Royer J, Wu E, Ayyagari R.

**An Application of Artificial Intelligence-Based Methodology in Literature Reviews.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Wu EQ, Ayyagari R, Royer J, Li J, Wang J, Lefebvre P, Patterson-Lomba O.

**Artificial Intelligence Assisted Literature Reviews: Key Considerations for Implementation in Health Care Research.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Wu EQ, Royer J, Ayyagari R, Signorovitch J, Thokala P.

**CMS hospital readmission reduction program and anticoagulants received following a total hip and knee arthroplasty discharge.**

*Publication:* Current Medical Research and Opinion 2018 11; 34(11): 1967-1974. e-pub ahead of print 2018/05/12; doi: 10.1080/03007995.2018.1475347.

*Authors:* Laliberte F, Coleman CI, Bookhart B, Schein J, Martin S, Wynant W, Xiao Y, Lefebvre P, Kaatz S.

**Longitudinal Matching: A Method for Generating Comparable Samples of Treated and Treatment-Naive Patients with Progressive Conditions.**

*Abstract:* ISPOR Europe 2018: New Perspectives for Improving 21st Century Health Systems, Barcelona, Spain Nov 10-14, 2018.

*Authors:* Cook K, Ali O, Gupta D, Holmqvist D, Ilin C, Lee D, Tuttle E, Bradt P.

**Economic impact of non-medical switching from originator biologics to biosimilars-a systematic literature review.**

*Abstract:* Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, Netherlands Jun 13-16, 2018.

*Authors:* Liu Y, Garg V, Yang M, Wu EQ, Skup M.

**Examining a Statewide Educational Consulting Program for Pediatric Brain Injury.**

*Publication:* Clinical Pediatrics 2018 06; 57(6): 645-655. e-pub ahead of print 2017/09/22; doi: 10.1177/0009922817732146.

*Authors:* Myers RK, Eagan-Brown BL, Conway AT, Nagele DA, Vaccaro MJ, Kendi S, Zonfrillo MR.

**Removal of ineligible outcome cases reduces confounding.**

*Publication:* Clinical Epidemiology 2018 06; 10: 575-579. e-pub ahead of print 2018/06/07; doi: 10.2147/CLEP.S160482.

*Authors:* Walker AM, Schneeweiss S, DerSarkissian M, Duh MS.

**One-Year Effect of the Medicare Annual Wellness Visit on Detection of Cognitive Impairment: A Cohort Study.**

*Publication:* Journal of the American Geriatrics Society 2018 04. e-pub ahead of print 2018/04/03; doi: 10.1111/jgs.15330.

*Authors:* Fowler NR, Campbell NL, Pohl GM, Munsie LM, Kirson NY, Desai U, Trieschman EJ, Meiselbach MK, Andrews JS, Boustani MA.

**Community health workers improve disease control and medication adherence among patients with diabetes and/or hypertension in Chiapas, Mexico: an observational stepped-wedge study.**

*Publication:* BMJ Glob Health 2018 03; 3(1): e000566. e-pub ahead of print 2018/03/13; doi: 10.1136/bmjgh-2017-000566.

*Authors:* Newman PM, Franke MF, Arrieta J, Carrasco H, Elliott P, Flores H, Friedman A, Graham S, Martinez L, Palazuelos L, Savage K, Tymeson H, Palazuelos D.

**Activity-based costing of health-care delivery, Haiti.**

*Publication:* Bulletin of the World Health Organization 2018 01; 96(1): 10-17. e-pub ahead of print 2018/02/07; doi: 10.2471/BLT.17.198663.

*Authors:* McBain RK, Jerome G, Leandre F, Browning M, Warsh J, Shah M, Mistry B, Faure PAI, Pierre C, Fang AP, Mugunga JC, Gottlieb G, Rhatigan J, Kaplan R.

**Retention in Care among Patients with Early HIV Disease in Haiti.**

*Publication:* J Int Assoc Provid AIDS Care 2017 11; 16(6): 523-526. e-pub ahead of print 2017/12/01; doi: 10.1177/2325957417742670.

*Authors:* Hennessey KA, Leger TD, Rivera VR, Marcelin A, McNairy ML, Guiteau C, Devieux JG, Marcelin Y, Charles B, Cremieux PY, Koenig SP, Pape JW.

**Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?**

*Publication:* Cns Drugs 2017 10; 31(10): 899-910. e-pub ahead of print 2017/09/01; doi: 10.1007/s40263-017-0462-8.

*Authors:* Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S.

**Matching-adjusted indirect comparison (MAIC): Sensitivity analyses and graphical diagnostics.**

*Abstract:* ISPOR 20th Annual European Congress, Glasgow, UK Nov 4-8, 2017.

*Authors:* Signorovitch J, Gao W, Rybkin V, Yao Z, Hellstern M.

**Outcomes-Based Contracting Experience: Research Findings from U.S. and European Stakeholders.**

*Publication:* J Manag Care Spec Pharm 2017 10; 23(10): 1018-1026. e-pub ahead of print 2017/09/26; doi: 10.18553/jmcp.2017.23.10.1018.

*Authors:* Nazareth T, Ko JJ, Sasane R, Frois C, Carpenter S, Demean S, Vegesna A, Wu E, Navarro RP.

**Consider Value Vs. Budget Impact In Mass. Drug Prices.**

*Publication:* Law360 2017 09.

*Authors:* Kirson N.

**Insurer And Provider Market Share.**

*Publication:* Health Affairs 2017 05; 36(5): 961. e-pub ahead of print 2017/05/04; doi: 10.1377/hlthaff.2017.0238.

*Authors:* Dyckman Z.

**Tracing the Path to Health Care Investigation Settlements.**

*Publication:* Law360 2017 04.

*Authors:* Weinstein KA, Pike CT, Greenberg PE.

**Can social media data lead to earlier detection of drug-related adverse events?**

*Publication:* Pharmacoepidemiology and Drug Safety 2016 12; 25(12): 1425-1433. doi: 10.1002/pds.4090.

*Authors:* Duh MS, Cremieux P, Audenrode MV, Vekeman F, Karner P, Zhang H, Greenberg P.

**Reliable Analysis Is Key To Addressing Ascertainability.**

*Publication:* Law360 2016 12.

*Authors:* Cacciola S, Fink S.

**Rethinking the cost of healthcare in low-resource settings: the value of time-driven activity-based costing.**

*Publication:* BMJ Glob Health 2016 11; 1(3): e000134. e-pub ahead of print 2017/06/08; doi: 10.1136/bmjgh-2016-000134.

*Authors:* McBain RK, Jerome G, Warsh J, Browning M, Mistry B, Faure PAI, Pierre C, Fang AP, Mugunga JC, Rhatigan J, Leandre F, Kaplan R.

**Following Recent Trends in Affordable Care Act Insurance.**

*Publication:* Law360 2016 09.

*Authors:* Chawla A, Cook K.

**The Potential for Litigation in New Era of Biosimilars.**

*Publication:* Law360 2016 09.

*Authors:* Frois C, R M, White A.

**Practical Uses For Machine Learning In Health Care Cases.**

*Publication:* Law360 2016 09.

*Authors:* Yenikomshian M, Pinheiro LB, Royer J, Greenberg PE.

**Updated trends in US brand-name and generic drug competition.**

*Publication:* Journal of Medical Economics 2016 09; 19(9): 836-844. e-pub ahead of print 2016/04/12; doi: 10.1080/13696998.2016.1176578.

*Authors:* Grabowski H, Long G, Mortimer R, Boyo A.

**Machine-Learning Algorithms Can Help Health Care Litigation.**

*Publication:* Law360 2016 06.

*Authors:* Pinheiro L, Royer J, Dadson N, Greenberg P.

**The Myth of 'Price Disconnects' In US Pharma Markets.**

*Publication:* Law360 2016 05.

*Authors:* Fink S, Lewis M.

**Can The Life Sciences Industry Bank On Biosimilars?**

*Publication:* Law360 2016 04.

*Authors:* Greenberg P, Sisitsky T, Mortimer R.

**Viewing Recent Opioid Regulations In Context.**

*Publication:* Law360 2016 04.

*Authors:* Pike C, Weinstein K, Darling P, Greenberg P.

**Correlation Or Cause: Brand-Name Drug Prescription Rates.**

*Publication:* Law360 2016 03.

*Authors:* Greenbert P, Sisitsky T, R M.

**Retention of clinically stable art patients in a rapid model of care in Haiti.**

*Abstract:* 23rd Conference on Retroviruses and Opportunistic Infections, Boston, MA Feb 22-25, 2016.

*Authors:* Moise CG, Bellot C, Hennessey KA, Rivera VR, Severe P, Aubin D, Homeus F, Saint-Vil A, Koenig SP, Pape JW.

**Care pathways in US healthcare settings: current successes and limitations, and future challenges.**

*Publication:* American Journal of Managed Care 2016 01; 22(1): 53-62. e-pub ahead of print 2016/01/23.

*Authors:* Chawla A, Westrich K, Matter S, Kaltenboeck A, Dubois R.

**Outcomes-based pricing and reimbursement arrangements for pharmaceutical products in the U.S. and EU-5: Payer and manufacturer experience and outlook.**

*Abstract:* AMCP Nexus 2015, Orlando, FL Oct 26-29, 2015.

*Authors:* Ko J, Nazareth T, Carpenter S, Demean S, Wu E, Sasane R, Navarro R.

**Economists' Perspective on the Efficiency Defense in Provider Consolidations: What Works, What Doesn't Work, and What We Still Don't Know.**

*Publication:* AHLA Connections 2015 09.

*Authors:* Chipty T, Sendonaris A.

**The Expected Net Present Value of Developing Weight Management Drugs in the Context of Drug Safety Litigation.**

*Publication:* Pharmacoeconomics 2015 07; 33(7): 749-763. doi: 10.1007/s40273-015-0300-0.

*Authors:* Chawla A, Carls G, Deng E, Tuttle E.

**Gap Between Evidence and Patient Access: Policy Implications for Bariatric and Metabolic Surgery in the Treatment of Obesity and its Complications.**

*Publication:* Pharmacoeconomics 2015 07; 33(7): 629-641. doi: 10.1007/s40273-015-0302-y.

*Authors:* Chawla AS, Hsiao CW, Romney MC, Cohen R, Rubino F, Schauer P, Cremieux P.

**The importance of patents to innovation: updated cross-industry comparisons with biopharmaceuticals.**

*Publication:* Expert Opinion on Therapeutic Patents 2015 07; 25(7): 739-742. doi: 10.1517/13543776.2015.1040762.

*Authors:* Cockburn I, Long G.

**Outcomes-based pricing and reimbursement arrangements for pharmaceutical products in The US and EU-5: Payer and manufacturer experience and outlook.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Nazareth T, Ko JJ, Frois C, Carpenter S, Demean S, Wu EQ, Sasane R, Navarro R.

**Statistical identification of potential selection bias in retrospective chart reviews.**

*Abstract:* ISPOR 20th Annual International Meeting, Philadelphia, PA May 16-20, 2015.

*Authors:* Signorovitch JE, Reichmann WM, Li N, Liu Z, Hao Y, Perez JR.

**Nomenclature and traceability debate for biosimilars: small-molecule surrogates lend support for distinguishable nonproprietary names.**

*Publication:* Advances in Therapy 2015 03; 32(3): 270-283. doi: 10.1007/s12325-015-0193-5.

*Authors:* Chao J, Skup M, Alexander E, Tundia N, Macaulay D, Wu E, Mulani P.

**The roles of patents and research and development incentives in biopharmaceutical innovation.**

*Publication:* Health Affairs 2015 02; 34(2): 302-310. doi: 10.1377/hlthaff.2014.1047.

*Authors:* Grabowski HG, DiMasi JA, Long G.

**Cost of illness: an ongoing battle worth fighting.**

*Publication:* Pharmacoeconomics 2014 12; 32(12): 1151-1152. doi: 10.1007/s40273-014-0217-z.

*Authors:* Greenberg PE.

**Evolving provider payment models and patient access to innovative medical technology.**

*Publication:* Journal of Medical Economics 2014 12; 17(12): 883-893. doi: 10.3111/13696998.2014.965255.

*Authors:* Long G, Mortimer R, Sanzenbacher G.

**The randomized blind start trial: Evaluation of a new study design for assessing clinical outcomes in rare and heterogeneous patient populations.**

*Abstract:* ISPOR 17th Annual European Congress, Amsterdam, Netherlands Nov 8-12, 2014.

*Authors:* Signorovitch J, Ayyagari R, Kakkis E.

**Advanced Diagnostics: Innovation, Reimbursement, and Coverage Challenges.**

*Publication:* In Vivo 2014 10.

*Authors:* Gorin B, Tuttle E.

**Cost-effectiveness of health research study participant recruitment strategies: a systematic review.**

*Publication:* Clinical Trials (London, England) 2014 10; 11(5): 576-583. doi: 10.1177/1740774514540371.

*Authors:* Huynh L, Johns B, Liu SH, Vedula SS, Li T, Puhan MA.

**Evaluation of the value of webdata for detecting drug adverse events.**

*Abstract:* 30th International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Taipei, Taiwan (Republic of China) Oct 24-27, 2014.

*Authors:* Duh MS, Cremieux P, Van Audenrode M, Vekeman F, Karner P, Giguere-Duval P, Xiao Y, Damron J, Greenberg P.

**Random Selection Is Best For MDL Bellwether Trials.**

*Publication:* Law360 2014 10.

*Authors:* Brown L, Holian M, Rothman D.

**Big Data Can Yield Big Insights on Promotional Practices.**

*Publication:* Law360 2014 08.

*Authors:* Greenberg P, Sisitsky T.

**Identifying high-value treatment populations in clinical trials and real-world data.**

*Abstract:* ISPOR 19th Annual International Meeting, Montreal, QC, Canada May 31 - Jun 4, 2014.

*Authors:* Signorovitch J, Shaw J, Betts K, Wu EQ.

**The impact of Brazil's Bolsa Familia conditional cash transfer program on children's health care utilization and health outcomes.**

*Publication:* BMC International Health and Human Rights 2014 04; 14: 10. doi: 10.1186/1472-698X-14-10.

*Authors:* Shei A, Costa F, Reis MG, Ko Al.

**Outcomes-based contracting for pharmaceutical products in the United States: payer and manufacturer experience and outlook.**

*Abstract:* AMCP's 26th Annual Meeting, Tampa, FL Apr 1-4, 2014.

*Authors:* Frois C, Carpenter S, Demean S, Wu E, Navarro R.

**Recent trends in brand-name and generic drug competition.**

*Publication:* Journal of Medical Economics 2014 03; 17(3): 207-214. doi: 10.3111/13696998.2013.873723.

*Authors:* Grabowski H, Long G, Mortimer R.

**The role of health economics and outcomes research in health care reform in China.**

*Publication:* Pharmacoeconomics 2014 03; 32(3): 231-234. doi: 10.1007/s40273-014-0141-2.

*Authors:* Liang W, Xie J, Fu H, Wu EQ.

**What Attorneys Should Know about FDA's MedWatch Data.**

*Publication:* Law360 2014 01.

*Authors:* Duh MS CP, Greenberg P, Ellman B.

**Biosimilars.**

*Publication:* Encyclopedia of health Economics 2014.

*Authors:* Grabowski H, Long G, Mortimer R.

**Estimating chronic disease prevalence from claims data: Reducing bias by accounting for diseased individuals who do not generate claims.**

*Abstract:* ISPOR 16th Annual European Congress, Dublin, Ireland Nov 2-6, 2011.

*Authors:* Signorovitch J, De G, Drabo E, Guerin A.

**Effects of care management and telehealth: a longitudinal analysis using Medicare data.**

*Publication:* Journal of the American Geriatrics Society 2013 09; 61(9): 1560-1567. doi: 10.1111/jgs.12407.

*Authors:* Baker LC, Macaulay DS, Sorg RA, Diener MD, Johnson SJ, Birnbaum HG.

**Recent Average Price Trends for Implantable Medical Devices, 2007-2011.**

*Publication:* White paper 2013 09.

*Authors:* Long G, Mortimer R, Sanzenbalcher G.

**Little Guidance for Lower Courts in FTC v. Actavis.**

*Publication:* Today's General Council 2013 08; 10(4).

*Authors:* John L, Leckerman J, Greenberg P.

**Brazil's conditional cash transfer program associated with declines in infant mortality rates.**

*Publication:* Health Affairs 2013 07; 32(7): 1274-1281. doi: 10.1377/hlthaff.2012.0827.

*Authors:* Shei A.

**On-Market Pricing Strategies.**

*Publication:* Pharmaceutical Executive 2013 06.

*Authors:* Works J, Parece A.

**Beyond average adherence: Temporal patterns of medication adherence predict hospitalization risk more accurately than the medication possession ratio.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Signorovitch J, Chopra P, Cheng D, Ayyagari R, Wu EQ.

**Investigator-initiated approach to address an optimization problem in designing cost-efficient studies.**

*Abstract:* ISPOR 18th Annual International Meeting, New Orleans, LA May 18-22, 2013.

*Authors:* Huynh L, Clark M, Frick KD.

**Matching-adjusted indirect comparisons: A simulation study of statistical performance.**

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research 2013, May 18-22, 2013.

*Authors:* Signorovitch J, Ayyagari R, Cheng D, Wu E.

**The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication.**

*Publication:* JHEOR 2013 01: 54-61.

*Authors:* C CF, TI OC, Pesa J, Fastenau J, Doshi D.

**Innovation in the Biopharmaceutical Pipeline: A Multidimensional View.**

*Publication:* White paper 2013 01.

*Authors:* Long G, Works J.

**Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research.**

*Publication:* Value in Health 2012 10; 15(6): 940-947. doi: 10.1016/j.jval.2012.05.004.

*Authors:* Signorovitch JE, Sikirica V, Erder MH, Xie J, Lu M, Hodgkins PS, Betts KA, Wu EQ.

**How to use Clinical-Trial Data in Court.**

*Publication:* Law360 2012 07.

*Authors:* Cremieux P GA, Pinheiro L.

**Identifying patient subgroups who benefit most from a treatment: using administrative claims data to uncover treatment heterogeneity.**

*Publication:* Journal of Medical Economics 2012 06; 15(6): 1078-1087. doi: 10.3111/13696998.2012.689270.

*Authors:* Erder MH, Signorovitch JE, Setyawan J, Yang H, Parikh K, Betts KA, Xie J, Hodgkins P, Wu EQ.

**Impact of Medicare part D coverage gap on beneficiaries' adherence to prescription medications.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Desai U, Carroll NV.

**Modeling the progression of chronic diseases in a dynamic market: Implications for budget impact analysis.**

*Abstract:* ISPOR 17th Annual International Meeting, Washington, DC Jun 2-6, 2012.

*Authors:* Eldar-Lissai A, Banerjee R, McBride S, Leaf-Herrmann W.

**Prioritizing Safety versus Budget: FDA and CMS Adopt Different Stances.**

*Publication:* FDLI Update 2012 05.

*Authors:* Sisitsky T, Greenberg P.

**Recently Released FDA Guidance and Biosimilar Development: Implications for the Litigation Environment.**

*Publication:* Food and Drug Law Institute *Update* 2012 03: 19-21.

*Authors:* Long G, Mulhern C.

**Confounding factors in off-label drug use.**

*Publication:* Health Affairs 2012 02; 31(2): 460; author reply 460. doi: 10.1377/hlthaff.2011.1394.

*Authors:* Greenberg PE, Pike C, Sisitsky T.

**Evolving brand-name and generic drug competition may warrant a revision of the Hatch-Waxman Act.**

*Publication:* Health Affairs 2011 11; 30(11): 2157-2166. doi: 10.1377/hlthaff.2010.0270.

*Authors:* Grabowski HG, Kyle M, Mortimer R, Long G, Kirson N.

**Interprofessional education about decision support for patients across cultures.**

*Publication:* Journal of Interprofessional Care 2011 11; 25(6): 431-433. e-pub ahead of print 2011/10/21; doi: 10.3109/13561820.2011.618072.

*Authors:* Hagoel L, Volz S, Palileo LM, Eldar-Lissai A, Kamath CC, Cox ED.

**Integrated telehealth and care management program for Medicare beneficiaries with chronic disease linked to savings.**

*Publication:* Health Affairs 2011 09; 30(9): 1689-1697. doi: 10.1377/hlthaff.2011.0216.

*Authors:* Baker LC, Johnson SJ, Macaulay D, Birnbaum H.

**Implementation of the biosimilar pathway: economic and policy issues.**

*Publication:* Seton Hall Law Rev 2011 07; 41(2): 511-557.

*Authors:* Grabowski H, Long G, Mortimer R.

**Real-world practice patterns, health-care utilization, and costs in patients with low back pain: the long road to guideline-concordant care.**

*Publication:* Spine J 2011 07; 11(7): 622-632. doi: 10.1016/j.spinee.2011.03.017.

*Authors:* Ivanova JI, Birnbaum HG, Schiller M, Kantor E, Johnstone BM, Swindle RW.

**Comparative effectiveness research using matching-adjusted indirect comparison – A method for improving the reliability and interpretability of indirect comparisons by incorporating individual patient data.**

*Abstract:* 3rd DEcIDE Symposium on Comparative Effectiveness Research Methods, Baltimore, MD Jun 6-7, 2011.

*Authors:* Signorovitch JE, Wu EQ, Xie J, Lu M, Sikirica V, Hodgkins P, Erder MH.

**Increased olanzapine discontinuation and health care resource utilization following a Medicaid policy change.**

*Publication:* Journal of Clinical Psychiatry 2011 06; 72(6): 787-794. doi: 10.4088/JCP.09m05868yel.

*Authors:* Signorovitch J, Birnbaum H, Ben-Hamadi R, Yu AP, Kidolezi Y, Kelley D, Phillips G, Lawson A, Ball DE.

**Utilizing rich data sources to identify patients' subgroups that can benefit most from a treatment.**

*Abstract:* 3rd DEcIDE Symposium on Comparative Effectiveness Research Methods, Baltimore, MD Jun 6-7, 2011.

*Authors:* Wei LJ, Signorovitch JE, Wu EQ, Betts K, Yang H, Xie J, Setyawon J, Hodgkins P, Erder MH.

**Competitor Collaborations in Health Care: Understanding the Proposed ACO Antitrust Review Process.**

*Publication:* CPI Antitrust Chronicle 2011 05.

*Authors:* Chipty T.



**Improved indirect treatment comparisons for comparative effectiveness research.**

*Abstract:* ISPOR 16th Annual International Meeting, Baltimore, MD May 21-25, 2011.

*Authors:* Signorovitch J, Navarro R, Betts K, Wu EQ.

**Commercial importation of prescription drugs in the United States: short-run implications.**

*Publication:* Journal of Health Politics, Policy and Law 2011 04; 36(2): 295-316. doi: 10.1215/03616878-1222730.

*Authors:* Danzon PM, Johnson SJ, Long G, Furukawa MF.

**President Reignites Biologics Exclusivity Battle with Proposal for Seven Years.**

*Publication:* Specialty Pharmacy News 2011 03.

*Authors:* Long G.

**Budget Proposals on Biosimilars, "Pay for Delay" Spark Controversy.**

*Publication:* AIS's Health Reform Week 2011 02; 2(6).

*Authors:* Long G.

**Reading of Biosimilar Law Could Mean One Day or Years Until Competitors on Market.**

*Publication:* Specialty Pharmacy News 2011 02; 8(2).

*Authors:* Long G.

**The role of public-sector research in the discovery of drugs and vaccines.**

*Publication:* New England Journal of Medicine 2011 02; 364(6): 535-541. doi: 10.1056/NEJMsa1008268.

*Authors:* Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML.

**Data exclusivity for biologics.**

*Publication:* Nat Rev Drug Discov 2011 01; 10(1): 15-16. e-pub ahead of print 2011/01/05; doi: 10.1038/nrd3277.

*Authors:* Grabowski H, Long G, Mortimer R.

**An Effective Way to Quantify the Safety Profile of a Drug or Device When Background Toxicity Rates Are Low.**

*Publication:* FDLI Update 2011 01; Jan/Feb.

*Authors:* Wei E, Claggett B, Greenberg P, Wei LJ.

**CER The Fruits of Comparative Effectiveness Sometimes it's necessary to compare apples to oranges, as well as to other apples. New tools and a commitment to managing the impact of comparative effectiveness research grants payers the evidence they need to control drug costs.**

*Publication:* Pharmaceutical Executive 2010 11: 78.

*Authors:* Tuttle E, Chawla A, Nellesen D, Works J.

**Introducing perspectives on comparative effectiveness research.**

*Publication:* Pharmacoeconomics 2010 09; 28(10): 787-788. doi: 10.2165/11535820-000000000-00000.

*Authors:* Birnbaum HG, Greenberg PE.

**Perspectives on comparative effectiveness research: views from diverse constituencies.**

*Publication:* Pharmacoeconomics 2010 09; 28(10): 789-798. doi: 10.2165/11535790-000000000-00000.

*Authors:* Nellesen D, Birnbaum HG, Greenberg PE.

**Selecting the optimal target population for formulary coverage.**

*Abstract:* ISPOR 4th Asia-Pacific Conference, Phuket, Thailand Sep 5-7, 2010.

*Authors:* Wu EQ, Yu D, Xie J, Gu.

**Methodological issues in a meta-analysis.**

*Publication:* Hepatology 2010 07; 52(1): 395-396; author reply 396-397. doi: 10.1002/hep.23762.

*Authors:* Cremieux P.

**Comparative Effectiveness Research for Personalized Medicine.**

*Abstract:* ISPOR 15th Annual International Meeting, Atlanta, GA May 15-19, 2010.

*Authors:* Signorovitch J, Wu EQ, We LJ.

**Panel discussion: New imperatives for evidence to support successful licensing, reimbursement, and commercial strategy.**

*Abstract:* BIO International Convention, Chicago, IL May 6, 2010.

*Authors:* Chawla A (moderator), Szela M, Blansett L, Garrison L, Schroeder T.

**The role of compliance in telehealth adoption.**

*Abstract:* 15th Annual International Meeting of the American Telemedicine Association, San Antonio, TX May 16-18, 2010.

*Authors:* Newell D, Johnson S, Rutherford P, Welte I.

**ICONS: Managing Care and Costs: The Sustained Cost Impact of Reduced Hospitalizations in a Partnership-Measurement Model of Disease Management.**

*Publication:* Healthc Q 2010 01; 13(4): 30-39.

*Authors:* Paradis PE, Nemis-White J, Meilleur MC, Ginn M, Cox J, Montague T.

**The Growing Role of Economic Analysis in Off-Label Promotion Cases.**

*Publication:* Rx Compliance Report 2009 11; VIII(8): 7-8.

*Authors:* Greenberg P, Sisitsky T.

**The impact of drug vintage on patient survival: a patient-level analysis using Quebec's provincial health plan data.**

*Publication:* Value in Health 2009 09; 12(6): 847-856. doi: 10.1111/j.1524-4733.2009.00532.x.

*Authors:* Lichtenberg FR, Grootendorst P, Van Audenrode M, Latremouille-Viau D, Lefebvre P.

**A comparative analysis of Medicaid long-term care policies and their effects on elderly dual enrollees.**

*Publication:* Health Economics 2009 05; 18(3): 275-290.

*Authors:* Rice JB, Kasper JD, Pezzin LE.

**Comparative Effectiveness without Head- To- Head Trials: Indirect Comparisons Using Primary and Published Clinical Trial Data.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Wu EQ, Signorovitch J, Yu A.

**Personalized medicine:trends in clinical studies based on national registry data.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Nellesen D, Person A, Yee K, Chawla A.

**Societal cost of rheumatoid arthritis (RA) in the United States: Methodology for incorporating intangible costs.**

*Abstract:* ISPOR 14th Annual International Meeting, Orlando, FL May 16-20, 2009.

*Authors:* Birnbaum H, Pike C, Kaufman R, Marynchenko M, Kidolezi Y, Cifaldi M.

**Exact and efficient inference procedure for meta-analysis and its application to the analysis of independent 2 x 2 tables with all available data but without artificial continuity correction.**

*Publication:* Biostatistics 2009 04; 10(2): 275-281. doi: 10.1093/biostatistics/kxn034.

*Authors:* Tian L, Cai T, Pfeffer MA, Piankov N, Cremieux PY, Wei LJ.

**Economic Analysis in Off-Label Promotion Cases.**

*Publication:* Law360 2009 02.

*Authors:* Greenberg P, Sisitsky T.

**Legal and economic perspectives concerning US government investigations of alleged off-label promotion by drug manufacturers.**

*Publication:* Pharmacoeconomics 2009 27(8): 623-625.

*Authors:* Kalb PE, Greenberg PE.

**Drug Safety And Risk Management Practice: What Drug Companies Can Do.**

*Publication:* FDLI Update 2008 05; (3).

*Authors:* Duh MS, Greenberg P, Antras L.

**Does generic substitution always make sense?**

*Publication:* Journal of Medical Economics 2008 11(3): 547-553.

*Authors:* Greenberg PE.

**The Role of Epidemiology in Drug Safety Litigations.**

*Publication:* Update (National Minority AIDS Council) 2007 11: 31-34.

*Authors:* Duh MS, Greenberg PE, Weiner JR.

**The economic consequences of generic substitution for antiepileptic drugs in a public payer setting: the case of lamotrigine.**

*Publication:* Disease Management 2007 08; 10(4): 216-225. doi: 10.1089/dis.2007.104649.

*Authors:* Duh MS, Andermann F, Paradis PE, Weiner J, Manjunath R, Cremieux PY.

**The Effect on Federal Spending of Legislation Creating a Regulatory Framework for Follow-on Biologics: Key Issues and Assumptions.**

*Publication:* White paper 2007 08.

*Authors:* Grabowski H, Cockburn I, Long G, Mortimer R, Johnson S.

**Retrospective economic and outcomes analyses using non-US databases: a review.**

*Publication:* Pharmacoeconomics 2007 07; 25(7): 563-576.

*Authors:* Shi L, Wu EQ, Hodges M, Yu A, Birnbaum H.

**Authorized generic drugs, price competition, and consumers' welfare.**

*Publication:* Health Affairs 2007 05; 26(3): 790-799. doi: 10.1377/hlthaff.26.3.790.

*Authors:* Berndt ER, Mortimer R, Bhattacharjya A, Parece A, Tuttle E.

**Do drugs reduce utilization of other healthcare resources?**

*Publication:* Pharmacoeconomics 2007 03; 25(3): 209-221.

*Authors:* Cremieux PY, Ouellette P, Petit P.

**The value of antihypertensive drugs: a perspective on medical innovation.**

*Publication:* Health Affairs 2007 01; 26(1): 97-110. doi: 10.1377/hlthaff.26.1.97.

*Authors:* Cutler DM, Long G, Berndt ER, Royer J, Fournier AA, Sasser A, Cremieux P.

**Assessing Step Therapy/Generic Switching: Clinical and Economic implications of Acquisition Costs vs. Total Health Care Costs Paradigm.**

*Abstract:* Congressional Budget Office, Washington DC 2007.

*Authors:* Wu EQ, Greenberg P, Erder MH.

**Competition between Generic and Branded Drugs.**

*Publication:* Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective 2007.

*Authors:* Grabowski H.

**The Drug Delivery Delimma.**

*Publication:* SCRIP Supplement, Informa Health Care 2007.

*Authors:* Gorin B, Tuttle E.

**Pharmaceutical spending and health outcomes.**

*Publication:* Pharmaceutical Innovation: Incentives, Competition, and Cost-Benefit Analysis in International Perspective 2007: 226-241.

*Authors:* Cremieux P-Y, Jarvinen D, Long G, Merrigan P.

**Off-Label Marketing Investigations in the Pharmaceutical Industry.**

*Publication:* Analysis Group Forum 2006 11.

*Authors:* Greenberg P, Sisitsky T.

**A Roundtable Discussion: The Importance of Causation Analysis in Mass Tort Cases.**

*Publication:* Food and Drug Law Institute Update 2006 11.

*Authors:* Greenberg PE, Lykos G, Gourley S, Davies C.

**The market for follow-on biologics: how will it evolve?**

*Publication:* Health Affairs 2006 09; 25(5): 1291-1301. doi: 10.1377/hlthaff.25.5.1291.

*Authors:* Grabowski H, Cockburn I, Long G.

**Retirement patterns from career employment.**

*Publication:* Gerontologist 2006 08; 46(4): 514-523.

*Authors:* Cahill KE, Giandrea MD, Quinn JF.

**A Regulatory Perspective on Productivity Claims: Implications for Future Productivity Research.**

*Publication:* Health and Work Productivity: Emerging Issues in Research and Policy. 2006 04; (Spring).

*Authors:* Greenberg PE, Birnbaum HG.

**Generic competition in the U.S. pharmaceutical industry.**

*Publication:* International Journal of the Economics of Business 2006 02: 15-38.

*Authors:* Saha A, Grabowski H, Birnbaum H, Greenberg P.

**Hospital cost flexibility in the presence of many outputs: a public-private comparison.**

*Publication:* Health Care Manag Sci 2005 05; 8(2): 111-120.

*Authors:* Cremieux PY, Ouellette P, Rimbaud F, Vigeant S.

**Public and private pharmaceutical spending as determinants of health outcomes in Canada.**

*Publication:* Health Economics 2005 02; 14(2): 107-116. e-pub ahead of print 2004/09/24; doi: 10.1002/hec.922.

*Authors:* Cremieux PY, Meilleur MC, Ouellette P, Petit P, Zelder M, Potvin K.

**Systematic Differences in Subjective vs. Societal Preferences.**

*Abstract:* International Society for Quality of Life Research.

*Authors:* Sullivan PW, Ghushchyan V, Wu EQ.

**Your patent is about to expire: what now.**

*Publication:* Pharm Exec 2004 11; 24(11): 88-98.

*Authors:* Parece A, Tuttle E, Hector A.

**Money can't buy happiness.**

*Publication:* Business and Health 2004 04; 2004.

*Authors:* Greenberg PE BH, Kessler RC.

**Product Liability in the Pharmaceutical Industry.**

*Publication:* Update (National Minority AIDS Council) 2004 03.

*Authors:* Cremieux P, Greenberg PE.

**Administrative Claims Data: A Valuable Tool in Pharmaceutical Litigation.**

*Publication:* FDLI Update 2004 01.

*Authors:* Birnbaum HG, Greenberg PE.

**Economic Impact Analysis: Proposition 71 - California Stem Cell Research and Cures Initiative.**

*Publication:* Report Commissioned by Californians for Stem Cell Research and Cures 2004.

*Authors:* Baker L, Deal B.

**Measuring hospital performance in the presence of quasi-fixed inputs: an analysis of Québec hospitals.**

*Publication:* Journal of Productivity Analysis 2004 21(2): 183-199.

*Authors:* Bilodeau D, Crémieux P-Y, Jaumard B, Ouellette P, Vovor T.

**The relationship between technology availability and health care spending.**

*Publication:* Health Affairs 2003 07; Suppl Web Exclusives: W3-537-551.

*Authors:* Baker L, Birnbaum H, Geppert J, Mishol D, Moyneur E.

**PMD3: Instrument strength and performance of a parametric latent index model in estimating average treatment effect (ate).**

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research 2003, 2003.

*Authors:* Wu E, Johnson K, Nichol M.

**PMD4: Performance of two conditional expectation methods under unobserved selection bias.**

*Abstract:* International Society for Pharmacoeconomics and Outcomes Research 2003, 2003.

*Authors:* Wu E, Nichol M, Johnson K.

**Provision of pharmacy services in community health centers and migrant health centers.**

*Publication:* Journal of the American Pharmaceutical Association (Washington,D.C.: 1996) 2002 09; 42(5): 713-722.

*Authors:* Barner JC, Brown CM, Shepherd MD, Chou JY, Yang M.

**Switching costs, price sensitivity and health plan choice.**

*Publication:* Journal of Health Economics 2002 01; 21(1): 89-116.

*Authors:* Strombom BA, Buchmueller TC, Feldstein PJ.

**China's urban health insurance reform experiment in Zhenjiang: cost and utilization analyses.**

*Publication:* The economics of health care in Asia+ Pacific countries 2002: 143.

*Authors:* Liu GG, Cai R, Chao S, Xiong X, Zhao Z, Wu E.

**Hospital technology in a nonmarket health care system.**

*Publication:* Southern Economic Journal 2002: 511-529.

*Authors:* Bilodeau D, Cremieux P-Y, Ouellette P.

**Actual and perceived impacts of tobacco regulation on restaurants and firms.**

*Publication:* Tobacco Control 2001 03; 10(1): 33-37.

*Authors:* Cremieux PY, Ouellette P.

**Omitted variable bias and hospital costs.**

*Publication:* Journal of Health Economics 2001 03; 20(2): 271-282.

*Authors:* Cremieux PY, Ouellette P.

**Impact of illness and its treatment on workplace costs: regulatory and measurement issues.**

*Publication:* Journal of Occupational Environmental Medicine 2001 01; 43(1): 56-63.

*Authors:* Greenberg PE, Birnbaum HG, Kessler RC, Morgan M, Stang P.

**Évaluation de l'efficience budgétaire des CLSC au Québec à partir de la méthode DEA.**

*Publication:* L'Actualité économique 2001 77(3): 409-424.

*Authors:* Crémieux P-Y, Gadbois D, Jaumard B, Ouellette P, Vovor T.

**Modeling for health care and other policy decisions: uses, roles, and validity.**

*Publication:* Value in Health 2001 4(5): 348-361. doi: 10.1046/j.1524-4733.2001.45061.x.

*Authors:* Weinstein MC, Toy EL, Sandberg EA, Neumann PJ, Evans JS, Kuntz KM, Graham JD, Hammitt JK.

**Pharmaceutical spending and health outcomes in the United States.**

*Publication:* RESEARCH IN HUMAN CAPITAL AND DEVELOPMENT 2001: 59-76.

*Authors:* Cremieux P-Y, Ouellette P, Meilleur M-C, Leong S, Greenberg P, Birnbaum H.

**Comparative Econometric Models of Medical Costs.**

*Abstract:* International Society for Pharmacoeconomics & Outcomes Research (ISPOR) 2000, 2000.

*Authors:* Wu EQ, Hay JW.

**Diagnosing the illness.**

*Publication:* POLICY OPTIONS-MONTREAL- 2000 21(4): 12-13.

*Authors:* Cremieux P-Y, Ouellette P.

**Hospital cost function in a non-market health care system.**

*Publication:* Review of Economics and Statistics 2000 82(3): 489-498.

*Authors:* Bilodeau D, Cremieux P-Y, Ouellette P.

**Health care spending as determinants of health outcomes.**

*Publication:* Health Economics 1999 11; 8(7): 627-639.

*Authors:* Cremieux PY, Ouellette P, Pilon C.

**Pharmacoeconomics and health policy. Current applications and prospects for the future.**

*Publication:* Pharmacoeconomics 1999 11; 16(5 Pt 1): 425-432.

*Authors:* Greenberg PE, Arcelus A, Birnbaum HG, Cremieux PY, LeLorier J, Ouellette P, Slavin MB.

**Using healthcare claims data for outcomes research and pharmacoeconomic analyses.**

*Publication:* Pharmacoeconomics 1999 07; 16(1): 1-8.

*Authors:* Birnbaum HG, Cremieux PY, Greenberg PE, LeLorier J, Ostrander JA, Venditti L.

**Tackling costs one disease at a time.**

*Publication:* Business and Health 1999 05; 17(5): 31-32, 37.

*Authors:* Greenberg P.

**Epidemiologic interpretation of artificial neural networks.**

*Publication:* American Journal of Epidemiology 1998 06; 147(12): 1112-1122.

*Authors:* Duh MS, Walker AM, Ayanian JZ.

**The Home Infusion Therapy/Relative Benefit Index: summary of an analysis using insurance claims data.**

*Publication:* Medical Care 1998 05; 36(5): 757-765.

*Authors:* Birnbaum HG, Tang M.

**Calculating Return on Investment from Reducing Workplace Costs of Illness.**

*Publication:* Drug Benefit Trends 1998 03.

*Authors:* Greenberg PE, Baker A, Berndt E, Finkelstein S, Russell J.

**Prediction and cross-validation of neural networks versus logistic regression: using hepatic disorders as an example.**

*Publication:* American Journal of Epidemiology 1998 02; 147(4): 407-413.

*Authors:* Duh MS, Walker AM, Pagano M, Kronlund K.

**Interpretation of the Weight Matrix in an Artificial Neural Network.**

*Publication:* American Journal of Epidemiology 1998: 1112-1122.

*Authors:* Duh MS, Walker Am, Ayanian JZ.

**La Performance des CLSC au Quebec, (Local health clinic performance in Quebec).**

*Publication:* L'Actualite Economique 1998 74(2): 157-181.

*Authors:* Cremieux PY, Ouellette P, Gadbois D.

**Prediction and cross-validation in modeling incident cases of hepatic disorders using automated medical data.**

*Publication:* American Journal of Epidemiology 1998 1998: 407-413.

*Authors:* Duh M, Walker A, Pagano M, Kronlund K.

**Une analyse de la performance des CLSC au Québec.**

*Publication:* L'Actualité économique 1998 74(2): 157-181.

*Authors:* Crémieux P-Y, Gadbois D, Ouellette P.

**The Next Phase of Managed Care: Targeting Investments in Employee Health.**

*Publication:* On Managed Care 1997 09.

*Authors:* Greenberg PE, Berndt E, Finkelstein S.

**Une analyse du contexte budgétaire de l'activité médicale au Quebec (An analysis of the budgetary context of medical activity in Quebec).**

*Publication:* Le Medecin du Quebec 1997 08.

*Authors:* Cremieux PY, Ouellette P.

**Etude d'impact du projet de loi sur le tabac (Impact report on the proposed tobacco law).**

*Publication:* Ministry of Health and Social Services 1997.

*Authors:* Cremieux PY FP, Lavoie F, Ouellette P, St Pierre Y.

**Hospital Consolidation: Optimal Strategy for a Two-Hospital Town.**

*Publication:* Ambulatory Health Care 1996.

*Authors:* Deal B, Tiscornia JF.

**Price Growth of prescription pharmaceutical preparations: an update and extension.**

*Publication:* Competitive Strategies in the Pharmaceutical Industry 1996.

*Authors:* Berndt E, Greenberg P.

**Consolidation and restructuring: the next step in managed care.**

*Publication:* Health Care Management 1995 10; 2(1): 221-235.

*Authors:* Danzon PM, Boothman LG, Greenberg PE.

**Consolidation is a Tonic for Health Care Providers: Trend Toward Managed Care and Ascent of Information Technology Fuel Restructuring of an Industry.**

*Publication:* The national Law Journal 1995 09.

*Authors:* Danzon P, Stamm L, Greenberg P.

**Economic consequences of illness in the workplace.**

*Publication:* MIT Sloan Management Review 1995 08; 36(4): 26.

*Authors:* Greenberg PE, Finkelstein SN, Berndt ER.

**The Health Care System in Canada.**

*Publication:* Financing Health Care 1994.

*Authors:* Mulhern C, Rozek R.

**Navigating the Changing Tides of Managed Care and Health Reform.**

*Publication:* American Medical Association Monograph 1994.

*Authors:* Sherwin R.

**When can a Medicare Insured Group (MIG) Succeed ?**

*Publication:* Inquiry 1994.

*Authors:* Birnbaum HG CN, Lang K.

**Savings estimate for a Medicare insured group.**

*Publication:* Health Care Financing Review 1991 08; 12(4): 39-48.

*Authors:* Birnbaum H, Holland SK, Lenhart G, Reilly HL, Hoffman K, Pardo DP.

**Impacts of the New York long-term home health care program.**

*Publication:* Medical Care 1986 24(7).

*Authors:* Birnbaum HG, Gaumer G, Pratter F, Burke R, Franklin S, Ellington-Otto K.

**Implementing community-based long-term care: experience of New York's Long Term Home Health Care Program.**

*Publication:* Gerontologist 1984 08; 24(4): 380-386.

*Authors:* Birnbaum H, Burke R, Swearingen C, Dunlop B.

**What does hospice cost?**

*Publication:* American Journal of Public Health 1984 07; 74(7): 689-697.

*Authors:* Birnbaum HG, Kidder D.

**The determinants of nursing home operating costs in New York State.**

*Publication:* Health Services Research 1983 08; 18(2 Pt 2): 285-308.

*Authors:* Lee AJ, Birnbaum H.

**Medicare legislation for hospice care: implications of national hospice study data.**

*Publication:* Health Affairs 1983 08; 2(2): 80-90.

*Authors:* Mor V, Birnbaum H.

**Home care in hospices.**

*Publication:* Caring 1983 06; 2(6): 40-44.

*Authors:* Birnbaum H, Mor V, Greer DS.

**Managing programs for the elderly: design of a social information systems.**

*Publication:* Health Care Financing Review 1983 02; 5(2): 11-23.

*Authors:* Birnbaum H, Burke R, Pratter F.



**National hospice study analysis plan.**

*Publication:* Journal of Chronic Diseases 1983 01; 36(11): 737-780.

*Authors:* Greer DS, Mor V, Sherwood S, Morris JN, Birnbaum H.

**How nursing homes behave: a multi-equation model of nursing home behavior.**

*Publication:* Social Science and Medicine 1983 17(23): 1897-1906.

*Authors:* Birnbaum HG, Lee AJ, Bishop C.

**Why do nursing home costs vary? The determinants of nursing home costs.**

*Publication:* Medical Care 1981 11; 19(11): 1095-1107.

*Authors:* Birnbaum H, Bishop C, Lee AJ, Jensen G.

#### **About Analysis Group's HEOR Practice**

Founded in 1981, Analysis Group is one of the largest economics consulting firms, with more than 1,000 professionals across 14 offices. Analysis Group's health care experts apply analytical expertise to health economics and outcomes research, clinical research, market access and commercial strategy, and health care policy engagements, as well as drug-safety related engagements in epidemiology. Analysis Group's internal experts, together with its network of affiliated experts from academia, industry, and government, provide our clients with exceptional breadth and depth of expertise and end-to-end consulting services globally.



[www.analysisgroup.com](http://www.analysisgroup.com)